CUI,Canonical Name,Keyword,Aliases,Source
C0001056,acetylglucosamine,glucose,"2 Acetamido 2 Deoxyglucose; Acetylglucosamine; acetylglucosamine; 2-Acetamido-2-Deoxy-D-Glucose; N-Acetylchitosamine; N-Acetyl-D-Glucosamine; N Acetyl D Glucosamine; n-Acetyl glucosamine; n-acetyl glucosamine; 2-Acetamido-2-Deoxyglucose; N-Acetyl-D-glucosamine; n-acetylglucosamine; N acetylglucosamine; N-ACETYLGLUCOSAMINE; N-Acetylglucosamine; 2 Acetamido 2 Deoxy D Glucose; 2-Acetamido-2-deoxy-D-glucose; N-Acetylglucosamine (substance); N-Acetyl Glucosamine D-; aldehydo-N-acetyl-D-glucosamine; D-Glucose, 2-(acetylamino)-2-deoxy-; N-acetylglucosamine; D-GlcNAc",
C0001460,Adenosine Diphosphate Glucose,glucose,"Glucose, Adenosine Diphosphate; Diphosphoglucose, Adenosine; Adenosine 5'-(trihydrogen diphosphate), P'-alpha-D-glucopyranosyl ester; Glucose, ADP; Adenosine Pyrophosphateglucose; ADPG; ADP Glucose; Pyrophosphateglucose, Adenosine; Adenosine Diphosphoglucose; Diphosphate Glucose, Adenosine",
C0002152,Alloxan Diabetes,diabetes,"Diabetes, Alloxan",
C0003729,arbutin,glucose,"arbutin; 4-Hydroxyphenyl-beta-D-glucopyranoside; Arbutin; beta-Arbutin; p-hydroxyphenyl β-D-glucoside; Arbutoside; Arbutinum; Hydroquinone Glucose; p-hydroxyphenyl β-D-glucopyranoside; 4-Hydroxyphenyl-beta-D-Glucopyranoside; Ursin; beta-D-Glucopyranoside, 4-hydroxyphenyl; 4-hydroxyphenyl-glucopyranoside; Hydroquinone-O-beta-D-glucopyranoside; ARBUTIN; hydroquinone O-β-D-glucopyranoside",
C0004076,"Glucose measurement, urine",glucose measurement,"urine test glucose; glucose test urine; glucose urine; urine glucose; urine test for glucose; urine glucose test; Glucose measurement, urine; Glucose, urine, measurement; glucose tests urine; glucose urine test; Urine Glucose Test; Glucose measurement, urine (procedure); Urine test for glucose; glucose testing urine",
C0004606,Nonproliferative diabetic retinopathy,diabetes,Non-Proliferative Diabetic Retinopathy; Background diabetic retinopathy; Non proliferative diabetic retinopathy; Nonproliferative diabetic retinopathy NOS; Nonproliferative retinopathy due to diabetes mellitus (disorder); Background Diabetic Retinopathy; NPDR - Non proliferative diabetic retinopathy; Nonproliferative diabetic retinopathy; Nonproliferative retinopathy due to diabetes mellitus; BDR - Background diabetic retinopathy; background diabetic retinopathy,
C0005800,Blood Gas Analysis,BG,"Blood gas measurement (procedure); Blood Gas Analyses; blood gase; blood gas measurement; Blood gas levels; Blood gas measurement; analysis blood gas; blood gases; BGA - Blood gas analysis; Blood gas studies; BG - Blood gases; blood gas analyses; blood gas analysis; Gas Analyses, Blood; Blood gas analysis (procedure); blood gas measurements; analyse blood gas; Blood Gas Analysis; Analysis, Blood Gas; Gas Analysis, Blood; Blood gas analysis; Analyses, Blood Gas; Blood gases--Analysis",
C0005802,Blood Glucose,blood sugar,"bloods sugar; blood glucose; Sugar, Blood; Blood sugar; sugar blood; blood sugars; glucose blood; Blood Glucose; blood sugar; Glucose, Blood; Blood Sugar",
C0005803,Blood Glucose Self-Monitoring,blood sugar,"Glucose Self-Monitoring, Blood; home blood glucose monitoring; Glucose, Blood, Self Monitoring; blood glucose self-monitoring; Self-Monitoring, Blood Sugar; Sugar Self-Monitorings, Blood; Monitoring, Home Blood Glucose; Glucose Self-Monitorings, Blood; self monitoring blood sugar; self-monitoring of blood glucose; Blood Sugar Self-Monitoring; blood glucose monitored self; blood glucose home monitoring; Self-Monitorings, Blood Glucose; Glucose, Blood, Self-Monitoring; Self-Monitorings, Blood Sugar; Self-monitoring of blood glucose (procedure); Blood Glucose Self-Monitorings; Self-Monitoring, Blood Glucose; Self-monitoring of blood glucose; Self Monitoring, Blood Glucose; Blood Sugar Self-Monitorings; Home Blood Glucose Monitoring; Blood Sugar Self Monitoring; blood glucose monitoring self; self monitoring blood glucose; Blood Glucose Self Monitoring; Sugar Self-Monitoring, Blood; self blood glucose monitoring",
C0011847,Diabetes,diabetes,Diabetes,
C0011848,Diabetes Insipidus,diabetes,"diabete insipidus; diabetes insipidus; Diabetes Insipidus; DI; DIABETES INSIPIDUS; Diabetes insipidus (disorder); Diabetes insipidus, NOS; Diabetes insipidus; DI - Diabetes insipidus",
C0011849,Diabetes Mellitus,diabetes,"Diabetes mellitus (disorder); diabete mellitus; Diabetes NOS; diabetes mellitus; dm; diabetes; diabetes (DM); Diabetes mellitus (DM); Diabetes; DM; DIABETES MELLITUS; Diabetes mellitus, NOS; Diabetes mellitus; Diabetes Mellitus; DM - Diabetes mellitus; diabetes mellitus (DM); Diabetes mellitus NOS; disorder diabetes mellitus",
C0011853,"Diabetes Mellitus, Experimental",diabetes,Experimental Diabetes Mellitus,
C0011854,"Diabetes Mellitus, Insulin-Dependent",diabetes,"Diabetes, type 1; DIABETES MELLITUS, INSULIN DEPENDENT; diabetes mellitus type 1; Insulin-dependent diabetes; Diabetes Mellitus, Insulin Dependent; Insulin-Dependent Diabetes Mellitus 1; Diabetes mellitus, growth onset type; INSULIN-DEPENDENT DIABETES MELLITUS 1; Insulin-Dependent Diabetes Mellitus; diabetes type i; DIABETES MELLITUS, TYPE I; Diabetes Mellitus, Type I; Juvenile diabetes mellitus; Diabetes Mellitus, Insulin-Dependent, 1; Diabetes Mellitus, Juvenile-Onset; DIABETES MELLITUS, TYPE 1; Diabetes mellitus type 1 (disorder); type 1 diabetes mellitus; IDDM1; Insulin Dependent Diabetes Mellitus 1; Diabetes mellitus, Type 1; Sudden-Onset Diabetes Mellitus; juvenile-onset diabetes mellitus; Type 1 Diabetes; JUVENILE ONSET DIABETES MELLITUS; JOD; Insulin-dependent diabetes mellitus; IDDM; Juvenile-Onset Diabetes Mellitus; type I diabetes mellitus; DIABETES MELLITUS INSULIN DEPENDENT; insulin dependent diabetes mellitus; diabetes, type i; type i diabetes; DIABETES MELLITUS (JUVENILE ONSET); TYPE 1 DIABETES MELLITUS; Insulin dependent diabetes mellitus; Diabetes mellitus, type I; Juvenile diabetes; Type 1 Diabetes Mellitus; Diabetes Mellitus, Sudden-Onset; Diabetes mellitus Type I; Type 1 diabetes mellitus; Diabetes, Juvenile-Onset; Diabetes Mellitus, Juvenile Onset; diabetes mellitus type i; Diabetes mellitus, insulin-dependent; DIABETES MELLITUS, INSULIN-DEPENDENT; Diabetes mellitus, juvenile onset type; T1DM - type 1 diabetes mellitus; diabetes type 1; Type I Diabetes Mellitus; Diabetes mellitus type I; T1D; Juvenile Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Insulin-Dependent; type 1 diabetes; insulin dependent diabetes; Insulin Dependent Diabetes Mellitus; Insulin-dependent diabetes mellitus (type I); Diabetes Type 1; Type I diabetes mellitus; Juvenile-Onset Diabetes; Type 1 diabetes; jodm; juvenile diabetes mellitus; Diabetes mellitus, type 1; DIABETES MELLITUS, INSULIN-DEPENDENT, 1; Insulin Dependent Diabetes; Type I diabetes; Diabetes, Type 1; Type I Diabetes; juvenile onset diabetes mellitus; IDD; type i diabetes mellitus; iddm; Diabetes mellitus type 1; Juvenile Onset Diabetes; T1d; Diabetes Mellitus, Sudden Onset; JUVENILE-ONSET DIABETES",
C0011859,Lipoatrophic Diabetes Mellitus,diabetes,"Diabetes Mellitus, Lipoatrophic; Lipoatrophic diabetes; lipoatrophic diabetes; Lipoatrophic Diabete; Diabete, Lipoatrophic; Lipoatrophic diabetes, NOS; Lipoatrophic Diabetes Mellitus; Lipoatrophic Diabetes; DIABETES, LIPOATROPHIC; Diabetes, Lipoatrophic; Lipoatrophic diabetes (disorder); Diabetes mellitus, lipoatrophic; Lipodystrophic diabetes; Lipodystrophic diabetes, NOS; lipoatrophic diabetes mellitus",
C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",diabetes,"MATURITY-ONSET DIABETES; Diabetes mellitus type 2; type II diabetes mellitus; AODM; Diabetes, Maturity-Onset; non-insulin dependent diabetes; type 2 diabetes mellitus; Noninsulin-dependent diabetes; Adult-Onset Diabetes Mellitus; DIABETES MELLITUS, NON-INSULIN DEPENDENT; Maturity onset diabetes; DIABETES, KETOSIS RESISTANT; Diabetes Mellitus, Maturity Onset; DIABETES MELLITUS, NONINSULIN-DEPENDENT; Type II diabetes mellitus; diabetes mellitus type ii; T2DM - diabetes mellitus type 2; NIDDM; Non-Insulin Dependent Diabetes; DIABETES MELLITUS NON INSULIN-DEP; Type II Diabetes; Diabetes mellitus (NIDDM); diabetes type 2; NCDMM; Maturity-Onset Diabetes; Noninsulin-dependent diabetes mellitus; Diabetes mellitus, type 2; Diabetes Mellitus, Slow Onset; Diabetes Mellitus, Type II; Type 2 diabetes mellitus; diabetes, type ii; Non-insulin dependent diabetes mellitus; Diabetes mellitus Type II; Type II diabetes; Stable Diabetes Mellitus; Diabetes mellitus type 2 (disorder); non-insulin dependent diabetes mellitus; Diabetes Mellitus, Adult-Onset; Diabetes Mellitus, Non-Insulin-Dependent; ADULT ONSET DIABETES MELLITUS; Maturity Onset Diabetes; NONINSULIN-DEPENDENT DIABETES MELLITUS; maturity onset diabetes; aodm; Diabetes Mellitus, Adult Onset; adult onset diabetes; Diabetes mellitus, noninsulin-dependent; Non-Insulin Dependent Diabetes Mellitus; TYPE 2 DIABETES MELLITUS; Diabetes Mellitus, Noninsulin Dependent; Type 2 Diabetes; Diabetes Mellitus, Type 2; MODY; Type 2 Diabetes Mellitus; Type II Diabetes Mellitus; Diabetes Mellitus, Non Insulin Dependent; DIABETES MELLITUS, TYPE 2; Diabetes mellitus type II; Non-insulin-dependent diabetes; Diabetes, Type 2; Non-insulin dependent diabetes; noninsulin dependent diabetes mellitus; Slow-Onset Diabetes Mellitus; late onset diabetes; type II diabetes; Noninsulin Dependent Diabetes Mellitus; MOD; Diabetes mellitus, adult onset type; adult onset diabetes mellitus; DIABETES MELLITUS (ADULT ONSET); Diabetes Mellitus, Stable; diabetes type ii; Diabetes Mellitus, Maturity-Onset; ketosis resistant diabetes; DIABETES MELLITUS, TYPE II; Diabetes Type 2; DIABETES, ADULT ONSET; Diabetes Mellitus, Ketosis Resistant; Maturity-Onset Diabetes Mellitus; diabete type 2; type 2 diabetes; diabetes mellitus type 2; type ii diabetes mellitus; Noninsulin-Dependent Diabetes Mellitus; Maturity Onset Diabetes Mellitus; T2D; Adult-Onset Diabetes; Type 2 Diabetes Mellitus Non-Insulin Dependent; Diabetes mellitus, type II; DIABETES, MATURITY ONSET; Non-Insulin-Dependent Diabetes Mellitus; Diabetes mellitus, Type 2; Noninsulin dependent diabetes mellitus; T2DM - Type 2 Diabetes mellitus; niddm; Ketosis-Resistant Diabetes Mellitus; Type 2 diabetes; Diabetes Mellitus, Slow-Onset; Diabetes Mellitus, Ketosis-Resistant; Diabetes Mellitus, Noninsulin-Dependent; NIDDM diabetes mellitus",
C0011870,Diabetes with other coma,diabetes,Diabetes with other coma,
C0011871,Diabetic peripheral angiopathy,diabetes,Diabetic peripheral vascular disease; Peripheral angiopathy due to diabetes mellitus (disorder); Diabetic peripheral angiopathy; Diabetes with peripheral circulatory disorder; Diabetic peripheral vascular disorder; Peripheral angiopathy due to diabetes mellitus; Diabetes with peripheral circulatory disorders,
C0011876,Cataract due to diabetes mellitus,diabetes,diabetic cataract; cataract diabetic; Cataract of eye due to diabetes mellitus; Cataract of eye due to diabetes mellitus (disorder); Diabetic cataract,
C0011877,Ketoacidotic coma due to diabetes mellitus,diabetes,Diabetic coma with ketoacidosis; Ketoacidotic coma due to diabetes mellitus (disorder); Diabetic acidosis with coma,
C0011878,Diabetic Diet,diabetes,"Diabetic diet; diabetic diet; Diabetes--Diet therapy; Diet, Diabetic; Diets, Diabetic; Diabetic Diet; diabetic diets; Diabetic diet (finding); diabetes mellitus diet; Diabetic Diets; DD - Diabetic diet",
C0011880,Diabetic Ketoacidosis,diabetes,"Diabetic Acidoses; KETOACIDOSIS, DIABETIC; diabetic ketosis; Diabetic keto-acidosis; Acidosis, Diabetic; Ketoacidosis due to diabetes mellitus (disorder); Ketoacidosis due to diabetes mellitus; diabetic ketoacidosis; DIABETIC ACIDOSIS; Diabetic Ketosis; DKA - diabetic ketoacidosis; Diabetic acidosis without coma; Diabetes Mellitus with Ketoacidosis; Ketoses, Diabetic; Diabetic Acidosis; Diabetic ketosis; Diabetic Ketoses; Diabetic acidosis; Ketosis, Diabetic; Diabetic ketosis without coma; DKA; diabetic ketoacidoses; diabetic acidosis; DIABETIC KETOACIDOSIS; Diabetes with ketoacidosis; Ketoacidosis in diabetes mellitus; Diabetic Ketoacidosis, DKA; DKA Diabetic Ketoacidosis; Acidoses, Diabetic; Diabetic acidosis, NOS; ACIDOSIS DIABETIC; DKA Diabetic Ketoacidoses; Diabetic Ketoacidoses; diabetic ketoses; Diabetes mellitus with ketoacidosis; ACIDOSIS, DIABETIC; Ketoacidosis, Diabetic; Diabetic Ketoacidosis; Diabetic ketoacidosis; Ketoacidoses, Diabetic; Ketoacidosis, DKA Diabetic",
C0011881,Diabetic Nephropathy,diabetes,"Kidney Diseases, Diabetic; Nephropathies, Diabetic; Nephropathy, Diabetic; Renal disorder associated with diabetes mellitus; diabetic nephropathy; Diabetic Kidney Diseases; Diabetic renal disease; Kidney disorder due to diabetes mellitus; Diabetic nephropathy; diabetic nephropathies; Diabetes with renal manifestations; nephropathy diabetic; Diabetic Nephropathy; Diabetic Nephropathies; Diabetic nephropathies; Kidney Disease, Diabetic; DIABETIC NEPHROPATHY; Disorder of kidney due to diabetes mellitus (disorder); Diabetic nephropathy syndrome; Diabetic Kidney Problems; Disorder of kidney due to diabetes mellitus; Diabetic Kidney Disease; diabetic renal disease",
C0011882,Diabetic Neuropathies,diabetes,"diabetic neuropathy; Neuropathies, Diabetic; Diabetic neuropathies; Neuropathy, diabetic; Diabetic Neuropathies; Neuropathy, Diabetic; Diabetic neuropathy; diabetic nerve damage; Diabetic Neuropathy; diabetic neuropathies; NEUROPATHY, DIABETIC; Diabetes with neurological manifestations; Diabetes mellitus with neuropathy; Neuropathy due to diabetes mellitus (disorder); DIABETIC NEUROPATHY; Neuropathy due to diabetes mellitus",
C0011884,Diabetic Retinopathy,diabetes,"Diabetic retinopathy; DIABETIC RETINOPATHY; Diabetic Retinopathies; Retinopathy, diabetic; Retinopathies, Diabetic; Retinopathy due to diabetes mellitus; Retinopathy due to diabetes mellitus (disorder); DR - Diabetic retinopathy; Diabetic retinopathy, NOS; Diabetic retinopathy NOS; Retinopathy, Diabetic; Retinal abnormality - diabetes-related; diabetic retinopathy; Diabetic Retinopathy",
C0015159,Glucose Clamping,glucose,"Euglycaemic Clamping; Euglycemic Clamping; Clamping, Glucose; Clamping, Euglycaemic; Clamping, Euglycemic",
C0017132,Gastric Inhibitory Polypeptide,glucose,"Polypeptide, Gastric-Inhibitory; Glucose Dependent Insulinotropic Peptide; GIP - Glucose dependent insulinotropic peptide; Glucose dependent insulinotropic peptide; Gastric inhibitory peptide; Glucose-Dependent Insulinotropic Peptide; Gastric-Inhibitory Polypeptide; Gastric inhibitory polypeptide (GIP); Gastric Inhibitory Polypeptide; Inhibitory Polypeptide, Gastric; Peptide, Glucose-Dependent Insulin-Releasing; Glucose dependent insulinotropic peptide (substance); Glucose-Dependent Insulin-Releasing Peptide; Glucose Dependent Insulin Releasing Peptide; GIP - Gastric inhibitory peptide; Insulin-Releasing Peptide, Glucose-Dependent; Insulinotropic Peptide, Glucose-Dependent; GIP - Gastric inhibitory polypeptide; GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE; Gastric inhibitory polypeptide (substance); Polypeptide, Gastric Inhibitory; gastric inhibitory polypeptide; gastric inhibitory peptide; gastric inhibitory polypeptide (GIP); Gastric inhibitory polypeptide; Peptide, Glucose-Dependent Insulinotropic; GIP",
C0017696,Glucans,glucose,"Glucose Polymer; glucans; Polymer, Glucose; Polyglucose; polyglucose; Glucans; Polyglucoses; glucan; Glucan; glucose polymers",
C0017713,Glucokinase,glucose,Hexokinase type IV; Glucokinase (substance); glucokinase; Glucokinase; ATP:D-glucose 6-phosphotransferase,
C0017715,Gluconeogenesis,glucose,Gluconeogenesis; gluconeogenesis; glucose biosynthetic process; glucose biosynthesis; Gluconeogenic Process,
C0017718,glucosamine,glucose,"Glucosamina; D-Glucosamine; Glucosamine (substance); glucosamine; glycosamine; Glucosamine; GLUCOSAMINE; D-Glucose, 2-amino-2-deoxy-; 2-amino-2-deoxy-D-glucose; Glucosamine-containing product; glucosamines; 2-Amino-2-Deoxyglucose; glucosamine products; Product containing glucosamine (medicinal product); 2 Amino 2 Deoxyglucose; Glycosamine; Chitosamine",
C0017723,Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing),glucose,"L-Glutamine:D-fructose-6-phosphate aminotransferase (hexose-isomerizing); Glucosaminephosphate Isomerase (Glutamine-Forming); Glucosaminephosphate Isomerase (Glutamine Forming); Glutamine-Fructose-6-P Aminotransferase; Aminotransferase, Hexosephosphate; 6-Phosphate Synthetase, Glucosamine; Hexosephosphate Aminotransferase; Glutamine-fructose-6-phosphate aminotransferase (isomerising); Glutamine Fructose 6 Phosphate Aminotransferase; 2-Amino-2-Deoxy-D-Glucose-6-Phosphate Ketol-Isomerase; Aminotransferase, Glutamine-Fructose-6-P; Glutamine-fructose-6-phosphate aminotransferase (isomerizing) (substance); Glucosamine-6-phosphate isomerase (glutamine-forming); Glutamine Fructose 6 P Aminotransferase; Hexosephosphate aminotransferase; Glucosamine Synthetase; Glucosamine-6-Phosphate Synthase; Glucosamine 6-Phosphate Synthetase; Glucosamine 6 Phosphate Synthase; Aminotransferase, Glutamine-Fructose-6-Phosphate; Glutamine:Fructose 6 Phosphate Amidotransferase; Ketol-Isomerase, 2-Amino-2-Deoxy-D-Glucose-6-Phosphate; Glucosamine 6 Phosphate Synthetase; 2 Amino 2 Deoxy D Glucose 6 Phosphate Ketol Isomerase; Glutamine:Fructose-6-Phosphate-Amidotransferase; Glutamine-Fructose-6-Phosphate Aminotransferase; Glutamine-fructose-6-phosphate aminotransferase (isomerizing)",
C0017725,glucose,glucose,"Dextrose, Unspecified Form; endocrine glucose; dextrose; Glucose-containing product; Dextrosa; Glucose (substance); D Glucose; Dextrose; DEXTROSE; glucose preparations; Dextrose, unspecified form; d-Glucose preparation; glucoses; Glucose; Glucose, NOS; GLUCOSE; D-Glucose; Glucosa; Dextrose, unspecified; D-glucopyranose monohydrate preparation; DEXTROSE, UNSPECIFIED FORM; Grape sugar; Product containing glucose (medicinal product); d-glucose; Dextrose preparation; glucose; dextrose, unspecified form; D-glucose preparation; Glucose preparation; D-glucose; D(+)-Glucose",
C0017728,Glucose Clamp Technique,glucose,"Glucose Clamp Techniques; Technique, Glucose Clamp; Glucose Clamp Technic; glucose clamp technique; Technics, Glucose Clamp; Glucose Clamp Technics; Technic, Glucose Clamp; Techniques, Glucose Clamp",
C0017730,Glucose Dehydrogenases,glucose,"Glucose Oxidoreductases; Oxidoreductases, Glucose; Dehydrogenases, Glucose; glucose dehydrogenase; Glucose Dehydrogenases",
C0017734,dextrose monohydrate,glucose,"Monohydrate, Glucose; Dextrose Monohydrate; dextrose monohydrate; Glucose Monohydrate; Dextrose monohydrate; Glucose monohydrate (substance); DEXTROSE MONOHYDRATE; Glucose monohydrate",
C0017735,glucose oxidase,glucose,"Glucose oxidase; beta-D-glucose:quinone Oxidoreductase; Microcid; Glucose oxidase (substance); Oxidase, Glucose; Glucose oxyhydrase; beta-D-Glucose:oxygen 1-oxidoreductase; Penatin; Corylophyline; GLUCOSE OXIDASE; glucose oxidase; Glucose Oxidase",
C0017739,Sodium-Glucose Transport Proteins,glucose,"Glucose Cotransporter, Sodium; Sodium-Glucose Transport Protein; SGLT Protein; Sodium Glucose Transport Proteins; Sodium Glucose Cotransporters; Glucose Sodium Transport System; SGLT Proteins; Glucose-Sodium Transport System; Sodium Glucose Cotransporter; Glucose Transporter, Sodium; Sodium Glucose Transport Protein; Transporter, Sodium Glucose; Sodium-Glucose Transport System; Sodium Glucose Transport System; Glucose Cotransporters, Sodium; Protein, Sodium-Glucose Transport; Cotransporter, Sodium Glucose; Transport Protein, Sodium-Glucose; Glucose Transporters, Sodium; Sodium Glucose Transporters; Protein, SGLT; Sodium Glucose Transporter",
C0017740,"Glucose Solution, Hypertonic",glucose,"Hypertonic Solutions, Glucose; Hypertonic Glucose Solutions; Solution, Hypertonic Glucose; hypertonic glucose solution; Glucose Hypertonic Solutions; Solutions, Hypertonic Glucose; Hypertonic Solution, Glucose; Solution, Glucose Hypertonic; Solutions, Glucose Hypertonic; Glucose Solutions, Hypertonic; Glucose Hypertonic Solution; Hypertonic Glucose Solution",
C0017741,Glucose tolerance test,glucose,"OGTT - Oral glucose tolerance test; glucose procedure testing tolerance; glucose challenge test; Glucose challenge test; glucose tolerance tests; GTT - Glucose tolerance test; Glucose tolerance test (procedure); Glucose tolerance test, NOS; challenge glucose testing; glucose tests tolerance; glucose tolerance test; Glucose Tolerance Test; Glucose tolerance tests; gtts; Glucose tolerance test; gtt; glucose test tolerance; glucose testing tolerance; Glucose Tolerance Tests",
C0017742,Glucose Transporter,glucose,"glucose transporter; Glucose Transporter; Glucose Transport Facilitators; Glucose Transport Protein; Glucose Transport Proteins, Facilitative; SLC2A Proteins; protein bound glucose; glucose transport protein; GLUT Proteins",
C0017743,Glucose Transport-Inducing Protein,glucose,"Glucose Transport Inducing Protein; Transport-Inducing Protein, Glucose",
C0017745,Abnormal presence of glucose,glucose,"Glucose, abnormal presence; Abnormal presence of glucose; Abnormal presence of glucose (finding)",
C0017746,Decreased glucose level,glucose level,"Decreased glucose level (finding); Glucose, decreased level; Decreased glucose level",
C0017747,Increased glucose level,glucose level,"Glucose, increased level; Increased glucose level (finding); increased glucose level; glucose increasing level; Increased glucose level",
C0017755,GLUCOSE-6-PHOSPHATASE,glucose,glucose 6 phosphatase; Glucose-6-phosphatase (substance); 6 glucose phosphatase; glucose-6-phosphatase; glucose 6-phosphatase; Glucose 6 Phosphatase; Glucose-6-phosphatase; 6-phosphatase glucose; Glucose 6-Phosphatase; Glucose-6-Phosphatase; Glucose-6-Phosphate Phosphohydrolase; D-Glucose-6-phosphate phosphohydrolase,
C0017757,Glucosephosphate Dehydrogenase,glucose,"g-6pd; Glucose 6 Phosphate Dehydrogenase; Glucose-6-Phosphate Dehydrogenase; Dehydrogenase, Glucose-6-Phosphate; Glucose-6-Phosphate dehydrogenase; Glucosephosphate dehydrogenase; G6P - Glucose-6-phosphate dehydrogenase; glucose-6-phosphate dehydrogenase (G6PD); glucosephosphate dehydrogenase; Glucosephosphate Dehydrogenase; G6PD; Dehydrogenase, Glucosephosphate; g6pd; G6PD - Glucose-6-phosphate dehydrogenase; D-Glucose-6-phosphate:NADP+ 1-oxidoreductase; Glucose-6-phosphate dehydrogenase (G-6PD); glucose 6 phosphate dehydrogenase; Glucose-6-phosphate dehydrogenase (substance); G-6PD; Glucose-6-phosphate dehydrogenase; GLUCOSE 6 PHOSPHATE DEHYDROGENASE",
C0017759,Glucosephosphate Isomerase,glucose,"Glucose phosphate isomerase; phosphoglucoisomerase; GPI; Glucose-6-phosphate isomerase; Sperm Antigen 36; Isomerase, Phosphohexose; Phosphoglucoisomerase; Hexose phosphate isomerase; Hexose Monophosphate Isomerase; D-Glucose-6-Phosphate Ketol-Isomerase; Glucose-6-Phosphate Isomerase; Isomerase, Glucose 6 Phosphate; Glucose 6 Phosphate Isomerase; Hexosephosphate Isomerase; Isomerase, Glucosephosphate; glucose 6 phosphate isomerase; Glucosephosphate Isomerase; Hexosephosphate isomerase; Phoshoglucoisomerase; Phosphoglucose Isomerase; Isomerase, Phosphoglucose; phosphohexomutase; phosphohexoisomerase; hexosephosphate isomerase; Phosphohexose isomerase; Phosphohexomutase; phosphohexose isomerase; glucose phosphate isomerase; oxoisomerase; Isomerase, Glucose-6-Phosphate; glucose-6-phosphate isomerase; phosphosaccharomutase; D-Glucose-6-phosphate ketol-isomerase; Glucose-6-phosphate isomerase (substance); Phosphohexose Isomerase; Oxoisomerase; Phosphosaccharomutase",
C0017760,UTP-Glucose-1-Phosphate Uridylyltransferase,glucose,"Glucosephosphate Uridylyltransferase; UTP-glucose-1-phosphate uridylyltransferase; Uridine triphosphate-glucose-1-phosphate uridylyltransferase (substance); UDP Glucose Pyrophosphorylase; UTP Glucose 1 Phosphate Uridylyltransferase; Uridylyltransferase, UTP-Glucose-1-Phosphate; Uridylyltransferase, Glucosephosphate; UTP glucose 1 phosphate uridylyltransferase; UDPG Pyrophosphorylase; UTP:alpha-D-glucose-1-phosphate uridylyltransferase; UTP-Glucose-1-Phosphate Uridylyltransferase; Pyrophosphorylase, UDP Glucose; Pyrophosphorylase, UDPG; Uridine triphosphate-glucose-1-phosphate uridylyltransferase; UDPglucose pyrophosphorylase; Glucose-1-phosphate uridylyltransferase; Uridine triphosphate (UTP)-glucose-1-phosphate uridylyltransferase; Uridine diphosphate glucose pyrophosphorylase",
C0017761,Glucosephosphates,glucose,glucose phosphate; glucosephosphate,
C0017920,Glycogen Storage Disease Type I,glucose,"Von Gierke disease; Disease, von Gierke's; Gierke Disease; Glycogen Storage Disease 1 (GSD I); Glycogen storage disease due to glucose-6-phosphatase deficiency; von Gierke disease; von Gierkes Disease; Disease, Gierke; Deficiency, Glucosephosphatase; Hepatorenal glycogen storage disease; Hepatorenal Glycogen Storage Disease; von gierkes disease; glycogenosis type i; gierke's disease; GLYCOGENOSIS, TYPE I; type i glycogen storage disease; Deficiencies, Glucosephosphatase; von gierke's disease; von Gierke Disease; glycogen storage disease i; Glucosephosphatase Deficiencies; Glycogen storage disease type 1; glycogen storage disease type i; Gierke's Disease; Deficiency of glucose-6-phosphatase; Glycogenosis 1; Disease, Gierke's; Glycogen storage disease due to G6P deficiency; von gierke disease; Von Gierke's disease; Glycogenosis type I; Hepatorenal glycogenosis; glycogenosis type I; Glycogen storage disease, type 1; G6P deficiency; GLUCOSE 6 PHOSPHATASE DEFICIENCY; Glycogenosis type 1; Glucose 6 Phosphatase Deficiency; hepatorenal glycogen storage disease; disease glycogen i storage type; GLYCOGENOSIS, HEPATORENAL; Glucose-6-Phosphatase Deficiencies; GSD type I; Glycogen storage disease, type I; von Gierke's Disease; Glucose-6-phosphatase deficiency; diseases gierke's von; Glycogen Storage Disease Type I; Deficiency of glucose-6-phosphatase (disorder); GLYCOGEN STORAGE DISEASE TYPE I; Glycogen storage disease, type I (disorder); Deficiencies, Glucose-6-Phosphatase; Glucosephosphatase Deficiency; GSD due to G6P deficiency; GSD I; Liver glycogen disease; Glycogen storage disease type I; glucose 6 phosphatase deficiency; Disease, von Gierke; i glycogen storage disease; Deficiency, Glucose-6-Phosphatase; Gierkes Disease; VON GIERKE DISEASE; glycogen storage disease type I; HEPATORENAL GLYCOGENOSIS; hepatorenal glycogenosis; von Gierke's disease; glucose-6-phosphatase deficiency; GSD type 1; Glucose-6-Phosphatase Deficiency",
C0017932,Glycogen (Starch) Synthase,glucose,"Glycogen (starch) synthase; Glycogen synthetase; UDPglucose-glycogen glucosyltransferase; Synthetase, Glycogen; UDPglucose:glycogen 4-alpha-D-glucosyltransferase; UDP-Glucose Glycogen Glucosyl Transferase; glycogen synthase; Glycogen (starch) synthase (substance); Glycogen (Starch) Synthase; Synthase, Glycogen; Glycogen Synthetase; Glycogen synthase; UDP Glucose Glycogen Glucosyl Transferase; Glycogen Synthase",
C0017979,Glycosuria,glucose,SUGAR URINARY; Glucose in urine; sugar in urine; urine glucose; SUGAR URINARY PRESENT; sugar urine; glycosuria; URINE GLUCOSE; Glycosuria; GLUCOSURIA; sugar urinary; sugars urine; urine sugar; Glycosuria (finding); glucosuria; urinary sugar; Glucosuria; GLYCOSURIA,
C0017980,"Glycosuria, Renal",diabetes,"renal diabetes; renal glucosuria; renal glycosuria; RENAL GLYCOSURIA; Renal glycosuria, NOS; Renal glucosuria, NOS; diabetes renal; GLYCOSURIA, RENAL; Renal glycosuria (disorder); Renal glucosuria; Renal diabetes; GLYCOSURIA RENAL; Renal glycosuria",
C0018995,Hemochromatosis,diabetes,"bronzed diabetes; IRON STORAGE DISEASE; Pigmentary Cirrhoses; Cirrhoses, Pigmentary; Cirrhosis, Bronzed; Bronzed diabetes; HAEMOCHROMATOSIS; Syndromes, Troisier-Hanot-Chauffard; Cirrhoses, Bronzed; Recklenhausen-Applebaum Diseases, Von; Hemochromatosis; Iron storage disease, NOS; Storage Disorder, Iron; Von Recklenhausen Applebaum Disease; Iron Storage Disorder; Disorder, Iron Storage; Troisier-Hanot-Chauffard Syndrome; Bronze diabetes (disorder); Hemochromatoses; hemochromatoses; Recklenhausen-Applebaum Disease, Von; Bronze Diabetes; haemochromatosis; Iron storage disease; Hemochromatosis (disorder); iron storage disease; Disorders, Iron Storage; iron storage disorder; Iron overload disease; Troisier Hanot Chauffard Syndrome; Hemosiderosis; Disease, Von Recklenhausen-Applebaum; iron accumulation disorders; Hemochromatose; Storage Disorders, Iron; Hematochromatosis; DIABETES, BRONZE; Troisier-Hanot-Chauffard Syndromes; Haemochromatosis; Bronzed Cirrhosis; TROISIER-HANOT-CHAUFFARD SYNDROME; bronze diabetes; Diabetes, Bronze; hemochromatosis; Rare hereditary hemochromatosis; Bronzed Cirrhoses; diabetes bronze; Von Recklenhausen-Applebaum Diseases; disorders iron storage; Bronze diabetes; Von Recklenhausen-Applebaum Disease; Cirrhosis, Pigmentary; HEMOCHROMATOSIS; Hemochromatosis NOS; von Recklinghausen-Appelbaum disease; Iron Storage Disorders; Iron Overload Disease; Hemochromatosis, NOS; Pigmentary Cirrhosis; Haemochromatoses; Diseases, Von Recklenhausen-Applebaum; Syndrome, Troisier-Hanot-Chauffard",
C0019018,Glycosylated hemoglobin A,a1c,"HbA1; hba1c; haemoglobin a1c; Hemoglobin A, Glycosylated; Glycosylated haemoglobin A; glycosylated hemoglobin a; Glycohemoglobin A; Hemoglobin A(1); hba1; hemoglobin a1c; Hb A1a+b; HbA1c; Hb A1; Glycated Hemoglobin A; Hemoglobin A1c; Glycosylated hemoglobin A; Hemoglobin A, Glycated; Glycosylated Hemoglobin A; hemoglobin a 1; Hb A1c; hb a1",
C0019472,HEXOKINASE,glucose,Hexokinase type IV; HK - Hexokinase; hexokinase IV; Hexokinase; ATP-Dependent Hexokinase; Hexokinase (substance); ATP:D-hexose 6-phosphotransferase; ATP:D-Hexose 6-Phosphotransferase; HK; Hexokinase D; hexokinase D; Glucose ATP Phosphotransferase; hexokinase,
C0019492,UDPglucose-Hexose-1-Phosphate Uridylyltransferase,glucose,"Transferase, Phosphogalactose Uridyl; Galactose 1 P Uridyltransferase; UDPglucose-hexose-1-phosphate uridylyltransferase; Phosphogalactose Uridyl Transferase; Uridine diphosphate (UDP) glucose-hexose-1-phosphate uridylyltransferase; Uridylyltransferase, Hexosephosphate; Uridylyltransferase, UDPglucose-Hexose-1-Phosphate; Uridyl transferase; Uridine diphosphate glucose-hexose-1-phosphate uridylyltransferase (substance); UDPglucose-Hexose-1-Phosphate Uridylyltransferase; Hexose-1-phosphate uridylyltransferase; Transferase, Uridyl; Galactose-1-P-Uridyltransferase; Uridine diphosphate glucose-hexose-1-phosphate uridylyltransferase; UTP hexose 1 phosphate uridylyltransferase; UDPglucose:alpha-D-galactose-1-phosphate uridylyltransferase; Hexosephosphate Uridylyltransferase; Uridine diphosphate galactose transferase; Uridyl Transferase, Phosphogalactose; Uridyl Transferase",
C0020445,"Hypercholesterolemia, Familial",hyper,"familial hypercholesterolemia; FAMILIAL HYPERBETALIPOPROTEINEMIA; Type II Hyperlipoproteinemia; Hyperbetalipoproteinemia (disorder); hyperlipidemia type ii; Hyperlipoproteinemia Type IIs; Type II Hyperlipoproteinemias; Familial hyperbetalipoproteinaemia; Xanthomatosis, Familial Hypercholesterolemic; Hypercholesterolemia, Essential; familial hypercholesteremia; Type II Hyperlipidemia; Hyper-Low Density Lipoproteinemia; Hyper-beta-Lipoproteinemias; Familial hypercholesterolemia (disorder); Essential Hypercholesterolemias; HYPERLIPIDEMIA TYPE II; Hypercholesterolemia, Familial; Essential Hypercholesterolemia; HYPERBETALIPOPROTEINEMIA; Familial Hypercholesterolemia; Low density lipoprotein catabolic defect; Hyperlipoproteinemia Type 2; Hyper-beta-Lipoproteinemia; HYPERLIPOPROTEINEMIA TYPE II; Familial Hypercholesterolemias; familial hyperlipoproteinemia type II; Familial hypercholesterolemia; HYPERLIPOPROTEINEMIA, TYPE II; HYPERCHOLESTEROLEMIA, ESSENTIAL FAMILIAL; Hypercholesterolemias, Familial; FAMILIAL HYPERCHOLESTEROLEMIA; Essential familial hypercholesterolaemia; Density Lipoproteinemias, Hyper-Low; Familial Hypercholesterolemic Xanthomatoses; ESSENTIAL FAMILIAL HYPERCHOLESTEROLEMIA; familial hypercholesterolaemia; Hyperlipoproteinemias, Type II; Familial hyperbetalipoproteinemia; Hyperlipoproteinemia, Type II; Hypercholesterolemic Xanthomatoses, Familial; Hyper-Low-Density-Lipoproteinemias; Hyper-Low-Density-Lipoproteinemia; Lipoproteinemia, Hyper-Low Density; Hyperbetalipoproteinemias; hyperbetalipoproteinemia; Lipoproteinemias, Hyper-Low Density; Hypercholesterolemic Xanthomatosis, Familial; type ii hyperlipoproteinemia; Hyper-Low Density Lipoproteinemias; Hyperlipoproteinemia Type 2s; Hyperbetalipoproteinaemia; Familial hypercholesterolaemia; Hyperbetalipoproteinemia; Hypercholesterolemias, Essential; Hyperlipoproteinemia Type II; Density Lipoproteinemia, Hyper-Low; Hyper beta Lipoproteinemia; Hyper Low Density Lipoproteinemia; familial hyperbetalipoproteinemia; Type 2, Hyperlipoproteinemia; LDL - Low density lipoprotein receptor disorder; Familial Hypercholesterolemic Xanthomatosis; Xanthomatoses, Familial Hypercholesterolemic; LDL receptor disorder; Essential familial hypercholesterolemia",
C0020456,Hyperglycemia,blood sugar,"High blood glucose; Hyperglycaemic disorder; High Blood Sugar; High Blood Glucose; elevated blood sugar; hyperglycemia; Hyperglycemia, NOS; Hyperglycaemia; high blood sugar level; elevated glucose; Hyperglycemic disorder; Hyperglycemia (disorder); Hyperglycemia; HYPERGLYCEMIA; Hyperglycemia NOS; hyperglycaemia; Hyperglycaemia, NOS; High blood sugar; HYPERGLYCAEMIA; Hyperglycemias; Hyperglycemic disorder (disorder)",
C0020457,Hyperglycemic Hyperosmolar Nonketotic Coma,diabetes,"Coma, Hyperglycemic Hyperosmolar Nonketotic; Coma, Nonketotic Hyperosmolar; Diabetes with hyperosmolar coma; hyperosmolar nonketotic coma; hhnc; Nonketotic Hyperosmolar Coma; HYPEROSMOLAR COMA; Coma, Nonketotic Hyperglycemic; Nonketotic Comas, Hyperosmolar; nkhhc; Hyperosmolar Coma, Nonketotic; NON-KETOTIC HYPEROSMOLAR COMA; Hyperosmolar nonketotic coma; Coma, Hyperosmolar Nonketotic; Nonketotic Hyperosmolar Comas; Hyperosmolar nonketotic coma in diabetes; diabetic hyperosmolar coma; Nonketotic Hyperglycemic Coma; Hyperosmolar Nonketotic Coma; Comas, Nonketotic Hyperosmolar; Comas, Hyperosmolar Nonketotic; Hyperosmolar Comas, Nonketotic; Hyperosmolar coma; Hyperosmolar Nonketotic Comas; Hyperosmolar Hyperglycemic Nonketotic Coma; nonketotic hyperosmolar coma; Nonketotic Coma, Hyperosmolar; hyperosmolar coma; hyperosmolar non-ketotic coma; coma hyperosmolar; Hyperglycemic Coma, Nonketotic",
C0020480,Hyperlipoproteinemia Type IV,hyper,"Hyperlipemia, Carbohydrate Inducible; VLDL hyperlipoproteinemia; Pure hyperglyceridemia; Hyperlipemia, Carbohydrate-Inducible; Hypertriglyceridemia, essential; Hyper prebeta lipoproteinemia; Carbohydrate Inducible Hyperlipemia; Pure hyperglyceridemia (disorder); endogenous hyperlipidemia; Fredrickson type IV hyperlipoproteinemia; familial hyperprebetalipoproteinemia; Hyperlipidemia, Group B; Hyperlipoproteinemia, Type IV; Inducible Hyperlipemia, Carbohydrate; familial hypertriglyceridaemia; Fredrickson type IV hyperlipoproteinaemia; Fredrickson type IV lipidaemia; Familial Hyperlipoproteinemia Type 4; Carbohydrate induced hyperlipoproteinemia; Familial hypertriglyceridemia (disorder); Endogenous hyperglyceridemia; Type IV, Hyperlipoproteinemia; Hyperlipoproteinemia, Frederickson type IV; endogenous hyperglyceridemia; type iv hyperlipidemia; HYPERLIPOPROTEINEMIA TYPE IV; Fredrickson Type IV Lipidemia; Type IV Hyperlipoproteinemias; Fredrickson Type IV hyperlipoproteinemia; Endogenous hyperlipidemia; HYPERPREBETALIPOPROTEINEMIA; Very-low-density-lipoid-type hyperlipoproteinemia; Carbohydrate Inducible Hyperlipemias; Fredrickson type IV lipidemia; Type IV Hyperlipoproteinemia; Familial Hypertriglyceridemia; CARBOHYDRATE-INDUCIBLE HYPERLIPEMIA; Hyperlipemias, Carbohydrate Inducible; familial hypertriglyceridemia; Pure hyperglyceridaemia; Familial hypertriglyceridaemia; Hyperlipoproteinemia Type IV; Carbohydrate-Inducible Hyperlipemia; Fredrickson type IV hyperlipoproteinemia (disorder); Endogenous hyperlipemia; Inducible Hyperlipemias, Carbohydrate; HYPERLIPOPROTEINEMIA, TYPE IV; HYPERLIPIDEMIA TYPE IV; familial hyperlipoproteinemia type IV; Familial hypertriglyceridemia; Endogenous hyperlipidemia (disorder); Hyperprebetalipoproteinemia; Endogenous hyperlipaemia; Hyperlipemias, Carbohydrate-Inducible; type iv hyperlipoproteinemia; hyperlipidemia type iv; Familial Type IV Hyperlipoproteinemia; Endogenous hyperlipidaemia; Carbohydrate-Inducible Hyperlipemias; Hypertriglyceridemia, Familial; Hyperlipoproteinemias, Type IV",
C0020597,Hypobetalipoproteinemias,hypo,Hypo beta Lipoproteinemia; Hypo-beta-lipoproteinemia; Hypo beta Lipoproteinemias; Familial Hypobetalipoproteinemia; Hypobetalipoproteinemias; hypobetalipoproteinemia; Hypo-beta-lipoproteinemia (disorder); Hypobetalipoproteinemia; Hypo-beta-lipoproteinaemia,
C0020615,Hypoglycemia,blood sugar,"Hypoglycemic syndrome, NOS; Hypoglycaemia, NOS; HYPOGLYCEMIA; Hypoglycemic syndrome; Hypoglycemia (disorder); Hypoglycaemic disorder; hypoglycaemia; Hypoglycemic disorder; low blood sugar level; Low Blood Sugar; Hypoglycemia; Low blood sugar; hypoglycemia nos; Hypoglycaemic syndrome, NOS; Hypoglycaemia; Hypoglycemia, NOS; Hypoglycemic disorder (disorder); Hypoglycemia, unspecified; HYPOGLYCAEMIA; Hypoglycemia NOS; Hypoglycemic syndrome (disorder); hypoglycemia; Hypoglycaemic syndrome",
C0020616,Hypoglycemic Agents,diabetes,"Hypoglycemic drug, NOS; Diabetes Medicines; Hypoglycaemic agent; hypoglycemic drugs; Agent, Antihyperglycemic; Antihyperglycemics; Drugs, Hypoglycemic; Hypoglycaemic drug, NOS; Anti-hyperglycemics; Antihyperglycemic; Hypoglycemic agent (product); hypoglycaemic; Hypoglycemic; Antihyperglycemic Agent; Agents, Antihyperglycemic; Hypoglycemic product; hypoglycemic drug; Hypoglycemic agent; Hypoglycemic drug; Hypoglycemics; Hypoglycemic agents; hypoglycemic agent; hypoglycemic agents; Hypoglycemic Drug; Hypoglycemic Agent; Hypoglycaemic product; Drug, Hypoglycemic; Hypoglycemic Medicines; Hypoglycemic Drugs; Antihyperglycemic Agents; antihyperglycemic; Agent, Hypoglycemic; hypoglycemic; Agents, Hypoglycemic",
C0020617,Hypoglycemic coma,blood sugar,"Coma due to hypoglycaemia; Coma, hypoglycemic; Coma due to hypoglycemia; Loss of consciousness due to hypoglycemia; Coma associated with hypoglycemia; hypoglycaemic coma; COMA HYPOGLYCAEMIC; Coma due to hypoglycemia (disorder); Coma caused by low blood sugar; hypoglycemic coma; Hypoglycaemic coma; Hypoglycemic coma; Hypoglycemic Coma; COMA HYPOGLYCEMIC",
C0020645,Hyposmolality and/or hyponatremia,hypo,Hypo-osmolality and or hyponatremia (disorder); Hypo-osmolality and or hyponatraemia; Hyposmolality and/or hyponatremia; Hypo-osmolality and or hyponatremia,
C0021911,Intravenous Glucose Tolerance Test,glucose,Intravenous Glucose Tolerance; Intravenous glucose tolerance test,
C0022200,Isomaltose,glucose,"isomaltose; D-Glucose, 6-O-alpha-D-glucopyranosyl-",
C0022840,"Glucose, (L)-Isomer",glucose,L-Glucose; L-glucose; L Glucose; l-glucose; L(-)-Glucose; L-glucose (substance),
C0022949,lactose,glucose,"Product containing lactose (medicinal product); LACTOSE, UNSPECIFIED FORM; Lactose, Unspecified form; Lactose; Lactose (substance); lactose; Lactose-containing product; D-Glucose, 4-O-beta-D-galactopyranosyl-; lactose, unspecified form; LACTOSE; Lactose, Unspecified Form; Milk sugar",
C0022952,Lactose Synthase,glucose,"Synthase, Lactose; Synthetase, Lactose; Lactose Synthetase; Lactose synthase; UDPgalactose-glucose galactosyltransferase; lactose synthase; Lactose Synthase; Lactose synthase (substance); UDPgalactose:D-glucose 4-beta-D-galactosyltransferase",
C0024658,maltose,glucose,"D-Glucose, 4-O-alpha-D-glucopyranosyl-; MALTOSE, UNSPECIFIED FORM; MALTOSE; maltose; maltoses; Maltose, Unspecified Form; Maltose; Maltose (substance)",
C0025228,Melibiose,glucose,"D-Glucose, 6-O-alpha-D-galactopyranosyl-",
C0025869,metrizamide,glucose,"Metrizamide (substance); METRIZAMIDE; Product containing metrizamide (medicinal product); metrizamide; D-Glucose, 2-((3-(acetylamino)-5-(acetylmethylamino)-2,4,6-triiodobenzoyl)amino)-2-deoxy-; Metrizamide-containing product; Metrizamide",
C0029161,Oral Glucose Tolerance Test,glucose,"ogtt; Oral Glucose Tolerance; OGTT; oral glucose tolerance; Glucose Tolerance, Oral; oral glucose tolerance test; glucose oral testing tolerance",
C0031653,PHOSPHOGLUCOMUTASE,glucose,"Phosphoglucomutase; PGM; glucose phosphomutase; phosphoglucomutase; EC 5.4.2.2; alpha-D-Glucose 1,6-phosphomutase; Phosphomutase, Glucose; Alpha-D-Glucose 1,6-Phosphomutase; Glucose phosphomutase; Glucose Phosphomutase; Phosphoglucomutase (substance); Phosphoglucose Mutase",
C0032969,Pregnancy in Diabetics,diabetes,"diabetes in pregnancy; Pregnancy in Diabete; in diabetic pregnancy; pregnancy diabetes; Diabetes mellitus, antepartum; pregnancy in diabetes; diabetics in pregnancy; DIABETES MELLITUS, IN PREGNANCY; diabetes mellitus pregnancy; diabetic in pregnancy; Pregnancy in Diabetes; Diabetes in pregnancy; pregnancy diabetes mellitus; Pregnancy in Diabetics; Diabetes mellitus of mother, complicating pregnancy, childbirth, or the puerperium, antepartum condition or complication; pregnancy diabetic; diabetics pregnancy; diabetic pregnancies; Pregnancy and Diabetes; diabetic pregnancy; diabetes pregnancy; Pregnancy in Diabetic",
C0035228,Respiratory Hypersensitivity,hyper,"respiratory hypersensitivity; Hyper-Responsiveness, Airway; Hyperresponsiveness, Airway; Airway Hyperresponsivenesses; Airway Hyper-Responsiveness; Respiratory Hypersensitivities; Airway Hyper Responsiveness; Airway Hyperresponsiveness; Hypersensitivity, Respiratory; Airway hyperresponsiveness",
C0038180,Starch (Bacterial Glycogen) Synthase,glucose,"Synthase, Granule-Bound Starch; Starch (Bacterial Glycogen) Synthase; Starch (bacterial glycogen) synthase; Starch Synthase, Granule-Bound; GBSS; ADPglucose-starch glucosyltransferase; starch synthase; Starch (bacterial glycogen) synthase (substance); Synthase, Starch; Starch Synthase; Granule-Bound Starch Synthase; ADP Glucose Starch Glucosyltransferase; ADPglucose:1,4-alpha-D-glucan 4-alpha-D-glucosyltransferase; Granule Bound Starch Synthase",
C0038432,streptozocin,glucose,"2-Deoxy-2-((methylnitrosoamino)carbonyl)amino-D-glucose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; Streptozocin-containing product; 2-deoxy-2-[[(methylnitrosamino)-carbonyl]amino]-D-glucopyranose; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-; Streptozotocin; SZN; Streptozocinum; N-D-Glucosyl-(2)-N'-nitrosomethylurea; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; Estreptozocina; STZ; Streptozocine; 2-deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; Streptozotocine; streptozocin; Streptozocinium; STREPTOZOCIN; SZC; stz; Streptozocin; streptozotocin; Streptozocin (substance); Product containing streptozocin (medicinal product)",
C0038433,Streptozotocin Diabetes,diabetes,"Streptozocin Diabete; Diabete, Streptozocin; Diabetes, Streptozocin; Streptozocin Diabetes; Diabetes, Streptozotocin",
C0041988,Uridine Diphosphate Glucose,glucose,"Uridine Diphosphate Glucose; Diphosphate Glucose, Uridine; uridine diphosphate glucose; Glucose, UDP; UDP Glucose; Uridine Diphosphoglucose; UDPG; UDP - Uridyl diphosphate glucose; Uridyl diphosphate glucose; Glucose, Uridine Diphosphate; Uridine diphosphate glucose; Uridine 5'-(trihydrogen diphosphate), P'-alpha-D-glucopyranosyl ester; Diphosphoglucose, Uridine; Uridine diphosphate glucose (substance); UDP glucose",
C0041989,Uridine Diphosphate Glucose Dehydrogenase,glucose,"UDP glucose dehydrogenase; Uridine diphosphate (UDP) glucose dehydrogenase; UDPglucose:NAD+ 6-oxidoreductase; UDP Glucose Dehydrogenase; Glucose Dehydrogenase, UDP; UDPglucose dehydrogenase; Uridine diphosphate glucose dehydrogenase; Uridine diphosphate glucose dehydrogenase (substance); uridine diphosphate glucose dehydrogenase; Dehydrogenase, UDPG; Dehydrogenase, UDP Glucose; UDPG Dehydrogenase",
C0041990,UDP-Glucose 4-Epimerase,glucose,"Uridyl diphosphate glucose-4-epimerase (substance); Uridine diphosphate galactose-4-epimerase; UDPglucose 4-epimerase; Uridyl diphosphate glucose-4-epimerase; Uridine diphosphate glucose 4-epimerase (substance); 4-Epimerase, UDP-Glucose; UDP Galactose Epimerase; UDPgalactose 4-Epimerase; 4-Epimerase, UDP-Galactose; 4-Epimerase, UDPgalactose; UDPgalactose 4 Epimerase; Uridine diphosphate glucose 4-epimerase; Uridine Diphosphate Glucose Epimerase; Epimerase, UDP Glucose; UDP-Galactose 4-Epimerase; 4-Epimerase, UDPglucose; Epimerase, UDP Galactose; UDP galactose 4 epimerase; UDP-Glucose 4-Epimerase; Glucose Epimerase, UDP; Uridyl diphosphate galactose-4-epimerase; UDP Galactose 4 Epimerase; UDPglucose 4 Epimerase; UDP Glucose 4 Epimerase; UDP Glucose Epimerase; UDP - Uridyl diphosphate glucose-4-epimerase; Galactose Epimerase, UDP; Uridine diphosphate glucose-4-Epimerase; UDPgalactose 4-epimerase; UDPglucose 4-Epimerase; Uridine diphosphate (UDP) glucose 4-epimerase",
C0043207,Wolfram Syndrome,diabetes,"DIABETES INSIPIDUS AND MELLITUS WITH OPTIC ATROPHY AND DEAFNESS; diabetes insipidus and mellitus with optic atrophy and deafness (DIDMOAD); Wolfram Syndrome; Marquardt-Loriaux syndrome; Wolfram syndrome; Diabetes insipidus, diabetes mellitus, optic atrophy and deafness; diabetes insipidus-diabetes mellitus-optic atrophy syndrome; diabetes insipidus and mellitus with optic atrophy and deafness; didmoad syndrome; DIDMOADUD; WFS; DIDMOAD syndrome; diabetes insipidus-diabetes mellitus-optic atrophy (DIDMO) syndrome; Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness; Diabetes mellitus and insipidus with optic atrophy and deafness; Diabetes mellitus AND insipidus with optic atrophy AND deafness; DIDMOAD; didmoad; Diabetes insipidus-diabetes mellitus-optic atrophy-hearing loss syndrome; wolfram syndrome; Syndrome, Wolfram; DIDMOAD - Diabetes insipidus, diabetes mellitus, optic atrophy and deafness; Diabetes mellitus AND insipidus with optic atrophy AND deafness (disorder); DIDMOAD Syndrome; Diabetes Insipidus and Mellitus with Optic Atrophy and Deafness; Diabetes insipidus-diabetes mellitus-optic atrophy-deafness syndrome",
C0043771,"1,2-5,6-di-O-isopropylidene-D-glucofuranose",glucose,diacetone glucose,
C0043897,"1,3-beta-Glucan synthase",glucose,"1,3-beta-Glucan synthase; UDP glucose beta(1--3)glucan-beta-3-glucosyltransferase; 1,3-beta-D-Glucan-UDP glucosyltransferase; UDPglucose-1,3-beta-D-glucan glucosyltransferase; Callose synthetase; callose synthase; 1,3-beta-glucan synthase (substance); 1,3-beta-glucan synthase; 1,3-beta-D-glucan-UDP glucosyltransferase",
C0044029,"1,5-Anhydrosorbitol",glucose,"1,5-anhydro-D-sorbitol; 1-deoxy-D-glucose; 1,5-anhydro-D-glucitol; 1,5-anhydrosorbitol; 1,5-anhydrosorbitol (substance); 1-deoxyglucose; 1,5-Anhydroglucitol; 1,5-anhydroglucitol; polygalitol; aceritol; D-glucitol, 1,5-anhydro-; 1,5-sorbitan; D-glucose, 1-deoxy-; 1-deoxy-D-glucopyranose",
C0044786,12-(4-azido-2-nitrophenoxy)stearoylglucosamine,glucose,"D-Glucose-1-14C, 2-((12-(4-azido-2-nitrophenoxy)-1-oxooctadecyl)amino)-2-deoxy-",
C0045319,"2,3,4,5,6-pentagalloylglucose",glucose,"D-Glucose, 2,3,4,5,6-pentakis(3,4,5-trihydroxybenzoate); 3-O-digalloyl-1,2,6-trigalloylglucose",
C0045352,"2,3-diamino-2,3-dideoxyglucose",glucose,"2,3-dideoxy-2,3-diamino-D-glucose; D-Glucose, 2,3-diamino-2,3-dideoxy-; 2,3-diamino-2,3-dideoxy-D-glucose; 2,3-DADOG",
C0046056,fluorodeoxyglucose F18,glucose,"fluorodeoxyglucose; 18 FDG; Fluorine 18 fluorodeoxyglucose; (18F)-FDG; 18fdg; 2-F18-Fluoro-2-deoxy-D-glucose; fdg 18; fluorodeoxyglucose F18; Fluorodeoxyglucose F 18; F18, Fluorodeoxyglucose; fludeoxyglucose (18F); 2-F18-fluoro-2-deoxy-D-glucose; Fludeoxyglucose F18; fludeoxyglucose F 18; Fludeoxyglucose, F-18; Fluorodeoxyglucose F18; 2-Deoxy-2-(18F)Fluoro-D-Glucose; Fluorodeoxyglucose (18-F); FLUDEOXYGLUCOSE F 18; 2-F18-fluoro-2-deoxyglucose; Fluorodeoxyglucose, 18F; Fludeoxyglucose F-18; 18FDG; F 18, Fludeoxyglucose; 18F Fluorodeoxyglucose; Fludeoxyglucose (18F); fluorodeoxyglucose F 18; Fluorine (18F) fludeoxyglucose; Fluorine-18-fluorodeoxyglucose; 18f-fdg; FDG; fludeoxyglucose F-18; FLUDEOXYGLUCOSE F-18; F 18, Fluorodeoxyglucose; Fluorodeoxyglucose (18-F) (substance); 2-F18-Fluoro-2-deoxyglucose; Fludeoxyglucose F 18; Fluorine-18 2-Fluoro-2-deoxy-D-Glucose; fludeoxyglucose F18; 18-F FDG; 18 fdg; 18F-FDG",
C0046065,2-deoxymaltose,glucose,alpha-glucopyranosyl-(1-4)-2-deoxy-D-glucose,
C0046819,3'-galactosyllactose,glucose,"GAGGL; D-Glucose, O-beta-D-galactopyranosyl-(1-3)-O-beta-D-galactopyranosyl-(1-4)-",
C0047066,"3,6-dideoxy-4-keto-D-glucose",glucose,"3,6-dideoxy-D-erytho-hexos-4-ulose",
C0047343,3-deoxy-3-fluoro-D-glucose,glucose,3-fluoro-3-deoxyglucose,
C0047529,3-ketolactose,glucose,4-O-(beta-D-xylo-hexopyranosyl-3-ulose)-D-glucopyranose; 4-O-beta-D-xylo-hexopyranos-3-ulos-1-yl-D-glucose,
C0047666,3-O-Methylglucose,glucose,"3 O Methyl D Glucose; 3-o-methylglucose; D-glucose, 3-O-methyl-; 3-O-Methyl-D-Glucose; 3 O Methylglucose; 3-o-methyl-d-glucose",
C0048657,4-O-mannopyranosyl-2-acetamido-2-deoxyglucose,glucose,"D-Glucose, 2-(acetylamino)-2-deoxy-4-O-beta-D-mannopyranosyl-; mannosyl-beta(1-4)-N-acetylglucosamine; 4-O-beta-D-mannopyranosyl-2-acetamido-2-deoxy-D-glucose; mannosyl-(1-4)-N-acetylglucosamine; ManB(1-4)GlcNAc; 4-MPADG; mannosyl-(1-4)-acetylglucosamine",
C0049072,5-azidouridine 5'-diphosphoglucose,glucose,5-azidouridine diphosphate glucose; 5-azido-UDP-glucose,
C0049237,"5-hydroxymethyl-1,2,3,4-cyclohexanetetrol",glucose,5a-carba-glucopyranose; 5a-carba-aldohexopyranose; pseudo-DL-glucose,
C0049366,5-thio-D-glucose,glucose,,
C0049528,6-chloro-6-deoxyglucose,glucose,6-chloro-6-deoxy-D-glucose,
C0049543,6-deoxy-6-fluoroglucose,glucose,"D-Glucose, 6-deoxy-6-fluoro-",
C0049551,6-deoxyglucose,glucose,quinovose; 6-deoxy-D-glucose,
C0049557,6-desoxy-D-glucosamine,glucose,"quinovosamine; 2-amino-2,6-dideoxy-D-glucose",
C0050393,acarbose,glucose,"O-4,6-dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose; ACARBOSE; acarbose; D-glucose, O-4,6-dideoxy-4-(((1S-(1 alpha,4 alpha,5 beta,6 alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyr anosyl-(1-4)-; Product containing acarbose (medicinal product); Acarbosum; Acarbosa; Acarbose-containing product; Acarbose (substance); O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose; Acarbose",
C0050552,acid citrate dextrose,glucose,"D-glucose, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt); Acid citrate dextrose; acd solution; Acid Citrate Dextrose; acid citrate dextrose; ACD solution; Acid-Citrate-Dextrose",
C0052017,antibiotic SF 1933,glucose,"antibiotic SF-1933; substance SF-1933; D-Glucose, 2-((aminocarbonyl)amino)-2-deoxy-",
C0053308,benzylidene glucose,glucose,"alpha-D-Glucopyranose, 4,6-O-(phenylmethylene)-; 4,6-benzylidene-D-glucose; benzylidene glucopyranose",
C0054648,carbamylphosphate-D-glucose phosphotransferase,glucose,CPG phosphotransferase,
C0055038,cellotetraose,glucose,"cellotetrose; D-Glucose, O-beta-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranosyl-(1-4)-",
C0055465,chlorozotocin,glucose,"D-glucopyranose; D-glucose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy- (9CI); 2-[[[(2-chloroethyl)nitrosamino]carbonyl]amino]-2-deoxy-D-glucose; Chlorozotocin; D-glucopyranose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy; chlorozotocin; 2-((((2-chloroethyl)nitrosoamino)-carbonyl)amino)-2-deoxy-D-glucose; 2-(3-(2-chloroethyl)-3-nitrodoureido)-2-deoxy-D-glucopyranose; CZT; DCNU; CLZ; Chlorozotocyna; 1-(2-chloroethyl)-1-nitroso-3-(D-glucos-2-yl)urea; 2-[3-(2-chloroethyl)-3-nitrosoureido]-2-deoxy-D-glucopyranose; CHLZ",
C0055816,citrate phosphate dextrose,glucose,"D-Glucose, mixt. with 2-hydroxy-1,2,3-propanetricarboxylic acid and phosphoric acid; citroglucophosphate; citrate phosphate dextrose; Citrate Phosphate Dextrose; ANTICOAGULANT CITRATE DEXTROSE PHOSPHATE",
C0058542,DNA beta-glucosyltransferase,glucose,UDP-glucose-DNA beta-D-glucosyltransferase; DNA beta-glucosyltransferase; Deoxyribonucleic acid beta-glucosyltransferase (substance); Deoxyribonucleic acid beta-glucosyltransferase; UDP-glucose - 5-hydroxymethylcytosine beta-glucosyltransferase,
C0058662,dolichol-D-glucosylmonophosphate,glucose,"dolichylglucose phosphate; dolichyl monophosphate glucose; beta-D-Glucopyranose, 1-ester with dolichol dihydrogen phosphate; dolichol monophosphate glucose; glucosylphosphodolichol; Dol-P-Glc",
C0058681,Dona 200,glucose,"2-amino-2-deoxy-D-glucose hydriodide, mixt. with 2-amino-2-deoxy-D-glucose hydrochloride, 2-amino-2-deoxy-D-glucose sulfate (salt) & 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide monohydrochloride",
C0058777,"dTDPglucose 4,6-dehydratase",glucose,"dTDPglucose 4,6 dehydratase; TDP D-glucose oxidoreductase; Deoxythymidine diphosphate-glucose 4,6 dehydratase; Deoxythymidine diphosphate-glucose 4,6 dehydratase (substance); thymidine-diphospho-D-glucose 4,6-dehydratase",
C0059829,ethylidene glucose,glucose,"4,6-O-ethylidene glucose",
C0060009,factor III(Glc),glucose,glucose-specific enzyme III; factor IIIGlc,
C0060574,"glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination",glucose,"glucose - glycerol - hydroxyethyl starch - perfluorodecalin - perfluorotripropylamine - pluronic F-68 - salts - yolk phospholipids; Fluosol DA; glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination",
C0061126,gastric inhibitory polypeptide receptor,glucose,"receptor, gastric inhibitory polypeptide; gastric inhibitory polypeptide receptors; gastric inhibitory polypeptide receptor; GIP receptor; glucose-dependent insulinotropic polypeptide receptor",
C0061213,gentiobiose,glucose,"amygdalose; D-glucose, 6-O-beta-D-glucopyranosyl-",
C0061295,GLA 60,glucose,"GLA-60; 2-deoxy-2-(((3R)-3-hydroxy-1-oxotetradecyl)amino)-, 4-(dihydrogen phosphate) 3-((3R)-3-((1-oxotetradecyl)oxy)tetradecanoate)-D-glucose",
C0061377,glucametacin,glucose,"glucametacine; glucametacin; glucometacin; Glucametacin; D-Glucose, 2-(((1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetyl)amino)-2-deoxy-; GLUCAMETACIN; glucamethacin1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid monohydrate glucosamide; glucometacine",
C0061390,"glucopyranose-1,2-cyclic phosphate",glucose,"glucose-1,2-cyclic phosphate; G-1,2-CP; alpha-D-Glucopyranose, cyclic 1,2-(hydrogen phosphate)",
C0061400,"glucose 1,6-bisphosphate synthase",glucose,"Glucose-1,6-bisphosphate synthase (substance); Glucose-1,6-bisphosphate synthase; glucose 1,6-diphosphate synthase; glucose 1,6-bisphosphate synthase",
C0061401,"glucose 1,6-diphosphate phosphatase",glucose,"glucose 1,6-bisphosphatase; Glc-1,6-P(2) phosphatase; glucose bisphosphatase",
C0061402,glucose 6-arsenate,glucose,"D-Glucose, 6-ester with arsenic acid (H3AsO4)",
C0061405,glucose dehydrogenase (pyrroloquinoline-quinone),glucose,quinoprotein aldose-(glucose-)dehydrogenase; Glucose dehydrogenase (pyrroloquinolinequinone); glucose dehydrogenase (pyrroloquinoline-quinone); quinoprotein glucose dehydrogenase; QPAG dehydrogenase; glucose dehydrogenase (PQQ); Glucose dehydrogenase (pyrroloquinolinequinone) (substance),
C0061406,glucose peroxidase,glucose,,
C0061407,glucose receptor,glucose,"glucose receptor; receptor, glucose; glucose receptors; glucoreceptors",
C0061408,glucose tetrasaccharide,glucose,"Glucose tetrasaccharide; (Glc)4; D-Glucose, O-alpha-D-glucopyranosyl- (1-6)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-",
C0061409,glucose tolerance factor,glucose,LMCr; glucose tolerance factor,
C0061410,glucose utilization inhibitor,glucose,"inhibitor, glucose utilization; IGU",
C0061411,"glucose 1,6-bisphosphate",glucose,"glucose 1,6-diphosphate; glucose-1,6-bisphosphate; glucose-1,6-diphosphate; GLUCOSE 1,6-BISPHOSPHATE",
C0061412,glucose-1-fructose-2-oxidoreductase,glucose,,
C0061413,Glucose-1-phosphatase,glucose,"Glucose-1-phosphatase; Glucose-1-phosphatase (substance); glucose-1-phosphatase, E coli; agp protein, E coli; glucose 1 phosphatase",
C0061414,glucose-1-phosphate,glucose,Glucose-1-phosphate; Glucose-1-phosphate (substance); glucose 1 phosphate,
C0061415,Glucose-1-phosphate adenylyltransferase,glucose,"Pyrophosphorylase, Adenosine Diphosphoglucose; ADPglucose pyrophosphorylase; Synthase, ADP-Glucose; Adenylyltransferase, Glucose-1-Phosphate; Adenosine Diphosphoglucose Pyrophosphorylase; ADP-Glucose Synthase; Synthetase, ADPG; Adenosine Diphosphate Glucose Pyrophosphorylase; Glucose 1 Phosphate Adenylyltransferase; Synthetase, ADP-Glucose; Glucose-1-phosphate adenylyltransferase (substance); Diphosphoglucose Pyrophosphorylase, Adenosine; ADPGlucose Pyrophosphorylase; ADP-Glucose Pyrophosphorylase; ADP Glucose Synthase; ADP-Glucose Synthetase; ADP Glucose Pyrophosphorylase; Pyrophosphorylase, ADP-Glucose; Glucose-1-phosphate adenylyltransferase; Glucose-1-Phosphate Adenylyltransferase; ADPG Synthetase; ADP Glucose Synthetase; Pyrophosphorylase, ADPGlucose",
C0061416,glucose-1-phosphate cytidylyltransferase,glucose,Glucose-1-phosphate cytidylyltransferase; CDPglucose pyrophosphorylase; Glucose-1-phosphate cytidylyltransferase (substance),
C0061417,glucose-1-phosphate thymidylyltransferase,glucose,dTDPG pyrophosphorylase; deoxythymidine diphosphate D-glucose pyrophosphorylase; dTDP-glucose synthase; dTDPglucose pyrophosphorylase; glucose-1-phosphate thymidylyltransferase; Glucose 1-phosphate thymidylyltransferase (substance); Glucose 1-phosphate thymidylyltransferase,
C0061418,glucose-6-phosphate,glucose,Glucose 6 Phosphate; Glucose-6-phosphate; glucose-6-phosphate; glucose 6 phosphate; Glucose-6-Phosphate; 6 glucose phosphate; Glucose-6-phosphate (substance); GLUCOSE-6-PHOSPHATE,
C0061419,Glucose-6-phosphate translocase,glucose,Glucose-6-phosphate translocase (substance); Glucose-6-phosphate translocase,
C0061420,glucose-insulin-potassium cardioplegic solution,glucose,GIK solution; GIKCS; glucose-insulin-potassium substrate,
C0061421,glucose-regulated proteins,glucose,,
C0061434,glucosylgalactosylhydroxylysine,glucose,"hydroxylysine-glucose-galactose; hydroxylysine-galactose-glucose; 1,2 alpha-glucosylgalactosyl-O-hydroxylysine",
C0061437,glucosylurea,glucose,N-carbamoyl-D-glucopyranosylamine; glucoseureide; glucose-ureide; glucosyl urea,
C0061982,guanosine diphosphate glucose,glucose,GDP glucose; GDPG; guanosine diphosphoglucose,
C0062495,hemostimulin,glucose,"D-Glucose, mixt. with copper(2+) sulfate (1:1), hematogen and 2-hydroxypropanoic acid iron(3+) salt (3:1)",
C0062805,HLA-A28 antigen,BG,HLA - Human leukocyte antigen A28; HLA-28 antigen; HLA - Human leucocyte antigen A28; Human leukocyte antigen-A28; Blood group antigen Bg^c^ (substance); HLA-A28 antigen; W28 antigen; Blood group antigen Bg^c^; Human leukocyte antigen A28; Blood group antigen Bg c (substance); Human leucocyte antigen A28; HLA A28; Blood group antigen Bg<sup>c</sup> (substance); Blood group antigen Bg c; Blood group antigen Bg<sup>c</sup>; Blood group antigen HLA-A28; HLA-A28,
C0062820,HLA-B17 antigen,BG,HLA - Human leucocyte antigen B17; Human leucocyte antigen B17; Blood group antigen Bg^b^; HLA-B17; HLA-B17 antigen; Blood group antigen HLA-B17; Human leukocyte antigen B17; Human leukocyte antigen B17 (substance); HLA - Human leukocyte antigen B17; Blood group antigen Bg b; HLA B17; Blood group antigen Bg<sup>b</sup>; Human leukocyte antigen-B17,
C0063272,IC 831423,glucose,"D-Glucose, O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1-4); IC-83.1423",
C0063500,indoleacetyl-glucose-myo-inositol indoleacetyl transferase,glucose,IAA-myoinositol synthase; IAA transferase; indol-3-ylacetylglucose-myo-inositol indol-3-ylacetyltransferase,
C0063684,Amylin,diabetes,"pancreatic amylin; Polypeptide, Islet Amyloid; IAPP; Pancreatic Amylin; Amylin (substance); amylin; Amyloid Polypeptide, Islet; islet amyloid polypeptide; Amylin; diabetes associated peptide; Insulinoma Amyloid Polypeptide; Amlintide; insulinoma amyloid polypeptide; IAPP Protein; Amylin, Pancreatic; Islet Amyloid Polypeptide; Product containing amylin (medicinal product); iapp; Polypeptide, Insulinoma Amyloid; Amylin-containing product; Amyloid Polypeptide, Insulinoma; Islet amyloid polypeptide",
C0064000,isomaltohexose,glucose,O-alpha-D-glucopyranosyl-(1-6)-O-alpha-D-glucopyranosyl-(1-6)-O-alpha-D-glucopyranosyl-(1-6)-O-alpha-D-glucopyranosyl-(1-6)-O-alpha-D- glucopyranosyl-(1-6)-D-glucose; isomaltohexaose,
C0064046,isoprimeverose,glucose,alpha-xylosyl-(1-6)-glucose,
C0064400,kojibiose,glucose,2-O-alpha-D-glucopyranosyl-D-glucose,
C0064595,lacto-N-neotetraose,glucose,"lacto-N-neotetraose; LNnT; N-neotetraose; D-glucose, O-beta-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->3)-O-beta-D-galactopyranosyl-(1->4)-",
C0064610,lactosamine,glucose,"D-Glucose, 2-amino-2-deoxy-4-O-beta-D-galactopyranosyl-",
C0064632,laminaribiose,glucose,laminarabiose; 3-O-(beta-D-glucopyranosyl)-D-glucose,
C0065423,M 254,hyper,Hyper-Sialylated Immunoglobulin G M254; hsIgG M254; Hyper-Sialylated IgG M254; M 254; M254; M-254,
C0065603,maltoheptaose,glucose,"maltoheptose; maltoheptaose, (D-glucose)-isomer",
C0065610,maltose tetrapalmitate,glucose,"maltose tetrapalmitate (MTP); MTP; Maltose tetrapalmitate; maltose tetrapalmitate; Maltose tetrapalmitate (substance); D-Glucose, 4-O-alpha-D-glucopyranosyl-, tetrahexadecanoate",
C0065615,maltotetraose,glucose,O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyrano- syl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D- glucose,
C0065616,maltotriose,glucose,O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose,
C0065700,mannosyl(5)-N-acetyl(2)-glucose diphosphate dolichol,glucose,Man5GlcNAc2-P-P-dolichol,
C0066995,mycaminose,glucose,"3,6-dideoxy-3-(dimethylamino)-D-glucose",
C0067279,"N,N',N''-triacetylchitotriose",glucose,"O-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-4)-O-2-(acetylamino)-2-deoxy-beta-D-glucopyran osyl-(1-4)-2-(acetylamino)-2-deoxy-D-glucose; triGlcNAc; N,N',N''- triacetyl chitotriose; tri-GlcNAc; (G1cNAC)3; N,N',N''-triacetyl chitotriose; O-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1-4)-O-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1-4)-2-acetamido-2-deoxy-D-glucopyranose; N,N',N''-triacetylchitintriose",
C0067339,"N,N-diacetylchitobiose",glucose,"2-(acetylamino)-4O-(2-(acetylamino)-2-deoxy-beta-D- glucopyranosyl)-2-deoxy-D-glucose; (GlcNAc)2; di-N-acetylchitobiose; N,N'-diacetylchitobiose; bis(N-acetyl)chitobiose; N,N'-diacetylchitobioside",
C0067706,N-acetylgalactosaminyl-(1-4)-glucose,glucose,"D-Glucose, 4-O-(2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl)-, trans-; GalNAc-1-4-Glc; GalNAcbeta1-4Glc; N-AcGln-1,4-Glu",
C0067713,N-acetylglucosamine-6-sulfate,glucose,"GlcNAc-6-O-sulfate; AGA-6-S; D-Glucose, 2-(acetylamino)-2-deoxy-, 6-(hydrogen sulfate)",
C0067750,N-acetylmuramic acid,glucose,N-acetylisomuramic acid; 2-acetamido-3-O-((S)-1-carboxyethyl)-2-deoxy-D-glucose; acetylmuramic acid,
C0068551,nephritogenoside,glucose,"D-Glucose, O-alpha-D-glucopyranosyl-(1-6)-O-D-glucopyranosyl-(1-6)-; nephritogenic glycoprotein; nephritogenic glycopeptide",
C0069236,O-6-deoxy-6-((2-pyridyl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucitol,glucose,"D-Glucose, O-6-deoxy-6-(2-pyridinylamino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D(S)-",
C0069443,oligostatin C,glucose,"D-Glucose, O-4,6-dideoxy-4-((2,3,4,6-tetrahydroxy-5-(hydroxymethyl)cyclohexyl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-, (1S-(1alpha,2alpha,3beta,4alpha,5beta,6beta))-",
C0069444,oligostatin D,glucose,"D-Glucose,O-4,6-dideoxy-4-((2,3,4,6-tetrahydroxy-5-(hydroxymethyl)cyclohexyl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-,(1S-(1alpha,2alpha,3beta,4alpha,5beta,6beta))-",
C0069445,oligostatin E,glucose,"D-Glucose, O-4,6-dideoxy-4-((4-(alpha-D-glucopyranosyloxy)-2,3,6-trihydroxy-5-(hydroxymethyl)cyclohexyl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-, (1S-(1alpha,2alpha,3beta,4alpha,5beta,6beta))-",
C0069895,P(1)-(adenosine-5')-P(3)-(glucose-6)triphosphate,glucose,"Adenosine 5'-(tetrahydrogentriphosphate), 5'-6-ester with D-glucose; Ap(3)glucose",
C0070027,panose,glucose,"glucosyl-alpha-(1,6)-glucosyl-alpha-(1,4)-glucose",
C0070287,pentaglycosyl ceramide,glucose,"pentaglycosylceramide; Paragloboside, O-alpha-D-galactopyranosyl-(1-3D)-; IV(3)Gal alpha-neolactotetraosylceramide; alpha-D-galactosyl(1-3)beta-D-galactosyl(1-4)-N-acetyl-beta-D-galactosamine(1-3)beta-D-galactosyl(1-4)-D-glucose-ceramide; GANLTC; galactosyl-alpha-neolactotetraosylceramide",
C0070842,phosphoenolpyruvate-glucose phosphotransferase,glucose,,
C0070858,phosphoglucokinase,glucose,Phosphoglucokinase; glucose-1-phosphate kinase; Glucose-phosphate kinase; Phosphoglucokinase (substance),
C0071488,poly-N-acetyllactosamine,glucose,"PNALA; poly(N-acetyllactosamine); D-Glucose, 2-(acetylamino)-2-deoxy-4-O-beta-D-galactopyranosyl-, homopolymer",
C0071596,polyisoprenol phosphate glucose,glucose,"glucosyl monophosphoryl undecaprenol; D-Glucopyranose, mono(3,7,11,15,19,23,27,31,35,39,43-undecamethyl-2,6,10,14,18,22,26,30,34,38,42-tetratetracontaundecaenyl hydrogen phosphate)",
C0071654,polyphosphate-glucose phosphotransferase,glucose,Polyphosphate-glucose phosphotransferase; polyphosphate glucokinase; Polyphosphate-glucose phosphotransferase (substance),
C0072653,pyranose oxidase,glucose,Pyranose oxidase; glucose-2-oxidase; Pyranose oxidase (substance); Glucose 2-oxidase,
C0072708,pyridoxal phosphoglucose,glucose,"pyridoxal(5')phospho(1)-beta-D-glucose; beta-D-Glucopyranose, 1-((4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl hydrogen phosphate)",
C0072709,pyridoxal(5')diphospho(1)-glucose,glucose,"alpha-D-Glucopyranose, 1-(P'-((4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl) dihydrogen diphosphate), disodium salt; 5-PDPG",
C0074906,sophorose,glucose,2-O-beta-D-glucopyranosyl-alpha-D-glucose,
C0075485,Sucrose synthase,glucose,sucrose synthetase; Sucrose synthase (substance); UDPglucose-fructose glucosyltransferase; sucrose synthase; Sucrose-UDP glucosyltransferase; Sucrose-uridine diphosphate glucosyltransferase; UDP-glucose-D-fructose-2-glycosyltransferase; Uridine diphosphoglucose-fructose glucosyltransferase; Sucrose synthase,
C0077685,UDP glucose-collagen glucosyltransferase,glucose,Procollagen glucosyltransferase; UDPglucose galactosylhydroxylysine-basement membrane glucosyltransferase; galactosylhydroxylysyl glucosyltransferase; Procollagen glucosyltransferase (substance); UDPG GALHLC glucosyltransferase; Galactosylhydroxylysine glucosyltransferase; collagen glucosyltransferase; procollagen glucosyltransferase; UDPglucose galactosylhydroxylysine collagen glucosyl-transferase,
C0077702,UDP-glucose-indoleacetic acid glucosyl transferase,glucose,,
C0077752,UDPglucose-glycoprotein glucose-1-phosphotransferase,glucose,Glc-phosphotransferase; GlcPTase,
C0077753,Lipopolysaccharide glucosyltransferase I,glucose,"UDP-glucose-(glucosyl)lipopolysaccharide 1,3-glucosyltransferase; UDPglucose-(heptosyl)lipopolysaccharide alpha-1,3-glucosyltransferase I; Lipopolysaccharide glucosyltransferase I (substance); Lipopolysaccharide glucosyltransferase I; UDPglucose-lipopolysaccharide glucosyltransferase I",
C0077754,UDPglucose-poriferasterol glucosyltransferase,glucose,UDPGlc-POR-glucosyltransferase; UDP-glucose stigmasterol glucosyltransferase,
C0077887,uridine diphosphate 2-deoxyglucose,glucose,"UDP-2-deoxyglucose; uridine diphosphate 2-deoxyglucose, beta-D-glucopyranosyl cpd; UDP-2-deoxy-D-glucose; uridine diphosphate 2-deoxy-D-glucose",
C0079318,Euglycemic Clamp,glucose,"Clamps, Glucose; Clamps, Euglycaemic; Clamps, Euglycemic; Euglycaemic Clamp; Euglycaemic Clamps; Euglycemic Clamps; euglycaemic clamp; glucose clamp; Clamp, Glucose; Clamp, Euglycaemic; glucose clamps; euglycaemic clamps; Glucose Clamps; euglycemic clamp; Clamp, Euglycemic; Glucose Clamp",
C0081773,BG 104,BG,BG-104,
C0082716,glucose 6-(hydrogen sulfate),glucose,glucose sulfate,
C0082717,glucose mycolate,glucose,glucosylmonomycolate; glucose monomycolate,
C0083812,O(6)-benzylguanine,BG,o6-benzylguanine; O6-BG; O(6)-Benzylguanine; 2-amino-6-(phenylmethoxy)-9h-purine; 06-Benzylguanine; 06-Benzyl Guanine; O6-Benzylguanine; O(6)-benzylguanine; O-6-Benzylguanine; 6-O-benzylguanine; O6-benzylguanine; 2-amino-6-(benzyloxy)purine; BG; o6 benzylguanine; O(6)-bGua; O(6) benzylguanine,
C0084119,polylactosamine,glucose,"D-Glucose, 2-amino-2-deoxy-4-O-beta-D-galactopyranosyl-, homopolymer",
C0084630,"CYC8 protein, S cerevisiae",glucose,"YBR112C protein, S cerevisiae; glucose repression mediator protein, S cerevisiae; SSN6 protein, S cerevisiae; CRT8 protein, S cerevisiae",
C0085005,woodfordin C,glucose,"woodfruticosin; D-Glucose, cyclic 4-2:6-2'-(4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 3-(3,4,5-trihydroxybenzoate), cyclic diester with alpha-D-glucopyranose cyclic 4-2':6-2-(4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1,3-bis(3,4,5-trihydroxybenzoate), (2(S),4(S))-",
C0085207,Gestational Diabetes,diabetes,"diabetes during pregnancy; Maternal diabetes; Gestational diabetes; Diabetes, Gestational; Diabetes in Pregnancy; gestational diabetes mellitus; Diabetes, Pregnancy-Induced; pregnancy induced diabetes; Gestational Diabetes; Diabetes Mellitus, Gestational; maternal diabetes; gdm; GDM - Gestational diabetes mellitus; GDM; Pregnancy-Induced Diabetes; Gestational diabetes mellitus (disorder); MATERNAL DIABETES; Gestational diabetes mellitus; Gestational diabetes mellitus, NOS; Diabetes gestatational; Diabetes and Pregnancy; Diabetes mellitus arising in pregnancy; Diabetes, Pregnancy Induced; Diabetes mellitus, pregnancy related; pregnancy-induced diabetes; Gestational Diabetes Mellitus; gestational diabetes; diabetes pregnancy; Maternal gestational diabetes mellitus; DIABETES MELLITUS (GESTATIONAL)",
C0085860,"Autoimmune Syndrome Type II, Polyglandular",diabetes,"DIABETES MELLITUS, ADDISON DISEASE, MYXEDEMA; syndrome schmidt; Syndrome, Schmidt's; Multiple Endocrine Deficiency Syndrome, Type 2; Polyglandular autoimmune syndrome - type II; Autoimmune Polyendocrine Syndrome, Type II; APS II; Schmidt syndrome; SCHMIDT SYNDROME; Autoimmune Polyglandular Syndrome Type II; Autoimmune Polyglandular Syndrome Type 2; Diabetes Mellitus, Addison Disease, Myxedema; PGA - Polyglandular autoimmune syndrome - type II; Primary hypothyroidism and adrenocortical insufficiency; POLYENDOCRINE AUTOIMMUNE SYNDROME, TYPE II; Autoimmune polyendocrinopathy type 2; Addison's disease with struma lymphomatosa; Autoimmune Syndrome Type II, Polyglandular; Polyglandular Autoimmune Syndrome, Type 2; Polyglandular autoimmune syndrome, type 2 (disorder); Polyendocrine Autoimmune Syndrome, Type II; schmidt syndrome; Autoimmune polyglandular syndrome type 2; Diabetes mellitus, Addison's disease and myxedema; schmidts syndrome; Autoimmune polyendocrine syndrome type 2; Schmidt's Syndrome; Schmidt Syndrome; Diabetes Mellitus, Addison's Disease, Myxedema; Syndrome, Schmidt; Primary hypothyroidism AND adrenocortical insufficiency; POLYGLANDULAR AUTOIMMUNE SYNDROME, TYPE II; Polyglandular Type II Autoimmune Syndrome; Autoimmune thyroid disease and/or type 1 diabetes-Addison disease syndrome; Type 2 polyendocrine autoimmunity syndrome; PGA II; Diabetes mellitus, Addison's disease and myxoedema; schmidt's syndrome; Polyglandular Deficiency Syndrome, Type 2; Schmidt's syndrome; APS2; APS type 2; Autoimmune Polyendocrine Syndrome, Type 2; Polyglandular autoimmune syndrome, type 2; AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II",
C0088960,1-(N-L-tryptophan)-1-deoxy-D-glucose,glucose,,
C0089647,1-O-(indol-3-ylacetyl)-beta-D-glucose synthase,glucose,,
C0091755,"2,6-diamino-2,6-dideoxy-D-glucose",glucose,,
C0092882,2-Fluoro-2-deoxy-D-glucose,glucose,2-Fluoro-2-deoxyglucose; 2 Fluoro 2 deoxyglucose; 2 Fluoro 2 deoxy D glucose,
C0092892,2-deoxy-4-O-phosphono-3-O-tetradecanoyl-2-(3-tetradecanoyloxytetradecanamido)-D-glucose,glucose,,
C0093000,2-fluoro-2-deoxyglucose-6-phosphate,glucose,2-fluoro-2-deoxyglucose 6-phosphate; 2-deoxy-2-fluoroglucose 6-phosphate; FDG-6-P; 2-FDGuP; 2-fluoro-2-deoxy-D-glucose-6-phosphate,
C0094407,"3,3'-O-(5-(acetylamino)-2,4,6-triiodo-1,3-phenylene)bis-D-glucose",glucose,,
C0096145,4'-galactooligosaccharide,glucose,4'-galacto-oligosaccharide; 4'-GL; O-beta-D-galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-D-glucose,
C0098141,5-amino-D-glucose,glucose,,
C0105916,1-thio-beta-D-glucose,glucose,beta-D-thioglucose,
C0106201,BG 8865,BG,BG8865; BG-8865,
C0108863,CDP-4-keto-6-deoxy-D-glucose-3-dehydrase,glucose,cytidine diphosphate-4-keto-6-deoxy-D-glucose-3-dehydrase; CKDG dehydrase; CDP-6-deoxy-L-threo-D-glycero-4-hexulose 3-dehydrase,
C0109565,cholesterol-3-glucose,glucose,,
C0116250,enzyme II (glucose),glucose,enzyme II(Glc),
C0116600,esterbut-3,glucose,"MAG-3BUT; 3n-But; monobut-3; 3n-butyrate; monoacetone glucose 3-butyrate; 3-O-butanoyl-1,2-O-isopropylidene-alpha-D-glucofuranose",
C0116601,esterbut-6,glucose,"monoacetone glucose 6-butyrate; MAG-6BUT; 6-O-butanoyl-1,2-O-isopropylidene-alpha-D-glucofuranose; monobut-6",
C0118598,Gal(alphal-3)-Gal(betal-4)Glc,glucose,galactosyl alpha (1-3)-galactosyl beta (1-4)glucose,
C0118599,Gal(beta1-3)-Gal(beta1-4)Glc,glucose,galactosyl beta (1-3)-galactosyl beta (1-4)glucose,
C0119421,glucose isomerase,glucose,,
C0119422,glucose permease,glucose,ptsG; glucose permease,
C0119431,glucose-regulated protein 100,glucose,GRP100,
C0119432,glucose-regulated protein 94,glucose,,
C0119433,glucose-related protein 75,glucose,,
C0119435,"glucose-specific permease, phosphotransferase system",glucose,,
C0119484,Glucose Transporter Type 3,glucose,"SLC2A3 Protein; GLUT3 Protein; GLUT 3 Protein; GLUT-3 Protein; Solute Carrier Family 2, Facilitated Glucose Transporter, Member 3 Protein",
C0119659,glyceraldehyde 3-phosphate dehydrogenase (304-313),BG,ACE inhibitor BG-2; Gly-Lys-Met-Val-Lys-Val-Val-Ser-Trp-Tyr,
C0120370,glucose related protein GRP75,glucose,GRP75,
C0120372,glucose-regulated protein GRP94,glucose,GRP94,
C0123497,indole-3-acetate beta-glucosyltransferase,glucose,IAGlc synthase; 1-O-IAGlc synthase; Indole-3-acetate beta-glucosyltransferase (substance); Indole-3-acetate beta-glucosyltransferase; IAA-glucose synthetase,
C0126991,"mannosylglycoprotein 1,3-glucosyltransferase",glucose,"UDP-glucose-glycoprotein glucosyltransferase; UDP-glucose glycoprotein glucosyltransferase; UDPGlc-glycoprotein glucosyltransferase; UGGT enzyme; UGGP 1,3-glucosyltransferase",
C0130711,N-Acetylglucosamine kinase,glucose,N-acetylglucosamine kinase; ATP acetamide-2-deoxy-D-glucose - 6-phosphotransferase; N-acetyl-D-glucosamine kinase; N-Acetylglucosamine kinase (substance); acetylaminodeoxyglucose kinase; GlcNAc kinase; N-Acetylglucosamine kinase,
C0138006,potassium glucose 6-O-sulfate,glucose,,
C0140293,retinoylglucose,glucose,retinoyl beta-glucose,
C0145056,technetium Tc 99m glucose-1-phosphate,glucose,Tc-99m-alpha-glucose-1-phosphate; Tc-99m-GP,
C0147660,UDP-glucose-indol-3-ylacetate beta-D-glucosyltransferase,glucose,,
C0149942,Ophthalmoplegia due to diabetes mellitus,diabetes,"PALSY, DIABETIC OCULOMOTOR; Ophthalmoplegia with diabetes mellitus; PALSY, DIABETIC EXTRAOCULAR MUSCLE; Ophthalmoplegia due to diabetes mellitus (disorder); OPHTHALMOPLEGIA, DIABETIC; Diabetic ophthalmoplegia",
C0150252,Hyperglycemia management,hyperglycemia,Hyperglycaemia management; Hyperglycemia management (procedure),
C0150254,Hypoglycemia management,hypoglycemia,Hypoglycaemia management; hypoglycaemia management; hypoglycemia management; Hypoglycemia management (procedure),
C0151367,"Synovial fluid glucose, mg%",glucose,,
C0151407,"Serum glucose, mg%",serum glucose,,
C0151671,Glucose tolerance decreased (finding),glucose,Impaired glucose tolerance; Decreased glucose tolerance; GLUCOSE TOLERANCE DECREASED; Glucose tolerance decreased; Glucose Tolerance Decreased; TOLERANCE GLUCOSE DECREASED,
C0151672,GLUCOSURIA FALSE POSITIVE,glucose,GLYCOSURIA FALSE POSITIVE; GLYCOSURIA FALSE POSITIVE TEST; GLUCOSE URINE FALSE POSITIVE TEST,
C0154183,Diabetes with other specified manifestations,diabetes,,
C0154830,Proliferative diabetic retinopathy,diabetes,Proliferative diabetic retinopathy; PDR - proliferative diabetic retinopathy; Proliferative retinopathy with diabetes mellitus; Proliferative Diabetic Retinopathy; proliferative diabetic retinopathy (PDR); proliferative diabetic retinopathy; Proliferative retinopathy due to diabetes mellitus (disorder); Proliferative retinopathy due to diabetes mellitus,
C0156878,"Abnormal glucose tolerance in mother complicating pregnancy, childbirth AND/OR puerperium",glucose,"Abnormal glucose tolerance of mother, complicating pregnancy, childbirth, or the puerperium; Abnormal glucose tolerance in mother complicating pregnancy, childbirth or puerperium; Abnormal glucose tolerance in mother complicating pregnancy, childbirth AND/OR puerperium (disorder)",
C0156879,"Abnormal glucose tolerance of mother, unspecified as to episode of care or not applicable",glucose,"Abnormal glucose tolerance of mother, complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care",
C0156880,"Abnormal glucose tolerance of mother, delivered, with or without mention of antepartum condition",glucose,"Abnormal glucose tolerance of mother, with delivery",
C0156881,"Abnormal glucose tolerance of mother, delivered, with mention of postpartum complication",glucose,"Abnormal glucose tolerance of mother, with delivery, with mention of postpartum complication",
C0156882,"Abnormal glucose tolerance of mother, antepartum condition or complication",glucose,"Abnormal glucose tolerance of mother, antepartum",
C0156883,"Abnormal glucose tolerance of mother, postpartum condition or complication",glucose,"Abnormal glucose tolerance of mother, postpartum",
C0158981,Neonatal diabetes mellitus,diabetes,Neonatal diabetes; Neonatal diabetes mellitus; Neonatal Diabetes Mellitus; Neonatal diabetes mellitus (disorder); NDM; Diabetes mellitus syndrome in newborn infant,
C0158986,Neonatal hypoglycemia,blood sugar,"Neonatal hypoglycaemia; Hypoglycemia, neonatal; HYPOGLYCEMIA, INFANTILE; hypoglycemia neonatal; Low blood sugar in newborn; neonatal hypoglycemia; Hypoglycemia (neonatal); HYPOGLYCAEMIA NEONATAL; Neonatal hypoglycemia (disorder); Neonatal hypoglycemia; neonatal hypoglycaemia; Neonatal Hypoglycemia; HYPOGLYCEMIA NEONATAL",
C0159069,abnormal glucose tolerance test,glucose,Abnormal glucose tolerance test; GTT ABNORMAL; Glucose tolerance test positive; Glucose tolerance test impaired; Abnormal glucose tolerance test (finding); Impaired glucose tolerance test; Impaired glucose tolerance test (finding),
C0162283,Nephrogenic Diabetes Insipidus,diabetes,"nephrogenic diabetes insipidus; NDI - Nephrogenic diabetes insipidus; Nephrogenic Diabetes Insipidus; Nephrogenic diabetes insipidus (disorder); diabete insipidus nephrogenic; diabetes insipidus nephrogenic; DIABETES INSIPIDUS NEPHROGENIC; Nephrogenic diabetes insipidus, NOS; Diabetes Insipidus, Nephrogenic; DIABETES INSIPIDUS, NEPHROGENIC; Nephrogenic diabetes insipidus",
C0163410,Ceramide glucosyltransferase,glucose,Ceramide glucosyltransferase (substance); Ceramide glucosyltransferase; UDP-glucose-ceramide glucosyltransferase; glycosylceramide synthetase; GlcCer synthase; glucosylceramide synthase; ceramide UDPG glucosyltransferase; UDPglucose-ceramide glucosyltransferase; ceramide glucosyltransferase; glucocerebroside synthetase; UDP-glucose-N-acylsphingosine glucosyltransferase,
C0163570,"1,2-O-isopropylidene-D-glucofuranose",glucose,monoacetone-glucose,
C0164537,5-fluorouridine diphosphate glucose,glucose,FUDP-glucose,
C0166441,Glucose Transporter Type 4,glucose,"Insulin Responsive Glucose Transporter; Glucose Transporter Type 4; Glucose Transporter, Insulin-Responsive; Insulin-Responsive Glucose Transporter; Solute Carrier Family 2, Facilitated Glucose Transporter, Member 4 Protein; GLUT 4 protein; GLUT4 Protein; GLUT-4 Protein; SLC2A4 Protein; GLUT 4 Protein",
C0166821,cytidine diphosphate-glucose,glucose,CDP-D-glucose; CDP-glucose,
C0167638,glucose-fructose oxidoreductase,glucose,Glucose--fructose oxidoreductase (substance); Glucose--fructose oxidoreductase,
C0168458,GLUT-1 protein,glucose,"GLUT 1 Protein; SLC2A1 Protein; Glucose Transporter Type 1; GLUT-1 Protein; Glucose Transporter, Erythrocyte; Erythrocyte Glucose Transporter; GLUT1 Protein; Solute Carrier Family 2, Facilitated Glucose Transporter, Member 1 Protein",
C0172870,Glucose Transporter Type 5,glucose,SLC2A5 Protein; GLUT-5 Protein; D-Fructose Transporter; GLUT 5 Protein; GLUT5 Protein,
C0174599,"SLC2A2 protein, human",glucose,"Solute Carrier Family 2, Facilitated Glucose Transporter Member 2; GLUT2 protein, human; GLUT-2 protein, human; GLUT-2; SLC2A2 protein, human; Glucose Transporter Type 2, Liver; solute carrier family 2 (facilitated glucose transporter), member 2 protein, human; Glucose Transporter 2",
C0174600,"Slc2a2 protein, mouse",glucose,"liver-type glucose transporter protein, mouse; GLUT-2 protein, mouse; solute carrier family 2 (facilitated glucose transporter), member 2 protein, mouse; Glut2 protein, mouse",
C0174601,"Slc2a2 protein, rat",glucose,"GTT2 protein, rat; solute carrier family 2 (facilitated glucose transporter), member 2 protein, rat; GLUT-2 protein, rat; Glut2 protein, rat",
C0174602,Glucose Transporter Type 2,glucose,"SLC2A2 Protein; GLUT-2 Protein; GLUT 2 Protein; Solute Carrier Family 2, Facilitated Glucose Transporter, Member 2 Protein; GLUT2 Protein",
C0178665,glucose tolerance,glucose,glucose tolerance; Glucose tolerance,
C0178666,glucose transport,glucose,transport glucose; glucose transport,
C0181254,"Blankets, Circulating-Liquid",hypo,"Circulating-Fluid Blankets; Circulating-Liquid Blankets; Blankets, Hypo/Hyperthermia; Hypo/Hyperthermia Blankets; Blankets, Circulating-Fluid",
C0181255,"Warming/Cooling Units, Patient",hypo,"Thermoregulators; Hypo/Hyperthermia Units; SYSTEM, THERMAL REGULATING; Heater/Cooler Units",
C0181256,"Hypo/Hyperthermia Units, Central",hypo,,
C0181257,"Hypo/Hyperthermia Units, Mobile",hypo,,
C0181258,"Hypo/Hyperthermia Units, Mobile, General-Purpose",hypo,,
C0181259,"Warming/Cooling Units, Patient, Heart-Lung Bypass",hypo,"Hypo/Hyperthermia Units, Mobile, Heart-Lung Bypass",
C0181260,"Hypoglycemia Detection Units, Nocturnal",hypoglycemia,,
C0182876,"Reagents, Strip, Glucose",glucose,"glucose strips; Strip Test Reagents, Glucose; Glucose Strips; Reagents, Clinical Chemistry, Rapid Test, Whole Blood, Glucose, Strip; Strips, Glucose; Glucose Determination Reagents, Rapid Test, Strip",
C0199229,Screening for diabetes,diabetes,diabetes screening; diabetes screen; for diabetes screening; Screening for diabetes; screening diabetes; screening for diabetes,
C0202040,"Glucose measurement, CSF",glucose measurement,"Glucose measurement, cerebrospinal fluid (procedure); Glucose measurement, CSF; Glucose CSF; csf glucose; Glucose in CSF; Glucose, CSF, measurement; Glucose measurement, cerebrospinal fluid; CSF Glucose Test",
C0202041,"Glucose measurement, serum",serum glucose,"Glucose measurement, serum; glucose serum test; serum glucose; serum glucose test; glucose serum tests; Serum Glucose Test; Glucose measurement, serum (procedure); Glucose, serum, measurement; Serum Glucose; Serum Glucose Measurement; glucose serum",
C0202042,Plasma Glucose Measurement,plasma glucose,"Plasma Glucose Measurement; Glucose Plasma Concentration Measurement; Glucose measurement, plasma (procedure); Glucose, plasma, measurement; Plasma glucose; Glucose measurement, plasma",
C0202045,"Glucose measurement, fasting",glucose measurement,"Glucose measurement, fasting; Glucose measurement, fasting (procedure)",
C0202046,"Glucose measurement, random",glucose measurement,"Glucose measurement, random; Glucose measurement, random (procedure)",
C0202048,Glucose measurement by monitoring device,glucose measurement,Glucose measurement by monitoring device; Glucose measurement by monitoring device (procedure); monitoring glucose; glucose monitoring,
C0202049,Measurement of glucose 2 hours after glucose challenge for glucose tolerance test,glucose,"Measurement of glucose 2 hours after glucose challenge for glucose tolerance test (procedure); Glucose tolerance test, 2 hours",
C0202050,Measurement of glucose 3 hours after glucose challenge for glucose tolerance test,glucose,"Glucose tolerance test, 3 hours; 3 hour glucose tolerance test; Measurement of glucose 3 hours after glucose challenge for glucose tolerance test (procedure); 3 hours glucose tolerance test; 3 glucose hour testing tolerance",
C0202051,Measurement of glucose 5 hours after glucose challenge for glucose tolerance test,glucose,"Glucose tolerance test, 5 hours; Measurement of glucose 5 hours after glucose challenge for glucose tolerance test (procedure)",
C0202052,Glucose phosphate isomerase measurement,glucose,Glucose phosphate isomerase measurement; Glucose phosphate isomerase measurement (procedure),
C0202054,Glucohemoglobin measurement,a1c,"Glucohemoglobin measurement, NOS; Glycosylated haemoglobin measurement; Glycated hemoglobin measurement; HbA1C; Glycosylated hemoglobin measurement; Glycated haemoglobin measurement; Hemoglobin A1c; glycosylated hemoglobin test; Glycosylated Hemoglobin Measurement; glycated hemoglobin test; Glycosylated Hemoglobins Test; Glycohemoglobin",
C0202509,Urinalysis glucose qualitative measurement,glucose,"Urinalysis, glucose, qualitative; Urinalysis, glucose, qualitative (procedure)",
C0204935,Diabetic education,diabetes,diabetic patient education; Diabetic education (procedure); Diabetes mellitus education; Education about diabetes; Diabetic patient education,
C0205734,"Diabetes, Autoimmune",diabetes,diabetes autoimmune; Autoimmune Diabetes; autoimmune diabetes,
C0207715,"galactosyl-1,3-N-acetylglucosamine",glucose,"Gal-1,3-GlcNAc; lacto-N-biose I; D-Glucose, 2-(acetylamino)-2-deoxy-3-O-beta-D-galactopyranosyl-",
C0208019,uridine-2-deoxy-2-fluoro-D-glucose diphosphate ester,glucose,UDP-FGlc; UDP-2-fluoro-2-deoxy-D-glucose,
C0208413,"3,6-di-O-methylglucose",glucose,"D-Glucose, 3,6-di-O-methyl-; 3,6-DMG",
C0210056,BG 8967,BG,BG8967; BG-8967,
C0212337,alpha-D-glucose-1-methylenephosphonate,glucose,,
C0212338,glucose-1-methylenephosphonate,glucose,Glu-1-MePhos,
C0220292,low potassium dextran glucose solution,glucose,LPDG solution,
C0220837,glucose dehydrogenase,glucose,"Dehydrogenase, Glucose; Glucose 1 Dehydrogenase; Glucose 1-Dehydrogenase; Glucose dehydrogenase (substance); Glucose dehydrogenase; Glucose Dehydrogenase",
C0220989,Acquired partial lipodystrophy,diabetes,"Lipodystrophy, Partial, Acquired; Hollander-Simons syndrome; Lipodystrophy, partial; Progressive lipodystrophy disease; SIMONS SYNDROME; Barraquer-Simons syndrome; Acquired Partial Lipodystrophy; Simons' syndrome; Progressive cephalothoracic lipodystrophy; Barraquer-Simons disease; Partial lipoatrophy; HOLLAENDER-SIMONS DISEASE; Macrodystrophia lipomatosa progressiva; LIPODYSTROPHY, PROGRESSIVE; Barraquer-Simons Syndrome; Progressive partial lipodystrophy; BARRAQUER-SIMONS DISEASE; Acquired partial lipodystrophy (disorder); Barraquer syndrome; Lipodystrophic diabetes with partial lipoatrophy; Lipodystrophy, Partial, Progressive; Lipodystrophy, Cephalothoracic Type; Progressive lipodystrophy; Acquired partial lipodystrophy",
C0221005,Mauriac's syndrome,diabetes,Mauriac's syndrome; Mauriac Syndrome; Mauriac syndrome; mauriac syndrome; MAURIAC SYNDROME; mauriac's syndrome; Mauriac's syndrome (disorder); Dwarfism-hepatomegaly-obesity-juvenile diabetes syndrome; DIABETES-DWARFISM-OBESITY SYNDROME,
C0221032,Familial generalized lipodystrophy,diabetes,"Berardinelli lipodystrophy syndrome; Berardinelli Seip Congenital Lipodystrophy; Berardinelli-Seip Syndrome; Berardinelli Seip Syndrome; Lipodystrophies, Generalized; Lipodystrophy, Generalized; Lawrence syndrome; Lipodystrophy, Berardinelli-Seip Congenital; Lipodystrophy with muscular hypertrophy; Generalized Lipodystrophies, Congenital; Congenital generalised lipodystrophy; Congenital generalized lipodystrophy; Lipodystrophies, Congenital Generalized; Lipodystrophy, Total; Congenital Generalized Lipodystrophy; BERARDINELLI-SEIP SYNDROME; Congenital lipoatrophic diabetes; lipoatrophic diabetes mellitus; Total Lipodystrophies; Generalized Lipodystrophy; Brunzell Syndrome (with Bone Cysts); congenital lipoatrophic diabetes; Total Lipodystrophy; Miescher syndrome 2; Total lipoatrophy; lipodystrophy-acromegaloid gigantism syndrome; Seip's syndrome; LIPODYSTROPHY, GENERALIZED; Lipoatrophic diabetes mellitus; Familial generalized lipodystrophy; SEIP-LAWRENCE SYNDROME; BSCL; Congenital Generalized Lipodystrophies; Lipodystrophy of Berardinelli; Congenital lipodystrophy; Generalized Lipodystrophy, Congenital; Beradinelli-Seip syndrome; Familial lipodystrophic diabetes; Lipoatrophic diabetes; SEIP SYNDROME; Congenital total lipodystrophy (disorder); LAWRENCE SYNDROME; congenital lipodystrophy; Syndrome, Brunzell (with Bone Cysts); Berardinelli-Seip-Lawrence syndrome; Berardinelli's syndrome; Berardinelli-Seip congenital lipodystrophy; Congenital total lipodystrophy; Congenital lipodystrophic diabetes; Lipodystrophies, Total; lawrence-seip syndrome; Lipodystrophy, Congenital Generalized; Congenital lipo-atrophy; Berardinelli-Seip syndrome; Congenital Lipodystrophy, Berardinelli-Seip; Berardinelli syndrome; berardinelli syndrome; Lawrence-Seip syndrome; Berardinelli-Seip Congenital Lipodystrophy; lipoatrophic diabetes; Seip syndrome; Generalized lipodystrophy; CGL; generalized lipodystrophy; Generalized Lipodystrophies; Syndrome, Berardinelli-Seip; Total lipodystrophy and acromegaloid gigantism",
C0235397,DIABETES MELLITUS PRECIPITATED,diabetes,DIABETES MELLITUS PRECIPITATED,
C0235398,DIABETES MELLITUS AGGRAVATED,diabetes,DIABETES MELLITUS AGGRAVATED,
C0235399,DIABETES MELLITUS REACTIVATED,diabetes,DIABETES MELLITUS REACTIVATED,
C0235401,Abnormal glucose tolerance,glucose,GLUCOSE TOLERANCE ABNORMAL; Abnormal glucose tolerance,
C0235402,GLUCOSE TOLERANCE CURVE ABNORMAL,glucose,GLUCOSE TOLERANCE CURVE ABNORMAL,
C0236460,Whole Blood Glucose Test,blood glucose,,
C0237987,Glucose-6-phosphate dehydrogenase deficiency anemia,glucose,"G6PD deficiency anemia; ANEMIA HEMOLYTIC G6PD; ANEMIA, HEMOLYTIC, G6PD DEFICIENCY; G-6-PD deficiency anaemia; G-6-PD deficiency anaemia, NOS; G6PD deficiency anaemia; HEMOLYTIC ANEMIA GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENC; Glucose-6-phosphate dehydrogenase deficiency anemia, NOS; ANAEMIA HAEMOLYTIC G6PD; G-6-PD deficiency anemia, NOS; Glucose-6-phosphate dehydrogenase deficiency anemia (disorder); G-6-PD deficiency anemia; ANEMIA HEMOLYTIC G6PD DEFICIENCY; Glucose-6-phosphate dehydrogenase deficiency anaemia, NOS; Glucose-6-phosphate dehydrogenase deficiency anemia; G-6-PD DEFICIENCY ANEMIA; Glucose-6-phosphate dehydrogenase deficiency (G6PD) anemia; Glucose-6-phosphate dehydrogenase deficiency anaemia",
C0238036,Bronchocentric granulomatosis,BG,BG - Bronchocentric granulomatosis; BRONCHOCENTRIC GRANULOMATOSIS; Bronchocentric granulomatosis (disorder); Bronchocentric granulomatosis,
C0238086,"DIABETES MELLITUS, TRANSIENT, OF NEWBORN",diabetes,,
C0238179,"HYPOGLYCEMIA, EXOGENOUS",hypoglycemia,,
C0238181,"HYPOGLYCEMIA, REACTIVE FUNCTIONAL",hypoglycemia,,
C0238922,CEREBRAL SPINAL FLUID GLUCOSE DECREASED,glucose,,
C0239979,"HYPERGLYCEMIA, SEVERE",hyperglycemia,,
C0239980,"HYPERGLYCEMIA, SLIGHT",hyperglycemia,,
C0241861,"DIABETES, STABLE",diabetes,,
C0241862,"DIABETES, TRUE RENAL",diabetes,,
C0242019,NON-KETOTIC HYPEROSMOLAR HYPERGLYCEMIA,hyperglycemia,,
C0244541,3-deoxy-3-iodo-D-glucose,glucose,,
C0245291,dolichol-P-glucose-dolichol-P-P-oligosaccharide glucosyltransferase,glucose,,
C0245293,dolichyl-P-glucose-Man(9)(GlcNAc)2-PP-dolichol glucosyltransferase,glucose,,
C0245294,dolichol phosphate glucose-dolichol diphosphate oligosaccharide glucosyltransferase,glucose,,
C0245715,UPD-glucose-thiohydroximate glucosyltransferase,glucose,UDP-Glc-TH-glucosyltransferase,
C0248419,pancreatic and duodenal homeobox 1 protein,glucose,insulin promoter factor 1; somatostatin transactivating factor 1; pancreatic-duodenal homeobox factor-1; islet-duodenum homeobox-1 protein; pancreatic and duodenal homeobox gene-1; glucose-sensitive factor (GSF); pancreatic and duodenal homeobox 1 protein,
C0248805,Sodium-Glucose Transporter 1,glucose,SGLT1 Protein; SLC5A1 Protein; Sodium-Glucose Cotransporter 1; Sodium Glucose Cotransporter 1; Sodium Glucose Transporter 1; Sodium-Glucose Transporter 1,
C0249652,3-O-(2-iodoethyl)glucose,glucose,3-O-(2-iodoethyl)-D-glucose,
C0250680,dTDP-D-glucose synthase,glucose,deltaTDP-glucose synthase,
C0250899,sterol 3-beta-glucosyltransferase,glucose,UDP-glucose sterol beta-D-glucosyltransferase; UDPG-SGTase; UDP-glucose-sterol-beta-glucosyltransferase,
C0251708,thymidine-diphospho-4-keto-6-deoxyglucose epimerase,glucose,"TDKD-glucose epimerase; TDP-4-keto-6-deoxyglucose 3,5-epimerase",
C0251796,glucose-cysteine,glucose,D-glucose-L-cysteine; glucose-Cys,
C0251880,glucose-3-phosphatase,glucose,,
C0251914,"PDIA3 protein, human",glucose,"ER60 protein, human; ERp57; endoplasmic reticulum protein p61, human; HIP-70 protein, human; PDIA3; EC 5.3.4.1; Endoplasmic Reticulum Resident Protein 60; ER Protein 57; ER-60 protein, human; PIA3 protein, human; ERp60; ERp57 protein, human; ERp60 protein, human; p58; 58 kDa Microsomal Protein; glucose regulated protein, 58 kDa, human; 1,25D3-MARRS (membrane activated rapid response to steroids) protein, human; ERp61 protein, human; membrane activated rapid response to steroids protein, human; Endoplasmic Reticulum p58; ER Protein 60; Protein Disulfide Isomerase-Associated 3; 58 kDa microsomal protein, human; protein disulfide isomerase family A, member 3 protein, human; 58 kDa Glucose-Regulated Protein; PDIA3 protein, human; Endoplasmic Reticulum Resident Protein 57; Disulfide Isomerase ER-60; GRP58 protein, human; Protein Disulfide-Isomerase A3",
C0253164,glucose-6-phosphate dehydrogenase Kobe,glucose,G6PD Kobe,
C0253266,"glucose facilitator protein, Zymomonas",glucose,"GLF protein, Zymomonas",
C0254476,6-O-galloylglucose,glucose,6-O-galloyl-D-glucose,
C0255225,maltose 6-phosphate,glucose,maltose-6P; 6-O-phosphoryl-alpha-D-glucopyranosyl-(1-4)-D-glucose,
C0255472,Acid Leather Red BG,BG,,
C0255673,Bg II toxin,BG,"BgII toxin, Bunodosoma granulifera",
C0255674,BG III toxin,BG,"BgIII toxin, Bunodosoma granulifera",
C0257665,medikhronal,glucose,glucose-glycine-formate; medichronal; glucose-glycine-formiate,
C0257753,glucose aldonitrile pentaacetate,glucose,,
C0258123,Hypocal,hypo,Hypocal; Hypo-cal,
C0258623,"CDP-glucose 4,6-dehydratase",glucose,"Cytidine diphosphate glucose 4,6-dehydratase (substance); Cytidine diphosphate (CDP) glucose 4,6-dehydratase; Cytidine diphosphate glucose 4,6-dehydratase; CDPglucose 4,6-dehydratase",
C0259112,soyasaponin beta g,BG,soyasaponin betag; soyasaponin Bg,
C0259741,"Diabetes mellitus, latent",diabetes,Diabetes Mellitus (Latent),
C0260526,Encounter due to family history of diabetes mellitus,diabetes,Family history of diabetes mellitus,
C0260925,Encounter for screening for diabetes mellitus,diabetes,Screening for diabetes mellitus,
C0262448,"Diabetes mellitus, chemical",diabetes,DIABETES MELLITUS (CHEMICAL),
C0263422,Pretibial pigmental patches due to diabetes mellitus,diabetes,Pretibial pigmented patches in diabetes; Pretibial pigmental patches due to diabetes mellitus (disorder); Pretibial pigmental patches in diabetes,
C0264614,Hypernasality,hyper,Hypernasality syndrome; Rhinolalia aperta; Hyper-rhinolalia; hypernasality; Hypernasality; Open nasality; Hypernasality syndrome (disorder); rhinolalia aperta,
C0265222,Royer Syndrome,diabetes,"Prader-Willi syndrome and diabetes; Royers Syndrome; Syndrome, Royer; Royer's syndrome; Syndrome, Royer's; Royer's Syndrome",
C0267176,Gastroparesis due to diabetes mellitus,diabetes,Gastroparesis with diabetes mellitus; Diabetic gastroparesis; diabetic gastroparesis; DIABETIC GASTROPARESIS; Gastroparesis due to diabetes mellitus (disorder),
C0267650,Hypoglycemia following gastrointestinal surgery,hypoglycemia,Hypoglycemia following gastrointestinal surgery; Hypoglycaemia following gastrointestinal surgery,
C0268005,Hyposmolality syndrome,hypo,"Hyposmolality syndrome, NOS; Hypotonic disorder, NOS; Hyposmolality syndrome; hyposmolality; Hyposmolality, NOS; Hypotonic disorder (disorder); Hypoosmolality; Hypotonic disorder; hypo-osmolality; Hyposmolality (disorder); Hyposmolality; Hyposmolality syndrome (disorder)",
C0268146,Glucose-6-phosphate transport defect,glucose,GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT; GSDIb; Glycogen Storage Disease Type Ib; G6P deficiency type Ib; Glycogen storage disease type 1b; Glycogenosis type 1b; G6PT deficiency; Glycogen storage disease type Ib; GSD due to G6P deficiency type Ib; Glycogen Storage Disease Type I non-a; Glucose-6-phosphate transport defect (disorder); Glycogenosis due to glucose-6-phosphatase transport defect type Ib; GSD1B; GLYCOGEN STORAGE DISEASE Ib; GSD due to G6PT deficiency; Glucose 6-phosphate transport defect; GSD type 1b; GSD type Ib; Glucose-6-phosphate transport defect; Glycogenosis due to glucose-6-phosphatase deficiency type 1b; G6P translocase deficiency; GSD Ib; GSD type 1 non a; Glucose-6-Phosphate Transport Defect; Glycogen Storage Disease IB; Glycogen storage disease due to G6P deficiency type Ib; Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib; Glycogenosis type Ib; GSD due to G6P deficiency type 1b,
C0268151,Classical galactosemia,glucose,"classic galactosemia; UDPGlucose Hexose 1 Phosphate Uridylyltransferase Deficiency; Galactose-1-Phosphate Uridyltransferase Deficiencies; Classical galactosaemia; Transferase deficiency galactosemia; Deficiency of uridine diphosphate-glucose-hexose-1-phosphate uridylyltransferase; Deficiency Disease, Galactose-1-Phosphate Uridyl-Transferase; Galactose-1-Phosphate Uridyl-Transferase Deficiency Disease; Deficiency Disease, Galactose 1 Phosphate Uridyl Transferase; Classic galactosemia; Epimerase Deficiency Galactosemias; Galactosemia, Classic; Uridylyltransferase Deficiencies, Galactose-1-Phosphate; UTP Hexose 1 Phosphate Uridylyltransferase Deficiency Disease; Deficiency, Galactose-1-Phosphate Uridyltransferase; GALT; Classic Galactosemia; GALT deficiency; Galactose-1-Phosphate Uridyltransferase Deficiency; GALAC1; Deficiency of uridine triphosphate-hexose-1-phosphate uridylyltransferase; Galactose 1 Phosphate Uridyltransferase Deficiency; Deficiency of UTP-hexose-1-phosphate uridylyltransferase; UTP-Hexose-1-Phosphate Uridylyltransferase Deficiency; UTP Hexose-1-Phosphate Uridylyltransferase Deficiency; Galactose-1-Phosphate Uridylyltransferase Deficiencies; Deficiencies, Galactose-1-Phosphate Uridylyltransferase; Galactose-1-Phosphate Uridylyltransferase Deficiency; Deficiency of uridyl transferase; Galactosemia, Epimerase Deficiency; GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE DEFICIENCY; Deficiency of uridine triphosphate-hexose-1-phosphate uridylyltransferase (disorder); Classic Galactosemias; Uridyltransferase Deficiency, Galactose-1-Phosphate; GALACTOSEMIA, CLASSIC; GALACTOSEMIA I; Deficiency, GALT; Uridylyltransferase Deficiency, Galactose-1-Phosphate; Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase; Deficiency of uridine diphosphate-glucose-hexose-1-phosphate uridylyltransferase (disorder); galactose 1 phosphate uridylyl transferase deficiency; UDPGlucose Hexose-1-Phosphate Uridylyltransferase Deficiency; Deficiencies, Galactose-1-Phosphate Uridyltransferase; Galactose-1-phosphate uridyltransferase deficiency; Galactosemias, Epimerase Deficiency; Transferase deficiency galactosaemia; Deficiency of galactose-1-phosphate uridyl transferase; Deficiency Galactosemia, Epimerase; Epimerase Deficiency Galactosemia; Galactosemia type 1; Deficiency, Galactose-1-Phosphate Uridylyltransferase; UTP-hexose-1-phosphate uridyltransferase deficiency; Galactose-1-phosphate uridyl transferase deficiency; Galactose 1 Phosphate Uridyl Transferase Deficiency Disease; Classical galactosemia; Deficiency of hexose-1-phosphate uridylyltransferase; uridyl transferase deficiency; Galactose 1 Phosphate Uridylyltransferase Deficiency; Deficiencies, GALT; GALT DEFICIENCY; GALT Deficiencies; UTP-Hexose-1-Phosphate Uridylyltransferase Deficiency Disease; Galactosemias, Classic; UTP Hexose 1 Phosphate Uridylyltransferase Deficiency; Galactosemia, type I; Deficiency Galactosemias, Epimerase; Uridyltransferase Deficiencies, Galactose-1-Phosphate; GALT Deficiency",
C0268176,Nonglucosuric melituria,glucose,"Nonglucosuric melituria (disorder); Nonglucosuric melituria; Non glucose melituria; Non-glucose melituria; Melituria, non-glucosuric",
C0268186,Congenital glucose-galactose malabsorption,glucose,Congenital glucose-galactose malabsorption; SGLT1 deficiency; MONOSACCHARIDE MALABSORPTION; GLUCOSE/GALACTOSE MALABSORPTION; Complex Carbohydrate Intolerance; Glucose-galactose malabsorption (disorder); Congenital glucose-galactose malabsorption syndrome; Glucose-Galactose Malabsorption; Glucose-galactose malabsorption; GGM; Monosaccharide malabsorption syndrome; glucose galactose malabsorption; Carbohydrate Intolerance; glucose-galactose malabsorption; Congenital glucose-galactose intolerance; Congenital glucose-galactose malabsorption (disorder); Monosaccharide Malabsorption; GM; Glucose Galactose Malabsorption,
C0268443,Acquired Nephrogenic Diabetes Insipidus,diabetes,Acquired nephrogenic diabetes insipidus (disorder); Secondary nephrogenic diabetes insipidus; Acquired nephrogenic diabetes insipidus,
C0268630,Hyper-beta-alaninemia,hyper,Hyper-Beta-Alaninemia; HYPER-BETA-ALANINEMIA; Hyperalaninaemia; Hyperalaninemia; HYPERALANINEMIA; Hyper-beta-alaninemia (disorder); Hyper-beta-alaninemia; Hyper-beta-alaninaemia,
C0268813,Dipsogenic Diabetes Insipidus,diabetes,dipsogenic diabetes insipidus; Dipsogenic Diabetes Insipidus; Dipsogenic diabetes insipidus (disorder); Dipsogenic diabetes insipidus,
C0270221,Syndrome of infant of diabetic mother,diabetes,"Maternal diabetes syndrome; Infant of a diabetic mother syndrome; Syndrome of infant of diabetic mother (disorder); Syndrome of infant of a diabetic mother; diabetic infant mother syndrome; maternal diabetes syndrome; Syndrome of ""infant of a diabetic mother""; Infant of Diabetic Mother; Syndrome of infant of diabetic mother",
C0270230,Hypoglycemia of piglets,hypoglycemia,Hypoglycaemia of piglets; Hypoglycemia of piglets; Hypoglycemia of piglets (disorder),
C0271064,Microaneurysm of retinal artery due to diabetes mellitus,diabetes,Retinal microaneurysm with diabetes mellitus; Microaneurysm of retinal artery due to diabetes mellitus (disorder); Diabetic retinal microaneurysm; Diabetic retinal microaneurysms,
C0271591,Idiopathic diabetes insipidus,diabetes,Idiopathic diabetes insipidus; Idiopathic diabetes insipidus (disorder),
C0271592,Familial diabetes insipidus,diabetes,Familial diabetes insipidus (disorder); Familial diabetes insipidus,
C0271593,Secondary diabetes insipidus,diabetes,Secondary diabetes insipidus; Secondary diabetes insipidus (disorder),
C0271632,DISEASES OF THE ENDOCRINE PANCREAS INCLUDING DIABETES,diabetes,,
C0271635,Diabetes mellitus without complication,diabetes,Diabetes mellitus without complication; Diabetes Mellitus without Complications; Uncomplicated Diabetes Mellitus; Uncomplicated Diabetes; Diabetes mellitus without complication (disorder); Diabetes mellitus without mention of complication; Diabetes without complications,
C0271636,Insulin dependent diabetes mellitus type 1A,diabetes,Insulin dependent diabetes mellitus type IA; Insulin dependent diabetes mellitus type IA (disorder); Immune-mediated type 1 diabetes mellitus,
C0271637,Insulin dependent diabetes mellitus type 1B,diabetes,Insulin dependent diabetes mellitus type IB (disorder); Idiopathic type 1 diabetes mellitus; Primary autoimmune diabetes mellitus; Insulin dependent diabetes mellitus type IB,
C0271638,Type 2 diabetes mellitus in obese,diabetes,Diabetes mellitus type 2 in obese (disorder); NIDDM in obese; Diabetes mellitus type 2 in obese,
C0271640,Secondary diabetes mellitus,diabetes,"Secondary diabetes mellitus (disorder); Secondary diabetes mellitus NOS; Secondary diabetes mellitus; Secondary diabetes mellitus, NOS",
C0271641,Malnutrition related diabetes mellitus,diabetes,MRDM; Malnutrition related diabetes mellitus; Malnutrition related diabetes mellitus (disorder),
C0271642,Fibrocalculous pancreatic diabetes,diabetes,Fibrocalculous pancreatic diabetes; Fibrocalculous pancreatic diabetes (disorder),
C0271645,Diabetes mellitus associated with hormonal etiology,diabetes,Diabetes mellitus associated with hormonal etiology; Diabetes mellitus associated with hormonal etiology (disorder); Diabetes mellitus associated with hormonal aetiology,
C0271646,Drug-induced diabetes mellitus,diabetes,"drug related diabetes mellitus; Diabetes mellitus, drug-related; Drug-induced diabetes mellitus; Drug-induced diabetes mellitus (disorder)",
C0271648,Diabetes mellitus associated with receptor abnormality,diabetes,Diabetes mellitus associated with receptor abnormality (disorder); Diabetes mellitus associated with receptor abnormality,
C0271649,Diabetes mellitus associated with unlisted condition,diabetes,"Rare form of diabetes mellitus, NOS",
C0271650,Glucose Intolerance (disease),glucose,"Impaired glucose tolerance; Prediabetic nonclinical diabetes; Impaired glucose tolerance, NOS; Chemical diabetes; GLUCOSE INTOLERANCE; Glucose Tolerance, Impaired; impaired glucose tolerance; diabetes chemical; Malabsorption of glucose (disorder); IGT - Impaired glucose tolerance; Glucose Tolerances, Impaired; Tolerance, Impaired Glucose; Glucose Intolerances; glucose intolerance; Glucose Intolerance; Impaired glucose tolerance (disorder); Glucose intolerance; Latent diabetes; chemicals diabetes; Impaired Glucose Tolerances; glucose impaired tolerance; latent diabetes; Impaired Glucose Tolerance; Tolerances, Impaired Glucose; Intolerances, Glucose; Malabsorption of glucose; glucose malabsorption; chemical diabetes; malabsorption of glucose; Intolerance, Glucose",
C0271651,Impaired glucose tolerance in obese,glucose,Impaired glucose tolerance in obese (disorder); Impaired glucose tolerance in obese,
C0271652,Impaired glucose tolerance in nonobese,glucose,Impaired glucose tolerance in nonobese (disorder); Impaired glucose tolerance in nonobese,
C0271653,Impaired glucose tolerance in MODY,glucose,Impaired glucose tolerance in and individual with a heritable form of maturity onset diabetes in the young; Impaired glucose tolerance in MODY; Impaired glucose tolerance in and individual with a heritable form of maturity onset diabetes in the young (disorder),
C0271654,Impaired glucose tolerance associated with pancreatic disease,glucose,Impaired glucose tolerance associated with pancreatic disease; Impaired glucose tolerance associated with pancreatic disease (disorder),
C0271655,Impaired glucose tolerance associated with hormonal etiology,glucose,Impaired glucose tolerance associated with hormonal etiology (disorder); Impaired glucose tolerance associated with hormonal etiology; Impaired glucose tolerance associated with hormonal aetiology,
C0271656,Impaired glucose tolerance associated with drugs,glucose,Impaired glucose tolerance associated with drugs (disorder); Impaired glucose tolerance associated with drugs,
C0271657,Impaired glucose tolerance associated with genetic syndrome,glucose,Impaired glucose tolerance associated with genetic syndrome; Impaired glucose tolerance associated with genetic syndrome (disorder),
C0271658,Impaired glucose tolerance associated with insulin receptor abnormality,glucose,Impaired glucose tolerance associated with insulin receptor abnormality; Impaired glucose tolerance associated with insulin receptor abnormality (disorder),
C0271659,Impaired glucose tolerance associated with unlisted conditions,glucose,,
C0271660,Previous abnormality of glucose tolerance,glucose,Previous abnormality of glucose tolerance; Previous AGT; Previous abnormality of glucose tolerance (disorder),
C0271661,Potential abnormality of glucose tolerance,glucose,Potential abnormality of glucose tolerance (disorder); Potential abnormality of glucose tolerance; Potential AGT,
C0271662,"Gestational diabetes mellitus, class A>1<",diabetes,"Gestational diabetes mellitus, class A<sub>1</sub> (disorder); Gestational diabetes mellitus, class A1 (disorder); Gestational diabetes mellitus, class A>1< (disorder); GDM, class A>1<; Gestational diabetes mellitus, class A<sub>1</sub>; GDM, class A1; Gestational Diabetes Mellitus, A1 White Classification; GDM, class A<sub>1</sub>; Gestational diabetes mellitus, class A1; Gestational Diabetes Mellitus, A1",
C0271663,"Gestational diabetes mellitus, class A>2<",diabetes,"GDM, class A2; Gestational Diabetes Mellitus, A2 White Classification; Gestational diabetes mellitus, class A2 (disorder); Gestational Diabetes Mellitus, A2; Gestational diabetes mellitus, class A<sub>2</sub>; Gestational diabetes mellitus, class A2; Gestational diabetes mellitus, class A>2< (disorder); GDM, class A>2<; Gestational diabetes mellitus, class A<sub>2</sub> (disorder); GDM, class A<sub>2</sub>",
C0271664,"Gestational diabetes mellitus, class B1",diabetes,"GDM, class B1",
C0271665,"Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class A",glucose,"Pregestational diabetes mellitus or impaired glucose tolerance, modified White class A; Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class A (disorder)",
C0271666,"Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class B",glucose,"Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class B (disorder); Pregestational diabetes mellitus or impaired glucose tolerance, modified White class B",
C0271667,"Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class C",glucose,"Pregestational diabetes mellitus or impaired glucose tolerance, modified White class C; Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class C (disorder)",
C0271668,"Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class D",glucose,"Pregestational diabetes mellitus or impaired glucose tolerance, modified White class D; Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class D (disorder)",
C0271669,"Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class F",glucose,"Pregestational diabetes mellitus or impaired glucose tolerance, modified White class F; Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class F (disorder)",
C0271670,"Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class R",glucose,"Pregestational diabetes mellitus or impaired glucose tolerance, modified White class R; Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class R (disorder)",
C0271671,"Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class FR",glucose,"Pregestational diabetes mellitus or impaired glucose tolerance, modified White class FR; Pregestational diabetes mellitus AND/OR impaired glucose tolerance, modified White class FR (disorder)",
C0271673,Symmetric Diabetic Proximal Motor Neuropathy,diabetes,Symmetric diabetic proximal motor neuropathy; Symmetric proximal motor neuropathy due to diabetes mellitus; Symmetric proximal motor neuropathy with diabetes mellitus; Symmetric proximal motor neuropathy due to diabetes mellitus (disorder),
C0271674,Asymmetric Diabetic Proximal Motor Neuropathy,diabetes,Asymmetric diabetic proximal motor neuropathy; Asymmetric proximal motor neuropathy due to diabetes mellitus; Asymmetric proximal motor neuropathy with diabetes mellitus; Asymmetric proximal motor neuropathy due to diabetes mellitus (disorder),
C0271675,Radiculoplexus neuropathy due to diabetes mellitus,diabetes,DRPN - diabetic radiculoplexus neuropathy; Radiculoplexus neuropathy with diabetes mellitus; Diabetic radiculopathy; Radiculoplexus neuropathy due to diabetes mellitus (disorder),
C0271678,Diabetic Mononeuropathy,diabetes,"Mononeuropathy simplex due to diabetes mellitus (disorder); Mononeuropathies, Diabetic; Diabetic mononeuropathy simplex; Mononeuropathy simplex due to diabetes mellitus; Mononeuropathy, Diabetic; Diabetic mononeuropathy; Mononeuropathy due to diabetes mellitus (disorder); Mononeuropathy simplex with diabetes mellitus; Diabetic Mononeuropathies; Mononeuropathy due to diabetes mellitus; Mononeuropathy Simplices, Diabetic; Mononeuropathy Simplex, Diabetic; Simplices, Diabetic Mononeuropathy; Diabetic Mononeuropathy Simplices; Simplex, Diabetic Mononeuropathy; Diabetic Mononeuropathy Simplex",
C0271679,Diabetic mononeuropathy multiplex,diabetes,Mononeuropathy multiplex due to diabetes mellitus; Mononeuropathy multiplex due to diabetes mellitus (disorder); Diabetic mononeuropathy multiplex,
C0271680,Diabetic Polyneuropathies,diabetes,"diabetic polyneuropathy; Diabetic polyneuropathy; Polyneuropathy, Diabetic; Polyneuropathy due to diabetes mellitus (disorder); Diabetic Polyneuropathies; diabetes polyneuropathy; Polyneuropathy in diabetes; polyneuropathy in diabetes; Polyneuropathy due to diabetes mellitus; Diabetic Polyneuropathy; Polyneuropathies, Diabetic; diabetics polyneuropathy; Diabetic polyneuropathy, NOS; polyneuropathy diabetes",
C0271684,Pseudotabes due to diabetes mellitus,diabetes,"Pseudotabes due to diabetes mellitus (disorder); Pseudotabes with diabetes mellitus; Diabetic pseudotabes; PSEUDOTABES, DIABETIC",
C0271686,Diabetic Autonomic Neuropathy,diabetes,"Neuropathy, Diabetic Autonomic; autonomic diabetic neuropathy; diabetic autonomic neuropathy; Autonomic Neuropathy, Diabetic; Autonomic neuropathy with diabetes mellitus; Autonomic neuropathy due to diabetes mellitus (disorder); Autonomic neuropathy due to diabetes mellitus; Autonomic neuropathy due to diabetes; Neuropathies, Diabetic Autonomic; Autonomic Neuropathies, Diabetic; Diabetic Autonomic Neuropathies; Diabetic Autonomic Neuropathy; Diabetic autonomic neuropathy",
C0271687,Diabetes mellitus due to structurally abnormal insulin,diabetes,"Insulinopathy, NOS; Diabetes mellitus due to structurally abnormal insulin (disorder); Insulinopathy; Diabetes mellitus due to abnormal insulin",
C0271690,Acanthosis nigricans due to type 2 diabetes mellitus,diabetes,Acanthosis nigricans due to type 2 diabetes mellitus (disorder); Insulin-resistant diabetes mellitus and acanthosis nigricans; Type 2 diabetes mellitus with acanthosis nigricans; Insulin-resistant diabetes mellitus AND acanthosis nigricans,
C0271693,Acquired generalized lipodystrophy,diabetes,Acquired total lipoatrophy; Acquired lipodystrophic diabetes; Lawrence-Seip syndrome; Acquired lipoatrophic diabetes; Lawrence syndrome; Acquired generalized lipodystrophy (disorder); Acquired Generalized Lipodystrophy; Acquired generalised lipodystrophy; Acquired generalized lipodystrophy,
C0271695,Rabson-Mendenhall Syndrome,diabetes,"Pineal hyperplasia and diabetes mellitus syndrome; PINEAL HYPERPLASIA, INSULIN-RESISTANT DIABETES MELLITUS, AND SOMATIC ABNORMALITIES; Mendenhall syndrome; MENDENHALL SYNDROME; Pineal Hyperplasia, Insulin-Resistant Diabetes Mellitus, And Somatic Abnormalities; Pineal hyperplasia, insulin-resistant diabetes mellitus and somatic abnormalities; Pineal hyperplasia AND diabetes mellitus syndrome (disorder); Rabson Mendenhall syndrome; Pineal hyperplasia AND diabetes mellitus syndrome; Syndrome, Rabson-Mendenhall; RABSON-MENDENHALL SYNDROME; Rabson Mendenhall Syndrome; Mendenhall Syndrome; Syndrome, Mendenhall; Rabson-Mendenhall syndrome; Rabson-Mendenhall Syndrome",
C0271699,Nodular type diabetic glomerulosclerosis,diabetes,Nodular glomerulosclerosis of kidney due to diabetes mellitus; Nodular glomerulosclerosis of kidney due to diabetes mellitus (disorder); Nodular type diabetic glomerulosclerosis,
C0271700,Diffuse glomerulosclerosis of kidney due to diabetes mellitus,diabetes,Diffuse glomerulosclerosis of kidney due to diabetes mellitus (disorder); Diffuse type diabetic glomerulosclerosis,
C0271701,Diabetes mellitus due to insulin receptor antibodies,diabetes,Diabetes mellitus caused by insulin receptor antibodies (disorder); DM due to insulin receptor ab; Diabetes mellitus due to insulin receptor antibodies; DM caused by insulin receptor ab; Diabetes mellitus caused by insulin receptor antibodies,
C0271703,Factitious hypoglycemia,hypoglycemia,HYPOGLYCEMIA FACTITIOUS; Factitious hypoglycemia (disorder); Factitious hypoglycaemia; Factitious hypoglycemia,
C0271707,Autoimmune hypoglycemia,hypoglycemia,"Autoimmune hypoglycemia, NOS; Autoimmune hypoglycaemia, NOS; Autoimmune hypoglycemia (disorder); Autoimmune hypoglycaemia",
C0271708,Fasting Hypoglycemia,blood sugar,"Low blood sugar when fasting; Postabsorptive Hypoglycemia; Fasting hypoglycemia (disorder); Fasting hypoglycaemia; Hypoglycemia, Fasting; Hypoglycemia, Postabsorptive; fasting hypoglycemia; Fasting hypoglycemia",
C0271709,Idiopathic postprandial hypoglycemia,hypoglycemia,Idiopathic postprandial hypoglycemia (disorder); Idiopathic postprandial hypoglycemia; Idiopathic postprandial hypoglycaemia,
C0271710,Reactive hypoglycemia,blood sugar,"Hypoglycemia, Postprandial; Post-prandial hypoglycemia (disorder); Low blood sugar after a meal; Postprandial hypoglycemia; HYPOGLYCEMIC REACTION; Reactive Hypoglycemia; Postprandial Hypoglycemia; Post-prandial hypoglycemia; hypoglycemia postprandial; Hypoglycemia, Reactive; hypoglycemia reactive; postprandial hypoglycemia; Post-prandial hypoglycaemia; HYPOGLYCAEMIC REACTION; post prandial hypoglycemia; reactive hypoglycemia; hypoglycemic reactions; Reactive hypoglycemia (disorder); Hypoglycemic reaction; hypoglycemic reaction; Hypoglycemia, postprandial; Reactive hypoglycemia; HYPOGLYCEMIA REACTIVE; REACTION HYPOGLYCEMIC; Reactive hypoglycaemia; Hypoglycaemic reaction; Hypoglycemia, reactive; reactive hypoglycaemia",
C0271711,Spontaneous hypoglycemia,hypoglycemia,Spontaneous hypoglycemia (disorder); Spontaneous hypoglycemia; Spontaneous hypoglycaemia,
C0271712,Hypoglycemia of childhood,hypoglycemia,Hypoglycemia of childhood (disorder); Hypoglycaemia of childhood; Hypoglycemia in children; Hypoglycemia of childhood; Hypoglycemia of childhood syndrome,
C0271713,Ketotic hypoglycemia,blood sugar,Ketotic hypoglycemia; Ketotic hypoglycaemia; Ketotic Hypoglycemia; ketotic hypoglycemia; Ketotic hypoglycemia (disorder); Ketotic low blood sugar,
C0271714,"Hypoglycemia, leucine-induced",hypoglycemia,"LEUCINE-SENSITIVE HYPOGLYCEMIA OF INFANCY; Leucine-induced hypoglycemia; Hypoglycemia, leucine-induced; HYPOGLYCEMIA, LEUCINE-INDUCED; Leucine-induced hypoglycemia (disorder); Leucine-induced hypoglycaemia; LIH; Leucine-sensitive hypoglycemia of infancy",
C0271715,Mixed hypoglycemia,hypoglycemia,Mixed hypoglycaemia; Mixed hypoglycemia; Mixed hypoglycemia (disorder),
C0271716,Postpancreatectomy hyperglycemia,hyperglycemia,Postpancreatectomy hyperglycemia (disorder); Postpancreatectomy hyperglycemia; Postpancreatectomy hyperglycaemia,
C0271732,Achard-Thiers syndrome,diabetes,Achard-Thiers syndrome (disorder); Diabetic-bearded woman syndrome; Achard-Thiers syndrome; Bearded female with diabetes; Diabetes in bearded women; Diabetic-bearded women syndrome; Adenoma associated virilism of older women,
C0271931,Anemia due to diabetes mellitus,diabetes,Anaemia of diabetes; Anemia of diabetes; Anemia due to diabetes mellitus (disorder); anemia diabetes; anemia of diabetes; Anaemia due to diabetes mellitus; diabetes anemia,
C0272055,Glucose-6-phosphate dehydrogenase variant enzyme deficiency anemia,glucose,"Glucose-6-phosphate dehydrogenase variant enzyme deficiency anemia; G-6-PD variant enzyme deficiency anemia, NOS; Glucose-6-phosphate dehydrogenase variant enzyme deficiency anaemia; G-6-PD variant enzyme deficiency anemia; Glucose-6-phosphate dehydrogenase variant enzyme deficiency anemia (disorder); G-6-PD variant enzyme deficiency anaemia, NOS; G-6-PD variant enzyme deficiency anaemia",
C0272056,G-6-PD class I variant anemia,glucose,G-6-PD class I variant anaemia; Glucose-6-phosphate dehydrogenase deficiency class I variant anemia (disorder); G-6-PD class I variant anemia; Glucose-6-phosphate dehydrogenase deficiency class I variant anaemia; Glucose-6-phosphate dehydrogenase deficiency class I variant anemia,
C0272057,G-6-PD class II variant anemia,glucose,Glucose-6-phosphate dehydrogenase deficiency class II variant anaemia; G-6-PD class II variant anemia; G-6-PD class II variant anaemia; Glucose-6-phosphate dehydrogenase deficiency class II variant anemia; Glucose-6-phosphate dehydrogenase deficiency class II variant anemia (disorder),
C0272058,G-6-PD class III variant anemia,glucose,Glucose-6-phosphate dehydrogenase deficiency class III variant anemia (disorder); G-6-PD class III variant anemia; Glucose-6-phosphate dehydrogenase deficiency class III variant anemia; Glucose-6-phosphate dehydrogenase deficiency class III variant anaemia; G-6-PD class III variant anaemia,
C0272059,G-6-PD class IV variant anemia,glucose,Glucose-6-phosphate dehydrogenase deficiency class IV variant anemia; G-6-PD class IV variant anaemia; Glucose-6-phosphate dehydrogenase deficiency class IV variant anemia (disorder); Glucose-6-phosphate dehydrogenase deficiency class IV variant anaemia; G-6-PD class IV variant anemia,
C0272060,G-6-PD class V variant anemia,glucose,Glucose-6-phosphate dehydrogenase deficiency class V variant anemia (disorder); G-6-PD class V variant anemia; G-6-PD class V variant anaemia; Glucose-6-phosphate dehydrogenase deficiency class V variant anemia; Glucose-6-phosphate dehydrogenase deficiency class V variant anaemia,
C0272064,HNSHA due to glucose phosphate isomerase deficiency,glucose,Hereditary nonspherocytic hemolytic anemia due to glucose phosphate isomerase deficiency (disorder); HNSHA due to glucose phosphate isomerase deficiency; Hereditary nonspherocytic hemolytic anemia due to glucose phosphate isomerase deficiency; Hereditary nonspherocytic hemolytic anemia (HNSHA) due to glucose phosphate isomerase deficiency; Hereditary nonspherocytic haemolytic anaemia (HNSHA) due to glucose phosphate isomerase deficiency; Hereditary nonspherocytic haemolytic anaemia due to glucose phosphate isomerase deficiency,
C0272236,Hyperimmunoglobulin M syndrome,hyper,"Syndromes, Hyper-IgM Immunodeficiency; Immunodeficiency with Hyper-IgM; Hyper IgM; Immunodeficiency with IgM hypergammaglobulinaemia; hyperimmunoglobulin m syndrome; Immunodeficiency with IgM hypergammaglobulinemia; Syndrome, Hyper-IgM Immunodeficiency; Hyper-IgM Syndromes; Hyper-IgM Immunodeficiency Syndromes; Hyperimmunoglobulin M syndrome; Hyper-IgM Immunodeficiency Syndrome; Immunodeficiency Syndrome, Hyper-IgM; Immunodeficiency Syndromes, Hyper-IgM; hyper igm syndrome; Immunodeficiency with Hyper-IgM Syndrome; Hyperimmunoglobulin M Syndrome; Hyperimmunoglobulin M syndrome (disorder); Hyper IgM syndrome; Hyper IgM Immunodeficiency Syndrome; Immunodeficiency with Hyper IgM Syndrome; Hyper-IgM Syndrome; Hyper IgM Syndrome",
C0281639,Carmustine/O6-Benzylguanine,BG,BCNU/BG; carmustine/O6-benzylguanine,
C0282201,Phosphate Diabetes,diabetes,"PHOSPHATE DIABETES; Renal phosphaturia (disorder); Phosphate diabetes; Renal phosphaturia; Phosphate Diabetes; phosphate diabetes; Hyperphosphaturia; Renal hyperphosphaturia; Diabetes, Phosphate; Phosphaturia",
C0285843,BG 5P,BG,BG5P,
C0289635,camelliatannin H,glucose,"D-Glucose, cyclic 2->2:3->2'-(4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) cyclic 4,6-(4,4',5,5',6,6'-hexahydroxy01,1'-biphenyl)-2,2'-dicarboxylate, 2-ester with D-glucose cyclic 4,6-(4,4')",
C0291227,thionigerose,glucose,3-S-(alpha-D-glucopyranosyl)-3-thio-D-glucose; 3-S-glucopyranosyl-3-thioglucose,
C0292048,camellioferin A,glucose,"D-Glucose, cyclic 4->2':6->2-(4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) cyclic 2,3-(4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate), 2-ester with beta-D-glucopyranose cyc",
C0294297,"PEA15 protein, human",diabetes,"phosphoprotein enriched in astrocytes 15, human; PED protein, human; vanishin protein, human; PEA-15 protein, human; phosphoprotein enriched in diabetes, 15kDa, human; PEA-15 phosphoprotein, human",
C0298810,2-(3-aminobenzamido)-2-deoxyglucose,glucose,3-AB-G; 2-(3-aminobenzamido)-2-deoxy-D-glucose,
C0301579,Adult diabetes diet,diabetes,"Adult diabetes diet (finding); Adult diabetes diet; Diet, diabetes, adult",
C0301580,Child diabetes diet,diabetes,"Diet, diabetes, child; Child diabetes diet; Child diabetes diet (finding)",
C0305373,B-D Glucose Tablets,glucose,,
C0306308,Glucerna Specialized Nutrition with Fiber for Patients with Abnormal Glucose,glucose,,
C0306410,Hyper-Tet Tetanus Immune Globulin (Human),hyper,,
C0306465,Insta-Glucose,glucose,insta-glucose; Insta-Glucose,
C0307332,Polycose Glucose Polymers,glucose,,
C0308812,calcium chloride 0.001 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution,glucose,"Dextrose 5% and Lactated Ringers, Dextrose 5% in Lactated Ringers Injection intravenous solution; dextrose monohydrate 50 mg in 1 mL / sodium lactate 3.1 mg in 1 mL / sodium chloride 6 mg in 1 mL / potassium chloride 0.3 mg in 1 mL / calcium chloride 0.2 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [VETIVEX Veterinary Lactated Ringers and Dextrose]; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 600 mg in 100 mL / SODIUM LACTATE 310 mg in 100 mL / POTASSIUM CHLORIDE 30 mg in 100 mL / CALCIUM CHLORIDE 20 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Lactated Ringers and Dextrose]; Dextrose 5% and Lactated Ringers; Calcium Chloride 0.001 MEQ/ML / Glucose 50 MG/ML / Pot Chloride 0.004 MEQ/ML / NaCl 0.103 MEQ/ML / Sodium Lactate 0.028 MEQ/ML Injectable Solution; DEXTROSE 5%/NACL 0.117%/SODIUM LACTATE 0.056% INJ; Dextrose 5% and Ringers; 5% dextrose lactated ringers; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 600 mg in 100 mL / POTASSIUM CHLORIDE 30 mg in 100 mL / CALCIUM CHLORIDE 20 mg in 100 mL / SODIUM LACTATE 310 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Lactated Ringer and Dextrose]; SODIUM LACTATE 310 mg in 100 mL / POTASSIUM CHLORIDE 30 mg in 100 mL / CALCIUM CHLORIDE 20 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 600 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [LACTATED RINGERS AND DEXTROSE]; 5 dextrose lactate ringers; DEXTROSE 5%/LACTATED RINGERS INJ; DEXTROSE 5% IN LACTATED RINGER'S; dextrose 5% in lactated ringers; calcium chloride 0.001 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution; SODIUM CHLORIDE 600 mg in 100 mL / SODIUM LACTATE 310 mg in 100 mL / POTASSIUM CHLORIDE 30 mg in 100 mL / CALCIUM CHLORIDE 20 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Lactated Ringers and Dextrose]; lactated Ringers with dextrose 5 % Injectable Solution; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.6 g in 100 mL / SODIUM LACTATE 0.31 g in 100 mL / POTASSIUM CHLORIDE 0.03 g in 100 mL / CALCIUM CHLORIDE 0.02 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose in Lactated Ringers]; Calcium Chloride 0.001 MEQ/ML / Glucose 50 MG/ML / K+ Chloride 0.004 MEQ/ML / NaCl 0.103 MEQ/ML / Sodium Lactate 0.028 MEQ/ML Injectable Solution; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM LACTATE 310 mg in 100 mL / SODIUM CHLORIDE 600 mg in 100 mL / POTASSIUM CHLORIDE 30 mg in 100 mL / CALCIUM CHLORIDE 20 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [LACTATED RINGERS AND DEXTROSE]; DEXTROSE 5%/LACTATED RINGER'S INJ",
C0308817,glucose 500 MG/ML Oral Solution,glucose,Product containing precisely glucose 500 milligram/1 milliliter conventional release oral solution (clinical drug); Glucose 500 mg/mL oral solution; DEXTROSE MONOHYDRATE 50 g in 100 mL ORAL LIQUID [Dextrose 50%]; DEXTROSE 50% SOLUTION,
C0309192,GLUCOSE SOLUTION 50%,glucose,,
C0309254,HYPER SALINE-7,hyper,,
C0309255,HYPO-CHLOR FORMULA 640,hypo,,
C0311196,Hypoglycemia diet,hypoglycemia,Hypoglycaemia diet; diets hypoglycemia; hypoglycemia diet; Hypoglycemia diet (finding); Hypoglycemia diet; diet hypoglycemia,
C0311518,Glucose dehydrogenase (NAD),glucose,Glucose dehydrogenase (nicotinamide adenine dinucleotide); Glucose dehydrogenase (NAD); Glucose dehydrogenase (nicotinamide adenine dinucleotide) (substance),
C0311519,Glucose dehydrogenase (NADP^+^),glucose,Glucose dehydrogenase (nicotinamide adenine dinucleotide phosphate +); Glucose dehydrogenase (nicotinamide adenine dinucleotide phosphate <sup>+</sup>) (substance); Glucose dehydrogenase (NADP+); Glucose dehydrogenase (nicotinamide adenine dinucleotide phosphate <sup>+</sup>); Glucose dehydrogenase (nicotinamide adenine dinucleotide phosphate ^+^) (substance); Glucose dehydrogenase (NADP<sup>+</sup>); Glucose dehydrogenase (nicotinamide adenine dinucleotide phosphate +) (substance); Glucose dehydrogenase (nicotinamide adenine dinucleotide phosphate ^+^),
C0311596,Glucose dehydrogenase (acceptor),glucose,Glucose dehydrogenase (acceptor); Glucose dehydrogenase (acceptor) (substance); Glucose dehydrogenase (Aspergillus),
C0311826,Cellulose synthase (GDP-forming),glucose,Cellulose synthase (GDP-forming); Cellulose synthase (guanosine diphosphate-forming); cellulose synthetase; Cellulose synthase (guanosine diphosphate-forming) (substance); GDP-glucose-cellulose glucosyltransferase; GDP-glucose-beta-D-glucan glucosyltransferase; cellulose synthase (GDP-forming),
C0311850,cyanohydrin beta-glucosyltransferase,glucose,UDP-glucose p-hydroxymandelonitrile-O-glucosyltransferase; Cyanohydrin beta-glucosyltransferase (substance); Cyanohydrin beta-glucosyltransferase,
C0311863,"alpha-1,4-glucan-protein synthase (UDP-forming)",glucose,"UDP-Glc-protein transglucosylase I; UDP glucose-protein 4 alpha-D-glucosyltransferase; Alpha-1,4-glucan-protein synthase (UDP-forming); UDPG-protein transglucosylase I; Alpha-1,4-glucan-protein synthase (uridine diphosphate-forming) (substance); Alpha-1,4-glucan-protein synthase (uridine diphosphate-forming); alpha-1,4-Glucan-protein synthase (UDP-forming)",
C0311920,"dTDP4-amino-4,6-dideoxy-D-glucose aminotransferase",glucose,"Deoxythymidine diphosphate-4-amino-4,6-dideoxy-D-glucose aminotransferase; Deoxythymidine diphosphate-4-amino-4,6-dideoxy-D-glucose aminotransferase (substance); dTDP4-amino-4,6-dideoxy-D-glucose aminotransferase",
C0311921,"UDP-4-amino-2-acetamido-2,4,6-trideoxy-glucose aminotransferase",glucose,"Uridine diphosphate-4-amino-2-acetamido-2,4,6-trideoxy-glucose aminotransferase (substance); Uridine diphosphate (UDP)-4-amino-2-acetamido-2,4,6-trideoxy-glucose aminotransferase; UDP-4-amino-2-acetamido-2,4,6-trideoxy-glucose aminotransferase; Uridine diphosphate-4-amino-2-acetamido-2,4,6-trideoxy-glucose aminotransferase",
C0311944,glucose-1-phosphate phosphodismutase,glucose,Glucose-1-phosphate phosphodismutase (substance); Glucose-1-phosphate phosphodismutase; glucose-1-phosphate transphosphorylase,
C0311995,glucose-1-phosphate guanylyltransferase,glucose,GDPgIucose pyrophosphorylase; GDPglucose pyrophosphorylase; Glucose-1-phosphate guanylyltransferase; Glucose-1-phosphate guanylyltransferase (substance); GDP-Glc pyrophosphorylase; GDP-glucose pyrophosphorylase,
C0312319,"UDP glucose 4,6-dehydratase",glucose,"Uridine diphosphate glucose 4,6-dehydratase; UDPglucose 4,6-dehydratase; Uridine diphosphate glucose 4,6-dehydratase (substance); Uridine diphosphate (UDP) glucose 4,6-dehydratase",
C0312349,Glucose-6-phosphate 1-epimerase,glucose,Glucose-6-phosphate 1-epimerase; Glucose-6-phosphate 1-epimerase (substance),
C0312365,Phosphoglucomutase (glucose-cofactor),glucose,Phosphoglucomutase (glucose-cofactor) (substance); Phosphoglucomutase (glucose-cofactor),
C0313639,Bg AND RELATED ANTIGENS,BG,,
C0313640,Blood group antigen Bg^a^,BG,DBG Ag; B little g super little a Ag; Blood group antigen Bg<sup>a</sup>; Blood group antigen Ot; DBG Antigen; Blood group antigen DBG (Donna-Bennett-Goodspeed); Bg^a Antigen; Blood group antigen Bg^a^ (substance); Blood group antigen DBG; Blood group antigen Bg<sup>a</sup> (substance); Bg^a Ag; Blood group antigen Bg a (substance); Blood group antigen Stobo; Blood group antigen Bg a; Blood group antigen Ho; Blood group antigen HLA-B7,
C0313737,Bg AND/OR related antibody,BG,Bg AND RELATED ANTIBODIES; Bg AND/OR related antibody (substance),
C0313738,Blood group antibody Bg^a^,BG,Blood group antibody Bg a (substance); B little g super little a Ab; Blood group antibody Ot; Blood group antibody DBG; Blood group antibody Bg^a^ (substance); Blood group antibody Bg<sup>a</sup> (substance); Blood group antibody Stobo; Blood group antibody Bg a; Bg^a Ab; Blood group antibody Ho; Bg^a Antibody; Blood group antibody HLA-B7; Blood group antibody Bg<sup>a</sup>,
C0313739,Blood group antibody Bg^b^,BG,Blood group antibody HLA-B17; Blood group antibody Bg<sup>b</sup> (substance); Blood group antibody Bg^b^ (substance); Blood group antibody Bg b (substance); Blood group antibody Bg b; Blood group antibody Bg<sup>b</sup>,
C0313740,Blood group antibody Bg^c^,BG,Blood group antibody Bg c; Blood group antibody Bg<sup>c</sup> (substance); Blood group antibody HLA-A28; Blood group antibody Bg^c^ (substance); Blood group antibody Bg c (substance); Blood group antibody Bg<sup>c</sup>,
C0337438,Glucose measurement,glucose level,"glucose level; Glucose measurement, NOS; sugar level test; glucose measurement; Glucose Measurement; Glucose; glucose test; glucose measurements; Glucose measurement; sugar test; glucose level test; Glucose measurement (procedure)",
C0338545,Neuropathy associated with hypoglycemia,hypoglycemia,Polyneuropathy in hypoglycemia; Polyneuropathy in hypoglycaemia; Neuropathy associated with hypoglycemia (disorder); Neuropathy associated with hypoglycaemia,
C0339310,Iritis due to diabetes mellitus,diabetes,Iritis due to diabetes mellitus (disorder); Diabetic iritis,
C0339470,Visually threatening diabetic retinopathy,diabetes,Visually threatening retinopathy due to diabetes mellitus; Sight threatening diabetic retinopathy; Visually threatening retinopathy due to diabetes mellitus (disorder),
C0339471,Disorder of macula due to diabetes mellitus,diabetes,Maculopathy due to diabetes mellitus; Diabetic maculopathy; Maculopathy with diabetes mellitus; Disorder of macula due to diabetes mellitus (disorder),
C0339472,Advanced maculopathy due to diabetes mellitus,diabetes,Advanced maculopathy with diabetes mellitus; Advanced maculopathy due to diabetes mellitus (disorder); Advanced diabetic maculopathy,
C0339473,Preproliferative diabetic retinopathy,diabetes,Preproliferative diabetic retinopathy; Preproliferative retinopathy due to diabetes mellitus; Preproliferative retinopathy due to diabetes mellitus (disorder); PPDR - Preproliferative diabetic retinopathy,
C0339474,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,diabetes,Proliferative diabetic retinopathy new vessels on disc; Proliferative diabetic retinopathy with new vessels on disc; Proliferative retinopathy with optic disc neovascularisation due to diabetes mellitus; Proliferative retinopathy new vessels on disc; Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus (disorder),
C0339475,Proliferative retinopathy with neovascularization elsewhere than the optic disc due to diabetes mellitus,diabetes,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus; Proliferative retinopathy with new vessels elsewhere than on disc; Proliferative retinopathy with neovascularization elsewhere than the optic disc due to diabetes mellitus (disorder); Proliferative diabetic retinopathy with new vessels elsewhere than on disc,
C0339476,Traction detachment of retina due to diabetes mellitus,diabetes,Traction retinal detachment with diabetes mellitus; Traction detachment of retina due to diabetes mellitus (disorder); Diabetic traction retinal detachment,
C0341703,Adult Fanconi syndrome,glucose,"FRTS; ADULT FANCONI SYNDROME; Fanconi Syndrome, Renal; Amino acid-glucose defective tubular absorption; Renal Fanconi Syndrome; Fanconi Renotubular Syndrome; Glucoaminophosphaturia syndrome; Adult Fanconi's Syndrome; Luder-Sheldon syndrome; Glucoaminophosphate diabetes; FANCONI RENOTUBULAR SYNDROME; Renal Fanconi syndrome; Syndrome, Fanconi Renotubular; Fanconi Syndrome, Adult; Syndrome, Adult Fanconi; Luder Sheldon Syndrome; LUDER-SHELDON SYNDROME; Syndrome, Luder-Sheldon; Adult Fanconi syndrome (disorder); RENAL FANCONI SYNDROME; FANCONI SYNDROME WITHOUT CYSTINOSIS; Syndrome, Renal Fanconi; Adult Fanconi syndrome; Renal tubular fanconi syndrome; Adult Fanconi Syndrome; RFS; Fanconi Syndrome without Cystinosis; 'de toni-fanconi-debre' syndrome; Renotubular Syndrome, Fanconi; Renal tubular Fanconi syndrome; Luder-Sheldon Syndrome",
C0341893,"Diabetes mellitus in mother complicating pregnancy, childbirth AND/OR puerperium",diabetes,"Diabetes mellitus of mother, complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care or not applicable; Diabetes mellitus during pregnancy, childbirth and the puerperium; Gestational diabetes complicating pregnancy, childbirth, or the puerperium; Diabetes mellitus in mother complicating pregnancy, childbirth AND/OR puerperium (disorder); Diabetes mellitus of mother, complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care; Diabetes mellitus complicating pregnancy, childbirth, or the puerperium; Diabetes mellitus during pregnancy, childbirth and the puerperium (disorder); Diabetes mellitus in mother complicating pregnancy, childbirth or puerperium",
C0341894,Diabetes mellitus in the puerperium - baby delivered during previous episode of care,diabetes,"Diabetes mellitus of mother, complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication; Diabetes mellitus, postpartum; Diabetes mellitus in the puerperium - baby delivered during previous episode of care (disorder)",
C0341896,Diabetes mellitus in the puerperium - baby delivered during current episode of care,diabetes,"Diabetes mellitus of mother, with delivery, with mention of postpartum complication; Diabetes mellitus of mother, complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication; Diabetes mellitus in the puerperium - baby delivered during current episode of care (disorder)",
C0341897,Diabetes mellitus during pregnancy - baby delivered,diabetes,"Diabetes mellitus of mother, with delivery; Diabetes mellitus of mother, complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition; Diabetes mellitus during pregnancy - baby delivered (disorder)",
C0342242,Disorder of glucose regulation,glucose,Disorder of glucose regulation (disorder),
C0342245,Disorder of eye due to diabetes mellitus,diabetes,"Diabetic eye disease; eye disease diabetic; Diabetic Eye Disease; Ophthalmic manifestations of diabetes; Eye disorder due to diabetes mellitus; Diabetic Eye Problems; Disorder of eye due to diabetes mellitus (disorder); Diabetes with ophthalmic manifestations; Diabetic oculopathy; diabetic diseases eye; Diabetic oculopathy, NOS; diabetic eye disease; Diabetic eye disease, NOS",
C0342257,Complications of Diabetes Mellitus,diabetes,"diabetic complications; Disorder associated with diabetes mellitus; diabetic complication; Diabetes mellitus with complications; Diabetes with unspecified complication; complications diabetic; complication diabetes mellitus; Diabetes-Related Complications; Diabetes Complications; Diabetes with unspecified complications; Diabetic complication; Diabetes Mellitus Complication; Diabetes mellitus with complication; Diabetes--Complications; complication diabetic; Diabetes Mellitus Complications; Complications of Diabetes Mellitus; Diabetic complications; Diabetic complication, NOS; Diabetic Complication; Complication due to diabetes mellitus (disorder); Diabetes Related Complications; Diabetic Complications; complications diabetics; diabetes mellitus complications; Complication due to diabetes mellitus; Diabetes Complication; Diabetes-Related Complication; diabetes mellitus complication; complicate diabetes; complications diabetes mellitus",
C0342266,Insulin treated type 2 diabetes mellitus,diabetes,Diabetes type 2 on insulin; Insulin treated type 2 diabetes mellitus (disorder); Insulin treated Type II diabetes mellitus,
C0342267,Malnutrition-related diabetes mellitus - fibrocalculous,diabetes,Malnutrition-related diabetes mellitus - fibrocalculous (disorder),
C0342268,Protein-deficient diabetes mellitus,diabetes,Malnutrition-related diabetes mellitus - protein-deficient; Protein-deficient diabetes mellitus; Protein-deficient diabetes mellitus (disorder),
C0342269,Steroid-induced diabetes,diabetes,Steroid Induced Diabetes Mellitus; Steroid-induced diabetes (disorder),
C0342270,Diabetes mellitus associated with pancreatic disease,diabetes,Secondary pancreatic diabetes mellitus; Pancreatogenic type 3c diabetes mellitus; Diabetes mellitus associated with pancreatic disease (disorder); Diabetes mellitus associated with pancreatic disease,
C0342271,Secondary endocrine diabetes mellitus,diabetes,Secondary endocrine diabetes mellitus (disorder),
C0342273,Transitory neonatal diabetes mellitus,diabetes,"Diabetes mellitus, transient neonatal; Transitory neonatal diabetes mellitus; TNDM; Transitory neonatal diabetes mellitus (disorder); Transient neonatal diabetes mellitus; Transient Neonatal Diabetes Mellitus",
C0342274,Diabetes mellitus associated with genetic syndrome,diabetes,Diabetes mellitus associated with genetic syndrome (disorder); Diabetes mellitus associated with genetic syndrome; Genetic syndromes of diabetes mellitus,
C0342276,Maturity onset diabetes mellitus in young,diabetes,"Maturity Onset Diabetes of the Young; Autosomal dominant diabetes mellitus; modi; Maturity onset diabetes mellitus in young; Mason-Type Diabetes; NIDDY; mody; Diabetes, maturity-onset, of the young (MODY); Maturity-onset diabetes of the young (MODY); Maturity onset diabetes of the young; diabetes maturity onset youth; MODY - maturity onset diabetes of young; Maturity-onset diabetes of the young (disorder); maturity onset diabetes in youth; MODY; diabetes maturity onset young; Maturity-onset diabetes of the young; MATURITY-ONSET DIABETES OF THE YOUNG; Maturity-Onset Diabetes of the Young; MASON-TYPE DIABETES",
C0342277,Diabetes mellitus autosomal dominant type II (disorder),diabetes,"Maturity-Onset Diabetes of the Young, Type 2; Glucokinase-Associated Diabetes Mellitus; DIABETES MELLITUS, TYPE II, AUTOSOMAL DOMINANT; MODY - Maturity onset diabetes glucokinase-related; Diabetes mellitus autosomal dominant type II; Maturity onset diabetes of the young, type 2; MODY, Type 2; Diabetes Mellitus, Type II, Autosomal Dominant; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 2; MODY, TYPE 2; Maturity onset diabetes of the young, type 2 (disorder); MODY, GLUCOKINASE-RELATED; MODY - Maturity onset diabetes in youth type 2; GCK monogenic diabetes mellitus; Maturity onset diabetes in youth type 2; MODY, Glucokinase-Related; Maturity onset diabetes in youth type II; MODY2; MODY - Maturity onset diabetes in youth type II; GCK (glucokinase) monogenic diabetes mellitus",
C0342278,"Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans",diabetes,"Hereditary benign acanthosis nigricans with insulin resistance; Insulin Receptor Defect with Insulin-Resistant Diabetes Mellitus and Acanthosis Nigricans; INSULIN RECEPTOR, DEFECT IN, WITH INSULIN-RESISTANT DIABETES MELLITUS AND ACANTHOSIS NIGRICANS; Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans; Hereditary benign acanthosis nigricans with insulin resistance (disorder); DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS, TYPE A; Insulin-resistant acanthosis nigricans type A; DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS; IRAN, TYPE A; Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans, Type A; IRAN, Type A",
C0342279,"Lipodystrophy, partial, with Rieger anomaly, short stature, and insulinopenic diabetes mellitus",diabetes,"Lipodystrophy, partial, with Rieger anomaly, short stature, and insulinopenic diabetes mellitus (disorder)",
C0342280,AREDYLD Syndrome,diabetes,"Acrorenal defect-ectodermal dysplasia-diabetes syndrome; Acral renal ectodermal dysplasia lipoatrophic diabetes; Acrorenal field defect, ectodermal dysplasia, and lipoatrophic diabetes (disorder); Acrorenal field defect, ectodermal dysplasia, and lipoatrophic diabetes; ACRORENAL FIELD DEFECT, ECTODERMAL DYSPLASIA, AND LIPOATROPHIC DIABETES; AREDYLD syndrome; AREDYLD",
C0342281,"Muscular Atrophy, Ataxia, Retinitis Pigmentosa, and Diabetes Mellitus",diabetes,"Furukawa Takagi Nakao syndrome; Muscular Atrophy, Ataxia, Retinitis Pigmentosa, and Diabetes Mellitus; Muscular atrophy, ataxia, retinitis pigmentosa, and diabetes mellitus (disorder); Muscular atrophy, ataxia, retinitis pigmentosa, and diabetes mellitus; MUSCULAR ATROPHY, ATAXIA, RETINITIS PIGMENTOSA, AND DIABETES MELLITUS",
C0342284,Bangstad syndrome,diabetes,"Bird-headed dwarfism with progressive ataxia, insulin-resistant diabetes, goiter, and primary gonadal insufficiency (disorder); Ataxia-diabetes-goiter-gonadal insufficiency syndrome; BANGSTAD SYNDROME; Bird-headed dwarfism with progressive ataxia, insulin-resistant diabetes, goiter, and primary gonadal insufficiency; Bangstad syndrome; Bird-headed dwarfism with progressive ataxia, insulin-resistant diabetes, goitre, and primary gonadal insufficiency; BIRD-HEADED DWARFISM WITH PROGRESSIVE ATAXIA, INSULIN-RESISTANT DIABETES, GOITER, AND PRIMARY GONADAL INSUFFICIENCY",
C0342286,Woodhouse Sakati syndrome,diabetes,"WOODHOUSE-SAKATI SYNDROME; Diabetes, hypogonadism, deafness, intellectual disability syndrome; Hypogonadism, diabetes mellitus, alopecia, mental retardation and electrocardiographic abnormalities (disorder); Woodhouse-Sakati Syndrome; Hypogonadism, diabetes mellitus, alopecia, mental retardation and electrocardiographic abnormalities; Woodhouse Sakati syndrome; HYPOGONADISM, ALOPECIA, DIABETES MELLITUS, MENTAL RETARDATION, DEAFNESS, AND EXTRAPYRAMIDAL SYNDROME; Diabetes-hypogonadism-deafness-intellectual disability syndrome; WDSKS; Diabetes-hypogonadism-hearing loss-intellectual disability syndrome; Hypogonadism, Alopecia, Diabetes Mellitus, Mental Retardation, and Extrapyramidal Syndrome; EXTRAPYRAMIDAL DISORDER, PROGRESSIVE, WITH PRIMARY HYPOGONADISM, MENTAL RETARDATION, AND ALOPECIA; Diabetes, hypogonadism, deafness, intellectual disability syndrome (disorder); Woodhouse-Sakati syndrome; Extrapyramidal Disorder, Progressive, With Primary Hypogonadism, Mental Retardation, and Alopecia",
C0342287,Thiamine responsive megaloblastic anemia syndrome,diabetes,"Abboud syndrome; Thiamine-responsive megaloblastic anemia syndrome; Megaloblastic Anemia, Thiamine-Responsive, With Diabetes Mellitus And Sensorineural Deafness; ROGERS SYNDROME; THIAMINE-RESPONSIVE ANEMIA SYNDROME; Thiamine-Responsive Megaloblastic Anemia Syndrome; Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness; Thiamine-responsive megaloblastic anaemia syndrome; Thiamine-Responsive Anemia Syndrome; Rogers syndrome; rogers syndrome; Thiamine-responsive megaloblastic anemia with diabetes mellitus and sensorineural deafness; Thiamine-responsive megaloblastic anemia with diabetes mellitus and sensorineural hearing loss; THMD1; THIAMINE METABOLISM DYSFUNCTION SYNDROME 1 (MEGALOBLASTIC ANEMIA, DIABETES MELLITUS, AND DEAFNESS TYPE); roger syndrome; THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME; Thiamine-Responsive Myelodysplasia; Megaloblastic anaemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness; MEGALOBLASTIC ANEMIA, THIAMINE-RESPONSIVE, WITH DIABETES MELLITUS AND SENSORINEURAL DEAFNESS; Thiamine responsive myelodysplasia; TRMA; Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness (disorder); THIAMINE-RESPONSIVE MYELODYSPLASIA; Thiamine responsive megaloblastic anemia syndrome",
C0342288,Insulin-dependent diabetes mellitus secretory diarrhea syndrome,diabetes,"XLAAD; POLYENDOCRINOPATHY, IMMUNE DYSFUNCTION, AND DIARRHEA, X-LINKED; Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome; IDDM-SECRETORY DIARRHEA SYNDROME; XPID; IPEX; X-linked immune dysregulation, polyendocrinopathy, enteropathy syndrome; IMMUNODEFICIENCY, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED, FORMERLY; X-Linked Autoimmunity-Allergic Dysregulation Syndrome; Immune Dysregulation, Polyendocrinopathy, and Enteropathy X-Linked Syndrome; Immunodysregulation, Polyendocrinopathy, and Enteropathy, X-Linked; IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED; Diabetes Mellitus, Congenital Insulin-Dependent, with Fatal Secretory Diarrhea; DMSD; Enteropathy, Autoimmune, with Hemolytic Anemia and Polyendocrinopathy; X-LINKED AUTOIMMUNITY-ALLERGIC DYSREGULATION SYNDROME; Autoimmunity-Immunodeficiency Syndrome, X-Linked; Ipex Syndrome; AUTOIMMUNITY-IMMUNODEFICIENCY SYNDROME, X-LINKED; ENTEROPATHY, AUTOIMMUNE, WITH HEMOLYTIC ANEMIA AND POLYENDOCRINOPATHY; Diarrhea, Polyendocrinopathy, Fatal Infection Syndrome, X-Linked; Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome; Autoimmune enteropathy type 1; X-linked immune dysregulation, polyendocrinopathy, enteropathy syndrome (disorder); DIABETES MELLITUS, CONGENITAL INSULIN-DEPENDENT, WITH FATAL SECRETORY DIARRHEA; DIARRHEA, POLYENDOCRINOPATHY, FATAL INFECTION SYNDROME, X-LINKED; IDDM-Secretory Diarrhea Syndrome; Polyendocrinopathy, Immune Dysfunction, and Diarrhea, X-Linked",
C0342289,Diabetes-deafness syndrome maternally transmitted,diabetes,"Ballinger-Wallace Syndrome; Noninsulin-dependent diabetes mellitus with deafness; Diabetes-deafness syndrome maternally transmitted (disorder); Diabetes Mellitus, Type II, With Deafness; NIDDM WITH DEAFNESS; BALLINGER-WALLACE SYNDROME; Maternally-inherited diabetes and deafness; Diabetes-deafness syndrome, maternally transmitted; Diabetes mellitus, type 2, with deafness; Mitochondrial Inherited Diabetes and Deafness; Maternal Diabetes and Deafness Syndrome; Mitochondrial diabetes; Diabetes and deafness, maternally inherited; DIABETES MELLITUS, TYPE II, WITH DEAFNESS; Diabetes-deafness syndrome maternally transmitted; MIDD; Maternally-inherited diabetes and hearing loss; DIABETES AND DEAFNESS, MATERNALLY INHERITED; NIDDM with deafness; Maternally inherited diabetes and deafness; Maternally Transmitted Diabetes-Deafness Syndrome; Ballinger-Wallace syndrome; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS; DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED",
C0342290,Abnormal metabolic state due to diabetes mellitus,diabetes,Abnormal metabolic state in diabetes mellitus; Abnormal metabolic state due to diabetes mellitus (disorder),
C0342294,Ketoacidosis due to type 1 diabetes mellitus,diabetes,Ketoacidosis in type I diabetes mellitus; Ketoacidosis due to type 1 diabetes mellitus (disorder); Ketoacidosis in type 1 diabetes mellitus; Diabetes type 1 with ketoacidosis,
C0342295,Ketoacidosis due to type 2 diabetes mellitus,diabetes,Ketoacidosis due to type 2 diabetes mellitus (disorder); Ketoacidosis in type 2 diabetes mellitus; Diabetes type 2 with ketoacidosis; Ketoacidosis in type II diabetes mellitus,
C0342296,Hyperosmolar coma due to type 1 diabetes mellitus,diabetes,Type 1 diabetes mellitus with hyperosmolar coma; Hyperosmolar coma due to type 1 diabetes mellitus (disorder),
C0342297,Hyperosmolar coma due to type 2 diabetes mellitus,diabetes,Type 2 diabetes mellitus with hyperosmolar coma; Hyperosmolar coma due to type 2 diabetes mellitus (disorder),
C0342298,Severe hyperglycemia due to diabetes mellitus,hyperglycemia,Diabetic severe hyperglycemia; Severe hyperglycemia due to diabetes mellitus (disorder); Severe hyperglycaemia due to diabetes mellitus; Diabetic severe hyperglycaemia,
C0342299,Poor glycemic control,glycaemic,Poor glycemic control (disorder); Poor glycaemic control,
C0342300,Chronic hyperglycemia,hyperglycemia,Chronic hyperglycaemia; Chronic hyperglycemia (disorder),
C0342301,Acute hyperglycemia,hyperglycemia,Acute hyperglycemia (disorder); Acute hyperglycaemia,
C0342302,Brittle diabetes,diabetes,"Diabetes Mellitus, Brittle; Brittle diabetes; Brittle diabetes mellitus (finding); Labile diabetes; Diabetes mellitus, brittle; Brittle diabetes mellitus; Diabetes mellitus, labile; labile diabetes; Unstable diabetes mellitus; Brittle Diabetes Mellitus; brittle diabetes",
C0342303,Metabolic stress hyperglycemia,hyperglycemia,stress hyperglycemia; Metabolic stress hyperglycaemia; Stress hyperglycemia; Metabolic stress hyperglycemia (disorder); hyperglycemia stress,
C0342305,pregnancy and insulin-dependent diabetes mellitus,diabetes,iddm pregnancy,
C0342306,Pregnancy and type 2 diabetes mellitus,diabetes,Pregnancy and type 2 diabetes mellitus (disorder),
C0342307,Impaired glucose tolerance in pregnancy,glucose,Impaired glucose tolerance in pregnancy (disorder); Pregnancy and impaired glucose tolerance; IGT - Impaired glucose tolerance in pregnancy,
C0342312,Hypoglycemic event due to diabetes,diabetes,Hypoglycemic event in diabetes; Hypoglycaemic event due to diabetes; Hypoglycaemic event in diabetes; Hypoglycemic event due to diabetes (disorder),
C0342313,Hypoglycemia due to diabetes mellitus,hypoglycemia,Hypoglycemic state in diabetes; Hypoglycemic state due to diabetes mellitus; Hypoglycaemic state due to diabetes mellitus; Hypoglycemia due to diabetes mellitus (disorder); Hypoglycaemic state in diabetes; Hypoglycaemia due to diabetes mellitus,
C0342314,Dawn phenomenon,hyperglycemia,Rebound phenomenon; Rebound hyperglycemia; Dawn phenomenon (disorder); rebound hyperglycemia; Rebound hyperglycaemia; rebound phenomenon; dawn phenomenon; hyperglycemia rebound,
C0342315,Nocturnal hypoglycemia due to diabetes mellitus,hypoglycemia,Nocturnal hypoglycemia due to diabetes mellitus (disorder); Nocturnal hypoglycaemia; Nocturnal hypoglycaemia due to diabetes mellitus; Nocturnal hypoglycemia,
C0342316,Recurrent severe hypoglycemia,hypoglycemia,Recurrent severe hypoglycemia (disorder); Recurrent severe hypoglycaemia,
C0342317,Loss of hypoglycemic warning due to diabetes mellitus,hypoglycemia,Loss of hypoglycaemic warning due to diabetes mellitus; Loss of hypoglycemic warning due to diabetes mellitus (disorder); Hypoglycaemia unawareness; Loss of hypoglycemic warning; Hypoglycemia unawareness; Loss of hypoglycaemic warning,
C0342318,Non-diabetic hypoglycemia,hypoglycemia,non-diabetic hypoglycemia; hypoglycemia non-diabetic; hypoglycemia non diabetics; Non-diabetic hypoglycemia (disorder); Non-diabetic hypoglycaemia,
C0342320,Alimentary hypoglycemia,hypoglycemia,Alimentary hypoglycaemia; Alimentary hypoglycemia (disorder),
C0342321,Drug induced hypoglycemia,hypoglycemia,Drug-induced hypoglycaemia; Drug-induced hypoglycemia; Drug-induced hypoglycemia (disorder),
C0342322,Alcohol-induced hypoglycemia,hypoglycemia,Alcohol-induced hypoglycemia (disorder); Alcohol-induced hypoglycaemia; Alcohol Induced Hypoglycemia,
C0342323,Ectopic IGF hypoglycemia,hypoglycemia,Ectopic insulin-like growth factor hypoglycaemia; Ectopic insulin-like growth factor hypoglycemia; Ectopic insulin-like growth factor hypoglycemia (disorder); Ectopic IGF hypoglycaemia,
C0342324,Ectopic IGF-1 hypoglycemia,hypoglycemia,Ectopic insulin-like growth factor-1 hypoglycemia; Ectopic insulin-like growth factor-1 hypoglycaemia; Ectopic insulin-like growth factor-1 hypoglycemia (disorder); Ectopic IGF-1 hypoglycaemia,
C0342325,Ectopic IGF-2 hypoglycemia,hypoglycemia,Ectopic insulin-like growth factor-2 hypoglycaemia; Ectopic insulin-like growth factor-2 hypoglycemia (disorder); Ectopic insulin-like growth factor-2 hypoglycemia; Ectopic IGF-2 hypoglycaemia,
C0342326,Tumor-induced hypoglycemia,hypoglycemia,Tumor-induced hypoglycemia (disorder); Tumour-induced hypoglycaemia,
C0342335,insulin resistance in diabetes,diabetes,diabetes insulin resistance; insulin resistance diabetes,
C0342336,Insulin resistance - type A,diabetes,"Insulin resistance syndrome, type A; Insulin-resistance syndrome type A; Insulin resistance - type A (disorder); Type A insulin resistance; Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism",
C0342394,Familial central diabetes insipidus,diabetes,Familial central diabetes insipidus (disorder),
C0342750,Glycogen storage disease type Id,glucose,GLYCOGEN STORAGE DISEASE Id; GSD1d; Glycogen storage disease type Id; Glucose transport defect; Glucose transport defect (disorder); Glycogen Storage Disease Id; GSD1D,
C0343178,Neuropathic arthropathy due to diabetes mellitus,diabetes,Diabetic Charcot's arthropathy; Diabetic neuropathic arthropathy; Neuropathic arthropathy due to diabetes mellitus (disorder),
C0347890,Post gastrointestinal tract surgery hypoglycemia,hypoglycemia,Post gastrointestinal tract surgery hypoglycemia (disorder); Post gastrointestinal tract surgery hypoglycaemia,
C0348917,"Pre-existing diabetes mellitus, insulin-dependent",diabetes,Pre-existing type 1 diabetes mellitus (disorder); Pre-existing type 1 diabetes mellitus,
C0348919,Disorder of eye due to type 2 diabetes mellitus,diabetes,Diabetic oculopathy associated with type 2 diabetes mellitus; Disorder of eye due to type 2 diabetes mellitus (disorder); Diabetic oculopathy associated with type II diabetes mellitus; Disorder of eye with type 2 diabetes mellitus,
C0348921,"Pre-existing diabetes mellitus, non-insulin-dependent",diabetes,Pre-existing type 2 diabetes mellitus; Pre-existing type 2 diabetes mellitus (disorder),
C0348924,Malnutrition-related diabetes mellitus with renal complications,diabetes,Malnutrition-related diabetes mellitus with renal complications (disorder),
C0348925,Disorder of eye due to malnutrition related diabetes mellitus,diabetes,Disorder of eye due to malnutrition related diabetes mellitus (disorder); Ophthalmic complication of malnutrition-related diabetes mellitus,
C0348927,Malnutrition-related diabetes mellitus with peripheral circulatory complications,diabetes,Malnutrition-related diabetes mellitus with peripheral circulatory complications (disorder),
C0348929,Malnutrition-related diabetes mellitus without complications,diabetes,Malnutrition-related diabetes mellitus without complications (disorder),
C0348930,Pre-existing malnutrition-related diabetes mellitus,diabetes,Pre-existing malnutrition-related diabetes mellitus (disorder); Pre-existing malnutrition-related diabetes mellitus,
C0348942,Drug-induced hypoglycemia without coma,hypoglycemia,Drug-induced hypoglycaemia without coma; Drug-induced hypoglycemia without coma (disorder),
C0349474,Diabetes mellitus in neonate small for gestational age,diabetes,Diabetes mellitus in neonate small for gestational age (disorder),
C0349901,fructose 374 MG/ML / glucose 374 MG/ML / phosphoric acid 4.3 MG/ML Oral Solution [Emetrol],glucose,"Emetrol (dextrose 1.87 GM / fructose 1.87 GM / phosphoric acid 21.5 MG) per 5 ML Oral Solution; Emetrol, Lemon-Mint, oral solution; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [Emetrol Cherry]; Emetrol, Cherry, oral solution; Emetrol 1.87 GM / 1.87 GM / 21.5 MG in 5 mL Oral Solution; Emetrol for Nausea, oral solution; Emetrol (sucrose 3.74 GM / phosphoric acid 21.5 MG) per 5 ML Oral Solution",
C0353441,Other drugs used in diabetes,diabetes,,
C0357181,Glucose/galactose intolerance food,glucose,Glucose/galactose intolerance food (product),
C0359237,glucose 150 MG/ML Injectable Solution,glucose,Product containing precisely glucose 150 milligram/1 milliliter conventional release solution for injection (clinical drug); Glucose 150 mg/mL solution for injection,
C0359244,Glucose 500 MG/ML Prefilled Syringe,glucose,,
C0359264,500 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection,glucose,"potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.45 % per 500 ML Injection; DEXTROSE MONOHYDRATE 50 g in 1000 mL / SODIUM CHLORIDE 4.5 g in 1000 mL / POTASSIUM CHLORIDE 1.49 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]_#1; 500 ML Glucose 50 MG/ML / K+ Chloride 0.02 MEQ/ML / NaCl 4.5 MG/ML Injection; POTASSIUM CHLORIDE 150 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]_#1; potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.45 % in 500 ML Injection; 500 ML Glucose 50 MG/ML / Pot Chloride 0.02 MEQ/ML / NaCl 4.5 MG/ML Injection; DEXTROSE 5%/NACL 0.45%/KCL 20MEQ/L INJ_#1; Dextrose 5% and 0.45% Sodium Chloride with Potassium Chloride 20 mEq/L, Dextrose 5% with 0.45% NaCl and KCl 20 mEq/L intravenous solution_#1",
C0360665,glucose / sodium chloride,glucose,Product containing glucose and sodium chloride (medicinal product); Glucose- and sodium chloride-containing product,
C0362046,Prediabetes syndrome,diabetes,"Borderline Diabetes; Prediabetic States; pre-diabetic; pre-diabetes; pre diabetic; Prediabetic State; borderline diabetes; diabetes borderline; Prediabetic state; Prediabetes syndrome; States, Prediabetic; pre diabetes; State, Prediabetic; Pre-diabetes NOS; prediabetic state; prediabetes; pre diabetics; Prediabetes (finding); Prediabetes",
C0362086,Drug-induced hyperglycemia,hyperglycemia,drug-induced hyperglycemia; Drug-induced hyperglycaemia; drug induced hyperglycemia; hyperglycemia drug induced; Drug-induced hyperglycemia; Drug-induced hyperglycemia (disorder),
C0363625,Glucose^30M post 100 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose^30 minutes post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 30 Min post 100 g glucose PO (U) [Mass/Vol]; Glucose [Mass/volume] in Urine --30 minutes post 100 g glucose PO; Glucose 30M p 100 g Glc PO Ur-mCnc,
C0363626,Glucose^1.5H post 0.5 g/kg glucose IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 0.5 g/kg glucose IV; Glucose^1.5 hours post 0.5 g/kg glucose Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5h p .5 g/kg Glc IV SerPl-mCnc; Glucose 1.5 Hr post 0.5 g/kg glucose IV [Mass/Vol],
C0363627,Glucose^1.5H post 0.05-0.15 U insulin/kg IV post 12H CFst:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5 Hr post 0.05-0.15 U insulin/kg IV 12 Hr fasting [Mass/Vol]; Glucose^1.5 hours post 0.05-0.15 U insulin/kg Intravenous post 12 hours Calorie fast:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5h p U/kg Ins IV SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 0.05-0.15 U insulin/kg IV 12 hours fasting,
C0363628,Glucose^1.5H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1.5 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5 Hr post 100 g glucose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 100 g glucose PO; Glucose 1.5h p 100 g Glc PO SerPl-mCnc,
C0363629,Glucose^1.5H post 100 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose^1.5 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose [Mass/volume] in Urine --1.5 hours post 100 g glucose PO; Glucose 1.5h p 100 g Glc PO Ur-mCnc; Glucose 1.5 Hr post 100 g glucose PO (U) [Mass/Vol],
C0363631,Glucose^1.5H post dose insulin IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose insulin IV; Glucose^1.5 hours post dose insulin Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5h p Ins IV SerPl-mCnc; Glucose 1.5 Hr post dose insulin IV [Mass/Vol],
C0363632,Glucose^10M post 0.5 g/kg glucose IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --10 minutes post 0.5 g/kg glucose IV; Glucose 10M p .5 g/kg Glc IV SerPl-mCnc; Glucose^10 minutes post 0.5 g/kg glucose Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 10 Min post 0.5 g/kg glucose IV [Mass/Vol],
C0363633,Glucose^1H post 0.5 g/kg glucose IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1 hour post 0.5 g/kg glucose Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1 Hr post 0.5 g/kg glucose IV [Mass/Vol]; Glucose 1h p .5 g/kg Glc IV SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1 hour post 0.5 g/kg glucose IV,
C0363634,Glucose^1H post 0.05-0.15 U insulin/kg IV post 12H CFst:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p U/kg Ins IV SerPl-mCnc; Glucose 1 Hr post 0.05-0.15 U insulin/kg IV post 12H CFst [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --1 hour post 0.05-0.15 U insulin/kg IV post 12H CFst; Glucose^1 hour post 0.05-0.15 U insulin/kg Intravenous post 12 hours Calorie fast:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0363635,Glucose^1H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --1 hour post 100 g glucose PO; Glucose^1 hour post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1h p 100 g Glc PO SerPl-mCnc; Glucose 1 Hr post 100 g glucose PO [Mass/Vol],
C0363636,Glucose 1 Hr post 100 g glucose PO (S) [Mass/Vol],glucose,,
C0363637,Glucose^1H post 100 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose^1 hour post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 1h p 100 g Glc PO Ur-mCnc; Glucose 1 Hr post 100 g glucose PO (U) [Mass/Vol]; Glucose [Mass/volume] in Urine --1 hour post 100 g glucose PO,
C0363638,Glucose^1H post 50 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p 50 g Glc PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g glucose PO; Glucose^1 hour post 50 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1 Hr post 50 g glucose PO [Mass/Vol],
C0363639,Glucose^1H post 50 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose^1 hour post 50 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose [Mass/volume] in Urine --1 hour post 50 g glucose PO; Glucose 1 Hr post 50 g glucose PO (U) [Mass/Vol]; Glucose 1h p 50 g Glc PO Ur-mCnc,
C0363640,Glucose^1H post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g lactose PO; Glucose 1 Hr post 50 g lactose PO [Mass/Vol]; Glucose^1 hour post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1h p 50 g Lac PO SerPl-mCnc,
C0363641,Glucose^1H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1 Hr post 75 g glucose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --1 hour post 75 g glucose PO; Glucose^1 hour post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1h p 75 g Glc PO SerPl-mCnc,
C0363642,Glucose 1 Hr post 75 g glucose PO (S) [Mass/Vol],glucose,,
C0363643,Glucose^1H post 75 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose 1 Hr post 75 g glucose PO (U) [Mass/Vol]; Glucose 1h p 75 g Glc PO Ur-mCnc; Glucose^1 hour post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose [Mass/volume] in Urine --1 hour post 75 g glucose PO,
C0363644,Glucose^1 hour post dose insulin Intravenous:Mass Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Glucose 1h p Ins IV SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1 hour post dose insulin IV; Glucose^1 hour post dose insulin Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose^1H post dose insulin IV:MCnc:Pt:Ser/Plas:Qn; Glucose 1 Hr post dose insulin IV [Mass/Vol],
C0363645,Glucose^1M post 0.5 g/kg glucose IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1 Min post 0.5 g/kg glucose IV [Mass/Vol]; Glucose^1 minute post 0.5 g/kg glucose Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --1 minute post 0.5 g/kg glucose IV; Glucose 1M p .5 g/kg Glc IV SerPl-mCnc,
C0363646,Glucose^20M post 0.5 g/kg glucose IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^20 minutes post 0.5 g/kg glucose Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 20M p .5 g/kg Glc IV SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --20 minutes post 0.5 g/kg glucose IV; Glucose 20 Min post 0.5 g/kg glucose IV [Mass/Vol],
C0363647,Glucose^2H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2 Hr post 100 g glucose PO [Mass/Vol]; Glucose^2 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2h p 100 g Glc PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --2 hours post 100 g glucose PO,
C0363648,Glucose 2 Hr post 100 g glucose PO (S) [Mass/Vol],glucose,,
C0363649,Glucose^2H post 100 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose [Mass/volume] in Urine --2 hours post 100 g glucose PO; Glucose 2h p 100 g Glc PO Ur-mCnc; Glucose 2 Hr post 100 g glucose PO (U) [Mass/Vol]; Glucose^2 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative,
C0363650,Glucose^2H post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2h p 50 g Lac PO SerPl-mCnc; Glucose^2 hours post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2 Hr post 50 g lactose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --2 hours post 50 g lactose PO,
C0363651,Glucose^2H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2 Hr post 75 g glucose PO [Mass/Vol]; Glucose 2h p 75 g Glc PO SerPl-mCnc; Glucose^2 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --2 hours post 75 g glucose PO,
C0363652,Glucose 2 Hr post 75 g glucose PO (S) [Mass/Vol],glucose,,
C0363653,Glucose^2H post 75 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose [Mass/volume] in Urine --2 hours post 75 g glucose PO; Glucose^2 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 2h p 75 g Glc PO Ur-mCnc; Glucose 2 Hr post 75 g glucose PO (U) [Mass/Vol],
C0363655,Glucose^30M post 0.5 g/kg glucose IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30 Min post 0.5 g/kg glucose IV [Mass/Vol]; Glucose^30 minutes post 0.5 g/kg glucose Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30M p .5 g/kg Glc IV SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --30 minutes post 0.5 g/kg glucose IV,
C0363656,Glucose^30M post 0.05-0.15 U insulin/kg IV post 12H CFst:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30M p U/kg Ins IV SerPl-mCnc; Glucose^30 minutes post 0.05-0.15 U insulin/kg Intravenous post 12 hours Calorie fast:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min post 0.05-0.15 U insulin/kg IV post 12H CFst [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --30 minutes post 0.05-0.15 U insulin/kg IV post 12H CFst,
C0363658,Glucose^30M post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30M p 100 g Glc PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --30 minutes post 100 g glucose PO; Glucose^30 minutes post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min post 100 g glucose PO [Mass/Vol],
C0363659,Glucose^30M post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --30 minutes post 50 g lactose PO; Glucose 30M p 50 g Lac PO SerPl-mCnc; Glucose 30 Min post 50 g lactose PO [Mass/Vol]; Glucose^30 minutes post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0363661,Glucose^30 minutes post dose insulin Intravenous:Mass Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Glucose 30M p Ins IV SerPl-mCnc; Glucose^30M post dose insulin IV:MCnc:Pt:Ser/Plas:Qn; Glucose 30 Min post dose insulin IV [Mass/Vol]; Glucose^30 minutes post dose insulin Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose insulin IV,
C0363662,Glucose^3H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3h p 100 g Glc PO SerPl-mCnc; Glucose^3 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --3 hours post 100 g glucose PO; Glucose 3 Hr post 100 g glucose PO [Mass/Vol],
C0363663,Glucose 3 Hr post 100 g glucose PO (S) [Mass/Vol],glucose,,
C0363664,Glucose^3H post 100 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose 3h p 100 g Glc PO Ur-mCnc; Glucose^3 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose [Mass/volume] in Urine --3 hours post 100 g glucose PO; Glucose 3 Hr post 100 g glucose PO (U) [Mass/Vol],
C0363665,Glucose^3H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --3 hours post 75 g glucose PO; Glucose^3 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3h p 75 g Glc PO SerPl-mCnc; Glucose 3 Hr post 75 g glucose PO [Mass/Vol],
C0363666,Glucose^3M post 0.5 g/kg glucose IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^3 minutes post 0.5 g/kg glucose Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --3 minutes post 0.5 g/kg glucose IV; Glucose 3 Min post 0.5 g/kg glucose IV [Mass/Vol]; Glucose 3M p .5 g/kg Glc IV SerPl-mCnc,
C0363667,Glucose^40M post 0.5 g/kg glucose IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --40 minutes post 0.5 g/kg glucose IV; Glucose 40M p .5 g/kg Glc IV SerPl-mCnc; Glucose 40 Min post 0.5 g/kg glucose IV [Mass/Vol]; Glucose^40M post 0.5 g/kg glucose Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0363668,Glucose^45M post dose insulin IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^45M post dose insulin Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 45 Min post dose insulin IV [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --45 minutes post dose insulin IV; Glucose 45M p Ins IV SerPl-mCnc,
C0363669,Glucose^4H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4 Hr post 100 g glucose PO [Mass/Vol]; Glucose 4h p 100 g Glc PO SerPl-mCnc; Glucose^4 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --4 hours post 100 g glucose PO,
C0363670,Glucose^4H post 100 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose^4 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 4h p 100 g Glc PO Ur-mCnc; Glucose [Mass/volume] in Urine --4 hours post 100 g glucose PO; Glucose 4 Hr post 100 g glucose PO (U) [Mass/Vol],
C0363671,Glucose^4H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^4 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4 Hr post 75 g glucose PO [Mass/Vol]; Glucose 4h p 75 g Glc PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --4 hours post 75 g glucose PO,
C0363672,Glucose^5H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^5 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5h p 100 g Glc PO SerPl-mCnc; Glucose 5 Hr post 100 g glucose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --5 hours post 100 g glucose PO,
C0363673,Glucose^5H post 100 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose 5h p 100 g Glc PO Ur-mCnc; Glucose^5 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 5 Hr post 100 g glucose PO (U) [Mass/Vol]; Glucose [Mass/volume] in Urine --5 hours post 100 g glucose PO,
C0363674,Glucose^5H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5h p 75 g Glc PO SerPl-mCnc; Glucose^5 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5 Hr post 75 g glucose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --5 hours post 75 g glucose PO,
C0363675,Glucose^5M post 0.5 g/kg glucose IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5M p .5 g/kg Glc IV SerPl-mCnc; Glucose^5 minutes post 0.5 g/kg glucose Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5 Min post 0.5 g/kg glucose IV [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --5 minutes post 0.5 g/kg glucose IV,
C0363676,Glucose 6 Hr post 100 g glucose PO (S) [Mass/Vol],glucose,,
C0363677,Glucose^6H post 100 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose^6 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 6 Hr post 100 g glucose PO (U) [Mass/Vol]; Glucose 6h p 100 g Glc PO Ur-mCnc; Glucose [Mass/volume] in Urine --6 hours post 100 g glucose PO,
C0363678,Glucose^baseline:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --baseline; Glucose^baseline:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose baseline [Mass/Vol]; Glucose BS SerPl-mCnc,
C0363685,Glucose^post 12H CFst:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose p 12h fast SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --12 hours fasting; Glucose^post 12 hours Calorie fast:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose post 12 Hr fast [Mass/Vol],
C0363686,Glucose^post 12H CFst:MCnc:Pt:Urine:Qn,glucose,Glucose p 12h fast Ur-mCnc; Glucose [Mass/volume] in Urine --12 hours fasting; Glucose^post 12 hours Calorie fast:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose post 12 Hr fast (U) [Mass/Vol],
C0363687,Glucose^post CFst:MCnc:Pt:BldC:Qn,glucose,Glucose p fast BldC-mCnc; Glucose post fast (BldC) [Mass/Vol]; Fasting glucose [Mass/volume] in Capillary blood; Glucose^post Calorie fast:Mass Concentration:To identify measures at a point in time:Blood capillary:Quantitative,
C0363688,Glucose^post CFst:MCnc:Pt:BldV:Qn,glucose,Glucose^post Calorie fast:Mass Concentration:To identify measures at a point in time:Blood venous:Quantitative; Fasting glucose [Mass/volume] in Venous blood; Glucose p fast BldV-mCnc; Glucose post fast (BldV) [Mass/Vol],
C0363693,Insulin^1H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin 1 Hr post 75 g glucose PO [Mass/Vol]; Insulin^1 hour post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 1h p 75 g Glc PO SerPl-mCnc; Insulin [Mass/volume] in Serum or Plasma --1 hour post 75 g glucose PO,
C0363696,Insulin^2H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin^2 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 2 Hr post 75 g glucose PO [Mass/Vol]; Insulin [Mass/volume] in Serum or Plasma --2 hours post 75 g glucose PO; Insulin 2h p 75 g Glc PO SerPl-mCnc,
C0363699,Insulin^3H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin 3h p 75 g Glc PO SerPl-mCnc; Insulin 3 Hr post 75 g glucose PO [Mass/Vol]; Insulin [Mass/volume] in Serum or Plasma --3 hours post 75 g glucose PO; Insulin^3 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0363700,Insulin^4H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin^4 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 4 Hr post 75 g glucose PO [Mass/Vol]; Insulin [Mass/volume] in Serum or Plasma --4 hours post 75 g glucose PO; Insulin 4h p 75 g Glc PO SerPl-mCnc,
C0363701,Insulin^5H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin 5h p 75 g Glc PO SerPl-mCnc; Insulin 5 Hr post 75 g glucose PO [Mass/Vol]; Insulin^5 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin [Mass/volume] in Serum or Plasma --5 hours post 75 g glucose PO,
C0363759,Somatotropin^1H post 1 g/kg glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin [Mass/volume] in Serum or Plasma --1 hour post 1 g/kg glucose PO; Somatotropin 1 Hr post 1 g/kg glucose PO [Mass/Vol]; GH 1h p 1 g/kg Glc PO SerPl-mCnc; Somatotropin^1 hour post 1 g/kg glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0363761,Somatotropin^2H post 1 g/kg glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin^2 hours post 1 g/kg glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Somatotropin 2 Hr post 1 g/kg glucose PO [Mass/Vol]; GH 2h p 1 g/kg Glc PO SerPl-mCnc; Somatotropin [Mass/volume] in Serum or Plasma --2 hours post 1 g/kg glucose PO,
C0363763,Somatotropin^3H post 1 g/kg glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,GH 3h p 1 g/kg Glc PO SerPl-mCnc; Somatotropin 3 Hr post 1 g/kg glucose PO [Mass/Vol]; Somatotropin [Mass/volume] in Serum or Plasma --3 hours post 1 g/kg glucose PO; Somatotropin^3 hours post 1 g/kg glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0364477,Glucose:MCnc:Pt:Amnio fld:Qn,glucose,Glucose (Amn fld) [Mass/Vol]; Glucose:Mass Concentration:To identify measures at a point in time:Amniotic fluid:Quantitative; Glucose Amn-mCnc; Glucose [Mass/volume] in Amniotic fluid,
C0364478,Glucose:PrThr:Pt:Bld:Ord:Test strip,glucose,Glucose:Presence or Threshold:To identify measures at a point in time:Whole blood:Ordinal:Test strip; Glucose Bld Ql Strip; Glucose [Presence] in Blood by Test strip; Glucose Test strip Ql (Bld),
C0364479,Glucose:MCnc:Pt:Bld:Qn,glucose,Glucose:Mass Concentration:To identify measures at a point in time:Whole blood:Quantitative; Glucose (Bld) [Mass/Vol]; Glucose [Mass/volume] in Blood; Glucose Bld-mCnc,
C0364480,Glucose:MCnc:Pt:Bld:Qn:Test strip.automated,glucose,Glucose Bld Strip.auto-mCnc; Glucose:Mass Concentration:To identify measures at a point in time:Whole blood:Quantitative:Test strip.automated; Glucose [Mass/volume] in Blood by Automated test strip; Glucose Auto test strip (Bld) [Mass/Vol],
C0364481,Glucose:MCnc:Pt:Bld:Qn:Test strip manual,glucose,Glucose Test strip manual (Bld) [Mass/Vol]; Glucose [Mass/volume] in Blood by Test strip manual; Glucose Bld Manual Strip-mCnc; Glucose:Mass Concentration:To identify measures at a point in time:Whole blood:Quantitative:Test strip manual,
C0364482,Glucose:MCnc:Pt:CSF:Qn,glucose,Glucose (CSF) [Mass/Vol]; Glucose [Mass/volume] in Cerebral spinal fluid; Glucose CSF-mCnc; Glucose:Mass Concentration:To identify measures at a point in time:Cerebral spinal fluid:Quantitative,
C0364483,Glucose:MCnc:Pt:Dial fld:Qn,glucose,Glucose [Mass/volume] in Dialysis fluid; Glucose:Mass Concentration:To identify measures at a point in time:Dialysis fluid:Quantitative; Glucose (Dial fld) [Mass/Vol]; Glucose Dial fld-mCnc,
C0364484,Glucose:MCnc:Pt:Body fld:Qn,glucose,"Glucose [Mass/volume] in Body fluid; Glucose:Mass Concentration:To identify measures at a point in time:Body fluid, unsp:Quantitative; Glucose Fld-mCnc; Glucose (Body fld) [Mass/Vol]",
C0364486,Glucose:MCnc:Pt:Plr fld:Qn,glucose,Glucose:Mass Concentration:To identify measures at a point in time:Pleural fluid (thoracentesis fld):Quantitative; Glucose [Mass/volume] in Pleural fluid; Glucose Plr-mCnc; Glucose (Pleur fld) [Mass/Vol],
C0364487,Glucose:MCnc:Pt:Periton fld:Qn,glucose,Glucose (Periton fld) [Mass/Vol]; Glucose [Mass/volume] in Peritoneal fluid; Glucose:Mass Concentration:To identify measures at a point in time:Peritoneal fluid /ascites:Quantitative; Glucose Prt-mCnc,
C0364488,Glucose:MCnc:Pt:Synv fld:Qn,glucose,Glucose (Syn fld) [Mass/Vol]; Glucose:Mass Concentration:To identify measures at a point in time:Synovial fluid (Joint fluid):Quantitative; Glucose Snv-mCnc; Glucose [Mass/volume] in Synovial fluid,
C0364489,Glucose:PrThr:Pt:Urine:Ord,glucose,Glucose Ql (U); Glucose [Presence] in Urine; Glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Glucose Ur Ql,
C0364490,Glucose [Mass/volume] in Urine,glucose,Glucose [Mass/volume] in Urine; Glucose:MCnc:Pt:Urine:Qn; Glucose (U) [Mass/Vol]; Glucose Ur-mCnc; Glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative,
C0364491,Glucose:MRat:24H:Urine:Qn,glucose,Glucose [Mass/time] in 24 hour Urine; Glucose (24H U) [Mass/Time]; Glucose:Mass Rate:24 hours:Urine:Quantitative; Glucose 24h Ur-mRate,
C0364492,Glucose CSF/Glucose plas:Relative Mass Concentration:Point in time:Plasma+Cerebral spinal fluid:Quantitative,glucose,Glucose in CSF/Glucose plas (P+CSF) [Relative mass conc]; Glucose CSF/Glucose plas:Relative Mass Concentration:To identify measures at a point in time:Plasma+Cerebral spinal fluid:Quantitative; Glucose CSF/Glucose plas:RelMCnc:Pt:Plas+CSF:Qn; Glucose CSF/SerPl; Glucose in CSF/Glucose plas,
C0364493,GPI Ser-cCnc,glucose,Glucose phosphate isomerase (S) [Catalytic activity/Vol]; Glucose phosphate isomerase [Enzymatic activity/volume] in Serum; Glucose phosphate isomerase:Catalytic Concentration:To identify measures at a point in time:Serum:Quantitative; Glucose phosphate isomerase:CCnc:Pt:Ser:Qn; GPI Ser-cCnc,
C0364494,Glucose-6-Phosphatase:CCnc:Pt:Ser:Qn,glucose,Glucose-6-Phosphatase (S) [Catalytic activity/Vol]; Glucose-6-Phosphatase:Catalytic Concentration:To identify measures at a point in time:Serum:Quantitative; G6Pas Ser-cCnc; Glucose-6-Phosphatase [Enzymatic activity/volume] in Serum,
C0364495,Glucose-6-Phosphatase:CCnt:Pt:Tiss:Qn,glucose,"Glucose-6-Phosphatase (Tiss) [Catalytic activity/Mass]; G6Pas Tiss-cCnt; Glucose-6-Phosphatase:Catalytic Content:To identify measures at a point in time:Tissue, unspecified:Quantitative; Glucose-6-Phosphatase [Enzymatic activity/mass] in Tissue",
C0364496,Glucose-6-Phosphate dehydrogenase:PrThr:Pt:RBC:Ord,glucose,Glucose-6-Phosphate dehydrogenase [Presence] in Red Blood Cells; G6PD Ql (RBC); Glucose-6-Phosphate dehydrogenase:Presence or Threshold:To identify measures at a point in time:Erythrocytes:Ordinal; G6PD RBC Ql,
C0364497,Glucose-6-Phosphate dehydrogenase:CCnc:Pt:RBC:Qn,glucose,Glucose-6-Phosphate dehydrogenase:Catalytic Concentration:To identify measures at a point in time:Erythrocytes:Quantitative; Glucose-6-Phosphate dehydrogenase [Enzymatic activity/volume] in Red Blood Cells; G6PD (RBC) [Catalytic activity/Vol]; G6PD RBC-cCnc,
C0364498,Glucose-6-Phosphate dehydrogenase:PrThr:Pt:Ser:Ord,glucose,Glucose-6-Phosphate dehydrogenase [Presence] in Serum; G6PD Ser Ql; Glucose-6-Phosphate dehydrogenase:Presence or Threshold:To identify measures at a point in time:Serum:Ordinal; G6PD Ql (S),
C0364499,Glucose-6-Phosphate dehydrogenase:CCnc:Pt:Ser:Qn,glucose,G6PD (S) [Catalytic activity/Vol]; G6PD Ser-cCnc; Glucose-6-Phosphate dehydrogenase:Catalytic Concentration:To identify measures at a point in time:Serum:Quantitative; Glucose-6-Phosphate dehydrogenase [Enzymatic activity/volume] in Serum,
C0364500,Glucose-6-Phosphate dehydrogenase:CCnc:Pt:WBC:Qn,glucose,G6PD (WBC) [Catalytic activity/Vol]; Glucose-6-Phosphate dehydrogenase:Catalytic Concentration:To identify measures at a point in time:Leukocytes:Quantitative; G6PD WBC-cCnc; Glucose-6-Phosphate dehydrogenase [Enzymatic activity/volume] in Leukocytes,
C0364942,Deprecated Glucose phosphate isomerase [Enzymatic activity/volume] in Serum,glucose,Glucose phosphate isomerase (S) [Catalytic activity/Vol],
C0365245,Uridine diphosphate glucose-4-Epimerase:CCnc:Pt:Plas:Qn,glucose,Uridine diphosphate glucose-4-Epimerase [Enzymatic activity/volume] in Plasma; Uridine diphosphate glucose-4-Epimerase (P) [Catalytic activity/Vol]; UDPG4Epimerase Plas-cCnc; Uridine diphosphate glucose-4-Epimerase:Catalytic Concentration:To identify measures at a point in time:Plasma:Quantitative,
C0366495,Glucose.PO:Mass:Pt:Dose:Qn,glucose,Glucose.PO:Mass:To identify measures at a point in time:Dose:Quantitative; Glucose.PO [Mass] of Dose; Glucose PO Dose; Glucose.PO (Dose) [Mass],
C0366781,Hemoglobin A1c/Hemoglobin.total:MFr:Pt:Bld:Qn,a1c,Hemoglobin A1c/Hemoglobin.total in Blood; HbA1c MFr Bld; Hemoglobin A1c/Hemoglobin.total:Mass Fraction:To identify measures at a point in time:Whole blood:Quantitative; HbA1c (Bld) [Mass fraction],
C0366782,Hemoglobin A1c/Hemoglobin.total:MFr:Pt:Bld:Qn:Electrophoresis,a1c,Hemoglobin A1c/Hemoglobin.total:Mass Fraction:To identify measures at a point in time:Whole blood:Quantitative:Electrophoresis; Hemoglobin A1c/Hemoglobin.total in Blood by Electrophoresis; HbA1c MFr Bld Elph; HbA1c Elph (Bld) [Mass fraction],
C0368018,Glucose:MCnc:Pt:Urine:Qn:Test strip,glucose,Glucose Test strip (U) [Mass/Vol]; Glucose Ur Strip-mCnc; Glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip; Glucose [Mass/volume] in Urine by Test strip,
C0369269,Glucose CSF/Glucose plas,glucose,Glucose CSF/Glucose plas,
C0373503,Glucagon tolerance panel; for insulinoma This panel must include the following: Glucose (82947 x 3) Insulin (83525 x 3),glucose,,
C0373507,Growth hormone suppression panel (glucose administration) This panel must include the following: Glucose (82947 x 3) Human growth hormone (HGH) (83003 x 4),glucose,,
C0373509,Insulin tolerance panel; for ACTH insufficiency This panel must include the following: Cortisol (82533 x 5) Glucose (82947 x 5),glucose,,
C0373510,Insulin tolerance panel; for growth hormone deficiency This panel must include the following: Glucose (82947 x 5) Human growth hormone (HGH) (83003 x 5),glucose,,
C0373620,blood glucose determination by reagent strip (lab test),blood glucose,,
C0373621,Glucose test; post glucose dose (includes glucose),glucose,,
C0373622,"Glucose; tolerance test (GTT), 3 specimens (includes glucose)",glucose,,
C0373627,"Glucose test, blood by glucose monitoring device(s) cleared by the FDA specifically for home use",glucose,,
C0375113,"Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled",diabetes,"Adult-onset type diabetes mellitus or unspecified type, not stated as uncontrolled, without mention of complication; Type II diabetes mellitus or unspecified type, not stated as uncontrolled, without mention of complication; Non-insulin dependent type diabetes mellitus or unspecified type, not stated as uncontrolled, without mention of complication; NIDDM type or unspecified type, not stated as uncontrolled, without mention of complication; type II diabetes mellitus [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, without mention of complication",
C0375114,"Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled",diabetes,"Type I diabetes mellitus not stated as uncontrolled, without mention of complication; IDDM not stated as uncontrolled, without mention of complication; Insulin dependent type not stated as uncontrolled, without mention of complication; type I diabetes mellitus [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, without mention of complication; Juvenile type diabetes mellitus not stated as uncontrolled, without mention of complication",
C0375115,"Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled",diabetes,"type II diabetes mellitus [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, without mention of complication; Non-insulin dependent type diabetes mellitus or unspecified type, uncontrolled, without mention of complication; Type II diabetes mellitus or unspecified type, uncontrolled, without mention of complication; Adult-onset type diabetes mellitus or unspecified type, uncontrolled, without mention of complication; NIDDM type or unspecified type, uncontrolled, without mention of complication",
C0375116,"Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled",diabetes,"Type I diabetes mellitus, uncontrolled, without mention of complication; Juvenile type diabetes mellitus, uncontrolled, without mention of complication",
C0375117,"Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled",diabetes,"Non-insulin dependent type diabetes mellitus or unspecified type, not stated as uncontrolled, with ketoacidosis; Type II diabetes mellitus or unspecified type, not stated as uncontrolled, with ketoacidosis; type II diabetes mellitus [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with ketoacidosis; Adult-onset type diabetes mellitus or unspecified type, not stated as uncontrolled, with ketoacidosis; NIDDM type or unspecified type, not stated as uncontrolled, with ketoacidosis",
C0375118,"Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled",diabetes,"Type I diabetes mellitus, not stated as uncontrolled, with ketoacidosis; Insulin dependent type diabetes mellitus, not stated as uncontrolled, with ketoacidosis; type I diabetes mellitus [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with ketoacidosis; Juvenile type diabetes mellitus, not stated as uncontrolled, with ketoacidosis; IDDM, not stated as uncontrolled, with ketoacidosis",
C0375119,"Diabetes with ketoacidosis, type II or unspecified type, uncontrolled",diabetes,"NIDDM type or unspecified type, uncontrolled, with ketoacidosis; type II diabetes mellitus [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with ketoacidosis; Adult-onset type diabetes mellitus or unspecified type, uncontrolled, with ketoacidosis; Non-insulin dependent type diabetes mellitus or unspecified type, uncontrolled, with ketoacidosis; Type II diabetes mellitus or unspecified type, uncontrolled, with ketoacidosis",
C0375120,"Diabetes with ketoacidosis, type I [juvenile type], uncontrolled",diabetes,"type I diabetes mellitus [juvenile type], uncontrolled, with ketoacidosis; Juvenile type diabetes mellitus, uncontrolled, with ketoacidosis; Type I diabetes mellitus, uncontrolled, with ketoacidosis",
C0375121,Diabetes mellitus with hyperosmolarity,diabetes,,
C0375122,"Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled",diabetes,"Diabetes mellitus, NIDDM type or unspecified type with hyperosmolarity, not stated as uncontrolled; Diabetes mellitus, non-insulin dependent type or unspecified type with hyperosmolarity, not stated as uncontrolled; Diabetes mellitus, type II or unspecified type with hyperosmolarity, not stated as uncontrolled; Diabetes mellitus, adult-onset type or unspecified type with hyperosmolarity, not stated as uncontrolled; Diabetes mellitus, type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type with hyperosmolarity, not stated as uncontrolled",
C0375123,"Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled",diabetes,"Diabetes mellitus, juvenile type with hyperosmolarity, not stated as uncontrolled; Diabetes mellitus, type I with hyperosmolarity, not stated as uncontrolled; Diabetes mellitus, IDDM with hyperosmolarity, not stated as uncontrolled; Diabetes mellitus, insulin dependent type with hyperosmolarity, not stated as uncontrolled; Diabetes mellitus, type I [insulin dependent type] [IDDM] [juvenile type] with hyperosmolarity, not stated as uncontrolled",
C0375124,"Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled",diabetes,"Diabetes mellitustype II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type with hyperosmolarity, uncontrolled; Diabetes mellitus non-insulin dependent type or unspecified type with hyperosmolarity, uncontrolled; Diabetes mellitus NIDDM type or unspecified type with hyperosmolarity, uncontrolled; Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type with hyperosmolarity, uncontrolled; Diabetes mellitus adult-onset type or unspecified type with hyperosmolarity, uncontrolled; Diabetes mellitus type II or unspecified type with hyperosmolarity, uncontrolled",
C0375125,"Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled",diabetes,"Diabetes mellitus, type I with hyperosmolarity, uncontrolled; Diabetes mellitus, type I [juvenile type] with hyperosmolarity, uncontrolled; Diabetes mellitus, juvenile type with hyperosmolarity, uncontrolled",
C0375126,"Diabetes with other coma, type II or unspecified type, not stated as uncontrolled",diabetes,"Diabetes mellitus, adult-onset type or unspecified type, not stated as uncontrolled; Diabetes mellitus, type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled; Diabetes mellitus, NIDDM type or unspecified type, not stated as uncontrolled; Diabetes mellitus, non-insulin dependent type or unspecified type, not stated as uncontrolled; Diabetes mellitus, type II or unspecified type, not stated as uncontrolled",
C0375127,"Diabetes with other coma, type I [juvenile type], not stated as uncontrolled",diabetes,"Diabetes mellitus, juvenile type, not stated as uncontrolled; Diabetes mellitus, type I, not stated as uncontrolled; Diabetes mellitus, type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled; Diabetes mellitus, insulin dependent type, not stated as uncontrolled; Diabetes mellitus, IDDM, not stated as uncontrolled",
C0375128,"Diabetes with other coma, type II or unspecified type, uncontrolled",diabetes,"Diabetes mellitus with other coma, type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled; Diabetes mellitus with other coma, non-insulin dependent type or unspecified type, uncontrolled; Diabetes mellitus with other coma, adult-onset type or unspecified type, uncontrolled; Diabetes mellitus with other coma, type II or unspecified type, uncontrolled; Diabetes mellitus with other coma, NIDDM type or unspecified type, uncontrolled",
C0375129,"Diabetes with other coma, type I [juvenile type], uncontrolled",diabetes,"Diabetes mellitus with other coma, juvenile type, uncontrolled; Diabetes mellitus with other coma, type I [juvenile type], uncontrolled; Diabetes mellitus with other coma, type I, uncontrolled",
C0375130,"Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled",diabetes,"Diabetes mellitus NIDDM type or unspecified type, not stated as uncontrolled, with renal manifestations; Diabetes mellitus adult-onset type or unspecified type, not stated as uncontrolled, with renal manifestations; Diabetes mellitus type II or unspecified type, not stated as uncontrolled, with renal manifestations; Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with renal manifestations; Diabetes mellitus non-insulin dependent type or unspecified type, not stated as uncontrolled, with renal manifestations",
C0375131,"Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled",diabetes,"Diabetes mellitus IDDM, not stated as uncontrolled, with renal manifestations; Diabetes mellitus juvenile type, not stated as uncontrolled, with renal manifestations; Diabetes mellitus insulin dependent type, not stated as uncontrolled, with renal manifestations; Diabetes mellitus type I, not stated as uncontrolled, with renal manifestations; Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with renal manifestations",
C0375132,"Diabetes with renal manifestations, type II or unspecified type, uncontrolled",diabetes,"Diabetes mellitus NIDDM type or unspecified type, uncontrolled, with renal manifestations; Diabetes mellitus adult-onset type or unspecified type, uncontrolled, with renal manifestations; Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with renal manifestations; Diabetes mellitus non-insulin dependent type or unspecified type, uncontrolled, with renal manifestations; Diabetes mellitus type II or unspecified type, uncontrolled, with renal manifestations",
C0375133,"Diabetes with renal manifestations, type I [juvenile type], uncontrolled",diabetes,"Diabetes mellitus type I [juvenile type], uncontrolled, with renal manifestations; Diabetes mellitus type I, uncontrolled, with renal manifestations; Diabetes mellitus juvenile type, uncontrolled, with renal manifestations",
C0375134,"Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled",diabetes,"Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with ophthalmic manifestations; Diabetes mellitus NIDDM type or unspecified type, not stated as uncontrolled, with ophthalmic manifestations; Diabetes mellitus non-insulin dependent type or unspecified type, not stated as uncontrolled, with ophthalmic manifestations; Diabetes mellitus adult-onset type or unspecified type, not stated as uncontrolled, with ophthalmic manifestations; Diabetes mellitus type II or unspecified type, not stated as uncontrolled, with ophthalmic manifestations",
C0375135,"Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled",diabetes,"Diabetes mellitus insulin dependent type, not stated as uncontrolled, with ophthalmic manifestations; Diabetes mellitus IDDM, not stated as uncontrolled, with ophthalmic manifestations; Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with ophthalmic manifestations; Diabetes mellitus type I, not stated as uncontrolled, with ophthalmic manifestations; Diabetes mellitus juvenile type, not stated as uncontrolled, with ophthalmic manifestations",
C0375136,"Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled",diabetes,"Diabetes mellitus juvenile type, uncontrolled, with ophthalmic manifestations; Diabetes mellitus type I, uncontrolled, with ophthalmic manifestations; Diabetes mellitus type I [juvenile type], uncontrolled, with ophthalmic manifestations",
C0375137,"Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled",diabetes,"Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with neurological manifestations; Diabetes mellitus type II or unspecified type, not stated as uncontrolled, with neurological manifestations; Diabetes mellitus non-insulin dependent type or unspecified type, not stated as uncontrolled, with neurological manifestations; Diabetes mellitus adult-onset type or unspecified type, not stated as uncontrolled, with neurological manifestations; Diabetes mellitus NIDDM type or unspecified type, not stated as uncontrolled, with neurological manifestations",
C0375138,"Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled",diabetes,"Diabetes mellitus insulin dependent type, not stated as uncontrolled, with neurological manifestations; Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with neurological manifestations; Diabetes mellitus juvenile type, not stated as uncontrolled, with neurological manifestations; Diabetes mellitus type I, not stated as uncontrolled, with neurological manifestations; Diabetes mellitus IDDM, not stated as uncontrolled, with neurological manifestations",
C0375139,"Diabetes with neurological manifestations, type II or unspecified type, uncontrolled",diabetes,"Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with neurological manifestations; Diabetes mellitus non-insulin dependent type or unspecified type, uncontrolled, with neurological manifestations; Diabetes mellitus adult-onset type or unspecified type, uncontrolled, with neurological manifestations; Diabetes mellitus NIDDM type or unspecified type, uncontrolled, with neurological manifestations; Diabetes mellitus type II or unspecified type, uncontrolled, with neurological manifestations",
C0375140,"Diabetes with neurological manifestations, type I [juvenile type], uncontrolled",diabetes,"Diabetes mellitus juvenile type, uncontrolled, with neurological manifestations; Diabetes mellitus type I [juvenile type], uncontrolled, with neurological manifestations",
C0375141,"Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled",diabetes,"Diabetes mellitus non-insulin dependent type or unspecified type, not stated as uncontrolled, with peripheral circulatory disorders; Diabetes mellitus adult-onset type or unspecified type, not stated as uncontrolled, with peripheral circulatory disorders; Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with peripheral circulatory disorders; Diabetes mellitus type II or unspecified type, not stated as uncontrolled, with peripheral circulatory disorders; Diabetes mellitus NIDDM type or unspecified type, not stated as uncontrolled, with peripheral circulatory disorders",
C0375142,"Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled",diabetes,"Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with peripheral circulatory disorders; Diabetes mellitus insulin dependent type, not stated as uncontrolled, with peripheral circulatory disorders; Diabetes mellitus juvenile type, not stated as uncontrolled, with peripheral circulatory disorders; Diabetes mellitus IDDM, not stated as uncontrolled, with peripheral circulatory disorders; Diabetes mellitus type I, not stated as uncontrolled, with peripheral circulatory disorders",
C0375143,"Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled",diabetes,"Diabetes mellitus NIDDM type or unspecified type, uncontrolled, with peripheral circulatory disorders; Diabetes mellitus adult-onset type or unspecified type, uncontrolled, with peripheral circulatory disorders; Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with peripheral circulatory disorders; Diabetes mellitus type II or unspecified type, uncontrolled, with peripheral circulatory disorders; Diabetes mellitus non-insulin dependent type or unspecified type, uncontrolled, with peripheral circulatory disorders",
C0375144,"Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled",diabetes,"Diabetes mellitus type I, uncontrolled, with peripheral circulatory disorders; Diabetes mellitus juvenile type, uncontrolled, with peripheral circulatory disorders; Diabetes mellitus type I [juvenile type], uncontrolled, with peripheral circulatory disorders",
C0375145,"Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled",diabetes,"Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with other specified manifestations; Diabetes mellitus type II or unspecified type, not stated as uncontrolled, with other specified manifestations; Diabetes mellitus non-insulin dependent type or unspecified type, not stated as uncontrolled, with other specified manifestations; Diabetes mellitus NIDDM type or unspecified type, not stated as uncontrolled, with other specified manifestations; Diabetes mellitus adult-onset type or unspecified type, not stated as uncontrolled, with other specified manifestations",
C0375146,"Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled",diabetes,"Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with other specified manifestations; Diabetes mellitus type I, not stated as uncontrolled, with other specified manifestations; Diabetes mellitus juvenile type, not stated as uncontrolled, with other specified manifestations; Diabetes mellitus IDDM, not stated as uncontrolled, with other specified manifestations; Diabetes mellitus insulin dependent type, not stated as uncontrolled, with other specified manifestations",
C0375147,"Diabetes with other specified manifestations, type II or unspecified type, uncontrolled",diabetes,"Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with other specified manifestations; Diabetes mellitus NIDDM type or unspecified type, uncontrolled, with other specified manifestations; Diabetes mellitus adult-onset type or unspecified type, uncontrolled, with other specified manifestations; Diabetes mellitus non-insulin dependent type or unspecified type, uncontrolled, with other specified manifestations; Diabetes mellitus type II or unspecified type, uncontrolled, with other specified manifestations",
C0375148,"Diabetes with other specified manifestations, type I [juvenile type], uncontrolled",diabetes,"Diabetes mellitus type I [juvenile type], uncontrolled, with other specified manifestations; Diabetes mellitus type I, uncontrolled, with other specified manifestations; Diabetes mellitus juvenile type, uncontrolled, with other specified manifestations",
C0375149,"Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled",diabetes,"Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, not stated as uncontrolled, with unspecified complication; Diabetes mellitus adult-onset type or unspecified type, not stated as uncontrolled, with unspecified complication; Diabetes mellitus NIDDM type or unspecified type, not stated as uncontrolled, with unspecified complication; Diabetes mellitus non-insulin dependent type or unspecified type, not stated as uncontrolled, with unspecified complication",
C0375150,"Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled",diabetes,"Diabetes mellitus type I, not stated as uncontrolled, with unspecified complication; Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with unspecified complication; Diabetes mellitus IDDM, not stated as uncontrolled, with unspecified complication; Diabetes mellitus insulin dependent type, not stated as uncontrolled, with unspecified complication; Diabetes mellitus juvenile type, not stated as uncontrolled, with unspecified complication",
C0375151,"Diabetes with unspecified complication, type II or unspecified type, uncontrolled",diabetes,"Diabetes mellitus adult-onset type or unspecified type, uncontrolled, with unspecified complication; Diabetes mellitus type II or unspecified type, uncontrolled, with unspecified complication; Diabetes mellitus NIDDM type or unspecified type, uncontrolled, with unspecified complication; Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with unspecified complication; Diabetes mellitus non-insulin dependent type or unspecified type, uncontrolled, with unspecified complication",
C0375152,"Diabetes with unspecified complication, type I [juvenile type], uncontrolled",diabetes,"Diabetes mellitus type I, uncontrolled, with unspecified complication; Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], uncontrolled, with unspecified complication; Diabetes mellitus insulin dependent type, uncontrolled, with unspecified complication; Diabetes mellitus IDDM, uncontrolled, with unspecified complication; Diabetes mellitus juvenile type, uncontrolled, with unspecified complication",
C0375153,Other specified hypoglycemia,hypoglycemia,,
C0376128,"Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled",diabetes,"Diabetes mellitus type II or unspecified type, uncontrolled, with ophthalmic manifestations; Diabetes mellitus type II [non-insulin dependent type] [NIDDM type] [adult-onset type] or unspecified type, uncontrolled, with ophthalmic manifestations; Diabetes mellitus adult-onset type or unspecified type, uncontrolled, with ophthalmic manifestations; Diabetes mellitus NIDDM type or unspecified type, uncontrolled, with ophthalmic manifestations; Diabetes mellitus non-insulin dependent type or unspecified type, uncontrolled, with ophthalmic manifestations",
C0377640,2-deoxy-2-fluoro-3-O-methylglucose,glucose,"D-Glucose, 2-deoxy-2-fluoro-3-O-methyl-; D-Glucose, 2-deoxy-2-(fluoro-18F)-3-O-methyl-",
C0379455,"gsiB protein, Bacillus subtilis",glucose,"general stress protein B, Bacillus subtilis; glucose starvation-inducible protein B, Bacillus subtilis",
C0381074,glucose-6-phosphate dehydrogenase Wisconsin,glucose,G6PD Wisconsin,
C0381076,glucose-6-phosphate dehydrogenase Calvo Mackenna,glucose,G6PD Calvo Mackenna,
C0381078,glucose-6-phosphate dehydrogenase Riley,glucose,G6PD Riley,
C0381341,4-O-glucopyranosyl-6-deoxyglucose,glucose,Glc-6-deoxy-Glc; 4-O-beta-D-glucopyranosyl-6-deoxy-D-glucose,
C0385266,"mannose-glucose-binding lectin, Cladrastis lutea",glucose,,
C0386425,"3,6-dideoxy-3-formamidoglucose",glucose,"3,6-dideoxy-3-formamido-D-glucose; 3-formamido-3,6-d2Glu",
C0387255,GM2-1 ganglioside,glucose,NeuAc-O-Gal-O-GalN-O-GalN-O-Glc-Cer; N-acetylneuraminic acid-galactose-galactosamine-galactosamine-glucose-ceramide,
C0387261,"2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose",glucose,"2-deoxy-2-((7-nitro-2,1,3-benzoxadiazol-4-yl)amino)-D-glucose; 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxy-D-glucose; 2-NBDG",
C0387407,glucose-regulated protein 170,glucose,"GRP170; glucose-regulated protein 170; glucose regulated stress protein, 170 kDa",
C0390341,"sodium glucose symporter, Vibrio parahaemolyticus",glucose,"Na-Glc symporter, Vibrio parahaemolyticus; sglS protein, Vibrio parahaemolyticus",
C0391941,Glucose-6-phosphate dehydrogenase Measurement,glucose,Glucose-6-phosphate dehydrogenase measurement; G6pd Test; Glucose-6-phosphate dehydrogenase measurement (procedure); Glucose-6-Phosphate Dehydrogenase Measurement,
C0392201,Blood glucose measurement,glucose level,"blood glucose measurements; blood sugar test; glucose blood test; Blood Glucose; Blood Glucose Measurement; Glucose measurement, blood (procedure); Glucose measurement, blood; blood glucose testing; blood glucose measurement; blood sugar levels; BS - Blood glucose level; blood levels sugar; Blood glucose; blood sugar level; Glucose, blood, measurement; blood glucose tests; blood glucose; blood test glucose; Blood Glucose Monitoring; Blood sugar level; blood glucose test; Blood Sugar",
C0393829,Acute painful diabetic neuropathy,diabetes,Acute painful neuropathy due to diabetes mellitus (disorder); Acute painful neuropathy due to diabetes mellitus,
C0393830,Chronic painful neuropathy due to diabetes mellitus,diabetes,Chronic painful neuropathy due to diabetes mellitus (disorder); Chronic painful diabetic neuropathy,
C0393831,Asymptomatic neuropathy due to diabetes mellitus,diabetes,Asymptomatic neuropathy due to diabetes mellitus (disorder); Asymptomatic diabetic neuropathy; Asymptomatic neuropathy with diabetes mellitus,
C0393833,Diabetic acute painful polyneuropathy,diabetes,Acute painful polyneuropathy due to diabetes mellitus (disorder); Acute painful polyneuropathy due to diabetes mellitus,
C0393834,Chronic painful polyneuropathy due to diabetes mellitus,diabetes,Diabetic chronic painful polyneuropathy; Chronic painful polyneuropathy due to diabetes mellitus (disorder),
C0393835,Diabetic Asymmetric Polyneuropathy,diabetes,"Diabetic Asymmetric Polyneuropathies; Asymmetric Polyneuropathies, Diabetic; Polyneuropathy, Diabetic Asymmetric; Asymmetric polyneuropathy due to diabetes mellitus (disorder); Diabetic asymmetric polyneuropathy; Asymmetric Polyneuropathy, Diabetic; Polyneuropathies, Diabetic Asymmetric; Asymmetric polyneuropathy due to diabetes mellitus",
C0393838,Thoracic radiculopathy due to diabetes mellitus,diabetes,Diabetic truncal radiculopathy; Thoracic radiculopathy with diabetes mellitus; Diabetic thoracic radiculopathy; Thoracic radiculopathy due to diabetes mellitus (disorder),
C0398561,Glucose phosphate isomerase deficiency,glucose,Glucose phosphate isomerase deficiency; Glucose Phosphate Isomerase Deficiency; Glucose phosphate isomerase deficiency (disorder); GPI - Glucose phosphate isomerase deficiency,
C0398689,"Hyper-IgM Immunodeficiency Syndrome, Type 1",hyper,"X-linked hyper-immunoglobulin M syndrome (disorder); Immunodeficiency with Hyper-IgM, X-Linked, Type 1; Immunodeficiency with Hyper-IgM, Type 1; XHIGM; IHIS; HIGM1 Syndromes; X-Linked Hyper-IgM Syndrome; X-Linked Hyper-IgM Immunodeficiencies; Immunodeficiency, X-Linked Hyper-IgM; IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1; Hyper IgM Syndrome 1; X-linked hyper-immunoglobulin M syndrome; IMD3; X Linked Hyper IgM Syndrome; Hyper-IgM syndrome type 1; HYPER-IgM SYNDROME 1; X-linked hyper-IgM syndrome; Hyper-IgM Syndrome 1; Immunodeficiencies, X-Linked Hyper-IgM; HYPER-IgM SYNDROME; Hyper IgM Immunodeficiency Syndrome, Type 1; Immunodeficiency with Hyper IgM, Type 1; X-linked with hyper-IgM immunodeficiency; X-Linked Hyper-IgM Immunodeficiency; HIGM1; HIGM1 Syndrome; HYPER-IgM IMMUNODEFICIENCY, X-LINKED; Hyper-IgM Immunodeficiency Syndrome, Type 1; Hyper-IgM syndrome due to CD40 ligand deficiency; Hyper-IgM Immunodeficiency, X-Linked; IMMUNODEFICIENCY 3; X-linked immunodeficiency with hyper IgM; XHIM; X-linked immunodeficiency with hyper-IgM; Hyper-IgM syndrome due to CD40L deficiency; HIGM; X-Linked Hyper IgM Syndrome; Hyper IgM Immunodeficiency, X Linked; Hyper-IgM Immunodeficiencies, X-Linked",
C0398691,Hyperimmunoglobulinemia D,hyper,"Hyperimmunoglobinemia D with recurrent fever; Hyper-IgD Syndrome; HIDS; Hyperimmunoglobulin D with periodic fever (finding); HYPER-IgD SYNDROME; Hyper-IgD syndrome; Hyperimmunoglobulinemia D with periodic fever; Hyperimmunoglobulin D with periodic fever; Hyper-IgD Syndromes; Periodic fever - Dutch type; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; PERIODIC FEVER, DUTCH TYPE; Hyperimmunoglobulinemia D; Hyperimmunoglobulinemia D syndrome; Hyper IgD Syndromes; Partial mevalonate kinase deficiency; Hyperimmunoglobulinemia D And Periodic Fever Syndrome; Periodic Fever, Dutch Type; Hyper IgD Syndrome; Syndrome, Hyper-IgD",
C0398743,Leukocyte glucose-6-phosphate dehydrogenase deficiency,glucose,Leukocyte glucose-6-phosphate dehydrogenase deficiency (disorder); Leucocyte glucose-6-phosphate dehydrogenase deficiency,
C0400875,Hollow visceral neuropathy,diabetes,Hollow visceral neuropathy (disorder); Diarrhea due to diabetes mellitus (disorder); diarrhoea diabetes; diabetic enteropathy; Diabetic diarrhea; Diabetic enteropathy; Diarrhea due to diabetes mellitus; diabetic diarrhea; diabetes diarrhea; Diarrhea with diabetes mellitus; hollow visceral neuropathy; Diarrhoea due to diabetes mellitus; Diarrhoea with diabetes mellitus; Diabetic diarrhoea; Visceral diabetic neuropathy; diarrhea diabetes; Diarrhoea in diabetes; diabetics diarrhea; Diarrhea in diabetes,
C0403502,Low renal threshold for glucose,glucose,Low renal threshold for glucose (disorder),
C0403503,High renal threshold for glucose,glucose,High renal threshold for glucose (disorder),
C0403518,Microalbuminuric diabetic nephropathy,diabetes,Incipient diabetic nephropathy; Microalbuminuric nephropathy due to diabetes mellitus (disorder); Microalbuminuric nephropathy due to diabetes mellitus,
C0403519,Proteinuric nephropathy due to diabetes mellitus,diabetes,Clinical diabetic nephropathy; Proteinuric diabetic nephropathy; Proteinuric nephropathy due to diabetes mellitus (disorder),
C0404733,Abnormal glucose tolerance test in the puerperium - baby delivered during previous episode of care,glucose,Abnormal glucose tolerance test in the puerperium - baby delivered during previous episode of care (finding),
C0404734,Abnormal glucose tolerance test during pregnancy - baby not yet delivered,glucose,Abnormal glucose tolerance test during pregnancy - baby not yet delivered (finding),
C0404735,Abnormal glucose tolerance test during pregnancy - baby delivered (finding),glucose,Abnormal glucose tolerance test during pregnancy - baby delivered; Abnormal glucose tolerance test during pregnancy - baby delivered (finding),
C0404736,Abnormal glucose tolerance test in the puerperium - baby delivered during current episode of care,glucose,Abnormal glucose tolerance test in the puerperium - baby delivered during current episode of care (finding),
C0406132,Cellulitis of foot due to diabetes mellitus,diabetes,Cellulitis of foot due to diabetes mellitus (disorder); Cellulitis in diabetic foot,
C0406526,Neuropathic ulcer of foot due to diabetes mellitus,diabetes,Neuropathic ulcer of foot due to diabetes mellitus (disorder); Neuropathic diabetic ulcer - foot,
C0406681,Disorder of soft tissue due to diabetes mellitus,diabetes,Soft tissue complication of diabetes mellitus; Disorder of soft tissue due to diabetes mellitus (disorder),
C0406682,Diabetic dermopathy,diabetes,Dermopathy due to diabetes mellitus (disorder); Dermopathy due to diabetes mellitus,
C0406683,Bullosis diabeticorum,diabetes,Bullous disease due to diabetes mellitus (disorder); Bullous disease due to diabetes mellitus; Bullosis diabeticorum; Diabetic bulla,
C0406684,Diabetic thick skin syndrome,diabetes,Thick skin syndrome due to diabetes mellitus; Thick skin syndrome due to diabetes mellitus (disorder); Diabetic scleredema,
C0406685,Diabetic hand syndrome,diabetes,diabetic cheiropathy; Diabetic cheirarthropathy; Diabetic cheiropathy; diabetic hand syndrome; Cheiroarthropathy due to diabetes mellitus; Diabetic cheiroarthropathy; Cheiroarthropathy due to diabetes mellitus (disorder),
C0406686,Rubeosis faciei due to diabetes mellitus,diabetes,Rubeosis faciei diabeticorum; Diabetic rubeosis; Rubeosis faciei due to diabetes mellitus (disorder),
C0406721,Hypohidrosis-diabetes insipidus syndrome,diabetes,Fleck syndrome; Hypohidrosis-diabetes insipidus syndrome (disorder),
C0410988,Neonatal jaundice due to glucose-6-phosphate dehydrogenase deficiency,glucose,Neonatal jaundice with glucose-6-phosphate dehydrogenase deficiency; Neonatal jaundice due to glucose-6-phosphate dehydrogenase deficiency (disorder),
C0412495,Positron emission tomography of brain using fluorodeoxyglucose (18-F),glucose,Positron emission tomography of brain using fluorodeoxyglucose (18-F) (procedure); PET brain glucose metabolism study,
C0412499,PET myocardial glucose metabolism study,glucose,Positron emission tomography myocardial glucose metabolism study (procedure); Positron emission tomography myocardial glucose metabolism study,
C0420743,Urine glucose test not done,glucose,Urine glucose test not done (situation),
C0421246,Diabetic on diet only,diabetes,Diabetic on diet only (finding); Diet controlled diabetes mellitus,
C0421249,Last hypoglycemia attack,hypo,Last hypoglycaemia attack; Last hypo. attack; Last hypoglycemia attack (finding),
C0421251,Has seen dietitian - diabetes,diabetes,Has seen dietitian - diabetes (finding); Has seen dietician - diabetes,
C0421252,Understands diet - diabetes,diabetes,Understands diet - diabetes (finding),
C0421254,Blood sugar charts,blood sugar,Blood sugar charts (finding); blood sugar chart; blood sugar charts,
C0421258,Diabetic - poor control,diabetes,Diabetes mellitus uncontrolled; Diabetic - poor control (finding),
C0422578,Attends diabetes monitoring,diabetes,Attends diabetes monitoring (finding),
C0422579,Refuses diabetes monitoring,diabetes,Diabetes monitoring declined; Diabetes monitoring declined (situation),
C0422580,Diabetes monitoring default,diabetes,Diabetes monitoring default (finding),
C0422581,Diabetes monitoring first letter,diabetes,Diabetes monitoring first letter (procedure),
C0422582,Diabetes monitoring second letter,diabetes,Diabetes monitoring second letter (procedure),
C0422583,Diabetes monitoring third letter,diabetes,Diabetes monitoring third letter (procedure),
C0422584,Diabetes monitoring verbal invite,diabetes,Diabetes monitoring verbal invite (procedure),
C0422585,Diabetes monitoring telephone invite,diabetes,Diabetes monitoring telephone invite (procedure),
C0422586,Diabetes monitoring deleted,diabetes,Diabetes monitoring deleted (finding),
C0422587,Diabetes monitoring check done,diabetes,diabetes monitoring check done; diabetes monitoring; diabetes monitor; Diabetes monitoring check done (finding); diabetes monitors; Diabetes monitored; diabete monitoring,
C0423343,Lens nuclear hyper-refringence,hyper,Lens nuclear hyper-refringence (finding),
C0423397,Diabetic retinal venous beading,diabetes,Venous beading of retina due to diabetes mellitus (disorder); Diabetic retinal venous beading; Retinal venous beading with diabetes mellitus; Venous beading of retina due to diabetes mellitus,
C0424295,Hyperactive behavior,hyper,"Hyperkinesis, NOS; HYPERACTIVITY; HA - Hyperactivity; BEHAVIOUR HYPERACTIVE; hyperkinetic movement; Hyperactive; hyperkinesis; BEHAVIOR HYPERACTIVE; hyperactivity; hyperactivity (behavior); HYPER; hyperactive behavior; Hyperactive behaviour; Hyperactivity, NOS; Hyperactive behavior (finding); motor hyperactivity; hyperactivities; Increased purposeful goal-directed activity; Hyperactivity; Hyperkinesis; Hyperactive behavior; HYPERACTIVE; Increased purposeful goal-directed activity, NOS; More active than typical; hyperactive",
C0426674,Abdomen hyper-resonant,hyper,Abdomen hyper-resonant (finding); Abdominal resonance increased,
C0427508,"Glucose-6-phosphate dehydrogenase measurement, quantitative",glucose,"Glucose-6-phosphate dehydrogenase measurement, quantitative (procedure); Glucose-6-Phosphate Dehydrogenase Activity; Red cell glucose-6-phosphate dehydrogenase level; Glucose-6-phosphate dehydrogenase measurement, quantitative; G6PD Activity; Glucose-6-phosphate dehydrogenase activity; G6PD - Glucose-6-phosphate dehydrogenase activity",
C0427743,"Glucose concentration, test strip measurement",glucose,"Glucose concentration, test strip measurement; concentrations glucose; glucose concentration; concentration glucose; glucose concentration test; Glucose concentration, test strip measurement (procedure)",
C0427744,Urine glucose test negative,glucose,Urine glucose test negative (finding),
C0427745,Urine glucose test = trace,glucose,Urine glucose test = trace (finding),
C0427746,Urine glucose test is 1+,glucose,urine glucose test = +; urine test glucose; Urine glucose test = + (finding); Urine glucose test = +; glucose urine test; glucose tests urine; glucose test urine; glucose testing urine,
C0427747,Urine glucose test is 2+,glucose,urine test glucose; urine glucose test = ++; glucose urine test; Urine glucose test = ++ (finding); glucose tests urine; Urine glucose test = ++; glucose test urine; glucose testing urine,
C0427748,Urine glucose test is 3+,glucose,urine test glucose; Urine glucose test = +++; Urine glucose test = +++ (finding); glucose urine test; glucose tests urine; glucose test urine; urine glucose test = +++; glucose testing urine,
C0427749,Urine glucose test is 4+,glucose,urine test glucose; Urine glucose test = ++++ (finding); Urine glucose test = ++++; urine glucose test = ++++; glucose urine test; glucose tests urine; glucose test urine; glucose testing urine,
C0428548,Glucose level - finding,glucose level,glucose level; Finding of glucose level; Glucose level; glucose levels; Glucose level - finding; Finding of glucose level (finding),
C0428549,Fluid sample glucose measurement,glucose level,"Glucose measurement, body fluid; Fluid sample glucose measurement; Body Fluid Glucose Test; Fluid sample glucose level; Fluid sample glucose measurement (procedure)",
C0428550,CSF: glucose level - finding,glucose level,csf glucose levels; finding of cerebrospinal fluid: glucose level; Finding of cerebrospinal fluid: glucose level (finding); Finding of cerebrospinal fluid: glucose level; CSF: glucose level - finding; CSF: glucose level,
C0428551,CSF: glucose normal,glucose,Cerebrospinal fluid: glucose normal; Cerebrospinal fluid glucose normal; Cerebrospinal fluid glucose normal (finding),
C0428552,Cerebrospinal fluid glucose decreased,glucose,Cerebrospinal fluid (CSF) glucose concentration decreased; CSF: glucose decreased; Cerebrospinal fluid: glucose decreased; CSF glucose decreased; Cerebrospinal fluid glucose decreased (finding); Cerebrospinal fluid glucose decreased,
C0428553,CSF: glucose increased,glucose,Hyperglycorrhachia; Cerebrospinal fluid glucose increased; Increased CSF glucose; Cerebrospinal fluid glucose increased (finding); Cerebrospinal fluid: glucose increased,
C0428554,Finding of blood glucose level,glucose level,blood glucose level; blood glucose results; Blood glucose result - finding; blood glucose levels; blood sugar levels; Blood glucose level; Blood glucose level - finding; Finding of blood glucose level; blood sugar level; Finding of blood glucose level (finding); blood glucose result; Blood glucose result,
C0428556,Blood glucose 0-1.4 mmol/L,blood glucose,Blood glucose 0-1.4 mmol/L (finding),
C0428557,Blood glucose 1.5-2.4 mmol/L,blood glucose,Blood glucose 1.5-2.4 mmol/L (finding),
C0428558,Blood glucose 2.5-4.9 mmol/L,blood glucose,Blood glucose 2.5-4.9 mmol/L (finding),
C0428559,Blood glucose 5-6.9 mmol/L,blood glucose,Blood glucose 5-6.9 mmol/L (finding),
C0428560,Blood glucose 7-9.9 mmol/L,blood glucose,Blood glucose 7-9.9 mmol/L (finding),
C0428561,Blood glucose 10-13.9 mmol/L,blood glucose,Blood glucose 10-13.9 mmol/L (finding),
C0428562,Blood glucose 14+ mmol/L,blood glucose,Blood glucose 14+ mmol/L (finding),
C0428564,Lunch time blood sugar measurement,glucose measurement,Lunch time blood glucose measurement; Lunch time blood sugar measurement; Lunch time blood sugar measurement (procedure); Lunch time blood sugar level,
C0428565,Supper time blood sugar measurement,glucose measurement,Supper time blood sugar level; Supper time blood sugar measurement (procedure); Supper time blood sugar measurement; Supper time blood glucose measurement,
C0428566,Bedtime blood sugar measurement,glucose measurement,Bedtime blood sugar measurement; Bedtime blood sugar level; Bedtime blood glucose measurement; Bedtime blood sugar measurement (procedure),
C0428567,Random blood glucose measurement,glucose level,random blood glucose; RBG - Random blood glucose; Random blood glucose; Random blood glucose measurement; Random blood glucose level; blood glucose levels random; Random blood glucose measurement (procedure); random blood glucose level,
C0428568,Fasting blood glucose measurement,glucose level,FBS - Fasting blood sugar; fasting blood glucose level; blood glucose fasting; blood fasting glucose; Fasting blood glucose measurement; fasting blood glucose; fasting blood glucose test; Fasting blood glucose level; FBG - Fasting blood glucose; blood fasting glucose levels; Fasting blood glucose measurement (procedure); Fasting blood glucose,
C0428569,Post-prandial blood glucose measurement,glucose measurement,Post-prandial blood sugar; post prandial blood glucose; Post-prandial blood glucose measurement; post prandial blood sugar; Post-prandial blood glucose; Post-prandial blood glucose measurement (procedure),
C0429236,Urinary glucose output,glucose,Urinary glucose output (observable entity),
C0429241,Small intestine glucose tolerance,glucose,Small intestine glucose tolerance (observable entity),
C0429242,Small intestine glucose intolerance,glucose,Small intestine glucose intolerance (finding),
C0430030,Blood glucose method (procedure),blood glucose,Blood glucose method (procedure); Blood glucose method,
C0430031,Laboratory blood glucose,blood sugar,Laboratory blood sugar (procedure); Laboratory blood sugar,
C0430032,Glucometer blood glucose,blood sugar,Glucometer blood sugar (procedure); Glucometer blood sugar,
C0430252,Glucose-6-phosphate dehydrogenase deficiency spot test,glucose,G6PD - Glucose-6-phosphate dehydrogenase deficiency spot test; Glucose-6-phosphate dehydrogenase deficiency spot test (procedure),
C0430376,Urine dipstick for glucose,glucose,Urine dipstick for glucose (procedure),
C0431693,Renal cysts and diabetes syndrome,diabetes,"HNF1B-related nephropathy; Renal dysfunction-early-onset diabetes syndrome; Familial hypoplastic, glomerulocystic kidney (disorder); HNF1B-MODY - HNF1 homeobox B maturity-onset diabetes of the young type 5; Maturity-onset diabetes of the young type 5; Glomerulocystic kidney disease, hypoplastic type; RCAD; Maturity-onset diabetes of the young, type 5; TUBULOINTERSTITIAL KIDNEY DISEASE, AUTOSOMAL DOMINANT, 3; HNF1B-related autosomal dominant tubulointerstitial kidney disease; Maturity-onset diabetes of the young, type 5 (disorder); ADTKD-HNF1B; MODY5; RCAD syndrome; Renal cysts and diabetes syndrome; Hyperuricemic nephropathy, familial juvenile, atypical; CAKUT WITH DIABETES; Glomerulocystic kidney, familial hypoplastic; Renal Cysts and Diabetes Syndrome; Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes; Maturity Onset Diabetes of the Young, Type 5; HNF1B-MODY; HNF1B (HNF1 homeobox B) monogenic diabetes mellitus; RENAL CYSTS AND DIABETES SYNDROME; CONGENITAL ANOMALIES OF THE KIDNEY AND URINARY TRACT WITH DIABETES; Familial hypoplastic, glomerulocystic kidney; HNF1B-Related Autosomal Dominant Tubulointerstitial Kidney Disease; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 5; MODY5 - maturity-onset diabetes of the young type 5; ADTKD3; FJHN, ATYPICAL; GLOMERULOCYSTIC KIDNEY DISEASE, HYPOPLASTIC TYPE; HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, ATYPICAL; HNF1B monogenic diabetes mellitus; GLOMERULOCYSTIC KIDNEY, FAMILIAL HYPOPLASTIC",
C0432217,Wolcott-Rallison syndrome,diabetes,"Wolcott-Rallison dysplasia; WRS; MED-IDDM SYNDROME; IDDM-MED syndrome; Early-onset diabetes mellitus with multiple epiphyseal dysplasia; Wolcott-Rallison syndrome; spondylo-epiphyseal dysplasia-diabetes mellitus syndrome; Epiphyseal dysplasia, multiple, with early-onset diabetes mellitus; early-onset diabetes mellitus-epiphyseal dysplasia syndrome; MED-IDDM syndrome; WOLCOTT-RALLISON SYNDROME; EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS; IDDM-MED SYNDROME; multiple epiphyseal dysplasia-early onset diabetes mellitus syndrome; Wolcott-Rallison Syndrome; Wolcott-Rallison dysplasia (disorder); Epiphyseal dysplasia, multiple, with early onset diabetes mellitus; infancy-onset diabetes mellitus-multiple epiphyseal dysplasia syndrome; multiple epiphyseal dysplasia-early onset diabetes mellitus (MED-IDDM) syndrome",
C0438251,Glucose tolerance test normal,glucose,Glucose tolerance test normal (finding),
C0438272,Glucose tolerance test indicates diabetes mellitus,glucose,Glucose tolerance test indicates diabetes mellitus (finding),
C0438273,GTT = renal glycosuria,glucose,Glucose tolerance test = renal glycosuria; Glucose tolerance test = renal glycosuria (finding),
C0438276,Hemoglobin A1c less than 7 percent indicating good diabetic control,a1c,Hemoglobin A1c (HbA1c) less than 7% indicating good diabetic control; Haemoglobin A1c (HbA1c) less than 7% indicating good diabetic control; Haemoglobin A1c less than 7% indicating good diabetic control; Haemoglobin A1c less than 7 percent indicating good diabetic control; Hemoglobin A1c less than 7 percent indicating good diabetic control (finding); Hemoglobin A1c less than 7% indicating good diabetic control,
C0438277,Hemoglobin A1c between 7 percent to 10 percent indicating borderline diabetic control,a1c,Hemoglobin A1c between 7 percent to 10 percent indicating borderline diabetic control (finding); Haemoglobin A1c (HbA1c) between 7%-10% indicating borderline diabetic control; Haemoglobin A1c between 7 percent to 10 percent indicating borderline diabetic control; Haemoglobin A1c between 7%-10% indicating borderline diabetic control; Hemoglobin A1c (HbA1c) between 7%-10% indicating borderline diabetic control; Hemoglobin A1c between 7%-10% indicating borderline diabetic control,
C0438278,Hemoglobin A1c greater than 10 percent indicating poor diabetic control,a1c,Haemoglobin A1c (HbA1c) greater than 10% indicating poor diabetic control; Haemoglobin A1c greater than 10 percent indicating poor diabetic control; Hemoglobin A1c greater than 10% indicating poor diabetic control; Hemoglobin A1c (HbA1c) greater than 10% indicating poor diabetic control; Haemoglobin A1c greater than 10% indicating poor diabetic control; Hemoglobin A1c greater than 10 percent indicating poor diabetic control (finding),
C0438420,Mononeuritis multiplex with diabetes mellitus,diabetes,Mononeuritis multiplex due to diabetes mellitus; Mononeuritis multiplex due to diabetes mellitus (disorder); Diabetic mononeuritis multiplex,
C0449355,Method of giving glucose,glucose,Method of giving glucose (attribute),
C0451115,Diabetes clinic satisfaction questionnaire,diabetes,CSQ - Diabetes clinic satisfaction questionnaire; Diabetes clinic satisfaction questionnaire (assessment scale),
C0451116,Diabetes treatment satisfaction questionnaire,diabetes,DTSQ - Diabetes treatment satisfaction questionnaire; Diabetes treatment satisfaction questionnaire (assessment scale),
C0451117,Diabetes wellbeing questionnaire,diabetes,Diabetes wellbeing questionnaire (assessment scale); DWBQ - Diabetes wellbeing questionnaire,
C0452312,Low glucose diet,low glucose,Low glucose diet (finding),
C0455280,Plasma glucose result,plasma glucose,glucose plasma; plasma glucose; plasma glucose level; glucose levels plasma,
C0455434,FH: Diabetes in pregnancy,diabetes,Family history: Diabetes in pregnancy (situation); Family history: Diabetes in pregnancy,
C0455488,H/O: diabetes mellitus,diabetes,History of diabetes mellitus; Pre-existing diabetes mellitus; History of diabetes mellitus (situation),
C0455678,No family history diabetes,diabetes,no family history diabetes; No family history diabetes (situation); No family history of diabetes; No significant family history of diabetes,
C0456028,Perinatal disorder of glucose regulation of fetus and/or neonate,glucose,Perinatal disorder of glucose regulation; Perinatal disorder of glucose regulation of fetus and/or neonate (disorder),
C0457578,Capillary blood glucose measurement,glucose level,Capillary blood glucose measurement; Capillary blood glucose measurement (procedure); Capillary blood glucose level,
C0462900,Blood glucose testing strips,blood glucose,Blood glucose testing strips (physical object); Blood Glucose Test Strips; blood glucose testing strips; Diabetic test strips; blood glucose test strip; blood glucose strips test; Blood glucose testing strips,
C0462926,Urine glucose testing strips,glucose,Urine glucose testing strips (physical object); urine glucose testing strips; glucose strips test urine,
C0472226,Blood glucose meters (medical device),blood glucose,glucometer; Glucose Analyzers; glucose analyzer; glucometers; Glucometer; Blood glucose meter; blood glucose meter; Blood glucose meter (physical object); blood glucose meters; Glucometers,
C0473524,Postpancreatectomy hypoinsulinemia,diabetes,Postpancreatectomy hypoinsulinemia (disorder); Postpancreatectomy diabetes mellitus; Postpancreatectomy hypoinsulinaemia,
C0473527,Hypoalphalipoproteinemias,hypo,"Lipoproteinemias, Hypo alpha; HDL Cholesterol, Low Serum; High-density lipoid deficiency; Lipoproteinemia, Hypo alpha; Hypo alpha Lipoproteinemia; Hypoalphalipoproteinemia (disorder); Hypoalphalipoproteinemias; Hypoalphalipoproteinemia; Hypoalphalipoproteinaemia; Hypo alpha Lipoproteinemias; alpha Lipoproteinemia, Hypo",
C0473559,Ischemic ulcer of foot due to diabetes mellitus,diabetes,Ischemic ulcer of foot due to diabetes mellitus (disorder); Ischaemic ulcer diabetic foot; Ischaemic ulcer of foot due to diabetes mellitus; Ischemic ulcer diabetic foot,
C0473942,PET study for tumor uptake of glucose,glucose,Positron emission tomography study for tumor uptake of glucose; Positron emission tomography study for tumor uptake of glucose (procedure); PET study for tumour uptake of glucose; Positron emission tomography study for tumour uptake of glucose,
C0474296,Diabetes: practice program,diabetes,Diabetes: practice programme; Diabetes: practice program (finding),
C0474297,Diabetes: shared care program,diabetes,Diabetes: shared care programme; Diabetes: shared care program (finding),
C0474680,Hemoglobin A1c measurement,a1c,Hemoglobin A1C test; Hemoglobin A1c measurement (procedure); Haemoglobin A1c measurement; a1c hemoglobin testing; hemoglobin a1c test; Hemoglobin A1c Test; A1C; HBA1c (hemoglobin A1c) level; HBA1c (haemoglobin A1c) level; Hemoglobin A1c measurement; a1c hemoglobin test,
C0474681,Glucose present in stool specimen by chromatography,glucose,Glucose present in stool specimen by chromatography (finding),
C0474690,Urine glucose chemical titer measurement,glucose,Urine glucose chemical titer measurement; Urine glucose: chem. titer; Urine glucose: chem. titre; Urine glucose chemical titre measurement; Urine glucose chemical titer measurement (procedure),
C0475636,High glycemic index food,glycaemic,High glycemic index food (substance); High glycaemic index food,
C0475638,Low glycemic index food,glycaemic,foods glycemic index low; Low glycemic index food (substance); low glycemic index food; Low glycaemic index food,
C0475718,Neonatal hyperglycemia,hyperglycemia,neonatal hyperglycemia; Neonatal hyperglycaemia; Neonatal hyperglycemia (disorder); Neonatal Hyperglycemia,
C0475719,Transient neonatal hyperglycemia,hyperglycemia,Transient neonatal hyperglycaemia; Transient neonatal hyperglycemia (disorder),
C0475720,Iatrogenic neonatal hyperglycemia,hyperglycemia,Iatrogenic neonatal hyperglycemia (disorder); Iatrogenic neonatal hyperglycaemia,
C0475721,Transitory neonatal hypoglycemia,hypoglycemia,Transitory neonatal hypoglycaemia; Transitory neonatal hypoglycemia (disorder),
C0475722,Iatrogenic neonatal hypoglycemia,hypoglycemia,Iatrogenic neonatal hypoglycaemia; Iatrogenic neonatal hypoglycemia (disorder),
C0477821,"Pre-existing diabetes mellitus, unspecified",diabetes,,
C0481814,"Dietary surveillance and counseling, diabetes mellitus",diabetes,,
C0481906,Encounter for dietary counselling in hypoglycemia,hypoglycemia,"Dietary surveillance and counseling, hypoglycemia",
C0482534,Glucose^1.5H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1.5 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5h p 75 g Glc PO SerPl-mCnc; Glucose 1.5 Hr post 75 g glucose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO,
C0482535,Glucose^2H post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2 hours post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --2 hours post meal; Glucose 2h p meal SerPl-mCnc; Glucose 2 Hr post meal [Mass/Vol],
C0482536,Glucose^30M post 0.1 U/kg insulin:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30M p 0.1 U/kg Ins SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --30 minutes post 0.1 U/kg insulin; Glucose 30 Min post 0.1 U/kg insulin [Mass/Vol]; Glucose^30 minutes post 0.1 U/kg insulin:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0482537,Glucose^30M post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30 Min post 75 g glucose PO [Mass/Vol]; Glucose^30 minutes post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --30 minutes post 75 g glucose PO; Glucose 30M p 75 g Glc PO SerPl-mCnc,
C0482538,Glucose^pre 0.5 g/kg glucose IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --pre 0.5 g/kg glucose IV; Glucose pre 0.5 g/kg glucose IV [Mass/Vol]; Glucose pre .5 g/kg Glc IV SerPl-mCnc; Glucose^pre 0.5 g/kg glucose Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0482539,Glucose^pre 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre 100 g glucose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --pre 100 g glucose PO; Glucose^pre 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre 100 g Glc PO SerPl-mCnc,
C0482540,Glucose^pre 12H CFst:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^pre 12 hours Calorie fast:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre 12h fast SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --pre 12 hour fast; Glucose pre 12 hour fast [Mass/Vol],
C0482541,Glucose^pre 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^pre 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre 50 g lactose PO [Mass/Vol]; Glucose pre 50 g Lac PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --pre 50 g lactose PO,
C0482542,Glucose^pre 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre 75 g glucose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --pre 75 g glucose PO; Glucose^pre 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre 75 g Glc PO SerPl-mCnc,
C0482543,Glucose^pre dose insulin IV:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^pre dose insulin Intravenous:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre dose insulin IV [Mass/Vol]; Glucose pre Ins IV SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --pre dose insulin IV,
C0482544,Glucose [Mass/volume] in Serum or Plasma --post CFst,glucose,Glucose p fast SerPl-mCnc; Glucose post fast [Mass/Vol]; Glucose^post Calorie fast:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Fasting glucose [Mass/volume] in Serum or Plasma; Glucose^post CFst:MCnc:Pt:Ser/Plas:Qn,
C0482545,Hydrogen/Expired gas^post 50 g glucose PO:VFr:Pt:Exhl gas:Qn,glucose,Hydrogen/Expired gas^post 50 g glucose Oral:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --post 50 g glucose PO; Breath H2 p 50 g Glc PO; Hydrogen/Expired gas post 50 g glucose PO (Exhl gas) [Volume fraction],
C0482553,Insulin^pre 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin pre 75 g Glc PO SerPl-mCnc; Insulin pre 75 g glucose PO [Mass/Vol]; Insulin [Mass/volume] in Serum or Plasma --pre 75 g glucose PO; Insulin^pre 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0482581,Somatotropin^pre 1 g/kg glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin [Mass/volume] in Serum or Plasma --pre 1 g/kg glucose PO; Somatotropin pre 1 g/kg glucose PO [Mass/Vol]; Somatotropin^pre 1 g/kg glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; GH pre 1 g/kg Glc PO SerPl-mCnc,
C0484576,Glucose^1.5H post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5 Hr post 50 g lactose PO [Mass/Vol]; Glucose^1.5 hours post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --1.5 hours post 50 g lactose PO; Glucose 1.5h p 50 g Lac PO SerPl-mCnc,
C0484577,Glucose^1.5H post 50 g lactose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose [Presence] in Urine by Test strip --1.5 hours post 50 g lactose PO; Glucose 1.5 Hr post 50 g lactose PO Test strip Ql (U); Glucose 1.5h p 50 g Lac PO Ur Ql Strip; Glucose^1.5 hours post 50 g lactose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0484578,Glucose^1.5H post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose^1.5 hours post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 1.5 Hr post 75 g glucose PO Test strip Ql (U); Glucose [Presence] in Urine by Test strip --1.5 hours post 75 g glucose PO; Glucose 1.5h p 75 g Glc PO Ur Ql Strip,
C0484579,Glucose^1H post 50 g lactose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose [Presence] in Urine by Test strip --1 hour post 50 g lactose PO; Glucose 1h p 50 g Lac PO Ur Ql Strip; Glucose 1 Hr post 50 g lactose PO Test strip Ql (U); Glucose^1 hour post 50 g lactose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0484580,Glucose^1H post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose 1h p 75 g Glc PO Ur Ql Strip; Glucose 1 Hr post 75 g glucose PO Test strip Ql (U); Glucose [Presence] in Urine by Test strip --1 hour post 75 g glucose PO; Glucose^1 hour post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0484581,Glucose^1H post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p meal SerPl-mCnc; Glucose 1 Hr post meal [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --1 hour post meal; Glucose^1 hour post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0484582,Glucose^2.5H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2.5h p 100 g Glc PO SerPl-mCnc; Glucose^2.5 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --2.5 hours post 100 g glucose PO; Glucose 2.5 Hr post 100 g glucose PO [Mass/Vol],
C0484583,Glucose^2.5H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2.5 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2.5 Hr post 75 g glucose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --2.5 hours post 75 g glucose PO; Glucose 2.5h p 75 g Glc PO SerPl-mCnc,
C0484584,Glucose^2H post 50 g lactose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose [Presence] in Urine by Test strip --2 hours post 50 g lactose PO; Glucose^2 hours post 50 g lactose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 2h p 50 g Lac PO Ur Ql Strip; Glucose 2 Hr post 50 g lactose PO Test strip Ql (U),
C0484585,Glucose^2H post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose^2 hours post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 2h p 75 g Glc PO Ur Ql Strip; Glucose [Presence] in Urine by Test strip --2 hours post 75 g glucose PO; Glucose 2 Hr post 75 g glucose PO Test strip Ql (U),
C0484586,Glucose^2H post meal:MCnc:Pt:Bld:Qn,glucose,Glucose 2 Hr post meal (Bld) [Mass/Vol]; Glucose 2h p meal Bld-mCnc; Glucose [Mass/volume] in Blood --2 hours post meal; Glucose^2 hours post meal:Mass Concentration:To identify measures at a point in time:Whole blood:Quantitative,
C0484587,Glucose^3.5H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3.5h p 100 g Glc PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --3.5 hours post 100 g glucose PO; Glucose^3.5 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3.5 Hr post 100 g glucose PO [Mass/Vol],
C0484588,Glucose^3.5H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^3.5 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3.5 Hr post 75 g glucose PO [Mass/Vol]; Glucose 3.5h p 75 g Glc PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --3.5 hours post 75 g glucose PO,
C0484589,Glucose^30M post 50 g lactose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose 30 Min post 50 g lactose PO Test strip Ql (U); Glucose^30 minutes post 50 g lactose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 30M p 50 g Lac PO Ur Ql Strip; Glucose [Presence] in Urine by Test strip --30 minutes post 50 g lactose PO,
C0484590,Glucose^30M post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose [Presence] in Urine by Test strip --30 minutes post 75 g glucose PO; Glucose^30 minutes post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 30M p 75 g Glc PO Ur Ql Strip; Glucose 30 Min post 75 g glucose PO Test strip Ql (U),
C0484591,Glucose^3H post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose^3 hours post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose [Presence] in Urine by Test strip --3 hours post 75 g glucose PO; Glucose 3h p 75 g Glc PO Ur Ql Strip; Glucose 3 Hr post 75 g glucose PO Test strip Ql (U),
C0484592,Glucose^4.5H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^4.5 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4.5 Hr post 100 g glucose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --4.5 hours post 100 g glucose PO; Glucose 4.5h p 100 g Glc PO SerPl-mCnc,
C0484593,Glucose^4.5H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4.5h p 75 g Glc PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --4.5 hours post 75 g glucose PO; Glucose 4.5 Hr post 75 g glucose PO [Mass/Vol]; Glucose^4.5 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0484594,Glucose^4H post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose [Presence] in Urine by Test strip --4 hours post 75 g glucose PO; Glucose 4h p 75 g Glc PO Ur Ql Strip; Glucose 4 Hr post 75 g glucose PO Test strip Ql (U); Glucose^4 hours post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0484595,Glucose^5.5H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^5.5 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5.5 Hr post 100 g glucose PO [Mass/Vol]; Glucose 5.5h p 100 g Glc PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --5.5 hours post 100 g glucose PO,
C0484596,Glucose^5H post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose [Presence] in Urine by Test strip --5 hours post 75 g glucose PO; Glucose 5h p 75 g Glc PO Ur Ql Strip; Glucose^5 hours post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 5 Hr post 75 g glucose PO Test strip Ql (U),
C0484597,Glucose^6H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 6h p 75 g Glc PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --6 hours post 75 g glucose PO; Glucose 6 Hr post 75 g glucose PO [Mass/Vol]; Glucose^6 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0484598,Glucose^6H post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose 6h p 75 g Glc PO Ur Ql Strip; Glucose [Presence] in Urine by Test strip --6 hours post 75 g glucose PO; Glucose 6 Hr post 75 g glucose PO Test strip Ql (U); Glucose^6 hours post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0484599,Glucose^post 10H CFst:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose p 10h fast SerPl-mCnc; Glucose post 10 Hr fast [Mass/Vol]; Glucose^post 10H Calorie fast:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --10 hours fasting,
C0484600,Glucose^post CFst:PrThr:Pt:Urine:Ord:Test strip,glucose,Fasting glucose [Presence] in Urine by Test strip; Glucose post fast Test strip Ql (U); Glucose p fast Ur Ql Strip; Glucose^post Calorie fast:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0484601,Insulin^30M post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin 30 Min post 75 g glucose PO [Mass/Vol]; Insulin [Mass/volume] in Serum or Plasma --30 minutes post 75 g glucose PO; Insulin^30 minutes post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 30M p 75 g Glc PO SerPl-mCnc,
C0484602,Insulin^6H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin [Mass/volume] in Serum or Plasma --6 hours post 75 g glucose PO; Insulin^6 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 6 Hr post 75 g glucose PO [Mass/Vol]; Insulin 6h p 75 g Glc PO SerPl-mCnc,
C0484731,Glucose:Mass Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma; Glucose [Mass/Vol]; Glucose:MCnc:Pt:Ser/Plas:Qn,
C0484732,Glucose.protein bound:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose.protein bound [Mass/volume] in Serum or Plasma; Glucose.protein bound:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; PB Glucose SerPl-mCnc; Glucose.protein bound [Mass/Vol],
C0490218,"HEXOKINASE, GLUCOSE",glucose,,
C0490220,"COPPER REDUCTION, GLUCOSE",glucose,,
C0490221,"GLUCOSE OXIDASE, GLUCOSE",glucose,,
C0490223,"FERRICYANIDE, GLUCOSE",glucose,,
C0490224,"ORTHOTOLUIDINE, GLUCOSE",glucose,,
C0492234,"GLUCOSE-6-PHOSPHATE DEHYDROGENASE (ERYTHROCYTIC), SCREENING",glucose,,
C0492235,"GLUCOSE-6-PHOSPHATE DEHYDROGENASE (ERYTHROCYTIC), SPOT",glucose,,
C0492236,"GLUCOSE-6-PHOSPHATE DEHYDROGENASE (ERYTHROCYTIC), MICROMETHOD",glucose,,
C0492237,"GLUCOSE-6-PHOSPHATE DEHYDROGENASE (ERYTHROCYTIC), CATALASE INHIBITION",glucose,,
C0492238,"GLUCOSE-6-PHOSPHATE DEHYDROGENASE (ERYTHROCYTIC), METHEMOGLOBIN REDUCTION",glucose,,
C0492239,"GLUCOSE-6-PHOSPHATE DEHYDROGENASE (ERYTHROCYTIC), U.V. KINETIC",glucose,,
C0492240,"GLUCOSE-6-PHOSPHATE DEHYDROGENASE (ERYTHROCYTIC), QUANTITATIVE",glucose,,
C0492241,"GLUCOSE-6-PHOSPHATE DEHYDROGENASE (ERYTHROCYTIC), ELECTROPHORESIS",glucose,,
C0492364,"METHOD, ENZYMATIC, GLUCOSE (URINARY, NON-QUANTITATIVE)",glucose,,
C0492365,"METHOD, METALLIC REDUCTION, GLUCOSE (URINARY, NON-QUANTITATIVE)",glucose,,
C0492428,"ISOENZYMES, ELECTROPHORETIC, GLUCOSE-6-PHOSPHATE DEHYDROGENASE",glucose,,
C0492441,"VISUAL, SEMI-QUANT. (COLORIMETRIC), GLUCOSE-6-PHOSPHATE DEHYDROGENASE",glucose,,
C0492442,"NADP REDUCTION (U.V.), GLUCOSE-6-PHOSPHATE DEHYDROGENASE",glucose,,
C0492465,"GLUCOSE-6-PHOSPHATE (COLORIMETRIC), PHOSPHOHEXOSE ISOMERASE",glucose,,
C0492563,"KIT, IDENTIFICATION, GLUCOSE NONFERMENTER",glucose,,
C0492907,"ASSAY, ERYTHROCYTIC GLUCOSE-6-PHOSPHATE DEHYDROGENASE",glucose,,
C0493195,"GLUCOSE DEHYDROGENASE, GLUCOSE",glucose,,
C0493227,"CONTROLLER, CLOSED-LOOP BLOOD GLUCOSE",blood glucose,,
C0493682,"SENSOR, GLUCOSE, INVASIVE",glucose,,
C0494284,Type 1 diabetes mellitus without complication,diabetes,Type I diabetes mellitus without complication; Insulin-dependent diabetes without complication; Type I diabetes mellitus without complication (disorder),
C0494290,Type 2 diabetes mellitus without complication,diabetes,Type II diabetes mellitus without complication; Type II diabetes mellitus without complication (disorder),
C0494291,Malnutrition-related diabetes mellitus with ketoacidosis,diabetes,Ketoacidosis due to malnutrition related diabetes mellitus; Ketoacidosis due to malnutrition related diabetes mellitus (disorder),
C0494356,Hyponatremia with Hypoosmolality,hypo,Hyponatremia with Hypo-osmolality,
C0495706,elevated blood glucose level,glucose level,blood elevated glucose levels,
C0497798,"Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips",blood glucose,,
C0497799,"Platforms for home blood glucose monitor, 50 per box",blood glucose,,
C0520091,"Enteral formula, nutritionally incomplete/modular nutrients, includes specific nutrients, carbohydrates (e.g., glucose polymers), proteins/amino acids (e.g., glutamine, arginine), fat (e.g., medium chain triglycerides) or combination, administered through an enteral feeding tube, 100 calories = 1 unit",glucose,,
C0520602,Maternal diabetes mellitus with hypoglycemia affecting fetus OR newborn,hypoglycemia,Maternal diabetes mellitus with hypoglycaemia affecting foetus or newborn; Maternal diabetes mellitus affecting fetus or newborn with hypoglycemia; Maternal diabetes mellitus affecting fetus or newborn; Maternal diabetes mellitus with hypoglycemia affecting fetus OR newborn (disorder); Maternal diabetes mellitus with hypoglycaemia affecting foetus OR newborn; Maternal diabetes mellitus with hypoglycaemia affecting fetus OR newborn; Maternal diabetes mellitus with hypoglycemia affecting fetus or newborn,
C0522082,Normal glucose level,glucose level,Normal glucose level; glucose level normal; Normal glucose level (finding); normal glucose level; glucose levels normal,
C0522083,Abnormal glucose level,glucose level,Abnormal Glucose Level; abnormal glucose levels; abnormal glucose level; Abnormal Glucose Level Finding; Abnormal glucose level (finding); Abnormal glucose level,
C0522814,"Glucagon tolerance panel, for insulinoma, including glucose and insulin measurements",glucose,,
C0522818,"Growth hormone suppression panel, including glucose and HGH measurement",glucose,,
C0522819,"Insulin-induced C-peptide suppression panel, including glucose, C-peptide and insulin measurement",glucose,,
C0522820,"Insulin tolerance panel, for ACTH insufficiency, including cortisol and glucose measurements",glucose,,
C0522821,"Insulin tolerance panel, for growth hormone deficiency, including glucose and HGH measurements",glucose,,
C0522822,"Automated multichannel test, any combination of ALT, albumin, AST, direct bilirubin, total bilirubin, calcium, CO2, chloride, cholesterol, creatinine, glucose, LDH, alkaline phosphatase, phosphorus, potassium, total protein, sodium, BUN, or uric acid",glucose,,
C0522971,Bg^a^ blood group typing,BG,Bg a blood group typing (procedure); Bg a blood group typing; Bg<sup>a</sup> blood group typing (procedure); Bg^a^ blood group typing (procedure); Bg<sup>a</sup> blood group typing,
C0523070,Bg^a^ blood group antibody identification,BG,Bg<sup>a</sup> blood group antibody identification; Bg a blood group antibody identification (procedure); Bg^a^ blood group antibody identification (procedure); Bg a blood group antibody identification; Bg<sup>a</sup> blood group antibody identification (procedure),
C0523655,Glucose CSF/glucose plasma ratio measurement,glucose,Glucose cerebrospinal fluid/glucose plasma ratio measurement (procedure); Glucose cerebrospinal fluid/glucose plasma ratio measurement; Glucose CSF/glucose plasma ratio measurement,
C0523657,"Glucose measurement, tolbutamide tolerance test",glucose measurement,"Glucose measurement, tolbutamide tolerance test; Glucose measurement, tolbutamide tolerance test (procedure)",
C0523658,"Glucose measurement, quantitative",glucose measurement,"Glucose measurement, quantitative (procedure); Glucose measurement, quantitative",
C0523659,"Glucose measurement, glucose tolerance test, each additional beyond 3 specimens",glucose measurement,,
C0523660,"Glucose measurement, post glucose dose",glucose measurement,"Glucose measurement, post glucose dose (procedure); Glucose measurement, post glucose dose",
C0523661,Glucose-6-phosphatase measurement,glucose,Glucose-6-phosphatase measurement; Glucose-6-phosphatase measurement (procedure),
C0523668,"Glucose-6-phosphate dehydrogenase measurement, screen",glucose,"Glucose-6-phosphate dehydrogenase measurement, screen; Glucose-6-phosphate dehydrogenase measurement, screen (procedure)",
C0523965,Uridine diphosphate glucose-4-epimerase measurement,glucose,Uridine diphosphate glucose-4-epimerase measurement (procedure); Uridine diphosphate glucose-4-epimerase measurement,
C0524305,"Urinalysis, qualitative or semi-quantitative, except immunoassay, substance other than bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen",glucose,"Urinalysis, qualitative or semi-quantitative, except immunoassay, substance other than bilirubin, glucose, haemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen",
C0527401,solanidine UDP glucose glucosyltransferase,glucose,,
C0530472,gastric inhibitory polypeptide (1-42),glucose,glucose-dependent-insulinotropic polypeptide (1-42); GIP(1-42); GIP 1-42,
C0532052,BG 325,BG,BG-325,
C0532053,BG 374,BG,BG-374,
C0533218,"3,6-dideoxy-3-(3-hydroxybutyramido)glucose",glucose,"3,6-dideoxy-3-((R)-3-hydroxybutyramido)-D-glucose; Qui3NAcyl",
C0534039,deoxythymidine diphosphate-glucose,glucose,dTDP-glucose,
C0534346,"1,2-diacylglycerol 3-glucosyltransferase",glucose,"UDPG DAG glucosyltransferase; 1,2-diacylglycerol 3-glucosyltransferase (substance); 1,2-diacylglycerol 3-glucosyltransferase; UDP-glucose 1,2-diacylglycerol 3-glucosyltransferase",
C0534714,tocopherol succinate-3-glucose,glucose,,
C0536008,UDP-glucose diosgenin-tigogenin glucosyltransferase,glucose,UDPGlc-diosgenin-tigogenin Glc-Tase; diosgenin glucosyltransferase; UDPGlc-DT-GlcTase,
C0536010,UDP-glucose solasodine glucosyltransferase,glucose,UDPGlc solasodine GlcTase,
C0536012,UDP-glucose spirostanol glucosyltransferase,glucose,UDPGlc spirostanol GlcTase,
C0537306,glucose pentaacetate,glucose,penta-O-acetyl-alpha-D-glucopyranose; GLUCOSE PENTAACETATE; penta-O-acetylglucopyranose; glucose pentaacetate,
C0538907,6-deoxy-6-iodoglucose,glucose,6-deoxy-6-iodo-D-glucose; 6-DIG cpd,
C0541880,DIABETES NEPHROGENIC (EXCLUDES GLYCOSURIA),diabetes,,
C0543511,Hypo-osmolality syndrome,hypo,Hypo-osmolarity syndrome,
C0543516,"Hypoglycemia, fasting and metabolic acidosis syndrome",hypoglycemia,,
C0543567,"Diabetes mellitus, overt",diabetes,,
C0543569,"Diabetes mellitus, starvation",diabetes,,
C0543570,"Diabetes mellitus, neurogenic",diabetes,,
C0543571,"Diabetes mellitus, corticosteroid induced",diabetes,,
C0543572,"Diabetes mellitus, leucine induced",diabetes,,
C0543573,Hypoinsulinemia-hyperglycemia syndrome,hyperglycemia,,
C0543574,Diabetes-hypertension-cheilitis syndrome,diabetes,Grienspan's syndrome,
C0543575,"Maternal diabetes, type A",diabetes,,
C0543576,"Maternal diabetes, type B",diabetes,,
C0543577,"Maternal diabetes, type C",diabetes,,
C0543578,"Maternal diabetes, type D",diabetes,,
C0543579,"Maternal diabetes, type E",diabetes,,
C0543580,"Maternal diabetes, type F",diabetes,,
C0543665,Adult G6PD deficiency of leukocytes syndrome,glucose,Adult G6PD deficiency of leucocytes syndrome; Adult G6PD deficiency of leukocytes syndrome; Adult glucose-6-phosphate dehydrogenase deficiency of leukocytes syndrome; Adult glucose-6-phosphate dehydrogenase deficiency of leukocytes syndrome (disorder),
C0549348,BLOOD GLUCOSE FALSE POSITIVE,blood glucose,,
C0549443,HYPOGLYCEMIA AGGRAVATED,hypoglycemia,HYPOGLYCAEMIA AGGRAVATED,
C0549964,Glucose^10H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^10H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --10 hours post XXX challenge; Glucose 10h p chal SerPl-mCnc; Glucose 10 Hr post Unsp challenge [Mass/Vol],
C0549965,Glucose^10M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 10M p chal SerPl-mCnc; Glucose^10 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --10 minutes post XXX challenge; Glucose 10 Min post Unsp challenge [Mass/Vol],
C0549966,Glucose^10M pre XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 10 Min pre Unsp challenge [Mass/Vol]; Glucose 10M pre chal SerPl-mCnc; Glucose^10 minutes pre XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --10 minutes pre XXX challenge,
C0549967,Glucose^10th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^10th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp10 p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --10th specimen post XXX challenge; Glucose 10th specimen post Unsp challenge [Mass/Vol],
C0549968,Glucose^11th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 11th specimen post Unsp challenge [Mass/Vol]; Glucose^11th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp11 p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --11th specimen post XXX challenge,
C0549969,Glucose^12H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --12 hours post XXX challenge; Glucose^12 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 12h p chal SerPl-mCnc; Glucose 12 Hr post Unsp challenge [Mass/Vol],
C0549970,Glucose^12th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^12th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp12 p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --12th specimen post XXX challenge; Glucose 12th specimen post Unsp challenge [Mass/Vol],
C0549971,Glucose^13th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --13th specimen post XXX challenge; Glucose^13th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp13 p chal SerPl-mCnc; Glucose 13th specimen post Unsp challenge [Mass/Vol],
C0549972,Glucose^14th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose sp14 p chal SerPl-mCnc; Glucose 14th specimen post Unsp challenge [Mass/Vol]; Glucose^14th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --14th specimen post XXX challenge,
C0549973,Glucose^15M post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 15M p 50 g Lac PO SerPl-mCnc; Glucose 15 Min post 50 g lactose PO [Mass/Vol]; Glucose^15 minutes post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --15 minutes post 50 g lactose PO,
C0549974,Glucose^15M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^15 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15 Min post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --15 minutes post XXX challenge; Glucose 15M p chal SerPl-mCnc,
C0549975,Glucose^15M post dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 15M p Lac PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --15 minutes post dose lactose PO; Glucose^15 minutes post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15 Min post dose lactose PO [Mass/Vol],
C0549976,Glucose^15th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^15th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15th specimen post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --15th specimen post XXX challenge; Glucose sp15 p chal SerPl-mCnc,
C0549977,Glucose^1H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1 hour post XXX challenge; Glucose 1 Hr post Unsp challenge [Mass/Vol]; Glucose^1 hour post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0549978,Glucose^1st specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1st specimen post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge; Glucose^1st specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp1 p chal SerPl-mCnc,
C0549979,Glucose^2.5H post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose^2.5 hours post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose [Presence] in Urine by Test strip --2.5 hours post 75 g glucose PO; Glucose 2.5 Hr post 75 g glucose PO Test strip Ql (U); Glucose 2.5h p 75 g Glc PO Ur Ql Strip,
C0549980,Glucose^20M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 20 Min post Unsp challenge [Mass/Vol]; Glucose 20M p chal SerPl-mCnc; Glucose^20 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --20 minutes post XXX challenge,
C0549981,Glucose^2H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --2 hours post XXX challenge; Glucose 2h p chal SerPl-mCnc; Glucose 2 Hr post Unsp challenge [Mass/Vol]; Glucose^2 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0549982,Glucose^2M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2M p chal SerPl-mCnc; Glucose^2 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --2 minutes post XXX challenge; Glucose 2 Min post Unsp challenge [Mass/Vol],
C0549983,Glucose^2nd specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2nd specimen post Unsp challenge [Mass/Vol]; Glucose sp2 p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge; Glucose^2nd specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0549984,Glucose^3.5H post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose 3.5h p 75 g Glc PO Ur Ql Strip; Glucose^3.5 hours post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 3.5 Hr post 75 g glucose PO Test strip Ql (U); Glucose [Presence] in Urine by Test strip --3.5 hours post 75 g glucose PO,
C0549985,Glucose^3.5H post dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3.5 Hr post dose lactose PO [Mass/Vol]; Glucose^3.5 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --3.5 hours post dose lactose PO; Glucose 3.5h p Lac PO SerPl-mCnc,
C0549986,Glucose^3rd specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3rd specimen post Unsp challenge [Mass/Vol]; Glucose^3rd specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp3 p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge,
C0549987,Glucose^4.5H post 75 g glucose PO:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose^4.5 hours post 75 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 4.5h p 75 g Glc PO Ur Ql Strip; Glucose 4.5 Hr post 75 g glucose PO Test strip Ql (U); Glucose [Presence] in Urine by Test strip --4.5 hours post 75 g glucose PO,
C0549988,Glucose^40M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 40M p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --40 minutes post XXX challenge; Glucose 40 Min post Unsp challenge [Mass/Vol]; Glucose^40M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0549989,Glucose^45M post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --45 minutes post 50 g lactose PO; Glucose 45M p 50 g Lac PO SerPl-mCnc; Glucose 45 Min post 50 g lactose PO [Mass/Vol]; Glucose^45M post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0549990,Glucose^4M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --4 minutes post XXX challenge; Glucose 4 Min post Unsp challenge [Mass/Vol]; Glucose^4 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4M p chal SerPl-mCnc,
C0549991,Glucose^4th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge; Glucose sp4 p chal SerPl-mCnc; Glucose^4th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4th specimen post Unsp challenge [Mass/Vol],
C0549992,Glucose^50M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 50M p chal SerPl-mCnc; Glucose 50 Min post Unsp challenge [Mass/Vol]; Glucose^50M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --50 minutes post XXX challenge,
C0549993,Glucose^5th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5th specimen post Unsp challenge [Mass/Vol]; Glucose sp5 p chal SerPl-mCnc; Glucose^5th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge,
C0549994,Glucose^6.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --6.5 hours post XXX challenge; Glucose^6.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 6.5 Hr post Unsp challenge [Mass/Vol]; Glucose 6.5h p chal SerPl-mCnc,
C0549995,Glucose^6th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge; Glucose^6th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp6 p chal SerPl-mCnc; Glucose 6th specimen post Unsp challenge [Mass/Vol],
C0549996,Glucose^6th specimen post dose lactose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --6th specimen post dose lactose; Glucose^6th specimen post dose lactose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp6 p Lac SerPl-mCnc; Glucose 6th specimen post dose lactose [Mass/Vol],
C0549997,Glucose^7.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --7.5 hours post XXX challenge; Glucose 7.5 Hr post Unsp challenge [Mass/Vol]; Glucose 7.5h p chal SerPl-mCnc; Glucose^7.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0549998,Glucose^70M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 70M p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --70 minutes post XXX challenge; Glucose^70M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 70 Min post Unsp challenge [Mass/Vol],
C0549999,Glucose^7H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^7 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 7h p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --7 hours post XXX challenge; Glucose 7 Hr post Unsp challenge [Mass/Vol],
C0550000,Glucose^7H post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 7 Hr post meal [Mass/Vol]; Glucose 7h p meal SerPl-mCnc; Glucose^7 hours post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --7 hours post meal,
C0550001,Glucose^8H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 8 Hr post Unsp challenge [Mass/Vol]; Glucose^8 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --8 hours post XXX challenge; Glucose 8h p chal SerPl-mCnc,
C0550002,Glucose^8M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 8 Min post Unsp challenge [Mass/Vol]; Glucose 8M p chal SerPl-mCnc; Glucose^8 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --8 minutes post XXX challenge,
C0550003,Glucose^8th specimen post XXX challenge:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose 8th specimen post Unsp challenge (Perit dial fld) [Mass/Vol]; Glucose sp8 p chal DiafP-mCnc; Glucose^8th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose [Mass/volume] in Peritoneal dialysis fluid --8th specimen post XXX challenge,
C0550004,Glucose^9H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^9H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --9 hours post XXX challenge; Glucose 9h p chal SerPl-mCnc; Glucose 9 Hr post Unsp challenge [Mass/Vol],
C0550005,Glucose^9th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 9th specimen post Unsp challenge [Mass/Vol]; Glucose sp9 p chal SerPl-mCnc; Glucose^9th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge,
C0550006,Glucose^pre dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre dose lactose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --pre dose lactose PO; Glucose pre Lac PO SerPl-mCnc; Glucose^pre dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0550041,Insulin^7H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin 7 Hr post 75 g glucose PO [Mass/Vol]; Insulin^7 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin [Mass/volume] in Serum or Plasma --7 hours post 75 g glucose PO; Insulin 7h p 75 g Glc PO SerPl-mCnc,
C0550350,Glucose:MCnc:24H:Dial fld prt:Qn,glucose,Glucose [Mass/volume] in 24 hour Peritoneal dialysis fluid; Glucose:Mass Concentration:24 hours:Peritoneal dialysis fluid:Quantitative; Glucose 24h DiafP-mCnc; Glucose (24H Perit dial fld) [Mass/Vol],
C0550351,Glucose:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose [Mass/volume] in Peritoneal dialysis fluid; Glucose DiafP-mCnc; Glucose (Perit dial fld) [Mass/Vol]; Glucose:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative,
C0550352,Glucose^12H post peritoneal dialysis:MCnc:Pt:Periton fld:Qn,glucose,Glucose^12 hours post peritoneal dialysis:Mass Concentration:To identify measures at a point in time:Peritoneal fluid /ascites:Quantitative; Glucose 12h p PD Prt-mCnc; Glucose [Mass/volume] in Peritoneal fluid --12 hours post peritoneal dialysis; Glucose 12 Hr post PD (Periton fld) [Mass/Vol],
C0550353,Glucose^2H post peritoneal dialysis:MCnc:Pt:Periton fld:Qn,glucose,Glucose [Mass/volume] in Peritoneal fluid --2 hours post peritoneal dialysis; Glucose 2h p PD Prt-mCnc; Glucose^2 hours post peritoneal dialysis:Mass Concentration:To identify measures at a point in time:Peritoneal fluid /ascites:Quantitative; Glucose 2 Hr post PD (Periton fld) [Mass/Vol],
C0550354,Glucose^4H post peritoneal dialysis:MCnc:Pt:Periton fld:Qn,glucose,Glucose^4 hours post peritoneal dialysis:Mass Concentration:To identify measures at a point in time:Peritoneal fluid /ascites:Quantitative; Glucose [Mass/volume] in Peritoneal fluid --4 hours post peritoneal dialysis; Glucose 4 Hr post PD (Periton fld) [Mass/Vol]; Glucose 4h p PD Prt-mCnc,
C0550355,Deprecated Mean Glucose Bld gHb Est-aCnc,glucose,Glucose mean value Estimated from glycated hemoglobin Qn (Bld),
C0550356,Glucose phosphate isomerase:CCnc:Pt:RBC:Qn,glucose,Glucose phosphate isomerase (RBC) [Catalytic activity/Vol]; Glucose phosphate isomerase [Enzymatic activity/volume] in Red Blood Cells; GPI RBC-cCnc; Glucose phosphate isomerase:Catalytic Concentration:To identify measures at a point in time:Erythrocytes:Quantitative,
C0550357,Glucose^15M post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --15 minutes post 100 g glucose PO; Glucose 15M p 100 g Glc PO SerPl-mCnc; Glucose^15 minutes post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15 Min post 100 g glucose PO [Mass/Vol],
C0550358,Glucose^1st specimen:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose sp1 DiafP-mCnc; Glucose [Mass/volume] in Peritoneal dialysis fluid --1st specimen; Glucose spec 1 (Perit dial fld) [Mass/Vol]; Glucose^1st specimen:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative,
C0550359,Glucose^2H specimen:MCnc:Pt:Dial fld:Qn,glucose,Glucose 2h spec Dial fld-mCnc; Glucose [Mass/volume] in Dialysis fluid --2 hour specimen; Glucose 2 hour specimen (Dial fld) [Mass/Vol]; Glucose^2 hours specimen:Mass Concentration:To identify measures at a point in time:Dialysis fluid:Quantitative,
C0550360,Glucose^2H dwell specimen:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose^2 hours dwell specimen:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose 2 Hr dwell specimen (Perit dial fld) [Mass/Vol]; Glucose [Mass/volume] in Peritoneal dialysis fluid --2 hour dwell specimen; Glucose 2H dwell spec DiafP-mCnc,
C0550361,Glucose^2nd specimen:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose spec 2 (Perit dial fld) [Mass/Vol]; Glucose [Mass/volume] in Peritoneal dialysis fluid --2nd specimen; Glucose sp2 DiafP-mCnc; Glucose^2nd specimen:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative,
C0550362,Glucose^3rd specimen:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose^3rd specimen:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose sp3 DiafP-mCnc; Glucose [Mass/volume] in Peritoneal dialysis fluid --3rd specimen; Glucose spec 3 (Perit dial fld) [Mass/Vol],
C0550363,Glucose^45M post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 45M p 100 g Glc PO SerPl-mCnc; Glucose^45M post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --45 minutes post 100 g glucose PO; Glucose 45 Min post 100 g glucose PO [Mass/Vol],
C0550364,Glucose^4H specimen:MCnc:Pt:Dial fld:Qn,glucose,Glucose^4 hours specimen:Mass Concentration:To identify measures at a point in time:Dialysis fluid:Quantitative; Glucose 4 Hr specimen (Dial fld) [Mass/Vol]; Glucose 4h spec Dial fld-mCnc; Glucose [Mass/volume] in Dialysis fluid --4 hour specimen,
C0550365,Glucose^4H dwell specimen:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose^4 hours dwell specimen:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose [Mass/volume] in Peritoneal dialysis fluid --4 hour dwell specimen; Glucose 4 hour dwell specimen (Perit dial fld) [Mass/Vol]; Glucose 4H dwell spec DiafP-mCnc,
C0550366,Glucose^4H specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^4 hours specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --4 hour specimen; Glucose 4 Hr specimen [Mass/Vol]; Glucose 4h spec SerPl-mCnc,
C0550367,Glucose^4th specimen:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose [Mass/volume] in Peritoneal dialysis fluid --4th specimen; Glucose spec 4 (Perit dial fld) [Mass/Vol]; Glucose^4th specimen:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose sp4 DiafP-mCnc,
C0550368,Glucose^5th specimen:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose [Mass/volume] in Peritoneal dialysis fluid --5th specimen; Glucose^5th specimen:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose sp5 DiafP-mCnc; Glucose 5th specimen (Perit dial fld) [Mass/Vol],
C0550369,Glucose^6th specimen:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose sp6 DiafP-mCnc; Glucose^6th specimen:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose 6th specimen (Perit dial fld) [Mass/Vol]; Glucose [Mass/volume] in Peritoneal dialysis fluid --6th specimen,
C0550370,Glucose^7th specimen:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose 7th specimen (Perit dial fld) [Mass/Vol]; Glucose sp7 DiafP-mCnc; Glucose [Mass/volume] in Peritoneal dialysis fluid --7th specimen; Glucose^7th specimen:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative,
C0550371,Glucose^pre dialysis:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose pre dial DiafP-mCnc; Glucose [Mass/volume] in Peritoneal dialysis fluid --pre dialysis; Glucose pre dialysis (Perit dial fld) [Mass/Vol]; Glucose^pre dialysis:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative,
C0552468,Glucose mean value,glucose,Glucose mean value,
C0553708,SERUM GLUCOSE DECREASED,serum glucose,,
C0554436,Gangrene due to diabetes mellitus,diabetes,"Gangrene due to diabetes mellitus (disorder); diabetic gangrenes; diabetic gangrene; GANGRENE, DIABETIC; GANGRENE, GLYCEMIC; Diabetic gangrene",
C0554876,poorly controlled diabetes mellitus,diabetes,"Diabetes mellitus, poorly controlled",
C0555170,Sample glucose &/or fluid (finding),glucose,Glucose in sample (finding); Glucose in sample,
C0555792,Hemoglobin A1C - diabetic control interpretation,a1c,Hemoglobin A1C - diabetic control interpretation (observable entity); Haemoglobin A1C - diabetic control interpretation; Hb. A1C - diabetic control,
C0556133,Glucose intake,glucose,Dextrose intake; Glucose intake (observable entity),
C0559198,BM stix glucose level measurement,glucose level,BM stix glucose measurement (procedure); BM stix glucose level; BM stix glucose measurement,
C0562216,Diabetes mellitus diet education,diabetes,Diabetes mellitus diet education (procedure),
C0565877,Pregnancy with abnormal glucose tolerance test,glucose,Pregnancy with abnormal glucose tolerance test (finding),
C0567407,Brittle type 1 diabetes mellitus,diabetes,Labile type I diabetes mellitus; Unstable type I diabetes mellitus; Brittle type I diabetes mellitus; Brittle type I diabetes mellitus (finding); Unstable type 1 diabetes mellitus,
C0577556,Hyper-resonant,hyper,hyper resonant; hyper-resonant; Hyper-resonant (qualifier value),
C0579065,Type 1 diabetes mellitus with ulcer,diabetes,Type I diabetes mellitus with ulcer (disorder); Type I diabetes mellitus with ulcer; Insulin-dependent diabetes mellitus with ulcer,
C0579066,Type 2 diabetes mellitus with ulcer,diabetes,Type II diabetes mellitus with ulcer; Type II diabetes mellitus with ulcer (disorder),
C0579119,Gangrene due to type 1 diabetes mellitus,diabetes,Gangrene due to type 1 diabetes mellitus (disorder); Diabetes type 1 with gangrene,
C0579122,Gangrene due to type 2 diabetes mellitus,diabetes,Gangrene due to type 2 diabetes mellitus (disorder),
C0580237,Random blood sugar normal,blood sugar,Random blood sugar normal (finding),
C0580321,At risk of diabetes mellitus,diabetes,At risk of diabetes mellitus (finding),
C0580400,Random blood sugar raised,blood sugar,Random blood sugar raised (finding),
C0580401,Random blood sugar low,blood sugar,Random blood sugar low (finding),
C0580545,Blood glucose normal,blood glucose,normoglycemic; Normoglycaemic; normal glucose blood; normal blood glucose; Normoglycemic; blood glucose normal; Normal blood glucose; Blood glucose normal (finding),
C0580546,Blood glucose abnormal,blood sugar,Blood glucose abnormal (finding); abnormal glucose; blood glucose abnormal; Abnormal glucose NOS; abnormal blood sugar; Abnormal glucose,
C0581383,Type 1 diabetes mellitus maturity onset,diabetes,Type I diabetes mellitus maturity onset; Type I diabetes mellitus maturity onset (disorder); Insulin-dependent diabetes maturity onset,
C0582652,Perceived control of insulin-dependent diabetes,diabetes,Perceived control of insulin-dependent diabetes (assessment scale),
C0583332,serum glucose level,serum glucose,glucose level serum; glucose levels serum,
C0583333,Serum random glucose measurement,glucose level,Serum random glucose level; Serum random glucose measurement (procedure); Serum random glucose measurement,
C0583334,Serum fasting glucose measurement,glucose level,Serum fasting glucose level; Serum fasting glucose measurement; Serum fasting glucose measurement (procedure),
C0583335,Serum 2-hr post-prandial glucose measurement,glucose level,Serum 2-hr post-prandial glucose measurement (procedure); Serum 2-hr post-prandial glucose level; Serum 2-hr post-prandial glucose measurement,
C0583512,Plasma random glucose measurement,glucose level,Plasma random glucose measurement (procedure); Plasma random glucose level; Plasma random glucose measurement,
C0583513,Plasma fasting glucose measurement,glucose level,Plasma fasting glucose measurement (procedure); Plasma fasting glucose measurement; Plasma fasting glucose level,
C0583514,Plasma 2-hr post-prandial glucose measurement,glucose level,Plasma 2-hr post-prandial glucose measurement (procedure); Plasma 2-hr post-prandial glucose measurement; Plasma 2-hr post-prandial glucose level,
C0585939,Self-monitoring of urine glucose,glucose,Self-monitoring of urine glucose (procedure),
C0585940,Self-monitoring of blood and urine glucose,glucose,Self-monitoring of blood and urine glucose (procedure),
C0586113,Diabetes monitoring call,diabetes,Diabetes monitoring call (procedure),
C0586282,Hypoglycemia-induced convulsion,hypoglycemia,Hypoglycemia-induced seizure; Hypoglycemia-induced convulsion (disorder); Hypoglycemia-induced fit; Hypoglycaemia-induced seizure; Hypoglycaemia-induced convulsion; Hypoglycaemia-induced fit,
C0586942,Diabetes dietitian,diabetes,Diabetes dietitian (occupation),
C0587098,Frequency of hospital-treated hypoglycemia attack,hypoglycemia,Frequency of hospital-treated hypoglycaemia attack; Frequency of hospital-treated hypoglycemia attack (observable entity),
C0587100,Education score - diabetes,diabetes,Education score - diabetes (assessment scale),
C0587102,Retinal abnormality - non-diabetes,diabetes,Retinal abnormality - non-diabetes (disorder),
C0587104,Foot abnormality - non-diabetes,diabetes,Foot abnormality - non-diabetes (finding),
C0587125,H/O: Admission in last year for diabetes foot problem,diabetes,History of admission in last year for diabetes foot problem (situation); History of admission in last year for diabetes foot problem,
C0587181,"Glucose measurement, 2 hour post prandial",glucose measurement,"2 hours post-food blood sugar; Glucose measurement, 2 hour post prandial; Glucose measurement, 2 hour post prandial (procedure); 2 hours post-food blood sugar level",
C0587359,Test strip blood glucose measurement,glucose measurement,"Glucose measurement, blood, test strip; Glucose measurement, blood, test strip (procedure); Dipstick blood sugar level; Dipstick blood sugar",
C0587941,Diabetes monitoring invitation,diabetes,Diabetes monitoring invitation (procedure),
C0589117,Steroid-induced diabetes mellitus without complication,diabetes,Steroid-induced diabetes mellitus without complication (disorder),
C0589354,Advanced retinal disease due to diabetes mellitus,diabetes,Advanced diabetic retinal disease; Advanced retinal disease with diabetes mellitus; Advanced retinal disease due to diabetes mellitus (disorder),
C0595310,Blood glucose testing kit,blood glucose,glucose test; glucose testing; glucose tests; GLUCOSE TEST,
C0595877,Blood glucose increased,blood sugar,increased blood glucose; GLUCOSE BLOOD INCREASED; blood glucose increased; BLOOD SUGAR INCREASED; increased blood sugar; SUGAR BLOOD INDREASED; blood increasing sugar; SUGAR BLOOD LEVEL INCREASED; BLOOD GLUCOSE ELEVATED; elevated blood glucose,
C0595883,Blood glucose decreased,glucose level,Blood glucose decreased below normal; GLUCOSE BLOOD DECREASED; blood glucose decreased; Blood glucose level below normal; SUGAR BLOOD DECREASED; BLOOD SUGAR DECREASED; blood decreasing sugar; Blood glucose level below normal (finding),
C0595931,SERUM GLUCOSE INCREASED,serum glucose,,
C0596425,diabetes mellitus genetics,diabetes,,
C0596619,glucose analog,glucose,,
C0596620,glucose metabolism,glucose,glucose metabolism; glucose metabolic process; cellular glucose metabolic process,
C0596744,hypoketonemic hypoglycemia,hypoglycemia,hypoglycemia associated with hypoketonemia,
C0597655,virus related diabetes mellitus,diabetes,,
C0598121,Hypoglycorrhachia,low glucose,Decreased CSF glucose; Low glucose levels in cerebral spinal fluid; hypoglycorrhachia; Hypoglycorrhachia,
C0598284,diabetes amputation,diabetes,amputation diabetes; amputations diabetes; diabetes amputation,
C0599003,diabetes mellitus nursing,diabetes,diabetes mellitus nursing,
C0599782,glucose output,glucose,glucose output,
C0601479,N-acetylbacillosamine,glucose,"D-Glucose, 4-(acetylamino)-2-amino-2,4,6-trideoxy-, monohydrochloride; 4-acetamido-2-amino-2,4,6-trideoxy-D-glucose",
C0604572,glucose-N-acetylaminomannuronic acid polymer,glucose,"D-Mannuronic acid, 2-(acetylamino)-2-deoxy-, polymer with D-glucose",
C0604979,guanosine diphosphate 2-deoxy-D-glucose,glucose,,
C0605884,P(1)-(adenosine-5')-P(4)-(glucose-6)tetraphosphate,glucose,"Adenosine 5'-(pentahydrogen-tetraphosphate), 5'-6-ester with D-glucose; Ap(4)glucose",
C0606201,"2,4-diamino-2,4,6-trideoxy-D-glucose",glucose,,
C0606261,hippomannin A,glucose,"D-Glucose, cyclic 4,6-(4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 2-(3,4,5-trihydroxybenzoate)",
C0606380,2-toluoylglucosamine,glucose,"o-toluoylglucosamine; D-Glucose, 2-deoxy-2-((2-methylbenzoyl)amino)-",
C0607611,"Thiazolium, 3-(4-amino-2-methyl-5-pyrimidinyl)methyl-4-methyl-5-(2-(phosphonooxy)ethyl)-, chloride, compd. with 2-amino-2-deoxy-D-glucose (1:2)",glucose,,
C0607613,thiamine monophosphate bis(glucosamine),glucose,"D-Glucose, 2-amino-2-deoxy-, compd. with 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-4-methyl-5-(2-(phosphonooxy)ethyl)thiazolium chloride (2:1)",
C0608221,2-deoxy-2-amino-N-(5-dimethylamino-1-naphthalenesulfonyl)glucose,glucose,"D-Glucose, 2-deoxy-2-(((5-(dimethylamino)-1-naphthalenyl)sulfonyl)amino)-",
C0608316,UDP-glucose cyanidin-3-O-glucosyltransferase,glucose,,
C0608317,UDP-glucose cyanidin-3-rhamnosyl-(1-6)-glucoside-5-O- glucosyltransferase,glucose,"Glucosyltransferase, uridine diphosphoglucose-cyanidin 3-rhamnosylglucoside 5-O-",
C0609116,N-(N-bromoacetyl)-6-aminohexanoylglucosamine,glucose,"D-Glucose, 2-((6-((bromoacetyl)amino)-1-oxohexyl)amino)-2-deoxy-",
C0609685,1-isonicotinyl-2-lactosylhydrazine,glucose,4-pyridinecarboxylic acid hydrazide hydazone with 4-O-beta-D-galactopyranosyl-D-glucose,
C0610437,"N-acetyl-4,6-(4-oxy-benzylidene)glycosamine",glucose,"N-acetyl-4-6-(4-oxy-benzylidene)glycosamine; N-acetyl-4-6-(p-oxy-benzylidene)glycosamine; D-Glucose, 2-(acetylamino)-2-deoxy-4,6-O-((4-hydroxyphenyl)methylene)-; N-acetyl-4-6-(p-oxy-benzylidene)-D-glycosamine",
C0610649,4-azido-4-deoxyglucose,glucose,4-azido-4-deoxy-D-glucose; 4-azido-4-deoxy-beta-D-glucose,
C0610756,"3,6-dideoxy-3-(L-glyceroylamino)-D-glucose",glucose,"D-Glucose, 3,6-dideoxy-3-((2,3-dihydroxy-1-oxopropyl)amine)-, (S)-; 3,6-DD-3-GAG",
C0611461,methyl glucose,glucose,"methyl alpha-D-glucoside; methyl-alpha-glucopyranoside; METHYL GLUCOSE; alpha-methylglucose; alpha-methyl-D-glucoside; methyl glucose; methyl alpha-D-glucopyranoside; alphaMG; methylglucoside, (alpha-D)-isomer; alpha-methyl-D-glucopyranoside; alpha-methylglucoside; methyl-alpha-D-glucoside",
C0612123,UDP-glucose-specific starch synthetase,glucose,UDP-GASS,
C0612213,BG 25,BG,,
C0612215,BG 26,BG,,
C0612217,BG 9,BG,,
C0612654,Malun 25,glucose,"D-Glucose, 4-O beta-D-galactopyranosyl-, mixt. with 4-((chloroamino)sulfonyl)benzoic acid disodium salt, (17 beta)-17-hydroxyestra-1,3,5(10)-trien-3-yl benzoate and sodium dodecyl sulfate; Malun-25",
C0613450,alpha-galactose-(1-3)-N-acetyllactosamine,glucose,"AGNALA; D-Glucose, O-alpha-D-galactopyranosyl-(1-3)-O-beta-D-galactopyranosyl-(1-4)-2-(acetylamino)-2-deoxy-",
C0615040,UDP-glucose-isoflavone 7-O-glucosyltransferase,glucose,UDP-GIGtransferase,
C0615643,thiocellobiose,glucose,"D-Glucose, 4-S-beta-D-glucopyranosyl-4-thio-",
C0615719,"3-acetamido-3,6-dideoxyglucose",glucose,"L-Glucose, 3-(acetylamino)-3,6-dideoxy-; 3-acetamido-3,6-dideoxy-L-glucose",
C0616294,4-O-acetyl-alpha-N-acetylneuraminyl-(2-3)-lactose,glucose,"4-AANL; D-Glucose, O-(N-acetyl-4-O-acetyl-alpha-neuraminosyl)-(1-3)-O-beta-D-galactopyranosyl-(1-4)-",
C0616801,UDP-glucose-13-hydroxydocosanoic acid glucosyltransferase,glucose,UDPG-13-HDA glucosyltransferase,
C0616803,UDP-glucose-13-glucosyloxydocosanoic acid glucosyltransferase,glucose,UDPG-13-GODA glucosyltransferase,
C0617236,"D-glucofuranose cyclic 1,2-3,5 bis(butylboronate)-6-acetate",glucose,"glucose BBA; alpha-D-Glucofuranose, cyclic 1,2:3,5-bis(butylboronate) 6-acetate",
C0617919,1-O-indol-3-ylacetylglucose,glucose,1-O-indol-3-ylacetyl-beta-D-glucose; IAA-glucose,
C0618182,"3-((N-acetyl-L-seryl)amino)-3,6-dideoxy-D-glucose",glucose,,
C0618184,"3-((N-acetylseryl)amino)-3,6-dideoxyglucose",glucose,"D-Glucose, 3-((2-(acetylamino)-3-hydroxy-1-oxopropyl)amino)-3,6-dideoxy-, (S)-; ASADOG",
C0618207,glucosyl (1-4) N-acetylglucosamine,glucose,"Glu(1-4)GlnAc; D-Glucose, 2-(acetylamino)-2-deoxy-4-O-beta-D-glucopyranosyl-",
C0618647,2-amino-6-O-(2-amino-2-deoxy-glucopyranosyl)-2-deoxyglucose,glucose,"D-Glucose, 2-amino-6-O-(2-amino-2-deoxy-beta-D-glucopyranosyl)-2-deoxy-; 2-amino-6-O-(2-amino-2-deoxy-beta-D-glucopyranosyl)-2-deoxy-D-glucose; Bordetella pertussis endotoxin disaccharide; BPE disaccharide",
C0618668,glucose-1-(1-naphthalene)acetate,glucose,beta-D-glucose 1-(1-naphthalene)acetate,
C0620228,lactose 6'-phosphate,glucose,"D-Glucose, 4-O-(6-O-phosphono-beta-D-galactopyranosyl)-",
C0620373,"4,6-pyruvylated glucose",glucose,"4,6-PYDGLC; 4,6-pyruvylated D-glucose",
C0621067,N-acetylglucosaminylglucuronic acid-N-acetylglucosamine,glucose,"AGGAG; D-Glucose, O-2-(acetyl-t-amino)-2-deoxy-beta-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-3)-2-(acetyl-t-amino)-2-deoxy-",
C0621416,guanosine-2-deoxy-2-fluoro-D-glucose diphosphate ester,glucose,"GDP-FGlc; Guanosine 5'-(trihydrogen diphosphate), 2-(((3alpha,5beta,7alpha)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl)amino)-, (S)-",
C0621628,disialyl-N-tetraose,glucose,"D-Glucose, O-(N-acetyl-alpha-neuraminosyl)-(2-6)-O-(O-(N-acetyl-alpha-neuraminosyl)-(2-3)-beta-D-galactopyranosyl-(1-3))-O-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-3)-stereoisomer",
C0621862,X 2616,glucose,X-2616; glucose polymer mixture X-2616; X 2616,
C0622442,maltose hexastearate,glucose,"D-Glucose, 4-O-alpha-D-glucopyranosyl-, (2S-(1(R*(R*)),2alpha,3abeta,7abeta))-",
C0622761,"3,4,6-tri-O-methyl-D-glucose",glucose,,
C0622762,"3,4,6-tri-O-methylglucose",glucose,"3,4,6-TMG; D-Glucose, 3,4,6-tri-O-methyl-, (S)-",
C0623413,"6-N-(4-azido-2-hydroxy-3,5-diiodobenzoyl)glucosamine",glucose,"D-Glucose, 6-((4-azido-2-hydroxy-3,5-diiodobenzoyl)amino)-6-deoxy-, (7R-(7alpha,8beta,10beta))-; 6-AHDG",
C0624467,glucose-6-vanadate,glucose,G-6-VAN,
C0625152,lacto-N-hexaose,glucose,"D-Glucose, O- beta-D-galactopyranosyl-(1-3)-O-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-3)-O-(O-beta-D-galactopyranosyl-(1-4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-6))-O-beta-D-galactopyranosyl-(1-4)-",
C0625183,2-deoxy-2-(3-hydroxytetradecanoyl)amino-D-glucose 6-phosphate,glucose,,
C0625850,8-azidoadenosine diphosphate glucose,glucose,8-azido-ADPglucose,
C0626140,copoly(gamma-benzylglutamate-gamma-hydroxyethylglutamine),BG,poly-BG-HEG,
C0627178,t-cinnamoyl glucose,glucose,,
C0627182,hydroxycinnamoyl-D-glucose-quinate hydroxycinnamoyl transferase,glucose,,
C0628665,6-arbutinphosphoglycerol,glucose,4-hydroxyphenyl-O-beta-glucose-6-phospho-sn-1-glycerol; arbutin-P-glycerol,
C0628673,arbutin-6-phosphoethanolamine,glucose,arbutin-P-ethanolamine; 4-hydroxyphenyl-O-beta-D-glucose-6-phosphoethanolamine,
C0629257,dTDP-4-keto-6-deoxyglucose aminotransferase,glucose,dTDP-KDG transaminase; glutamate-dTDP-4-keto-6-deoxy-D-glucose transaminase,
C0629626,melibiouronic acid,glucose,O-(galactopyranosyluronic acid)-(1-6)glucose,
C0629882,glucose-6-phosphate dehydrogenase inhibition controlling cofactor,glucose,,
C0630863,2-O-(4-iodobenzyl)glucose,glucose,2-IBG,
C0631951,2-acetamido-2-deoxy-3-O-(gluco-4-enepyranosyluronic acid)glucose,glucose,2-acetamido-2-deoxy-3-O-(beta-D-gluco-4-enepyranosyluronic acid)-D-glucose; 2-ADGPUAG,
C0632002,roxbin A,glucose,"D-Glucose, cyclic 4-2':6-2-(4-(6-(((2,3:4,6-bis-O-((4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-diyl)dicarbonyl)-beta-D-glucopyranosyl)oxy)carbonyl)-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) c",
C0632246,uridine phosphate-beta-thiophosphate glucose,glucose,UP-beta-SP-Glc,
C0632855,"3-(3-hydroxy-2,3-dimethyl-5-oxoprolyl)amino-3-6-dideoxyglucose",glucose,HDOA-glucose,
C0636237,mannosyl(5)-N-acetyl(2)-glucose,glucose,Man5GlcNAc2,
C0636743,UDP-glucose-N-acetylglucosaminyl pyrophosphorylundecaprenol glucosyltransferase,glucose,UDPglucose-GlcNAc-PP-undecaprenol glucosyltransferase; UGGPPUGtransferase,
C0637088,"3-O-(3-(N',N'-dimethylamino)-n-propyl)glucose",glucose,,
C0637593,mannosyl(2)-N-acetyl(2)-glucose,glucose,Man2GlcNAc2,
C0637812,"4,6-ethylidene glucose streptozotocin",glucose,EG-STZ,
C0638910,glucose-1-phospho-D-mannosylglycoprotein phosphodiesterase,glucose,Alpha-glucose-1-phosphate phosphodiesterase; AG1P phosphodiesterase; alpha-glucose-1-phosphate phosphodiesterase; Glucose-1-phospho-D-mannosylglycoprotein phosphodiesterase (substance); Glucose-1-phospho-D-mannosylglycoprotein phosphodiesterase,
C0638921,xylose-xylose-glucose,glucose,Xyl-Xyl-Glc,
C0638923,xylose-glucose,glucose,xylosyl-glucose; Xyl-Glc,
C0638968,glycerol-3-phosphate - glucose phosphotransferase,glucose,glycerol 3-phosphate-glucose transphorylase; Glycerol-3-phosphate-glucose phosphotransferase; Glycerol-3-phosphate-glucose phosphotransferase (substance); Gro3P-glucose transphorylase,
C0639055,glucose-6-phosphate dehydrogenase Thessaloniki,glucose,G6PD Thessaloniki,
C0639697,O-glucopyranosyl-(1-4)-O-glucopyranosyl-(1-6)glucopyranose,glucose,1-4-Glu-Glu-Glu; O-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-6)-D-glucose,
C0640362,"substance P (6-11), N(1,6)(beta-glucopyranosyl)Glu(5)-Pro(9)-",BG,"substance P (6-11), N(1,6)(beta-glucopyranosyl)glutamyl(5)-proline(9)-; BG-Glu-Pro-SP(6-11); 5-N(1,6)(beta-glucopyranosyl)Glu-9-Pro-substance P (6-11)",
C0640396,camelliin B,glucose,"D-Glucose, cyclic 4-2':6-2-(4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 3-(3,4,5-trihydroxybenzoate), cyclic diester with beta-D-glucopyranose cyclic 4-2:6-2'-(4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 2,3-bis(3,4,5-trihydroxybenzoate), (2(S),4(S))-",
C0641401,N-alpha-tert-butyloxycarbonylglutamic acid gamma-fluorenylmethyl ester,BG,Nalpha-Boc-Glu-gamma-fluorenylmethyl ester; BG-gamma-FME,
C0641404,N-alpha-tert-butyloxycarbonyl-glutamic acid beta-fluorenylmethyl ester,BG,BG-beta-FME; Nalpha-Boc-Glu-beta-fluorenylmethyl ester,
C0641608,ristotetraose,glucose,"D-Glucose, O-alpha-D-arabinofuranosyl-(1-2)-O-alpha-D-mannopyranosyl-(1-2)-O-(6-deoxy-alpha-L-mannopyranosyl-(1-6))-",
C0641939,quercetin-3-O-neohesperidose,glucose,quercetin-3-O-rhamnose-glucose; quercetin-3-O-rhamnosylglucoside,
C0643830,4-coumaroyl-D-glucose hydroxylase,glucose,p-coumaroyl-D-glucose hydroxylase; CDG hydroxylase,
C0645647,polyprenyl-phosphate glucose,glucose,1-PPPG,
C0645661,"2-N-acetyl-4-N-(3-hydroxybutanoyl)-2,4,6-trideoxyglucose",glucose,"2-NHBTG; 2(N)-acetyl-4-N-(3-hydroxybutanoyl)-2,4,6-trideoxy-D-glucose",
C0646794,"2,4,6-tri-O-galloylglucose",glucose,"2,4,6-tri-O-galloyl-D-glucose; 2,4,6-TGDG",
C0647365,"glucose transporter 3 protein, Gallus gallus",glucose,"CEF-CT3 protein, Gallus gallus; glucose transporter 3, chicken embryo fibroblasts; chicken embryo fiboblast glucose transporter 3",
C0647969,4-hydroxybenzoate 4-O-glucosyltransferase,glucose,UDP-glucose- p-hydroxybenzoate glucosyltransferase,
C0649403,galactosyl-N-acetyl(1-4)-glucose ceramide,glucose,GalNacbeta1-4Glc-ceramide; GNBGC,
C0650864,CDP-glucose oxidoreductase,glucose,,
C0652315,glucose regulated protein 95,glucose,GRP95,
C0652901,6-amino-6-deoxyglucopyranose,glucose,6-amino-6-deoxy-D-glucose,
C0655451,N-acetylgalactosaminyl-1-3-galactosyl-1-4-glucose,glucose,GalNAc-1-3-Gal-1-4-Glc,
C0655938,2-chloro-2-deoxyglucose,glucose,2-deoxy-2-chloro-D-glucose; 2-chloro-2-deoxy-D-glucose; ClDG,
C0657510,retinylglucose,glucose,retinyl beta-glucose,
C0658269,"3,6-anhydroglucose",glucose,"3,6-anhydro-D-glucose",
C0660589,8-azidoguanosine diphosphate-glucose,glucose,8-azido-GDP-glucose,
C0660801,2-O-carboxymethyl-D-glucose,glucose,,
C0660886,UDPglucose-glycogen glucose 1-phosphotransferase,glucose,UGG-GlcPTase,
C0660981,glucose phenylosazone,glucose,"D-arabino-Hexos-2-ulose, bis(phenylhydrazone); glucosephenylosazone",
C0660985,A 103,glucose,"D-Glucose, 2-deoxy-2-((1-oxo-3-((1-oxotetradecyl)oxy)tetradecyl)amino)-, 4-(dihydrogen phosphate) 3-(3-((1-oxotetradecyl)oxy)tetradecanoate), (2(R),3(R))-; A-103",
C0661101,"4,6-dideoxy-4-malonylaminoglucose",glucose,"Qui4NMal; 4,6-dideoxy-4-malonylamino-D-glucose",
C0665798,3-O-(1-carboxyethyl)glucose,glucose,,
C0666593,"glucose-inhibited division protein A, bacteria",glucose,"GidA protein, bacterial",
C0666725,glucose-6-phosphate dehydrogenase Sumare,glucose,G6PD Sumare,
C0669768,UDP-galactose 2-acetamido-2-deoxy-D-glucose 3-galactosyltransferase,glucose,,
C0670071,6-O-acetyl-D-glucose,glucose,6-acetyl glucose,
C0670591,1-O-(indole-3-acetyl)glucose,glucose,,
C0670592,"1,6-di-O-(indole-3-acetyl)glucose",glucose,,
C0671587,"1,3,4,6-tetraacetyl-2-18F-2-deoxy-D-glucose",glucose,,
C0672761,glucose 6-phosphate(transporter),glucose,glycerol-6-phosphate transporter; GP-transporter,
C0674107,oxo(bisglucoheptonate)(Technetium Tc 99m)technetate(V),BG,oxo(bg)Tc 99m technetate(V),
C0674229,coenzyme F420-dependent glucose-6-phosphate dehydrogenase,glucose,,
C0674623,mannosyl(6)-N-acetylglucosamine-p-nitrophenyl-alpha-D-glucose,glucose,Man(6)GlcNAc-Glc-pNP; MGNAcNP,
C0675321,dTDP-6-deoxy-4-ketoglucose,glucose,dTDP-KDG; TDP-4-keto-6-deoxy-D-glucose; dTDP-4-keto-6-deoxy-D-glucose,
C0677438,"DRINK, GLUCOSE TOLERANCE",glucose,,
C0677501,Congenital Nephrogenic Diabetes Insipidus,diabetes,"Vasopressin-resistant hyposthenuria; Hereditary nephrogenic diabetes insipidus; Vasopressin-unresponsiveness hyposthenuria; Primary nephrogenic diabetes insipidus; Hereditary nephrogenic diabetes insipidus (disorder); Vasopressin-resistant diabetes insipidus; ADH-resistant diabetes insipidus; Congenital Nephrogenic Diabetes Insipidus; Congenital nephrogenic diabetes insipidus; vasopressin resistant diabetes insipidus; Adiuretin-resistant diabetes insipidus; Familial nephrogenic diabetes insipidus; Renal diabetes insipidus; Nephrogenic/vasopressin-resistant diabetes insipidus; DIABETES INSIPIDUS, VASOPRESSIN-RESISTANT; Hereditary nephrogenic diabetes insipidus, NOS",
C0687720,Central Diabetes Insipidus,diabetes,"Vasopressin deficiency syndrome; Diabetes Insipidus, Central; Primary central diabetes insipidus; Cranial diabetes insipidus; pituitary diabetes insipidus; Neurohypophyseal diabetes insipidus; Central Diabetes Insipidus; antidiuretic hormone defective syndrome; Pituitary diabetes insipidus; Neurogenic Diabetes Insipidus; Central diabetes insipidus; Diabetes Insipidus, Pituitary; Neurohypophyseal diabetes insipidus, NOS; DIABETES INSIPIDUS, NEUROHYPOPHYSEAL; DIABETES INSIPIDUS, CRANIAL TYPE; Neurohypophyseal diabetes insipidus (disorder); cranial diabetes insipidus; vasopressin deficiency; Vasopressin Defective Diabetes Insipidus; Diabetes Insipidus Primary Central; Pituitary Diabetes Insipidus; vasopressin defective diabetes insipidus; Neurohypophyseal Diabetes Insipidus; central diabetes insipidus; Neurogenic diabetes insipidus; Diabetes insipidus, neurogenic; Diabetes Insipidus Secondary To Vasopressin Deficiency; neurogenic diabetes insipidus; DIABETES INSIPIDUS, PRIMARY CENTRAL; Vasopressin Deficiency; Diabetes Insipidus, Neurogenic; Diabetes Insipidus, Cranial Type; Diabetes insipidus - pituitary; Diabetes Insipidus, Neurohypophyseal Type; Diabetes insipidus secondary to vasopressin deficiency; Vasopressin deficiency; CDI; Diabetes Insipidus, Primary Central; Diabetes Insipidus Cranial Type; Diabetes Insipidus, Neurohypophyseal",
C0688540,"DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.9 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]",glucose,"DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 900 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION; Glucose 50 mg/mL and sodium chloride 9 mg/mL solution for injection; DEXTROSE 5%/NACL 0.9% INJ; Product containing precisely glucose 50 milligram/1 milliliter and sodium chloride 9 milligram/1 milliliter conventional release solution for injection (clinical drug); LVP solution Dextrose 5% with 0.9% NaCl intravenous solution; Dextrose 5% and 0.9% Sodium Chloride, Dextrose 5% with 0.9% NaCl intravenous solution; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.9 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]",
C0690073,Glucose 50 MG/ML / Potassium Chloride 0.02 MEQ/ML / Sodium Chloride 4.5 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 50 g in 1000 mL / SODIUM CHLORIDE 4.5 g in 1000 mL / POTASSIUM CHLORIDE 1.49 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; POTASSIUM CHLORIDE 150 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; LVP solution with potassium Dextrose 5% with 0.45% NaCl and KCl 20 mEq/L intravenous solution; Dextrose 5% and 0.45% Sodium Chloride with Potassium Chloride 20 mEq/L, Dextrose 5% with 0.45% NaCl and KCl 20 mEq/L intravenous solution; DEXTROSE 5%/NACL 0.45%/KCL 20MEQ/L INJ",
C0690074,1000 ML glucose 50 MG/ML / potassium chloride 0.03 MEQ/ML / sodium chloride 4.5 MG/ML Injection,glucose,"Dextrose 5% and 0.45% Sodium Chloride with Potassium Chloride 30 mEq/L, Dextrose 5% with 0.45% NaCl and KCl 30 mEq/L intravenous solution; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.03 MEQ/ML / NaCl 4.5 MG/ML Injection; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.03 MEQ/ML / NaCl 4.5 MG/ML Injection; DEXTROSE MONOHYDRATE 50 g in 1000 mL / SODIUM CHLORIDE 4.5 g in 1000 mL / POTASSIUM CHLORIDE 2.24 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL / POTASSIUM CHLORIDE 0.22 g in 100 mL INTRAVENOUS INJECTION [Potassium Chloride in Dextrose and Sodium Chloride]; LVP solution with potassium Dextrose 5% with 0.45% NaCl and KCl 30 mEq/L intravenous solution; potassium chloride 30 MEQ / dextrose 5 % / sodium chloride 0.45 % per 1000 ML Injection; 1000 ML glucose 50 MG/ML / potassium chloride 0.03 MEQ/ML / sodium chloride 4.5 MG/ML Injection; potassium chloride 30 MEQ / dextrose 5 % / sodium chloride 0.45 % in 1000 ML Injection; DEXTROSE 5%/NACL 0.45%/KCL 30MEQ/L INJ; POTASSIUM CHLORIDE 224 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]",
C0690075,1000 ML Glucose 50 MG/ML / Potassium Chloride 0.04 MEQ/ML / Sodium Chloride 4.5 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 50 g in 1000 mL / SODIUM CHLORIDE 4.5 g in 1000 mL / POTASSIUM CHLORIDE 2.98 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL / POTASSIUM CHLORIDE 0.3 g in 100 mL INTRAVENOUS INJECTION [Potassium Chloride in Dextrose and Sodium Chloride]; potassium chloride 40 MEQ / dextrose 5 % / sodium chloride 0.45 % in 1000 ML Injection; LVP solution with potassium Dextrose 5% with 0.45% NaCl and KCl 40 mEq/L intravenous solution; potassium chloride 40 MEQ / dextrose 5 % / sodium chloride 0.45 % per 1000 ML Injection; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.04 MEQ/ML / NaCl 4.5 MG/ML Injection; 1000 ML glucose 50 MG/ML / potassium chloride 0.04 MEQ/ML / sodium chloride 4.5 MG/ML Injection; POTASSIUM CHLORIDE 300 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.04 MEQ/ML / NaCl 4.5 MG/ML Injection; DEXTROSE 5%/NACL 0.45%/KCL 40MEQ/L INJ; Dextrose 5% and 0.45% Sodium Chloride with Potassium Chloride 40 mEq/L, Dextrose 5% with 0.45% NaCl and KCl 40 mEq/L intravenous solution",
C0690077,glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection,glucose,"LVP solution with potassium Dextrose 5% with 0.2% NaCl and KCl 20 mEq/L intravenous solution; DEXTROSE 5%/NACL 0.2%/KCL 20MEQ/L INJ; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.2 g in 100 mL / POTASSIUM CHLORIDE 0.15 g in 100 mL INTRAVENOUS INJECTION [Potassium Chloride in Dextrose and Sodium Chloride]; POTASSIUM CHLORIDE 150 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 200 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; LVP solution with potassium Dextrose 5% with 0.225% NaCl and KCl 20 mEq/L intravenous solution; Dextrose 5% and 0.2% Sodium Chloride with Potassium Chloride 20 mEq/L, Dextrose 5% with 0.2% NaCl and KCl 20 mEq/L intravenous solution",
C0690079,1000 ML Glucose 50 MG/ML / Potassium Chloride 0.04 MEQ/ML / Sodium Chloride 2.25 MG/ML Injection,glucose,1000 ML Glucose 50 MG/ML / K+ Chloride 0.04 MEQ/ML / NaCl 2.25 MG/ML Injection; potassium chloride 40 MEQ / dextrose 5 % / sodium chloride 0.225 % in 1000 ML Injection; potassium chloride 40 MEQ / dextrose 5 % / sodium chloride 0.225 % per 1000 ML Injection; 1000 ML glucose 50 MG/ML / potassium chloride 0.04 MEQ/ML / sodium chloride 2.25 MG/ML Injection; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.04 MEQ/ML / NaCl 2.25 MG/ML Injection,
C0690080,1000 ML Glucose 50 MG/ML / Potassium Chloride 0.02 MEQ/ML / Sodium Chloride 9 MG/ML Injection,glucose,"1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection; DEXTROSE 5%/NACL 0.9%/KCL 20MEQ/L INJ; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.02 MEQ/ML / NaCl 9 MG/ML Injection; LVP solution with potassium Dextrose 5% with 0.9% NaCl and KCl 20 mEq/L intravenous solution; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.02 MEQ/ML / NaCl 9 MG/ML Injection; Dextrose 5% and 0.9% Sodium Chloride with Potassium Chloride 20 mEq/L, Dextrose 5% with 0.9% NaCl and KCl 20 mEq/L intravenous solution; potassium chloride 20 MEQ / dextrose 5 % / sodium chloride 0.9 % per 1000 ML Injection; DEXTROSE MONOHYDRATE 50 g in 1000 mL / SODIUM CHLORIDE 9 g in 1000 mL / POTASSIUM CHLORIDE 1.49 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; potassium chloride 20 MEQ / dextrose 5 % / sodium chloride 0.9 % in 1000 ML Injection; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.9 g in 100 mL / POTASSIUM CHLORIDE 0.15 g in 100 mL INTRAVENOUS INJECTION [Potassium Chloride in Dextrose and Sodium Chloride]; POTASSIUM CHLORIDE 150 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 900 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]",
C0690082,1000 ML Glucose 50 MG/ML / Potassium Chloride 0.04 MEQ/ML / Sodium Chloride 9 MG/ML Injection,glucose,"POTASSIUM CHLORIDE 300 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 900 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; 1000 ML glucose 50 MG/ML / potassium chloride 0.04 MEQ/ML / sodium chloride 9 MG/ML Injection; DEXTROSE MONOHYDRATE 50 g in 1000 mL / SODIUM CHLORIDE 9 g in 1000 mL / POTASSIUM CHLORIDE 2.98 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; LVP solution with potassium Dextrose 5% with 0.9% NaCl and KCl 40 mEq/L intravenous solution; Dextrose 5% and 0.9% Sodium Chloride with Potassium Chloride 40 mEq/L, Dextrose 5% with 0.9% NaCl and KCl 40 mEq/L intravenous solution; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.04 MEQ/ML / NaCl 9 MG/ML Injection; DEXTROSE 5%/NACL 0.9%/KCL 40MEQ/L INJ; potassium chloride 40 MEQ / dextrose 5 % / sodium chloride 0.9 % per 1000 ML Injection; potassium chloride 40 MEQ / dextrose 5 % / sodium chloride 0.9 % in 1000 ML Injection; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.04 MEQ/ML / NaCl 9 MG/ML Injection",
C0690083,Glucose 50 MG/ML / Potassium Chloride 0.02 MEQ/ML / Sodium Chloride 3 MG/ML Injection,glucose,,
C0691368,DEXTROSE 100GM/180ML,glucose,DEXTROSE 100GM/180ML LIQUID; glucose 100 g/180 mL oral liquid,
C0691497,glucose 0.4 MG/MG Oral Gel,glucose,"glucose 32 GM per 80 GM Oral Gel; DEXTROSE 15GM/45GM SQUEEZE TUBE; glucose 15 GM per 37.5 GM Oral Gel; glucose 18 GM per 45 GM Oral Gel; glucose 40% oral gel; DEXTROSE 18GM/45GM SQUEEZE TUBE; SugarUp, 40% preservative-free oral gel; Glucose 400 mg/g oral gel; Sweet Cheeks, 40% oral gel; glucose 40% preservative-free oral gel; dextrose 40 % Oral Gel; Product containing precisely glucose 400 milligram/1 gram conventional release oral gel (clinical drug); DEXTROSE 15GM/37.5GM SQUEEZE TUBE",
C0694038,glucose 100 MG/ML Oral Solution,glucose,dextrose 10 % Oral Solution,
C0694039,glucose 50 MG/ML Oral Solution,glucose,dextrose 5 % Oral Solution,
C0694916,Glucose monitor supply for diabetic beneficiary not treated with insulin,glucose,,
C0694930,"Diabetes outpatient self-management training services, individual, per 30 minutes",diabetes,,
C0694931,"Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes",diabetes,,
C0697269,beta-glucose-1-phosphate,glucose,,
C0700436,Glucose^6H post 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^6 hours post 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 6 Hr post 100 g glucose PO [Mass/Vol]; Glucose 6h p 100 g Glc PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --6 hours post 100 g glucose PO,
C0705578,glucose compounding powder,glucose,,
C0713419,glucose 0.4 MG/MG Oral Gel [Insta-Glucose],glucose,Insta-Glucose 0.4 MG/MG Oral Gel; Insta-Glucose 40 % Oral Gel,
C0714787,polyethylene glycols 10 MG/ML / polyvinyl alcohol 0.01 ML/ML Ophthalmic Solution [Hypotears],hypo,"Hypo Tears (polyethylene glycols 1 % / polyvinyl alcohol 1 % ) Ophthalmic Solution; Hypotears, preserved ophthalmic solution; Hypo Tears 1 % / 1 % Ophthalmic Solution",
C0715387,dextromethorphan hydrobromide 2 MG/ML Oral Solution [Scot-tussin Diabetic CF],diabetes,"Scot-Tussin Diabetic, 10 mg/5 mL oral syrup; SCOT-TUSSIN Diabetes Cough Suppressant Formula with DM 10 MG in 5 mL Oral Solution; DEXTROMETHORPHAN HYDROBROMIDE 10 mg in 5 mL ORAL LIQUID [Scot-Tussin Diabetes Cough Formula with DM]; Scot-tussin Diabetic CF 2 MG/ML Oral Solution; Scot-tussin Diabetic Cough Formula 10 MG per 5 ML Oral Solution",
C0719838,Glucose / Potassium Chloride,glucose,glucose / potassium chloride; Dextrose and Potassium Chloride; Glucose- and potassium chloride-containing product; Product containing glucose and potassium chloride (medicinal product); DEXTROSE/POTASSIUM CHLORIDE,
C0719849,Glucose + Potassium Chloride + Sodium Chloride,glucose,Product containing glucose and potassium chloride and sodium chloride (medicinal product); Glucose- and potassium chloride- and sodium chloride-containing product; DEXTROSE/POTASSIUM CHLORIDE/SODIUM CHLORIDE; glucose / potassium chloride / sodium chloride; Dextrose/Potassium Chloride/Sodium Chloride,
C0720991,Hyper-Tet,hyper,hyper-tet; hyper tet,
C0724897,Accu-Chek Advanced Glucose Kit,glucose,,
C0724904,ACCU-CHEK COMFORT CURVE (GLUCOSE) TEST STRIP,glucose,Accu-Chek Comfort Curve Strips; Accu-Chek Comfort Curve Test Strip; ACCU-CHEK COMFORT CV(GLUCOSE) TEST STRIP,
C0724912,Accu-Chek Glucose Control,glucose,,
C0725150,Answer Blood Glucose,blood glucose,,
C0725353,Blood Glucose Book,blood glucose,,
C0725354,Blood Glucose Strip,blood glucose,,
C0725598,Chemstrip BG Diary,BG,,
C0725599,Chemstrip BG Kit Visual Only,BG,,
C0725600,Chemstrip BG Visual Only,BG,,
C0725838,Diabetes Ancillary,diabetes,,
C0726153,Exactech Blood Glucose Sensor,blood glucose,,
C0726154,ExacTech Blood Glucose Strips,blood glucose,Exactech Blood Glucose Strip,
C0726156,Exactech Glucose Control Solution,glucose,,
C0726398,GLUCOSE CONTROL,glucose,glucose control; Glucose Control,
C0726399,Glucose Control II Low plus High,glucose,,
C0726400,Glucose Control Solution Low-Norm-High Accuch,glucose,,
C0726401,Glucose Control Tracer,glucose,,
C0726402,Glucose Reagent,glucose,,
C0727552,Precision Glucose Control Solution,glucose,Precision G Control Solution,
C0727790,Select Glucose Meter,glucose,,
C0727791,Select Glucose Meter Kit,glucose,,
C0727792,Select Glucose Test Strips,glucose,,
C0727815,Seralyzer Glucose Strip,glucose,,
C0728148,Surestep Blood Glucose Control Solution,blood glucose,,
C0728149,Sure/S Blood Glucose Monitoring System with M,blood glucose,,
C0728423,Tracer BG Test Strip,BG,,
C0730232,Referral to diabetes nurse,diabetes,Referral to diabetes nurse (procedure),
C0730262,Attending diabetes clinic,diabetes,Attending diabetes clinic (finding),
C0730276,Mild non-proliferative diabetic retinopathy,diabetes,Mild nonproliferative retinopathy due to diabetes mellitus; Mild non proliferative retinopathy; Mild non-proliferative diabetic retinopathy; Mild non-proliferative retinopathy; Mild nonproliferative retinopathy; Mild nonproliferative retinopathy due to diabetes mellitus (disorder); Mild nonproliferative diabetic retinopathy,
C0730277,Moderate nonproliferative retinopathy due to diabetes mellitus,diabetes,Moderate nonproliferative retinopathy; Moderate nonproliferative retinopathy due to diabetes mellitus (disorder); Moderate non-proliferative diabetic retinopathy; Moderate nonproliferative diabetic retinopathy,
C0730278,Severe nonproliferative diabetic retinopathy,diabetes,Severe nonproliferative retinopathy due to diabetes mellitus (disorder); Severe nonproliferative retinopathy due to diabetes mellitus; Severe nonproliferative retinopathy; Severe NPDR (nonproliferative diabetic retinopathy); Severe nonproliferative diabetic retinopathy,
C0730279,Non-high-risk proliferative retinopathy due to diabetes mellitus,diabetes,Non-high-risk proliferative retinopathy due to diabetes mellitus (disorder); Early PDR; Proliferative diabetic retinopathy - non high risk; PDR - non-high risk; Non-high risk PDR; Early proliferative diabetic retinopathy,
C0730280,High risk proliferative retinopathy due to diabetes mellitus,diabetes,Proliferative diabetic retinopathy - high risk; High risk PDR; High risk proliferative retinopathy; High risk proliferative retinopathy due to diabetes mellitus (disorder); High risk proliferative diabetic retinopathy,
C0730281,Quiescent proliferative retinopathy due to diabetes mellitus,diabetes,Proliferative diabetic retinopathy - quiescent; Inactive PDR; Inactive proliferative diabetic retinopathy; Quiescent proliferative retinopathy due to diabetes mellitus (disorder),
C0730282,Proliferative retinopathy with iris neovascularization due to diabetes mellitus,diabetes,PDR iris neovascularization; Proliferative diabetic retinopathy - iris neovascularization; Proliferative retinopathy with iris neovascularisation due to diabetes mellitus; PDR iris neovascularisation; Proliferative diabetic retinopathy - iris neovascularisation; Proliferative retinopathy with iris neovascularization due to diabetes mellitus (disorder),
C0730283,Vitreous hemorrhage due to diabetes mellitus,diabetes,Vitreous hemorrhage with diabetes mellitus; Vitreous haemorrhage due to diabetes mellitus; Diabetic vitreous hemorrhage; Vitreous hemorrhage due to diabetes mellitus (disorder); Diabetic vitreous haemorrhage; Vitreous haemorrhage with diabetes mellitus,
C0730285,Macular edema due to diabetes mellitus,diabetes,diabetic macular edema; Diabetic macular oedema; Diabetic macular edema; diabetic macular oedema; Macular oedema due to diabetes mellitus; edema diabetic macular; Macular edema due to diabetes mellitus (disorder),
C0730535,Glucose load test,glucose,Glucose load test (procedure),
C0731791,Low glucose concentration peritoneal dialysis solution,low glucose,Low glucose concentration peritoneal dialysis solution (product),
C0731792,Medium glucose concentration peritoneal dialysis solution,glucose,Medium glucose concentration peritoneal dialysis solution (product),
C0731793,High glucose concentration peritoneal dialysis solution,high glucose,High glucose concentration peritoneal dialysis solution (product),
C0731856,Glucose free acid hemodialysis liquid concentrate,glucose,No glucose acid hemodialysis liquid concentrate; Glucose free acid haemodialysis liquid concentrate; Glucose free acid hemodialysis liquid concentrate (product); No glucose acid haemodialysis liquid concentrate,
C0731858,Glucose free acetate hemodialysis liquid concentrate,glucose,No glucose acetate haemodialysis liquid concentrate; Glucose free acetate haemodialysis liquid concentrate; Glucose free acetate hemodialysis liquid concentrate (product); No glucose acetate hemodialysis liquid concentrate,
C0731869,Glucose free continuous hemodialysis solution,glucose,No glucose continuous haemodialysis solution; Glucose free continuous haemodialysis solution; Glucose free continuous hemodialysis solution (product); No glucose continuous hemodialysis solution,
C0731871,Glucose free hemofiltration solution,glucose,No glucose haemofiltration solution; No glucose hemofiltration solution; Glucose free hemofiltration solution (product); Glucose free haemofiltration solution,
C0740040,blood glucose monitoring supplies,blood glucose,,
C0740213,Diabetes Mellitus screen,diabetes,Diabetes mellitus screening (procedure); Diabetes mellitus screening,
C0740447,Diabetic peripheral neuropathy,diabetes,Peripheral neuropathy due to diabetes mellitus (disorder); diabetic neuropathy peripheral; Peripheral neuropathy due to diabetes mellitus; diabetic peripheral neuropathy; peripheral diabetic neuropathy,
C0743140,diabetes mellitus risk,diabetes,,
C0744431,Random glucose level abnormal,glucose level,Random glucose outside reference range (finding); Random glucose outside reference range,
C0744434,Alteration in glucose metabolism,glucose,,
C0744441,Pregnancy with normal glucose tolerance test,normal glucose,Pregnancy with normal glucose tolerance test (finding),
C0745095,hyperglycemia hyperosmolar,hyperglycemia,hyperosmolar hyperglycemia,
C0745098,Hyperglycemia steroid-induced,hyperglycemia,steroid-induced hyperglycemia; Steroid-induced hyperglycaemia; Steroid-induced hyperglycemia; steroid induced hyperglycemia; Steroid-induced hyperglycemia (disorder); hyperglycaemia steroid-induced,
C0745103,Hyperlipoproteinemia Type IIa,hyper,"Hyperlipoproteinemia, Frederickson type IIa; FHC; LDL Receptor Disorder; Fredrickson Type IIa hyperlipoproteinemia; HYPERCHOLESTEROLEMIA, FAMILIAL, 1; Hyperlipoproteinemia Type IIas; Fredrickson type IIa hyperlipoproteinaemia; Familial Hypercholesterolemia; Autosomal Dominant Hypercholesterolemias; Type IIa Hyperlipoproteinemias; Hyperlipoproteinemias, Type IIa; Hyperlipoproteinemia, Type IIa; HYPERLIPOPROTEINEMIA, TYPE II; LDL Receptor Disorders; HYPERLIPOPROTEINEMIA, TYPE IIA; Dominant Hypercholesterolemia, Autosomal; LDL RECEPTOR DISORDER; Disorder, LDL Receptor; Hyperlipoproteinemia Type IIa; HYPERCHOLESTEROLEMIC XANTHOMATOSIS, FAMILIAL; Receptor Disorders, LDL; Hypercholesterolemias, Autosomal Dominant; FHCL1; Type IIa Hyperlipoproteinemia; Disorders, LDL Receptor; Fredrickson type IIa hyperlipoproteinemia; Type IIa Hyperlipidemia; Hyperlipidemia Type IIa; FH; Receptor Disorder, LDL; Hypercholesterolemia, Autosomal Dominant; HYPER-LOW-DENSITY-LIPOPROTEINEMIA; Dominant Hypercholesterolemias, Autosomal; Fredrickson type IIa hyperlipoproteinemia (disorder); Autosomal Dominant Hypercholesterolemia",
C0745150,"Hypoglycemia, acute",hypoglycemia,acute hypoglycemia; hypoglycemia acute,
C0750705,"SENSOR,GLUCOSE,NON-INVASIVE,INFRARED",glucose,,
C0751161,UDPglucose 4-epimerase deficiency disease,glucose,"Epimerase deficiency galactosemia; UDP-Galactose-4-Epimerase Deficiency Diseases; GALAC3; UDP-galactose-4-epimerase deficiency; GALACTOSE EPIMERASE DEFICIENCY; GALE Deficiency; Deficiency, GALE; UDP-Galactose-4-Epimerase Deficiency Disease; Uridine diphosphate galactose-4 epimerase deficiency; Epimerase deficiency; Deficiency Disease, UDP-Galactose-4-Epimerase; UDP-GALACTOSE-4-EPIMERASE DEFICIENCY; Deficiency Diseases, UDP-Galactose-4-Epimerase; GALE-D; Deficiencies, GALE; Deficiency Disease, UDP Galactose 4 Epimerase; GALE deficiency; GALE Deficiencies; UDPglucose-4-epimerase deficiency; Uridine diphosphate glucose-4-epimerase deficiency (disorder); UDPglucose 4 Epimerase Deficiency Disease; Galactosemia IIIs; Uridine diphosphate galactose-4-epimerase deficiency; UDPglucose 4-Epimerase Deficiency Disease; Deficiency, Galactose Epimerase; Galactosaemia III; UDP Galactose 4 Epimerase Deficiency Disease; Galactosemia 3s; Deficiency, UDP-Galactose-4-Epimerase; Deficiency Disease, UDPglucose 4 Epimerase; Galactosaemia - epimerase deficiency; GALACTOSEMIA III; Galactosemia 3; Galactose epimerase deficiency; GALE DEFICIENCY; UDPgalactose-4-epimerase deficiency; Galactose Epimerase Deficiencies; Galactosemia III; Deficiencies, UDP-Galactose-4-Epimerase; Deficiencies, Galactose Epimerase; UDP Galactose 4 Epimerase Deficiency; GALE; Galactosemia - epimerase deficiency; Uridine diphosphate glucose-4-epimerase deficiency; Uridine diphosphate (UDP) glucose-4-epimerase deficiency; Galactose Epimerase Deficiency; Deficiency Disease, UDPglucose 4-Epimerase; Galactosemia type 3; UDP-Galactose-4-Epimerase Deficiencies; UDP-Galactose-4-Epimerase Deficiency; Galactoepimerase deficiency",
C0754937,"2-acetamido-2,6-dideoxy-glucose (N-acetyl-quinovosamine)",glucose,"2-acetamido-2,6-dideoxy-L-glucose (N-acetyl-L-quinovosamine); L-QuiNAc",
C0756246,"D-glucose, O-D-glucopyranosyl",glucose,"D-glucose,O-beta-D-glucopyranosyl",
C0756255,"D-Glc, O-beta-Glc-(1-4)-O-beta-D-mannopyranosyl",glucose,"D-glucose, O-beta-D-glucopyranosyl, (1-4)-O-beta-D-mannopyranosyl",
C0756258,"D-glucose, O-D-glucopyranosyl-(1-4)-O-D-mannopyranosyl-(1-4)",glucose,,
C0756953,"D-glucose, O-beta-D-mannopyranosyl-(1-4)-O-beta-D-glucopyranosyl",glucose,,
C0759360,"4,6-(R)-O-(4'-iodoethylidene)-alpha,beta-D-glucose",glucose,,
C0759361,"4,6-O-(4'-iodoethylidene)glucose",glucose,4'-IEDG,
C0759363,"4,6-(R)-O-(2'-iodoethylidene)-alpha,beta-D-glucose",glucose,,
C0759364,"4,6-O-(2'-iodoethylidene)glucose",glucose,2'-IEDG,
C0759569,2-deoxy-glucose tetraacetate,glucose,2-deoxy-D-glucose tetraacetate; 2-DOG TA,
C0759643,"glucose transporter, Leishmania",glucose,Leishmania mexicana glucose transporter,
C0759923,punicalin,glucose,"4,6-(S,S)-gallagyl-D-glucose",
C0762981,N-acetylglucosaminylasparagine,glucose,"2-acetamido-1-(beta-L-aspartamido)-1,2-dideoxy-beta-D-glucose; 2-acetamido-1-N-(4'-L-aspartyl)-2-deoxy-beta-D-glucopyranosylamine; 4-N-2-acetamido-2-deoxy-beta-D-glucopyranosyl-L-asparagine; N-(2-acetylamino)-2-deoxy-beta-D-glucopyranosyl-L-asparagine; N(4)-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparagine; acetylglucosaminylasparagine; L-Asparagine, N-(2-acetylamino)-2-deoxy-beta-D-glucopyranosyl-; N(4)-(2-acetamido-2-deoxyglucopyranosyl)asparagine; N-ADGP-Asn; AADG",
C0763139,BG 9015,BG,BG9015,
C0763300,glucose valproate,glucose,,
C0763405,GDP-2-deoxy-D-glucose,glucose,GDP2dGlc,
C0763469,2-hydroxy-3-methoxybenzoic acid glucose ester,glucose,,
C0765228,UDP-glucose anthocyanin 5-O-glucosyltransferase,glucose,5-GT enzyme; UDPglucose anthocyanin 5-O-glucosyltransferase; anthocyanin 5-O-glucosyltransferase,
C0765796,glucose-mannose-glucose,glucose,GMG; glucose-mannose-glucose (GMG),
C0768647,thymidine diphosphate-4-keto-6-deoxy-D-glucose reductase,glucose,dTDP-4-keto-6-deoxy-D-glucose reductase,
C0769424,glucose-dependent-insulinotropic-polypeptide (7-30)-amide,glucose,GIP-(7-30)-NH2,
C0769983,"glucose-binding protein gp65, Sulfolobus",glucose,Sulfolobus GBP,
C0771903,glucosamine hydrochloride,glucose,"GLUCOSAMINE HYDROCHLORIDE; Glucosamine Hydrochloride; glucosamine hcl; glucosamine hydrochloride; Glucosamine hydrochloride; D-Glucose, 2-Amino-2-Deoxy-, Hydrochloride; Glucosamine hydrochloride (substance)",
C0773222,Glucose powder,glucose,glucose powder; dextrose powder; DEXTROSE 100% PWDR; Glucose powder (product),
C0773367,Glucose 100 MG/ML Injection,glucose,"Dextrose 10% and Water, Dextrose 10% in Water intravenous solution; parenteral nutrition solution Dextrose 10% in Water intravenous solution; DEXTROSE MONOHYDRATE 100 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]; DEXTROSE MONOHYDRATE 10 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 10% Dextrose]; DEXTROSE MONOHYDRATE 100 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; DEXTROSE 10 g in 100 mL INTRAVENOUS SOLUTION; DEXTROSE 10% INJ; DEXTROSE MONOHYDRATE 10 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]",
C0773370,500 ML glucose 400 MG/ML Injection,glucose,"Glucose 400 mg/mL solution for injection; dextrose 40 % in 500 ML Injection; DEXTROSE MONOHYDRATE 40 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; parenteral nutrition solution Dextrose 40% in Water intravenous solution; Product containing precisely glucose 400 milligram/1 milliliter conventional release solution for injection (clinical drug); Dextrose 40% and Water, Dextrose 40% in Water intravenous solution; dextrose 40 % per 500 ML Injection; DEXTROSE 40% INJ",
C0773376,Glucose 500 MG/ML Injectable Solution,glucose,"DEXTROSE MONOHYDRATE 50 g in 100 mL INTRAMUSCULAR INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 250 g in 500 mL INTRAVENOUS INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 50 g in 100 mL SUBCUTANEOUS INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 50 g in 100 mL INTRAVENOUS INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 50 g in 100 mL INTRAPERITONEAL INJECTION, SOLUTION; Dextrose Monohydrate 250 g in 500 mL INTRAVENOUS INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 50 g in 100 mL INTRAVENOUS INJECTION [Dextrose]; glucose 500 MG/ML Injectable Solution; dextrose 50 % Injectable Solution; Dextrose Monohydrate 50 g in 100 mL INTRAVENOUS INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 50 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose 50% Solution]; dextrose 500 MG/ML Injectable Solution",
C0773377,Glucose 600 MG/ML Injectable Solution,glucose,Glucose 600 mg/mL solution for injection; glucose 600 MG/ML Injectable Solution; Product containing precisely glucose 600 milligram/1 milliliter conventional release solution for injection (clinical drug); dextrose 60 % Injectable Solution,
C0773380,glucose 700 MG/ML Injectable Solution,glucose,"DEXTROSE MONOHYDRATE 70 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]; Dextrose 70% and Water, Dextrose 70% in Water intravenous solution_#1; DEXTROSE 70% INJ; dextrose 70 % Injectable Solution; glucose 700 MG/ML Injectable Solution; DEXTROSE MONOHYDRATE 70 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; DEXTROSE 70 g in 100 mL INTRAVENOUS SOLUTION; parenteral nutrition solution Dextrose 70% in Water intravenous solution",
C0776076,glucose Oral Solution,glucose,,
C0781316,500 ML Glucose 300 MG/ML Injection,glucose,"Dextrose, 30% intravenous solution; Dextrose 30% and Water, Dextrose 30% in Water intravenous solution; parenteral nutrition solution Dextrose 30% in Water intravenous solution; DEXTROSE 30% INJ; dextrose 30 % per 500 ML Injection; dextrose 30 % in 500 ML Injection; 500 ML glucose 300 MG/ML Injection; glucose 30% intravenous solution; DEXTROSE MONOHYDRATE 30 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]",
C0782020,Glucose Gel,glucose,glucose gel,
C0784100,Glucose 25 MG/ML / Sodium Chloride 0.0769 MEQ/ML Injectable Solution,glucose,"Glucose 25 MG/ML / NaCl 0.0769 MEQ/ML Injectable Solution; dextrose 2.5 % / sodium chloride 0.45 % Injectable Solution; dextrose 2.5 GM / NaCl 450 MG in 100 ML Injectable Solution; DEXTROSE MONOHYDRATE 2.5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Veterinary Dextrose and Sodium Chloride]; glucose 25 MG/ML / sodium chloride 0.0769 MEQ/ML Injectable Solution",
C0784106,1000 ML glucose 100 MG/ML / sodium chloride 4.5 MG/ML Injection,glucose,"DEXTROSE 10 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]; dextrose 10 % / sodium chloride 0.45 % in 1000 ML Injection; 1000 ML Glucose 100 MG/ML / NaCl 4.5 MG/ML Injection; dextrose 10 % / sodium chloride 0.45 % per 1000 ML Injection; LVP solution Dextrose 10% with 0.45% NaCl intravenous solution; Dextrose 10% and 0.45% Sodium Chloride, Dextrose 10% with 0.45% NaCl intravenous solution; DEXTROSE 10%/NACL 0.45% INJ",
C0785704,Blood glucose monitoring equipment,blood glucose,Blood glucose monitoring equipment (physical object),
C0785877,250 ML glucose 100 MG/ML / sodium chloride 2 MG/ML Injection,glucose,"250 ML Glucose 100 MG/ML / NaCl 2 MG/ML Injection; Dextrose 10% and 0.2% Sodium Chloride, Dextrose 10% with 0.2% NaCl intravenous solution; dextrose 10 % / sodium chloride 0.2 % in 250 ML Injection; DEXTROSE 10%/NACL 0.2% INJ; dextrose 10 % / sodium chloride 0.2 % per 250 ML Injection; LVP solution Dextrose 10% with 0.2% NaCl intravenous solution; DEXTROSE 10 g in 100 mL / SODIUM CHLORIDE 0.2 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]",
C0788918,glucose 33 MG/ML / sodium chloride 0.0513 MEQ/ML Injectable Solution,glucose,"Glucose 33 MG/ML / NaCl 0.0513 MEQ/ML Injectable Solution; dextrose 3.3 % / sodium chloride 0.3 % Injectable Solution; DEXTROSE 3.3 g in 100 mL / SODIUM CHLORIDE 0.3 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]",
C0795706,Femoral mononeuropathy due to diabetes mellitus,diabetes,Femoral mononeuropathy with diabetes mellitus; Diabetic femoral mononeuropathy; Femoral mononeuropathy due to diabetes mellitus (disorder),
C0795923,diabetes mellitus-mental retardation-lipodystrophy-dysmorphic traits syndrome,diabetes,,
C0795985,hypogonadism-alopecia-diabetes mellitus-mental retardation-deafness-ECG abnormalities syndrome,diabetes,,
C0796093,Odontoonychodermal dysplasia,hypo,"OODD; ECTODERMAL DYSPLASIA 16, HYPO- OR HYPERHIDROTIC/HAIR/TOOTH/NAIL TYPE; Fadhil syndrome; Odonto-onycho-dermal dysplasia (disorder); ODONTOONYCHODERMAL DYSPLASIA; Odonto-onycho-dermal dysplasia; ECTD16; Odontoonychodermal dysplasia; odontoonychodermal dysplasia",
C0796106,osteosarcoma-cataracts-diabetes mellitus-osteoporosis-erythroid macrocytosis-growth and developmental deficiency syndrome,diabetes,,
C0796116,pigmentary retinopathy-hypogonadism-mental retardation-nerve deafness-glucose intolerance syndrome,glucose,insulin-resistant diabetes-acanthosis nigricans-hypogonadism-pigmentary retinopathy-deafness-mental retardation syndrome,
C0796286,cerebellar vermis hypo/aplasia-oligophrenia-congenital ataxia-ocular coloboma-hepatic fibrosis syndrome,hypo,cerebellar vermis hypo/aplasia-oligophrenia-congenital ataxia-ocular coloboma-hepatic fibrosis (COACH) syndrome,
C0796797,Glucose^3H post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3 Hr post 50 g lactose PO [Mass/Vol]; Glucose 3h p 50 g Lac PO SerPl-mCnc; Glucose^3 hours post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --3 hours post 50 g lactose PO,
C0796798,Glucose^4H post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4h p 50 g Lac PO SerPl-mCnc; Glucose 4 Hr post 50 g lactose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --4 hours post 50 g lactose PO; Glucose^4 hours post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0796799,Insulin^1.5H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin^1.5 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 1.5h p 75 g Glc PO SerPl-mCnc; Insulin [Mass/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO; Insulin 1.5 Hr post 75 g glucose PO [Mass/Vol],
C0796800,Insulin^2.5H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin [Mass/volume] in Serum or Plasma --2.5 hours post 75 g glucose PO; Insulin^2.5 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 2.5 Hr post 75 g glucose PO [Mass/Vol]; Insulin 2.5h p 75 g Glc PO SerPl-mCnc,
C0797054,Glucose^2.5H post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2.5h p 50 g Lac PO SerPl-mCnc; Glucose 2.5 Hr post 50 g lactose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --2.5 hours post 50 g lactose PO; Glucose^2.5 hours post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0797055,Glucose^5H post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5h p 50 g Lac PO SerPl-mCnc; Glucose 5 Hr post 50 g lactose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --5 hours post 50 g lactose PO; Glucose^5 hours post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0797323,Glucose^5.5H post 75 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --5.5 hours post 75 g glucose PO; Glucose 5.5 Hr post 75 g glucose PO [Mass/Vol]; Glucose^5.5 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5.5h p 75 g Glc PO SerPl-mCnc,
C0797566,Glucose:MCnc:Pt:Gast fld:Qn,glucose,Glucose (Gast fld) [Mass/Vol]; Glucose:Mass Concentration:To identify measures at a point in time:Gastric fluid/contents:Quantitative; Glucose [Mass/volume] in Gastric fluid; Glucose Gast-mCnc,
C0797917,Glucose:SCnc:Pt:BldC:Qn:Glucometer,glucose,Glucose:Substance Concentration:To identify measures at a point in time:Blood capillary:Quantitative:Glucometer; Glucose BldC Glucomtr-sCnc; Glucose Glucometer (BldC) [Moles/Vol]; Glucose [Moles/volume] in Capillary blood by Glucometer,
C0797918,Glucose:SCnc:Pt:CSF:Qn,glucose,Glucose CSF-sCnc; Glucose (CSF) [Moles/Vol]; Glucose [Moles/volume] in Cerebral spinal fluid; Glucose:Substance Concentration:To identify measures at a point in time:Cerebral spinal fluid:Quantitative,
C0797919,Glucose:SCnc:Pt:Body fld:Qn,glucose,"Glucose:Substance Concentration:To identify measures at a point in time:Body fluid, unsp:Quantitative; Glucose (Body fld) [Moles/Vol]; Glucose Fld-sCnc; Glucose [Moles/volume] in Body fluid",
C0797920,Glucose:SCnc:Pt:Dial fld prt:Qn,glucose,Glucose:SCnc:Pt:Dial fld prt:Qn; Glucose DiafP-sCnc; Glucose:Substance Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose [Moles/volume] in Peritoneal dialysis fluid; Glucose (Perit dial fld) [Moles/Vol],
C0797921,Glucose:SCnc:Pt:Plr fld:Qn,glucose,Glucose:Substance Concentration:To identify measures at a point in time:Pleural fluid (thoracentesis fld):Quantitative; Glucose [Moles/volume] in Pleural fluid; Glucose (Pleur fld) [Moles/Vol]; Glucose Plr-sCnc,
C0797922,Glucose:SCnc:Pt:Periton fld:Qn,glucose,Glucose (Periton fld) [Moles/Vol]; Glucose:Substance Concentration:To identify measures at a point in time:Peritoneal fluid /ascites:Quantitative; Glucose [Moles/volume] in Peritoneal fluid; Glucose Prt-sCnc,
C0797923,Glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma; Glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose SerPl-sCnc,
C0797924,Glucose:SCnc:Pt:Synv fld:Qn,glucose,Glucose (Syn fld) [Moles/Vol]; Glucose:Substance Concentration:To identify measures at a point in time:Synovial fluid (Joint fluid):Quantitative; Glucose Snv-sCnc; Glucose [Moles/volume] in Synovial fluid,
C0797925,Glucose^1.5H post 50 g lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5h p 50 g Lac PO SerPl-sCnc; Glucose^1.5 hours post 50 g lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5 Hr post 50 g lactose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --1.5 hours post 50 g lactose PO,
C0797926,Glucose^1.5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5 Hr post dose glucose [Moles/Vol]; Glucose 1.5h p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --1.5 hours post dose glucose,
C0797927,Glucose^1H post 100 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --1 hour post 100 g glucose PO; Glucose^1 hour post 100 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1h p 100 g Glc PO SerPl-sCnc; Glucose 1 Hr post 100 g glucose PO [Moles/Vol],
C0797928,Glucose^1H post 50 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p 50 g Glc PO SerPl-sCnc; Glucose 1 Hr post 50 g glucose PO [Moles/Vol]; Glucose^1 hour post 50 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --1 hour post 50 g glucose PO,
C0797929,Glucose^1H post 50 g lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p 50 g Lac PO SerPl-sCnc; Glucose 1 Hr post 50 g lactose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --1 hour post 50 g lactose PO; Glucose^1 hour post 50 g lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0797930,Glucose^1H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1 hour post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1h p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --1 hour post dose glucose; Glucose 1 Hr post dose glucose [Moles/Vol],
C0797931,Glucose^2H post 100 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2h p 100 g Glc PO SerPl-sCnc; Glucose 2 Hr post 100 g glucose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --2 hours post 100 g glucose PO; Glucose^2 hours post 100 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0797932,Glucose^2H post 50 g lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2h p 50 g Lac PO SerPl-sCnc; Glucose 2 Hr post 50 g lactose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --2 hours post 50 g lactose PO; Glucose^2 hours post 50 g lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0797933,Glucose^2H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2 Hr post dose glucose [Moles/Vol]; Glucose 2h p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --2 hours post dose glucose,
C0797934,Glucose^2H post meal:SCnc:Pt:BldC:Qn,glucose,Glucose 2h p meal BldC-sCnc; Glucose 2 Hr post meal (BldC) [Moles/Vol]; Glucose [Moles/volume] in Capillary blood --2 hours post meal; Glucose^2 hours post meal:Substance Concentration:To identify measures at a point in time:Blood capillary:Quantitative,
C0797935,Glucose^2H post meal:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2h p meal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --2 hours post meal; Glucose^2 hours post meal:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2 Hr post meal [Moles/Vol],
C0797936,Glucose^30M post 50 g lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^30 minutes post 50 g lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30M p 50 g Lac PO SerPl-sCnc; Glucose 30 Min post 50 g lactose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --30 minutes post 50 g lactose PO,
C0797937,Glucose^30M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30 Min post dose glucose [Moles/Vol]; Glucose 30M p Glc SerPl-sCnc; Glucose^30 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose glucose,
C0797938,Glucose^3H post 100 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --3 hours post 100 g glucose PO; Glucose^3 hours post 100 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3h p 100 g Glc PO SerPl-sCnc; Glucose 3 Hr post 100 g glucose PO [Moles/Vol],
C0797939,Glucose^3H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3h p Glc SerPl-sCnc; Glucose^3 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --3 hours post dose glucose; Glucose 3 Hr post dose glucose [Moles/Vol],
C0797940,Glucose^4H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4 Hr post dose glucose [Moles/Vol]; Glucose^4 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4h p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --4 hours post dose glucose,
C0797941,Glucose^5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5h p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --5 hours post dose glucose; Glucose 5 Hr post dose glucose [Moles/Vol]; Glucose^5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0797942,Glucose^baseline:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --baseline; Glucose BS SerPl-sCnc; Glucose baseline [Moles/Vol]; Glucose^baseline:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0797943,Glucose^pre 12H CFst:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^pre 12 hours Calorie fast:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre 12 hour fast [Moles/Vol]; Glucose pre 12h fast SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --pre 12 hour fast,
C0797944,Glucose^post CFst:SCnc:Pt:BldC:Qn:Glucometer,glucose,Glucose post fast Glucometer (BldC) [Moles/Vol]; Fasting glucose [Moles/volume] in Capillary blood by Glucometer; Glucose p fast BldC Glucomtr-sCnc; Glucose^post Calorie fast:Substance Concentration:To identify measures at a point in time:Blood capillary:Quantitative:Glucometer,
C0797945,Glucose^post CFst:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^post Calorie fast:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose p fast SerPl-sCnc; Fasting glucose [Moles/volume] in Serum or Plasma; Glucose post fast [Moles/Vol],
C0798168,Glucose^2H post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2 Hr post 75 g glucose PO [Moles/Vol]; Glucose 2h p 75 g Glc PO SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --2 hours post 75 g glucose PO; Glucose^2 hours post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0798169,Glucose^pre 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^pre 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --pre 75 g glucose PO; Glucose pre 75 g Glc PO SerPl-sCnc; Glucose pre 75 g glucose PO [Moles/Vol],
C0798246,Glucose:SCnc:Pt:Bld:Qn,glucose,Glucose (Bld) [Moles/Vol]; Glucose:Substance Concentration:To identify measures at a point in time:Whole blood:Quantitative; Glucose Bld-sCnc; Glucose [Moles/volume] in Blood,
C0798247,Glucose:SCnc:Pt:Dial fld:Qn,glucose,Glucose:Substance Concentration:To identify measures at a point in time:Dialysis fluid:Quantitative; Glucose [Moles/volume] in Dialysis fluid; Glucose (Dial fld) [Moles/Vol]; Glucose Dial fld-sCnc,
C0798248,Glucose:SCnc:Pt:Urine:Qn,glucose,Glucose Ur-sCnc; Glucose (U) [Moles/Vol]; Glucose:Substance Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose [Moles/volume] in Urine,
C0798249,Glucose:SRat:24H:Urine:Qn,glucose,Glucose (24H U) [Moles/Time]; Glucose 24h Ur-sRate; Glucose [Moles/time] in 24 hour Urine; Glucose:Substance Rate:24 hours:Urine:Quantitative,
C0799330,Glucose^10 AM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --10 AM specimen; Glucose 10 AM specimen [Mass/Vol]; Glucose 10 AM SerPl-mCnc; Glucose^10 AM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0799331,Glucose^11 AM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --11 AM specimen; Glucose^11 AM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 11 AM SerPl-mCnc; Glucose 11 AM specimen [Mass/Vol],
C0799332,Glucose^2 PM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2 PM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2 PM specimen [Mass/Vol]; Glucose 2 PM SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --2 PM specimen,
C0799333,Glucose^3 PM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --3 PM specimen; Glucose 3 PM specimen [Mass/Vol]; Glucose^3 PM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3 PM SerPl-mCnc,
C0799334,Glucose^4 PM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4 PM SerPl-mCnc; Glucose 4 PM specimen [Mass/Vol]; Glucose^4 PM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --4 PM specimen,
C0799335,Glucose^5 PM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --5 PM specimen; Glucose 5 PM specimen [Mass/Vol]; Glucose^5 PM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5 PM SerPl-mCnc,
C0800037,Glucose:MCnc:Pt:Vitr fld:Qn,glucose,Glucose [Mass/volume] in Vitreous fluid; Glucose:Mass Concentration:To identify measures at a point in time:Vitreous Fluid:Quantitative; Glucose (Vitr fld) [Mass/Vol]; Glucose Vitf-mCnc,
C0800038,Glucose^1st specimen post XXX challenge:PrThr:Pt:Urine:Ord,glucose,Glucose^1st specimen post XXX challenge:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Glucose 1st specimen post Unsp challenge Ql (U); Glucose [Presence] in Urine --1st specimen post XXX challenge; Glucose sp1 p chal Ur Ql,
C0800039,Glucose^2nd specimen post XXX challenge:PrThr:Pt:Urine:Ord,glucose,Glucose [Presence] in Urine --2nd specimen post XXX challenge; Glucose sp2 p chal Ur Ql; Glucose^2nd specimen post XXX challenge:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Glucose 2nd specimen post Unsp challenge Ql (U),
C0800040,Glucose^3rd specimen post XXX challenge:PrThr:Pt:Urine:Ord,glucose,Glucose [Presence] in Urine --3rd specimen post XXX challenge; Glucose sp3 p chal Ur Ql; Glucose^3rd specimen post XXX challenge:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Glucose 3rd specimen post Unsp challenge Ql (U),
C0800041,Glucose^4th specimen post XXX challenge:PrThr:Pt:Urine:Ord,glucose,Glucose 4th specimen post Unsp challenge Ql (U); Glucose^4th specimen post XXX challenge:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Glucose sp4 p chal Ur Ql; Glucose [Presence] in Urine --4th specimen post XXX challenge,
C0800042,Glucose^5th specimen post XXX challenge:PrThr:Pt:Urine:Ord,glucose,Glucose [Presence] in Urine --5th specimen post XXX challenge; Glucose sp5 p chal Ur Ql; Glucose^5th specimen post XXX challenge:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Glucose 5th specimen post Unsp challenge Ql (U),
C0800043,Glucose^6th specimen post XXX challenge:PrThr:Pt:Urine:Ord,glucose,Glucose sp6 p chal Ur Ql; Glucose [Presence] in Urine --6th specimen post XXX challenge; Glucose^6th specimen post XXX challenge:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Glucose 6th specimen post Unsp challenge Ql (U),
C0800044,Glucose^7th specimen post XXX challenge:PrThr:Pt:Urine:Ord,glucose,Glucose [Presence] in Urine --7th specimen post XXX challenge; Glucose sp7 p chal Ur Ql; Glucose^7th specimen post XXX challenge:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Glucose 7th specimen post Unsp challenge Ql (U),
C0800045,Glucose^8th specimen post XXX challenge:PrThr:Pt:Urine:Ord,glucose,Glucose [Presence] in Urine --8th specimen post XXX challenge; Glucose^8th specimen post XXX challenge:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Glucose sp8 p chal Ur Ql; Glucose 8th specimen post Unsp challenge Ql (U),
C0800046,Glucose^9th specimen post XXX challenge:PrThr:Pt:Urine:Ord,glucose,Glucose^9th specimen post XXX challenge:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Glucose [Presence] in Urine --9th specimen post XXX challenge; Glucose 9th specimen post Unsp challenge Ql (U); Glucose sp9 p chal Ur Ql,
C0800047,Glucose^post CFst:PrThr:Pt:Urine:Ord,glucose,Glucose p fast Ur Ql; Glucose^post Calorie fast:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Fasting glucose [Presence] in Urine; Glucose post fast Ql (U),
C0800048,Glucose^post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose post Unsp challenge [Mass/Vol]; Glucose p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --post XXX challenge; Glucose^post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0800049,Glucose^post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose p meal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --post meal; Glucose^post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose post meal [Mass/Vol],
C0800116,Hydrogen/Expired gas^1.5H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Breath H2 1.5h p Glc; Hydrogen/Expired gas 1.5 Hr post dose glucose (Exhl gas) [Volume fraction]; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1.5 hours post dose glucose; Hydrogen/Expired gas^1.5 hours post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative,
C0800117,Hydrogen/Expired gas^1H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Breath H2 1h p Glc; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --1 hour post dose glucose; Hydrogen/Expired gas^1 hour post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Hydrogen/Expired gas 1 Hr post dose glucose (Exhl gas) [Volume fraction],
C0800118,Hydrogen/Expired gas^2.5H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Hydrogen/Expired gas 2.5 Hr post dose glucose (Exhl gas) [Volume fraction]; Breath H2 2.5h p Glc; Hydrogen/Expired gas^2.5 hours post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2.5 hours post dose glucose,
C0800119,Hydrogen/Expired gas^2H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Breath H2 2h p Glc; Hydrogen/Expired gas 2 Hr post dose glucose (Exhl gas) [Volume fraction]; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --2 hours post dose glucose; Hydrogen/Expired gas^2 hours post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative,
C0800120,Hydrogen/Expired gas^3.5H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --3.5 hours post dose glucose; Hydrogen/Expired gas 3.5 Hr post dose glucose (Exhl gas) [Volume fraction]; Hydrogen/Expired gas^3.5 hours post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Breath H2 3.5h p Glc,
C0800121,Hydrogen/Expired gas^3H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Hydrogen/Expired gas^3 hours post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Breath H2 3h p Glc; Hydrogen/Expired gas 3 Hr post dose glucose (Exhl gas) [Volume fraction]; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --3 hours post dose glucose,
C0800122,Hydrogen/Expired gas^4.5H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --4.5 hours post dose glucose; Hydrogen/Expired gas 4.5 Hr post dose glucose (Exhl gas) [Volume fraction]; Breath H2 4.5h p Glc; Hydrogen/Expired gas^4.5 hours post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative,
C0800123,Hydrogen/Expired gas^4H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Breath H2 4h p Glc; Hydrogen/Expired gas^4 hours post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Hydrogen/Expired gas 4 Hr post dose glucose (Exhl gas) [Volume fraction]; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --4 hours post dose glucose,
C0800124,Hydrogen/Expired gas^5.5H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Hydrogen/Expired gas 5.5 Hr post dose glucose (Exhl gas) [Volume fraction]; Hydrogen/Expired gas^5.5 hours post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --5.5 hours post dose glucose; Breath H2 5.5h p Glc,
C0800125,Hydrogen/Expired gas^5H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Breath H2 5h p Glc; Hydrogen/Expired gas 5 Hr post dose glucose (Exhl gas) [Volume fraction]; Hydrogen/Expired gas^5 hours post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --5 hours post dose glucose,
C0800126,Hydrogen/Expired gas^6H post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Hydrogen/Expired gas^6 hours post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --6 hours post dose glucose; Hydrogen/Expired gas 6 Hr post dose glucose (Exhl gas) [Volume fraction]; Breath H2 6h p Glc,
C0800127,Hydrogen/Expired gas^pre dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Hydrogen/Expired gas^pre dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Hydrogen/Expired gas pre dose glucose (Exhl gas) [Volume fraction]; Breath H2 pre Glc; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --pre dose glucose,
C0800128,Hydrogen/Expired gas^post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --post dose glucose; Breath H2 p Glc; Hydrogen/Expired gas^post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Hydrogen/Expired gas post dose glucose (Exhl gas) [Volume fraction],
C0800962,Hemoglobin A1c/Hemoglobin.total:MFr:Pt:Bld:Qn:Calculated,a1c,HbA1c Calc (Bld) [Mass fraction]; HbA1c MFr Bld Calc; Hemoglobin A1c/Hemoglobin.total:Mass Fraction:To identify measures at a point in time:Whole blood:Quantitative:Calculated; Hemoglobin A1c/Hemoglobin.total in Blood by calculation,
C0800963,Hemoglobin A1c/Hemoglobin.total:MFr:Pt:Bld:Qn:HPLC,a1c,Hemoglobin A1c/Hemoglobin.total:Mass Fraction:To identify measures at a point in time:Whole blood:Quantitative:HPLC; HbA1c HPLC (Bld) [Mass fraction]; HbA1c MFr Bld HPLC; Hemoglobin A1c/Hemoglobin.total in Blood by HPLC,
C0800972,Glucose^post 8H CFst:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^post 8 hours Calorie fast:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose p 8h fast SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --8 hours fasting; Glucose post 8 Hr fast [Mass/Vol],
C0801273,Glucose:MRat:6H:Urine:Qn,glucose,Glucose (6H U) [Mass/Time]; Glucose [Mass/time] in 6 hour Urine; Glucose 6h Ur-mRate; Glucose:Mass Rate:6 hours:Urine:Quantitative,
C0801274,Glucose-6-Phosphate dehydrogenase:PrThr:Pt:Tiss:Ord,glucose,"Glucose-6-Phosphate dehydrogenase:Presence or Threshold:To identify measures at a point in time:Tissue, unspecified:Ordinal; G6PD Tiss Ql; Glucose-6-Phosphate dehydrogenase [Presence] in Tissue; G6PD Ql (Tiss)",
C0801342,Glucose^post dose glucose:Imp:Pt:Ser/Plas:Nom,glucose,Glucose^post dose glucose:Impression/interpretation of study:To identify measures at a point in time:Serum/Plasma:Nominal; Glucose post dose glucose [Interp]; Glucose p Glc SerPl-Imp; Glucose [Interpretation] in Serum or Plasma--post dose glucose,
C0801384,Glucose^3H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3h p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --3 hours post XXX challenge; Glucose^3 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3 Hr post Unsp challenge [Mass/Vol],
C0801395,Glucose^6H post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 6h p 50 g Lac PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --6 hours post 50 g lactose PO; Glucose 6 Hr post 50 g lactose PO [Mass/Vol]; Glucose^6 hours post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0801396,Glucose^12H post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^12 hours post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --12 hours post 50 g lactose PO; Glucose 12 Hr post 50 g lactose PO [Mass/Vol]; Glucose 12h p 50 g Lac PO SerPl-mCnc,
C0802042,Glucose^1H post dose glucose:Imp:Pt:Ser/Plas:Nom,glucose,Glucose 1 Hr post dose glucose [Interp]; Glucose^1 hour post dose glucose:Impression/interpretation of study:To identify measures at a point in time:Serum/Plasma:Nominal; Glucose [Interpretation] in Serum or Plasma--1 hour post dose glucose; Glucose 1h p Glc SerPl-Imp,
C0802043,Glucose^3H post dose glucose:Imp:Pt:Ser/Plas:Nom,glucose,Glucose 3h p Glc SerPl-Imp; Glucose^3 hours post dose glucose:Impression/interpretation of study:To identify measures at a point in time:Serum/Plasma:Nominal; Glucose [Interpretation] in Serum or Plasma--3 hours post dose glucose; Glucose 3 Hr post dose glucose [Interp],
C0803221,Deprecated Glucose [Mass/volume] in Urine by Test strip,glucose,Glucose Test strip (U) [Mass fraction],
C0803251,Glucose^2H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --2 hours post dose glucose; Glucose^2 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2 Hr post dose glucose [Mass/Vol]; Glucose 2h p Glc SerPl-mCnc,
C0803252,Glucose^3H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^3 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3 Hr post dose glucose [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --3 hours post dose glucose; Glucose 3h p Glc SerPl-mCnc,
C0803253,Glucose^1H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --1 hour post dose glucose; Glucose 1h p Glc SerPl-mCnc; Glucose 1 Hr post dose glucose [Mass/Vol]; Glucose^1 hour post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0803254,Glucose^30M post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30 Min post dose glucose [Mass/Vol]; Glucose 30M p Glc SerPl-mCnc; Glucose^30 minutes post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose glucose,
C0803255,Glucose^1.5H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose glucose; Glucose 1.5 Hr post dose glucose [Mass/Vol]; Glucose^1.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5h p Glc SerPl-mCnc,
C0803256,Glucose^post 50 g glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose post 50 g glucose [Mass/Vol]; Glucose p 50 g Glc SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --post 50 g glucose; Glucose^post 50 g glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0803801,Glucose tolerance:Impression/interpretation of study:Point in time:Serum/Plasma:Nominal,glucose,Glucose tolerance [Interp]; Glucose tolerance:Impression/interpretation of study:To identify measures at a point in time:Serum/Plasma:Nominal; Glucose tolerance [Interpretation] in Serum or Plasma; GTT SerPl-Imp; Glucose tolerance:Imp:Pt:Ser/Plas:Nom,
C0804099,Glucose:MCnc:24H:Urine:Qn,glucose,Glucose 24h Ur-mCnc; Glucose (24H U) [Mass/Vol]; Glucose [Mass/volume] in 24 hour Urine; Glucose:Mass Concentration:24 hours:Urine:Quantitative,
C0804100,Glucose:MRat:8H:Urine:Qn,glucose,Glucose 8h Ur-mRate; Glucose [Mass/time] in 8 hour Urine; Glucose (8H U) [Mass/Time]; Glucose:Mass Rate:8 hours:Urine:Quantitative,
C0804101,Glucose:MRat:10H:Urine:Qn,glucose,Glucose 10h Ur-mRate; Glucose [Mass/time] in 10 hour Urine; Glucose (10H U) [Mass/Time]; Glucose:Mass Rate:10 hours:Urine:Quantitative,
C0804102,Glucose^105M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 105M p chal SerPl-mCnc; Glucose 105 Min post Unsp challenge [Mass/Vol]; Glucose^105M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --105 minutes post XXX challenge,
C0804103,Glucose^45M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --45 minutes post XXX challenge; Glucose^45M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 45M p chal SerPl-mCnc; Glucose 45 Min post Unsp challenge [Mass/Vol],
C0804104,Glucose^75M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^75M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --75 minutes post XXX challenge; Glucose 75M p chal SerPl-mCnc; Glucose 75 Min post Unsp challenge [Mass/Vol],
C0806334,Hemoglobin A1c/Hemoglobin.total,a1c,Hemoglobin A1c/Hemoglobin.total,
C0810032,Pancreatic disorders (not diabetes),diabetes,Pancreatic disorders (not diabetes),
C0810044,Diabetes or abnormal glucose tolerance complicating pregnancy; childbirth; or the puerperium,glucose,Diabetes or abnormal glucose tolerance complicating pregnancy; childbirth; or the puerperium,
C0810250,Diabetes with ketoacidosis or uncontrolled diabetes,diabetes,,
C0810251,Diabetes with circulatory manifestations,diabetes,,
C0810252,Diabetes with other manifestations,diabetes,,
C0850356,diabetes education,diabetes,diabetes education; education diabetes,
C0850671,Non-diabetic hyperglycemia,hyperglycemia,Non-diabetic hyperglycemia (disorder); Non-diabetic hyperglycaemia,
C0851207,"Pre-existing diabetes mellitus, Type 1, in pregnancy",diabetes,Pre-existing type 1 diabetes mellitus in pregnancy (disorder); Pre-existing type 1 diabetes mellitus in pregnancy,
C0851208,"Pre-existing diabetes mellitus, Type 2, in pregnancy",diabetes,Pre-existing type 2 diabetes mellitus in pregnancy (disorder); Pre-existing type 2 diabetes mellitus in pregnancy,
C0851209,"Pre-existing malnutrition-related diabetes mellitus, predominantly related to pregnancy",diabetes,,
C0851217,"Pre-existing diabetes mellitus, unspecified, in pregnancy",diabetes,,
C0853897,Diabetic Cardiomyopathies,diabetes,"Cardiomyopathies, Diabetic; Diabetic cardiomyopathy; diabetic cardiomyopathy; Cardiomyopathy, Diabetic; Diabetic Cardiomyopathy; Cardiomyopathy due to diabetes mellitus; Cardiomyopathy due to diabetes mellitus (disorder)",
C0854110,Insulin-resistant diabetes mellitus,diabetes,"Diabetes mellitus, insulin-resistant; DIABETES MELLITUS, INSULIN-RESISTANT; Insulin-resistant diabetes; diabetes insulin resistant; insulin resistant diabetes; Insulin-resistant diabetes mellitus; Insulin resistant diabetes; Insulin resistant diabetes mellitus; diabetes resistant insulin",
C0856426,Normal plasma glucose,plasma glucose,,
C0857512,Hyper IgE,hyper,hyper ige; hie,
C0858734,insulin hypoglycemia,hypoglycemia,hypoglycemia insulin,
C0860800,Normal glucose,normal glucose,normal glucose; glucose normal,
C0860801,Glucose low,low glucose,decreased glucose; glucose low; low glucose,
C0860803,glucose high,high glucose,increased glucose; high glucose; glucose increased,
C0861117,glucose urine abnormal,glucose,urine glucose abnormal,
C0863147,glucose urine increased,glucose,high urine glucose; glucose high urine; elevated glucose urine; glucose increased urine,
C0863150,glucose urine normal,glucose,glucose normal urine; normal urine glucose,
C0865160,Hyper-TBG-nemia,hyper,,
C0865161,Hypo-TBG-nemia,hypo,,
C0865162,Diabetes mellitus without mention of complication or manifestation,diabetes,,
C0865166,diabetic hypoglycemia,hypoglycemia,Diabetic hypoglycemia NOS,
C0865194,Intolerance or malabsorption of glucose-galactose,glucose,,
C0865195,Congenital intolerance or malabsorption of glucose-galactose,glucose,,
C0865212,Autosomal recessive immunodeficiency with hyper-IgM,hyper,,
C0872182,"Monitors, Physiologic, Glucose, Personal",glucose,"glucose monitors; Glucose Monitors; Monitors, Personal, Glucose; monitor glucose; glucose monitor; Glucose monitor; Glucose Physiologic Personal Monitors",
C0872382,glucose sensor device,glucose,glucose sensors; GLUCOSE SENSOR; glucose sensor,
C0874530,Glucose 250 MG/ML Injectable Solution,glucose,glucose 250 MG/ML Injectable Solution; dextrose 250 MG/ML Injectable Solution; glucose 25% intravenous solution,
C0876291,Assure Blood Glucose Kit,blood glucose,,
C0876297,Atlast Blood Glucose System,blood glucose,,
C0876418,Precision Extra Glucose Monitor,glucose,,
C0876420,Precision Glucose/Ketone High/Low,glucose,,
C0876777,Accu-Chek Easy II Glucose Control,glucose,,
C0878684,SHORT syndrome,diabetes,"short syndrome; SHORT SYNDROME; Rieger anomaly-partial lipodystrophy syndrome; SHORT syndrome; Lipodystrophy-Rieger anomaly-diabetes syndrome; SHORT STATURE, HYPEREXTENSIBILITY, HERNIA, OCULAR DEPRESSION, RIEGER ANOMALY, AND TEETHING DELAY; LIPODYSTROPHY, PARTIAL, WITH RIEGER ANOMALY AND SHORT STATURE; syndrome short; Lipodystrophy, Partial, With Rieger Anomaly, And Short Stature",
C0879441,O6-Benzylguanine/Polifeprosan 20 With Carmustine Implant,BG,O6-benzylguanine/polifeprosan 20 with carmustine implant; BG/Gliadel,
C0879518,O6-benzylguanine/Temozolomide,BG,O6-benzylguanine/temozolomide; BG/TMZ,
C0879630,Blood Glucose Analyzers,blood glucose,,
C0880214,Glucose:SCnc:Pt:Urine:Qn:Test strip,glucose,Glucose [Moles/volume] in Urine by Test strip; Glucose Test strip (U) [Moles/Vol]; Glucose Ur Strip-sCnc; Glucose:Substance Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip,
C0882496,Glucose tolerance 2H gestational panel:-:-:Urine+Ser/Plas:Qn,glucose,Glucose tolerance 2 hours gestational panel (U+S/P); Glucose tolerance 2 hours gestational panel - Urine and Serum or Plasma; Glucose tolerance 2H gestational panel:-:-:Urine+Serum/Plasma:Quantitative; GTT gest 2h Pnl Ur+SerPl,
C0883087,Glucose tolerance gestational panel,glucose,Glucose tolerance gestational panel,
C0887283,"Glucose, (alpha-D)-Isomer",glucose,,
C0887284,"Glucose, (beta-D)-Isomer",glucose,,
C0887285,"Glucose, (DL)-Isomer",glucose,,
C0888758,"3-deoxy-3-fluoro-D-glucose, 18F-labeled",glucose,,
C0892105,"glucose-1-phosphate, (beta-D-Glc)-isomer",glucose,,
C0892106,"glucose-1-phosphate, sodium salt, (D-Glc)-isomer",glucose,,
C0892107,"glucose-1-phosphate, dipotassium salt, (D-Glc)-isomer",glucose,,
C0892108,"glucose-1-phosphate, disodium salt, (D-Glc)-isomer",glucose,,
C0892109,"glucose-1-phosphate, disodium salt",glucose,,
C0892110,"glucose-1-phosphate, dipotassium salt",glucose,,
C0892111,"glucose-1-phosphate, lead salt",glucose,,
C0892112,"glucose-1-phosphate, monocalcium salt",glucose,,
C0892113,"glucose-1-phosphate, (D-Glc)-isomer",glucose,,
C0892526,"3-deoxy-3-iodo-D-glucose, 131I-labeled",glucose,,
C0892527,"3-deoxy-3-iodo-D-glucose, 123I-labeled",glucose,,
C0893289,"guanosine diphosphate glucose, 14C-labeled",glucose,,
C0893290,"guanosine diphosphate glucose, (D)-isomer",glucose,,
C0893395,"glucose pentaacetate, (beta-(D))-isomer",glucose,beta-D-glucose pentaacetate,
C0893396,"glucose pentaacetate, (alpha-D)-isomer",glucose,,
C0893397,"glucose pentaacetate, (D)-isomer",glucose,,
C0901054,glucose(13C)ureide,glucose,,
C0910124,glucose-2-SNAP,glucose,,
C0911387,Tc-99m-thio-D-glucose,glucose,,
C0911388,Tc(99)-m-5-thio-d-glucose,glucose,,
C0911488,UDP-glucose - salicylic acid glucosyltransferase,glucose,SA GTase,
C0911489,UDP-glucose - salicylic acid carboxylglucosyltransferase,glucose,UDPG - SA carboxyl GTase,
C0912160,diacetone glucose butyrate,glucose,"3-O-butanoyl-1,2:5,6-di-O-isopropylidene-alpha-D-glucose",
C0912161,glucose pentabutyrate,glucose,"1,2,3,4,6-penta-O-butanoyl-alpha-D-glucose",
C0912555,glucose-6-phosphate dehydrogenase Aveiro,glucose,glucose-6-phosphate dehydrogenase Aveiro; G6PD Aveiro,
C0912825,"dNDPglucose 4,6-dehydratase",glucose,"dNDP-glucose 4,6-dehydratase",
C0915389,galactopyranosyl-(1-3)-galactopyranosyl-(1-4)-glucose,glucose,Gal-Gal-Glu; beta-D-galactopyranosyl-(1-3)-beta-D-galactopyranosyl-(1-4)-D-glucose,
C0916806,all-beta-D-glucose of (1-3)glucopentaose peracetate,glucose,,
C0917952,Blood Glucose Reflectance Photometers,blood glucose,,
C0917953,Home blood glucose monitor,blood glucose,,
C0919455,RRAD gene,diabetes,"RAD POLYMORPHISM 1; RAS-RELATED ASSOCIATED WITH DIABETES; RRAD, Ras Related Glycolysis Inhibitor and Calcium Channel Regulator Gene; RAS GENE ASSOCIATED WITH DIABETES; REM3; Ras-related associated with diabetes; RAD; RRAD; RRAD, Ras related glycolysis inhibitor and calcium channel regulator; RRAD gene; RRAD RAS-RELATED GLYCOLYSIS INHIBITOR AND CALCIUM CHANNEL REGULATOR; RRAD, Ras related glycolysis inihibitor and calcium channel regulator; RAD1; RRAD Gene",
C0939569,Glucose 5% Nursette,glucose,,
C0941572,Glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose Test strip Ql (U); Glucose [Presence] in Urine by Test strip; Glucose Ur Ql Strip; Glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0941756,Glucose^15M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose glucose; Glucose 15M p Glc SerPl-sCnc; Glucose^15 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15 Min post dose glucose [Moles/Vol],
C0941757,Glucose^1H post dose glucose:MCnc:Pt:Urine:Qn,glucose,Glucose 1h p Glc Ur-mCnc; Glucose [Mass/volume] in Urine --1 hour post dose glucose; Glucose^1 hour post dose glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 1 Hr post dose glucose (U) [Mass/Vol],
C0941758,Glucose^1H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p chal SerPl-sCnc; Glucose 1 Hr post Unsp challenge [Moles/Vol]; Glucose^1 hour post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --1 hour post XXX challenge,
C0941759,Glucose^2H post dose glucose:MCnc:Pt:Urine:Qn,glucose,Glucose 2 Hr post dose glucose (U) [Mass/Vol]; Glucose 2h p Glc Ur-mCnc; Glucose [Mass/volume] in Urine --2 hours post dose glucose; Glucose^2 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative,
C0941760,Glucose^2H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --2 hours post XXX challenge; Glucose 2h p chal SerPl-sCnc; Glucose 2 Hr post Unsp challenge [Moles/Vol]; Glucose^2 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0941761,Glucose^3.5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^3.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3.5 Hr post dose glucose [Moles/Vol]; Glucose 3.5h p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --3.5 hours post dose glucose,
C0941762,Glucose^30M post dose glucose:MCnc:Pt:Urine:Qn,glucose,Glucose 30 Min post dose glucose (U) [Mass/Vol]; Glucose 30M p Glc Ur-mCnc; Glucose [Mass/volume] in Urine --30 minutes post dose glucose; Glucose^30 minutes post dose glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative,
C0941763,Glucose^30M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^30 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge; Glucose 30 Min post Unsp challenge [Moles/Vol]; Glucose 30M p chal SerPl-sCnc,
C0941764,Glucose^4.5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4.5 Hr post dose glucose [Moles/Vol]; Glucose 4.5h p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --4.5 hours post dose glucose; Glucose^4.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0941765,Glucose^45M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 45 Min post dose glucose [Moles/Vol]; Glucose 45M p Glc SerPl-sCnc; Glucose^45M post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose glucose,
C0941766,Glucose^45M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^45M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 45M p chal SerPl-sCnc; Glucose 45 Min post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --45 minutes post XXX challenge,
C0941767,Glucose^4H post dose glucose:MCnc:Pt:Urine:Qn,glucose,Glucose 4h p Glc Ur-mCnc; Glucose^4 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 4 Hr post dose glucose (U) [Mass/Vol]; Glucose [Mass/volume] in Urine --4 hours post dose glucose,
C0941768,Glucose^5.5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5.5h p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --5.5 hours post dose glucose; Glucose 5.5 Hr post dose glucose [Moles/Vol]; Glucose^5.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0941769,Glucose^6H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 6 Hr post dose glucose [Moles/Vol]; Glucose^6 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 6h p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --6 hours post dose glucose,
C0941770,Glucose^1.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5h p chal SerPl-sCnc; Glucose^1.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --1.5 hours post XXX challenge,
C0941771,Glucose^pre 50 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre 50 g Glc PO SerPl-sCnc; Glucose^pre 50 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre 50 g glucose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --pre 50 g glucose PO,
C0941792,Ketones^1H post 50 g glucose PO:PrThr:Pt:Urine:Ord,glucose,Ketones 1 Hr post 50 g glucose PO Ql (U); Ketones^1 hour post 50 g glucose Oral:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal; Ketones [Presence] in Urine --1 hour post 50 g glucose PO; Ketones 1h p 50 g Glc PO Ur Ql,
C0941793,Ketones^2H post dose glucose:MCnc:Pt:Urine:Qn:Test strip,glucose,Ketones 2h p Glc Ur Strip-mCnc; Ketones [Mass/volume] in Urine by Test strip --2 hours post dose glucose; Ketones^2 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip; Ketones 2 Hr post dose glucose Test strip (U) [Mass/Vol],
C0941794,Ketones^4H post dose glucose:MCnc:Pt:Urine:Qn:Test strip,glucose,Ketones [Mass/volume] in Urine by Test strip --4 hours post dose glucose; Ketones 4h p Glc Ur Strip-mCnc; Ketones^4 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip; Ketones 4 Hr post dose glucose Test strip (U) [Mass/Vol],
C0941965,Glucose:SCnc:24H:Urine:Qn,glucose,Glucose:Substance Concentration:24 hours:Urine:Quantitative; Glucose [Moles/volume] in 24 hour Urine; Glucose (24H U) [Moles/Vol]; Glucose 24h Ur-sCnc,
C0942491,Glucose^2.5H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose [Presence] in Urine by Test strip --2.5 hours post dose glucose; Glucose^2.5 hours post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 2.5 Hr post dose glucose Test strip Ql (U); Glucose 2.5h p Glc Ur Ql Strip,
C0942492,Glucose^45M post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 45 Min post dose glucose [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --45 minutes post dose glucose; Glucose^45M post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 45M p Glc SerPl-mCnc,
C0942493,Glucose^3H post dose glucose:MCnc:Pt:Urine:Qn,glucose,Glucose^3 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 3 Hr post dose glucose (U) [Mass/Vol]; Glucose [Mass/volume] in Urine --3 hours post dose glucose; Glucose 3h p Glc Ur-mCnc,
C0942494,Glucose^4H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^4 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4 Hr post dose glucose [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --4 hours post dose glucose; Glucose 4h p Glc SerPl-mCnc,
C0942495,Glucose^5H post dose glucose:MCnc:Pt:Urine:Qn,glucose,Glucose [Mass/volume] in Urine --5 hours post dose glucose; Glucose 5 Hr post dose glucose (U) [Mass/Vol]; Glucose 5h p Glc Ur-mCnc; Glucose^5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative,
C0942496,Glucose^5H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --5 hours post dose glucose; Glucose 5 Hr post dose glucose [Mass/Vol]; Glucose 5h p Glc SerPl-mCnc; Glucose^5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0942497,Glucose^6H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^6 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --6 hours post dose glucose; Glucose 6h p Glc SerPl-mCnc; Glucose 6 Hr post dose glucose [Mass/Vol],
C0942498,Glucose^6H post dose glucose:MCnc:Pt:Urine:Qn,glucose,Glucose^6 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose [Mass/volume] in Urine --6 hours post dose glucose; Glucose 6 Hr post dose glucose (U) [Mass/Vol]; Glucose 6h p Glc Ur-mCnc,
C0942499,Glucose^1H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose^1 hour post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose [Presence] in Urine by Test strip --1 hour post dose glucose; Glucose 1h p Glc Ur Ql Strip; Glucose 1 Hr post dose glucose Test strip Ql (U),
C0942500,Glucose^2H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose 2h p Glc Ur Ql Strip; Glucose 2 Hr post dose glucose Test strip Ql (U); Glucose [Presence] in Urine by Test strip --2 hours post dose glucose; Glucose^2 hours post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0942501,Glucose^30M post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose^30 minutes post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 30M p Glc Ur Ql Strip; Glucose [Presence] in Urine by Test strip --30 minutes post dose glucose; Glucose 30 Min post dose glucose Test strip Ql (U),
C0942502,Glucose^3H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose [Presence] in Urine by Test strip --3 hours post dose glucose; Glucose 3 Hr post dose glucose Test strip Ql (U); Glucose^3 hours post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 3h p Glc Ur Ql Strip,
C0942503,Glucose^4H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose 4h p Glc Ur Ql Strip; Glucose [Presence] in Urine by Test strip --4 hours post dose glucose; Glucose^4 hours post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 4 Hr post dose glucose Test strip Ql (U),
C0942504,Glucose^5H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose 5h p Glc Ur Ql Strip; Glucose 5 Hr post dose glucose Test strip Ql (U); Glucose [Presence] in Urine by Test strip --5 hours post dose glucose; Glucose^5 hours post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0942505,Glucose^6H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose [Presence] in Urine by Test strip --6 hours post dose glucose; Glucose 6h p Glc Ur Ql Strip; Glucose 6 Hr post dose glucose Test strip Ql (U); Glucose^6 hours post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0942506,Glucose^2.5H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2.5h p Glc SerPl-mCnc; Glucose^2.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --2.5 hours post dose glucose; Glucose 2.5 Hr post dose glucose [Mass/Vol],
C0942507,Glucose^3.5H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^3.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --3.5 hours post dose glucose; Glucose 3.5 Hr post dose glucose [Mass/Vol]; Glucose 3.5h p Glc SerPl-mCnc,
C0942624,Glucose^7th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose sp7 p chal SerPl-mCnc; Glucose 7th specimen post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge; Glucose^7th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0942692,Glucose^1H post dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p Lac PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1 hour post dose lactose PO; Glucose^1 hour post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1 Hr post dose lactose PO [Mass/Vol],
C0942693,Glucose^2H post dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2 Hr post dose lactose PO [Mass/Vol]; Glucose^2 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --2 hours post dose lactose PO; Glucose 2h p Lac PO SerPl-mCnc,
C0942694,Glucose^5H post dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --5 hours post dose lactose PO; Glucose 5h p Lac PO SerPl-mCnc; Glucose 5 Hr post dose lactose PO [Mass/Vol]; Glucose^5 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0942723,Glucose^11H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --11 hour post XXX challenge; Glucose 11 Hr post Unsp challenge [Mass/Vol]; Glucose 11h p chal SerPl-mCnc; Glucose^11H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0942751,Glucose^7th specimen post XXX challenge:ACnc:Pt:Ser/Plas:Qn,glucose,Glucose sp7 p chal SerPl-aCnc; Glucose [Units/volume] in Serum or Plasma --7th specimen post XXX challenge; Glucose^7th specimen post XXX challenge:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 7th specimen post Unsp challenge Qn,
C0942752,Glucose^8th specimen post XXX challenge:ACnc:Pt:Ser/Plas:Qn,glucose,Glucose sp8 p chal SerPl-aCnc; Glucose^8th specimen post XXX challenge:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 8th specimen post Unsp challenge Qn; Glucose [Units/volume] in Serum or Plasma --8th specimen post XXX challenge,
C0943165,Estimated average glucose:MCnc:Pt:Bld:Qn:Estimated from glycated hemoglobin,glucose,Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin; Est. average glucose Bld gHb Est-mCnc; Average glucose Estimated from glycated hemoglobin (Bld) [Mass/Vol]; Estimated average glucose:Mass Concentration:To identify measures at a point in time:Whole blood:Quantitative:Estimated from glycated hemoglobin,
C0943522,Insulin^1H post 75 g glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin [Units/volume] in Serum or Plasma --1 hour post 75 g glucose PO; Insulin 1h p 75 g Glc PO SerPl-aCnc; Insulin^1 hour post 75 g glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 1 Hr post 75 g glucose PO Qn,
C0943524,Insulin^7H post 75 g glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin [Units/volume] in Serum or Plasma --7 hours post 75 g glucose PO; Insulin 7 Hr post 75 g glucose PO Qn; Insulin 7h p 75 g Glc PO SerPl-aCnc; Insulin^7 hours post 75 g glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0943525,Insulin 1.5H p 75 g Glc PO SerPl-aCnc,glucose,Insulin^1.5 hours post 75 g glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 1.5h p 75 g Glc PO SerPl-aCnc; Insulin [Units/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO; Insulin 1.5 Hr post 75 g glucose PO Qn; Insulin^1.5H post 75 g glucose PO:ACnc:Pt:Ser/Plas:Qn,
C0943549,Insulin^2H post 75 g glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin [Units/volume] in Serum or Plasma --2 hours post 75 g glucose PO; Insulin 2h p 75 g Glc PO SerPl-aCnc; Insulin^2 hours post 75 g glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 2 Hr post 75 g glucose PO Qn,
C0943550,Insulin^3H post 75 g glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin 3 Hr post 75 g glucose PO Qn; Insulin [Units/volume] in Serum or Plasma --3 hours post 75 g glucose PO; Insulin^3 hours post 75 g glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 3h p 75 g Glc PO SerPl-aCnc,
C0943551,Insulin^4H post 75 g glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin 4h p 75 g Glc PO SerPl-aCnc; Insulin [Units/volume] in Serum or Plasma --4 hours post 75 g glucose PO; Insulin^4 hours post 75 g glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 4 Hr post 75 g glucose PO Qn,
C0943560,Insulin^6H post 75 g glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin 6 Hr post 75 g glucose PO Qn; Insulin [Units/volume] in Serum or Plasma --6 hours post 75 g glucose PO; Insulin 6h p 75 g Glc PO SerPl-aCnc; Insulin^6 hours post 75 g glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0944796,Glucose^4H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --4 hours post XXX challenge; Glucose 4h p chal SerPl-mCnc; Glucose^4 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0944797,Glucose^5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --5 hours post XXX challenge; Glucose 5h p chal SerPl-mCnc,
C0944798,Glucose^2.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2.5 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --2.5 hours post XXX challenge; Glucose 2.5h p chal SerPl-mCnc; Glucose^2.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0945252,Glucose^2.5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2.5h p Glc SerPl-sCnc; Glucose 2.5 Hr post dose glucose [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --2.5 hours post dose glucose; Glucose^2.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0945253,Glucose^1.5H post dose glucose:MCnc:Pt:Urine:Qn,glucose,Glucose 1.5h p Glc Ur-mCnc; Glucose [Mass/volume] in Urine --1.5 hours post dose glucose; Glucose 1.5 Hr post dose glucose (U) [Mass/Vol]; Glucose^1.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative,
C0945368,Glucose^3.5H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose 3.5h p Glc Ur Ql Strip; Glucose 3.5 Hr post dose glucose Test strip Ql (U); Glucose [Presence] in Urine by Test strip --3.5 hours post dose glucose; Glucose^3.5 hours post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C0945369,Glucose^1.5H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Glucose 1.5h p Glc Ur Ql Strip; Glucose [Presence] in Urine by Test strip --1.5 hours post dose glucose; Glucose^1.5 hours post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip; Glucose 1.5 Hr post dose glucose Test strip Ql (U),
C0945403,Glucose^1.5H post dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5h p Lac PO SerPl-mCnc; Glucose^1.5 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose lactose PO; Glucose 1.5 Hr post dose lactose PO [Mass/Vol],
C0945404,Glucose^4H post dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4 Hr post dose lactose PO [Mass/Vol]; Glucose^4 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --4 hours post dose lactose PO; Glucose 4h p Lac PO SerPl-mCnc,
C0945506,Glucose^8th specimen post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 8th specimen post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge; Glucose sp8 p chal SerPl-mCnc; Glucose^8th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0945746,Glucose^6H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 6 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --6 hours post XXX challenge; Glucose 6h p chal SerPl-mCnc; Glucose^6 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0947224,Glucose^30M post dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^30 minutes post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min post dose lactose PO [Mass/Vol]; Glucose 30M p Lac PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose lactose PO,
C0947225,Glucose^3H post dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3 Hr post dose lactose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --3 hours post dose lactose PO; Glucose 3h p Lac PO SerPl-mCnc; Glucose^3 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C0947266,Glucose^3.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3.5 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --3.5 hours post XXX challenge; Glucose^3.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3.5h p chal SerPl-mCnc,
C0948092,diabetes mellitus management,diabetes,diabetes mellitus therapies; diabetes management mellitus; diabetes managements mellitus; diabetes mellitus therapy,
C0948275,Somogyi phenomenon,hyperglycemia,Post hypoglycemic hyperglycemia due to diabetes mellitus (disorder); Post hypoglycaemic hyperglycaemia due to diabetes mellitus; somogyi effect; somogyi phenomenon; effect somogyi; Post hypoglycemic hyperglycemia due to diabetes mellitus,
C0950503,alpha-glucose-1-phosphate,glucose,,
C0951156,"5-thio-D-glucose, 6-phosphate",glucose,,
C0952235,"glucose 6-(hydrogen sulfate), monosodium salt, (D)-isomer",glucose,,
C0952236,"glucose 6-(hydrogen sulfate), monopotassium salt, (D)-isomer",glucose,,
C0953226,"N-fluoroacetyl-D-glucosamine, alpha-D-glucose isomer",glucose,,
C0953227,"N-fluoroacetyl-D-glucosamine, beta-D-glucose isomer",glucose,,
C0953733,aquo-MetHb A1C,a1c,,
C0957025,"t-cinnamoyl glucose, (beta-D)-isomer",glucose,,
C0959567,"dodecyl laminarapentaoside peracetate, all-beta-D-glucose",glucose,,
C0960291,lysozyme-glucose stearic acid monoester,glucose,HEL-GE,
C0962925,UDP-glucose baicalein 7-O-glucosyltransferase,glucose,UBGT enzyme,
C0964414,UDP-glucose hydroxamic acid glucosyltransferase,glucose,UDP-glucose Hx glucosyltransferase,
C0967100,"4,6-O-isoterchebuloylglucose",glucose,"4,6-O-isoterchebuloyl-D-glucose; 4,6-O-iso-terchebuloylglucose",
C0967709,"SLC2A10 protein, human",glucose,"solute carrier family 2 (facilitated glucose transporter), member 10, human; GLUT10 protein, human",
C0968027,"1-O-galloyl-6-O-(4-hydroxy-3,5-dimethoxy)benzoylglucose",glucose,GHDB glucose,
C0968028,"1-O-galloyl-6-O-(4-hydroxy-3,5-dimethoxy)benzoyl-beta-D-glucose",glucose,,
C0968751,cercidinin A,glucose,"1,2,6-tri-O-galloyl-3,4-(R)-hexahydroxydiphenoyl-beta-D-glucose",
C0971438,cyclo-tetra-glucose,glucose,,
C0972486,Glucose Phosphate Isomerase Determination Reagents,glucose,"Reagents, Clinical Chemistry, Enzyme, Glucose Phosphate Isomerase; Phosphohexose Isomerase Reagents; Phosphohexose Isomerase Determination Reagents",
C0972539,"Glucose Determination Reagents, Rapid Test",glucose,"Reagents, Clinical Chemistry, Rapid Test, Whole Blood, Glucose",
C0972546,"Reagents, Clinical Chemistry, Saccharide, Glucose",glucose,,
C0972598,"Reagents, Home-Test Kit, Urine, Glucose",glucose,,
C0972608,Glucose Determination Reagent Kits,glucose,"Reagents, Home-Test Kit, Whole Blood, Glucose",
C0972628,Diabetes Autoimmune Test Reagents,diabetes,"Autoimmune Test Reagents, Diabetes; Reagents, Immunoassay, Autoimmune, Diabetes",
C0972640,C-Peptide Determination Reagents,diabetes,"Reagents, Immunoassay, Diabetes, C-Peptide",
C0972641,Insulin Determination Reagents,diabetes,"Reagents, Immunoassay, Diabetes, Insulin",
C0973161,"Reagents, Immunoassay, Diabetes",diabetes,,
C0973735,ACCU-CHEK COMFORT CURVE (GLUCOSE) HI/LO CONTROL SOLN,glucose,ACCU-CHEK COMFORT CURVE HI/LO CONTL SOLN,
C0973736,ACCU-CHEK COMFORT CURVE (GLUCOSE) HI/MED/LO CONTROL SOLN,glucose,ACCU-CHEK COMFORT CURVE H/M/L CNTRL SOLN,
C0973740,ACCU-CHEK INSTANT (GLUCOSE) CONTROL SOLN,glucose,ACCU-CHEK INSTANT (GLUCOSE) CONTROL SOLN,
C0973741,ACCU-CHEK INSTANT (GLUCOSE) METER,glucose,Accu-Chek Instant; ACCU-CHEK INSTANT (GLUCOSE) METER,
C0973742,ACCU-CHEK INSTANT (GLUCOSE) TEST STRIP,glucose,ACCU-CHEK INSTANT (GLUCOSE) TEST STRIP,
C0973832,ADVANTAGE (ACCU-CHEK GLUCOSE) METER,glucose,ADVANTAGE (ACCU-CHEK GLUCOSE) METER,
C0973833,ADVANTAGE (ACCU-CHEK GLUCOSE) TEST STRIP,glucose,ADVANTAGE ACCU-CHEK GLUCOSE TEST STRIP; Accu-Chek Advantage Strip,
C0974267,Alanine 4.22 MG/ML / Arginine 4.32 MG/ML / Aspartate 2.98 MG/ML / Glucose 100 MG/ML / Glutamate 3.14 MG/ML / Glycine 2.12 MG/ML / Histidine 1.28 MG/ML / Isoleucine 2.8 MG/ML / Leucine 4.25 MG/ML / Lysine 4.46 MG/ML / Magnesium Chloride 0.00148 MEQ/ML / Methionine 0.73 MG/ML / Phenylalanine 1.26 MG/ML / Potassium Chloride 0.013 MEQ/ML / Proline 3.07 MG/ML / Serine 2.25 MG/ML / Sodium Chloride 0.0205 MEQ/ML / sodium phosphate 0.00347 MEQ/ML / Threonine 1.7 MG/ML / Tryptophan 0.85 MG/ML / Tyrosine 1.15 MG/ML / Valine 2.12 MG/ML Injectable Solution [Aminosyn II 4.5 % M in 10 % Dextrose],glucose,,
C0975495,"CHEMSTRIP 2 GP (GLUCOSE,PROTEIN) TEST STRIP",glucose,"Chemstrip 2 GP; Chemstrip 2 Strip; CHEMSTRIP 2GP GLUCOSE,PROTEIN TEST STRIP",
C0975504,CHEMSTRIP BG ACCU-CHEK/VISUAL TEST STRIP,BG,Chemstrip BG Accu-Chek Strip; CHEMSTRIP BG ACCU-CHEK/VISUAL TEST STRIP,
C0976227,glucose 0.417 MG/MG Oral Gel,glucose,glucose 25 GM per 60 GM Oral Gel; DEXTROSE 25GM/60GM SQUEEZE TUBE,
C0976237,Glucose 50 MG/ML Injectable Solution,glucose,"DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Veterinary 5% Dextrose]; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.9 g in 100 mL INTRAVENOUS SOLUTION [Sykes 5% Dextrose and 0.9% Sodium Chloride]; DEXTROSE 5% INJ_#1; dextrose 5 GM per 100 ML Injectable Solution; glucose 50 MG/ML Injectable Solution; dextrose 5 % Injectable Solution; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS SOLUTION [Sykes 5% Dextrose]; dextrose 50 MG/ML Injectable Solution; DEXTROSE MONOHYDRATE 50 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Veterinary Dextrose]",
C0976244,1000 ML glucose 50 MG/ML / potassium chloride 0.03 MEQ/ML Injection,glucose,potassium chloride 30 MEQ / dextrose 5 % in 1000 ML Injection; potassium chloride 30 MEQ / glucose 5 % per 1000 ML Injection; potassium chloride 30 MEQ / dextrose 5 % per 1000 ML Injection; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.03 MEQ/ML Injection; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.03 MEQ/ML Injection; dextrose 5 % / potassium chloride 30 MEQ per 1000 ML Injection; DEXTROSE 5%/KCL 30MEQ/L INJ,
C0976245,1000 ML glucose 50 MG/ML / potassium chloride 0.04 MEQ/ML Injection,glucose,DEXTROSE 5%/KCL 40MEQ/L INJ; dextrose 5 % / potassium chloride 40 MEQ per 1000 ML Injection; potassium chloride 40 MEQ / dextrose 5 % per 1000 ML Injection; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.04 MEQ/ML Injection; potassium chloride 40 MEQ / dextrose 5 % in 1000 ML Injection; potassium chloride 40 MEQ / glucose 5 % per 1000 ML Injection; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.04 MEQ/ML Injection,
C0976256,1000 ML glucose 50 MG/ML / potassium chloride 0.03 MEQ/ML / sodium chloride 2.25 MG/ML Injection,glucose,1000 ML Glucose 50 MG/ML / K+ Chloride 0.03 MEQ/ML / NaCl 2.25 MG/ML Injection; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.03 MEQ/ML / NaCl 2.25 MG/ML Injection; potassium chloride 30 MEQ / dextrose 5 % / sodium chloride 0.225 % per 1000 ML Injection; potassium chloride 30 MEQ / dextrose 5 % / sodium chloride 0.225 % in 1000 ML Injection; DEXTROSE 5%/NACL 0.225%/KCL 30MEQ/L INJ,
C0976266,glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION; DEXTROSE 5%/NACL 0.45% INJ; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]; Dextrose 5% and 0.45% Sodium Chloride, Dextrose 5% with 0.45% NaCl intravenous solution",
C0976305,DIASTIX (GLUCOSE) TEST STRIP,glucose,DIASTIX GLUCOSE TEST STRIP,
C0976576,EASY (GLUCOSE) TEST STRIP,glucose,EASY GLUCOSE TEST STRIP,
C0976858,FAST TAKE (GLUCOSE) CONTROL SOLN,glucose,FAST TAKE (GLUCOSE) CONTROL SOLN,
C0976859,FAST TAKE (GLUCOSE) METER,glucose,Fast Take Monitor; FAST TAKE (GLUCOSE) METER,
C0977046,FREESTYLE (GLUCOSE) TEST STRIP,glucose,FREESTYLE (GLUCOSE) TEST STRIP,
C0977151,glucagon (rDNA) 1 MG Injection,blood sugar,"GLUCAGON KIT; GLUCAGON 1 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, FOR SOLUTION; GLUCAGON 1 mg in 1 mL INTRAVENOUS INJECTION, POWDER, FOR SOLUTION; Glucagon Emergency Kit for Low Blood Sugar, 1 mg injectable powder for injection; GLUCAGON 1 mg in 1 mL INTRAMUSCULAR INJECTION, POWDER, FOR SOLUTION; GLUCAGON 1MG/VIL INJ,EMERGENCY KIT; GLUCAGON HYDROCHLORIDE 1 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; GLUCAGON HYDROCHLORIDE 1 mg in 1 mL INTRAMUSCULAR INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; GLUCAGON 1MG/VIL INJ; GLUCAGON 1 mg in 1 mL INTRAMUSCULAR INJECTION, POWDER, FOR SOLUTION [Glucagon]; Glucagon, 1 mg injectable powder for injection; GLUCAGON 1 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, FOR SOLUTION [Glucagon]; glucagon 1 mg in 1 mL INTRAMUSCULAR INJECTION, POWDER, FOR SOLUTION [Glucagon]; glucagon 1 mg in 1 mL INTRAVENOUS INJECTION, POWDER, FOR SOLUTION [Glucagon]; glucagon 1 mg injectable powder for injection; glucagon 1 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, FOR SOLUTION [Glucagon]; GLUCAGON 1MG/VI INJ; Glucagon KIT; glucagon (rDNA) 1 MG Injection; GLUCAGON 1MG/VIL INJ EMERGENCY KIT; GLUCAG0N KIT; GLUCAGON 1 mg in 1 mL INTRAVENOUS INJECTION, POWDER, FOR SOLUTION [Glucagon]",
C0977160,GLUCOMETER DEX (GLUCOSE) LOW CONTROL,glucose,GLUCOMETER DEX GLUCOSE LOW CONTROL,
C0977161,GLUCOMETER DEX (GLUCOSE) METER,glucose,GLUCOMETER DEX GLUCOSE METER,
C0977164,GLUCOMETER ELITE (GLUCOSE) TEST STRIP,glucose,GLUCOMETER ELITE GLUCOSE TEST STRIP,
C0977173,glucose 4000 MG Chewable Tablet,glucose,"Good Sense Grape Glucose, 4 g oral tablet, chewable; Relion Citrus Punch, 4 g oral tablet, chewable; Relion Orange, 4 g oral tablet, chewable; Leader Orange Glucose, 4 g oral tablet, chewable; Brite Life Raspberry Glucose, 4 g oral tablet, chewable; Glucose Raspberry, 4 g oral tablet, chewable; Good Sense Assorted Fruit Glucose, 4 g oral tablet, chewable; Glucose Orange, 4 g oral tablet, chewable; Equaline Raspberry, 4 g oral tablet, chewable; GLUCOSE 4GM CHEW TAB; Relion Raspberry, 4 g oral tablet, chewable; Good Neighbor Orange Glucose, 4 g oral tablet, chewable; Kinray Preferred Plus Grape Glucose, 4 g oral tablet, chewable; Equaline Orange, 4 g oral tablet, chewable; Up and Up Tropical Fruit, 4 g oral tablet, chewable; glucose 4 GM Chewable Tablet; Good Sense Orange Glucose, 4 g oral tablet, chewable; Good Neighbor Watermelon Glucose, 4 g oral tablet, chewable; Smart Sense Grape, 4 g oral tablet, chewable; Smart Sense Assorted Fruit, 4 g oral tablet, chewable; Leader Watermelon Glucose, 4 g oral tablet, chewable; Kinray Preferred Plus Raspberry Glucose, 4 g oral tablet, chewable; Up and Up Orange Glucose, 4 g oral tablet, chewable; Publix Glucose Sour Apple, 4 g oral tablet, chewable; GLUCOSE 4GM TAB,CHEW; GNP Quick Dissolve Strawberries and Cream, 4 g oral tablet, chewable; Publix Glucose Raspberry, 4 g oral tablet, chewable; Publix Glucose Assorted Flavors, 4 g oral tablet, chewable; glucose 4 g oral tablet, chewable; GNP Glucose Orange, 4 g oral tablet, chewable; Good Neighbor Grape Glucose, 4 g oral tablet, chewable; Kroger Citrus Punch Glucose, 4 g oral tablet, chewable; Smart Sense Orange, 4 g oral tablet, chewable; Relion Tropical Fruit, 4 g oral tablet, chewable; Kroger Orange Glucose, 4 g oral tablet, chewable; Kinray Preferred Plus Orange Glucose, 4 g oral tablet, chewable; CVS Glucose, 4 g oral tablet, chewable; Good Sense Raspberry Glucose, 4 g oral tablet, chewable; Publix Glucose Orange, 4 g oral tablet, chewable; Relion Grape, 4 g oral tablet, chewable; Leader Raspberry Glucose, 4 g oral tablet, chewable; Smart Sense Citrus Punch, 4 g oral tablet, chewable; Glucose, 4 g oral tablet, chewable; Good Sense Citrus Punch Glucose, 4 g oral tablet, chewable; Kroger Grape Glucose, 4 g oral tablet, chewable; Good Sense Tropical Fruit Glucose, 4 g oral tablet, chewable; Up and Up Raspberry Glucose, 4 g oral tablet, chewable",
C0977175,"GLUCOSE CONTROL 2 LEVEL (ACCU-CHEK II,IIM,III) SOLN",glucose,"GLUCOSE CONTROL 2L ACCU-CHEK II,IIM,III",
C0977177,GLUCOSE CONTROL 2 LEVEL ADVANTAGE-H SOLN #986,glucose,GLUCOSE CONTROL 2L ADVANTAGE-H SOLN #986,
C0978045,"KETO-DIASTIX (GLUCOSE,KETONE) TEST STRIP",glucose,Keto-Diastix Reagent Strip; KETODIASTIX GLUCOSE KETONE TEST STRIP,
C0978371,MEDISENSE 2 (GLUCOSE) TEST STRIP,glucose,MEDISENSE 2 (GLUCOSE) TEST STRIP,
C0979120,ONE TOUCH (GLUCOSE) METER,glucose,ONE TOUCH (GLUCOSE) METER,
C0979121,ONE TOUCH HIGH GLUCOSE CONTROL SOLN,high glucose,ONE TOUCH HIGH GLUCOSE CONTROL SOLN,
C0979122,ONE TOUCH LOW GLUCOSE CONTROL SOLN,low glucose,ONE TOUCH LOW GLUCOSE CONTROL SOLN,
C0979123,ONE TOUCH NORMAL GLUCOSE CONTROL SOLN,normal glucose,ONE TOUCH NORMAL GLUCOSE CONTROL SOLN,
C0979124,ONE TOUCH PROFILE (GLUCOSE) METER,glucose,ONE TOUCH PROFILE (GLUCOSE) METER,
C0979125,ONE TOUCH ULTRA (GLUCOSE) TEST STRIP,glucose,ONE TOUCH ULTRA (GLUCOSE) TEST STRIP; OneTouch Ultra Test Strip,
C0979733,PRECISION PCX (GLUCOSE) TEST STRIP,glucose,PRECISION PCX (GLUCOSE) TEST STRIP,
C0979734,PRECISION Q-I-D (GLUCOSE) TEST STRIP,glucose,PRECISION Q-I-D GLUCOSE TEST STRIP; Precision QID Test Strip; Precision QID Test Strips,
C0979769,PRESTIGE SMART SYSTEM (GLUCOSE) TEST STRIP,glucose,PRESTIGE SMART (GLUCOSE) TEST STRIP,
C0980446,SURE STEP (GLUCOSE) TEST STRIP,glucose,SURE STEP GLUCOSE TEST STRIP,
C0980447,SURESTEP GLUCOSE CONTROL SOLN,glucose,SURESTEP GLUCOSE CONTROL SOLN,
C0980448,SURESTEP PRO (GLUCOSE) TEST STRIP,glucose,SURESTEP PRO (GLUCOSE) TEST STRIP,
C0980449,SURESTEP PRO HIGH GLUCOSE CONTROL SOLN,high glucose,SURESTEP PRO HIGH GLUCOSE CONTROL SOLN,
C0980450,SURESTEP PRO LOW GLUCOSE CONTROL SOLN,low glucose,SURESTEP PRO LOW GLUCOSE CONTROL SOLN,
C0980451,SURESTEP PRO NORMAL GLUCOSE CONTROL SOLN,normal glucose,SURESTEP PRO NORMAL GLUCOSE CONTROL SOLN,
C0980509,TES-TAPE (GLUCOSE) TEST STRIP,glucose,TESTAPE GLUCOSE TEST STRIP,
C0980933,"URISTIX (GLUCOSE,PROTEIN) TEST STRIP",glucose,"URISTIX GLUCOSE,PROTEIN TEST STRIP",
C0981245,ADVANTAGE-H (GLUCOSE) TEST STRIP #787,glucose,ADVANTAGE-H GLUCOSE TEST STRIP #787,
C0981327,COMBISTIX (GLUCOSE/pH/PROTEIN) TEST STRIP,glucose,COMBISTIX GLUCOSE/pH/PROTEIN TEST STRIP,
C0981335,CHEMSTRIP UG (GLUCOSE) TEST STRIP,glucose,CHEMSTRIP UG GLUCOSE TEST STRIP,
C0981438,FAST TAKE (GLUCOSE) TEST STRIP,glucose,FAST TAKE (GLUCOSE) TEST STRIP; Fast Take Test Strips,
C0981453,GLUCOSTIX (GLUCOSE) TEST STRIP,glucose,GLUCOSTIX GLUCOSE TEST STRIP,
C0981631,ONE TOUCH (GLUCOSE) TEST STRIP,glucose,ONE TOUCH GLUCOSE TEST STRIP,
C0981796,GLUCOSE CONTROL 2 LEVEL ACCU-CHEK ADVANTAGE SOLN,glucose,GLUCOSE CONTRL 2L ACCU-CHK ADVANTAGE SLN,
C0982177,GLUCOSE LIQUID,glucose,"liquid glucose; glucose liquid; Liquid glucose; Glucose, liquid",
C0982311,PEG-120 methyl glucose dioleate,glucose,PEG-120 Methyl glucose dioleate; PEG-120 Methyl Glucose Dioleate; PEG-120 methyl glucose dioleate; Peg-120 Methyl Glucose Dioleate; PEG-120 METHYL GLUCOSE DIOLEATE,
C0982358,PPG-20 methyl glucose ether distearate,glucose,PPG-20 Methyl Glucose Ether Distearate; PPG-20 methyl glucose ether distearate; PPG-20 METHYL GLUCOSE ETHER DISTEARATE,
C0985432,glucose 25 MG/ML,glucose,,
C0985438,glucose 300 MG/ML,glucose,,
C0985452,glucose 50 MG/ML,glucose,Dextrose 5%; 5% dextrose; 5 dextrose; dextrose 5%; dextrose 5,
C0985453,glucose 500 MG/ML,glucose,dextrose 50%; dextrose 50; DEXTROSE 50%; 50% dextrose,
C0991661,CLINISTIX (GLUCOSE) TEST STRIP,glucose,CLINISTIX GLUCOSE TEST STRIP,
C0992246,glucose 250 MG/ML,glucose,,
C0992367,glucose 4000 MG,glucose,,
C0993326,glucose 100 MG/ML,glucose,,
C0993702,"BLOOD GLUCOSE TEST STRIPS, FOR DIALYSIS, PER 50",blood glucose,"Blood glucose test strips, for dialysis, per 50",
C0993879,Blood glucose monitor with integrated voice synthesizer,blood glucose,,
C0993880,Blood glucose monitor with integrated lancing/blood sample,blood glucose,,
C0994101,"Continuous noninvasive glucose monitoring device, purchase (for physician interpretation of data, use cpt code)",glucose,,
C0994102,"Continuous noninvasive glucose monitoring device, rental, including sensor, sensor replacement, and download to monitor (for physician interpretation of data, use cpt code)",glucose,,
C0994206,"Home management of gestational diabetes, includes administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately); per diem (do not use this code with any home infusion per diem code)",diabetes,,
C0994798,Alanine 3.48 MG/ML / Arginine 3.56 MG/ML / Aspartate 2.45 MG/ML / Glucose 250 MG/ML / Glutamate 2.58 MG/ML / Glycine 1.75 MG/ML / Histidine 1.05 MG/ML / Isoleucine 2.31 MG/ML / Leucine 3.5 MG/ML / Lysine 3.68 MG/ML / Methionine 0.6 MG/ML / Phenylalanine 1.04 MG/ML / Proline 2.52 MG/ML / Serine 1.86 MG/ML / Threonine 1.4 MG/ML / Tryptophan 0.7 MG/ML / Tyrosine 0.94 MG/ML / Valine 1.75 MG/ML Injectable Solution [Aminosyn II 3.5 % in 25 % Dextrose],glucose,,
C0994914,fructose 374 MG/ML / glucose 374 MG/ML / phosphoric acid 4.3 MG/ML Oral Solution,glucose,"DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [leader nausea relief]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [Discount Drug Mart nausea control Cherry Flavor]; DEXTROSE 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [nausea relief]; fructose 374 MG/ML / glucose 374 MG/ML / phosphoric acid 4.3 MG/ML Oral Solution; dextrose 1.87 GM / fructose 1.87 GM / phosphoric acid 21.5 MG per 5 ML Oral Solution; DEXTROSE 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [formula em]; DEXTROSE 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [signature care anti nausea]; DEXTROSE 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [good sense nausea relief]; DEXTROSE 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [Nausea Relief]; DEXTROSE 1.87GM/LEVULOSE 1.87GM/PHOSPHORIC ACID 21.5MG/5ML SOLN; DEXTROSE 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [sunmark anti nausea]; SUCROSE 3.74 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [Select Brand Anti-Nausea]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [Nausea Relief]; DEXTROSE 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [Good Neighbor Pharmacy Nausea Relief]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [nausea relief]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL LIQUID [CVS Anti Nausea Cherry Flavor]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL LIQUID [HEB Anti Nausea]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [Anti Nausea Liquid]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL LIQUID [Kroger Anti Nausea Cherry Flavor]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL LIQUID [Best Choice Anti Nausea Cherry Flavor]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [Premier Value Nausea Control Cherry Flavor]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [Health Mart anti nausea]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [Anti Nausea Liquid Cherry Flavor]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL LIQUID [Meijer Anti Nausea]; DEXTROSE 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL SOLUTION [equaline anti nausea]; DEXTROSE, UNSPECIFIED FORM 1.87 g in 5 mL / FRUCTOSE 1.87 g in 5 mL / PHOSPHORIC ACID 21.5 mg in 5 mL ORAL LIQUID [Anti Nausea]; DEXTROSE/FRUCTOSE/PHOSPHORIC AC SOLN; Formula EM, oral solution; dextrose 1.87 GM / fructose 1.87 GM / phosphoric acid 21.5 MG in 5 mL Oral Solution",
C1016247,mastodon intestinal bacterium 18.37.BG.2,BG,,
C1037219,Centaurium cf. barrelieri Mainz BG 124-562,BG,,
C1050202,Phomopsis sp. BG-96,BG,,
C1070928,Glomus sp. Bg,BG,,
C1097130,pentagalloylglucose,glucose,"1,2,3,4,6-penta-O-galloyl-beta-glucose; 1,2,3,4,6-penta-O-galloyl beta-glucopyranose; beta-D-glucopyranose, 1,2,3,4,6-pentakis(3,4,5-trihydroxybenzoate); 1,2,3,4,6-pentagalloylglucose; penta-O-galloyl-beta-D-glucoside; 1,2,3,4,6-pentagalloyl glucose; beta-penta-O-galloyl-glucose, (D)-isomer; 1,2,3,4,6-penta-O-galloylglucose; beta-D-glucopyranose pentakis(3,4,5-trihydroxybenzoate); penta-1,2,3,4,6-O-galloyl-beta-D-glucose; 1,2,3,4,6-penta-O-galloyl-beta-D-glucose; beta-D-pentagalloylglucose; gallotannin 15; beta-penta-O-galloyl-glucose; 1,2,3,4,6-PGG",
C1097672,"NDP-4-keto-6-deoxy-D-glucose 3',5'-epimerase",glucose,,
C1097675,NDP-glucose dehydratase,glucose,,
C1098235,"1-O-methyl-2,3-di-O-galloyl-beta-D-glucose",glucose,,
C1098706,human AVP protein,diabetes,"AVP; Arg-Vasopressin; ARVP protein, human; VP protein, human; Vasopressin; ADH protein, human; arginine vasopressin (neurophysin II, antidiuretic hormone, diabetes insipidus, neurohypophyseal) protein, human; AVP protein, human; arginine vasopressin protein, human; ADH; AVP-NP II protein, human; Arginine-Vasopressin; Arginine Vasopressin; Antidiuretic Hormone",
C1101427,NDP-glucose synthase,glucose,,
C1101469,"1,2,3,-tri-O-galloyl-beta-D-glucose",glucose,,
C1114129,Glucose^2.6H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --2.6 hours post dose glucose; Glucose 2.6h p Glc SerPl-sCnc; Glucose 2.6 Hr post dose glucose [Moles/Vol]; Glucose^2.6 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1114130,Glucose^3.3H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3.3h p Glc SerPl-sCnc; Glucose^3.3 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --3.3 hours post dose glucose; Glucose 3.3 Hr post dose glucose [Moles/Vol],
C1114131,Glucose^3.6H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^3.6 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3.6 Hr post dose glucose [Moles/Vol]; Glucose 3.6h p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --3.6 hours post dose glucose,
C1114140,Glucose^20M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 20 Min post dose glucose [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --20 minutes post dose glucose; Glucose 20M p Glc SerPl-sCnc; Glucose^20 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1114141,Glucose^1.3H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --1.3 hours post dose glucose; Glucose 1.3h p Glc SerPl-sCnc; Glucose^1.3 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.3 Hr post dose glucose [Moles/Vol],
C1114142,Glucose^2.3H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2.3 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2.3h p Glc SerPl-sCnc; Glucose 2.3 Hr post dose glucose [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --2.3 hours post dose glucose,
C1114209,Glucose^1H post 1.2 g/kg lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1 hour post 1.2 g/kg lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1h p 1.2 g/kg Lac PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1 hour post 1.2 g/kg lactose PO; Glucose 1 Hr post 1.2 g/kg lactose PO [Mass/Vol],
C1114210,Glucose^2H post 1.2 g/kg lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2 hours post 1.2 g/kg lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2h p 1.2 g/kg Lac PO SerPl-mCnc; Glucose 2 Hr post 1.2 g/kg lactose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --2 hours post 1.2 g/kg lactose PO,
C1114224,Insulin^30M post 75 g glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin [Units/volume] in Serum or Plasma --30 minutes post 75 g glucose PO; Insulin 30M p 75 g Glc PO SerPl-aCnc; Insulin 30 Min post 75 g glucose PO Qn; Insulin^30 minutes post 75 g glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1114881,Glucose^40M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 40 Min post dose glucose [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --40 minutes post dose glucose; Glucose^40M post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 40M p Glc SerPl-sCnc,
C1114882,Glucose^1.6H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1.6 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.6h p Glc SerPl-sCnc; Glucose 1.6 Hr post dose glucose [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --1.6 hours post dose glucose,
C1114892,Glucose^3H post 1.2 g/kg lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3h p 1.2 g/kg Lac PO SerPl-mCnc; Glucose 3 Hr post 1.2 g/kg lactose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --3 hours post 1.2 g/kg lactose PO; Glucose^3 hours post 1.2 g/kg lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1120330,"1,2-di-O-(9Z,12Z,15Z-octadecatrienoyl)-3-O-(glucose(1-6)-allose)-glycerol",glucose,"1,2-di-(O)-(G-A)-G; 1,2-di-O-(9Z,12Z,15Z-octadecatrienoyl)-3-O-(alpha-D-glucose(1-6)-beta-D-allose)-glycerol",
C1120694,2-glucose-diaminopropane-dichloroplatinum(II),glucose,2-beta-D-glucose-diaminopropane-dichloroplatinum(II); PtCl2(2-beta-D-Glc-pn),
C1120841,"RRG1 protein, S pombe",glucose,"rapid response to glucose protein 1, S pombe",
C1121586,"Hpt permease, Listeria monocytogenes",glucose,"glucose-6-phosphate translocase, Listeria",
C1122005,"Atp5md protein, rat",diabetes,"upregulated during skeletal muscle growth 5 protein, rat; Usmg5 protein, rat; diabetes-associated protein in insulin-sensitive tissues, rat; Dapit protein, rat",
C1124158,glucose 0.4 MG/MG,glucose,,
C1124170,glucose 200 MG/ML,glucose,,
C1124171,glucose 700 MG/ML,glucose,,
C1124193,glucose 400 MG/ML,glucose,,
C1124194,glucose 600 MG/ML,glucose,,
C1133818,glucose 374 MG/ML,glucose,,
C1136817,"dTDP-4-amino-4,6-dideoxy-glucose",glucose,"dTDP-4-A-DDG; dTDP-4-amino-4,6-dideoxy-alpha-D-glucose",
C1136915,"SLC5A11 protein, human",glucose,"solute carrier family 5 (sodium-glucose cotransporter), member 11, human; sodium-glucose cotransporter KST1, human; KST1 protein, human",
C1136985,"GidB protein, E coli",glucose,"RsmG protein, E coli; glucose-inhibited division protein B, Escherichia coli",
C1138702,"SYSTEM, TEST, BLOOD GLUCOSE, OVER THE COUNTER",blood glucose,,
C1138715,"Monitors, Physiologic, Glucose, Personal, Noninvasive",glucose,"Glucose Monitors, Noninvasive; Glucose Personal Noninvasive Monitors; Monitors, Personal, Glucose, Noninvasive; noninvasive personal glucose monitors; noninvasive glucose monitor; INSTRUMENT, GLUCOSE, NONINVASIVE TECHNOLOGY; glucose monitoring noninvasive",
C1138906,"Monitors, Physiologic, Glucose, Personal, Implantable Sensor",glucose,"Glucose Personal Implantable Sensor Monitors; Monitors, Personal, Glucose, Implantable Sensor",
C1139049,"Control Reagents, Diabetes",diabetes,"Reagents, Immunoassay, Control, Diabetes",
C1139133,Glucagon Determination Reagents,diabetes,"Reagents, Immunoassay, Diabetes, Glucagon",
C1139309,Proinsulin Determination Reagents,diabetes,"Reagents, Immunoassay, Diabetes, Proinsulin",
C1139592,Gastric Inhibitory Polypeptide (GIP) Determination Reagents,glucose,"GIP (Gastric Inhibitory Polypeptide) Determination Reagents; Reagents, Immunoassay, Gastrointestinal Hormone, Gastric Inhibitory Polypeptide; Glucose-Dependent Insulinotropic Polypeptide Determination Reagents",
C1139612,"Diabetes Reagents, Calibration",diabetes,"Reagents, Immunoassay, Calibration, Diabetes; Calibration Reagents, Diabetes",
C1139634,"Standard Reagents, Diabetes",diabetes,"Reagents, Immunoassay, Standard, Diabetes; Diabetes Reagents, Standard",
C1139664,Insulin Antibody Determination Reagents,diabetes,"Insulin Auto-Antibody (IAA) Determination Reagents; Reagents, Immunoassay, Autoimmune, Diabetes, Insulin Autoantibody; IAA (Insulin Auto-Antibody) Determination Reagents",
C1139899,Glucose Determination Reagents,glucose,,
C1139932,"Reagents, Immunoassay, Diabetes, Glycated Hemoglobin",diabetes,,
C1139983,GAD II Antibody Determination Reagents,diabetes,"Islet Cell Antibody (ICA) Determination Reagents; ICA (Islet Cell Antibody) Determination Reagents; Reagents, Immunoassay, Autoimmune, Diabetes, Islet Cell Antibody",
C1141228,glucose 33 MG/ML,glucose,,
C1141679,glucose 0.417 MG/MG,glucose,,
C1143081,glucose-6-phosphate dehydrogenase Amsterdam,glucose,glucose-6-phosphate dehydrogenase Amsterdam; G6PD Amsterdam,
C1143127,BG-289,BG,,
C1143128,BG-203,BG,,
C1143129,BG-237,BG,,
C1143360,methylanthraniloyl-UDP-glucose,glucose,MUG cpd,
C1143459,"Slc2a5 protein, mouse",glucose,"GLUT5 protein, mouse; solute carrier family 2 (facilitated glucose transporter), member 5 protein, mouse",
C1144342,"UTr1 protein, Arabidopsis",glucose,"AtUTr1 protein, Arabidopsis; UDP-galactose-UDP-glucose transporter protein, Arabidopsis",
C1145313,"Routine foot care; removal and/or trimming of corns, calluses and/or nails and preventive maintenance in specific medical conditions (e.g., diabetes), per visit",diabetes,,
C1147700,Glucose:MCnc:Pt:BldC:Qn,glucose,Glucose (BldC) [Mass/Vol]; Glucose [Mass/volume] in Capillary blood; Glucose:Mass Concentration:To identify measures at a point in time:Blood capillary:Quantitative; Glucose BldC-mCnc,
C1147858,Glucose:PrThr:24H:Urine:Ord,glucose,Glucose 24h Ur Ql; Glucose [Presence] in 24 hour Urine; Glucose Ql (24H U); Glucose:Presence or Threshold:24 hours:Urine:Ordinal,
C1148002,Glucose:SCnc:Pt:XXX:Qn,glucose,Glucose [Moles/volume] in Specimen; Glucose (Specimen) [Moles/Vol]; Glucose:Substance Concentration:To identify measures at a point in time:Not specified:Quantitative; Glucose Spec-sCnc,
C1148003,Glucose^30M post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --30 minutes post 75 g glucose PO; Glucose 30M p 75 g Glc PO SerPl-sCnc; Glucose^30 minutes post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min post 75 g glucose PO [Moles/Vol],
C1148004,Glucose^3H post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3h p 75 g Glc PO SerPl-sCnc; Glucose 3 Hr post 75 g glucose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --3 hours post 75 g glucose PO; Glucose^3 hours post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1148005,Glucose^4H post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4h p 75 g Glc PO SerPl-sCnc; Glucose^4 hours post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --4 hours post 75 g glucose PO; Glucose 4 Hr post 75 g glucose PO [Moles/Vol],
C1148006,Glucose^5H post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5 Hr post 75 g glucose PO [Moles/Vol]; Glucose^5 hours post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5h p 75 g Glc PO SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --5 hours post 75 g glucose PO,
C1148043,Glucose^10M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --10 minutes post dose glucose; Glucose 10M p Glc SerPl-sCnc; Glucose 10 Min post dose glucose [Moles/Vol]; Glucose^10 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1148230,Glucose-6-Phosphate dehydrogenase:CCnt:Pt:RBC:Qn,glucose,Glucose-6-Phosphate dehydrogenase:Catalytic Content:To identify measures at a point in time:Erythrocytes:Quantitative; G6PD (RBC) [Catalytic activity/Mass]; G6PD RBC-cCnt; Glucose-6-Phosphate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells,
C1148590,glucose binding,glucose,,
C1148973,galactose/glucose (methylgalactoside) porter activity,glucose,galactose/glucose (methylgalactoside) porter activity,
C1149765,N-acetylglucosamine-6-phosphate deacetylase activity,glucose,2-acetamido-2-deoxy-D-glucose-6-phosphate amidohydrolase activity; acetylaminodeoxyglucosephosphate acetylhydrolase activity; N-acetyl-D-glucosamine-6-phosphate amidohydrolase activity; N-acetylglucosamine-6-phosphate deacetylase activity; acetylglucosamine phosphate deacetylase activity,
C1149810,UDPsulfoquinovose synthase activity,glucose,UDP-6-sulfo-6-deoxyglucose sulfohydrolase activity; UDPsulphoquinovose synthase activity; UDP-sulfoquinovose synthase activity; sulfite:UDP-glucose sulfotransferase activity,
C1149881,2-deoxyglucose-6-phosphatase activity,glucose,2-deoxy-D-glucose-6-phosphate phosphohydrolase activity; 2-deoxyglucose-6-phosphatase activity; 2-deoxyglucose-6-phosphate phosphatase activity,
C1149894,glucose-1-phosphatase activity,glucose,glucose-1-phosphatase activity; D-glucose-1-phosphate phosphohydrolase activity; alpha-D-glucose-1-phosphate phosphohydrolase activity,
C1149895,glucose-6-phosphatase activity,glucose,glucose 6-phosphate phosphatase activity; D-glucose-6-phosphate phosphohydrolase activity; glucose-6-phosphatase activity,
C1149975,N-acetylglucosamine-6-sulfatase activity,glucose,"acetylglucosamine 6-sulfatase activity; N-acetylglucosamine 6-sulfate sulfatase activity; O,N-disulfate O-sulfohydrolase activity; N-acetylglucosamine-6-sulfatase activity; N-acetyl-D-glucosamine-6-sulfate 6-sulfohydrolase activity; 2-acetamido-2-deoxy-D-glucose 6-sulfate sulfatase activity; glucosamine-6-sulfatase activity; N-acetylglucosamine-6-sulphatase activity",
C1150057,6-phospho-beta-glucosidase activity,glucose,"6-phospho-beta-D-glucosyl-(1,4)-D-glucose glucohydrolase activity; phosphocellobiase activity; phospho-beta-glucosidase activity; 6-phospho-beta-glucosidase activity",
C1150060,"glucan 1,4-alpha-glucosidase activity",glucose,"1,4-alpha-D-glucan glucohydrolase activity; amyloglucosidase activity; exo-1,4-alpha-glucosidase activity; glucan 1,4-alpha-glucosidase activity; glucoamylase activity; gamma-1,4-glucan glucohydrolase activity; glucose amylase activity; gamma-amylase activity",
C1150073,N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase activity,glucose,N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase activity; 2-acetamido-2-deoxy-alpha-D-glucose 1-phosphodiester acetamidodeoxyglucohydrolase activity; glycoprotein-N-acetyl-D-glucosaminyl-phospho-D-mannose N-acetyl-D-glucosaminylphosphohydrolase activity; alpha-N-acetylglucosaminyl phosphodiesterase activity; alpha-N-acetyl-D-glucosamine-1-phosphodiester N-acetylglucosaminidase activity; phosphodiester glycosidase activity,
C1150314,glucosamine-6-phosphate deaminase activity,glucose,phosphoglucosaminisomerase activity; aminodeoxyglucosephosphate isomerase activity; glucosamine-6-phosphate deaminase activity; glucosamine-6-phosphate isomerase activity; phosphoglucosamine isomerase activity; GlcN6P deaminase activity; 2-amino-2-deoxy-D-glucose-6-phosphate aminohydrolase (ketol isomerizing); glucosamine phosphate deaminase activity,
C1150315,glucose-6-phosphate isomerase activity,glucose,glucose-6-phosphate isomerase activity; D-glucose-6-phosphate ketol-isomerase activity; glucose phosphate isomerase activity; phosphoglucose isomerase activity; phosphoglucoisomerase activity; hexosephosphate isomerase activity; D-glucose-6-phosphate aldose-ketose-isomerase activity; hexose phosphate isomerase activity,
C1150355,inositol-3-phosphate synthase activity,glucose,D-glucose 6-phosphate cycloaldolase activity; glucose-6-phosphate inositol monophosphate cycloaldolase activity; inositol 1-phosphate synthatase activity; inositol-3-phosphate synthase activity; glucocycloaldolase activity; inositol 1-phosphate synthetase activity; glucose 6-phosphate cyclase activity; 1L-myo-inositol-1-phosphate lyase (isomerizing),
C1150360,beta-phosphoglucomutase activity,glucose,"beta-phosphoglucomutase activity; beta-D-glucose 1,6-phosphomutase activity",
C1150363,phosphoglucomutase activity,glucose,"alpha-D-glucose 1,6-phosphomutase activity; glucose phosphomutase activity; phosphoglucose mutase activity; phosphoglucomutase activity",
C1150369,phosphopentomutase activity,glucose,"alpha-D-ribose 1,5-phosphomutase activity; alpha-D-glucose-1,6-bisphosphate:deoxy-D-ribose-1-phosphate phosphotransferase activity; phosphoribomutase activity; phosphopentomutase activity; D-ribose 1,5-phosphomutase activity",
C1150406,"dTDP-4-dehydrorhamnose 3,5-epimerase activity",glucose,"TDP-4-keto-L-rhamnose-3,5-epimerase activity; TDP-4-ketorhamnose 3,5-epimerase activity; dTDP-4-dehydro-6-deoxy-D-glucose 3,5-epimerase activity; dTDP-4-dehydrorhamnose 3,5-epimerase activity; dTDP-4-keto-6-deoxyglucose 3,5-epimerase activity",
C1150409,UDP-glucose 4-epimerase activity,glucose,UDP-galactose 4-epimerase activity; uridine diphosphoglucose 4-epimerase activity; UDPglucose 4-epimerase activity; UDP-glucose epimerase activity; uridine diphospho-galactose-4-epimerase activity; UDP-D-galactose 4-epimerase activity; 4-epimerase activity; UDPG-4-epimerase activity; uridine diphosphate glucose 4-epimerase activity; UDP-glucose 4-epimerase activity; UDPgalactose 4-epimerase activity; uridine diphosphoglucose epimerase activity; uridine diphosphate galactose 4-epimerase activity,
C1150444,glucokinase activity,glucose,glucokinase (phosphorylating); glucokinase activity; ATP:D-glucose 6-phosphotransferase activity; glucose kinase activity,
C1150445,hexokinase activity,glucose,ATP:D-hexose 6-phosphotransferase activity; ATP-dependent hexokinase activity; glucose ATP phosphotransferase activity; hexokinase type IV; hexokinase activity; hexokinase type IV (glucokinase) activity; hexokinase type IV glucokinase activity; hexokinase D; hexokinase (phosphorylating),
C1150450,N-acetylglucosamine kinase activity,glucose,N-acetylglucosamine kinase activity; ATP:N-acetyl-D-glucosamine 6-phosphotransferase activity; acetylglucosamine kinase (phosphorylating); GlcNAc kinase activity; acetylaminodeoxyglucokinase activity; 2-acetylamino-2-deoxy-D-glucose kinase activity; ATP:2-acetylamino-2-deoxy-D-glucose 6-phosphotransferase activity,
C1150955,"dTDP-glucose 4,6-dehydratase activity",glucose,"dTDP-glucose 4,6-hydro-lyase (dTDP-4-dehydro-6-deoxy-D-glucose-forming); dTDP-glucose 4,6-hydro-lyase activity; thymidine diphosphoglucose oxidoreductase activity; TDP-glucose oxidoreductase activity; dTDPglucose 4,6-hydro-lyase activity; dTDPglucose 4,6-dehydratase activity",
C1151226,glucose-6-phosphate dehydrogenase activity,glucose,G6PDH; D-glucose-6-phosphate:NADP+ 1-oxidoreductase activity; glucose-6-phosphate dehydrogenase activity; glucose 6-phosphate dehydrogenase (NADP) activity; NADP-dependent glucose 6-phosphate dehydrogenase activity; 6-phosphoglucose dehydrogenas; G6PD activity; GDH; D-glucose 6-phosphate dehydrogenase activity; NADP-glucose-6-phosphate dehydrogenase activity; 6-phosphoglucose dehydrogenase activity; glucose-6-phosphate 1-dehydrogenase activity; Zwischenferment; Entner-doudoroff enzyme,
C1151268,UDP-glucose 6-dehydrogenase activity,glucose,,
C1151276,glucose dehydrogenase (acceptor) activity,glucose,glucose dehydrogenase activity; glucose dehydrogenase (acceptor) activity; soluble glucose dehydrogenase,
C1151277,glucose dehydrogenase (pyrroloquinoline-quinone) activity,glucose,D-glucose:ubiquinone oxidoreductase activity; D-glucose:(pyrroloquinoline-quinone) 1-oxidoreductase activity; glucose dehydrogenase (PQQ-dependent) activity; quinoprotein glucose dehydrogenase activity; glucose dehydrogenase (pyrroloquinoline-quinone) activity; quinoprotein D-glucose dehydrogenase activity,
C1151286,beta-D-glucose oxidase activity,glucose,beta-D-glucose:oxygen 1-oxido-reductase activity; beta-D-glucose oxidase activity; glucose aerodehydrogenase activity; penatin; GOD activity; beta-D-glucose:oxygen 1-oxidoreductase activity; beta-D-glucose:quinone oxidoreductase activity; D-glucose-1-oxidase activity; D-glucose oxidase activity; glucose oxyhydrase activity; glucose oxidase activity; corylophyline,
C1151927,"dTDP-4-amino-4,6-dideoxygalactose transaminase activity",glucose,"dTDP-fucosamine aminotransferase activity; thymidine diphosphate 4-keto-6-deoxy-D-glucose transaminase activity; thymidine diphosphoaminodideoxygalactose aminotransferase activity; dTDP-4-amino-4,6-dideoxygalactose aminotransferase activity; dTDP-4,6-dideoxy-D-galactose:2-oxoglutarate aminotransferase activity",
C1152000,sinapoylglucose-malate O-sinapoyltransferase activity,glucose,sinapoylglucose:malate sinapoyltransferase activity; 1-O-sinapoyl-beta-D-glucose:(S)-malate O-sinapoyltransferase activity; 1-sinapoylglucose-L-malate sinapoyltransferase activity,
C1152068,UDP-N-acetylglucosamine 1-carboxyvinyltransferase activity,glucose,phosphopyruvate-uridine diphosphoacetylglucosamine pyruvatetransferase activity; phosphoenolpyruvate-UDP-acetylglucosamine-3-enolpyruvyltransferase activity; phosphoenolpyruvate:uridine diphosphate N-acetylglucosamine enolpyruvyltransferase activity; pyruvate-uridine diphospho-N-acetylglucosamine transferase activity; pyruvic-uridine diphospho-N-acetylglucosaminyltransferase activity; UDP-N-acetylglucosamine 1-carboxyvinyl-transferase activity; pyruvate-uridine diphospho-N-acetyl-glucosamine transferase activity; enoylpyruvate transferase activity; phosphoenolpyruvate:UDP-N-acetyl-D-glucosamine 1-carboxyvinyltransferase activity; pyruvate-UDP-acetylglucosamine transferase activity; phosphoenolpyruvate:UDP-2-acetamido-2-deoxy-D-glucose 2-enoyl-1-carboxyethyltransferase activity; UDP-N-acetylglucosamine enoylpyruvyltransferase activity; phosphoenolpyruvate:uridine-5'-diphospho-N-acetyl-2-amino-2-deoxyglucose 3-enolpyruvyltransferase activity; UDP-N-acetylglucosamine 1-carboxyvinyltransferase activity,
C1152109,lactose synthase activity,glucose,uridine diphosphogalactose-glucose galactosyltransferase activity; UDPgalactose:D-glucose 4-beta-D-galactotransferase activity; lactose synthase activity; UDP-galactose-glucose galactosyltransferase activity; UDP-galactose:D-glucose 4-beta-D-galactotransferase activity; UDPgalactose-glucose galactosyltransferase activity; lactose synthetase activity,
C1152120,"1,3-beta-D-glucan synthase activity",glucose,"1,3-beta-glucan-uridine diphosphoglucosyltransferase activity; UDP-glucose:(1,3)beta-glucan synthase activity; uridine diphosphoglucose-1,3-beta-glucan glucosyltransferase activity; UDP-glucose:1,3-beta-D-glucan 3-beta-D-glucosyltransferase activity; 1,3-beta-D-glucan-UDP glucosyltransferase activity; 1,3-beta-glucan synthase activity; UDP-glucose-1,3-beta-D-glucan glucosyltransferase activity; (1,3)-beta-glucan (callose) synthase activity; callose synthetase activity; beta-1,3-glucan synthase activity; beta-1,3-glucan synthetase activity; UDP-glucose-1,3-beta-glucan glucosyltransferase activity; UDPglucose-1,3-beta-D-glucan glucosyltransferase activity; GS-II; 1,3-beta-D-glucan synthetase activity; UDP-glucose-beta-glucan glucosyltransferase activity; UDPglucose:1,3-beta-D-glucan 3-beta-D-glucosyltransferase activity; callose synthase activity",
C1152121,"alpha,alpha-trehalose-phosphate synthase (UDP-forming) activity",glucose,"transglucosylase activity; alpha,alpha-trehalose phosphate synthase (UDP-forming); trehalose phosphate synthetase activity; phosphotrehalose-uridine diphosphate transglucosylase activity; UDPglucose-glucose-phosphate glucosyltransferase activity; uridine diphosphoglucose phosphate glucosyltransferase activity; trehalose-phosphate synthetase activity; trehalose phosphate synthase activity; trehalose 6-phosphate synthase activity; trehalose-P synthetase activity; trehalosephosphate-UDP glucosyl transferase activity; trehalose-phosphate synthase activity; trehalose 6-phosphate synthetase activity; UDP-glucose:D-glucose-6-phosphate 1-alpha-D-glucosyltransferase activity; UDPglucose:D-glucose-6-phosphate 1-alpha-D-glucosyltransferase activity; UDP-glucose-glucosephosphate glucosyltransferase activity; UDP-glucose-glucose-phosphate glucosyltransferase activity; trehalosephosphate-UDP glucosyltransferase activity; trehalose phosphate-uridine diphosphate glucosyltransferase activity",
C1152123,cellulose synthase (GDP-forming) activity,glucose,"GDP-glucose:1,4-beta-D-glucan 4-beta-D-glucosyltransferase activity; guanosine diphosphoglucose-1,4-beta-glucan glucosyltransferase activity; GDP-glucose-cellulose glucosyltransferase activity; GDP-glucose-beta-D-glucan glucosyltransferase activity; cellulose synthase (GDP-forming) activity; GDPglucose:1,4-beta-D-glucan 4-beta-D-glucosyltransferase activity; guanosine diphosphoglucose-cellulose glucosyltransferase activity; cellulose synthase (guanosine diphosphate-forming) activity",
C1152124,cellulose synthase (UDP-forming) activity,glucose,"beta-1,4-glucan synthase activity; 1,4-beta-glucan synthase activity; uridine diphosphoglucose-1,4-beta-glucan glucosyltransferase activity; uridine diphosphoglucose-cellulose glucosyltransferase activity; glucan synthase activity; UDP-glucose-1,4-beta-glucan glucosyltransferase activity; cellulose synthase (UDP-forming) activity; UDPglucose-beta-glucan glucosyltransferase activity; beta-1,4-glucan synthetase activity; UDPglucose-cellulose glucosyltransferase activity; GS-I; UDP-glucose-beta-D-glucan glucosyltransferase activity; beta-1,4-glucosyltransferase activity; UDPglucose:1,4-beta-D-glucan 4-beta-D-glucosyltransferase activity; UDP-glucose-cellulose glucosyltransferase activity; beta-glucan synthase activity; 1,4-beta-D-glucan synthase activity; UDP-glucose:1,4-beta-D-glucan 4-beta-D-glucosyltransferase activity",
C1152125,ceramide glucosyltransferase activity,glucose,uridine diphosphoglucose-ceramide glucosyltransferase activity; glucosylceramide synthase activity; ceramide:UDPGlc glucosyltransferase activity; UDP-glucose:ceramide glucosyltransferase activity; UDP-glucose:N-acylsphingosine D-glucosyltransferase activity; ceramide glucosyltransferase activity; ceramide:UDP-glucose glucosyltransferase activity; UDP-glucose-ceramide glucosyltransferase activity; UDPglucose:N-acylsphingosine D-glucosyltransferase activity,
C1152128,dolichyl-phosphate beta-glucosyltransferase activity,glucose,uridine diphosphoglucose-dolichol glucosyltransferase activity; UDP-glucose dolichyl-phosphate glucosyltransferase activity; UDPglucose:dolichyl-phosphate beta-D-glucosyltransferase activity; UDP-glucose:dolicholphosphoryl glucosyltransferase activity; UDP-glucose:dolichol phosphate glucosyltransferase activity; polyprenyl phosphate:UDP-D-glucose glucosyltransferase activity; UDP-glucose:dolichyl phosphate glucosyltransferase activity; UDP-glucose:dolichyl-phosphate beta-D-glucosyltransferase activity; dolichyl-phosphate beta-glucosyltransferase activity; UDP-glucose:dolichyl monophosphate glucosyltransferase activity,
C1152129,dolichyl-phosphate-glucose-glycolipid alpha-glucosyltransferase activity,glucose,,
C1152130,glycogen (starch) synthase activity,glucose,uridine diphosphoglucose-glycogen glucosyltransferase activity; UDPglucose:glycogen 4-alpha-D-glucosyltransferase activity; UDP-glycogen synthase activity; UDPG-glycogen synthetase activity; UDP-glucose-glycogen glucosyltransferase activity; UDPG-glycogen transglucosylase activity; glycogen (starch) synthase activity; glycogen (starch) synthetase activity; UDP-glucose:glycogen 4-alpha-D-glucosyltransferase activity,
C1152131,glycogenin glucosyltransferase activity,glucose,"glycogenin glucosyltransferase activity; UDP-alpha-D-glucose:glycogenin alpha-D-glucosyltransferase activity; alpha-1,4-glucan-protein synthase (UDP-forming) activity; UDP-glucose:glycogenin glucosyltransferase activity; 1,4alpha-glucan-protein synthase (UDP-forming) activity",
C1152132,lipopolysaccharide glucosyltransferase I activity,glucose,lipopolysaccharide glucosyltransferase activity; lipopolysaccharide glucosyltransferase I activity; LPS glucosyltransferase I activity; UDP-glucose:lipopolysaccharide glucosyltransferase activity; UDPglucose:lipopolysaccharide glucosyltransferase activity; uridine diphosphoglucose-lipopolysaccharide glucosyltransferase activity; UDPglucose:lipopolysaccharide glucosyltransferase I,
C1152133,starch (bacterial glycogen) synthase activity,glucose,"starch synthetase activity; adenosine diphosphoglucose-starch glucosyltransferase activity; ADPglucose:1,4-alpha-D-glucan 4-alpha-D-glucosyltransferase activity; ADP-glucose:1,4-alpha-D-glucan 4-alpha-D-glucosyltransferase activity; adenosine diphosphate glucose-starch glucosyltransferase activity; starch synthase activity; ADPG-starch glucosyltransferase activity; ADP-glucose transglucosylase activity; ADPglucose-starch glucosyltransferase activity; ADPG starch synthetase activity; ADP-glucose--starch glucosyltransferase activity; glycogen synthase activity; starch (bacterial glycogen) synthase activity; ADP-glucose starch synthase activity",
C1152134,sterol glucosyltransferase activity,glucose,UDP-glucose-sterol glucosyltransferase activity; UDPG-SGTase activity; uridine diphosphoglucose-sterol glucosyltransferase activity; sterol-beta-D-glucosyltransferase activity; UDP-glucose:sterol 3-O-beta-D-glucosyltransferase activity; sterol glucosyltransferase activity; UDPglucose:sterol 3-O-beta-D-glucosyltransferase activity; UDP-glucose:sterol glucosyltransferase activity; UDPG:sterol glucosyltransferase activity; uridine diphosphoglucose-poriferasterol glucosyltransferase activity; sterol:UDPG glucosyltransferase activity; UDP-glucose-sterol beta-glucosyltransferase activity; sterol 3beta-glucosyltransferase activity; sterol 3-beta-glucosyltransferase activity,
C1152135,sucrose synthase activity,glucose,sucrose synthase activity; sucrose-uridine diphosphate glucosyltransferase activity; uridine diphosphoglucose-fructose glucosyltransferase activity; sucrose synthetase activity; NDP-glucose:D-fructose 2-alpha-D-glucosyltransferase activity; sucrose-UDP glucosyltransferase activity; UDPglucose-fructose glucosyltransferase activity; UDP-glucose-fructose glucosyltransferase activity,
C1152136,sucrose-phosphate synthase activity,glucose,sucrose phosphate synthetase activity; UDP-glucose-fructose-phosphate glucosyltransferase activity; sucrosephosphate-UDP glucosyltransferase activity; UDP-glucose:D-fructose-6-phosphate 2-alpha-D-glucosyltransferase activity; UDPglucose-fructose-phosphate glucosyltransferase activity; sucrose phosphate-uridine diphosphate glucosyltransferase activity; sucrose 6-phosphate synthase activity; SPS; sucrose-phosphate synthase activity; UDPglucose:D-fructose-6-phosphate 2-alpha-D-glucosyltransferase activity; uridine diphosphoglucose-fructose phosphate glucosyltransferase activity,
C1152137,UDP-glucose:glycoprotein glucosyltransferase activity,glucose,UGGT activity,
C1152222,"dTDP-4-amino-4,6-dideoxy-D-glucose transaminase activity",glucose,"thymidine diphospho-4-keto-6-deoxy-D-glucose transaminase activity; thymidine diphospho-4-amino-4,6-dideoxyglucose aminotransferase activity; dTDP-4-amino-4,6-dideoxy-D-glucose:2-oxoglutarate aminotransferase activity; TDP-4-oxo-6-deoxy-D-glucose transaminase activity; thymidine diphospho-4-amino-6-deoxyglucose aminotransferase activity; dTDP-4-amino-4,6-dideoxy-D-glucose aminotransferase activity; TDP-4-keto-6-deoxy-D-glucose transaminase activity; thymidine diphospho-4-keto-6-deoxy-D-glucose-glutamic transaminase activity",
C1152396,glucose-1-phosphate adenylyltransferase activity,glucose,ADP:alpha-D-glucose-1-phosphate adenylyltransferase activity; ADP-glucose synthase activity; ATP:alpha-D-glucose-1-phosphate adenylyltransferase activity; adenosine diphosphoglucose pyrophosphorylase activity; ADP-glucose diphosphorylase activity; ADP glucose pyrophosphorylase activity; glucose 1-phosphate adenylyltransferase activity; glucose-1-phosphate adenylyltransferase activity; ADGase activity; ATP:alpha-glucose-1-phosphate adenylyl transferase activity; ADPG pyrophosphorylase activity; ADP-glucose pyrophosphorylase activity; adenosine diphosphate glucose pyrophosphorylase activity; ADP-glucose synthetase activity,
C1152397,glucose-1-phosphate thymidylyltransferase activity,glucose,dTTP:alpha-D-glucose-1-phosphate thymidylyltransferase activity; TDP-glucose pyrophosphorylase activity; dTDP-glucose diphosphorylase activity; dTDP-glucose pyrophosphorylase activity; glucose 1-phosphate thymidylyltransferase activity; glucose-1-phosphate thymidylyltransferase activity; thymidine diphosphate glucose pyrophosphorylase activity; thymidine diphosphoglucose pyrophosphorylase activity; dTDP-glucose synthase activity,
C1152420,UDP-glucose:hexose-1-phosphate uridylyltransferase activity,glucose,UDPglucose-hexose-1-phosphate uridylyltransferase activity; hexose-1-phosphate uridylyltransferase activity; UDP-glucose-hexose-1-phosphate uridylyltransferase activity; UDP-glucose:alpha-D-galactose-1-phosphate uridylyltransferase activity; hexose 1-phosphate uridyltransferase activity; UDPglucose:alpha-D-galactose-1-phosphate uridylyltransferase activity,
C1152421,UDP-N-acetylglucosamine pyrophosphorylase activity,glucose,UDP-N-acetylglucosamine pyrophosphorylase activity; UTP:2-acetamido-2-deoxy-alpha-D-glucose-1-phosphate uridylyltransferase activity; uridine diphosphate-N-acetylglucosamine pyrophosphorylase activity; N-acetylglucosamine-1-phosphate uridyltransferase activity; GlmU uridylyltransferase activity; uridine diphosphoacetylglucosamine pyrophosphorylase activity; UTP:N-acetyl-alpha-D-glucosamine-1-phosphate uridylyltransferase activity; UDP-GlcNAc pyrophosphorylase activity; UDP-N-acetylglucosamine diphosphorylase activity; UDP-acetylglucosamine pyrophosphorylase activity; uridine diphosphoacetylglucosamine phosphorylase activity,
C1152423,UTP-glucose-1-phosphate uridylyltransferase activity,glucose,UDP-glucose pyrophosphorylase activity; uridine diphosphoglucose pyrophosphorylase activity; UDP glucose pyrophosphorylase activity; UTP:alpha-D-glucose-1-phosphate uridylyltransferase activity; UDP-glucose diphosphorylase activity; uridine diphosphate-D-glucose pyrophosphorylase activity; glucose-1-phosphate uridylyltransferase activity; uridine 5'-diphosphoglucose pyrophosphorylase activity; UDPG pyrophosphorylase activity; UDPG phosphorylase activity; UTP:glucose-1-phosphate uridylyltransferase activity; uridine-diphosphate glucose pyrophosphorylase activity; UTP-glucose-1-phosphate uridylyltransferase activity,
C1152440,glucose permease activity,glucose,glucose transmembrane transporter activity; glucose permease activity,
C1152462,phosphatidylglycerol-membrane-oligosaccharide glycerophosphotransferase activity,glucose,oligosaccharide glycerophosphotransferase activity; phosphatidylglycerol-membrane-oligosaccharide glycerophosphotransferase activity; phosphatidylglycerol:membrane-derived-oligosaccharide-D-glucose glycerophosphotransferase activity; phosphoglycerol transferase I,
C1152791,gastric inhibitory peptide receptor activity,glucose,glucose-dependent insulinotropic polypeptide receptor activity; GIP receptor activity,
C1153098,lactose/glucose efflux transporter activity,glucose,lactose/glucose efflux transporter activity,
C1153121,"galactose, glucose uniporter activity",glucose,"galactose, glucose uniporter activity",
C1153127,glucose uniporter activity,glucose,,
C1153128,glucose-6-phosphate transmembrane transporter activity,glucose,,
C1153129,glucose:sodium symporter activity,glucose,sodium/glucose symporter activity,
C1153152,UDP-glucose transmembrane transporter activity,glucose,,
C1153169,high-affinity glucose:proton symporter activity,glucose,high-affinity hydrogen/glucose transporter activity; high-affinity hydrogen:glucose symporter activity; high-affinity hydrogen:glucose transporter activity,
C1153172,low-affinity glucose:proton symporter activity,glucose,low-affinity hydrogen/glucose transporter activity; low-affinity hydrogen:glucose symporter activity; low-affinity hydrogen:glucose transporter activity,
C1153176,glucose 6-phosphate:phosphate antiporter activity,glucose,,
C1154542,response to glucose,glucose,response to glucose stimulus,
C1154954,hypotonic response,hypo,hypo-osmotic response,
C1155333,cellular response to glucose starvation,glucose,,
C1156258,cellular glucose homeostasis,glucose,cell glucose homeostasis,
C1156335,regulation of glucose biosynthesis,glucose,,
C1156395,glucose catabolic process,glucose,glucose degradation; glucose breakdown; glucose catabolism,
C1156396,non-phosphorylated glucose catabolic process,glucose,non-phosphorylated glucose breakdown; non-phosphorylated glucose catabolism; non-phosphorylated glucose degradation,
C1156435,glycolytic fermentation to ethanol,glucose,ethanol fermentation; glucose fermentation to ethanol; glucose catabolic process to ethanol,
C1156459,glucose 1-phosphate metabolic process,glucose,glucose 1-phosphate utilization; glucose 1-phosphate metabolism,
C1156460,glucose 1-phosphate phosphorylation,glucose,,
C1156463,non-phosphorylated glucose metabolic process,glucose,non-phosphorylated glucose metabolism,
C1156464,UDP-glucose metabolic process,glucose,UDP-glucose metabolism,
C1156465,UDP-glucose catabolic process,glucose,UDP-glucose degradation; UDP-glucose breakdown; UDP-glucose catabolism,
C1156466,UDP-glucose conversion,glucose,,
C1158161,regulation of glycolytic process,glucose,regulation of glycolysis involved in cellular glucose homeostasis,
C1158287,glucose catabolic process to butyrate,glucose,glucose fermentation to butyrate; butyrate fermentation,
C1158289,glycolytic fermentation to butanediol,glucose,glucose fermentation to butanediol; glucose catabolic process to butanediol; butanediol fermentation,
C1158290,glucose catabolic process to lactate via pyruvate,glucose,homofermentative pathway; homofermentative lactate fermentation; homofermentation; homolactate fermentation; homolactic fermentation; glucose fermentation to lactate via pyruvate,
C1158291,mixed acid fermentation,glucose,glucose fermentation to mixed acids,
C1158293,glucose catabolic process to lactate,glucose,glucose fermentation to lactate; lactate fermentation,
C1158294,glucose catabolic process to D-lactate and ethanol,glucose,heterolactic fermentation; heterofermentative pathway; heterolactate fermentation; heterofermentative lactate fermentation; heterofermentation; glucose fermentation to D-lactate and ethanol,
C1158299,glucose fermentation to lactate and acetate,glucose,glucose catabolic process to lactate and acetate; bifidum pathway,
C1158774,carbon catabolite repression of transcription by glucose,glucose,down-regulation of transcription by glucose; downregulation of transcription by glucose; glucose repression; glucose effect; down regulation of transcription by glucose,
C1158784,positive regulation of transcription by glucose,glucose,upregulation of transcription by glucose; up regulation of transcription by glucose; up-regulation of transcription by glucose,
C1158793,regulation of transcription by glucose,glucose,,
C1159527,glucose uptake,glucose,glucose import; glucose uptake,
C1159528,regulation of glucose import,glucose,regulation of glucose uptake,
C1159529,negative regulation of glucose import,glucose,downregulation of glucose import; down-regulation of glucose import; down regulation of glucose import; negative regulation of glucose uptake,
C1159530,positive regulation of glucose import,glucose,positive regulation of glucose import; positive regulation of glucose uptake; up-regulation of glucose import; upregulation of glucose import; up regulation of glucose import,
C1159531,glucose-6-phosphate transport,glucose,,
C1159549,UDP-glucose transmembrane transport,glucose,,
C1161064,Diabetic care education,diabetes,Health education - diabetes; Diabetic care education (procedure); Teach diabetic care,
C1165353,anhydrous dextrose,glucose,"ANHYDROUS DEXTROSE; Glucose, anhydrous; Anhydrous Dextrose; Dextrose Anhydrous; Dextrose, anhydrous; glucose (anhydrous); dextrose anhydrous; D-Glucose in linear form; D-glucose, anhydrous; Anhydrous glucose (substance); anhydrous dextrose; Dextrose anhydrous; Anhydrous dextrose; Anhydrous glucose; aldehydo-D-glucose; Dextrose, Anhydrous; Glucose anhydrous",
C1167419,"alpha,alpha-trehalose-phosphate synthase complex (UDP-forming)",glucose,"UDP-glucose-glucosephosphate glucosyltransferase complex location; trehalose-6-phosphate synthase complex location; UDP-glucose-glucosephosphate glucosyltransferase complex; alpha,alpha-trehalose-phosphate synthase complex location (UDP-forming); trehalose-6-phosphate synthase complex; trehalose-6-phosphate synthase/phosphatase",
C1167667,Diabetic mastopathy,diabetes,Mastopathy due to diabetes mellitus; Mastopathy due to diabetes mellitus (disorder); Lymphocytic mastitis,
C1170765,Accu-Chek Glucose Control High,glucose,,
C1170766,Accu-Chek Glucose Control Low,glucose,,
C1170820,In Charge Glucose-Protein Strip,glucose,,
C1171304,diabetes risk,diabetes,diabetes risks; risk diabetes; diabetes risk; Diabetes risk,
C1171820,sitosterol-3-glucose,glucose,,
C1171821,beta-sitosterol-3-beta-D-glucose,glucose,,
C1175052,"DARP protein, mouse",diabetes,"diabetes-related ankyrin repeat protein, mouse",
C1175053,"ANKRD23 protein, human",diabetes,"DARP protein, human; Muscle ankyrin repeat protein 3, human; diabetes-related ankyrin repeat protein, human; MARP3 protein, human; ankyrin repeat domain 23 protein, human",
C1175135,"2-O-digalloyl-1,3,4,6-tetra-O-galloyl-beta-D-glucose",glucose,,
C1175150,1-O-galloyl-beta-D-glucose,glucose,,
C1175901,poly(3-O-(4'-vinylbenzyl)-D-glucose),glucose,,
C1176136,"ATHXK1 protein, Arabidopsis",glucose,"hexokinase-1, Arabidopsis; hexokinase HXK1, Arabidopsis; hexokinase-like1 protein, Arabidopsis; GLUCOSE INSENSITIVE 2 protein, Arabidopsis; HKL1 protein, Arabidopsis; At4g29130 protein, Arabidopsis; HXK1 protein, Arabidopsis",
C1176269,"ALG8 protein, human",glucose,"dolichyl-P-glucose Glc1Man9GlcNAc2-PP-dolichyl-alpha3-glucosyltransferase, human; hALG8 protein, human; asparagine-linked glycosylation 8 homolog (yeast, alpha-1,3-glucosyltransferase) protein, human",
C1177050,ACCU-CHEK ACTIVE (GLUCOSE) TEST STRIP,glucose,ACCU-CHEK ACTIVE (GLUCOSE) TEST STRIP,
C1177052,ACCU-CHEK VOICEMATE (GLUCOSE) SYSTEM KIT,glucose,ACCU-CHEK VOICEMATE (GLUCOSE) SYSTEM KIT,
C1177089,DIABETES PATIENT EDUCATION PACK,diabetes,DIABETES PATIENT EDUCATION PACK,
C1177171,PRECISION (GLUCOSE) LOW/NORMAL/HIGH CONTROL SOLN,glucose,PRECISION(GLUCOSE)L0W/NORM/HI CONTL SOLN,
C1177172,PRECISION (GLUCOSE) NORMAL/MID CONTROL SOLN,glucose,PRECISION (GLUCOSE) NORM/MID CONTL SOLN,
C1177173,PRECISION XTRA (GLUCOSE) TEST STRIP,glucose,PRECISION XTRA (GLUCOSE) TEST STRIP,
C1238317,fructose / glucose / phosphoric acid Oral Solution [Emetrol],glucose,,
C1241133,glucose Oral Gel [Insta-Glucose],glucose,,
C1245815,glucose / sodium chloride Injectable Solution,glucose,Product containing glucose and sodium chloride in parenteral dose form (medicinal product form); Glucose- and sodium chloride-containing product in parenteral dose form,
C1251137,glucose Injectable Solution,glucose,,
C1251217,fructose / glucose / phosphoric acid Oral Solution,glucose,,
C1252218,glucose Oral Gel,glucose,,
C1254482,CHEM-7 Glucose Measurement,glucose measurement,,
C1254916,Operating Room Misc Labs: Glucose,glucose,,
C1255497,NYH Lab Procedure: Glycohgb A1c-Rogosin,a1c,,
C1255502,General Body Fluid Glucose Test,glucose,,
C1255553,24 Hour Urine Glucose Test,glucose,,
C1255642,Intravascular Fingerstick Glucose Test,glucose,,
C1255663,Ideatel Fingerstick Glucose Test,glucose,,
C1256145,"Intravascular Glucose Test, Not Timed",glucose,,
C1256175,Backoffice Urine Glucose Test,glucose,,
C1256377,Intravascular Glucose Test,glucose,,
C1256999,"rapA protein, Bacillus subtilis",glucose,"stage 0 sporulation protein L, Bacillus subtilis; glucose starvation-inducible protein A, Bacillus subtilis",
C1257958,Glucose Metabolism Disorders,glucose,"Glucose Metabolic Disorder; Metabolic Disorder, Glucose; Metabolism Disorder, Glucose; Disorder, Glucose Metabolic; Metabolism Disorders, Glucose; Disorder of glucose metabolism; Glucose Metabolism Disorder; Disorder of Glucose Metabolism; Glucose Metabolic Disorders; glucose metabolism disorders; Disorders, Glucose Metabolic; Metabolic Disorders, Glucose; Disorders, Glucose Metabolism; Disorder of glucose metabolism (disorder); Disorder, Glucose Metabolism; metabolic glucose disorders; disorders glucose metabolism",
C1258867,"SLC2A14 protein, human",glucose,"glucose transporter 14, human; GLUT14 protein, human; solute carrier family 2 (facilitated glucose transporter), member 14 protein, human",
C1259059,2-deoxy-2-(3-hydroxybutyramido)-glucose,glucose,2-D-HBA-G,
C1259060,2-deoxy-2-((R)-3-hydroxybutyramido)-D-glucose,glucose,,
C1259466,"CAP protein, Drosophila",glucose,"Rexin protein, Drosophila; DCAP glucose transport protein, Drosophila",
C1260027,glucose-6-phosphate dehydrogenase La Jolla,glucose,G6PD La Jolla,
C1260439,Elevated fasting glucose,glucose,Elevated fasting glucose,
C1260440,Elevated glucose tolerance test,glucose,,
C1260442,Abnormal non-fasting glucose,glucose,,
C1260443,Other abnormal glucose,glucose,,
C1261236,Hemoglobin A1c level result,a1c,,
C1261429,Random blood glucose level result,glucose level,random blood glucose; random blood glucose level; random blood sugar; blood glucose levels random,
C1261430,Fasting blood sugar result,glucose level,fasting blood glucose level; blood glucose fasting; fasting blood glucose; blood fasting glucose; fasting blood sugar; blood fasting glucose levels; fast blood sugar,
C1261431,Lunch time blood sugar level result,blood sugar,,
C1261432,Supper time blood sugar level result,blood sugar,,
C1261433,Bedtime blood sugar level result,blood sugar,,
C1261750,glucose 150 MG/ML,glucose,,
C1263738,Drug-induced nephrogenic diabetes insipidus,diabetes,Drug-induced nephrogenic diabetes insipidus (disorder),
C1263846,Attention deficit hyperactivity disorder,hyper,"Attention deficit hyperactivity disorder (ADHD); ADHD; ADHD (attention deficit hyperactivity disorder); Deficit-Hyperactivity Disorders, Attention; Attention deficit-hyperactivity disorder (ADHD); Attention deficit hyperactivity disorder, predominantly hyperactive impulsive type (disorder); Hyperkinetic syndrome NOS; Hyperkinetic syndrome of childhood; Attention deficit hyperactivity disorder, hyperactive impulsive type; Unspecified hyperkinetic syndrome; SYNDROME HYPERKINETIC; hyperactive child syndrome; Attention Deficit Hyperactivity Disorder; HYPERACTIVITY OF CHILDHOOD; Attention deficit disorder of childhood with hyperactivity; Childhood attention deficit/hyperactivity disorder; attention deficit disorder with hyperactivity; Hyperkinetic disorder; Disorders, Attention Deficit-Hyperactivity; Hyperactivity Disorder, Predominantly Hyperactive-Impulsive Type; Hyperactivity Disorder NOS; attention deficit hyper disorder; ADD; Attention deficit disorder with hyperactivity; Attention-deficit/hyperactivity disorder; Attention-Deficit Disorder, Predominantly Hyperactive-Impulsive Type; attention deficits disorder hyper; Attention-deficit hyperactivity disorder; attention deficit(hyper) disorder; Unspecified hyperkinetic syndrome of childhood; Disorder, Attention Deficit-Hyperactivity; Hyperkinetic Syndrome; Attention deficit/hyperactivity disorder; Attention Deficit Hyperactivity Disorders; ATTENTION DEFICIT-HYPERACTIVITY DISORDER; Attention-deficit hyperactivity disorder (ADHD); minimal brain dysfunction; Hyperkinetic syndrome; Overactive child syndrome; childhood hyperkinetic syndrome; Attention deficit hyperactivity disorder (disorder); hyperkinetic syndrome; disorder hyperactivity; ADHD - Attention deficit disorder with hyperactivity; Attention deficit hyperactivity disorder, predominantly hyperactive impulsive type; Attention Deficit Disorder with Hyperactivity; HYPERKINETIC SYNDROME; Attention Deficit Disorders with Hyperactivity; Attention Deficit-Hyperactivity Disorders; Attention deficit disorder; attention deficit hyperactivity disorder; addh; Attention deficit disorder with hyperactivity syndrome; Deficit-Hyperactivity Disorder, Attention; hyperactivity disorder; Attention Deficit-Hyperactivity Disorder; attention deficit hyperactivity disorder (ADHD); Hyperactive child syndrome; Syndromes, Hyperkinetic; Attention deficit-hyperactivity disorder; ADDH; Attention deficit hyperactivity disorder; hyperkinetic disorder; Attention-deficit/hyperactivity disorder (ADHD); Attention deficit hyperkinetic disorder; Attention deficit; Attention deficits",
C1263875,Impaired glucose tolerance with hyperinsulism,glucose,Impaired glucose tolerance with hyperinsulism (disorder),
C1263957,Sensory neuropathy due to diabetes mellitus,diabetes,Sensory neuropathy due to diabetes mellitus (disorder); Sensory neuropathy due to diabetes mellitus,
C1263959,Diabetic ketoacidosis without coma,diabetes,Ketoacidosis without coma due to diabetes mellitus; Ketoacidosis without coma due to diabetes mellitus (disorder),
C1263960,Diabetes with coma (disorder),diabetes,"Comas, Diabetic; Coma due to diabetes mellitus; Diabetic Coma; COMA HYPERGLYCAEMIC; diabetes with coma; Diabetic coma, NOS; diabetes coma; Coma due to diabetes mellitus (disorder); coma diabetes; Diabetic Comas; COMA DIABETIC; diabetic comas; Diabetic coma; hyperglycemic coma; COMA HYPERGLYCEMIC; coma diabetic; DIABETIC COMA; Coma, Diabetic; diabetic coma",
C1272092,Impaired fasting glycemia,glucose,Impaired fasting glycemia (disorder); Impaired fasting glycaemia; Impaired fasting glucose; impaired fasting glucose,
C1273344,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,diabetes,Hyperosmolar non-ketotic state in type 2 diabetes mellitus; Hyperosmolar non-ketotic state due to type 2 diabetes mellitus (disorder),
C1273420,Urine screening test for diabetes,diabetes,Urine screening test for diabetes (procedure),
C1273986,Diabetes medication review,diabetes,Diabetes medication review (procedure),
C1274299,Wet gangrene of foot due to diabetes mellitus,diabetes,Diabetic wet gangrene of the foot; Wet gangrene of foot due to diabetes mellitus (disorder),
C1275127,Hyper-IgD periodic fever syndrome (HIDS),hyper,Hyper-IgD periodic fever syndrome; Hyper-immunoglobulin D periodic fever syndrome (disorder); HIDS - hyper-IgD periodic fever syndrome; Hyper-immunoglobulin D periodic fever syndrome,
C1275128,Autosomal recessive hyperimmunoglobulin M syndrome,hyper,Autosomal recessive hyper- immunoglobulin M syndrome; Autosomal recessive hyperimmunoglobulin M syndrome (disorder); Autosomal recessive hyper-IgM syndrome,
C1275412,High risk proliferative retinopathy without macular edema due to diabetes mellitus,diabetes,Proliferative diabetic retinopathy - high risk with no macular oedema; High risk proliferative retinopathy without macular oedema due to diabetes mellitus; High risk proliferative retinopathy without macular edema due to diabetes mellitus (disorder); PDR - high risk with no macular edema; PDR - high risk with no macular oedema; Proliferative diabetic retinopathy - high risk with no macular edema,
C1275413,Very severe nonproliferative retinopathy without macular edema due to diabetes mellitus,diabetes,Very severe nonproliferative retinopathy without macular edema due to diabetes mellitus (disorder); Very severe nonproliferative retinopathy without macular oedema due to diabetes mellitus; Very severe NPDR (nonproliferative diabetic retinopathy) with no macular edema; Very severe nonproliferative diabetic retinopathy with no macular oedema; Very severe NPDR (nonproliferative diabetic retinopathy) with no macular oedema; Very severe nonproliferative diabetic retinopathy with no macular edema,
C1275414,Non-high-risk proliferative retinopathy with no macular edema due to diabetes mellitus,diabetes,Non-high-risk PDR with no macular edema; Non-high-risk proliferative diabetic retinopathy with no macular oedema; Non-high-risk PDR with no macular oedema; Non-high-risk proliferative retinopathy with no macular oedema due to diabetes mellitus; Non-high-risk proliferative retinopathy with no macular edema due to diabetes mellitus (disorder); Non-high-risk proliferative diabetic retinopathy with no macular edema,
C1275415,Severe nonproliferative retinopathy without macular edema due to diabetes mellitus,diabetes,Severe nonproliferative diabetic retinopathy with no macular oedema; Severe nonproliferative retinopathy without macular oedema due to diabetes mellitus; Severe NPDR (nonproliferative diabetic retinopathy) with no macular edema; Severe nonproliferative retinopathy without macular edema due to diabetes mellitus (disorder); Severe nonproliferative diabetic retinopathy with no macular edema; Severe NPDR (nonproliferative diabetic retinopathy) with no macular oedema,
C1275499,Diabetic optic papillopathy,diabetes,papillopathy; Diabetic disc edema; Optic papillopathy due to diabetes mellitus; Papillopathy; diabetic papillopathy; Optic papillopathy due to diabetes mellitus (disorder); Diabetic disc oedema; Diabetic papillopathy,
C1275951,High risk proliferative retinopathy not amenable to photocoagulation due to diabetes mellitus,diabetes,High risk proliferative diabetic retinopathy not amenable to photocoagulation; High risk proliferative retinopathy not amenable to photocoagulation due to diabetes mellitus (disorder); High risk PDR not amenable to photocoagulation,
C1275952,Severe nonproliferative retinopathy with clinically significant macular edema due to diabetes mellitus,diabetes,Severe nonproliferative diabetic retinopathy with clinically significant macular edema; Severe nonproliferative retinopathy with clinically significant macular oedema due to diabetes mellitus; Severe NPDR (nonproliferative diabetic retinopathy) with CSME (clinically significant macular edema); Severe NPDR (nonproliferative diabetic retinopathy) with CSME (clinically significant macular oedema); Severe nonproliferative diabetic retinopathy with clinically significant macular oedema; Severe nonproliferative retinopathy with clinically significant macular edema due to diabetes mellitus (disorder),
C1275953,High risk proliferative retinopathy with clinically significant macula edema due to diabetes mellitus,diabetes,High risk proliferative retinopathy with clinically significant macula edema due to diabetes mellitus (disorder); Proliferative diabetic retinopathy - high risk with clinically significant macular edema; Proliferative diabetic retinopathy - high risk with clinically significant macular oedema; PDR - high risk with CSME; High risk proliferative retinopathy with clinically significant macula oedema due to diabetes mellitus,
C1275954,Non-high-risk proliferative retinopathy with clinically significant macular edema due to diabetes mellitus,diabetes,Non-high-risk proliferative retinopathy with clinically significant macular edema due to diabetes mellitus (disorder); Non-high-risk proliferative diabetic retinopathy with clinically significant macular edema; Non-high-risk proliferative retinopathy with clinically significant macular oedema due to diabetes mellitus; Non-high-risk proliferative diabetic retinopathy with clinically significant macular oedema; Non-high risk PDR with CSME,
C1275955,Very severe nonproliferative retinopathy due to diabetes mellitus,diabetes,Very severe nonproliferative diabetic retinopathy; Very severe NPDR (nonproliferative diabetic retinopathy); Very severe nonproliferative retinopathy due to diabetes mellitus (disorder),
C1275956,Very severe nonproliferative retinopathy with clinically significant macular edema due to diabetes mellitus,diabetes,Very severe nonproliferative retinopathy with clinically significant macular oedema due to diabetes mellitus; Very severe NPDR (nonproliferative diabetic retinopathy) with CSME (clinically significant macular edema); Very severe nonproliferative diabetic retinopathy with clinically significant macular oedema; Very severe nonproliferative retinopathy with clinically significant macular edema due to diabetes mellitus (disorder); Very severe NPDR (nonproliferative diabetic retinopathy) with CSME (clinically significant macular oedema); Very severe nonproliferative diabetic retinopathy with clinically significant macular edema,
C1276391,Glucose monitoring at home,glucose,Glucose monitoring at home; home glucose monitor; home glucose monitoring; Glucose monitoring at home (regime/therapy); glucose monitoring at home,
C1276495,T1: Tumor limited to one subsite of hypo-pharynx and < 2 cm in greatest dimension,hypo,T1: Tumour limited to one subsite of hypo-pharynx and < 2 cm in greatest dimension; T1: Tumor limited to one subsite of hypo-pharynx and < 2 cm in greatest dimension (finding),
C1277607,Diabetes mellitus excluded,diabetes,Diabetes mellitus excluded (situation),
C1277712,HbA1c measurement (DCCT aligned),diabetes,Haemoglobin A1c measurement aligned to the Diabetes Control and Complications Trial; Hemoglobin A1c measurement aligned to the Diabetes Control and Complications Trial (procedure); HbA1c level (DCCT aligned); Hemoglobin A1c measurement aligned to the Diabetes Control and Complications Trial,
C1278095,30 minute blood glucose measurement,glucose level,30 minute blood glucose level; 30 minute blood glucose measurement (procedure),
C1278096,60 minute blood glucose measurement,glucose level,60 minute blood glucose measurement (procedure); 60 minute blood glucose level,
C1278097,90 minute blood glucose measurement,glucose level,90 minute blood glucose measurement (procedure); 90 minute blood glucose level,
C1278098,120 minute blood glucose measurement,glucose level,120 minute blood glucose level; 120 minute blood glucose measurement (procedure),
C1278099,150 minute blood glucose measurement,glucose level,150 minute blood glucose level; 150 minute blood glucose measurement (procedure),
C1278150,30 minute serum glucose measurement,serum glucose,30 minute serum glucose level; 30 minute serum glucose measurement (procedure),
C1278151,60 minute serum glucose measurement,serum glucose,60 minute serum glucose measurement (procedure); 60 minute serum glucose level,
C1278153,90 minute serum glucose measurement,serum glucose,90 minute serum glucose level; 90 minute serum glucose measurement (procedure),
C1278154,120 minute serum glucose measurement,serum glucose,120 minute serum glucose measurement (procedure); 120 minute serum glucose level,
C1278155,150 minute serum glucose measurement,serum glucose,150 minute serum glucose measurement (procedure); 150 minute serum glucose level,
C1278156,30 minute plasma glucose measurement,plasma glucose,30 minute plasma glucose measurement (procedure); 30 minute plasma glucose level,
C1278157,60 minute plasma glucose measurement,plasma glucose,60 minute plasma glucose measurement (procedure); 60 minute plasma glucose level,
C1278158,90 minute plasma glucose measurement,plasma glucose,90 minute plasma glucose level; 90 minute plasma glucose measurement (procedure),
C1278159,120 minute plasma glucose measurement,plasma glucose,120 minute plasma glucose measurement (procedure); 120 minute plasma glucose level,
C1278160,150 minute plasma glucose measurement,plasma glucose,150 minute plasma glucose measurement (procedure); 150 minute plasma glucose level,
C1278603,Diabetes resolved,diabetes,Diabetes resolved (finding),
C1279187,Diabetes mellitus insulin-glucose infusion in acute myocardial infarction,glucose,DIGAMI - diabetes mellitus insulin-glucose infusion in acute myocardial infarction; Diabetes mellitus insulin-glucose infusion in acute myocardial infarction (procedure),
C1279304,Hypoglycemic coma due to type 1 diabetes mellitus,diabetes,Diabetes type 1 with hypoglycemic coma; Hypoglycemic coma due to type 1 diabetes mellitus (disorder); Hypoglycaemic coma in type I diabetes mellitus; Hypoglycemic coma in type I diabetes mellitus; Hypoglycemic coma in type 1 diabetes mellitus; Hypoglycaemic coma in type 1 diabetes mellitus; Hypoglycaemic coma due to type 1 diabetes mellitus; Diabetes type 1 with hypoglycaemic coma,
C1279306,Type 1 diabetes mellitus with arthropathy,diabetes,Insulin dependent diabetes mellitus with arthropathy; Type I diabetes mellitus with arthropathy; Arthropathy due to type 1 diabetes mellitus (disorder); Arthropathy due to type 1 diabetes mellitus,
C1279307,Neuropathic arthropathy due to type 1 diabetes mellitus,diabetes,Type 1 diabetes mellitus with neuropathic arthropathy; Diabetes mellitus type 1 with diabetic Charcot's arthropathy; Diabetic neuropathic arthropathy due to type 1 diabetes mellitus; Neuropathic arthropathy due to type 1 diabetes mellitus (disorder),
C1279312,Hypoglycemic coma due to type 2 diabetes mellitus,diabetes,Hypoglycaemic coma due to type 2 diabetes mellitus; Hypoglycemic coma due to type 2 diabetes mellitus (disorder),
C1279313,Type 2 diabetes mellitus with peripheral angiopathy,diabetes,Type II diabetes mellitus with peripheral angiopathy; Peripheral angiopathy due to type 2 diabetes mellitus; Peripheral angiopathy due to type 2 diabetes mellitus (disorder),
C1279314,Arthropathy due to type 2 diabetes mellitus,diabetes,Type II diabetes mellitus with arthropathy; Arthropathy due to type 2 diabetes mellitus (disorder); Type 2 diabetes mellitus with arthropathy,
C1281922,Diffuse exudative maculopathy due to diabetes mellitus,diabetes,Diffuse exudative diabetic maculopathy; Diffuse exudative maculopathy due to diabetes mellitus (disorder); Diffuse exudative maculopathy with diabetes mellitus; Diffuse diabetic maculopathy,
C1281923,Focal exudative maculopathy due to diabetes mellitus,diabetes,Focal exudative maculopathy due to diabetes mellitus (disorder); Focal exudative diabetic maculopathy; Focal diabetic maculopathy,
C1281924,Ischemic maculopathy due to diabetes mellitus,diabetes,Ischaemic maculopathy with diabetes mellitus; Ischaemic diabetic maculopathy; Ischemic diabetic maculopathy; Ischemic maculopathy with diabetes mellitus; Ischaemic maculopathy due to diabetes mellitus; Ischemic maculopathy due to diabetes mellitus (disorder),
C1281925,Mixed maculopathy due to diabetes mellitus,diabetes,Mixed maculopathy due to diabetes mellitus (disorder); Mixed diabetic maculopathy; Mixed maculopathy with diabetes mellitus,
C1282941,Diabetic neuropathy with neurologic complication,diabetes,Neuropathy with neurologic complication due to diabetes mellitus; Neuropathy with neurologic complication due to diabetes mellitus (disorder); Diabetic neuropathy with neurologic complication,
C1282951,Type 2 diabetes mellitus in nonobese,diabetes,Diabetes mellitus type 2 in nonobese; NIDDM in nonobese; Diabetes mellitus type 2 in nonobese (disorder),
C1287281,"Finding of glucose concentration, dipstick",glucose,"glucose concentration; concentrations glucose; concentration glucose; Glucose concentration, dipstick - finding; Finding of glucose concentration, dipstick; Finding of glucose concentration, dipstick (finding)",
C1287394,Hemoglobin A1C - diabetic control finding,a1c,Hemoglobin A1C - diabetic control finding (finding); Haemoglobin A1C - diabetic control finding,
C1287787,Small intestine glucose tolerance - finding,glucose,Finding of small intestine glucose tolerance (finding); Finding of small intestine glucose tolerance,
C1290211,Mixed sensorimotor polyneuropathy due to diabetes mellitus,diabetes,Diabetic mixed sensory-motor polyneuropathy; Mixed sensorimotor polyneuropathy due to diabetes mellitus (disorder),
C1290212,Motor polyneuropathy due to diabetes mellitus,diabetes,Diabetic motor polyneuropathy; Motor polyneuropathy due to diabetes mellitus (disorder),
C1291220,Deficiency of UDPglucose dehydrogenase,glucose,Deficiency of uridine diphosphate-glucose dehydrogenase (disorder); Deficiency of uridine diphosphate-glucose dehydrogenase,
C1291240,Deficiency of glucose dehydrogenase,glucose,Deficiency of glucose dehydrogenase (disorder),
C1291250,Deficiency of glucose oxidase,glucose,Deficiency of glucose oxidase (disorder); Deficiency of glucose oxyhydrase,
C1291369,Deficiency of phosphoglucokinase,glucose,Deficiency of phosphoglucokinase (disorder); Deficiency of glucose-phosphate kinase,
C1291392,Deficiency of glucose-1-phosphate phosphodismutase,glucose,Deficiency of glucose-1-phosphate phosphodismutase (disorder),
C1291410,Deficiency of UTP-glucose-1-phosphate uridylyltransferase,glucose,Deficiency of uridine triphosphate-glucose-1-phosphate uridylyltransferase (disorder); Deficiency of uridine triphosphate-glucose-1-phosphate uridylyltransferase; Deficiency of glucose-1-phosphate uridylyltransferase; Deficiency of UDPglucose pyrophosphorylase,
C1291468,Deficiency of glucose-1-phosphatase,glucose,Deficiency of glucose-1-phosphatase (disorder),
C1291611,Deficiency of glucose-6-phosphate isomerase,glucose,Deficiency of hexosephosphate isomerase; Phosphohexose isomerase deficiency; Deficiency of phosphoglucoisomerase; Deficiency of glucose-6-phosphate isomerase; Deficiency of glucose-6-phosphate isomerase (disorder); Deficiency of phosphohexose isomerase; Glucosephosphate isomerase deficiency; Deficiency of oxoisomerase,
C1291618,Deficiency of phosphoglucomutase,glucose,Deficiency of phosphoglucomutase (disorder); Phosphoglucomutase deficiency; Deficiency of glucose phosphomutase,
C1292333,Antigen in Bg blood group series,BG,Antigen in Bg blood group series (substance),
C1292364,Antibody to antigen in Bg blood group series,BG,Antibody to antigen in Bg blood group series (substance),
C1295454,Dolichyl-phosphate-glucose phosphodiesterase,glucose,Dolichyl-phosphate-glucose phosphodiesterase (substance),
C1299632,Skin ulcer due to diabetes mellitus,diabetes,Skin ulcer due to diabetes mellitus (disorder); Diabetic skin ulcer,
C1300107,"Patient death or serious disability associated with hypoglycemia, the onset of which occurs while the patient is being cared for in a healthcare facility",hypoglycemia,"Patient death or serious disability associated with hypoglycemia, the onset of which occurs while the patient is being cared for in a healthcare facility (event); Patient death or serious disability associated with hypoglycaemia, the onset of which occurs whilst the patient is being cared for in a healthcare facility",
C1302691,Macular edema not clinically significant due to diabetes mellitus,diabetes,Macular edema not clinically significant with diabetes mellitus; Diabetic macular oedema not clinically significant; Macular edema not clinically significant due to diabetes mellitus (disorder); Diabetic macular edema not clinically significant; Macular oedema not clinically significant due to diabetes mellitus; Macular oedema not clinically significant with diabetes mellitus,
C1302692,Very severe proliferative retinopathy due to diabetes mellitus,diabetes,Very severe proliferative diabetic retinopathy; Very severe proliferative retinopathy due to diabetes mellitus (disorder),
C1303818,Blood glucose biosensor testing discs,blood glucose,Blood glucose biosensor testing discs (physical object),
C1303819,Blood glucose colorimetric testing strips,blood glucose,Blood glucose colorimetric testing strips (physical object); Blood glucose colourimetric testing strips,
C1304762,2 hours post-food blood sugar level result,blood sugar,,
C1304780,Dipstick blood sugar level result,blood sugar,,
C1305108,"Addison's disease, struma lymphomatosa and insulin-dependent diabetes mellitus",diabetes,"Addison's disease with struma lymphomatosa; Addison's disease, toxic diffuse goitre and insulin-dependent diabetes mellitus; Addison's disease, toxic diffuse goiter and insulin-dependent diabetes mellitus; Addison's disease, struma lymphomatosa and insulin-dependent diabetes mellitus",
C1306674,Diabetic intraretinal microvascular anomalies,diabetes,Intraretinal microvascular anomaly due to diabetes mellitus; diabetic intraretinal microvascular anomalies; Intraretinal microvascular anomaly due to diabetes mellitus (disorder); Diabetic intraretinal microvascular anomaly,
C1308876,"HGRG-14 protein, human",glucose,"high-glucose regulated gene 14 protein, human",
C1308931,"TGTP1 protein, Taenia solium",glucose,"glucose transporter TGTP1, Taenia solium",
C1308932,"TGTP2 protein, Taenia solium",glucose,"glucose transporter TGTP2, Taenia solium",
C1310424,"SLC2A12 protein, human",glucose,"solute carrier family 2 (facilitated glucose transporter), member 12 protein, human; GLUT-12 protein, human; GLUT12 protein, human",
C1311395,"ADP-glucose pyrophosphorylase, Arabidopsis",glucose,,
C1311410,"GRP78 protein, rat",glucose,"BIP protein, rat; steroidogenesis-activator polypeptide, rat; steroidogenesis-activator protein, rat; heat shock 70kD protein 5, rat; Hspa5 protein, rat; Immunoglobulin heavy chain binding protein, rat; SAPP protein, rat; 78 kDa glucose-regulated protein precursor protein, rat",
C1311600,"1,3,6-tri-O-galloyl-beta-D-glucose",glucose,,
C1312018,mannosyl(6)-N-acetyl(2)glucose,glucose,Man6GlcNAc2,
C1313414,"glucose-dependent insulinotropic polypeptide, Pro(3)-",glucose,"(Pro3)GIP; glucose-dependent insulinotropic polypeptide, prolyl(3)-; 3-Pro-GIP; (Pro(3))GIP",
C1313467,cyclic uridine diphosphate glucose,glucose,cUDPG; cyclic UDPG,
C1313937,Family history of diabetes mellitus,diabetes,Family history of diabetes mellitus; Family history: Diabetes mellitus; Family history of diabetes; Family history of diabetes mellitus (situation); FH: Diabetes mellitus,
C1314777,BG 9719,BG,BG9719; BG-9719,
C1315250,Glucose-6-Phosphatase:CCnc:Pt:RBC:Qn,glucose,Glucose-6-Phosphatase (RBC) [Catalytic activity/Vol]; Glucose-6-Phosphatase:Catalytic Concentration:To identify measures at a point in time:Erythrocytes:Quantitative; G6Pas RBC-cCnc; Glucose-6-Phosphatase [Enzymatic activity/volume] in Red Blood Cells,
C1315291,Glucose^45M post dose lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^45M post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --45 minutes post dose lactose PO; Glucose 45M p Lac PO SerPl-mCnc; Glucose 45 Min post dose lactose PO [Mass/Vol],
C1315495,Glucose^30M post 1.2 g/kg lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --30 minutes post 1.2 g/kg lactose PO; Glucose 30 Min post 1.2 g/kg lactose PO [Mass/Vol]; Glucose^30 minutes post 1.2 g/kg lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30M p 1.2 g/kg Lac PO SerPl-mCnc,
C1315719,Diabetes status:Prid:Pt:^Patient:Nom,diabetes,Diabetes status:Presence or Identity:To identify measures at a point in time:^Patient:Nominal; Diabetes status Nom; Diabetes status [Identifier]; Diabetes status Patient,
C1315756,Glucose-6-Phosphate dehydrogenase:PrThr:Pt:Bld.dot:Ord,glucose,G6PD DBS Ql; Glucose-6-Phosphate dehydrogenase:Presence or Threshold:To identify measures at a point in time:Dried blood spot:Ordinal; G6PD Ql (DBS); Glucose-6-Phosphate dehydrogenase [Presence] in DBS,
C1315821,Glucose/Creatinine:MRto:Pt:Urine:Qn,glucose,Glucose/Creatinine [Mass Ratio] in Urine; Glucose/Creatinine:Mass Ratio:To identify measures at a point in time:Urine:Quantitative; Glucose/Creat Ur; Glucose/Creatinine (U) [Mass ratio],
C1315874,Glucose:MCnc:Pt:Pericard fld:Qn,glucose,Glucose [Mass/volume] in Pericardial fluid; Glucose Pcar-mCnc; Glucose (Pericard fld) [Mass/Vol]; Glucose:Mass Concentration:To identify measures at a point in time:Pericardial fluid:Quantitative,
C1316519,Glucose^pre or post dose arginine:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --pre or post dose arginine; Glucose pre or post dose arginine [Moles/Vol]; Glucose^pre or post dose arginine:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre/p Arg SerPl-sCnc,
C1316520,Glucose^pre or post dose cloNIDine:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --pre or post dose cloNIDine; Glucose pre or post dose cloNIDine [Moles/Vol]; Glucose pre/p CLN SerPl-sCnc; Glucose^pre or post dose cloNIDine:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1316521,Glucose^pre or post dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre/p Gc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --pre or post dose glucagon; Glucose pre or post dose glucagon [Moles/Vol]; Glucose^pre or post dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1316522,Glucose^pre or post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^pre or post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre or post dose glucose [Moles/Vol]; Glucose pre/p Glc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --pre or post dose glucose,
C1316523,Glucose^pre or post dose insulin:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre or post dose insulin [Moles/Vol]; Glucose pre/p Ins SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --pre or post dose insulin; Glucose^pre or post dose insulin:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1316775,Glucose/Creatinine:SRto:Pt:Urine:Qn,glucose,Glucose/Creatinine [Molar ratio] in Urine; Glucose/Creat Ur-sRto; Glucose/Creatinine:Substance Ratio:To identify measures at a point in time:Urine:Quantitative; Glucose/Creatinine (U) [Molar ratio],
C1317007,Protein & Glucose panel:MCnc:Pt:CSF:Qn,glucose,Prot + Glucose Pnl CSF-mCnc; Protein & Glucose panel:Mass Concentration:To identify measures at a point in time:Cerebral spinal fluid:Quantitative; Protein and Glucose panel (CSF) [Mass/Vol]; Protein and Glucose panel [Mass/volume] - Cerebral spinal fluid,
C1317301,diabetes status,diabetes,Diabetes status,
C1317389,Glucose/Creatinine,glucose,Glucose/Creatinine,
C1317654,Protein & Glucose panel,glucose,Protein & Glucose panel; Protein and Glucose panel,
C1318280,Urine glucose: chem. titer result,glucose,,
C1318329,Post-prandial blood sugar result,blood sugar,post prandial blood sugar; post prandial blood glucose,
C1318336,Capillary blood glucose level result,glucose level,,
C1318337,BM stix glucose level result,glucose level,,
C1318371,Serum random glucose level result,glucose level,,
C1318372,Serum fasting glucose level result,glucose level,,
C1318373,Serum 2-hr post-prandial glucose level result,glucose level,,
C1318374,Plasma random glucose level observed,glucose level,,
C1318375,Plasma fasting glucose level observed,glucose level,,
C1318376,Plasma 2-hr post-prandial glucose level observed,glucose level,,
C1318395,Fluid sample glucose level result,glucose level,,
C1318605,Diabetes mellitus induced by non-steroid drugs,diabetes,Diabetes mellitus caused by non-steroid drugs; Diabetes mellitus caused by non-steroid drugs (disorder); DM caused by non-steroid drug; DM induced by non-steroid drug,
C1318607,HBA1c target,a1c,Haemoglobin A1c (HBA1c) target; Haemoglobin A1c target; Hemoglobin A1c (HBA1c) target; Target HbA1c level; Hemoglobin A1c target; Hemoglobin A1c target (observable entity),
C1319140,Diabetes self-management behavior,diabetes,Diabetes self-management behaviour; diabetes self-management; Diabetes self-management behavior (observable entity); Diabetes self-management,
C1319147,Knowledge level: diabetes management,diabetes,Knowledge level: diabetes management (observable entity); Knowledge: diabetes management,
C1319276,Fecal glucose level,glucose level,Fecal glucose level (procedure); Faecal glucose level; Fecal glucose measurement; Faecal glucose measurement,
C1319522,Under care of diabetes specialist nurse,diabetes,Under care of diabetes specialist nurse (finding),
C1319543,Disorder of right macula due to diabetes mellitus,diabetes,Maculopathy of right eye with diabetes mellitus; Disorder of right macula due to diabetes mellitus (disorder); Maculopathy of right eye due to diabetes mellitus; Diabetic maculopathy of right eye,
C1319544,Disorder of left macula due to diabetes mellitus,diabetes,Maculopathy of left eye due to diabetes mellitus; Maculopathy of left eye with diabetes mellitus; Disorder of left macula due to diabetes mellitus (disorder); Diabetic maculopathy of left eye,
C1319582,Diabetes key contact,diabetes,Diabetes key contact (occupation),
C1319905,Patient on maximal tolerated therapy for diabetes,diabetes,Patient on maximal tolerated therapy for diabetes (finding),
C1320655,Newly diagnosed diabetes,diabetes,Newly diagnosed diabetes (finding); newly diagnosed diabetes; diabetes diagnosed newly,
C1320657,Diabetes type,diabetes,diabetes type; diabete type; type diabetes; diabetes types; Diabetes type (observable entity),
C1320980,Blood glucose status,blood glucose,Blood glucose status (observable entity),
C1321510,Entire basal nuclei,BG,Entire basal nucleus; Entire BG - Basal ganglion; Entire basal ganglion; Entire basal ganglion (body structure); Entire basal nuclei; Entire BG - Basal ganglia,
C1322885,HbA1c Analyzers,a1c,HA1c Analyzers; Hemoglobin A1c Analyzers,
C1322958,"Analyzers, Laboratory, Body Fluid, Glucose",glucose,"Analyzers, Laboratory, Blood, Glucose",
C1322966,"Analyzers, Point-of-Care, Whole Blood, Glucose",blood glucose,"Blood Glucose Monitors, Portable",
C1322993,"Analyzers, Point-of-Care, Whole Blood/Urine, Multianalyte, Diabetes",diabetes,,
C1323555,6-acetylglucose deacetylase activity,glucose,6-acetyl-D-glucose acetylhydrolase activity; 6-O-acetylglucose deacetylase activity,
C1323611,dolichylphosphate-glucose phosphodiesterase activity,glucose,dolichyl-phosphate-glucose phosphodiesterase activity; dolichol phosphoglucose phosphodiesterase activity; Dol-P-Glc phosphodiesterase activity; dolichyl-beta-D-glucosyl-phosphate dolichylphosphohydrolase activity,
C1323613,glucose-1-phospho-D-mannosylglycoprotein phosphodiesterase activity,glucose,6-(D-glucose-1-phospho)-D-mannosylglycoprotein glucose-1-phosphohydrolase activity; alpha-glucose-1-phosphate phosphodiesterase activity,
C1323654,[glycogen-synthase-D] phosphatase activity,glucose,UDPglucose-glycogen glucosyltransferase phosphatase activity; UDP-glucose:glycogen 4-alpha-D-glucosyltransferase-D phosphohydrolase activity; UDPglucose:glycogen 4-alpha-D-glucosyltransferase-D phosphohydrolase activity; glycogen synthase phosphatase activity; glycogen-synthase-D phosphatase activity; UDP-glycogen glucosyltransferase phosphatase activity; glycogen synthase D phosphatase activity; glycogen glucosyltransferase phosphatase activity; uridine diphosphoglucose-glycogen glucosyltransferase phosphatase activity; Mg2+ dependent glycogen synthase phosphatase activity; glycogen synthetase phosphatase activity,
C1323702,GDP-glucosidase activity,glucose,GDPglucosidase activity; GDP-glucose glucohydrolase activity; GDPglucose glucohydrolase activity; guanosine diphosphate D-glucose glucohydrolase activity; guanosine diphosphoglucosidase activity,
C1323755,phosphoglucomutase (glucose-cofactor) activity,glucose,"glucose-1-phosphate phosphotransferase activity; alpha-D-glucose 1,6-phosphomutase (glucose-cofactor)",
C1323783,CDP-abequose epimerase activity,glucose,"CDP-paratose epimerase activity; cytidine diphosphoparatose epimerase activity; cytidine diphosphate paratose-2-epimerase activity; CDP-tyvelose 2-epimerase activity; CDP-D-abequose 2-epimerase activity; cytidine diphosphodideoxyglucose epimerase activity; cytidine diphosphoabequose epimerase activity; CDP-3,6-dideoxy-D-glucose 2-epimerase activity; CDP-paratose 2-epimerase activity",
C1323787,glucose-6-phosphate 1-epimerase activity,glucose,D-glucose-6-phosphate 1-epimerase activity; glucose-6 phosphate 1-epimerase activity,
C1323987,"CDP-glucose 4,6-dehydratase activity",glucose,"CDP-glucose 4,6-hydro-lyase (CDP-4-dehydro-6-deoxy-D-glucose-forming); cytidine diphosphoglucose oxidoreductase activity; CDPglucose 4,6-dehydratase activity; CDP-glucose 4,6-hydro-lyase activity; CDPglucose 4,6-hydro-lyase activity",
C1324016,"UDP-glucose 4,6-dehydratase activity",glucose,"UDP-glucose 4,6-hydro-lyase activity; UDP-D-glucose-4,6-hydrolyase activity; UDP-D-glucose oxidoreductase activity; UDPglucose 4,6-dehydratase activity; UDP-glucose 4,6-hydro-lyase (UDP-4-dehydro-6-deoxy-D-glucose-forming); UDPglucose 4,6-hydro-lyase activity",
C1324127,glucose 1-dehydrogenase (NAD+) activity,glucose,D-glucose:NAD+ 1-oxidoreductase activity; D-glucose:NAD oxidoreductase activity; D-aldohexose dehydrogenase activity,
C1324128,glucose 1-dehydrogenase (NADP+) activity,glucose,NADP-linked aldohexose dehydrogenase activity; nicotinamide adenine dinucleotide phosphate-linked aldohexose dehydrogenase activity; D-glucose:NADP+ 1-oxidoreductase activity; NADP-dependent glucose dehydrogenase activity,
C1324206,UDP-N-acetylglucosamine 6-dehydrogenase activity,glucose,UDP-N-acetyl-D-glucosamine:NAD+ 6-oxidoreductase activity; uridine diphosphoacetylglucosamine dehydrogenase activity; UDP-2-acetamido-2-deoxy-D-glucose:NAD oxidoreductase activity; UDPacetylglucosamine dehydrogenase activity; UDP-GLcNAc dehydrogenase activity,
C1324219,glucose-fructose oxidoreductase activity,glucose,D-glucose:D-fructose oxidoreductase activity,
C1324242,pyranose oxidase activity,glucose,glucose 2-oxidase activity; pyranose-2-oxidase activity; pyranose:oxygen 2-oxidoreductase activity,
C1324246,CDP-4-dehydro-6-deoxyglucose reductase activity,glucose,"CDP-4-keto-6-deoxyglucose reductase activity; cytidine diphospho-4-keto-6-deoxy-D-glucose reductase activity; CDP-4-keto-6-deoxy-D-glucose-3-dehydrogenase system activity; CDP-4-keto-deoxy-glucose reductase activity; NAD(P)H:CDP-4-keto-6-deoxy-D-glucose oxidoreductase activity; cytidine diphosphate 4-keto-6-deoxy-D-glucose-3-dehydrogenase activity; CDP-4-dehydro-3,6-dideoxy-D-glucose:NAD(P)+ 3-oxidoreductase activity",
C1324724,indoleacetylglucose-inositol O-acyltransferase activity,glucose,indole-3-acetyl-beta-1-D-glucoside:myo-inositol indoleacetyltransferase activity; 1-O-(indol-3-ylacetyl)-beta-D-glucose:myo-inositol indole-3-ylacetyltransferase activity; 1-O-(indol-3-yl)acetyl-beta-D-glucose:myo-inositol (indol-3-yl)acetyltransferase activity,
C1324728,sinapoylglucose-choline O-sinapoyltransferase activity,glucose,"1-O-(4-hydroxy-3,5-dimethoxycinnamoyl)-beta-D-glucose:choline 1-O-(4-hydroxy-3,5-dimethoxycinnamoyl)transferase activity; sinapine synthase activity",
C1324729,sinapoylglucose-sinapoylglucose O-sinapoyltransferase activity,glucose,"hydroxycinnamoylglucose-hydroxycinnamoylglucose hydroxycinnamoyltransferase activity; 1-O-(4-hydroxy-3,5-dimethoxycinnamoyl)-beta-D-glucoside:1-O-(4-hydroxy-3,5-dimethoxycinnamoyl-beta-D-glucoside 1-O-sinapoyltransferase activity; 1-(hydroxycinnamoyl)-glucose:1-(hydroxycinnamoyl)-glucose hydroxycinnamoyltransferase activity",
C1324738,beta-glucogallin O-galloyltransferase activity,glucose,1-O-galloyl-beta-D-glucose:1-O-galloyl-beta-D-glucose O-galloyltransferase activity,
C1324739,beta-glucogallin-tetrakisgalloylglucose O-galloyltransferase activity,glucose,"beta-glucogallin:1,2,3,6-tetra-O-galloyl-beta-D-glucose 4-O-galloyltransferase activity; beta-glucogallin:1,2,3,6-tetra-O-galloylglucose 4-O-galloyltransferase activity; beta-glucogallin-tetragalloylglucose 4-galloyltransferase activity; 1-O-galloyl-beta-D-glucose:1,2,3,6-tetrakis-O-galloyl-beta-D-glucose 4-O-galloyltransferase activity",
C1324810,"alpha,alpha-trehalose-phosphate synthase (GDP-forming) activity",glucose,GDP-glucose-glucosephosphate glucosyltransferase activity; trehalose phosphate synthase (GDP-forming) activity; GDPglucose-glucose-phosphate glucosyltransferase activity; guanosine diphosphoglucose-glucose phosphate glucosyltransferase activity; GDP-glucose:D-glucose-6-phosphate 1-alpha-D-glucosyltransferase activity; GDPglucose:D-glucose-6-phosphate 1-alpha-D-glucosyltransferase activity,
C1324811,"alpha-1,3-glucan synthase activity",glucose,"UDP-glucose:alpha-D-(1->3)-glucan 3-alpha-D-glucosyltransferase activity; uridine diphosphoglucose-1,3-alpha-glucan glucosyltransferase activity; 1,3-alpha-glucan synthase activity; 1,3-alpha-D-glucan synthase activity; UDPglucose:alpha-D-(1->3)-glucan 3-alpha-D-glucosyltransferase activity; a-1,3-glucan synthase activity",
C1324812,"alpha-1,4-glucan-protein synthase (ADP-forming) activity",glucose,"ADP-glucose:protein 4-alpha-D-glucosyltransferase activity; adenosine diphosphoglucose-protein glucosyltransferase activity; ADPglucose:protein 4-alpha-D-glucosyltransferase activity; ADPglucose:protein glucosyltransferase activity; 1,4alpha-glucan-protein synthase (ADP-forming) activity",
C1324817,diglucosyl diacylglycerol synthase activity,glucose,"DGlcDAG synthase activity; MGlcDAG (1->2) glucosyltransferase activity; UDP-glucose:1,2-diacyl-3-O-(alpha-D-glucopyranosyl)-sn-glycerol (1->2) glucosyltransferase activity; diglucosyl diacylglycerol (DGlcDAG) synthase activity; monoglucosyl diacylglycerol (1->2) glucosyltransferase activity",
C1324845,"1,2-diacylglycerol 3-glucosyltransferase activity",glucose,"UDP-glucose:1,2-diacylglycerol 3-D-glucosyltransferase activity; UDPglucose:1,2-diacylglycerol 3-D-glucosyltransferase activity; uridine diphosphoglucose-diacylglycerol glucosyltransferase activity; UDPglucose:diacylglycerol glucosyltransferase activity; UDP-glucose:1,2-diacylglycerol glucosyltransferase activity; UDP-glucose-diacylglycerol glucosyltransferase activity",
C1324846,13-hydroxydocosanoate 13-beta-glucosyltransferase activity,glucose,uridine diphosphoglucose-hydroxydocosanoate glucosyltransferase activity; UDP-glucose-13-hydroxydocosanoate glucosyltransferase activity; UDPglucose:13-hydroxydocosanoate 13-beta-D-glucosyltransferase activity; UDP-glucose:13-hydroxydocosanoate 13-beta-D-glucosyltransferase activity; 13-glucosyloxydocosanoate 2'-beta-glucosyltransferase activity; UDP-glucose:13-hydroxydocosanoic acid glucosyltransferase activity,
C1324847,"2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one 2-D-glucosyltransferase activity",glucose,"uridine diphosphoglucose-2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one 2-glucosyltransferase activity; UDPglucose:2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one 2-D-glucosyltransferase activity; UDP-glucose:2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one 2-D-glucosyltransferase activity",
C1324848,2-coumarate O-beta-glucosyltransferase activity,glucose,UDPglucose:trans-2-hydroxycinnamate O-beta-D-glucosyltransferase activity; UDP-glucose:trans-2-hydroxycinnamate O-beta-D-glucosyltransferase activity; uridine diphosphoglucose-o-coumarate glucosyltransferase activity; UDPG:o-coumaric acid O-glucosyltransferase activity,
C1324849,4-hydroxybenzoate 4-O-beta-D-glucosyltransferase activity,glucose,PHB-O-glucosyltransferase activity; uridine diphosphoglucose-4-hydroxybenzoate glucosyltransferase activity; UDP-glucose:4-(beta-D-glucopyranosyloxy)benzoic acid glucosyltransferase activity; HBA glucosyltransferase activity; UDPglucose:4-hydroxybenzoate 4-O-beta-D-glucosyltransferase activity; UDP-glucose:4-hydroxybenzoate 4-O-beta-D-glucosyltransferase activity; PHB glucosyltransferase activity; p-hydroxybenzoate glucosyltransferase activity,
C1324850,alizarin 2-beta-glucosyltransferase activity,glucose,"UDPglucose:1,2-dihydroxy-9,10-anthraquinone 2-O-beta-D-glucosyl-transferase activity; alizarin 2-b-glucosyltransferase activity; uridine diphosphoglucose-alizarin glucosyltransferase activity; UDP-glucose:1,2-dihydroxy-9,10-anthraquinone 2-O-beta-D-glucosyltransferase activity",
C1324851,anthocyanidin 3-O-glucosyltransferase activity,glucose,uridine diphosphoglucose-anthocyanidin 3-O-glucosyltransferase activity; UDP-glucose:anthocyanidin 3-O-D-glucosyltransferase activity; UDP-glucose:cyanidin-3-O-glucosyltransferase activity; 3-GT activity; UDP-glucose:anthocyanidin/flavonol 3-O-glucosyltransferase activity; UDP-D-glucose:anthocyanidin 3-O-beta-D-glucosyltransferase activity,
C1324852,arylamine glucosyltransferase activity,glucose,uridine diphosphoglucose-arylamine glucosyltransferase activity; UDPglucose:arylamine N-D-glucosyltransferase activity; UDP glucose-arylamine glucosyltransferase activity; UDP-glucose:arylamine N-D-glucosyltransferase activity,
C1324853,cinnamate beta-D-glucosyltransferase activity,glucose,UDPG:t-cinnamate glucosyltransferase activity; cinnamate b-D-glucosyltransferase activity; cinnamate glucosyltransferase activity; UDP-glucose:trans-cinnamate beta-D-glucosyltransferase activity; UDPglucose:trans-cinnamate beta-D-glucosyltransferase activity; uridine diphosphoglucose-cinnamate glucosyltransferase activity,
C1324854,cis-p-coumarate glucosyltransferase activity,glucose,UDP-glucose:cis-p-coumarate beta-D-glucosyltransferase activity,
C1324855,cis-zeatin O-beta-D-glucosyltransferase activity,glucose,UDPglucose:cis-zeatin O-beta-D-glucosyltransferase activity; cis-zeatin O-b-D-glucosyltransferase activity; UDP-glucose:cis-zeatin O-beta-D-glucosyltransferase activity,
C1324856,coniferyl-alcohol glucosyltransferase activity,glucose,UDP-glucose coniferyl alcohol glucosyltransferase activity; UDPglucose:coniferyl-alcohol 4'-beta-D-glucosyltransferase activity; UDP-glucose:coniferyl-alcohol 4'-beta-D-glucosyltransferase activity; uridine diphosphoglucose-coniferyl alcohol glucosyltransferase activity,
C1324857,cyanidin-3-rhamnosylglucoside 5-O-glucosyltransferase activity,glucose,"cyanidin-3-O-rutinoside 5-O-glucosyltransferase activity; UDP-glucose:cyanidin-3-O-D-rhamnosyl-1,6-D-glucoside 5-O-D-glucosyltransferase activity; UDP-glucose:cyanidin-3-O-beta-L-rhamnosyl-(1->6)-beta-D-glucoside 5-O-beta-D-glucosyltransferase activity; uridine diphosphoglucose-cyanidin 3-rhamnosylglucoside 5-O-glucosyltransferase activity",
C1324858,cyanohydrin beta-glucosyltransferase activity,glucose,UDP-glucose:(S)-4-hydroxymandelonitrile beta-D-glucosyltransferase activity; uridine diphosphoglucose-p-hydroxymandelonitrile glucosyltransferase activity; uridine diphosphoglucose:aldehyde cyanohydrin beta-glucosyltransferase activity; uridine diphosphoglucose-cyanohydrin glucosyltransferase activity; UDP-D-glucose:(S)-4-hydroxymandelonitrile beta-D-glucosyltransferase activity; UDP-glucose:p-hydroxymandelonitrile-O-glucosyltransferase activity; cyanohydrin b-glucosyltransferase activity; UDP-glucose-p-hydroxymandelonitrile glucosyltransferase activity,
C1324859,cytokinin 7-beta-glucosyltransferase activity,glucose,uridine diphosphoglucose-zeatin 7-glucosyltransferase activity; cytokinin 7-b-glucosyltransferase activity; cytokinin 7-glucosyltransferase activity; UDP-glucose:zeatin 7-glucosyltransferase activity; UDPglucose:zeatin 7-glucosyltransferase activity; UDP-glucose-zeatin 7-glucosyltransferase activity,
C1324861,flavanone 7-O-beta-glucosyltransferase activity,glucose,UDPglucose:flavanone 7-O-beta-D-glucosyltransferase activity; uridine diphosphoglucose-flavanone 7-O-glucosyltransferase activity; hesperetin 7-O-glucosyl-transferase activity; UDP-glucose:flavanone 7-O-beta-D-glucosyltransferase activity; naringenin 7-O-glucosyltransferase activity,
C1324862,flavone 7-O-beta-glucosyltransferase activity,glucose,"UDP-glucose:5,7,3',4'-tetrahydroxyflavone 7-O-beta-D-glucosyltransferase activity; UDPglucose:5,7,3',4'-tetrahydroxyflavone 7-O-beta-D-glucosyltransferase activity; UDP-glucose-apigenin beta-glucosyltransferase activity; UDPglucose-apigenin beta-glucosyltransferase activity; flavone 7-O-b-glucosyltransferase activity; UDPglucose-luteolin beta-D-glucosyltransferase activity; UDP-glucose-luteolin beta-D-glucosyltransferase activity; uridine diphosphoglucose-luteolin glucosyltransferase activity; uridine diphosphoglucose-apigenin 7-O-glucosyltransferase activity",
C1324863,flavonol 3-O-glucosyltransferase activity,glucose,uridine diphosphoglucose-flavonol 3-O-glucosyltransferase activity; UDPG:flavonoid-3-O-glucosyltransferase activity; GTI; UDP-glucose:flavonol 3-O-D-glucosyltransferase activity; UDP-glucose flavonol 3-O-glucosyltransferase activity; UDP-glucose:flavonol 3-O-glucosyltransferase activity; UDPglucose:flavonol 3-O-D-glucosyltransferase activity,
C1324864,gallate 1-beta-glucosyltransferase activity,glucose,gallate 1-b-glucosyltransferase activity; UDPglucose:gallate beta-D-glucosyltransferase activity; UDP-glucose-vanillate 1-glucosyltransferase activity; UDPglucose-vanillate 1-glucosyltransferase activity; UDP-glucose:gallate beta-D-glucosyltransferase activity; UDPglucose:vanillate 1-O-glucosyltransferase activity; UDPglucose:gallate glucosyltransferase activity,
C1324865,gibberellin beta-D-glucosyltransferase activity,glucose,uridine diphosphoglucose-gibberellate 3-O-glucosyltransferase activity; gibberellin b-glucosyltransferase activity; uridine diphosphoglucose-gibberellate 7-glucosyltransferase activity; UDPglucose:gibberellin 2-O-beta-D-glucosyltransferase activity; UDP-glucose:gibberellin 2-O-beta-D-glucosyltransferase activity,
C1324866,hydroquinone glucosyltransferase activity,glucose,UDPglucose:hydroquinone-O-beta-D-glucosyltransferase activity; hydroquinone:O-glucosyltransferase activity; UDP-glucose:hydroquinone-O-beta-D-glucosyltransferase activity; arbutin synthase activity,
C1324867,hydroxyanthraquinone glucosyltransferase activity,glucose,UDPglucose:hydroxyanthraquinone O-glucosyltransferase activity; uridine diphosphoglucose-anthraquinone glucosyltransferase activity; UDP-glucose:hydroxyanthraquinone O-glucosyltransferase activity; anthraquinone-specific glucosyltransferase activity,
C1324868,hydroxycinnamate 4-beta-glucosyltransferase activity,glucose,UDP-glucose-hydroxycinnamate glucosyltransferase activity; UDP-glucose:trans-4-hydroxycinnamate 4-O-beta-D-glucosyltransferase activity; hydroxycinnamoyl glucosyltransferase activity; UDPglucose:trans-4-hydroxycinnamate 4-O-beta-D-glucosyltransferase activity; uridine diphosphoglucose-hydroxycinnamate glucosyltransferase activity,
C1324869,hydroxymandelonitrile glucosyltransferase activity,glucose,cyanohydrin glucosyltransferase activity; UDPglucose:4-hydroxymandelonitrile glucosyltransferase activity; UDP-glucose:4-hydroxymandelonitrile glucosyltransferase activity,
C1324870,indole-3-acetate beta-glucosyltransferase activity,glucose,UDP-glucose:indol-3-ylacetate glucosyl-transferase activity; UDPG-indol-3-ylacetyl glucosyl transferase activity; UDP-glucose:indol-3-acetic acid glucosyltransferase activity; IAA-glucose synthase activity; UDP-glucose:(indol-3-yl)acetate beta-D-glucosyltransferase activity; IAGlu synthase activity; UDP-glucose:indol-3-ylacetate glucosyltransferase activity; IAA-Glu synthetase activity; UDPglucose:indole-3-acetate beta-D-glucosyltransferase activity; indol-3-ylacetylglucose synthase activity; uridine diphosphoglucose-indoleacetate glucosyltransferase activity,
C1324871,indoxyl-UDPG glucosyltransferase activity,glucose,indoxyl-UDPG-glucosyltransferase activity; UDP-glucose:indoxyl 3-O-beta-D-glucosyltransferase activity,
C1324872,isoflavone 7-O-glucosyltransferase activity,glucose,UDPglucose:isoflavone 7-O-beta-D-glucosyltransferase activity; UDP-glucose:isoflavone 7-O-beta-D-glucosyltransferase activity; UDPglucose:isoflavone 7-O-glucosyltransferase activity; uridine diphosphoglucose-isoflavone 7-O-glucosyltransferase activity; UDPglucose-flavonoid 7-O-glucosyltransferase activity,
C1324873,isovitexin beta-glucosyltransferase activity,glucose,UDPglucose:isovitexin 2''-O-beta-D-glucosyltransferase activity; uridine diphosphoglucose-isovitexin 2''-glucosyltransferase activity; UDP-glucose:isovitexin 2''-O-beta-D-glucosyltransferase activity; isovitexin b-glucosyltransferase activity,
C1324875,lipopolysaccharide glucosyltransferase II activity,glucose,UDP-glucose:galactosyl-lipopolysaccharide alpha-D-glucosyltransferase activity; uridine diphosphoglucose-galactosylpolysaccharide glucosyltransferase activity; UDPglucose:galactosyl-lipopolysaccharide alpha-D-glucosyltransferase activity; LPS glucosyltransferase II activity,
C1324876,methyl-ONN-azoxymethanol beta-D-glucosyltransferase activity,glucose,uridine diphosphoglucose-methylazoxymethanol glucosyltransferase activity; cycasin synthase activity; UDPglucose-methylazoxymethanol glucosyltransferase activity; UDP-glucose:methyl-ONN-azoxymethanol beta-D-glucosyltransferase activity; methyl-ONN-azoxymethanol glucosyltransferase activity,
C1324877,monoterpenol beta-glucosyltransferase activity,glucose,uridine diphosphoglucose-monoterpenol glucosyltransferase activity; UDP-glucose:(-)-menthol O-beta-D-glucosyltransferase activity; UDPglucose:(-)-menthol O-beta-D-glucosyltransferase activity; UDPglucose:monoterpenol glucosyltransferase activity,
C1324878,N-acetylglucosaminyldiphosphoundecaprenol glucosyltransferase activity,glucose,UDPglucose:N-acetyl-D-glucosaminyldiphosphoundecaprenol 4-beta-D-glucosyltransferase activity; UDP-glucose:N-acetyl-D-glucosaminyldiphosphoundecaprenol 4-beta-D-glucosyltransferase activity; uridine diphosphoglucose-acetylglucosaminylpyrophosphorylundecaprenol glucosyltransferase activity; UDP-D-glucose:N-acetylglucosaminyl pyrophosphorylundecaprenol glucosyltransferase activity,
C1324879,nicotinate-N-glucosyltransferase activity,glucose,UDP-glucose:nicotinate N-glucosyltransferase activity; nicotinate glucosyltransferase activity; UDP-glucose:nicotinic acid-N-glucosyltransferase activity; UDPglucose:nicotinate N-glucosyltransferase activity; uridine diphosphoglucose-nicotinate N-glucosyltransferase activity,
C1324880,nuatigenin 3-beta-glucosyltransferase activity,glucose,"nuatigenin 3beta-glucosyltransferase activity; uridine diphosphoglucose-nuatigenin glucosyltransferase activity; UDPglucose:(20S,22S,25S)-22,25-epoxyfurost-5-ene-3beta,26-diol 3-O-beta-D-glucosyltransferase activity; UDP-glucose:(20S,22S,25S)-22,25-epoxyfurost-5-ene-3beta,26-diol 3-O-beta-D-glucosyltransferase activity",
C1324881,o-dihydroxycoumarin 7-O-glucosyltransferase activity,glucose,"UDP-glucose:7,8-dihydroxycoumarin 7-O-beta-D-glucosyltransferase activity; uridine diphosphoglucose-o-dihydroxycoumarin 7-O-glucosyltransferase activity; UDPglucose:7,8-dihydroxycoumarin 7-O-beta-D-glucosyltransferase activity; UDP-glucose:o-dihydroxycoumarin glucosyltransferase activity",
C1324882,phenol beta-glucosyltransferase activity,glucose,UDPglucosyltransferase activity; UDP-glucosyltransferase activity; UDP-glucose glucosyltransferase activity; phenol b-glucosyltransferase activity; UDP-glucose:phenol beta-D-glucosyltransferase activity; UDP glucosyltransferase activity; phenol-beta-D-glucosyltransferase activity; uridine diphosphoglucosyltransferase activity; UDPglucose:phenol beta-D-glucosyltransferase activity,
C1324883,phosphopolyprenol glucosyltransferase activity,glucose,UDPglucose:polyprenol monophosphate glucosyltransferase activity; UDPglucose:phosphopolyprenol D-glucosyltransferase activity; uridine diphosphoglucose-polyprenol monophosphate glucosyltransferase activity; UDP-glucose:phosphopolyprenol D-glucosyltransferase activity,
C1324884,poly(glycerol-phosphate) alpha-glucosyltransferase activity,glucose,UDP glucose-poly(glycerol-phosphate) alpha-glucosyltransferase activity; uridine diphosphoglucose-poly(glycerol-phosphate) alpha-glucosyltransferase activity; UDPglucose:poly(glycerol-phosphate) alpha-D-glucosyltransferase activity; UDP-glucose:poly(glycerol-phosphate) alpha-D-glucosyltransferase activity,
C1324885,poly(ribitol-phosphate) beta-glucosyltransferase activity,glucose,UDP-D-glucose polyribitol phosphate glucosyl transferase activity; UDP-D-glucose:polyribitol phosphate glucosyl transferase activity; UDP-glucose:poly(ribitol-phosphate) beta-D-glucosyltransferase activity; UDPglucose:poly(ribitol-phosphate) beta-D-glucosyltransferase activity; UDP glucose-poly(ribitol-phosphate) beta-glucosyltransferase activity; uridine diphosphoglucose-poly(ribitol-phosphate) beta-glucosyltransferase activity,
C1324886,pyridoxine 5'-O-beta-D-glucosyltransferase activity,glucose,UDPglucose:pyridoxine 5'-O-beta-D-glucosyltransferase activity; UDP-glucose:pyridoxine 5'-O-beta-D-glucosyltransferase activity; UDP-glucose:pyridoxine 5'-O-beta-glucosyltransferase activity; UDP-glucose-pyridoxine glucosyltransferase activity; uridine diphosphoglucose-pyridoxine 5'-beta-glucosyltransferase activity,
C1324887,salicyl-alcohol beta-D-glucosyltransferase activity,glucose,salicyl-alcohol glucosyltransferase activity; UDPglucose:salicyl-alcohol beta-D-glucosyltransferase activity; UDPglucose:salicyl alcohol phenyl-glucosyltransferase activity; UDP-glucose:salicyl-alcohol beta-D-glucosyltransferase activity; salicyl-alcohol b-D-glucosyltransferase activity; uridine diphosphoglucose-salicyl alcohol 2-glucosyltransferase activity,
C1324888,sarsapogenin 3-beta-glucosyltransferase activity,glucose,UDPglucose:(25S)-5beta-spirostan-3beta-ol 3-O-beta-D-glucosyltransferase activity; sarsapogenin 3beta-glucosyltransferase activity; uridine diphosphoglucose-sarsapogenin glucosyltransferase activity; UDP-glucose:(25S)-5beta-spirostan-3beta-ol 3-O-beta-D-glucosyltransferase activity,
C1324889,scopoletin glucosyltransferase activity,glucose,uridine diphosphoglucose-scopoletin glucosyltransferase activity; UDP-glucose:scopoletin O-beta-D-glucosyltransferase activity; UDPglucose:scopoletin glucosyltransferase activity; UDPglucose:scopoletin O-beta-D-glucosyltransferase activity; SGTase activity,
C1324890,sinapate 1-glucosyltransferase activity,glucose,uridine 5'-diphosphoglucose-hydroxycinnamic acid acylglucosyltransferase activity; UDPglucose:sinapic acid glucosyltransferase activity; UDP-glucose:sinapate D-glucosyltransferase activity; UDPglucose:sinapate D-glucosyltransferase activity; uridine diphosphoglucose-sinapate glucosyltransferase activity,
C1324892,thiohydroximate beta-D-glucosyltransferase activity,glucose,N-hydroxythioamide S-beta-glucosyltransferase activity; thiohydroximate glucosyltransferase activity; thiohydroximate S-glucosyltransferase activity; desulfoglucosinolate-uridine diphosphate glucosyltransferase activity; UDP-glucose:thiohydroximate S-beta-D-glucosyltransferase activity; UDP-glucose:N-hydroxy-2-phenylethanethioamide S-beta-D-glucosyltransferase activity; uridine diphosphoglucose-thiohydroximate glucosyltransferase activity; UDPG:thiohydroximate glucosyltransferase activity,
C1324893,trans-zeatin O-beta-D-glucosyltransferase activity,glucose,zeatin O-b-D-glucosyltransferase activity; UDP-glucose:trans-zeatin O-beta-D-glucosyltransferase activity; UDPglucose:trans-zeatin O-beta-D-glucosyltransferase activity; uridine diphosphoglucose-zeatin O-glucosyltransferase activity; zeatin O-glucosyltransferase activity; zeatin O-beta-D-glucosyltransferase activity,
C1324894,vitexin beta-glucosyltransferase activity,glucose,UDPglucose:vitexin 2''-O-beta-D-glucosyltransferase activity; UDP-glucose:vitexin 2''-O-beta-D-glucosyltransferase activity; uridine diphosphoglucose-vitexin 2''-glucosyltransferase activity; vitexin b-glucosyltransferase activity,
C1324895,vomilenine glucosyltransferase activity,glucose,UDP-glucose:vomilenine 21-O-beta-D-glucosyltransferase activity; vomilenine-glucosyltransferase activity; UDPG:vomilenine 21-beta-D-glucosyltransferase activity; UDPG:vomilenine 21beta-D-glucosyltransferase activity,
C1324908,levansucrase activity,glucose,"beta-2,6-fructan:D-glucose 1-fructosyltransferase activity; sucrose 6-fructosyltransferase activity; beta-2,6-fructosyltransferase activity; sucrose:2,6-beta-D-fructan 6-beta-D-fructosyltransferase activity; sucrose 6-fructosyl transferase activity",
C1324909,linamarin synthase activity,glucose,UDPglucose:ketone cyanohydrin beta-glucosyltransferase activity; uridine diphosphoglucose-ketone cyanohydrin glucosyltransferase activity; uridine diphosphoglucose-ketone glucosyltransferase activity; UDP glucose ketone cyanohydrin glucosyltransferase activity; uridine diphosphate-glucose-ketone cyanohydrin beta-glucosyltransferase activity; UDPglucose:2-hydroxy-2-methylpropanenitrile beta-D-glucosyltransferase activity; UDP-glucose:2-hydroxy-2-methylpropanenitrile beta-D-glucosyltransferase activity,
C1324911,maltose synthase activity,glucose,alpha-D-glucose-1-phosphate:alpha-D-glucose-1-phosphate 4-alpha-D-glucosyltransferase (dephosphorylating),
C1324925,laminaribiose phosphorylase activity,glucose,3-beta-D-glucosyl-D-glucose:phosphate alpha-D-glucosyltransferase activity,
C1325104,aldose-1-phosphate adenylyltransferase activity,glucose,adenosine diphosphosugar phosphorylase activity; ADP sugar phosphorylase activity; ADP-aldose phosphorylase activity; ADP:alpha-D-aldose-1-phosphate adenylyltransferase activity; ADPaldose phosphorylase activity; adenosine diphosphate glucose:orthophosphate adenylyltransferase activity; ADP:aldose-1-phosphate adenylyltransferase activity; ADP-sugar phosphorylase activity,
C1325105,aldose-1-phosphate nucleotidyltransferase activity,glucose,glucose 1-phosphate inosityltransferase activity; nucleoside diphosphate sugar:orthophosphate nucleotidyltransferase activity; sugar phosphate nucleotidyltransferase activity; NDPaldose phosphorylase activity; NDP:alpha-D-aldose-1-phosphate nucleotidyltransferase activity; sugar nucleotide phosphorylase activity; NDP-sugar phosphorylase activity; NDP sugar phosphorylase activity; nucleoside diphosphosugar phosphorylase activity; NDP:aldose-1-phosphate nucleotidyltransferase activity; NDP-aldose phosphorylase activity,
C1325110,glucose-1-phosphate cytidylyltransferase activity,glucose,cytidine diphosphate-D-glucose pyrophosphorylase activity; CDP-glucose pyrophosphorylase activity; cytidine diphosphate glucose pyrophosphorylase activity; CTP:glucose-1-phosphate cytidylyltransferase activity; CTP:D-glucose-1-phosphate cytidylyltransferase activity; CDP glucose pyrophosphorylase activity; cytidine diphosphoglucose pyrophosphorylase activity; CDP-glucose diphosphorylase activity; CTP:alpha-D-glucose-1-phosphate cytidylyltransferase activity,
C1325111,glucose-1-phosphate guanylyltransferase activity,glucose,GDP-glucose diphosphorylase activity; GDP glucose pyrophosphorylase activity; guanosine diphosphoglucose pyrophosphorylase activity; GTP:glucose-1-phosphate guanylyltransferase activity; GDP-glucose pyrophosphorylase activity; GTP:alpha-D-glucose-1-phosphate guanylyltransferase activity,
C1325145,glucosamine kinase activity,glucose,ATP:2-amino-2-deoxy-D-glucose-6-phosphotransferase activity; glucosamine kinase (phosphorylating); aminodeoxyglucose kinase activity; ATP:D-glucosamine phosphotransferase activity,
C1325146,"glucose-1,6-bisphosphate synthase activity",glucose,"glucose 1,6-diphosphate synthase activity; 3-phospho-D-glyceroyl-phosphate:D-glucose-1-phosphate 6-phosphotransferase activity; glucose-1,6-bisphosphate synthetase activity; 3-phospho-D-glyceroyl-phosphate:alpha-D-glucose-1-phosphate 6-phosphotransferase activity",
C1325147,glucose-1-phosphate phosphodismutase activity,glucose,D-glucose-1-phosphate:D-glucose-1-phosphate 6-phosphotransferase activity; glucose 1-phosphate transphosphorylase activity; phosphodismutase activity,
C1325149,glycerol-3-phosphate-glucose phosphotransferase activity,glucose,sn-glycerol-3-phosphate:D-glucose 6-phosphotransferase activity,
C1325160,phosphoglucokinase activity,glucose,phosphoglucokinase (phosphorylating); ATP:D-glucose-1-phosphate 6-phosphotransferase activity; glucose-phosphate kinase activity; ATP:alpha-D-glucose-1-phosphate 6-phosphotransferase activity,
C1325163,polyphosphate-glucose phosphotransferase activity,glucose,polyphosphate glucokinase activity; polyphosphate-D-(+)-glucose-6-phosphotransferase activity; polyphosphate:D-glucose 6-phosphotransferase activity; polyphosphate-glucose 6-phosphotransferase activity,
C1325167,riboflavin phosphotransferase activity,glucose,alpha-D-glucose-1-phosphate:riboflavin 5'-phosphotransferase activity; D-glucose-1-phosphate:riboflavin 5'-phosphotransferase activity; riboflavine phosphotransferase activity; G-1-P phosphotransferase activity,
C1325193,membrane-oligosaccharide glycerophosphotransferase activity,glucose,membrane-derived-oligosaccharide-6-(glycerophospho)-D-glucose:membrane-derived-oligosaccharide-D-glucose glycerophosphotransferase activity,
C1325200,UDP-glucose-glycoprotein glucose phosphotransferase activity,glucose,UDP-glucose:glycoprotein glucose-1-phosphotransferase activity; UDPglucose:glycoprotein-D-mannose glucosephosphotransferase activity; Glc-phosphotransferase activity; UDPglucose-glycoprotein glucose phosphotransferase activity; GlcPTase activity; uridine diphosphoglucose-glycoprotein glucose-1-phosphotransferase activity; UDP-glucose:glycoprotein-D-mannose glucosephosphotransferase activity,
C1325835,glucose-1-phosphate adenylyltransferase complex,glucose,glucose-1-phosphate adenylyltransferase complex location,
C1326241,invasive growth in response to glucose limitation,glucose,,
C1326961,glucose homeostasis,glucose,homeostasis glucose; glucose homeostasis,
C1330747,Freestyle FLSH Blood Glucose,blood glucose,,
C1330755,Glucose/KET Control,glucose,,
C1330789,Medisense Glucose/Ket Control,glucose,,
C1332124,AVPR2 gene,diabetes,ADHR; nephrogenic diabetes insipidus; AVPR2 Gene; Arginine Vasopressin Receptor 2 Gene; ARGININE VASOPRESSIN RECEPTOR 2; ANTIDIURETIC HORMONE RECEPTOR; VASOPRESSIN V2 RECEPTOR; arginine vasopressin receptor 2; AVPR2; DIR3; V2R; AVPR2 gene; DIR,
C1332802,CTLA4 gene,diabetes,"CELIAC3; Cytotoxic T-Lymphocyte-Associated Protein 4 Gene; CYTOTOXIC T LYMPHOCYTE-ASSOCIATED 4; insulin-dependent diabetes mellitus 12; CTLA4; CTLA-4; celiac disease 3; CYTOTOXIC T LYMPHOCYTE-ASSOCIATED 4, SOLUBLE ISOFORM; CD152; IDDM12; CD; cytotoxic T-lymphocyte associated protein 4; CTLA4 Gene; CTLA4 gene; GSE",
C1333652,G6PD gene,glucose,G6PD Gene; glucose-6-phosphate dehydrogenase; G6PD; Glucose-6-Phosphate Dehydrogenase Gene; GLUCOSE-6-PHOSPHATE DEHYDROGENASE; G6PD1; G6PD gene,
C1333675,GIPR gene,glucose,"GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GIPR Gene; INSULINOTROPIC POLYPEPTIDE RECEPTOR, GLUCOSE-DEPENDENT; gastric inhibitory polypeptide receptor; GIPR; GIPR gene; Gastric Inhibitory Polypeptide Receptor Gene",
C1333690,GPI gene,glucose,glucose-6-phosphate isomerase; Glucose Phosphate Isomerase Gene; PHOSPHOHEXOSE ISOMERASE; NLK; GPI; glucose phosphate isomerase; GPI gene; AUTOCRINE MOTILITY FACTOR; PHI; AMF; NEUROLEUKIN; GPI Gene; GLUCOSE PHOSPHATE ISOMERASE; PGI; PHOSPHOGLUCOSE ISOMERASE; GLUCOSE-6-PHOSPHATE ISOMERASE,
C1333716,GTF2A1 gene,glucose,"general transcription factor IIA subunit 1; General Transcription Factor IIA, 1, 19/37kDa Gene; TFIIA; GENERAL TRANSCRIPTION FACTOR IIA, ALPHA/BETA SUBUNITS; GTF2A1; GTF2A1 gene; TFIIA alpha/beta subunits; general transcription factor IIA, 1, 19/37kDa; glucose regulated protein, 58kD pseudogene; TF2A1; GTF2A1 Gene; TRANSCRIPTION FACTOR IIA, 1; general transcription factor IIA 1",
C1333935,HYOU1 gene,glucose,"Grp170; HYPOXIA UP-REGULATED 1; HYOU1 Gene; HSP12A; Hypoxia Up-Regulated 1 Gene; glucose-regulated protein 170; HYOU1 gene; OXYGEN-REGULATED PROTEIN, 150-KD; hypoxia up-regulated 1; ORP150; HYOU1",
C1334114,IL2RA gene,diabetes,"CD25; IL2R; IL2 RECEPTOR; interleukin 2 receptor subunit alpha; IL2RA gene; insulin-dependent diabetes mellitus 10; T-CELL GROWTH FACTOR RECEPTOR; IL2RA; INTERLEUKIN 2 RECEPTOR, ALPHA; IL2RA Gene; Interleukin 2 Receptor, Alpha Gene; TCGFR; interleukin 2 receptor, alpha; TAC ANTIGEN; IL2R, ALPHA CHAIN; IDDM10",
C1335837,SLC2A1 gene,glucose,"DYT9; solute carrier family 2 (facilitated glucose transporter), member 1; GLUCOSE TRANSPORTER 1; CSE; GLUT; SLC2A1; Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 Gene; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 1; DYT18; choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity); HUMAN T-CELL LEUKEMIA VIRUS RECEPTOR; GLUT-1; SLC2A1 gene; SLC2A1 Gene; human T-cell leukemia virus (I and II) receptor; GLUT1; ERYTHROCYTE/HEPATOMA GLUCOSE TRANSPORTER; solute carrier family 2 member 1; HTLV-1 AND HTLV-2 RECEPTOR; HTLVR",
C1337112,INS gene,diabetes,IDDM2; insulin-dependent diabetes mellitus 2; Insulin Gene; INS-IGF2 SPLICED READ-THROUGH TRANSCRIPTS; INS; INSULIN; IDDM1; INSIGF; PROINSULIN; INS Gene; INS gene; insulin,
C1366535,AVP gene,diabetes,AVP gene; ANTIDIURETIC HORMONE; neurophysin II; arginine vasopressin; antidiuretic hormone; diabetes insipidus; AVP; AVP Gene; ADH; ARGININE VASOPRESSIN; copeptin; neurohypophyseal; NPII; NEUROPHYSIN II; Arginine Vasopressin Gene; prepro-arginine-vasopressin-neurophysin II; ARVP; VASOPRESSIN-NEUROPHYSIN II; prepro-AVP-NP II,
C1371486,Cell Glucose Transport Alteration,glucose,Cell Glucose Transport Alteration [PE],
C1371657,Decreased Glucose Transport into Cells,glucose,Decreased Glucose Transport into Cells [PE],
C1372343,Increased Glucose Transport into Cells,glucose,Increased Glucose Transport into Cells [PE],
C1382395,Glucose Metabolism Alteration,glucose,Glucose Metabolism Alteration [PE],
C1400213,Iatrogenic hypoglycemia,hypoglycemia,Iatrogenic hypoglycaemia; Iatrogenic hypoglycemia (disorder),
C1412484,APOH gene,BG,"Apolipoprotein H Gene; APOLIPOPROTEIN H; APOH gene; APOH; apolipoprotein H; GLYCOPROTEIN I, BETA-2; APOH Gene; GLYCOPROTEIN 1, BETA-2; B2GP1; BG; B2G1; beta-2-glycoprotein I; apolipoprotein H (beta-2-glycoprotein I)",
C1414892,G6PC1 gene,glucose,"G6PT; G6PT, FORMERLY; GLUCOSE-6-PHOSPHATASE, CATALYTIC; G6PC1; G6PC; GLUCOSE-6-PHOSPHATASE, CATALYTIC, 1; G6PC gene; glucose-6-phosphatase catalytic subunit; glucose-6-phosphatase catalytic subunit 1; glycogen storage disease type I, von Gierke disease; G6PC1 gene; GSD1a; glucose-6-phosphatase, catalytic (glycogen storage disease type I, von Gierke disease)",
C1414893,GLUCOSE-6-PHOSPHATE DEHYDROGENASE-LIKE,glucose,G6PDL,
C1414894,G6PR gene,glucose,"G6PR gene; glucose-6-phosphatase regulator; glucose-6-phosphatase, regulatory; G6PR; GSD1aSP",
C1414895,SLC37A4 gene,glucose,"G6PT2; SLC37A4 gene; GSD1d; GLUCOSE-6-PHOSPHATE TRANSLOCASE; GLUCOSE-6-PHOSPHATE TRANSPORTER 1; G6P TRANSLOCASE; glucose-6-phosphatase, transport (glucose-6-phosphate) protein 1; SLC37A4; G6PT3; Solute Carrier Family 37 Member 4 Gene; GSD1b; solute carrier family 37 member 4; G6PT1; SOLUTE CARRIER FAMILY 37 (GLUCOSE-6-PHOSPHATE TRANSPORTER), MEMBER 4; solute carrier family 37 (glucose-6-phosphate transporter), member 4; SLC37A4 Gene; GSD1c",
C1415014,GCK gene,diabetes,glucokinase (hexokinase 4); GCK gene; GK; HEXOKINASE 4; hexokinase 4; GLUCOKINASE; glucokinase; HK4; GCK; LIVER GLUCOKINASE; GLK; LGLK; MODY2; maturity onset diabetes of the young 2,
C1415067,GIP gene,glucose,gastric inhibitory polypeptide; GIP Gene; Gastric Inhibitory Polypeptide Gene; glucose-dependent insulinotropic polypeptide; GIP; GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE; GIP gene; GASTRIC INHIBITORY POLYPEPTIDE,
C1415455,H6PD gene,glucose,"hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase; G6PDH; GLUCOSE 1-DEHYDROGENASE; GDH/6PGL endoplasmic bifunctional protein; HEXOSE-6-PHOSPHATE DEHYDROGENASE; hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase); glucose dehyrogenase; GLUCOSE-6-PHOSPHATE DEHYDROGENASE, SALIVARY; H6PDH; GDH/6PGL ENDOPLASMIC BIFUNCTIONAL PROTEIN; GDH; H6PD gene; HEXOSE-6-PHOSPHATE DEHYDROGENASE PRECURSOR; GLUCOSE DEHYDROGENASE; H6PD; 6-phosphogluconolactonase; G6PD, H FORM",
C1415761,HSPA5 gene,glucose,"GRP78; BIP; Heat Shock 70kDa Protein 5 (Glucose-Regulated Protein, 78kDa) Gene; HEAT-SHOCK 70-KD PROTEIN 5; heat shock 70kD protein 5 (glucose-regulated protein, 78kD); GLUCOSE-REGULATED PROTEIN, 78-KD; heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa); glucose-regulated protein, 78kDa; heat shock protein family A (Hsp70) member 5; HSPA5 gene; IMMUNOGLOBULIN HEAVY CHAIN-BINDING PROTEIN; HSPA5; BiP; HSPA5 Gene",
C1415831,IAPP gene,diabetes,IAPP Gene; AMYLIN; DIABETES-ASSOCIATED PEPTIDE; ISLET AMYLOID POLYPEPTIDE; IAPP; IAPP gene; amylin; islet amyloid polypeptide; Islet Amyloid Polypeptide Gene; IAP; DAP,
C1418449,PEA15 gene,diabetes,"PEA15 Gene; MAT1H; phosphoprotein enriched in astrocytes 15; proliferation and apoptosis adaptor 15; homolog of mouse MAT-1 oncogene; Phosphoprotein enriched in astrocytes, 15kD; PEA-15; Phosphoprotein Enriched In Astrocytes 15 Gene; proliferation and apoptosis adaptor protein 15; PHOSPHOPROTEIN ENRICHED IN DIABETES; PED/PEA15; HUMMAT1H; PED-PEA15; PEA15 gene; HMAT1; MAT1, MOUSE, HOMOLOG OF; MAT1; PEA15; MAMMARY TRANSFORMING GENE 1, MOUSE, HOMOLOG OF; PED; Phosphoprotein enriched in diabetes; PHOSPHOPROTEIN ENRICHED IN ASTROCYTES, 15-KD",
C1418673,PMM1 gene,glucose,"PHOSPHOMANNOMUTASE 1; brain glucose-1,6-bisphosphatase; PMM1; Sec53; phosphomannomutase 1; PMM1 gene",
C1420172,SLC2A2 gene,glucose,"solute carrier family 2 member 2; SLC2A2; solute carrier family 2 (facilitated glucose transporter), member 2; GLUCOSE TRANSPORTER, LIVER/ISLET; GLUCOSE TRANSPORTER 2; SLC2A2 gene; SLC2A2 Gene; Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 2 Gene; GLUT2; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 2",
C1420173,SLC2A3 gene,glucose,"GLUCOSE TRANSPORTER 3; SLC2A3; solute carrier family 2 member 3; GLUT3; SLC2A3 gene; SLC2A3 Gene; Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 Gene; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 3; GLUCOSE TRANSPORTER, FETAL SKELETAL MUSCLE; solute carrier family 2 (facilitated glucose transporter), member 3",
C1420174,SLC2A3P1 gene,glucose,"solute carrier family 2 (facilitated glucose transporter), member 3 pseudogene 1; SLC2A3P1 Gene; GLUCOSE TRANSPORTER 3 PSEUDOGENE 1; solute carrier family 2 (facilitated glucose transporter), member 3 pseudogene; Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 Pseudogene; solute carrier family 2 member 3 pseudogene 1; GLUT3P1; GLUT6; SOLUTE CARRIER FAMILY 2, MEMBER 3 PSEUDOGENE; SLC2A3P1 gene; Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 Pseudogene 1; SLC2A3P; SLC2A3P1",
C1420175,SLC2A4 gene,glucose,"SLC2A4 gene; GLUCOSE TRANSPORTER, INSULIN-RESPONSIVE; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 4; GLUT4; GLUCOSE TRANSPORTER 4; SLC2A4 Gene; Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 4 Gene; solute carrier family 2 member 4; SLC2A4; solute carrier family 2 (facilitated glucose transporter), member 4",
C1420176,SLC2A5 gene,glucose,"solute carrier family 2 member 5; GLUCOSE TRANSPORTER, KIDNEY; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE/FRUCTOSE TRANSPORTER), MEMBER 5; solute carrier family 2 (facilitated glucose/fructose transporter), member 5; GLUT5; SLC2A5; GLUCOSE TRANSPORTER 5; SLC2A5 gene",
C1420177,SLC2A6 gene,glucose,"SLC2A6; solute carrier family 2 member 6; HSA011372; GLUT9; SOLUTE CARRIER FAMILY 2i (FACILITATED GLUCOSE TRANSPORTER), MEMBER 6; solute carrier family 2 (facilitated glucose transporter), member 6; GLUT6; SLC2A6 gene",
C1420190,SLC37A1 gene,glucose,"SOLUTE CARRIER FAMILY 37 (SUGAR-PHOSPHATE TRANSPORTER), MEMBER 1; GLYCEROL-3-PHOSPHATE PERMEASE; solute carrier family 37 (glucose-6-phosphate transporter), member 1; G3PP; solute carrier family 37 member 1; solute carrier family 37 (glycerol-3-phosphate transporter), member 1; SLC37A1 gene; SLC37A1",
C1420200,SLC5A1 gene,glucose,"SLC5A1 Gene; Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 1 Gene; SLC5A1 gene; NA+/GLUCOSE COTRANSPORTER, HIGH AFFINITY; D22S675; NAGT; SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 1; solute carrier family 5 member 1; solute carrier family 5 (sodium/glucose cotransporter), member 1; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE COTRANSPORTER, INTESTINAL; SLC5A1; SGLT1; sodium/glucose cotransporter 1",
C1420201,SLC5A2 gene,glucose,"SODIUM-GLUCOSE COTRANSPORTER, KIDNEY LOW AFFINITY; SODIUM-GLUCOSE COTRANSPORTER, RENAL; SGLT2; SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 2; solute carrier family 5 member 2; solute carrier family 5 (sodium/glucose cotransporter), member 2; Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 2 Gene; SLC5A2 gene; SLC5A2; SLC5A2 Gene; SODIUM-GLUCOSE TRANSPORTER 2",
C1420203,SLC5A4 gene,glucose,"solute carrier family 5 (low affinity glucose cotransporter), member 4; SOLUTE CARRIER FAMILY 5 (GLUCOSE-ACTIVATED ION CHANNEL), MEMBER 4; SODIUM/GLUCOSE COTRANSPORTER 3; solute carrier family 5 (glucose activated ion channel), member 4; SLC5A4; SAAT1; solute carrier family 5 member 4; SLC5A4 gene; SOLUTE CARRIER FAMILY 5 (LOW-AFFINITY GLUCOSE COTRANSPORTER), MEMBER 4; DJ90G24.4; SGLT3; SOLUTE CARRIER FAMILY 5 (NEUTRAL AMINO ACID TRANSPORTERS, SYSTEM A), MEMBER 4",
C1420319,SOX13 gene,diabetes,SRY (sex determining region Y)-box 13; ISLET CELL ANTIBODY 12; Sox-13; SRY-box transcription factor 13; SOX13 gene; ICA12; SRY-RELATED HMG-BOX GENE 12; SRY-related HMG-box gene 13; SRY-box 13; SOX13; SRY-BOX 13; type 1 diabetes autoantigen; islet cell antibody 12; MGC117216,
C1421282,UBE2H gene,glucose,"ubiquitin conjugating enzyme E2 H; UBC8; GID complex subunit 3, UBC8 homolog (S. cerevisiae); GLUCOSE-INDUCED DEGRADATION-DEFICIENT PROTEIN 3, S. CEREVISIAE, HOMOLOG OF; UBCH; UBIQUITIN-CONJUGATING ENZYME E2H; UBCH2; UBIQUITIN-CONJUGATING ENZYME UBC8, YEAST, HOMOLOG OF; UBIQUITIN-CONJUGATING ENZYME E2 H; GID COMPLEX, SUBUNIT 3; UBE2H; ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast); GID3; UBE2H gene",
C1421319,UGCG gene,glucose,UGCG gene; GLUCOSYLCERAMIDE SYNTHASE; CERAMIDE GLUCOSYLTRANSFERASE; UDP-Glucose Ceramide Glucosyltransferase Gene; UGCG; glucosylceramide synthase; GCS; UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE; UDP-glucose ceramide glucosyltransferase; ceramide glucosyltransferase; UGCG Gene,
C1421321,UGP2 gene,glucose,UGP1; UDP-glucose pyrophosphorylase 2; UGP2 gene; SVUGP2; URIDYL DIPHOSPHATE GLUCOSE PYROPHOSPHORYLASE 2; UDPG; UTP--glucose-1-phosphate uridylyltransferase; UDP-glucose pyrophosphorylase 1; UGPP2; UGPP1; UGP2,
C1421996,SLC2A10 gene,glucose,"SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 10; SLC2A10 gene; GLUCOSE TRANSPORTER 10; GLUT10; solute carrier family 2 member 10; solute carrier family 2 (facilitated glucose transporter), member 10; SLC2A10",
C1421997,SLC2A7 gene,glucose,"SLC2A7; solute carrier family 2 member 7; solute carrier family 2 (facilitated glucose transporter), member 7; SLC2A7 gene; intestinal facilitative glucose transporter 7; GLUT7; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 7; GLUCOSE TRANSPORTER 7",
C1421998,SLC2A9 gene,glucose,"SLC2A9; GLUT9; urate voltage-driven efflux transporter 1; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 9; solute carrier family 2 (facilitated glucose transporter), member 9; SLC2A9 gene; GLUCOSE TRANSPORTER 9; solute carrier family 2 member 9; GLUTX; Glut9; URATv1",
C1422169,MAEA gene,glucose,"HLC-10; GID9; ERYTHROBLAST MACROPHAGE PROTEIN; p44EMLP; MACROPHAGE ERYTHROBLAST ATTACHER; MAEA gene; macrophage erythroblast attacher, E3 ubiquitin ligase; MAEA; EMP; GID COMPLEX, SUBUNIT 9; GLUCOSE-INDUCED DEGRADATION-DEFICIENT PROTEIN 9, S. CEREVISIAE, HOMOLOG OF; GID complex subunit 9, FYV10 homolog (S. cerevisiae)",
C1422207,SLC2A8 gene,glucose,"SLC2A8 gene; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 8; solute carrier family 2 (facilitated glucose transporter), member 8; solute carrier family 2 member 8; SLC2A8; GLUCOSE TRANSPORTER 8; solute carrier family 2 (facilitated glucose transporter) member 8; GLUTX1; GLUT8; GLUCOSE TRANSPORTER X1",
C1422501,SLC2A11 gene,glucose,"GLUCOSE TRANSPORTER 11; SLC2A11 gene; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 11; solute carrier family 2 member 11; SLC2A11; GLUT11; GLUT10; solute carrier family 2 (facilitated glucose transporter), member 11",
C1423409,OR9M1P gene,BG,"OR9M1P gene; olfactory receptor, family 5, subfamily BG, member 1 pseudogene; OR5BG1P; olfactory receptor family 9 subfamily M member 1, pseudogene; OR9M1P",
C1423640,UGGT1 gene,glucose,UGCGL1; UGGT1; UDP-glucose ceramide glucosyltransferase-like 1; UDP-glucose glycoprotein glucosyltransferase 1; UGGT1 gene; UDP-GLUCOSE:GLYCOPROTEIN GLUCOSYLTRANSFERASE 1; HUGT1,
C1423641,UGGT2 gene,glucose,UGGT2 gene; UDP-glucose glycoprotein glucosyltransferase 2; MGC150689; UGGT2 Gene; FLJ11485; HUGT2; MGC117360; FLJ10873; UDP-glucose:glycoprotein glucosyltransferase 2; MGC87276; UDP-Glucose Glycoprotein Glucosyltransferase 2 Gene; UGCGL2; UDP-glucose ceramide glucosyltransferase-like 2; UGGT2; UDP-GLUCOSE:GLYCOPROTEIN GLUCOSYLTRANSFERASE 2,
C1423779,GID8 gene,glucose,"two hybrid associated protein No. 1 with RanBPM; GID COMPLEX, SUBUNIT 8; bA305P22.1; C20ORF11; TWO-HYBRID-ASSOCIATED PROTEIN WITH RANBPM 1; TWA1; chromosome 20 open reading frame 11; GID complex subunit 8 homolog; CHROMOSOME 20 OPEN READING FRAME 11; FLJ20602; GID complex subunit 8 homolog (S. cerevisiae); C20orf11; GID8 gene; GID complex subunit 8; GID8; GLUCOSE-INDUCED DEGRADATION-DEFICIENT PROTEIN 8, S. CEREVISIAE, HOMOLOG OF",
C1423860,SLC2A13 gene,glucose,"H(+)-myo-inositol symporter; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 13; solute carrier family 2 member 13; SLC2A13 gene; SLC2A13; PROTON (H+) MYOINOSITOL SYMPORTER; solute carrier family 2 (facilitated glucose transporter), member 13; HMIT",
C1425278,SLC2A12 gene,glucose,"SLC2A12 gene; solute carrier family 2 (facilitated glucose transporter), member 12; GLUT12; GLUCOSE TRANSPORTER 12; solute carrier family 2 member 12; GLUT8; SLC2A12; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 12",
C1425431,SLC2A14 gene,glucose,"solute carrier family 2 (facilitated glucose transporter), member 3 pseudogene 3; GLUT14; SLC2A14 gene; SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 14; GLUCOSE TRANSPORTER 14; SLC2A3P3; SLC2A14; solute carrier family 2 (facilitated glucose transporter), member 14; solute carrier family 2 member 14",
C1426725,NUDT14 gene,glucose,UGPP; nudix hydrolase 14; NUDT14 gene; NUDIX HYDROLASE 14; NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 14; uridine diphosphate glucose pyrophosphatase; nudix (nucleoside diphosphate linked moiety X)-type motif 14; URIDINE DIPHOSPHATE GLUCOSE PYROPHOSPHATASE; UDPG PYROPHOSPHATASE; NUDT14; NUDIX MOTIF 14; UGPPase,
C1426860,TGDS gene,glucose,"TGDS gene; short chain dehydrogenase/reductase family 2E, member 1; SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY 2E, MEMBER 1; SDR2E1; TDPGD; TGDS; TDP-GLUCOSE 4,6-DEHYDRATASE; GROWTH-INHIBITING PROTEIN 21; TDP-glucose 4,6-dehydratase",
C1427053,SLC37A2 gene,glucose,"solute carrier family 37 (glycerol-3-phosphate transporter), member 2; SPX2; SOLUTE CARRIER FAMILY 37 (GLUCOSE-6-PHOSPHATE TRANSPORTER), MEMBER A2; solute carrier family 37 member 2; SLC37A2 gene; solute carrier family 37 (glucose-6-phosphate transporter), member 2; SLC37A2; FLJ00171",
C1427132,SLC35D2 gene,glucose,"solute carrier family 35 member D2; solute carrier family 35, member D2; UGTREL8; UGTrel8; SQV7-LIKE PROTEIN; SQV7L; SLC35D2 gene; solute carrier family 35 (UDP-GlcNAc/UDP-glucose transporter), member D2; FRINGE CONNECTION, DROSOPHILA, HOMOLOG OF, 1; SLC35D2; SOLUTE CARRIER FAMILY 35, MEMBER D2; HFRC1",
C1427194,PGM2L1 gene,glucose,"BM32A; PGM2L1; PHOSPHOGLUCOMUTASE 2-LIKE 1; PGM2L1 gene; FLJ32029; glucose-1,6-bisphosphate synthase; phosphoglucomutase 2 like 1",
C1427275,MFSD4B gene,glucose,MGC33953; MFSD4B gene; SLC60A2; major facilitator superfamily domain containing 4B; MAJOR FACILITATOR SUPERFAMILY DOMAIN-CONTAINING PROTEIN 4B; MFSD4B; NAGLT1; KIAA1919; SODIUM-DEPENDENT GLUCOSE TRANSPORTER 1,
C1427315,GFOD1 gene,glucose,GFOD1; GLUCOSE-FRUCTOSE OXIDOREDUCTASE DOMAIN-CONTAINING PROTEIN 1; ADG-90; GFOD1 gene; C6orf114; chromosome 6 open reading frame 114; FLJ20330; glucose-fructose oxidoreductase domain containing 1,
C1427415,WDR26 gene,glucose,"WD Repeat Domain 26 Gene; WDR26 Gene; GID7; GID complex subunit 7 homolog (S. cerevisiae); GID COMPLEX, SUBUNIT 7; FLJ21016; GLUCOSE-INDUCED DEGRADATION-DEFICIENT PROTEIN 7, S. CEREVISIAE, HOMOLOG OF; WDR26 gene; WDR26; WD repeat domain 26; WD REPEAT-CONTAINING PROTEIN 26",
C1427757,SLC5A9 gene,glucose,"SLC5A9 gene; solute carrier family 5 (sodium/sugar cotransporter), member 9; solute carrier family 5 (sodium/glucose cotransporter), member 9; SGLT4; solute carrier family 5 member 9; SLC5A9",
C1427908,SLC5A11 gene,glucose,"SGLT6; solute carrier family 5 (sodium/inositol cotransporter), member 11; SLC5A11; SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 11; KST1, RABBIT, HOMOLOG OF; SODIUM/GLUCOSE TRANSPORTER 6; SODIUM MYOINOSITOL COTRANSPORTER 2; KST1; SMIT2; solute carrier family 5 member 11; SLC5A11 gene; solute carrier family 5 (sodium/glucose cotransporter), member 11",
C1427951,SLC5A10 gene,glucose,"solute carrier family 5 (sodium/sugar cotransporter), member 10; solute carrier family 5 member 10; SLC5A10 gene; SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 10; solute carrier family 5 (sodium/glucose cotransporter), member 10; SLC5A10; SODIUM/GLUCOSE COTRANSPORTER 5; SGLT5",
C1427957,ALG8 gene,glucose,"DOLICHYL-P-GLUCOSE:Glc-1-Man-9-GlcNAc-2-PP-DOLICHYL-ALPHA-3-GLUCOSYLTRANSFERASE; dolichyl-P-Glc:Glc(1)Man(9)GlcNAc(2)-PP-dolichol alpha- 1->3-glucosyltransferase; ALG8 alpha-1,3-glucosyltransferase; asparagine-linked glycosylation 8 homolog (yeast, alpha-1,3-glucosyltransferase); asparagine-linked glycosylation 8, alpha-1,3-glucosyltransferase homolog (S. cerevisiae); ALG8; MGC2840; ALG8, S. CEREVISIAE, HOMOLOG OF; ALG8 gene; ALG8 ALPHA-1,3-GLUCOSYLTRANSFERASE",
C1428378,ANKRD23 gene,diabetes,MARP3; DIABETES-RELATED ANKYRIN REPEAT PROTEIN; ankyrin repeat domain 23; ANKRD23; DARP; ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 23; FLJ32449; diabetes related ankyrin repeat protein; ANKRD23 gene,
C1428419,G6PC3 gene,glucose,"G6PC3; UGRP; GLUCOSE-6-PHOSPHATASE, CATALYTIC, 3; UBIQUITOUS GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT-RELATED PROTEIN; glucose 6 phosphatase, catalytic, 3; G6Pase-BETA; GLUCOSE-6-PHOSPHATASE, BETA; G6PC3 gene; Glucose-6-Phosphatase Catalytic Subunit 3 Gene; G6PC3 Gene; glucose-6-phosphatase catalytic subunit 3",
C1428751,G6PC2 gene,glucose,"glucose-6-phosphatase, catalytic, 2; IGRP; islet specific glucose 6 phosphatase catalytic subunit related protein; ISLET-SPECIFIC GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT-RELATED PROTEIN; G6PC2 gene; GLUCOSE-6-PHOSPHATASE, CATALYTIC, 2; ISLET-SPECIFIC G6CP-RELATED PROTEIN; glucose-6-phosphatase catalytic subunit 2; G6PC2",
C1429011,ATP5MK gene,diabetes,"upregulated during skeletal muscle growth 5 homolog (mouse); ATP5MD; ATP5MK gene; ATP5MK; ATP synthase membrane subunit DAPIT; ATP SYNTHASE MEMBRANE SUBUNIT DAPIT; Diabetes Associated Protein in Insulin-sensitive Tissues; UPREGULATED DURING SKELETAL MUSCLE GROWTH 5, MOUSE, HOMOLOG OF; DIABETES-ASSOCIATED PROTEIN IN INSULIN-SENSITIVE TISSUES; up-regulated during skeletal muscle growth 5 homolog (mouse); USMG5; AGP; bA792D24.4; DAPIT; upregulated during skeletal muscle growth 5; MGC14697; ATP synthase membrane subunit k",
C1429065,SLC2A3P2 gene,glucose,"solute carrier family 2 (facilitated glucose transporter), member 3 pseudogene 2; SLC2A3P2 gene; SLC2A3P2; solute carrier family 2 member 3 pseudogene 2",
C1429067,SLC2A3P4 gene,glucose,"solute carrier family 2 (facilitated glucose transporter), member 3 pseudogene 4; solute carrier family 2 member 3 pseudogene 4; SLC2A3P4 gene; SLC2A3P4",
C1429068,SLC2AXP1 gene,glucose,"solute carrier family 2 pseudogene 1; solute carrier family 2 (facilitated glucose transporter), pseudogene 1; SLC2AXP1 gene; SLC2AXP1",
C1430565,"lgtF protein, Neisseria meningitidis",glucose,"UDP-glucose LOS-beta-1,4-glucosyltransferase protein, Neisseria meningitidis",
C1430703,"UGCGL1 protein, human",glucose,"hUGT1 protein, human; UDP-glucose ceramide glucosyltransferase-like 1 protein, human",
C1430704,"UGCGL2 protein, human",glucose,"UGT 2 protein, human; UDP-glucose ceramide glucosyltransferase-like 2 protein, human; hUGT2 protein, human",
C1432300,"SLC2A13 protein, human",glucose,"solute carrier family 2 (facilitated glucose transporter), member 13 protein, human; HMIT protein, human",
C1432609,Xyl-GlcNAc,glucose,xylose-glucose-NAc,
C1432850,"glucose indicator protein, E coli",glucose,"GIP protein, E coli",
C1432912,"Slc2a13 protein, rat",glucose,"solute carrier family 2 (facilitated glucose transporter), member 13 protein, rat; Hmit protein, rat",
C1436199,glucose-6-phosphate dehydrogenase A-,glucose,G6PD A-; glucose-6-phosphate dehydrogenase A-,
C1436200,glucose-6-phosphate dehydrogenase Insuli,glucose,G6PD Insuli,
C1436816,"Slc2a8 protein, rat",glucose,"solute carrier family 2, (facilitated glucose transporter) member 8 protein, rat; Glut8 protein, rat; GLUTx1 protein, rat",
C1436916,"Slc2a9 protein, mouse",glucose,"solute carrier family 2 (facilitated glucose transporter), member 9 protein, mouse; Glut9 protein, mouse",
C1438820,"SLC2A8 protein, human",glucose,"solute carrier family 2, (facilitated glucose transporter) member 8 protein, human; GLUTX1 protein, human; GLUT8 protein, human",
C1438932,"GREM1 protein, human",high glucose,"CKTSF1B1 protein, human; gremlin 1 protein, human; Gremlin 1; DRM protein, human; Cysteine Knot Superfamily 1, BMP Antagonist 1; GREMLIN protein, human; IHG-2 protein, human; DAN Domain Family Member 2; cysteine knot superfamily 1, BMP antagonist 1 protein, human; Down-Regulated in Mos-Transformed Cells Protein; GREM1; Increased In High Glucose Protein 2; Increased In High Glucose-2; GREM1 protein, human; IHG-2; Cell Proliferation-Inducing Gene 2 Protein; Gremlin-1",
C1439086,"SLC2A9 protein, human",glucose,"solute carrier family 2 (facilitated glucose transporter), member 9 protein, human; GLUT6 protein, human; GLUT9 protein, human; GLUT-9 protein, human",
C1439333,GALE gene,glucose,"GALACTOSE EPIMERASE; short chain dehydrogenase/reductase family 1E, member 1; SDR1E1; GALE; UDP-GALACTOSE-4-EPIMERASE; galactose-4-epimerase, UDP-; UDP-glucose 4-epimerase; GALE gene; UDP-galactose-4-epimerase",
C1439393,1.3 hours post dose glucose,glucose,1.3H post dose glucose,
C1439397,1.5 hours post 0.5 g/kg glucose IV,glucose,1.5H post 0.5 g/kg glucose IV,
C1439398,1.5 hours post 100 g glucose PO,glucose,1.5H post 100 g glucose PO,
C1439405,1.5 hours post 75 g glucose PO,glucose,1.5H post 75 g glucose PO,
C1439406,1.5 hours post dose glucose,glucose,1.5H post dose glucose,
C1439416,1.6 hours post dose glucose,glucose,1.6H post dose glucose,
C1439425,10 minutes post 0.5 g/kg glucose IV,glucose,10M post 0.5 g/kg glucose IV,
C1439430,10 minutes post dose glucose,glucose,10M post dose glucose,
C1439453,15 minutes post 100 g glucose PO,glucose,15M post 100 g glucose PO,
C1439459,15 minutes post dose glucose,glucose,15M post dose glucose,
C1439483,1 hour post 0.5 g/kg glucose IV,glucose,1H post 0.5 g/kg glucose IV,
C1439484,1 hour post 1 g/kg glucose PO,glucose,1H post 1 g/kg glucose PO,
C1439487,One hour after one hundred grams of glucose by mouth,glucose,One hour after one hundred grams of glucose by mouth (qualifier value); 1H post 100 g glucose PO; 1 hour post 100 g glucose PO,
C1439500,One hour after fifty grams of glucose by mouth,glucose,1H post 50 g glucose PO; 1 hour post 50 g glucose PO; One hour after fifty grams of glucose by mouth (qualifier value),
C1439502,One hour after seventy five grams of glucose by mouth,glucose,One hour after seventy five grams of glucose by mouth (qualifier value); 1 hour post 75 g glucose PO; 1H post 75 g glucose PO,
C1439504,One hour after glucose dose,glucose,1H post dose glucose; One hour after glucose dose (qualifier value); 1 hour post dose glucose,
C1439520,1 minute post 0.5 g/kg glucose IV,glucose,1M post 0.5 g/kg glucose IV,
C1439530,2.3 hours post dose glucose,glucose,2.3H post dose glucose,
C1439533,2.5 hours post 100 g glucose PO,glucose,2.5H post 100 g glucose PO,
C1439535,2.5 hours post 75 g glucose PO,glucose,2.5H post 75 g glucose PO,
C1439536,2.5 hours post dose glucose,glucose,2.5H post dose glucose,
C1439541,2.6 hours post dose glucose,glucose,2.6H post dose glucose,
C1439544,20 minutes post 0.5 g/kg glucose IV,glucose,20M post 0.5 g/kg glucose IV,
C1439546,20 minutes post dose glucose,glucose,20M post dose glucose,
C1439587,2 hours post 1 g/kg glucose PO,glucose,2H post 1 g/kg glucose PO,
C1439589,Two hours after one hundred grams of glucose by mouth,glucose,2H post 100 g glucose PO; Two hours after one hundred grams of glucose by mouth (qualifier value); 2 hours post 100 g glucose PO,
C1439600,Two hours after seventy five grams of glucose by mouth,glucose,2H post 75 g glucose PO; 2 hours post 75 g glucose PO; Two hours after seventy five grams of glucose by mouth (qualifier value),
C1439602,Two hours after glucose dose,glucose,2H post dose glucose; Two hours after glucose dose (qualifier value); 2 hours post dose glucose,
C1439626,3.3 hours post dose glucose,glucose,3.3H post dose glucose,
C1439629,3.5 hours post 100 g glucose PO,glucose,3.5H post 100 g glucose PO,
C1439630,3.5 hours post 75 g glucose PO,glucose,3.5H post 75 g glucose PO,
C1439631,3.5 hours post dose glucose,glucose,3.5H post dose glucose,
C1439634,3.6 hours post dose glucose,glucose,3.6H post dose glucose,
C1439640,30 minutes post 0.5 g/kg glucose IV,glucose,30M post 0.5 g/kg glucose IV,
C1439643,30 minutes post 100 g glucose PO,glucose,30M post 100 g glucose PO,
C1439654,Thirty minutes after seventy five grams of glucose by mouth,glucose,30M post 75 g glucose PO; 30 minutes post 75 g glucose PO; Thirty minutes after seventy five grams of glucose by mouth (qualifier value),
C1439657,30 minutes post dose glucose,glucose,30M post dose glucose,
C1439686,3 hours post 1 g/kg glucose PO,glucose,3H post 1 g/kg glucose PO,
C1439688,Three hours after one hundred grams of glucose by mouth,glucose,3 hours post 100 g glucose PO; Three hours after one hundred grams of glucose by mouth (qualifier value); 3H post 100 g glucose PO,
C1439694,3 hours post 75 g glucose PO,glucose,3H post 75 g glucose PO,
C1439696,Three hours after glucose dose,glucose,3H post dose glucose; 3 hours post dose glucose; Three hours after glucose dose (qualifier value),
C1439702,3 minutes post 0.5 g/kg glucose IV,glucose,3M post 0.5 g/kg glucose IV,
C1439708,4.5 hours post 100 g glucose PO,glucose,4.5H post 100 g glucose PO,
C1439709,4.5 hours post 75 g glucose PO,glucose,4.5H post 75 g glucose PO,
C1439710,4.5 hours post dose glucose,glucose,4.5H post dose glucose,
C1439713,40 minutes post 0.5 g/kg glucose IV,glucose,40M post 0.5 g/kg glucose IV,
C1439715,40 minutes post dose glucose,glucose,40M post dose glucose,
C1439719,45 minutes post 100 g glucose PO,glucose,45M post 100 g glucose PO,
C1439724,45 minutes post dose glucose,glucose,45M post dose glucose,
C1439737,4 hours post 100 g glucose PO,glucose,4H post 100 g glucose PO,
C1439741,4 hours post 75 g glucose PO,glucose,4H post 75 g glucose PO,
C1439742,4 hours post dose glucose,glucose,4H post dose glucose,
C1439753,5.5 hours post 100 g glucose PO,glucose,5.5H post 100 g glucose PO,
C1439754,5.5 hours post 75 g glucose PO,glucose,5.5H post 75 g glucose PO,
C1439755,5.5 hours post dose glucose,glucose,5.5H post dose glucose,
C1439766,5 hours post 100 g glucose PO,glucose,5H post 100 g glucose PO,
C1439771,5 hours post 75 g glucose PO,glucose,5H post 75 g glucose PO,
C1439772,5 hours post dose glucose,glucose,5H post dose glucose,
C1439776,5 minutes post 0.5 g/kg glucose IV,glucose,5M post 0.5 g/kg glucose IV,
C1439787,6 hours post 100 g glucose PO,glucose,6H post 100 g glucose PO,
C1439791,6 hours post 75 g glucose PO,glucose,6H post 75 g glucose PO,
C1439793,6 hours post dose glucose,glucose,6H post dose glucose,
C1439813,7 hours post 75 g glucose PO,glucose,7H post 75 g glucose PO,
C1439863,post 50 g glucose,glucose,post 50 g glucose,
C1439864,post 50 g glucose PO,glucose,post 50 g glucose PO,
C1439874,post dose glucose,glucose,post dose glucose,
C1439888,pre 0.5 g/kg glucose IV,glucose,pre 0.5 g/kg glucose IV,
C1439890,pre 1 g/kg glucose PO,glucose,pre 1 g/kg glucose PO,
C1439893,Before one hundred grams of glucose by mouth,glucose,Before one hundred grams of glucose by mouth (qualifier value); pre 100 g glucose PO,
C1439903,pre 50 g glucose PO,glucose,pre 50 g glucose PO,
C1439911,pre 75 g glucose PO,glucose,pre 75 g glucose PO,
C1439930,pre or post dose glucose,glucose,pre or post dose glucose,
C1441390,Glucose plas,glucose,Glucose plas,
C1442771,UGDH gene,glucose,UDP-glucose 6-dehydrogenase; UDPGDH; UDP-glucose dehydrogenase; UDP-GLUCOSE DEHYDROGENASE; UGDH gene; UGDH,
C1445944,Diabetes clinical management plan,diabetes,Diabetes clinical management plan (record artifact),
C1446010,Dialysis fluid glucose measurement,glucose level,Dialysis fluid glucose measurement (procedure); Dialysis fluid glucose level,
C1446069,Blood glucose series,blood glucose,Blood glucose series (procedure),
C1446182,Ascitic fluid glucose measurement,glucose level,Ascitic fluid glucose measurement (procedure); Ascitic fluid glucose level,
C1446288,Pan retinal photocoagulation for diabetes,diabetes,Panretinal photocoagulation for diabetes; Pan retinal photocoagulation for diabetes (procedure),
C1446291,Diabetes mellitus induced by non-steroid drugs without complication,diabetes,Diabetes mellitus caused by non-steroid drugs without complication; Diabetes mellitus caused by non-steroid drugs without complication (disorder),
C1448794,"RfbA protein, E coli",glucose,"rmlA protein, E coli; dTDP-glucose pyrophosphorylase protein, E coli",
C1449243,"G6pc2 protein, mouse",glucose,"G-6-pase-related IGRP protein, mouse; glucose-6-phosphatase, catalytic, 2 protein, mouse; IGRP protein, mouse; islet IGRP protein, mouse",
C1451774,"HNF1A protein, human",diabetes,"maturity onset diabetes of the young 3 protein, human; HNF-1-Alpha; hepatic nuclear factor 1 alpha, human; TCF1 protein, human; Liver-Specific Transcription Factor LF-B1; LFB1; Transcription Factor 1; HNF1A protein, human; Hepatocyte Nuclear Factor 1-Alpha; HNF1A; transcription factor 1, human; LF-B1 transcription factor, human; MODY3 protein, human; HNF-1A; TCF-1; TCF1; HNF1 homeobox A protein, human",
C1452414,"G6PC2 protein, human",glucose,"glucose-6-phosphatase, catalytic, 2 protein, human; IGRP protein, human",
C1452415,"G6PC3 protein, human",glucose,"glucose 6 phosphatase, catalytic, 3 protein, human; UGRP protein, human; UGRP catalytic subunit, human",
C1453330,"Slc2a8 protein, mouse",glucose,"Glut8 protein, mouse; GlutX1 protein, mouse; solute carrier family 2, (facilitated glucose transporter), member 8 protein, mouse",
C1454068,"Lyst protein, mouse",BG,"lysosomal trafficking regulator protein, mouse; beige protein, mouse; bg protein, mouse; Chs1 protein, mouse; Lyst protein, murine",
C1454222,"SLC2A7 protein, human",glucose,"intestinal facilitative glucose transporter 7, human; GLUT7 protein, human; solute carrier family 2 (facilitated glucose transporter), member 7, human",
C1454305,"UDP-glucose:cyclo-DOPA 5-O-glucosyltransferase, Mirabilis jalapa",glucose,"UDP-G-c-DOPA-GT, M jalapa",
C1455664,Syndrome of infant of mother with gestational diabetes,diabetes,Syndrome of infant of mother with gestational diabetes (disorder),
C1456352,Hypoglycemia of infancy,hypoglycemia,hypoglycemia of infancy; Hypoglycemia of infancy; Hypoglycaemia of infancy,
C1456823,Urine screening for glucose,glucose,Urine screening for glucose (procedure); Urine screening for sugar,
C1456868,Diabetic foot ulcer,diabetes,"Foot Ulcer, Diabetic; Diabetic foot ulcers; Ulcer of foot due to diabetes mellitus (disorder); Diabetic foot ulcer; Diabetic foot ulcer(s); diabetic foot ulcers; Ulcer of foot due to diabetes mellitus; diabetic foot ulcer",
C1468666,Blennius sp. BG-2003,BG,,
C1501438,Pythium sp. BG12,BG,Pythium sp. BG 12,
C1504631,"SLC2A1 protein, human",glucose,"Solute Carrier Family 2, Facilitated Glucose Transporter Member 1; SLC2A1; HepG2 Glucose Transporter; GLUT1 protein, human; HepG2 glucose transporter, human; SLC2A1 protein, human; Glut-1; solute carrier family 2 (facilitated glucose transporter), member 1 protein, human; Glucose Transporter Type 1, Erythrocyte/Brain; GLUT1 Protein; Glucose transporter type 1, erythrocyte-brain protein, human",
C1504806,"SLC5A4 protein, human",glucose,"solute carrier family 5 (low affinity glucose cotransporter), member 4 protein, human; SGLT3 protein, human; SAAT1 protein, human",
C1505031,"SLC2A4 protein, human",glucose,"GLUT4 protein, human; solute carrier family 2 (facilitated glucose transporter), member 4 protein, human; Glucose Transporter Type 4, Insulin-Responsive; Solute Carrier Family 2, Facilitated Glucose Transporter Member 4; GLUT-4; SLC2A4 protein, human",
C1505032,"Slc2a4 protein, mouse",glucose,"Glut4 protein, mouse; solute carrier family 2 (facilitated glucose transporter), member 4 protein, mouse; Glut-4 protein, mouse",
C1505033,"Slc2a4 protein, rat",glucose,"Glut4 protein, rat; Glut-4 protein, rat; solute carrier family 2 (facilitated glucose transporter), member 4 protein, rat",
C1505125,"RRAD protein, human",diabetes,"RRAD protein, human; Ras-related associated with diabetes protein, human; RAD Protein; Ras-Related Associated with Diabetes Protein; RAD; GTP-Binding Protein RAD; RRAD; RAD1; RAD protein, human; Ras Associated with Diabetes",
C1505133,"SLC5A2 protein, human",glucose,"Low Affinity Sodium-Glucose Cotransporter; Na(+)/Glucose Cotransporter 2; SGLT2; Solute Carrier Family 5 Member 2; Sodium/Glucose Cotransporter 2; SLC5A2 protein, human; SGLT2 protein, human; SLC5A2; sodium-glucose cotransporter 2 protein, human; solute carrier family 5 (sodium-glucose cotransporter), member 2 protein, human",
C1505355,"Lyst protein, rat",BG,"lysosomal trafficking regulator protein, rat; Beige protein, rat; bg protein, rat",
C1505396,"Rrad protein, mouse",diabetes,"Rad protein, mouse; Ras-related associated with diabetes protein, mouse",
C1505397,"Rrad protein, rat",diabetes,"Ras-related associated with diabetes protein, rat; Rad protein, rat; Ras associated with diabetes protein, rat",
C1505478,"HYOU1 protein, human",glucose,"Glucose-Regulated Protein 170; 170 kDa Glucose-Regulated Protein; Oxygen Regulated Protein (150kD); oxygen regulated protein (150kD), human; 150 kD Oxygen-Regulated Protein; ORP150 protein, human; ORP-150; HYOU1; GRP170 protein, human; hypoxia up-regulated 1 protein, human; ORP150 Protein; 150 kDa Oxygen-Regulated Protein; Hypoxia Up-Regulated 1 Protein; HYOU1 protein, human; GRP-170",
C1505715,"Slc5a2 protein, rat",glucose,"Sglt2 protein, rat; low affinity Na-dependent glucose transporter protein, rat",
C1505716,"Slc5a2 protein, mouse",glucose,"Sglt2 protein, mouse; solute carrier family 5 (sodium-glucose cotransporter), member 2 protein, mouse; low affinity sodium-dependent glucose cotransporter protein, mouse",
C1505717,"Slc5a4b protein, mouse",glucose,"SGLT3 protein, mouse; low affinity sodium-glucose cotransporter protein, mouse; pSGLT2 protein, mouse; SGLT3-b protein, mouse; SAAT1 protein, mouse",
C1506264,"polymer D,L-poly(lactide-co-glycolide acid-glucose)",glucose,"PLG-GLU; poly(D,L-lactide-co-glycolide-glucose)",
C1506330,"4-(N-acetyl-L-aspart-4-yl)amino-4,6-dideoxy-D-glucose",glucose,,
C1506953,"SLC2A3 protein, human",glucose,"solute carrier family 2 (facilitated glucose transporter), member 3 protein, human; GLUT-3; GLUT3 protein, human; SLC2A3 protein, human; Glucose Transporter, Fetal Skeletal Muscle; Solute Carrier Family 2, Facilitated Glucose Transporter Member 3; Glucose Transporter Type 3, Brain; Glucose Transporter 3",
C1506954,"Slc2a3 protein, mouse",glucose,"solute carrier family 2 (facilitated glucose transporter), member 3 protein, mouse; Glut-3 protein, mouse; Glut3 protein, mouse",
C1506955,"Slc2a3 protein, rat",glucose,"Glut3 protein, rat; solute carrier family 2 (facilitated glucose transporter), member 3 protein, rat; solute carrier family 2 A3 (neuron glucose transporter) protein, rat",
C1507813,Glucose:MCnc:XXX:Urine:Qn,glucose,Glucose [Mass/volume] in Urine collected for unspecified duration; Glucose Unsp time (U) [Mass/Vol]; Glucose ?Tm Ur-mCnc; Glucose:Mass Concentration:Not specified:Urine:Quantitative,
C1509576,methyl glucose dioleate,glucose,METHYL GLUCOSE DIOLEATE; methyl glucose dioleate,
C1509674,PPG-20 methyl glucose ether,glucose,PPG-20 methyl glucose ether; PPG-20 METHYL GLUCOSE ETHER,
C1511874,Diabetes Management Nurse Specialist,diabetes,Clinical Specialist in Diabetes Management; Diabetic Educator,
C1512209,Glucose Transport Induction,glucose,,
C1512210,Glucose Transport Inhibition,glucose,,
C1513898,National Institute of Diabetes and Digestive and Kidney Diseases (U.S.),diabetes,NIDDK; National Institute of Diabetes and Digestive and Kidney Diseases,
C1523180,glucose 6-phosphate metabolic process,glucose,glucose 6-phosphate metabolism; glucose 6-phosphate utilization,
C1527589,"Slc2a1 protein, mouse",glucose,"Glut-1 protein, mouse; solute carrier family 2 (facilitated glucose transporter), member 1 protein, mouse; Glut1 protein, mouse",
C1527590,"Slc2a1 protein, rat",glucose,"Gtg3 protein, rat; Glut1 protein, rat; solute carrier family 2 (facilitated glucose transporter), member 1 protein, rat; Gtg1 protein, rat; GlutB protein, rat",
C1527710,"UDP-glucose flavonoid glucosyltransferase, Stevia rebaudiana",glucose,"srUFGT protein, Stevia rebaudiana",
C1528018,"PRKDC protein, human",hyper,"DNA- PKcs protein, human; DNA-Activated Protein Kinase Catalytic Subunit; Hyper-Radiosensitivity Of Murine SCID Mutation, Complementing 1; DNPK1; DNA-Dependent Protein Kinase, Catalytic Subunit; DNA-dependent protein kinase catalytic subunit, human; p460; DNA-Dependent Protein Kinase Catalytic Subunit; protein kinase, DNA-activated, catalytic polypeptide, human; EC 2.7.11.1; DNAPK; PRKDC; HYRC1; DNA-PK Catalytic Subunit; PRKDC protein, human; p350; XRCC7 protein, human; XRCC7; DNPK1 protein, human; HYRC1 protein, human; HYRC protein, human; DNAPK protein, human; DNA-PKcs",
C1528444,"4-amino-4,6-dideoxy-D-glucose",glucose,Qui4N sugar,
C1528563,"PDX1 protein, human",glucose,"MODY4 protein, human; IUF1 protein, human; PDX-1; Pancreas/Duodenum Homeobox Protein 1; IPF1 protein, human; Somatostatin Transcription Factor 1; PDX-1 protein, human; Insulin Promoter Factor 1; IUF-1; Insulin Upstream Factor 1; Pancreatic-Duodenal Homeobox Factor 1; Somatostatin-Transactivating Factor 1; PDX1 protein, human; IDX-1 protein, human; Glucose-Sensitive Factor; IDX-1; insulin promoter factor 1, homeodomain transcription factor protein, human; Islet/Duodenum Homeobox-1; Homeodomain Transcription Factor IPF1; GSF; STF-1",
C1529167,acarviosine-glucose,glucose,AcvGlc,
C1531128,2-(3-carboxy-1-oxopropyl)amino-2-deoxy-D-glucose,glucose,,
C1531168,BG 958,BG,BG958 cpd; BG-958,
C1531720,Attended diabetes structured education program,diabetes,Attended diabetes structured education program (finding); Attended diabetes structured education programme,
C1532352,Referral to diabetes preconception counseling clinic,diabetes,Referral to diabetes preconception counselling clinic; Referral to diabetes preconception counseling clinic (procedure),
C1532353,Referral to diabetes structured education program,diabetes,Referral to diabetes structured education programme; Referral to diabetes structured education program (procedure),
C1532375,Family/carer attended diabetes structured education program,diabetes,Family/carer attended diabetes structured education programme; Family/carer attended diabetes structured education program (finding),
C1532376,Family/carer referral to diabetes structured education program,diabetes,Family/carer referral to diabetes structured education program (procedure); Family/carer referral to diabetes structured education programme,
C1532413,Transition of diabetes care options discussed,diabetes,Transition of diabetes care options discussed (situation),
C1533485,glucose Chewable Tablet,glucose,,
C1536623,"Abnormal glucose tolerance test during pregnancy, childbirth and the puerperium",glucose,"Abnormal glucose tolerance test during pregnancy, childbirth and the puerperium (finding)",
C1538607,PDIA3 gene,glucose,"ER60; PDIA3 Gene; glucose regulated protein, 58kDa; ERp57; HsT17083; protein disulfide isomerase family A, member 3; PDIA3; PROTEIN DISULFIDE ISOMERASE, FAMILY A, MEMBER 3; ERp60; PI-PLC; GRP58; GLUCOSE-REGULATED PROTEIN, 58-KD; GRP57; PDIA3 gene; protein disulfide isomerase-associated 3; protein disulfide isomerase family A member 3; Protein Disulfide Isomerase Family A, Member 3 Gene; ERp61; P58",
C1538608,PDIA3P1 gene,glucose,"PDIA3P1; protein disulfide isomerase-associated 3 pseudogene; protein disulfide isomerase family A, member 3 pseudogene; PDIA3P; protein disulfide isomerase family A, member 3 pseudogene 1; PDIA3P1 gene; glucose regulated protein, 58kDa pseudogene; protein disulfide isomerase family A member 3 pseudogene 1; GRP58P",
C1539082,CD40LG gene,hyper,"CD40LG Gene; CD40 antigen ligand; CD40L; TRAP; CD40 Ligand Gene; CD40 ANTIGEN LIGAND; CD154; tumor necrosis factor (ligand) superfamily member 5; TNF-RELATED ACTIVATION PROTEIN; IMD3; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 5; CD40 LIGAND; CD40LG gene; HIGM1; hyper-IgM syndrome; T-B cell-activating molecule; CD40 ligand; TNFSF5; tumor necrosis factor (ligand) superfamily, member 5 (hyper-IgM syndrome); gp39; TNF-related activation protein; CD40LG; GP39; hCD40L",
C1539777,SLC5A12 gene,glucose,"solute carrier family 5 (sodium/monocarboxylate cotransporter), member 12; SLC5A12; SMCT2; SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 12; solute carrier family 5 (sodium/glucose cotransporter), member 12; solute carrier family 5 member 12; SLC5A12 gene; SODIUM-COUPLED MONOCARBOXYLATE TRANSPORTER 2; MGC52019",
C1539897,SUMO4 gene,diabetes,small ubiquitin like modifier 4; SUMO4 gene; SUMO4; IDDM5; dJ281H8.4; insulin-dependent diabetes mellitus 5; SMALL UBIQUITIN-LIKE MODIFIER 4; SMT3 suppressor of mif two 3 homolog 4 (S. cerevisiae); SMT3H4; SMT3 suppressor of mif two 3 homolog 4 (yeast),
C1540040,TP53INP2 gene,diabetes,FLJ23500; TP53INP2; DKFZp434B2411; TUMOR PROTEIN p53-INDUCIBLE NUCLEAR PROTEIN 2; TP53INP2 gene; CHROMOSOME 20 OPEN READING FRAME 110; PIGU; TP53-INDUCIBLE PROTEIN U; DKFZp434O0827; DOR; tumor protein p53 inducible nuclear protein 2; C20orf110; FLJ21759; DIABETES- AND OBESITY-REGULATED GENE; PINH; C20ORF110; chromosome 20 open reading frame 110; dJ1181N3.1; diabetes and obesity regulated,
C1540912,Hypereosinophilic syndrome,hyper,"Syndromes, Hypereosinophilic; Hypereosinophilic syndrome; hypereosinophilic syndrome; HES - hypereosinophilic syndrome; Hypereosinophilic syndrome (morphologic abnormality); Hypereosinophilic syndrome (disorder); HYPEREOSINOPHILIC SYNDROME; Hypereosinophilic Syndrome; Syndrome, Hypereosinophilic; HES; Hypereosinophilic Syndromes; Hyper Eosinophilic Syndrome",
C1541300,ifosfamide/O6-benzylguanine,BG,BG/IFF,
C1542842,CSF: glucose &/or level (procedure),glucose,,
C1542928,Glucose^27H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 27h p chal SerPl-mCnc; Glucose 27 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --27 hours post XXX challenge; Glucose^27H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1542929,Glucose^28H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 28h p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --28 hours post XXX challenge; Glucose^28H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 28 Hr post Unsp challenge [Mass/Vol],
C1542930,Glucose^29H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --29 hours post XXX challenge; Glucose 29h p chal SerPl-mCnc; Glucose 29 Hr post Unsp challenge [Mass/Vol]; Glucose^29H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1542931,Glucose^30H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --30 hours post XXX challenge; Glucose^30H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30H p chal SerPl-mCnc,
C1542932,Glucose^31H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --31 hour post XXX challenge; Glucose 31 Hr post Unsp challenge [Mass/Vol]; Glucose 31h p chal SerPl-mCnc; Glucose^31H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1542933,Glucose^36H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 36 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --36 hours post XXX challenge; Glucose 36h p chal SerPl-mCnc; Glucose^36H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1542934,Glucose^2D post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --2 days post XXX challenge; Glucose^2 days post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2 days post Unsp challenge [Mass/Vol]; Glucose 2D p chal SerPl-mCnc,
C1542946,Glucose^8M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 8 Min post Unsp challenge [Moles/Vol]; Glucose 8M p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --8 minutes post XXX challenge; Glucose^8 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1542947,Glucose^9M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 9M p chal SerPl-sCnc; Glucose^9 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --9 minutes post XXX challenge; Glucose 9 Min post Unsp challenge [Moles/Vol],
C1542948,Glucose^12M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 12 Min post Unsp challenge [Moles/Vol]; Glucose 12M p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --12 minutes post XXX challenge; Glucose^12M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1542949,Glucose^14M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 14 Min post Unsp challenge [Moles/Vol]; Glucose^14M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --14 minutes post XXX challenge; Glucose 14m p chal SerPl-sCnc,
C1542950,Glucose^16M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^16M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --16 minutes post XXX challenge; Glucose 16m p chal SerPl-sCnc; Glucose 16 Min post Unsp challenge [Moles/Vol],
C1542951,Glucose^19M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --19 minutes post XXX challenge; Glucose^19M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 19M p chal SerPl-sCnc; Glucose 19 Min post Unsp challenge [Moles/Vol],
C1542952,Glucose^22M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --22 minutes post XXX challenge; Glucose 22 Min post Unsp challenge [Moles/Vol]; Glucose^22M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 22M p chal SerPl-sCnc,
C1542953,Glucose^25M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --25 minutes post XXX challenge; Glucose 25M p chal SerPl-sCnc; Glucose^25 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 25 Min post Unsp challenge [Moles/Vol],
C1542954,Glucose^27M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --27 minutes post XXX challenge; Glucose^27M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 27 Min post Unsp challenge [Moles/Vol]; Glucose 27M p chal SerPl-sCnc,
C1542980,Glucose^4H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --4 hours post XXX challenge; Glucose^4 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4h p chal SerPl-sCnc,
C1542981,Glucose^5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5h p chal SerPl-sCnc; Glucose 5 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --5 hours post XXX challenge; Glucose^5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1542982,Glucose^6H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 6h p chal SerPl-sCnc; Glucose^6 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 6 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --6 hours post XXX challenge,
C1542983,Glucose^6.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 6.5 Hr post Unsp challenge [Moles/Vol]; Glucose^6.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --6.5 hours post XXX challenge; Glucose 6.5h p chal SerPl-sCnc,
C1542984,Glucose^7H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 7h p chal SerPl-sCnc; Glucose 7 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --7 hours post XXX challenge; Glucose^7 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1542985,Glucose^7.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 7.5h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --7.5 hours post XXX challenge; Glucose 7.5 Hr post Unsp challenge [Moles/Vol]; Glucose^7.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1542986,Glucose^8H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --8 hours post XXX challenge; Glucose 8h p chal SerPl-sCnc; Glucose 8 Hr post Unsp challenge [Moles/Vol]; Glucose^8 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1542987,Glucose^8.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 8.5 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --8.5 hours post XXX challenge; Glucose^8.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 8.5h p chal SerPl-sCnc,
C1542988,Glucose^9H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 9h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --9 hours post XXX challenge; Glucose 9 Hr post Unsp challenge [Moles/Vol]; Glucose^9H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1543066,VA C&P exam.diabetes mellitus note:Find:Pt:{Setting}:Doc:{Role},diabetes,VA C&P exam diabetes mellitus; VA C&P exam.diabetes mellitus note:Finding:To identify measures at a point in time:{Setting}:Document:{Role}; VA Compensation and Pension (C and P) examination diabetes mellitus,
C1543554,Glucose:SCnc:Pt:Vitr fld:Qn,glucose,Glucose [Moles/volume] in Vitreous fluid; Glucose (Vitr fld) [Moles/Vol]; Glucose Vitf-sCnc; Glucose:Substance Concentration:To identify measures at a point in time:Vitreous Fluid:Quantitative,
C1543555,Glucose:SCnc:Pt:Pericard fld:Qn,glucose,Glucose:Substance Concentration:To identify measures at a point in time:Pericardial fluid:Quantitative; Glucose (Pericard fld) [Moles/Vol]; Glucose [Moles/volume] in Pericardial fluid; Glucose Pcar-sCnc,
C1543556,Glucose:SCnc:Pt:BldV:Qn,glucose,Glucose BldV-sCnc; Glucose [Moles/volume] in Venous blood; Glucose:Substance Concentration:To identify measures at a point in time:Blood venous:Quantitative; Glucose (BldV) [Moles/Vol],
C1543557,Glucose:SCnc:Pt:BldA:Qn,glucose,Glucose [Moles/volume] in Arterial blood; Glucose (BldA) [Moles/Vol]; Glucose BldA-sCnc; Glucose:Substance Concentration:To identify measures at a point in time:Blood arterial:Quantitative,
C1543636,Glucose^1st specimen post dose lactose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose sp1 p Lac SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1st specimen post dose lactose; Glucose 1st specimen post dose lactose [Mass/Vol]; Glucose^1st specimen post dose lactose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1543637,Glucose^2nd specimen post dose lactose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --2nd specimen post dose lactose; Glucose^2nd specimen post dose lactose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2nd specimen post dose lactose [Mass/Vol]; Glucose sp2 p Lac SerPl-mCnc,
C1543638,Glucose^3rd specimen post dose lactose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3rd specimen post dose lactose [Mass/Vol]; Glucose^3rd specimen post dose lactose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --3rd specimen post dose lactose; Glucose sp3 p Lac SerPl-mCnc,
C1544010,Glucose^pre XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --pre XXX challenge; Glucose pre Unsp challenge [Mass/Vol]; Glucose^pre XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544011,Glucose^30M pre XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^30 minutes pre XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --30 minutes pre XXX challenge; Glucose 30M pre chal SerPl-mCnc; Glucose 30 Min pre Unsp challenge [Mass/Vol],
C1544012,Glucose^15M pre XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --15 minutes pre XXX challenge; Glucose 15M pre chal SerPl-mCnc; Glucose 15 Min pre Unsp challenge [Mass/Vol]; Glucose^15 minutes pre XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544013,Glucose^5M pre XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5M pre chal SerPl-mCnc; Glucose 5 Min pre Unsp challenge [Mass/Vol]; Glucose^5 minutes pre XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --5 minutes pre XXX challenge,
C1544014,Glucose^5M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5 Min post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --5 minutes post XXX challenge; Glucose 5M p chal SerPl-mCnc; Glucose^5 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544015,Glucose^80M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 80 Min post Unsp challenge [Mass/Vol]; Glucose 80M p chal SerPl-mCnc; Glucose^80M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --80 minutes post XXX challenge,
C1544016,Glucose^1.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --1.5 hours post XXX challenge; Glucose 1.5 Hr post Unsp challenge [Mass/Vol]; Glucose 1.5h p chal SerPl-mCnc,
C1544017,Glucose^100M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^100M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --100 minutes post XXX challenge; Glucose 100M p chal SerPl-mCnc; Glucose 100 Min post Unsp challenge [Mass/Vol],
C1544018,Glucose^110M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 110m p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --110 minutes post XXX challenge; Glucose^110M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 110 Min post Unsp challenge [Mass/Vol],
C1544019,Glucose^8.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 8.5 Hr post Unsp challenge [Mass/Vol]; Glucose 8.5h p chal SerPl-mCnc; Glucose^8.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --8.5 hours post XXX challenge,
C1544020,Glucose^9.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --9.5 hours post XXX challenge; Glucose^9.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 9.5h p chal SerPl-mCnc; Glucose 9.5 Hr post Unsp challenge [Mass/Vol],
C1544021,Glucose^11.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^11.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --11.5 hours post XXX challenge; Glucose 11.5 Hr post Unsp challenge [Mass/Vol]; Glucose 11.5h p chal SerPl-mCnc,
C1544022,Glucose^12.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 12.5h p chal SerPl-mCnc; Glucose^12.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --12.5 hours post XXX challenge; Glucose 12.5 Hr post Unsp challenge [Mass/Vol],
C1544023,Glucose^13H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 13 Hr post Unsp challenge [Mass/Vol]; Glucose 13h p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --13 hours post XXX challenge; Glucose^13H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544024,Glucose^13.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --13.5 hours post XXX challenge; Glucose 13.5h p chal SerPl-mCnc; Glucose 13.5 Hr post Unsp challenge [Mass/Vol]; Glucose^13.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544025,Glucose^14H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --14 hours post XXX challenge; Glucose 14 Hr post Unsp challenge [Mass/Vol]; Glucose 14h p chal SerPl-mCnc; Glucose^14H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544026,Glucose^15.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^15.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --15.5 hours post XXX challenge; Glucose 15.5 Hr post Unsp challenge [Mass/Vol]; Glucose 15.5h p chal SerPl-mCnc,
C1544027,Glucose^16H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 16h p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --16 hours post XXX challenge; Glucose^16H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 16 Hr post Unsp challenge [Mass/Vol],
C1544028,Glucose^17.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 17.5h p chal SerPl-mCnc; Glucose 17.5 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --17.5 hours post XXX challenge; Glucose^17.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544029,Glucose^18H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 18 Hr post Unsp challenge [Mass/Vol]; Glucose^18H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --18 hours post XXX challenge; Glucose 18h p chal SerPl-mCnc,
C1544030,Glucose^18.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^18.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 18.5 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --18.5 hours post XXX challenge; Glucose 18.5h p chal SerPl-mCnc,
C1544031,Glucose^19.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 19.5h p chal SerPl-mCnc; Glucose^19.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 19.5 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --19.5 hours post XXX challenge,
C1544032,Glucose^20H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^20H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 20H p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --20 hours post XXX challenge; Glucose 20 Hr post Unsp challenge [Mass/Vol],
C1544033,Glucose^20.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 20.5h p chal SerPl-mCnc; Glucose^20.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --20.5 hours post XXX challenge; Glucose 20.5 Hr post Unsp challenge [Mass/Vol],
C1544034,Glucose^21.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 21.5 Hr post Unsp challenge [Mass/Vol]; Glucose 21.5h p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --21.5 hours post XXX challenge; Glucose^21.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544035,Glucose^22H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^22H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --22 hours post XXX challenge; Glucose 22h p chal SerPl-mCnc; Glucose 22 Hr post Unsp challenge [Mass/Vol],
C1544036,Glucose^23.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 23.5h p chal SerPl-mCnc; Glucose 23.5 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --23.5 hours post XXX challenge; Glucose^23.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544037,Glucose^1D post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1 day post Unsp challenge [Mass/Vol]; Glucose^1 day post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --1 day post XXX challenge; Glucose 1D p chal SerPl-mCnc,
C1544038,Glucose^3M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3 Min post Unsp challenge [Mass/Vol]; Glucose^3 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3M p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --3 minutes post XXX challenge,
C1544039,Glucose^wapost XXX challenge:Mass Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Glucose [Mass/volume] in Serum or Plasma --6 minutes post XXX challenge; Glucose 6 Min post Unsp challenge [Mass/Vol]; Glucose^6 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 6M p chal SerPl-mCnc; Glucose^ 6M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,
C1544040,Glucose^9M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 9M p chal SerPl-mCnc; Glucose^9 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --9 minutes post XXX challenge; Glucose 9 Min post Unsp challenge [Mass/Vol],
C1544041,Glucose^12M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 12 Min post Unsp challenge [Mass/Vol]; Glucose 12M p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --12 minutes post XXX challenge; Glucose^12M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544042,Glucose^14M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --14 minutes post XXX challenge; Glucose 14m p chal SerPl-mCnc; Glucose 14 Min post Unsp challenge [Mass/Vol]; Glucose^14M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544043,Glucose^16M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --16 minutes post XXX challenge; Glucose^16M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 16m p chal SerPl-mCnc; Glucose 16 Min post Unsp challenge [Mass/Vol],
C1544044,Glucose^19M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 19 Min post Unsp challenge [Mass/Vol]; Glucose 19M p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --19 minutes post XXX challenge; Glucose^19M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544045,Glucose^22M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 22 Min post Unsp challenge [Mass/Vol]; Glucose^22M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --22 minutes post XXX challenge; Glucose 22M p chal SerPl-mCnc,
C1544046,Glucose^25M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --25 minutes post XXX challenge; Glucose^25 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 25 Min post Unsp challenge [Mass/Vol]; Glucose 25M p chal SerPl-mCnc,
C1544047,Glucose^27M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 27 Min post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --27 minutes post XXX challenge; Glucose^27M post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 27M p chal SerPl-mCnc,
C1544048,Glucose^4.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4.5 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --4.5 hours post XXX challenge; Glucose 4.5h p chal SerPl-mCnc; Glucose^4.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544049,Glucose^5.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --5.5 hours post XXX challenge; Glucose 5.5h p chal SerPl-mCnc; Glucose^5.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5.5 Hr post Unsp challenge [Mass/Vol],
C1544050,Glucose^25H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 25h p chal SerPl-mCnc; Glucose 25 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --25 hours post XXX challenge; Glucose^25H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544051,Glucose^26H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 26h p chal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --26 hours post XXX challenge; Glucose^26H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 26 Hr post Unsp challenge [Mass/Vol],
C1544143,Glucose^pre XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --pre XXX challenge; Glucose pre Unsp challenge [Moles/Vol]; Glucose^pre XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544144,Glucose^30M pre XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30 Min pre Unsp challenge [Moles/Vol]; Glucose^30 minutes pre XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --30 minutes pre XXX challenge; Glucose 30M pre chal SerPl-sCnc,
C1544145,Glucose^15M pre XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 15 Min pre Unsp challenge [Moles/Vol]; Glucose 15M pre chal SerPl-sCnc; Glucose^15 minutes pre XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --15 minutes pre XXX challenge,
C1544146,Glucose^10M pre XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 10 Min pre Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --10 minutes pre XXX challenge; Glucose^10 minutes pre XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 10M pre chal SerPl-sCnc,
C1544147,Glucose^5M pre XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^5 minutes pre XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5 Min pre Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --5 minutes pre XXX challenge; Glucose 5M pre chal SerPl-sCnc,
C1544148,Glucose^5M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^5 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5M p chal SerPl-sCnc; Glucose 5 Min post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --5 minutes post XXX challenge,
C1544149,Glucose^10M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --10 minutes post XXX challenge; Glucose 10M p chal SerPl-sCnc; Glucose^10 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 10 Min post Unsp challenge [Moles/Vol],
C1544150,Glucose^15M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --15 minutes post XXX challenge; Glucose 15 Min post Unsp challenge [Moles/Vol]; Glucose 15M p chal SerPl-sCnc; Glucose^15 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544151,Glucose^20M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 20 Min post Unsp challenge [Moles/Vol]; Glucose^20 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 20M p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --20 minutes post XXX challenge,
C1544152,Glucose^40M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --40 minutes post XXX challenge; Glucose 40M p chal SerPl-sCnc; Glucose^40M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 40 Min post Unsp challenge [Moles/Vol],
C1544153,Glucose^50M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 50M p chal SerPl-sCnc; Glucose 50 Min post Unsp challenge [Moles/Vol]; Glucose^50M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --50 minutes post XXX challenge,
C1544154,Glucose^70M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 70 Min post Unsp challenge [Moles/Vol]; Glucose^70M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 70M p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --70 minutes post XXX challenge,
C1544155,Glucose^75M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^75M post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 75 Min post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --75 minutes post XXX challenge; Glucose 75M p chal SerPl-sCnc,
C1544156,Glucose^2.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2.5h p chal SerPl-sCnc; Glucose 2.5 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --2.5 hours post XXX challenge; Glucose^2.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544157,Glucose^3H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3h p chal SerPl-sCnc; Glucose 3 Hr post Unsp challenge [Moles/Vol]; Glucose^3 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --3 hours post XXX challenge,
C1544158,Glucose^9.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 9.5h p chal SerPl-sCnc; Glucose 9.5 Hr post Unsp challenge [Moles/Vol]; Glucose^9.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --9.5 hours post XXX challenge,
C1544159,Glucose^10H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 10 Hr post Unsp challenge [Moles/Vol]; Glucose 10h p chal SerPl-sCnc; Glucose^10H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --10 hours post XXX challenge,
C1544160,Glucose^10.75H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^10.75H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 10.75 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --10.75 hours post XXX challenge; Glucose 10.75h p chal SerPl-sCnc,
C1544161,Glucose^11.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^11.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 11.5h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --11.5 hours post XXX challenge; Glucose 11.5 Hr post Unsp challenge [Moles/Vol],
C1544162,Glucose^12H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 12 Hr post Unsp challenge [Moles/Vol]; Glucose 12h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --12 hours post XXX challenge; Glucose^12 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544163,Glucose^12.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --12.5 hours post XXX challenge; Glucose 12.5 Hr post Unsp challenge [Moles/Vol]; Glucose 12.5h p chal SerPl-sCnc; Glucose^12.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544164,Glucose^13H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --13 hours post XXX challenge; Glucose 13h p chal SerPl-sCnc; Glucose^13H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 13 Hr post Unsp challenge [Moles/Vol],
C1544165,Glucose^13.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 13.5h p chal SerPl-sCnc; Glucose 13.5 Hr post Unsp challenge [Moles/Vol]; Glucose^13.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --13.5 hours post XXX challenge,
C1544166,Glucose^14H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 14 Hr post Unsp challenge [Moles/Vol]; Glucose 14h p chal SerPl-sCnc; Glucose^14H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --14 hours post XXX challenge,
C1544167,Glucose^15.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 15.5 Hr post Unsp challenge [Moles/Vol]; Glucose^15.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15.5h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --15.5 hours post XXX challenge,
C1544168,Glucose^16H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --16 hours post XXX challenge; Glucose 16 Hr post Unsp challenge [Moles/Vol]; Glucose 16h p chal SerPl-sCnc; Glucose^16H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544169,Glucose^17.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^17.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 17.5 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --17.5 hours post XXX challenge; Glucose 17.5h p chal SerPl-sCnc,
C1544170,Glucose^18H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^18H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --18 hours post XXX challenge; Glucose 18 Hr post Unsp challenge [Moles/Vol]; Glucose 18h p chal SerPl-sCnc,
C1544171,Glucose^18.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 18.5 Hr post Unsp challenge [Moles/Vol]; Glucose 18.5h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --18.5 hours post XXX challenge; Glucose^18.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544172,Glucose^19.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 19.5 Hr post Unsp challenge [Moles/Vol]; Glucose 19.5h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --19.5 hours post XXX challenge; Glucose^19.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544173,Glucose^20H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 20 Hr post Unsp challenge [Moles/Vol]; Glucose^20H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --20 hours post XXX challenge; Glucose 20H p chal SerPl-sCnc,
C1544174,Glucose^20.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^20.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 20.5h p chal SerPl-sCnc; Glucose 20.5 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --20.5 hours post XXX challenge,
C1544175,Glucose^21.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^21.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --21.5 hours post XXX challenge; Glucose 21.5h p chal SerPl-sCnc; Glucose 21.5 Hr post Unsp challenge [Moles/Vol],
C1544176,Glucose^22H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 22 Hr post Unsp challenge [Moles/Vol]; Glucose 22h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --22 hours post XXX challenge; Glucose^22H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544177,Glucose^23.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --23.5 hours post XXX challenge; Glucose^23.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 23.5h p chal SerPl-sCnc; Glucose 23.5 Hr post Unsp challenge [Moles/Vol],
C1544178,Glucose^1D post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1 day post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1D p chal SerPl-sCnc; Glucose 1 day post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --1 day post XXX challenge,
C1544179,Glucose^pre-meal:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --pre-meal; Glucose^pre-meal:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre-meal [Moles/Vol]; Glucose pre-meal SerPl-sCnc,
C1544180,Glucose^20M pre XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --20 minutes pre XXX challenge; Glucose^20 minutes pre XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 20 Min pre Unsp challenge [Moles/Vol]; Glucose 20M pre chal SerPl-sCnc,
C1544181,Glucose^13M pre XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 13m pre chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --13 minutes pre XXX challenge; Glucose 13 Min pre Unsp challenge [Moles/Vol]; Glucose^13M pre XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544182,Glucose^8M pre XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --8 minutes pre XXX challenge; Glucose^8 minutes pre XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 8 Min pre Unsp challenge [Moles/Vol]; Glucose 8M pre chal SerPl-sCnc,
C1544183,Glucose^3M pre XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3 Min pre Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --3 minutes pre XXX challenge; Glucose 3M pre chal SerPl-sCnc; Glucose^3 minutes pre XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544184,Glucose^2M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --2 minutes post XXX challenge; Glucose 2 Min post Unsp challenge [Moles/Vol]; Glucose 2M p chal SerPl-sCnc; Glucose^2 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544185,Glucose^3M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3 Min post Unsp challenge [Moles/Vol]; Glucose^3 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --3 minutes post XXX challenge; Glucose 3M p chal SerPl-sCnc,
C1544186,Glucose^4M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --4 minutes post XXX challenge; Glucose^4 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4 Min post Unsp challenge [Moles/Vol]; Glucose 4M p chal SerPl-sCnc,
C1544187,Glucose^6M post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 6M p chal SerPl-sCnc; Glucose 6 Min post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --6 minutes post XXX challenge; Glucose^6 minutes post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544188,Glucose^3.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^3.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --3.5 hours post XXX challenge; Glucose 3.5h p chal SerPl-sCnc; Glucose 3.5 Hr post Unsp challenge [Moles/Vol],
C1544189,Glucose^4.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4.5 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --4.5 hours post XXX challenge; Glucose^4.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4.5h p chal SerPl-sCnc,
C1544190,Glucose^5.5H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5.5h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --5.5 hours post XXX challenge; Glucose^5.5 hours post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5.5 Hr post Unsp challenge [Moles/Vol],
C1544191,Glucose^25H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 25 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --25 hours post XXX challenge; Glucose^25H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 25h p chal SerPl-sCnc,
C1544192,Glucose^26H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --26 hours post XXX challenge; Glucose 26 Hr post Unsp challenge [Moles/Vol]; Glucose^26H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 26h p chal SerPl-sCnc,
C1544193,Glucose^27H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 27 Hr post Unsp challenge [Moles/Vol]; Glucose^27H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 27h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --27 hours post XXX challenge,
C1544194,Glucose^28H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 28h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --28 hours post XXX challenge; Glucose 28 Hr post Unsp challenge [Moles/Vol]; Glucose^28H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544195,Glucose^29H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^29H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 29 Hr post Unsp challenge [Moles/Vol]; Glucose 29h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --29 hours post XXX challenge,
C1544196,Glucose^30H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30H p chal SerPl-sCnc; Glucose 30 Hr post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --30 hours post XXX challenge; Glucose^30H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544197,Glucose^31H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 31 Hr post Unsp challenge [Moles/Vol]; Glucose 31h p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --31 hour post XXX challenge; Glucose^31H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544198,Glucose^36H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --36 hours post XXX challenge; Glucose 36 Hr post Unsp challenge [Moles/Vol]; Glucose^36H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 36h p chal SerPl-sCnc,
C1544199,Glucose^2D post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2 days post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2 days post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --2 days post XXX challenge; Glucose 2D p chal SerPl-sCnc,
C1544235,Glucose^10.5H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^10.5 hours post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --10.5 hours post XXX challenge; Glucose 10.5 Hr post Unsp challenge [Mass/Vol]; Glucose 10.5h p chal SerPl-mCnc,
C1544236,Glucose^10.75H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^10.75H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 10.75 Hr post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --10.75 hours post XXX challenge; Glucose 10.75h p chal SerPl-mCnc,
C1544237,Glucose^13M pre XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 13 Min pre Unsp challenge [Mass/Vol]; Glucose^13M pre XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --13 minutes pre XXX challenge; Glucose 13m pre chal SerPl-mCnc,
C1544238,Glucose^3M pre XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --3 minutes pre XXX challenge; Glucose 3M pre chal SerPl-mCnc; Glucose 3 Min pre Unsp challenge [Mass/Vol]; Glucose^3 minutes pre XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544239,Glucose^30M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30M p chal SerPl-mCnc; Glucose^30 minutes post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --30 minutes post XXX challenge; Glucose 30 Min post Unsp challenge [Mass/Vol],
C1544252,Glucose^30M post dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose lactose PO; Glucose 30M p Lac PO SerPl-sCnc; Glucose^30 minutes post dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min post dose lactose PO [Moles/Vol],
C1544253,Glucose^1H post dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1 hour post dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --1 hour post dose lactose PO; Glucose 1 Hr post dose lactose PO [Moles/Vol]; Glucose 1h p Lac PO SerPl-sCnc,
C1544254,Glucose^1.5H post dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5h p Lac PO SerPl-sCnc; Glucose 1.5 Hr post dose lactose PO [Moles/Vol]; Glucose^1.5 hours post dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --1.5 hours post dose lactose PO,
C1544255,Glucose^2H post dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2 hours post dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2h p Lac PO SerPl-sCnc; Glucose 2 Hr post dose lactose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --2 hours post dose lactose PO,
C1544256,Glucose^3H post dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3h p Lac PO SerPl-sCnc; Glucose^3 hours post dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3 Hr post dose lactose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --3 hours post dose lactose PO,
C1544261,Glucose^75M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --75 minutes post dose glucose; Glucose 75 Min post dose glucose [Moles/Vol]; Glucose 75M p Glc SerPl-sCnc; Glucose^75M post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544262,Glucose^105M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 105M p Glc SerPl-sCnc; Glucose 105 Min post dose glucose [Moles/Vol]; Glucose^105M post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --105 minutes post dose glucose,
C1544263,Glucose^1H post meal:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1 Hr post meal [Moles/Vol]; Glucose^1 hour post meal:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --1 hour post meal; Glucose 1h p meal SerPl-sCnc,
C1544284,Somatotropin^pre or post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin pre or post dose glucose [Mass/Vol]; GH pre/p Glc SerPl-mCnc; Somatotropin [Mass/volume] in Serum or Plasma --pre or post dose glucose; Somatotropin^pre or post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544293,Glucose^pre dose triple bolus:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^pre dose triple bolus:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre dose triple bolus [Moles/Vol]; Glucose pre Triple Bolus SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --pre dose triple bolus,
C1544294,Glucose^15M post dose triple bolus:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^15 minutes post dose triple bolus:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15M p Triple Bolus SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose triple bolus; Glucose 15 Min post dose triple bolus [Moles/Vol],
C1544295,Glucose^30M post dose triple bolus:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose triple bolus; Glucose 30 Min post dose triple bolus [Moles/Vol]; Glucose 30M p Triple Bolus SerPl-sCnc; Glucose^30 minutes post dose triple bolus:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1544296,Glucose^45M post dose triple bolus:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^45M post dose triple bolus:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 45M p Triple Bolus SerPl-sCnc; Glucose 45 Min post dose triple bolus [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose triple bolus,
C1544297,Glucose^1H post dose triple bolus:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1 hour post dose triple bolus:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1 Hr post dose triple bolus [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --1 hour post dose triple bolus; Glucose 1h p Triple Bolus SerPl-sCnc,
C1544298,Glucose^2H post dose triple bolus:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2h p Triple Bolus SerPl-sCnc; Glucose^2 hours post dose triple bolus:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2 Hr post dose triple bolus [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --2 hours post dose triple bolus,
C1544299,Glucose^3H post dose triple bolus:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --3 hours post dose triple bolus; Glucose^3 hours post dose triple bolus:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3 Hr post dose triple bolus [Moles/Vol]; Glucose 3h p Triple Bolus SerPl-sCnc,
C1544341,Glucose:SRat:24H:Body fld:Qn,glucose,"Glucose [Moles/time] in 24 hour Body fluid; Glucose (24H Body fld) [Moles/Time]; Glucose:Substance Rate:24 hours:Body fluid, unsp:Quantitative; Glucose 24h Fld-sRate",
C1544463,Glucose/Creatinine:Ratio:Pt:Urine:Qn,glucose,Glucose/Creatinine [Ratio] in Urine; Glucose/Creatinine:Ratio:To identify measures at a point in time:Urine:Quantitative; Glucose/Creat Ur-Rto; Glucose/Creatinine (U) [Ratio],
C1544804,Glucose^1st specimen post XXX challenge:MCnc:Pt:Urine:Qn:Test strip,glucose,Glucose [Mass/volume] in Urine by Test strip --1st specimen post XXX challenge; Glucose sp1 p chal Ur Strip-mCnc; Glucose^1st specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip; Glucose 1st specimen post Unsp challenge Test strip (U) [Mass/Vol],
C1544805,Glucose^2nd specimen post XXX challenge:MCnc:Pt:Urine:Qn:Test strip,glucose,Glucose^2nd specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip; Glucose [Mass/volume] in Urine by Test strip --2nd specimen post XXX challenge; Glucose sp2 p chal Ur Strip-mCnc; Glucose 2nd specimen post Unsp challenge Test strip (U) [Mass/Vol],
C1544813,Glucose^baseline:MCnc:Pt:BldC:Qn,glucose,Glucose [Mass/volume] in Capillary blood --baseline; Glucose baseline (BldC) [Mass/Vol]; Glucose^baseline:Mass Concentration:To identify measures at a point in time:Blood capillary:Quantitative; Glucose BS BldC-mCnc,
C1544829,Glucose^1st specimen:MCnc:Pt:XXX:Qn,glucose,Glucose spec 1 (Specimen) [Mass/Vol]; Glucose [Mass/volume] in Specimen --1st specimen; Glucose sp1 Spec-mCnc; Glucose^1st specimen:Mass Concentration:To identify measures at a point in time:Not specified:Quantitative,
C1544830,Glucose^3rd specimen:MCnc:Pt:XXX:Qn,glucose,Glucose [Mass/volume] in Specimen --3rd specimen; Glucose spec 3 (Specimen) [Mass/Vol]; Glucose sp3 Spec-mCnc; Glucose^3rd specimen:Mass Concentration:To identify measures at a point in time:Not specified:Quantitative,
C1544971,Glucose^2H post 50 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2h p 50 g Glu PO SerPl-mCnc; Glucose^2 hours post 50 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --2 hours post 50 g glucose PO; Glucose 2 Hr post 50 g glucose PO [Mass/Vol],
C1545806,VA C&P exam.diabetes mellitus note,diabetes,VA C and P exam.diabetes mellitus; VA C&P exam.diabetes mellitus note,
C1545991,105 minutes post dose glucose,glucose,105M post dose glucose,
C1546037,2 hours post 50 g glucose PO,glucose,2H post 50 g glucose PO,
C1546065,75 minutes post dose glucose,glucose,75M post dose glucose,
C1549574,"Functional procedure that may consist of one or more interrelated measures (e.g., glucose tolerance test, creatinine clearance), usually done at different times and/or on different specimens",glucose,,
C1554555,Registered Nurse - Diabetes Educator,diabetes,,
C1554767,"Endocrinology, Diabetes & Metabolism - Physicians",diabetes,,
C1559244,"Pancreatic Endocrine Glucose Intolerance, CTCAE",glucose,,
C1559245,"Grade 1 Pancreatic Endocrine Glucose Intolerance, CTCAE",glucose,CTCAE Grade 1 Pancreatic endocrine: glucose intolerance,
C1559246,"Grade 2 Pancreatic Endocrine Glucose Intolerance, CTCAE",glucose,CTCAE Grade 2 Pancreatic endocrine: glucose intolerance,
C1559247,"Grade 3 Pancreatic Endocrine Glucose Intolerance, CTCAE",glucose,CTCAE Grade 3 Pancreatic endocrine: glucose intolerance,
C1559248,"Grade 4 Pancreatic Endocrine Glucose Intolerance, CTCAE",glucose,CTCAE Grade 4 Pancreatic endocrine: glucose intolerance,
C1559249,"Grade 5 Pancreatic Endocrine Glucose Intolerance, CTCAE",glucose,CTCAE Grade 5 Pancreatic endocrine: glucose intolerance,
C1559916,"Serum Hyperglycemia, CTCAE",hyperglycemia,,
C1559917,"Grade 1 Serum Hyperglycemia, CTCAE",hyperglycemia,"CTCAE Grade 1 Glucose, serum-high (hyperglycemia)",
C1559918,"Grade 2 Serum Hyperglycemia, CTCAE",hyperglycemia,"CTCAE Grade 2 Glucose, serum-high (hyperglycemia)",
C1559919,"Grade 3 Serum Hyperglycemia, CTCAE",hyperglycemia,"CTCAE Grade 3 Glucose, serum-high (hyperglycemia)",
C1559920,"Grade 4 Serum Hyperglycemia, CTCAE",hyperglycemia,"CTCAE Grade 4 Glucose, serum-high (hyperglycemia)",
C1559921,"Grade 5 Serum Hyperglycemia, CTCAE",hyperglycemia,"CTCAE Grade 5 Glucose, serum-high (hyperglycemia)",
C1559922,"Serum Hypoglycemia, CTCAE",hypoglycemia,,
C1559923,"Grade 1 Serum Hypoglycemia, CTCAE",hypoglycemia,"CTCAE Grade 1 Glucose, serum-low (hypoglycemia)",
C1559924,"Grade 2 Serum Hypoglycemia, CTCAE",hypoglycemia,"CTCAE Grade 2 Glucose, serum-low (hypoglycemia)",
C1559925,"Grade 3 Serum Hypoglycemia, CTCAE",hypoglycemia,"CTCAE Grade 3 Glucose, serum-low (hypoglycemia)",
C1559926,"Grade 4 Serum Hypoglycemia, CTCAE",hypoglycemia,"CTCAE Grade 4 Glucose, serum-low (hypoglycemia)",
C1559927,"Grade 5 Serum Hypoglycemia, CTCAE",hypoglycemia,"CTCAE Grade 5 Glucose, serum-low (hypoglycemia)",
C1561823,"Diabetes mellitus type I, uncontrolled, with neurological manifestations",diabetes,,
C1562166,Family history of diabetes mellitus in first degree relative,diabetes,Family history: Diabetes mellitus in first degree relative; Family history of diabetes mellitus in first degree relative (situation); FH: Diabetes mellitus in first degree relative,
C1562292,Incretins,glucose,"Hormone, Glucose-Dependent Insulin-Releasing; Incretin (substance); Insulin-Releasing Hormone, Glucose-Dependent; incretin; Glucose Dependent Insulin Releasing Hormone; Glucose-Dependent Insulin-Releasing Hormone; incretins; incretin hormone; Incretin; Incretins",
C1562525,Discharged from care of diabetes specialist nurse,diabetes,Discharged from care of diabetes specialist nurse (finding),
C1562925,Seen in community diabetes specialist clinic,diabetes,Seen in community diabetes specialist clinic (finding),
C1563705,"Nephrogenic Diabetes Insipidus, Type I",diabetes,"DIABETES INSIPIDUS, NEPHROGENIC, 1, X-LINKED; Diabetes Insipidus, Nephrogenic, Type 1; Diabetes Insipidus, Nephrogenic, X-Linked; DIABETES INSIPIDUS, NEPHROGENIC, TYPE I; NDI; Diabetes Insipidus, Nephrogenic, Type I; Nephrogenic Diabetes Insipidus, Type I; NDI1",
C1563706,"Nephrogenic Diabetes Insipidus, Type II",diabetes,"Diabetes Insipidus, Nephrogenic, Type II; DIABETES INSIPIDUS, NEPHROGENIC, 2, AUTOSOMAL; NDI2; Diabetes Insipidus, Nephrogenic, Autosomal; DIABETES INSIPIDUS, NEPHROGENIC, TYPE II",
C1564996,"Slc5a1 protein, mouse",glucose,"solute carrier family 5 (sodium-glucose cotransporter), member 1, mouse; Sglt1 protein, mouse; sodium glucose cotransporter 1 protein, mouse",
C1564997,"SLC5A1 protein, human",glucose,"SFXN1 protein, human; SGLT1 protein, human; Na(+)/Glucose Cotransporter 1; sodium glucose cotransporter 1 protein, human; High Affinity Sodium-Glucose Cotransporter; Solute Carrier Family 5 Member 1; solute carrier family 5 (sodium-glucose cotransporter), member 1, human; SLC5A1 protein, human; Sodium/Glucose Cotransporter 1; SLC5A1; SGLT1; Sodium-Glucose Transporter 1; Na+/Glucose Cotransporter 1",
C1564998,"Slc5a1 protein, rat",glucose,"Sglt1 protein, rat; sodium glucose cotransporter 1 protein, rat; solute carrier family 5 (sodium-glucose cotransporter), member 1, rat",
C1565026,N-(2'-hydroxybenzyl)-2-amino-2-deoxy-D-glucose,glucose,,
C1565118,"SLC2A5 protein, human",glucose,"solute carrier family 2 (facilitated glucose-fructose transporter), member 5 protein, human; GLUT5 protein, human",
C1565154,Sodium-Glucose Transporter 2,glucose,Sodium-Glucose Transporter 2; Sodium Glucose Transporter 2; SLC5A2 Protein; SGLT2 Protein,
C1567035,nor-rubrofusarin glucose,glucose,,
C1567189,"Slc2a12 protein, mouse",glucose,"solute carrier family 2 (facilitated glucose transporter), member 12, mouse; facilitative glucose transporter 12 protein, mouse; Glut12 protein, mouse",
C1567319,"glucose-dependent insulinotropic polypeptide, N-pyroglutamyl-epsilon-palmitoyllysyl(16)-",glucose,pGluGIP(LysPAL(16)),
C1567320,"glucose-dependent insulinotropic polypeptide, N-pyroglutamyl-epsilon-palmitoyllysyl(37)-",glucose,N-pGluGIP(LysPAL(37)),
C1567801,"UDP-glucose thiohydroximate S-glucosyltransferase UGT74B1, Arabidopsis",glucose,"UGT74B1 protein, Arabidopsis",
C1569258,6-O(4-O)-indole-3-ylacetyl-beta-D-glucose,glucose,IAGlc cpd,
C1569487,1-O-galloyl-6-O-luteoyl-alpha-D-glucose,glucose,GLAG cpd,
C1570515,"1,2,4-tri-O-galloyl-3,6-hexahydroxydiphenoyl-beta-D-glucose",glucose,punicafolin,
C1571502,"HGT1 protein, Candida albicans",glucose,"high-affinity glucose transporter protein, Candida albicans",
C1571562,"SLC2A11 protein, human",glucose,"GLUT11 protein, human; GLUT11 glucose transporter protein, human; solute carrier family 2 (facilitated glucose transporter), member 11 protein, human",
C1572079,BD MINIMED SYSTEM (GLUCOSE) TEST STRIP,glucose,BD MINIMED SYSTEM (GLUCOSE) TEST STRIP,
C1572099,ASCENSIA AUTODISC (GLUCOSE) TEST STRIP,glucose,Ascensia Autodisc Test Disc; ASCENSIA AUTODISC (GLUCOSE) TEST STRIP,
C1572102,BD (GLUCOSE) TEST STRIP,glucose,BD (GLUCOSE) TEST STRIP,
C1572648,"GLUCOSE 100GM/300ML LIQUID,ORAL",glucose,"GLUCOSE 100GM/300ML LIQUID,ORAL",
C1572649,"GLUCOSE 75GM/300ML LIQUID,ORAL",glucose,"GLUCOSE 75GM/300ML LIQUID,ORAL",
C1572678,GLUCOSE CONTROL ACCU-CHEK ADVANTAGE SOLN,glucose,GLUCOSE CONTROL ACCU-CHEK ADVANTAGE SOLN,
C1572679,ONE TOUCH ULTRA (GLUCOSE) METER,glucose,ONE TOUCH ULTRA (GLUCOSE) METER,
C1572680,GLUCOSE CONTROL GLUCOMETER ELITE NORMAL SOLN,glucose,GLUCOSE CONTRL GLUCOMETER ELITE NORM SLN,
C1578917,Islet cell adenomatosis,diabetes,Pancreatic B-cell adenomatosis; INSDM; Islet cell adenomatosis; Islet Cell Adenomatosis; ISLET CELL ADENOMATOSIS; INSULINOMATOSIS AND DIABETES MELLITUS; Islet cell adenomatosis (disorder),
C1579015,Sample glucose &/or fluid (specimen),glucose,,
C1579430,Blood Glucose Regulators,blood glucose,Blood Glucose Regulators,
C1586397,Glucose 43 MG/ML / Sodium Chloride 0.0308 MEQ/ML Injectable Solution,glucose,,
C1595391,fructose 374 MG/ML / glucose 374 MG/ML / phosphoric acid 4.3 MG/ML [Emetrol],glucose,,
C1606007,glucose 0.4 MG/MG [Insta-Glucose],glucose,,
C1609249,"SLC37A4 protein, human",glucose,"solute carrier family 37 (glycerol-6-phosphate transporter), member 4 protein, human; G6PT1 protein, human; glucose-6-phosphate translocase, human; Solute Carrier Family 37 Member 4; Microsomal Glucose-6-Phosphate Transporter; Glucose-5-Phosphate Transporter 1; Transformation-Related Gene 19 Protein; SLC37A4; TRG-19; SLC37A4 protein, human; Glucose-6-Phosphate Exchanger SLC37A4; G6PT protein, human; Glucose-6-Phosphate Translocase; G6P Translocase; Glucose-5-Phosphate Transporter",
C1609348,"phosphoenolpyruvate-glucose phosphocarrier protein, E coli",glucose,,
C1609448,"Reagents, Immunoassay, Autoimmune, Diabetes, Protein Tyrosine Phosphatase Antibody",diabetes,,
C1609942,"HSP90B1 protein, human",glucose,"HSP90B1 protein, human; heat shock protein 90B1, human; GRP-94; Heat Shock Protein 90 kDa Beta Member 1; 94 kDa Glucose-Regulated Protein; tumor rejection antigen (gp96) 1, human; glucose-regulated protein 94, human; Tumor Rejection Antigen 1; GP96 protein, human; Endoplasmin; HSP90B1; Gp96 Homolog; Stress-Inducible Tumor Rejection Antigen Gp96; Endothelial Cell (HBMEC) Glycoprotein; Epididymis Luminal Protein 35; GRP94 protein, human; TRA1 protein, human; Epididymis Secretory Sperm Binding Protein Li 125m",
C1610001,"Reagents, Immunoassay, Autoimmune, Diabetes, Glutamic Acid Decarboxylase Autoantibody",diabetes,,
C1610495,"Tra1 protein, mouse",glucose,"grp94 protein, mouse; tumor rejection antigen gp96, mouse; endoplasmin protein, mouse; 94-kDa glucose-regulated protein, mouse",
C1611047,"Tra1 protein, rat",glucose,"glucose-regulated protein 100, rat; Hsp90beta1 protein, rat; Grp100 protein, rat; Grp94 protein, rat; tumor rejection antigen gp96, rat; endoplasmin protein, rat",
C1612010,"Slc37a4 protein, rat",glucose,"G6PT1 protein, rat; solute carrier family 37 (glycerol-6-phosphate transporter), member 4 protein, rat; glucose-6-phosphate translocase, rat",
C1615567,gem-difluorocarba-D-glucose,glucose,,
C1616862,"Replacement battery, silver oxide, for use with medically necessary home blood glucose monitor owned by patient, each",blood glucose,,
C1617371,"Replacement battery, lithium, for use with medically necessary home blood glucose monitor owned by patient, each",blood glucose,,
C1617820,"Home glucose disposable monitor, includes test strips",glucose,,
C1617881,"Replacement battery, alkaline, j cell, for use with medically necessary home blood glucose monitor owned by patient, each",blood glucose,,
C1618396,"Replacement battery, alkaline (other than j cell), for use with medically necessary home blood glucose monitor owned by patient, each",blood glucose,,
C1619946,"benzoguanamine (2,4-diamino-6-phenyl-1,3,5-triazine)",BG,BG(DAP-T),
C1620154,"1,6-di-O-galloyl-beta-D-glucose",glucose,,
C1621643,"1,4-alpha-glucan 6-alpha-glucosyltransferase activity",glucose,"1,4-alpha-D-glucan:1,4-alpha-D-glucan(D-glucose) 6-alpha-D-glucosyltransferase activity; 1,4-alpha-D-glucan 6-alpha-D-glucosyltransferase activity",
C1622453,glucose mediated signaling pathway,glucose,glucose mediated signalling,
C1623634,Glucose-6-Phosphate dehydrogenase phenotype,glucose,Glucose-6-Phosphate dehydrogenase phenotype,
C1624104,Hemoglobin A1c:MCnc:Pt:Bld:Qn,a1c,Hemoglobin A1c [Mass/volume] in Blood; HbA1c Bld-mCnc; Hemoglobin A1c:Mass Concentration:To identify measures at a point in time:Whole blood:Quantitative; HbA1c (Bld) [Mass/Vol],
C1624124,HbA1c measurement device panel:-:Pt:^Patient:-,a1c,Hemoglobin A1c measurement device panel; HbA1c measurement device panel:-:To identify measures at a point in time:^Patient:-; Hb A1c Measurement Device Pnl,
C1625163,glucose sensor activity,glucose,glucose sensor,
C1627320,Insulin^pre 100 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Insulin [Mass/volume] in Serum or Plasma --pre 100 g glucose PO; Insulin^pre 100 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin pre 100 g Glc PO SerPl-mCnc; Insulin pre 100 g glucose PO [Mass/Vol],
C1627959,Glucose meter device panel,glucose,Glucose meter device panel,
C1632237,Glucose-6-phosphate dehydrogenase phenotype:Impression/interpretation of study:Point in time:Erythrocytes:Nominal,glucose,Glucose-6-Phosphate dehydrogenase phenotype [Interpretation] in Red Blood Cells; Glucose-6-Phosphate dehydrogenase phenotype:Impression/interpretation of study:To identify measures at a point in time:Erythrocytes:Nominal; G6PD phenotype (RBC) [Interp]; G6PD Phenotyp RBC-Imp; Glucose-6-Phosphate dehydrogenase phenotype:Imp:Pt:RBC:Nom,
C1638311,Blood glucose management,blood sugar,Blood sugar management; Blood sugar management (procedure),
C1640470,Glucose^3H post dose lactose PO:MCnc:Pt:Urine:Qn,glucose,Glucose^3 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose [Mass/volume] in Urine --3 hours post dose lactose PO; Glucose 3h p Lac PO Ur-mCnc; Glucose 3 Hr post dose lactose PO (U) [Mass/Vol],
C1641493,Glucose^1H post dose lactose PO:MCnc:Pt:Urine:Qn,glucose,Glucose [Mass/volume] in Urine --1 hour post dose lactose PO; Glucose 1 Hr post dose lactose PO (U) [Mass/Vol]; Glucose 1h p Lac PO Ur-mCnc; Glucose^1 hour post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative,
C1641496,Glucose^4H post dose lactose PO:MCnc:Pt:Urine:Qn,glucose,Glucose 4 Hr post dose lactose PO (U) [Mass/Vol]; Glucose 4h p Lac PO Ur-mCnc; Glucose [Mass/volume] in Urine --4 hours post dose lactose PO; Glucose^4 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative,
C1641518,Glucose:MCnc:Pt:BldV:Qn,glucose,Glucose (BldV) [Mass/Vol]; Glucose BldV-mCnc; Glucose:Mass Concentration:To identify measures at a point in time:Blood venous:Quantitative; Glucose [Mass/volume] in Venous blood,
C1642055,Glucose^2H post dose lactose PO:MCnc:Pt:Urine:Qn,glucose,Glucose [Mass/volume] in Urine --2 hours post dose lactose PO; Glucose^2 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 2h p Lac PO Ur-mCnc; Glucose 2 Hr post dose lactose PO (U) [Mass/Vol],
C1642554,Glucose^6H post dose lactose PO:MCnc:Pt:Urine:Qn,glucose,Glucose 6 Hr post dose lactose PO (U) [Mass/Vol]; Glucose^6 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 6h p Lac PO Ur-mCnc; Glucose [Mass/volume] in Urine --6 hours post dose lactose PO,
C1642556,Glucose^5H post dose lactose PO:MCnc:Pt:Urine:Qn,glucose,Glucose 5h p Lac PO Ur-mCnc; Glucose [Mass/volume] in Urine --5 hours post dose lactose PO; Glucose^5 hours post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 5 Hr post dose lactose PO (U) [Mass/Vol],
C1642836,Infection of foot due to diabetes mellitus,diabetes,Infection of foot associated with diabetes; Infection of foot due to diabetes mellitus (disorder),
C1643233,Glucose:MCnc:Pt:BldA:Qn,glucose,Glucose [Mass/volume] in Arterial blood; Glucose BldA-mCnc; Glucose:Mass Concentration:To identify measures at a point in time:Blood arterial:Quantitative; Glucose (BldA) [Mass/Vol],
C1644627,Glucose^post CFst:MCnc:Pt:BldC:Qn:Glucometer,glucose,Glucose^post Calorie fast:Mass Concentration:To identify measures at a point in time:Blood capillary:Quantitative:Glucometer; Fasting glucose [Mass/volume] in Capillary blood by Glucometer; Glucose p fast BldC Glucomtr-mCnc; Glucose post fast Glucometer (BldC) [Mass/Vol],
C1644656,Vendor device model code:ID:Pt:Glucose meter device:Nom,glucose,Vendor device model code of Glucose meter; Model Cd Glucose Mtr Dev; Vendor model code Nom (Glucose meter device) [ID]; Vendor device model code:Identifier:To identify measures at a point in time:Glucose meter device:Nominal,
C1644741,Easypro Blood Glucose Meter Kit,blood glucose,,
C1645723,Glucose:MCnc:Pt:BldC:Qn:Glucometer,glucose,Glucose Glucometer (BldC) [Mass/Vol]; Glucose [Mass/volume] in Capillary blood by Glucometer; Glucose BldC Glucomtr-mCnc; Glucose:Mass Concentration:To identify measures at a point in time:Blood capillary:Quantitative:Glucometer,
C1646009,Albertsons Glucose Watermelon,glucose,,
C1646062,Surestep Pro Glucose Control,glucose,,
C1647162,Dex4 Vertical Glucose Watermelon,glucose,,
C1647453,Glucose^30M post dose lactose PO:MCnc:Pt:Urine:Qn,glucose,Glucose^30 minutes post dose lactose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 30M p Lac PO Ur-mCnc; Glucose 30 Min post dose lactose PO (U) [Mass/Vol]; Glucose [Mass/volume] in Urine --30 minutes post dose lactose PO,
C1648310,Vendor serial number:ID:Pt:Glucose meter device:Nom,glucose,Glucose Mtr Dev Serial #; Glucose meter device Vendor serial number; Vendor serial number:Identifier:To identify measures at a point in time:Glucose meter device:Nominal,
C1649301,Kinray Preferred Plus Grape Glucose,glucose,,
C1650341,Vendor software version:ID:Pt:Glucose meter device:Nom,glucose,Glucose Mtr Dev Software vers; Glucose meter device Vendor software version; Vendor software version:Identifier:To identify measures at a point in time:Glucose meter device:Nominal,
C1651003,Longs Orange Glucose,glucose,,
C1651004,Longs Raspberry Glucose,glucose,,
C1651489,Glucose meter device,glucose,Glucose meter device,
C1651673,Class:Type:Pt:Glucose meter device:Nom,glucose,Class:Type:To identify measures at a point in time:Glucose meter device:Nominal; Type of Glucose meter device; Glucose Mtr Dev Class,
C1651674,Vendor device name:ID:Pt:Glucose meter device:Nom,glucose,Glucose meter device Vendor name; Vendor device name:Identifier:To identify measures at a point in time:Glucose meter device:Nominal; Glucose Mtr Dev Vendor name,
C1652100,Kinray Preferred Plus Orange Glucose,glucose,,
C1652101,Kinray Preferred Plus Raspberry Glucose,glucose,,
C1654667,Dex4 Vertical Glucose Raspberry,glucose,,
C1655313,Prestige LX Blood Glucose Meter,blood glucose,,
C1655416,Assure Blood Glucose Meter,blood glucose,,
C1655424,Advance Blood Glucose Monitoring Kit,blood glucose,,
C1655826,Leader Orange Glucose,glucose,,
C1655893,Brite Life Grape Glucose,glucose,,
C1656296,Leader Blood Glucose Monitor,blood glucose,,
C1656509,Diabetes Shoppe Lancets,diabetes,,
C1656874,Select Gt Glucose Control,glucose,,
C1657083,Good Neighbor Raspberry Glucose,glucose,,
C1657355,Dermiform Hypo-Allergenic Knitted Tape,hypo,,
C1657524,Family Pharmacy Orange Glucose,glucose,,
C1657527,Good Neighbor Orange Glucose,glucose,,
C1657528,Good Neighbor Watermelon Glucose,glucose,,
C1657533,Dex4 Vertical Glucose Grape,glucose,,
C1657596,Glucose meter device panel:-:Point in time:^Patient:-,glucose,Glucose meter device panel:-:Pt:^Patient:-; Glucose meter device panel; Glucose meter device panel:-:To identify measures at a point in time:^Patient:-; Glucose Meter Device Pnl,
C1657831,Leader Raspberry Glucose,glucose,,
C1657832,Leader Watermelon Glucose,glucose,,
C1657934,Accu-Chek Advantage II Glucose Control,glucose,,
C1658011,detection of glucose,glucose,glucose detection,
C1658027,Select Gt Blood Glucose Strip,blood glucose,,
C1658028,Supreme II Blood Glucose Meter,blood glucose,,
C1658056,Brite Life Watermelon Glucose,glucose,,
C1658150,glucose sensing,glucose,glucose perception,
C1658165,SideKick Disposable Blood Glucose Meter,blood glucose,,
C1658166,Sidekick Blood Glucose Testing System,blood glucose,,
C1658206,Good Neighbor Grape Glucose,glucose,,
C1658208,Dex4 Vertical Glucose Orange,glucose,,
C1658223,Family Pharmacy Raspberry Glucose,glucose,,
C1658257,In Charge Glucose Value Pack,glucose,,
C1658259,Kinray Preferred Plus Watermelon Glucose,glucose,,
C1658334,Precision Glucose Control,glucose,,
C1658378,Brite Life Orange Glucose,glucose,,
C1658562,Brite Life Raspberry Glucose,glucose,,
C1659523,Health Care America Raspberry Glucose,glucose,,
C1659524,Health Care America Watermelon Glucose,glucose,,
C1659987,How to Prevent Diabetes,diabetes,diabetes prevention; Diabetes Prevention,
C1660726,Dermicel Hypo-Allergenic Cloth Tape,hypo,,
C1665694,"glucose-6-phosphate dehydrogenase Jamnagar, human",glucose,"G6PD Jamnagar, human; G6PD Rohini, human",
C1666260,BG 9928,BG,BG-9928; BG9928,
C1666265,"Pdia3 protein, mouse",glucose,"ERp61 protein, mouse; glucose regulated protein, 58 kDa, mouse; ERp60 protein, mouse; Grp58 protein, mouse; protein disulfide isomerase associated 3 protein, mouse; ERp57 protein, mouse",
C1666266,"PDIA3 protein, rat",glucose,"Grp58 protein, rat; protein disulfide isomerase family A, member 3, rat; ERp57 protein, rat; ER60 protein, rat; glucose regulated protein, 58 kDa, rat",
C1669103,O6-(-(2-(18F)fluoroethoxymethyl)benzyl)guanine,BG,O6-FEM-BG,
C1677668,Otacanthus sp. Albach ex BG Bonn,BG,,
C1681886,BG 00012,BG,"BG00012; 00012, BG; BG-00012",
C1684791,Hypoglycemia education,hypoglycemia,Health education - hypoglycemia; Hypoglycemia education (procedure); Hypoglycaemia education; Health education - hypoglycaemia,
C1684792,Diabetes self-monitoring health education,diabetes,Diabetes self-monitoring health education (procedure); Health education - diabetes self-monitoring,
C1685092,BG 12 compound,BG,"BG-12 compound; compound, BG12; BG12 compound; compound, BG 12; 12 compound, BG",
C1689308,Blood glucose control education,blood glucose,Advice about blood glucose control; Blood glucose control education (procedure),
C1695668,Glucose 47 MG/ML / Sodium Chloride 0.034 MEQ/ML Injectable Solution,glucose,,
C1696283,1000 ML glucose 50 MG/ML / potassium chloride 0.01 MEQ/ML / sodium chloride 4.5 MG/ML Injection,glucose,"1000 ML Glucose 50 MG/ML / K+ Chloride 0.01 MEQ/ML / NaCl 4.5 MG/ML Injection; DEXTROSE 5%/NACL 0.45%/KCL 10MEQ/L INJ; Dextrose 5% and 0.45% Sodium Chloride with Potassium Chloride 10 mEq/L, Dextrose 5% with 0.45% NaCl and KCl 10 mEq/L intravenous solution; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.01 MEQ/ML / NaCl 4.5 MG/ML Injection; LVP solution with potassium Dextrose 5% with 0.45% NaCl and KCl 10 mEq/L intravenous solution; DEXTROSE MONOHYDRATE 50 g in 1000 mL / SODIUM CHLORIDE 4.5 g in 1000 mL / POTASSIUM CHLORIDE 0.745 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; POTASSIUM CHLORIDE 75 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL / POTASSIUM CHLORIDE 0.075 g in 100 mL INTRAVENOUS INJECTION [Potassium Chloride in Dextrose and Sodium Chloride]; potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.45 % per 1000 ML Injection",
C1696284,1000 ML Glucose 50 MG/ML / Potassium Chloride 0.02 MEQ/ML / Sodium Chloride 3 MG/ML Injection,glucose,"LVP solution with potassium Dextrose 5% with 0.33% NaCl and KCl 20 mEq/L intravenous solution; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.02 MEQ/ML / NaCl 3 MG/ML Injection; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.02 MEQ/ML / NaCl 3 MG/ML Injection; Dextrose 5% and 0.33% Sodium Chloride with Potassium Chloride 20 mEq/L, Dextrose 5% with 0.33% NaCl and KCl 20 mEq/L intravenous solution; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.33 g in 100 mL / POTASSIUM CHLORIDE 0.15 g in 100 mL INTRAVENOUS INJECTION [Potassium Chloride in Dextrose and Sodium Chloride]; POTASSIUM CHLORIDE 150 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 330 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; potassium chloride 20 MEQ / dextrose 5 % / sodium chloride 0.3 % per 1000 ML Injection; 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 3 MG/ML Injection; potassium chloride 20 MEQ / dextrose 5 % / sodium chloride 0.3 % in 1000 ML Injection",
C1697262,glucose Oral Gel [Dex4],glucose,,
C1700340,"glucose-dependent insulinotropic polypeptide, epsilon-palmitoyl-Lys(16)-",glucose,"16-epsilon-palmitoyl-Lys-GIP; GIP(Lys16PAL); glucose-dependent insulinotropic polypeptide, epsilon-palmitoyllysyl(16)-",
C1701335,glucose 0.4 MG/MG Oral Gel [Dex4],glucose,Dex4 0.4 MG/MG Oral Gel; Dex4 40 % Oral Gel,
C1702020,"glucose-dependent insulinotropic polypeptide, epsilon-palmitoyl-Lys(37)-",glucose,"GIP(Lys37PAL); glucose-dependent insulinotropic polypeptide, epsilon-palmitoyllysyl(37)-; 37-epsilon-palmitoyl-Lys-GIP",
C1702028,"mglB protein, E coli",glucose,"D-galactose D-glucose-binding protein, E coli; GGBP protein, E coli",
C1703674,glucose 0.4 MG/MG [Dex4],glucose,,
C1704381,Glucose decreased,glucose,,
C1704947,GPI wt Allele,glucose,NLK; GPI wt Allele; Glucose Phosphate Isomerase wt Allele; SA-36; AMF; SA36; PGI; GNPI; PHI,
C1705019,American Diabetes Association,diabetes,American Diabetes Association,
C1705508,AVPR2 wt Allele,diabetes,ADHR; Arginine Vasopressin Receptor 2 wt Allele; NDI; DI1; DIR3; V2R; AVPR2 wt Allele; DIR; Arginine Vasopressin Receptor 2 (Nephrogenic Diabetes Insipidus) Gene,
C1705560,PRKDC wt Allele,hyper,"HYRC; Hyperradiosensitivity Complementing 1, Mouse, Homolog of Gene; Hyper-Radiosensitivity of Murine SCID Mutation, Complementing 1 Gene; DNAPK; DNPK1; p350; IMD26; PRKDC wt Allele; HYRC1; XRCC7; Protein Kinase, DNA-Activated, Catalytic Polypeptide wt Allele; DNA-PKcs",
C1705603,SLC2A1 wt Allele,glucose,"GTR1; Glucose Transporter Type 1 Gene; SLC2A1; GLUT1; SLC2A1 wt Allele; GLUT; Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 wt Allele",
C1705625,RRAD wt Allele,diabetes,"RRAD wt Allele; RAD Gene; REM3; RRAD, Ras Related Glycolysis Inhibitor and Calcium Channel Regulator wt Allele; RAD; Ras-Related Associated with Diabetes Gene; Ras Gene Associated with Diabetes; RAS (RAD and GEM) Like GTP Binding 3 Gene; RAD1",
C1706005,CD40LG wt Allele,hyper,"Hyper-IgM Syndrome Gene; TRAP Gene; CD40L; TRAP; TNF Superfamily, Member 5 Gene; CD154; IMD3; CD40LG wt Allele; IGM; CD40 Ligand (TNF Superfamily, Member 5, Hyper-IgM Syndrome) Gene; RP3-527F8.3; T-BAM; HIGM1; Tumor Necrosis Factor Ligand Superfamily, Member 5 Gene; TNFSF5; gp39; CD40LG; hCD40L; CD40 Ligand wt Allele; Tumor Necrosis Factor (Ligand) Superfamily Member 5 Gene",
C1706109,AVP wt Allele,diabetes,"AVP; AVP-NPII; VP; AVRP; ARVP; Arginine Vasopressin wt Allele; Arginine Vasopressin (Neurophysin II, Antidiuretic Hormone, Diabetes Insipidus, Neurohypophyseal) Gene; AVP wt Allele; ADH",
C1708113,G6PD wt Allele,glucose,G6PD wt Allele; Glucose-6-Phosphate Dehydrogenase wt Allele; G6PD1,
C1708121,GIPR wt Allele,glucose,"GIPR wt Allele; Insulinotropic Polypeptide Receptor, Glucose-Dependent Gene; Gastric Inhibitory Polypeptide Receptor wt Allele; PGQTL2",
C1708295,HSPA5 wt Allele,glucose,"GRP78; Heat Shock 70kDa Protein 5 (Glucose-Regulated Protein, 78kDa) wt Allele; HSPA5 wt Allele; IGH-BIP Gene; D7G6",
C1711703,Publix Glucose Orange,glucose,Publix Glucose Raspberry; Publix Glucose Sour Apple,
C1711992,CVS Glucose,glucose,,
C1712395,Kroger Blood Glucose Monitor with Lancets,blood glucose,,
C1712396,Kroger Blood Glucose Test Strips,blood glucose,,
C1714484,Glucose^2H post meal:MCnc:Pt:Milk:Qn,glucose,Glucose 2h p meal Mlk-mCnc; Glucose 2 Hr post meal (Milk) [Mass/Vol]; Glucose^2 hours post meal:Mass Concentration:To identify measures at a point in time:Milk:Quantitative; Glucose [Mass/volume] in Milk --2 hours post meal,
C1714532,Glucose/Insulin:MRto:Pt:Ser/Plas:Qn,glucose,Glucose/Insulin [Mass Ratio] in Serum or Plasma; Glucose/Insulin SerPl; Glucose/Insulin [Mass ratio]; Glucose/Insulin:Mass Ratio:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1715281,Alpha-1-Fetoprotein^^adjusted for diabetes+weight:MoM:Pt:Ser/Plas:Qn,diabetes,AFP Diabetes+wt adj MoM SerPl; Alpha-1-Fetoprotein [Multiple of the median] adjusted for diabetes+weight in Serum or Plasma; AFP adjusted for diabetes+weight [MoM]; Alpha-1-Fetoprotein^^adjusted for diabetes+weight:Multiple of the Median:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1715283,Alpha-1-Fetoprotein^^adjusted for diabetes:MoM:Pt:Ser/Plas:Qn,diabetes,Alpha-1-Fetoprotein [Multiple of the median] adjusted for diabetes in Serum or Plasma; AFP adjusted for diabetes [MoM]; Alpha-1-Fetoprotein^^adjusted for diabetes:Multiple of the Median:To identify measures at a point in time:Serum/Plasma:Quantitative; AFP Diabetes adj MoM SerPl,
C1716125,Glucose^1.5H post meal:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1.5 hours post meal:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5 Hr post meal [Moles/Vol]; Glucose 1.5h p meal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --1.5 hours post meal,
C1716203,Glucose^12 AM specimen:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^12 AM specimen:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 12 AM SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --12 AM specimen; Glucose 12 AM specimen [Moles/Vol],
C1716204,Glucose^8 AM specimen:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 8 AM SerPl-sCnc; Glucose^8 AM specimen:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --8 AM specimen; Glucose 8 AM specimen [Moles/Vol],
C1716205,Glucose^12 PM specimen:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 12 PM specimen [Moles/Vol]; Glucose^12 PM specimen:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --12 PM specimen; Glucose 12 PM SerPl-sCnc,
C1716206,Glucose^4 PM specimen:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^4 PM specimen:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --4 PM specimen; Glucose 4 PM SerPl-sCnc; Glucose 4 PM specimen [Moles/Vol],
C1716223,Glucose^8 PM specimen:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^8 PM specimen:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 8 PM SerPl-sCnc; Glucose 8 PM specimen [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --8 PM specimen,
C1716341,Glucose^3rd specimen post XXX challenge:MCnc:Pt:Urine:Qn:Test strip,glucose,Glucose [Mass/volume] in Urine by Test strip --3rd specimen post XXX challenge; Glucose 3rd specimen post Unsp challenge Test strip (U) [Mass/Vol]; Glucose^3rd specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip; Glucose sp3 p chal Ur Strip-mCnc,
C1716342,Glucose^4th specimen post XXX challenge:MCnc:Pt:Urine:Qn:Test strip,glucose,Glucose 4th specimen post Unsp challenge Test strip (U) [Mass/Vol]; Glucose^4th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip; Glucose sp4 p chal Ur Strip-mCnc; Glucose [Mass/volume] in Urine by Test strip --4th specimen post XXX challenge,
C1716343,Glucose^5th specimen post XXX challenge:MCnc:Pt:Urine:Qn:Test strip,glucose,Glucose [Mass/volume] in Urine by Test strip --5th specimen post XXX challenge; Glucose^5th specimen post XXX challenge:Mass Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip; Glucose 5th specimen post Unsp challenge Test strip (U) [Mass/Vol]; Glucose sp5 p chal Ur Strip-mCnc,
C1716426,Glucose:SCnc:24H:Dial fld:Qn,glucose,Glucose:Substance Concentration:24 hours:Dialysis fluid:Quantitative; Glucose (24H Dial fld) [Moles/Vol]; Glucose 24h Dial fld-sCnc; Glucose [Moles/volume] in 24 hour Dialysis fluid,
C1716427,Glucose^2.5H post 50 g lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --2.5 hours post 50 g lactose PO; Glucose 2.5 Hr post 50 g lactose PO [Moles/Vol]; Glucose^2.5 hours post 50 g lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2.5h p 50 g Lac PO SerPl-sCnc,
C1716428,Glucose^45M post dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 45 Min post dose lactose PO [Moles/Vol]; Glucose 45M p Lac PO SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose lactose PO; Glucose^45M post dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1716742,Diabetes mellitus:Find:Pt:^Patient:Ord:MDS,diabetes,Diabetes mellitus [Minimum Data Set]; Diabetes mellitus:Finding:To identify measures at a point in time:^Patient:Ordinal:MDS,
C1717305,Glucose phosphate isomerase:CCnt:Pt:RBC:Qn,glucose,Glucose phosphate isomerase:Catalytic Content:To identify measures at a point in time:Erythrocytes:Quantitative; GPI RBC-cCnt; Glucose phosphate isomerase [Enzymatic activity/mass] in Red Blood Cells; Glucose phosphate isomerase (RBC) [Catalytic activity/Mass],
C1717373,Insulin dependent diabetes mellitus:PrThr:Pt:^Patient:Ord,diabetes,Insulin dependent diabetes mellitus [Presence]; Insulin dependent diabetes mellitus Ql; IDDM Patient Ql; Insulin dependent diabetes mellitus:Presence or Threshold:To identify measures at a point in time:^Patient:Ordinal,
C1717387,Protein & Glucose panel:-:Pt:Urine:-:Test strip,glucose,Prot + Glucose Pnl Ur Strip; Protein and Glucose panel Test strip (U); Protein and Glucose panel - Urine by Test strip; Protein & Glucose panel:-:To identify measures at a point in time:Urine:-:Test strip,
C1718582,adjusted for diabetes+weight,diabetes,adjusted for diabetes+weight,
C1719133,Glucose/Insulin,glucose,Glucose/Insulin,
C1719249,Adjusted for diabetes,diabetes,adjusted for diabetes; Adjusted for diabetes technique (qualifier value); Adjusted for diabetes technique,
C1719759,Renal disorder due to type 1 diabetes mellitus,diabetes,Renal disorder associated with type I diabetes mellitus; Renal disorder associated with type 1 diabetes mellitus; Renal disorder due to type 1 diabetes mellitus (disorder); Kidney disorder associated with type 1 diabetes mellitus,
C1719760,Peripheral vascular disorder due to diabetes mellitus,diabetes,Peripheral circulatory disorder associated with diabetes mellitus; Diabetic peripheral circulatory disorder; Peripheral vascular disorder due to diabetes mellitus (disorder),
C1719769,Exudative maculopathy due to type 1 diabetes mellitus,diabetes,Exudative maculopathy with type 1 diabetes mellitus; Exudative maculopathy due to type 1 diabetes mellitus (disorder); Exudative maculopathy associated with type 1 diabetes mellitus,
C1719783,Persistent proteinuria due to type 1 diabetes mellitus,diabetes,Persistent proteinuria due to type 1 diabetes mellitus (disorder),
C1719807,Cataract due to diabetes mellitus type 1,diabetes,Cataract of eye due to diabetes mellitus type 1 (disorder); Diabetic cataract associated with type 1 diabetes mellitus; Cataract of eye due to diabetes mellitus type 1; Diabetic cataract associated with type I diabetes mellitus; Diabetes type 1 with cataract,
C1719878,Non-ketotic non-hyperosmolar coma due to diabetes mellitus,diabetes,Non-ketotic non-hyperosmolar coma due to diabetes mellitus (disorder),
C1719887,Persistent proteinuria due to type 2 diabetes mellitus,diabetes,Persistent proteinuria due to type 2 diabetes mellitus (disorder),
C1719929,Persistent microalbuminuria due to type 1 diabetes mellitus,diabetes,Persistent microalbuminuria associated with type I diabetes mellitus; Persistent microalbuminuria due to type 1 diabetes mellitus (disorder),
C1719939,Disorder due to type 2 diabetes mellitus,diabetes,Disorder due to type 2 diabetes mellitus (disorder); Disorder due to type II diabetes mellitus,
C1719950,Retinopathy due to type 2 diabetes mellitus,diabetes,Diabetes type 2 with retinopathy; Diabetic retinopathy associated with type 2 diabetes mellitus; Retinopathy due to type 2 diabetes mellitus (disorder); Retinopathy with type 2 diabetes mellitus; Diabetic retinopathy associated with type II diabetes mellitus,
C1719988,Disorder of nervous system due to type 2 diabetes mellitus,diabetes,Disorder of nervous system due to type 2 diabetes mellitus (disorder); Neurologic disorder associated with type 2 diabetes mellitus; Neurological disorder with type 2 diabetes mellitus; Neurologic disorder associated with type II diabetes mellitus,
C1720042,Disorder of nervous system due to malnutrition related diabetes mellitus,diabetes,Disorder of nervous system due to malnutrition related diabetes mellitus (disorder),
C1720056,Peripheral circulatory disorder due to type 1 diabetes mellitus,diabetes,Peripheral circulatory disorder due to type 1 diabetes mellitus (disorder); Peripheral circulatory disorder associated with type 1 diabetes mellitus,
C1720078,Disorder of nervous system due to diabetes mellitus,diabetes,Nervous system disorder due to diabetes mellitus; Disorder of nervous system due to diabetes mellitus (disorder); Neurologic disorder associated with diabetes mellitus; Diabetic neurologic disease; Neurologic complication of diabetes mellitus,
C1720102,Persistent microalbuminuria due to type 2 diabetes mellitus,diabetes,Persistent microalbuminuria associated with type II diabetes mellitus; Persistent microalbuminuria due to type 2 diabetes mellitus (disorder),
C1720143,Hyperosmolar coma due to diabetes mellitus,diabetes,Hyperosmolar coma due to diabetes mellitus (disorder),
C1720165,Peripheral circulatory disorder due to type 2 diabetes mellitus,diabetes,Peripheral circulatory disorder due to type 2 diabetes mellitus (disorder); Peripheral circulatory disorder associated with type 2 diabetes mellitus,
C1720171,Cataract due to diabetes mellitus type 2,diabetes,Cataract of eye due to diabetes mellitus type 2 (disorder); Diabetic cataract associated with type II diabetes mellitus; Cataract of eye due to diabetes mellitus type 2; Diabetic cataract associated with type 2 diabetes mellitus; Diabetes type 2 with cataract,
C1720194,Disorder of nervous system due to type 1 diabetes mellitus,diabetes,Neurological disorder associated with type 1 diabetes mellitus; Disorder of nervous system due to type 1 diabetes mellitus (disorder); Diabetes type 1 with neurological disorder; Neurological disorder with type 1 diabetes mellitus; Neurological disorder associated with type I diabetes mellitus,
C1720223,Retinopathy due to type 1 diabetes mellitus,diabetes,Diabetic retinopathy associated with type I diabetes mellitus; Diabetic retinopathy associated with type 1 diabetes mellitus; Retinopathy with type 1 diabetes mellitus; Diabetes type 1 with retinopathy; Retinopathy due to type 1 diabetes mellitus (disorder),
C1720297,Disorder due to type 1 diabetes mellitus,diabetes,Disorder associated with type I diabetes mellitus; Disorder due to type 1 diabetes mellitus (disorder),
C1720409,Mononeuropathy due to type 1 diabetes mellitus,diabetes,Mononeuropathy due to type 1 diabetes mellitus (disorder); Mononeuropathy with type 1 diabetes mellitus,
C1720457,Renal disorder due to type 2 diabetes mellitus,diabetes,Kidney disorder associated with type 2 diabetes mellitus; Diabetes type 2 with nephropathy; Renal disorder associated with type II diabetes mellitus; Renal disorder due to type 2 diabetes mellitus (disorder),
C1720489,Coma due to malnutrition-related diabetes mellitus,diabetes,Coma due to malnutrition-related diabetes mellitus (disorder),
C1720567,Hypoglycemic coma due to diabetes mellitus,diabetes,Hypoglycemic coma due to diabetes mellitus (disorder); Hypoglycaemic coma due to diabetes mellitus; Hypoglycemic coma in diabetes mellitus; Hypoglycaemic coma in diabetes mellitus; Diabetic hypoglycemic coma,
C1720598,Ketoacidotic coma due to type 1 diabetes mellitus,diabetes,Ketoacidotic coma due to type 1 diabetes mellitus (disorder); Ketoacidotic coma in type I diabetes mellitus; Ketoacidotic coma in type 1 diabetes mellitus; Diabetes mellitus type 1 with ketoacidotic coma,
C1720626,Exudative maculopathy due to type 2 diabetes mellitus,diabetes,Exudative maculopathy associated with type II diabetes mellitus; Exudative maculopathy associated with type 2 diabetes mellitus; Exudative maculopathy with type 2 diabetes mellitus; Exudative maculopathy due to type 2 diabetes mellitus (disorder),
C1720648,Mononeuropathy due to type 2 diabetes mellitus,diabetes,Mononeuropathy with type 2 diabetes mellitus; Mononeuropathy due to type 2 diabetes mellitus (disorder),
C1720734,Ketoacidotic coma due to type 2 diabetes mellitus,diabetes,Ketoacidotic coma due to type 2 diabetes mellitus (disorder); Ketoacidotic coma in type II diabetes mellitus; Ketoacidotic coma in type 2 diabetes mellitus; Diabetes mellitus type 2 with ketoacidotic coma,
C1720860,"Familial Partial Lipodystrophy, Type 2",diabetes,"Reverse Partial Lipodystrophies; Familial partial lipodystrophy type 2; Familial partial lipodystrophy Dunnigan type; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK; Lipodystrophy, Reverse Partial; Partial Lipodystrophies, Reverse; Lipodystrophy, Familial Partial, Dunnigan Type; LIPODYSTROPHY, REVERSE PARTIAL; Lipodystrophy, Familial Partial, Type 2; FPL2; Dunnigan syndrome; Familial partial lipodystrophy, Dunnigan type; Lipodystrophy, Familial, of Limbs and Lower Trunk; Familial Partial Lipodystrophy Type 2; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE; Familial Partial Lipodystrophy, Type 2; FPLD2; Dunnigan Syndrome; Familial partial lipodystrophy type 2 (disorder); LIPOATROPHIC DIABETES; Partial Lipodystrophy, Reverse; LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; Reverse Partial Lipodystrophy",
C1720863,Congenital Generalized Lipodystrophy Type 2,diabetes,"Lipodystrophy, Total, And Acromegaloid Gigantism; BERARDINELLI SYNDROME; Berardinelli-Seip Congenital Lipodystrophy Type 2; Diabetes, Congenital Lipoatrophic; Diabete, Congenital Lipoatrophic; BSCL2-Related Brunzell Syndrome; Berardinelli-Seip Congenital Lipodystrophy, Type 2; Congenital Lipoatrophic Diabetes; Lipoatrophic Diabetes, Congenital; Syndrome, Seip; Lipodystrophy, Congenital Generalized, Type 2; LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2; Berardinelli Seip Congenital Lipodystrophy, Type 2; Syndrome, Berardinelli; BERARDINELLI-SEIP CONGENITAL LIPODYSTROPHY, TYPE 2; Berardinelli Syndrome; LIPOATROPHIC DIABETES, CONGENITAL; SEIP SYNDROME; Berardinelli Seip Congenital Lipodystrophy Type 2; Syndrome, BSCL2-Related Brunzell; Seip Syndrome; Total Lipodystrophy and Acromegaloid Gigantism; BRUNZELL SYNDROME, BSCL2-RELATED; Brunzell Syndrome, BSCL2-Related; Congenital Lipoatrophic Diabete; Lipodystrophy, Berardinelli-Seip Congenital, Type 2; Brunzell Syndrome; Congenital Generalized Lipodystrophy Type 2; LIPODYSTROPHY, BERARDINELLI-SEIP CONGENITAL, TYPE 2; Syndrome, Brunzell; Lipoatrophic Diabete, Congenital; Brunzell Syndrome, BSCL2 Related; LIPODYSTROPHY, TOTAL, AND ACROMEGALOID GIGANTISM",
C1720956,"Hyper-IgM Immunodeficiency Syndrome, Type 2",hyper,"Immunodeficiency with Hyper-IgM, Type 2; HIGM2 Syndrome; Immunodeficiency with Hyper-IgM Type 2; Hyper IgM Immunodeficiency Syndrome, Type 2; Hyper IgM Syndrome 2; IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 2; HIGM2; Immunodeficiency with Hyper IgM, Type 2; Hyper-IgM syndrome type 2; Hyper-IgM Immunodeficiency Syndrome Type 2; HYPER-IgM SYNDROME 2; Activation-induced cytidine deaminase deficiency; AID deficiency; Hyper IgM Immunodeficiency Syndrome Type 2; Hyper-IgM Syndrome 2; Hyper-IgM Immunodeficiency Syndrome, Type 2; HIGM2 Syndromes",
C1720957,"Hyper-IgM Immunodeficiency Syndrome, Type 3",hyper,"Hyper-IgM syndrome type 3; Hyper IgM Syndrome 3; HIGM3 Syndromes; Hyper-IgM Syndrome 3; CD40 Deficiency; HIGM3 Syndrome; Hyper IgM Immunodeficiency Syndrome, Type 3; IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 3; Hyper-IgM Immunodeficiency Syndrome Type 3; Hyper-IgM syndrome due to CD40 deficiency; HYPER-IgM SYNDROME 3; Immunodeficiency with Hyper IgM, Type 3; HIGM3; Hyper IgM Immunodeficiency Syndrome Type 3; Immunodeficiency with Hyper-IgM, Type 3",
C1720958,"Hyper-IgM Immunodeficiency Syndrome, Type 5",hyper,"Hyper-IgM syndrome type 5; Hyper-IgM syndrome due to uracil N-glycosylase; Immunodeficiency with Hyper-IgM, Type 5; HIGM5 Syndrome; HYPER-IgM SYNDROME 5; HIGM5 Syndromes; Hyper IgM Immunodeficiency Syndrome Type 5; Hyper-IgM Syndrome 5; Hyper-IgM syndrome due to UNG deficiency; IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 5; HIGM5; Hyper IgM Immunodeficiency Syndrome, Type 5; Immunodeficiency with Hyper IgM, Type 5; Hyper-IgM Syndrome 5s; Hyper IgM Syndrome 5; Hyper-IgM Immunodeficiency Syndrome, Type 5; Hyper-IgM Immunodeficiency Syndrome Type 5",
C1721853,2-deoxy-arabino-hexopyranosyl-1-4-glucose,glucose,,
C1721854,2-deoxy-beta-D-arabino-hexopyranosyl-1-4-D-glucose,glucose,2(II)-deoxycellobiose,
C1725327,Glucose Orange,glucose,,
C1725328,Glucose Raspberry,glucose,,
C1725351,BD Glucose,glucose,,
C1726036,Prescision Xtra Glucose and Ketone Test Strip,glucose,,
C1737720,Most recent hemoglobin A1c level > 9.0% (DM),a1c,,
C1739047,caffeoyl 1-O-glucose,glucose,,
C1739071,L-phenylalanyl-D-glucose,glucose,,
C1739108,Latent Autoimmune Diabetes in Adults,diabetes,"Diabetes Mellitus Type 1.5; Latent Autoimmune Diabetes of Adults; Type 1.5 Diabetes; Diabetes, Type 1.5; Type 1.5 Diabetes Mellitus; LADA, Latent Autoimmune Diabetes in Adults",
C1739803,"beta-D-glucose 1,6-(bis)phosphate",glucose,,
C1739804,S-xylo-hexos-4-ulose,glucose,4-keto-D-glucose,
C1740288,Diabetes Diagnostic Reagents,diabetes,,
C1740357,"Blood Glucose Meters, Portable",blood glucose,,
C1741236,"Hig1 protein, mouse",hypoglycemia,"hypoglycemia hypoxia inducible mitochondrial protein 1, mouse; HIMP1 protein, mouse",
C1741352,caffeoyl 1-O-beta-D-glucose,glucose,,
C1741681,"YMR099c protein, S cerevisiae",glucose,"glucose-6-phosphate mutarotase, S cerevisiae; glucose-6-phosphate 1-epimerase, S cerevisiae; hexose-6-phosphate mutarotase, S cerevisiae",
C1741895,feruloyl 1-O-glucose,glucose,,
C1741919,L-alanyl-D-glucose,glucose,,
C1741920,L-valyl-D-glucose,glucose,,
C1742177,4-O-((R)-1-carboxyethyl)-D-glucose,glucose,glucolactilic acid,
C1742445,4-O-(1-carboxyethyl)glucose,glucose,,
C1742845,hyperCVAD protocol,hyper,hyper CVAD protocol,
C1742976,poly(lactic acid-co-((glycolic acid)-alt-(L-glutamic acid))glucose)-poly(ethylene glycol)-poly(lactic acid-co-((glycolic acid)-alt-(L-glutamic acid))glucose),glucose,PLGG-PEG-PLGG,
C1743454,"thymidine diphosphate glucose 3-aminotransferase, Streptomyces achromogenes",glucose,"RubN4 protein, Streptomyces achromogenes",
C1743657,feruloyl 1-O-beta-D-glucose,glucose,,
C1743932,"thymidine diphosphate glucose 4-ketoreductase, Streptomyces achromogenes",glucose,"RubN6 protein, Streptomyces achromogenes",
C1764795,Deprecated Insulin [Units/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO,glucose,Insulin 1.5 Hr post 75 g glucose PO Qn,
C1809475,Herrmann syndrome,diabetes,"PHOTOMYOCLONUS, DIABETES MELLITUS, DEAFNESS, NEPHROPATHY, AND CEREBRAL DYSFUNCTION; Herrmann syndrome; Photomyoclonus, Diabetes Mellitus, Deafness, Nephropathy, And Cerebral Dysfunction; Photomyoclonus, diabetes mellitus, deafness, nephropathy and cerebral dysfunction (disorder); Photomyoclonus, diabetes mellitus, deafness, nephropathy and cerebral dysfunction; HERRMANN SYNDROME",
C1813969,Alanine 3.48 MG/ML / Arginine 3.56 MG/ML / Aspartate 2.45 MG/ML / Glucose 50 MG/ML / Glutamate 2.58 MG/ML / Glycine 1.75 MG/ML / Histidine 1.05 MG/ML / Isoleucine 2.31 MG/ML / Leucine 3.5 MG/ML / Lysine 3.68 MG/ML / Magnesium Chloride 0.00148 MEQ/ML / Methionine 0.6 MG/ML / Phenylalanine 1.04 MG/ML / Potassium Chloride 0.013 MEQ/ML / Proline 2.52 MG/ML / Serine 1.86 MG/ML / Sodium Chloride 0.0205 MEQ/ML / sodium phosphate 0.00347 MEQ/ML / Threonine 1.4 MG/ML / Tryptophan 0.7 MG/ML / Tyrosine 0.94 MG/ML / Valine 1.75 MG/ML Injectable Solution [Aminosyn II 3.5 % M in 5 % Dextrose],glucose,,
C1813971,Alanine 4.22 MG/ML / Arginine 4.32 MG/ML / Aspartate 2.98 MG/ML / Glucose 100 MG/ML / Glutamate 3.14 MG/ML / Glycine 2.12 MG/ML / Histidine 1.28 MG/ML / Isoleucine 2.8 MG/ML / Leucine 4.25 MG/ML / Lysine 4.46 MG/ML / Methionine 0.73 MG/ML / Phenylalanine 1.26 MG/ML / Proline 3.07 MG/ML / Serine 2.25 MG/ML / Threonine 1.7 MG/ML / Tryptophan 0.85 MG/ML / Tyrosine 1.15 MG/ML / Valine 2.12 MG/ML Injectable Solution [Aminosyn II 4.25% in 10% Dextrose],glucose,,
C1813983,glucose 50 MG/ML / magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.00497 MEQ/ML / sodium acetate 0.027 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution [Normosol-R in 5 % Dextrose],glucose,"LVP solution Dextrose 5% with Electrolytes (Normosol R) intravenous solution; Glucose 50 MG/ML / Magnesium Chloride 0.00148 MEQ/ML / K+ Chloride 0.00497 MEQ/ML / Sodium Acetate 0.027 MEQ/ML / NaCl 0.0899 MEQ/ML / Sodium gluconate 5.02 MG/ML Injectable Solution [Normosol-R in 5 % Dextrose]; Glucose 50 MG/ML / Magnesium Chloride 0.00148 MEQ/ML / Pot Chloride 0.00497 MEQ/ML / Sodium Acetate 0.027 MEQ/ML / NaCl 0.0899 MEQ/ML / Sodium gluconate 5.02 MG/ML Injectable Solution [Normosol-R in 5 % Dextrose]; Normosol-R in 5 % Dextrose (glucose 50 MG/ML / K+ chloride 0.00497 MEQ/ML / magnesium chloride 0.00148 MEQ/ML / sodium acetate 0.027 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML) Injectable Solution; DEXTROSE, UNSPECIFIED FORM 5 g in 100 mL / SODIUM CHLORIDE 526 mg in 100 mL / SODIUM ACETATE ANHYDROUS 222 mg in 100 mL / SODIUM GLUCONATE 502 mg in 100 mL / POTASSIUM CHLORIDE 37 mg in 100 mL / MAGNESIUM CHLORIDE 30 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Normosol-R and Dextrose]; Normosol-R in 5 % Dextrose Injectable Solution; NORMOSOL-R/DEXTROSE 5% INJ; Normosol-R and 5% Dextrose, Dextrose 5% with Electrolytes (Normosol R) intravenous solution; glucose 50 MG/ML / magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.00497 MEQ/ML / sodium acetate 0.027 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution [Normosol-R in 5 % Dextrose]",
C1813987,"dibasic potassium phosphate 1 MG/ML / glucose 50 MG/ML / magnesium chloride 0.00639 MEQ/ML / potassium chloride 0.0134 MEQ/ML / sodium chloride 0.0308 MEQ/ML / sodium lactate 0.025 MEQ/ML / sodium phosphate, monobasic 0.16 MG/ML Injectable Solution [Ionosol-B]",glucose,"IONOSOL B in 5 % DEXTROSE Injectable Solution; Dibasic Pot phosphate 1 MG/ML / Glucose 50 MG/ML / Magnesium Chloride 0.00639 MEQ/ML / Pot Chloride 0.0134 MEQ/ML / NaCl 0.0308 MEQ/ML / Sodium Lactate 0.025 MEQ/ML / Sodium Phosphate, Monobasic 0.16 MG/ML Injectable Solution [Ionosol-B]; IONOSOL B/DEXTROSE 5% INJ; Ionosol-B Dextrose 5 % Injectable Solution; Dibasic K+ phosphate 1 MG/ML / Glucose 50 MG/ML / Magnesium Chloride 0.00639 MEQ/ML / K+ Chloride 0.0134 MEQ/ML / NaCl 0.0308 MEQ/ML / Sodium Lactate 0.025 MEQ/ML / Sodium Phosphate, Monobasic 0.16 MG/ML Injectable Solution [Ionosol-B]",
C1813989,"glucose 50 MG/ML / magnesium chloride 0.00361 MEQ/ML / monobasic potassium phosphate 0.15 MG/ML / potassium chloride 0.0189 MEQ/ML / sodium lactate 0.0232 MEQ/ML / sodium phosphate, monobasic 0.25 MG/ML Injectable Solution [Ionosol-MB]",glucose,"DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM LACTATE 260 mg in 100 mL / POTASSIUM CHLORIDE 141 mg in 100 mL / MAGNESIUM CHLORIDE 30 mg in 100 mL / MONOBASIC POTASSIUM PHOSPHATE 15 mg in 100 mL / SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 25 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Ionosol MB and Dextrose]; Ionosol MB and 5% Dextrose, Dextrose 5% with Electrolytes (Ionosol MB) intravenous solution; IONOSOL MB and 5 % DEXTROSE Injectable Solution; LVP solution with potassium Dextrose 5% with Electrolytes (Ionosol MB) intravenous solution; Glucose 50 MG/ML / Magnesium Chloride 0.00361 MEQ/ML / Monobasic K+ phosphate 0.15 MG/ML / K+ Chloride 0.0189 MEQ/ML / Sodium Lactate 0.0232 MEQ/ML / Sodium Phosphate, Monobasic 0.25 MG/ML Injectable Solution [Ionosol-MB]; IONOSOL MB/DEXTROSE 5% INJ; Ionosol-MB Dextrose 5 % Injectable Solution; Glucose 50 MG/ML / Magnesium Chloride 0.00361 MEQ/ML / Monobasic Pot phosphate 0.15 MG/ML / Pot Chloride 0.0189 MEQ/ML / Sodium Lactate 0.0232 MEQ/ML / Sodium Phosphate, Monobasic 0.25 MG/ML Injectable Solution [Ionosol-MB]",
C1813990,Calcium Chloride 0.000996 MEQ/ML / Glucose 0.6 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / Sodium Chloride 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal Low Calcium 1.5],glucose,"DEXTROSE MONOHYDRATE 1.5 g in 100 mL / SODIUM CHLORIDE 538 mg in 100 mL / SODIUM LACTATE 448 mg in 100 mL / CALCIUM CHLORIDE 18.4 mg in 100 mL / MAGNESIUM CHLORIDE 5.08 mg in 100 mL INTRAPERITONEAL INJECTION, SOLUTION [DIANEAL Low Calcium with Dextrose]; calcium chloride 0.000996 MEQ/ML / glucose 0.6 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal Low Calcium 1.5]; DIANEAL LOW CALCIUM/DEXTROSE 1.5% SOLN; Dianeal Low Calcium 1.5 % Intraperitoneal Solution; DIANEAL/CA 2.5MEQ/DEXTROSE 1.5% SOLN; Dianeal Low Calcium with 1.5% Dextrose, Dextrose 1.5% with Electrolytes (Dianeal Low Calcium) intraperitoneal solution; LVP solution Dextrose 1.5% with Electrolytes (Dianeal Low Calcium) intraperitoneal solution; DEXTROSE MONOHYDRATE 1.5 g in 100 mL / SODIUM CHLORIDE 538 mg in 100 mL / SODIUM LACTATE 448 mg in 100 mL / CALCIUM CHLORIDE 18.3 mg in 100 mL / MAGNESIUM CHLORIDE 5.08 mg in 100 mL INTRAPERITONEAL INJECTION, SOLUTION [DIANEAL Low Calcium with Dextrose]; DIANEAL/CALCIUM 2.5MEQ/DEXTROSE 1.5% SOLN; Calcium Chloride 0.000996 MEQ/ML / Glucose 0.6 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal Low Calcium 1.5]",
C1813992,Calcium Chloride 0.000996 MEQ/ML / Glucose 1 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / Sodium Chloride 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal Low Calcium 2.5],glucose,"LVP solution Dextrose 2.5% with Electrolytes (Dianeal Low Calcium) intraperitoneal solution; calcium chloride 0.000996 MEQ/ML / glucose 1 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal Low Calcium 2.5]; Dianeal Low Calcium 2.5 % Intraperitoneal Solution; DIANEAL/CALCIUM 2.5MEQ/DEXTROSE 2.5% SOLN; DEXTROSE MONOHYDRATE 2.5 g in 100 mL / SODIUM CHLORIDE 538 mg in 100 mL / SODIUM LACTATE 448 mg in 100 mL / CALCIUM CHLORIDE 18.4 mg in 100 mL / MAGNESIUM CHLORIDE 5.08 mg in 100 mL INTRAPERITONEAL INJECTION, SOLUTION [DIANEAL Low Calcium with Dextrose]; DEXTROSE MONOHYDRATE 2.5 g in 100 mL / SODIUM CHLORIDE 538 mg in 100 mL / SODIUM LACTATE 448 mg in 100 mL / CALCIUM CHLORIDE 18.3 mg in 100 mL / MAGNESIUM CHLORIDE 5.08 mg in 100 mL INTRAPERITONEAL INJECTION, SOLUTION [DIANEAL Low Calcium with Dextrose]; Dianeal Low Calcium with 2.5% Dextrose, Dextrose 2.5% with Electrolytes (Dianeal Low Calcium) intraperitoneal solution; Calcium Chloride 0.000996 MEQ/ML / Glucose 1 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal Low Calcium 2.5]; DIANEAL/CA 2.5MEQ/DEXTROSE 2.5% SOLN",
C1813994,Calcium Chloride 0.000996 MEQ/ML / Glucose 1.4 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / Sodium Chloride 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal Low Calcium 3.5],glucose,,
C1813995,calcium chloride 0.000996 MEQ/ML / glucose 1.7 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal Low Calcium 4.25],glucose,"DIANEAL/CA 2.5MEQ/DEXTROSE 4.25% SOLN; DEXTROSE MONOHYDRATE 4.25 g in 100 mL / SODIUM CHLORIDE 538 mg in 100 mL / SODIUM LACTATE 448 mg in 100 mL / CALCIUM CHLORIDE 18.3 mg in 100 mL / MAGNESIUM CHLORIDE 5.08 mg in 100 mL INTRAPERITONEAL INJECTION, SOLUTION [DIANEAL Low Calcium with Dextrose]; DIANEAL/CALCIUM 2.5MEQ/DEXTROSE 4.25% SOLN; Calcium Chloride 0.000996 MEQ/ML / Glucose 1.7 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal Low Calcium 4.25]; DEXTROSE MONOHYDRATE 4.25 g in 100 mL / SODIUM CHLORIDE 538 mg in 100 mL / SODIUM LACTATE 448 mg in 100 mL / CALCIUM CHLORIDE 18.4 mg in 100 mL / MAGNESIUM CHLORIDE 5.08 mg in 100 mL INTRAPERITONEAL INJECTION, SOLUTION [DIANEAL Low Calcium with Dextrose]; Dianeal Low Calcium with 4.25% Dextrose, Dextrose 4.25% with Electrolytes (Dianeal Low Ca/Delflex Low Mag-Low Ca) intraperitoneal solution; Dianeal Low Calcium 4.25 % Intraperitoneal Solution",
C1813999,Alanine 3.48 MG/ML / Arginine 3.56 MG/ML / Aspartate 2.45 MG/ML / Glucose 50 MG/ML / Glutamate 2.58 MG/ML / Glycine 1.75 MG/ML / Histidine 1.05 MG/ML / Isoleucine 2.31 MG/ML / Leucine 3.5 MG/ML / Lysine 3.68 MG/ML / Methionine 0.6 MG/ML / Phenylalanine 1.04 MG/ML / Proline 2.52 MG/ML / Serine 1.86 MG/ML / Threonine 1.4 MG/ML / Tryptophan 0.7 MG/ML / Tyrosine 0.94 MG/ML / Valine 1.75 MG/ML Injectable Solution [Aminosyn II 3.5% in 5% Dextrose],glucose,,
C1814007,glucose 50 MG/ML / magnesium acetate 0.0015 MEQ/ML / potassium acetate 0.013 MEQ/ML / sodium chloride 0.04 MEQ/ML Injectable Solution [Plasma-Lyte 56 in 5 % Dextrose],glucose,Glucose 50 MG/ML / magnesium acetate 0.0015 MEQ/ML / K+ Acetate 0.013 MEQ/ML / NaCl 0.04 MEQ/ML Injectable Solution [Plasma-Lyte 56 in 5 % Dextrose]; PLASMA-LYTE 56/DEXTROSE 5% INJ; Glucose 50 MG/ML / magnesium acetate 0.0015 MEQ/ML / Pot Acetate 0.013 MEQ/ML / NaCl 0.04 MEQ/ML Injectable Solution [Plasma-Lyte 56 in 5 % Dextrose]; Plasma-Lyte 56 in 5 % Dextrose (glucose 50 MG/ML / magnesium acetate 0.0015 MEQ/ML / potassium acetate 0.013 MEQ/ML / sodium chloride 0.04 MEQ/ML) Injectable Solution; Plasma-Lyte 56 in 5 % Dextrose Injectable Solution,
C1814009,glucose 50 MG/ML / magnesium acetate 0.000979 MEQ/ML / potassium acetate 0.013 MEQ/ML / sodium chloride 0.04 MEQ/ML Injectable Solution [Normosol-M],glucose,"NORMOSOL-M/DEXTROSE 5% INJ; glucose 50 MG/ML / magnesium acetate 0.000979 MEQ/ML / potassium acetate 0.013 MEQ/ML / sodium chloride 0.04 MEQ/ML Injectable Solution [Normosol-M]; Normosol-M Dextrose Injectable Solution; Glucose 50 MG/ML / magnesium acetate 0.000979 MEQ/ML / Pot Acetate 0.013 MEQ/ML / NaCl 0.04 MEQ/ML Injectable Solution [Normosol-M]; Normosol-M in 5 % Dextrose Injectable Solution; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 234 mg in 100 mL / POTASSIUM ACETATE 128 mg in 100 mL / MAGNESIUM ACETATE 21 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [NORMOSOL-M AND DEXTROSE]; Normosol-M and 5% Dextrose, Dextrose 5% with Electrolytes (Normosol-M/Plasma-Lyte 56) intravenous solution; Glucose 50 MG/ML / magnesium acetate 0.000979 MEQ/ML / K+ Acetate 0.013 MEQ/ML / NaCl 0.04 MEQ/ML Injectable Solution [Normosol-M]",
C1814017,Calcium Chloride 0.002 MEQ/ML / Glucose 50 MG/ML / Potassium Chloride 0.004 MEQ/ML / Sodium Chloride 0.147 MEQ/ML Injectable Solution,glucose,Calcium Chloride 0.002 MEQ/ML / Glucose 50 MG/ML / Pot Chloride 0.004 MEQ/ML / NaCl 0.147 MEQ/ML Injectable Solution; Ringers in 5 % dextrose Injectable Solution; Calcium Chloride 0.002 MEQ/ML / Glucose 50 MG/ML / K+ Chloride 0.004 MEQ/ML / NaCl 0.147 MEQ/ML Injectable Solution; DEXTROSE 5%/RINGER'S INJ; calcium chloride 0.002 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.147 MEQ/ML Injectable Solution; Ringer's with dextrose 5 % Injectable Solution,
C1814189,50 ML glucose 500 MG/ML Prefilled Syringe,glucose,"dextrose 50 % in 50 ML Prefilled Syringe; Dextrose monohydrate 25 g in 50 mL INTRAVENOUS INJECTION, SOLUTION; dextrose 25 GM per 50 ML Prefilled Syringe; DEXTROSE MONOHYDRATE 25 g in 50 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; DEXTROSE 50% INJ_#1; Dextrose, 50% intravenous solution_#2; 50 ML glucose 500 MG/ML Prefilled Syringe; Dextrose Monohydrate 25 g in 50 mL INTRAVENOUS INJECTION, SOLUTION; Dextrose Monohydrate 25 g in 50 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; DEXTROSE MONOHYDRATE 25 g in 50 mL INTRAVENOUS INJECTION, SOLUTION; 50 ML dextrose 50 % Prefilled Syringe; DEXTROSE MONOHYDRATE 500 mg in 1 mL PARENTERAL INJECTION",
C1814190,calcium chloride 0.00014 MEQ/ML / glucose 1.7 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal PD-2/4.25],glucose,"DIANEAL PD-2/DEXTROSE 4.25% SOLN; DEXTROSE MONOHYDRATE 4.25 g in 100 mL / SODIUM CHLORIDE 538 mg in 100 mL / SODIUM LACTATE 448 mg in 100 mL / CALCIUM CHLORIDE 25.7 mg in 100 mL / MAGNESIUM CHLORIDE 5.08 mg in 100 mL INTRAPERITONEAL INJECTION, SOLUTION [DIANEAL PD-2 with Dextrose]; Dianeal PD-2 with 4.25% Dextrose, Dextrose 4.25% with Electrolytes (Dianeal PD-2) intraperitoneal solution; LVP solution Dextrose 4.25% with Electrolytes (Dianeal PD-2) intraperitoneal solution; Calcium Chloride 0.00014 MEQ/ML / Glucose 1.7 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal PD-2/4.25]; Dianeal PD-2/4.25 2500 ML Intraperitoneal Solution",
C1814193,10 ML glucose 250 MG/ML Prefilled Syringe,glucose,"dextrose 2500 MG per 10 ML Prefilled Syringe; Dextrose Monohydrate 250 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Infant Dextrose]; 10 ML glucose 250 MG/ML Prefilled Syringe; DEXTROSE 25% INJ; DEXTROSE MONOHYDRATE 250 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; 10 ML dextrose 25 % Prefilled Syringe; Dextrose, 25% intravenous solution; DEXTROSE MONOHYDRATE 250 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION; dextrose 25 % in 10 ML Prefilled Syringe; dextrose 2.5 GM per 10 ML Prefilled Syringe",
C1814335,FREESTYLE (GLUCOSE) HIGH/LOW CONTROL SOLN,glucose,FREESTYLE (GLUCOSE) HI/LO CONTROL SOLN,
C1814343,ONE TOUCH ULTRA (GLUCOSE) CONTROL SOLN,glucose,ONE TOUCH ULTRA (GLUCOSE) CONTROL SOLN; OneTouch Ultra Control Solution,
C1814617,DUO-CARE Glucose Plus Blood Pressure Monitor,glucose,,
C1815631,ACCU-CHEK AVIVA (GLUCOSE) TEST STRIP,glucose,ACCU-CHEK AVIVA (GLUCOSE) TEST STRIP; Accu-Chek Aviva Test Strips,
C1815706,BD LOGIC (GLUCOSE) DEVICE,glucose,BD LOGIC (GLUCOSE) DEVICE,
C1815712,BOOST GLUCOSE CONTROL LIQUID CHOCOLATE,glucose,Boost Glucose Control Liquid Chocolate; NUTR SUPL BOOST GLUCOSE CONTROL LIQ CHOC,
C1815713,BOOST GLUCOSE CONTROL LIQUID STRAWBERRY,glucose,Boost Glucose Control Liquid Strawberry; NUTR SUPL BOOST GLUCOSE CONTROL STRAW,
C1815714,BOOST GLUCOSE CONTROL LIQUID VANILLA,glucose,NUTR SUPL BOOST GLUCOSE CONTROL LIQ VAN; Boost Glucose Control Liquid Vanilla,
C1815816,TRUETRACK SMART (GLUCOSE) TEST STRIP,glucose,TRUETRACK SMART (GLUCOSE) TEST STRIP,
C1815884,Calcium Chloride 0.0014 MEQ/ML / Glucose 50 MG/ML / Potassium Chloride 0.024 MEQ/ML / Sodium Chloride 0.103 MEQ/ML / Sodium Lactate 0.028 MEQ/ML Injectable Solution,glucose,"Calcium Chloride 0.0014 MEQ/ML / Glucose 50 MG/ML / Pot Chloride 0.024 MEQ/ML / NaCl 0.103 MEQ/ML / Sodium Lactate 0.028 MEQ/ML Injectable Solution; DEXTROSE 5%/LACTATED RINGER'S/KCL 20MEQ/L INJ; Dextrose 5% in Lactated Ringers with Potassium Chloride 20 mEq/L, Dextrose 5% in Lactated Ringers with KCl 20 mEq/L intravenous solution; calcium chloride 0.0014 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.024 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution; potassium chloride 20 MEQ/L in lactated Ringers solution with dextrose 5 % Injectable Solution; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 600 mg in 100 mL / SODIUM LACTATE 310 mg in 100 mL / POTASSIUM CHLORIDE 179 mg in 100 mL / CALCIUM CHLORIDE 20 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Lactated Ringers and Dextrose]; Calcium Chloride 0.0014 MEQ/ML / Glucose 50 MG/ML / K+ Chloride 0.024 MEQ/ML / NaCl 0.103 MEQ/ML / Sodium Lactate 0.028 MEQ/ML Injectable Solution; potassium chloride 20 MEQ/L in lactated Ringer's solution with dextrose 5 % Injectable Solution; POTASSIUM CHLORIDE 1.79 g in 1000 mL / SODIUM CHLORIDE 6 g in 1000 mL / CALCIUM CHLORIDE 0.2 g in 1000 mL / SODIUM LACTATE 3.1 g in 1000 mL / DEXTROSE MONOHYDRATE 50 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Lactated Ringers and Dextrose]",
C1816224,Sidekick Blood Glucose Testing Plus Free Mete,blood glucose,,
C1817237,low-affinity glucose:sodium symporter activity,glucose,low-affinity glucose-sodium cotransporter activity,
C1817259,regulation of glucose biosynthetic process,glucose,,
C1817539,UDP-L-rhamnose synthase activity,glucose,"UDP-4-keto-6-deoxy-D-glucose 3,5-epimerase-4-reductase activity",
C1819003,regulation of glucose-6-phosphatase activity,glucose,,
C1820127,regulation of transcription from RNA polymerase II promoter by glucose,glucose,,
C1820129,positive regulation of transcription from RNA polymerase II promoter by glucose,glucose,up regulation of transcription from RNA polymerase II promoter by glucose; up-regulation of transcription from RNA polymerase II promoter by glucose; upregulation of transcription from RNA polymerase II promoter by glucose,
C1820130,carbon catabolite repression of transcription from RNA polymerase II promoter by glucose,glucose,downregulation of transcription from RNA polymerase II promoter by glucose; down regulation of transcription from RNA polymerase II promoter by glucose; down-regulation of transcription from RNA polymerase II promoter by glucose,
C1820407,Monitors blood glucose,blood glucose,blood glucose monitoring; blood glucose monitor; blood glucose monitors; monitor blood glucose,
C1823272,THG1L gene,high glucose,"FLJ11601; INTERPHASE CYTOPLASM FOCI PROTEIN 45; tRNA-HISTIDINE GUANYLYLTRANSFERASE 1-LIKE PROTEIN; THG1; interphase cytoplasmic foci protein 45; tRNA-histidine guanylyltransferase 1 like; hTHG1; THG1L; IHG1; THG1L gene; tRNA-HIS GUANYLYLTRANSFERASE 1, S. CEREVISIAE, HOMOLOG OF; tRNA-histidine guanylyltransferase 1-like (S. cerevisiae); IHG-1; FLJ20546; induced by high glucose-1; tRNA-histidine guanylyltransferase 1-like; INDUCED IN HIGH GLUCOSE 1; ICF45",
C1823391,TMEM132A gene,glucose,"HSPA5BP1; TRANSMEMBRANE PROTEIN 132A; FLJ20539; GBP; KIAA1583; transmembrane protein 132A; heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) binding protein 1; GRP78-BINDING PROTEIN; TMEM132A gene; TMEM132A",
C1825342,GFOD2 gene,glucose,GLUCOSE-FRUCTOSE OXIDOREDUCTASE DOMAIN-CONTAINING PROTEIN 2; FLJ23802; MGC11335; glucose-fructose oxidoreductase domain containing 2; GFOD2 gene; GFOD2,
C1825546,HSP90B1 gene,glucose,"tumor rejection antigen (gp96) 1; heat shock protein 90kDa beta (Grp94), member 1; GLUCOSE-REGULATED PROTEIN, 94-KD; HSP90B1; GP96; HSP90B1 gene; endoplasmin; TRA1; STRESS-INDUCIBLE TUMOR REJECTION ANTIGEN GP96; HSP90B1 Gene; Heat Shock Protein 90 Beta Family Member 1 Gene; HEAT-SHOCK PROTEIN, 90-KD, BETA, 1; heat shock protein 90 beta family member 1; TUMOR REJECTION ANTIGEN 1; GRP94",
C1825549,HSPA9 gene,glucose,"MORTALIN 2; MORTALIN, PERINUCLEAR; HEAT-SHOCK 70-KD PROTEIN 9; mortalin2; PBP74; Stress-70 protein, mitochondrial; HSPA9B; mot-2; HSPA9 gene; HSPA9; MORTALIN; MOT2; heat shock 70kDa protein 9 (mortalin); 75 kDa glucose-regulated protein; heat shock 70kDa protein 9B (mortalin-2); heat shock protein family A (Hsp70) member 9; GRP75; mthsp75; GLUCOSE-REGULATED PROTEIN, 75-KD; mortalin",
C1825836,ACSBG1 gene,BG,"LIPIDOSIN; BG1; ACYL-CoA SYNTHETASE, BUBBLEGUM FAMILY, MEMBER 1; FLJ30320; very long-chain acyl-CoA synthetase; acyl-CoA synthetase bubblegum family member 1; hBG1; lipidosin; bubblegum; hsBG; BUBBLEGUM, DROSOPHILA, HOMOLOG OF; ACSBG1 gene; BG; ACSBG1; MGC14352; BGM; KIAA0631",
C1826562,PDX1 gene,glucose,"PDX-1; PANCREAS/DUODENUM HOMEOBOX PROTEIN 1; Islet/duodenum homeobox-1; Pancreatic and Duodenal Homeobox 1 Gene; IUF-1; SOMATOSTATIN TRANSCRIPTION FACTOR 1; MODY4; PDX1 gene; IDX-1; somatostatin transcription factor 1; pancreatic and duodenal homeobox 1; PDX1 Gene; STF1; INSULIN PROMOTER FACTOR 1; insulin upstream factor 1; Glucose-sensitive factor; IPF1; IDX1; HOMEODOMAIN TRANSCRIPTION FACTOR IPF1; PANCREATIC AND DUODENAL HOMEOBOX 1; GSF; STF-1; PDX1; insulin promoter factor 1, homeodomain transcription factor",
C1827175,caffeine / glucose,glucose,Caffeine- and glucose-containing product; Product containing caffeine and glucose (medicinal product),
C1827843,Glucose- and molasses-containing product,glucose,Product containing glucose and molasses (medicinal product); Glucose- and treacle-containing product,
C1828208,At risk for unstable blood glucose level,serum glucose,At risk for unstable blood glucose level (finding); At risk for unstable serum glucose level,
C1828553,ACCU-CHEK AVIVA (GLUCOSE) 1-2 CONTROL SOLN,glucose,ACCU-CHEK AVIVA 1-2 CONTROL SOLN,
C1828762,Dibasic potassium phosphate 1.3 MG/ML / Glucose 50 MG/ML / Sodium Acetate 0.0302 MEQ/ML / Sodium Chloride 0.0155 MEQ/ML Injectable Solution [Isolyte M],glucose,,
C1828763,dibasic potassium phosphate 0.26 MG/ML / glucose 50 MG/ML / magnesium chloride 0.00373 MEQ/ML / potassium chloride 0.00174 MEQ/ML / sodium acetate 0.039 MEQ/ML Injectable Solution [Isolyte P],glucose,"Isolyte P in 5 % Dextrose Injectable Solution; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM ACETATE 0.32 g in 100 mL / POTASSIUM CHLORIDE 0.13 g in 100 mL / MAGNESIUM CHLORIDE 0.031 g in 100 mL / POTASSIUM PHOSPHATE, DIBASIC 0.026 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Isolyte P in Dextrose]; Isolyte P Injectable Solution; LVP solution with potassium Dextrose 5% with Electrolytes (Isolyte P) intravenous solution; Dibasic K+ phosphate 0.26 MG/ML / Glucose 50 MG/ML / Magnesium Chloride 0.00373 MEQ/ML / K+ Chloride 0.00174 MEQ/ML / Sodium Acetate 0.039 MEQ/ML Injectable Solution [Isolyte P]; ISOLYTE P/DEXTROSE 5% INJ; Dibasic Pot phosphate 0.26 MG/ML / Glucose 50 MG/ML / Magnesium Chloride 0.00373 MEQ/ML / Pot Chloride 0.00174 MEQ/ML / Sodium Acetate 0.039 MEQ/ML Injectable Solution [Isolyte P]; Isolyte P and 5% Dextrose, Dextrose 5% with Electrolytes (Isolyte P) intravenous solution",
C1829020,Calcium Chloride 0.00014 MEQ/ML / Glucose 0.6 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / Sodium Chloride 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal PD-2/1.5],glucose,"calcium chloride 0.00014 MEQ/ML / glucose 0.6 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal PD-2/1.5]; LVP solution Dextrose 1.5% with Electrolytes (Dianeal PD-2) intraperitoneal solution; DIANEAL PD-2/DEXTROSE 1.5% SOLN; Dianeal PD-2 with 1.5% Dextrose, Dextrose 1.5% with Electrolytes (Dianeal PD-2) intraperitoneal solution; Calcium Chloride 0.00014 MEQ/ML / Glucose 0.6 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal PD-2/1.5]; DEXTROSE MONOHYDRATE 1.5 g in 100 mL / SODIUM CHLORIDE 538 mg in 100 mL / SODIUM LACTATE 448 mg in 100 mL / CALCIUM CHLORIDE 25.7 mg in 100 mL / MAGNESIUM CHLORIDE 5.08 mg in 100 mL INTRAPERITONEAL INJECTION, SOLUTION [DIANEAL PD-2 with Dextrose]; Dianeal PD-2/1.5 2500 ML Intraperitoneal Solution",
C1829021,Calcium Chloride 0.00014 MEQ/ML / Glucose 1 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / Sodium Chloride 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal PD-2/2.5],glucose,"LVP solution Dextrose 2.5% with Electrolytes (Dianeal PD-2) intraperitoneal solution; Dianeal PD-2 with 2.5% Dextrose, Dextrose 2.5% with Electrolytes (Dianeal PD-2) intraperitoneal solution; Calcium Chloride 0.00014 MEQ/ML / Glucose 1 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal PD-2/2.5]; calcium chloride 0.00014 MEQ/ML / glucose 1 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution [Dianeal PD-2/2.5]; DEXTROSE MONOHYDRATE 2.5 g in 100 mL / SODIUM CHLORIDE 538 mg in 100 mL / SODIUM LACTATE 448 mg in 100 mL / CALCIUM CHLORIDE 25.7 mg in 100 mL / MAGNESIUM CHLORIDE 5.08 mg in 100 mL INTRAPERITONEAL INJECTION, SOLUTION [DIANEAL PD-2 with Dextrose]; Dianeal PD-2/2.5 2500 ML Intraperitoneal Solution; DIANEAL PD-2/DEXTROSE 2.5% SOLN",
C1829489,1.5 hours post 1 g/kg glucose PO,glucose,1.5H post 1 g/kg glucose PO,
C1829494,1.5 hours post dose glucose PO,glucose,1.5H post dose glucose PO,
C1829518,1 hour post dose glucose PO,glucose,1H post dose glucose PO,
C1829524,1 minute post dose glucose,glucose,1M post dose glucose,
C1829535,2 hours post dose glucose PO,glucose,2H post dose glucose PO,
C1829542,30 minutes post 1 g/kg glucose PO,glucose,30M post 1 g/kg glucose PO,
C1829547,30 minutes post dose glucose PO,glucose,30M post dose glucose PO,
C1829552,30 minutes pre 1 g/kg glucose PO,glucose,30M pre 1 g/kg glucose PO,
C1829556,3 hours post dose glucose PO,glucose,3H post dose glucose PO,
C1829558,3 minutes post dose glucose,glucose,3M post dose glucose,
C1829569,5 minutes post dose glucose,glucose,5M post dose glucose,
C1829571,5 minutes pre dose glucose,glucose,5m pre dose glucose,
C1829597,pre dose glucose,glucose,pre dose glucose,
C1829598,pre dose glucose PO,glucose,pre dose glucose PO,
C1830122,Glucose^2H specimen:SCnc:Pt:Dial fld:Qn,glucose,Glucose 2h spec Dial fld-sCnc; Glucose 2 hour specimen (Dial fld) [Moles/Vol]; Glucose^2 hours specimen:Substance Concentration:To identify measures at a point in time:Dialysis fluid:Quantitative; Glucose [Moles/volume] in Dialysis fluid --2 hour specimen,
C1830123,Glucose^4H specimen:SCnc:Pt:Dial fld:Qn,glucose,Glucose 4 Hr specimen (Dial fld) [Moles/Vol]; Glucose [Moles/volume] in Dialysis fluid --4 hour specimen; Glucose^4 hours specimen:Substance Concentration:To identify measures at a point in time:Dialysis fluid:Quantitative; Glucose 4h spec Dial fld-sCnc,
C1830124,Glucose^overnight:SCnc:Pt:Dial fld:Qn,glucose,Glucose Overnight Dial fld-sCnc; Glucose overnight (Dial fld) [Moles/Vol]; Glucose^overnight:Substance Concentration:To identify measures at a point in time:Dialysis fluid:Quantitative; Glucose [Moles/volume] in Dialysis fluid --overnight,
C1830294,Somatotropin^30M pre 1 g/kg glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin 30 Min pre 1 g/kg glucose PO [Mass/Vol]; GH 30M pre 1 g/kg Glc PO SerPl-mCnc; Somatotropin [Mass/volume] in Serum or Plasma --30 minutes pre 1 g/kg glucose PO; Somatotropin^30 minutes pre 1 g/kg glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1830295,Somatotropin^30M post 1 g/kg glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post 1 g/kg glucose PO; Somatotropin^30 minutes post 1 g/kg glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; GH 30M p 1 g/kg Glc PO SerPl-mCnc; Somatotropin 30 Min post 1 g/kg glucose PO [Mass/Vol],
C1830296,Somatotropin^1.5H post 1 g/kg glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin 1.5 Hr post 1 g/kg glucose PO [Mass/Vol]; Somatotropin^1.5 hours post 1 g/kg glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; GH 1.5h p 1 g/kg Glc PO SerPl-mCnc; Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post 1 g/kg glucose PO,
C1832386,"Diabetes Mellitus, Transient Neonatal, 1",diabetes,"6q24-RELATED DIABETES MELLITUS; Diabetes mellitus, transient neonatal 1; TNDM; DMTN; DIABETES MELLITUS, TRANSIENT NEONATAL, 1; Diabetes mellitus, transient neonatal 1 (disorder); K ATP Associated Transient Neonatal Diabetes Mellitus; Diabetes Mellitus, Transient Neonatal, 1; TNDM1",
C1832387,"DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (disorder)",diabetes,"DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2; TYPE 2 DIABETES MELLITUS 2; T2D2; NONINSULIN-DEPENDENT DIABETES MELLITUS 2; NIDDM2; Noninsulin-Dependent Diabetes Mellitus 2; Diabetes Mellitus, Noninsulin-Dependent, 2",
C1832392,"DIABETES MELLITUS, INSULIN-DEPENDENT, 12",diabetes,"Diabetes Mellitus, Insulin-Dependent, 12; INSULIN-DEPENDENT DIABETES MELLITUS 12; DIABETES MELLITUS, INSULIN-DEPENDENT, 12; TYPE 1 DIABETES MELLITUS 12; T1D12; Insulin-Dependent Diabetes Mellitus 12; IDDM12",
C1832443,Martinez-Frias Syndrome,diabetes,"MARTINEZ-FRIAS SYNDROME; Martinez Frias syndrome; Diabetes, Neonatal, with Pancreatic Hypoplasia, Intestinal Atresia, and Gallbladder Aplasia or Hypoplasia; Martinez-Frias Syndrome; Pancreatic Hypoplasia, Intestinal Atresia, and Gallbladder Aplasia or Hypoplasia, with or without Tracheoesophageal Fistula; PANCREATIC HYPOPLASIA, INTESTINAL ATRESIA, AND GALLBLADDER APLASIA OR HYPOPLASIA, WITH OR WITHOUT TRACHEOESOPHAGEAL FISTULA",
C1832474,"DIABETES MELLITUS, INSULIN-DEPENDENT, 13",diabetes,"Diabetes Mellitus, Insulin-Dependent, 13; DIABETES MELLITUS, INSULIN-DEPENDENT, 13; IDDM13; Insulin-Dependent Diabetes Mellitus 13; T1D13; INSULIN-DEPENDENT DIABETES MELLITUS 13; TYPE 1 DIABETES MELLITUS 13",
C1832544,"DIABETES MELLITUS, NONINSULIN-DEPENDENT, 1 (disorder)",diabetes,"TYPE 2 DIABETES MELLITUS 1; Noninsulin-Dependent Diabetes Mellitus 1; T2D1; NIDDM1; Diabetes Mellitus, Noninsulin-Dependent, 1; DIABETES MELLITUS, NONINSULIN-DEPENDENT, 1; NONINSULIN-DEPENDENT DIABETES MELLITUS 1",
C1832605,"DIABETES MELLITUS, INSULIN-DEPENDENT, 11",diabetes,"T1D11; INSULIN-DEPENDENT DIABETES MELLITUS 11; TYPE 1 DIABETES MELLITUS 11; DIABETES MELLITUS, INSULIN-DEPENDENT, 11; Diabetes Mellitus, Insulin-Dependent, 11; IDDM11; Insulin-Dependent Diabetes Mellitus 11",
C1833102,"DIABETES MELLITUS, PERMANENT NEONATAL, WITH NEUROLOGIC FEATURES",diabetes,"Diabetes Mellitus, Permanent Neonatal, With Neurologic Features",
C1833104,"DIABETES MELLITUS, PERMANENT NEONATAL",diabetes,"Permanent diabetes mellitus of infancy; Permanent neonatal diabetes mellitus; Permanent neonatal diabetes mellitus (disorder); Diabetes Mellitus, Permanent, of Infancy; Diabetes Mellitus, Permanent Neonatal; Permanent Neonatal Diabetes Mellitus",
C1833218,"DIABETES MELLITUS, INSULIN-DEPENDENT, 8",diabetes,"T1D8; TYPE 1 DIABETES MELLITUS 8; IDDM8; Diabetes Mellitus, Insulin-Dependent, 8; Insulin-Dependent Diabetes Mellitus 8; DIABETES MELLITUS, INSULIN-DEPENDENT, 8; INSULIN-DEPENDENT DIABETES MELLITUS 8",
C1833382,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE IV (disorder)",diabetes,"Maturity-onset diabetes of the young, type 4 (disorder); MODY, Type 4; MODY, TYPE 4; PDX1-Associated Monogenic Diabetes; Maturity-onset diabetes of the young, type 4; Maturity-Onset Diabetes of the Young, Type 4; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 4; MODY4",
C1833511,"CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE",hypoglycemia,"CPTII, severe infantile form; Carnitine palmitoyl transferase deficiency type 2, severe infantile form; CPT2, severe infantile form; CPT II Deficiency, Hepatic; Carnitine Palmitoyltransferase II Deficiency, Hepatocardiomuscular; Carnitine palmitoyl transferase II deficiency, hepatocardiomuscular form; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, HEPATOCARDIOMUSCULAR; CPT2 Deficiency, Infantile; Carnitine palmitoyl transferase II deficiency, severe infantile form; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE; CPTII, hepatocardiomuscular form; Carnitine Palmitoyltransferase II Deficiency with Hypoketotic Hypoglycemia; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY WITH HYPOKETOTIC HYPOGLYCEMIA; Carnitine Palmitoyltransferase II Deficiency, Infantile; CPT2 DEFICIENCY, INFANTILE; CPT II DEFICIENCY, HEPATIC; Carnitine palmitoyl transferase deficiency type 2, hepatocardiomuscular form; CPT2, hepatocardiomuscular form",
C1835172,Macules hereditary congenital hypopigmented and hyperpigmented,hypo,"Macules, Hereditary Congenital Hypopigmented and Hyperpigmented; Hereditary congenital hypomelanotic and hypermelanotic cutaneous macules, growth retardation, intellectual disability syndrome (disorder); Hypo-and hypermelanotic cutaneous macules, retarded growth, intellectual disability syndrome; Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome; Hereditary congenital hypopigmented and hyperpigmented macules; Hereditary congenital hypomelanotic and hypermelanotic cutaneous macules, growth retardation, intellectual disability syndrome; Congenital hypomelanotic and hypermelanotic macules; Westerhof Beemer Cormane syndrome; Westerhof-Beemer-Cormane syndrome",
C1835379,Insulin-resistant diabetes mellitus (onset around puberty),diabetes,,
C1835887,"DIABETES MELLITUS, TRANSIENT NEONATAL, 2 (disorder)",diabetes,"Diabetes Mellitus, Transient Neonatal, 2; Diabetes mellitus, transient neonatal 2; TNDM2; Diabetes mellitus, transient neonatal 2 (disorder); DIABETES MELLITUS, TRANSIENT NEONATAL, 2",
C1836780,PANCREATIC AND CEREBELLAR AGENESIS,diabetes,"Diabetes Mellitus, Permanent Neonatal, with Cerebellar Agenesis; Pancreatic and cerebellar agenesis; PANCREATIC AND CEREBELLAR AGENESIS; DIABETES MELLITUS, PERMANENT NEONATAL, WITH CEREBELLAR AGENESIS; PACA; Permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome; Pancreatic and Cerebellar Agenesis",
C1837786,Acanthosis nigricans in patients with diabetes,diabetes,,
C1837792,Insulin-resistant diabetes mellitus at puberty,diabetes,Insulin-resistant diabetes mellitus at puberty,
C1838100,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 3 (disorder)",diabetes,"Maturity-Onset Diabetes of the Young, Type 3; Maturity-onset diabetes of the young, type 3 (disorder); MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 3; MODY, TYPE 3; MODY, Type 3; MODY3; Hepatocyte Nuclear Factor 1-Alpha-Associated Monogenic Diabetes; Maturity-onset diabetes of the young, type 3",
C1838259,"DIABETES MELLITUS, INSULIN-DEPENDENT, 7",diabetes,"T1D7; TYPE 1 DIABETES MELLITUS 7; INSULIN-DEPENDENT DIABETES MELLITUS 7; IDDM7; Insulin-Dependent Diabetes Mellitus 7; DIABETES MELLITUS, INSULIN-DEPENDENT, 7; Diabetes Mellitus, Insulin-Dependent, 7",
C1838260,"DIABETES MELLITUS, INSULIN-DEPENDENT, 5",diabetes,"Insulin-Dependent Diabetes Mellitus 5; TYPE 1 DIABETES MELLITUS 5; Diabetes Mellitus, Insulin-Dependent, 5; INSULIN-DEPENDENT DIABETES MELLITUS 5; IDDM5; DIABETES MELLITUS, INSULIN-DEPENDENT, 5; T1D5",
C1838261,"DIABETES MELLITUS, INSULIN-DEPENDENT, 4",diabetes,"Diabetes Mellitus, Insulin-Dependent, 4; INSULIN-DEPENDENT DIABETES MELLITUS 4; DIABETES MELLITUS, INSULIN-DEPENDENT, 4; T1D4; IDDM4; TYPE 1 DIABETES MELLITUS 4; Insulin-Dependent Diabetes Mellitus 4",
C1838262,"DIABETES MELLITUS, INSULIN-DEPENDENT, 3",diabetes,"Diabetes Mellitus, Insulin-Dependent, 3; IDDM3; DIABETES MELLITUS, INSULIN-DEPENDENT, 3; Insulin-Dependent Diabetes Mellitus 3; T1D3; TYPE 1 DIABETES MELLITUS 3; INSULIN-DEPENDENT DIABETES MELLITUS 3",
C1838655,Pancreatic beta cell agenesis with neonatal diabetes mellitus,diabetes,PANCREATIC BETA CELL AGENESIS WITH NEONATAL DIABETES MELLITUS; Congenital absence of insulin-producing beta cells with diabetes mellitus,
C1838780,"Pancreatic Hypoplasia, Congenital, with Diabetes Mellitus and Congenital Heart Disease",diabetes,"PANCREATIC HYPOPLASIA, CONGENITAL, WITH DIABETES MELLITUS AND CONGENITAL HEART DISEASE",
C1838782,"Wolfram Syndrome, Mitochondrial Form",diabetes,"DIDMOAD SYNDROME, MITOCHONDRIAL FORM; DIDMOAD Syndrome, Mitochondrial Form; WOLFRAM SYNDROME, MITOCHONDRIAL FORM; Diabetes Insipidus And Mellitus With Optic Atrophy And Deafness, Mitochondrial Form; DIABETES INSIPIDUS AND MELLITUS WITH OPTIC ATROPHY AND DEAFNESS, MITOCHONDRIAL FORM",
C1839028,Mitochondrial Myopathy with Diabetes,diabetes,"Mitochondrial Myopathy, Lipid Type; MITOCHONDRIAL MYOPATHY, LIPID TYPE; MITOCHONDRIAL MYOPATHY WITH DIABETES",
C1840136,"DIABETES MELLITUS, INSULIN-DEPENDENT, SUSCEPTIBILITY TO",diabetes,,
C1840612,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 3, 1-BP INS, 872C (allelic variant)",diabetes,"HNF1A, 1-BP INS, 872C",
C1842248,No insulin-dependent diabetes mellitus,diabetes,,
C1842403,Increased incidence of fibrocalculus pancreatic diabetes (FCPD),diabetes,,
C1842404,Insulin-dependent but ketosis-resistant diabetes,diabetes,Insulin-dependent but ketosis-resistant diabetes,
C1842413,"IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 4",hyper,"HYPER-IgM SYNDROME 4; Immunodeficiency With Hyper-Igm, Type 4; Hyper-Igm Syndrome 4; Hyper-IgM syndrome type 4; HIGM4; IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 4",
C1842642,"Diabetes Mellitus, Noninsulin-Dependent, Type 4",diabetes,"T2D4; DIABETES MELLITUS, NONINSULIN-DEPENDENT, 4; Noninsulin-Dependent Diabetes Mellitus 4; TYPE 2 DIABETES MELLITUS 4; NONINSULIN-DEPENDENT DIABETES MELLITUS 4; NIDDM4",
C1844433,Variable hypoglycemia,hypoglycemia,,
C1846006,"Ectodermal dysplasia, hypohidrotic, with immune deficiency",hyper,"Hyper-IgM immunodeficiency with hypohidrotic ectodermal dysplasia; Hypohidrotic ectodermal dysplasia with immune deficiency; Hypohidrotic ectodermal dysplasia with immunodeficiency; Anhidrotic ectodermal dysplasia with immune deficiency; Ectodermal Dysplasia, Anhidrotic, with Immune Deficiency; Anhidrotic Ectodermal Dysplasia with Immune Deficiency; EDA-ID; Ectodermal Dysplasia and Immunodeficiency; HED-ID; ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY; Anhidrotic ectodermal dysplasia with immune deficiency (disorder); Anhidrotic ectodermal dysplasia with immunodeficiency; Ectodermal dysplasia, hypohidrotic, with immune deficiency; Eda-Id; HEDID; Hypohidrotic Ectodermal Dysplasia with Immune Deficiency",
C1846008,"HYPER-IgM IMMUNODEFICIENCY, X-LINKED, WITH ECTODERMAL DYSPLASIA, HYPOHIDROTIC",hyper,"Xhm-Ed; Ectodermal Dysplasia and Immunodeficiency 1; NEMO Deficiency Syndrome; ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH IMMUNE DEFICIENCY; ECTODERMAL DYSPLASIA AND IMMUNODEFICIENCY 1; HYPER-IgM IMMUNODEFICIENCY, X-LINKED, WITH HYPOHIDROTIC ECTODERMAL DYSPLASIA; XHMED; Hyper-IgM Immunodeficiency, X-Linked, with Ectodermal Dysplasia, Hypohidrotic; EDAID1",
C1846288,Recurrent hypoglycemia,blood sugar,"hypoglycemia, recurrent; Recurrent low blood sugar levels; Recurrent hypoglycemic episodes; Recurrent hypoglycemia; Recurrent hypoglycaemia; Hypoglycemic episodes; hypoglycaemia, recurrent",
C1847425,Abnormal oral glucose tolerance,glucose,Abnormal glucose oral tolerance test,
C1847426,Glucose breath hydrogen test shows malabsorption of glucose and galactose,glucose,,
C1847501,Glut1 Deficiency Syndrome,glucose,"Glucose transporter type1 (GLUT-1) deficiency; Glucose Transporter Protein Syndrome; De Vivo disease; Classic GLUT1-DS; Glucose transport defect, blood-brain barrier; Classic GLUT1 deficiency syndrome; Encephalopathy Due To Glut1 Deficiency; GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER; Encephalopathy due to GLUT1 deficiency; Glucose Transporter Type 1 Deficiency Syndrome; Classic glucose transporter type 1 deficiency syndrome; GLUT-1 deficiency syndrome",
C1847516,Hypoglycorrhachia (low glucose in CSF),low glucose,,
C1847518,Reduced erythrocyte glucose/hexose transport,glucose,,
C1847555,"Hyperinsulinemic hypoglycemia, familial, 6",hypoglycemia,"HI/HA syndrome; HYPERINSULINISM-HYPERAMMONEMIA SYNDROME; Glutamate Dehydrogenase 1 Hyperinsulinism; HHF6; Hyperinsulinism and hyperammonaemia syndrome; Hyperinsulinism and hyperammonemia syndrome; Hyperinsulinism-hyperammonemia syndrome; HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; Hyperinsulinism and hyperammonemia syndrome (disorder)",
C1848042,"TYPE 1 DIABETES MELLITUS, X-LINKED, SUSCEPTIBILITY TO",diabetes,"INSULIN-DEPENDENT DIABETES MELLITUS, X-LINKED, SUSCEPTIBILITY TO; DIABETES MELLITUS, INSULIN-DEPENDENT, X-LINKED, SUSCEPTIBILITY TO; IDDMX; T1DX",
C1849390,"Chromosome instability (hypo-/hyperdiploidy, chromosomal breaks, premature centromere division)",hypo,,
C1849401,"Retinitis Pigmentosa, Deafness, Mental Retardation, and Hypogonadism",diabetes,"RETINITIS PIGMENTOSA, DEAFNESS, MENTAL RETARDATION, AND HYPOGONADISM; INSULIN-RESISTANT DIABETES WITH ACANTHOSIS NIGRICANS, HYPOGONADISM, PIGMENTARY RETINOPATHY, DEAFNESS, AND MENTAL RETARDATION",
C1849798,Postprandial hyperglycemia (early in disease course),hyperglycemia,,
C1849799,Fasting hypoglycemia (early in disease course),hypoglycemia,,
C1850547,Diabetes (may develop later in life),diabetes,,
C1851552,Discrete 2 to 5-mm hyper- and hypopigmented macules,hyper,,
C1852087,"Diarrhea, Glucose-Stimulated Secretory, with Common Variable Immunodeficiency",glucose,"DIARRHEA, GLUCOSE-STIMULATED SECRETORY, WITH COMMON VARIABLE IMMUNODEFICIENCY",
C1852092,"DIABETES MELLITUS, INSULIN-DEPENDENT, 2",diabetes,"IDDM2; DIABETES MELLITUS, INSULIN-DEPENDENT, 2; Diabetes Mellitus, Insulin-Dependent, 2; Insulin-Dependent Diabetes Mellitus 2; INSULIN-DEPENDENT DIABETES MELLITUS 2; T1D2; TYPE 1 DIABETES MELLITUS 2",
C1852093,"Maturity-Onset Diabetes of the Young, Type 1",diabetes,"HNF4A monogenic diabetes mellitus; MODY, TYPE 1; Maturity-Onset Diabetes of the Young, Type 1; Maturity onset diabetes of the young, type 1 (disorder); Maturity onset diabetes of the young, type 1; Hepatocyte Nuclear Factor 4-Alpha Associated Monogenic Diabetes; MILD JUVENILE DIABETES MELLITUS; Mild Juvenile Diabetes Mellitus; HNF4A (hepatocyte nuclear factor 4 alpha) monogenic diabetes mellitus; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 1; MODY, Type 1; MODY1",
C1853297,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 8, WITH EXOCRINE DYSFUNCTION",diabetes,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 8, WITH EXOCRINE DYSFUNCTION; Diabetes-pancreatic exocrine dysfunction syndrome; Maturity-onset diabetes of the young, type 8 (disorder); Maturity-Onset Diabetes of the Young, Type 8, with Exocrine Dysfunction; Diabetes-Pancreatic Exocrine Dysfunction Syndrome; DIABETES-PANCREATIC EXOCRINE DYSFUNCTION SYNDROME; MODY8; DIABETES AND PANCREATIC EXOCRINE DYSFUNCTION; DPED; Maturity-onset diabetes of the young, type 8; Diabetes and Pancreatic Exocrine Dysfunction",
C1853371,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 6 (disorder)",diabetes,"Maturity-onset diabetes of the young, type 6 (disorder); MODY, TYPE 6; MODY, Type 6; MODY6; Maturity-onset diabetes of the young, type 6; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 6; Neurogenic Differentiation Factor 1-Associated Monogenic Diabetes; Maturity-Onset Diabetes of the Young, Type 6",
C1853564,"Developmental Delay, Epilepsy, and Neonatal Diabetes",diabetes,,
C1854125,"DIABETES MELLITUS, INSULIN-DEPENDENT, 18",diabetes,"INSULIN-DEPENDENT DIABETES MELLITUS 18; Insulin-Dependent Diabetes Mellitus 18; DIABETES MELLITUS, INSULIN-DEPENDENT, 18; Diabetes Mellitus, Insulin-Dependent, 18; TYPE 1 DIABETES MELLITUS 18; IDDM18; T1D18",
C1855303,"Mental retardation syndrome, Belgian type",diabetes,"Mental retardation syndrome Belgian type; MENTAL RETARDATION SYNDROME, BELGIAN TYPE; Intellectual disability, craniofacial dysmorphism, hypogonadism, diabetes mellitus syndrome; Belgian type mental retardation syndrome; Intellectual disability, craniofacial dysmorphism, hypogonadism, diabetes mellitus syndrome (disorder); Intellectual disability-dysmorphism-hypogonadism-diabetes mellitus syndrome",
C1855520,"Hyperglycemia, Postprandial",hyperglycemia,"Postprandial hyperglycemia; Hyperglycemias, Postprandial; Postprandial Hyperglycemias; Postprandial Hyperglycemia",
C1855676,Aplasia/Hypoplasia of the cerebellar vermis,hypo,Cerebellar vermis aplasia/ hypoplasia; Cerebellar vermis aplasia/hypoplasia; Hypo/aplastic vermis,
C1855800,"Hypopituitarism, Congenital, with Central Diabetes Insipidus",diabetes,"HYPOPITUITARISM, CONGENITAL, WITH CENTRAL DIABETES INSIPIDUS",
C1855861,"Glycogen Storage Disease 0, Liver",hypoglycemia,"Liver Glycogen Storage Disease 0; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER; LIVER GLYCOGEN STORAGE DISEASE 0; GSD0A; GSD 0a; Hypoglycemia With Deficiency Of Glycogen Synthetase In The Liver; LIVER GLYCOGEN SYNTHASE DEFICIENCY; Liver Glycogen Synthase Deficiency; GLYCOGEN STORAGE DISEASE 0, LIVER",
C1856263,Granulocytopenia with Immunoglobulin Abnormality,hypoglycemia,IMD59; IMMUNODEFICIENCY 59 AND HYPOGLYCEMIA; GRANULOCYTOPENIA WITH IMMUNOGLOBULIN ABNORMALITY,
C1856362,T1 transport protein (Glucose-6-phosphate translocase) defect,glucose,,
C1856381,Glucose-6-phosphate deficiency,glucose,,
C1856438,Hypoketotic hypoglycemia,hypoglycemia,"Hypoglycemia, hypoketotic; Hypoketotic hypoglycemia",
C1856903,Insulin-dependent diabetes mellitus (onset in infancy),diabetes,,
C1857223,"Hypoglycemia, episodic, in infants",hypoglycemia,,
C1857297,"Diabetes Insipidus, Nephrogenic, with Mental Retardation and Intracerebral Calcification",diabetes,"DIABETES INSIPIDUS, NEPHROGENIC, WITH MENTAL RETARDATION AND INTRACEREBRAL CALCIFICATION",
C1857662,COACH syndrome,hypo,"Cerebellar vermis hypo-aplasia, Oligophrenia, Ataxia congenital, Coloboma, and Hepatic fibrosis; Cerebellar Vermis Hypo-Aplasia, Oligophrenia, Congenital Ataxia, Ocular Coloboma, And Hepatic Fibrosis; JOUBERT SYNDROME WITH CONGENITAL HEPATIC FIBROSIS; Cerebellar vermis hypoplasia-oligophrenia-congenital ataxia-coloboma-hepatic fibrosis; COACH syndrome; Joubert syndrome with congenital hepatic fibrosis; COACH (cerebellar vermis hypoplasia, oligophrenia, congenital ataxia, coloboma, hepatic fibrosis) syndrome; Cerebellar vermis hypoplasia, oligophrenia, congenital ataxia, coloboma, hepatic fibrosis; CEREBELLAR VERMIS HYPO/APLASIA, OLIGOPHRENIA, CONGENITAL ATAXIA, OCULAR COLOBOMA, AND HEPATIC FIBROSIS; Joubert syndrome with congenital hepatic fibrosis (disorder); Joubert syndrome with hepatic defect; COACH SYNDROME; JS-H; Gentile syndrome",
C1857775,"Diabetes Mellitus, Neonatal, with Congenital Hypothyroidism",diabetes,"DIABETES MELLITUS, NEONATAL, WITH CONGENITAL HYPOTHYROIDISM; NDH SYNDROME; NDH",
C1857808,"DIABETES MELLITUS, INSULIN-DEPENDENT, 19 (disorder)",diabetes,"T1D19; DIABETES MELLITUS, INSULIN-DEPENDENT, 19; Diabetes Mellitus, Insulin-Dependent, 19; IDDM19; TYPE 1 DIABETES MELLITUS 19",
C1857958,"Diabetes Mellitus, Congenital Autoimmune",diabetes,"DIABETES MELLITUS, CONGENITAL AUTOIMMUNE",
C1859518,"Beta-Aminoisobutyric Acid, Urinary Excretion of",hyper,"BAIB URINARY EXCRETION; BAIB Urinary Excretion; Beta-aminoisobutyric aciduria; BAIBA - beta-aminoisobutyric aciduria; HYPER-BETA-AMINOISOBUTYRIC ACIDURIA; Beta-Aminoisobutyric Acid, Urinary Excretion of; BETA-AMINOISOBUTYRIC ACIDURIA; beta Aminoisobutyricaciduria; beta-Aminoisobutyricaciduria; BAIBA; Beta-aminoisobutyric aciduria (disorder); Hyper-Beta-Aminoisobutyric Aciduria; BETA-AMINOISOBUTYRIC ACID, URINARY EXCRETION OF",
C1859596,"Atherosclerosis, Premature, with Deafness, Nephropathy, Diabetes Mellitus, Photomyoclonus, and Degenerative Neurologic Disease",diabetes,"ATHEROSCLEROSIS, PREMATURE, WITH DEAFNESS, NEPHROPATHY, DIABETES MELLITUS, PHOTOMYOCLONUS, AND DEGENERATIVE NEUROLOGIC DISEASE",
C1859965,"Alaninuria with Microcephaly, Dwarfism, Enamel Hypoplasia, and Diabetes Mellitus",diabetes,"STIMMLER SYNDROME; Stimmler Syndrome; ALANINURIA WITH MICROCEPHALY, DWARFISM, ENAMEL HYPOPLASIA, AND DIABETES MELLITUS; Alaninuria, microcephaly, dwarfism, enamel hypoplasia, diabetes mellitus syndrome (disorder); Stimmler syndrome; Alaninuria, microcephaly, dwarfism, enamel hypoplasia, diabetes mellitus syndrome",
C1861473,"Associated with autoimmune disorders (e.g., diabetes mellitus, thyroiditis, pernicious anemia, vitiligo)",diabetes,,
C1863594,"Diabetes Mellitus, Noninsulin-Dependent, 3",diabetes,"NONINSULIN-DEPENDENT DIABETES MELLITUS 3; Noninsulin-Dependent Diabetes Mellitus 3; DIABETES MELLITUS, NONINSULIN-DEPENDENT, 3; NIDDM3; TYPE 2 DIABETES MELLITUS 3; T2D3",
C1864068,"DIABETES MELLITUS, INSULIN-DEPENDENT, 17",diabetes,"Diabetes Mellitus, Insulin-Dependent, 17; Insulin-Dependent Diabetes Mellitus 17; DIABETES MELLITUS, INSULIN-DEPENDENT, 17; INSULIN-DEPENDENT DIABETES MELLITUS 17; TYPE 1 DIABETES MELLITUS 17; TID17; IDDM17",
C1864445,Histiocytosis with joint contractures and sensorineural deafness,diabetes,"SLC29A3 spectrum disorder; Histiocytosis with joint contractures and sensorineural deafness; Faisalabad histiocytosis; SHML; H syndrome; Histiocytosis-lymphadenopathy plus syndrome (disorder); Pigmented Hypertrichosis With Insulin-Dependent Diabetes Mellitus Syndrome; HISTIOCYTOSIS AND LYMPHADENOPATHY WITH OR WITHOUT CUTANEOUS, CARDIAC, AND/OR ENDOCRINE FEATURES, JOINT CONTRACTURES, AND/OR DEAFNESS; HYPERPIGMENTATION, CUTANEOUS, WITH HYPERTRICHOSIS, HEPATOSPLENOMEGALY, HEART ANOMALIES, AND HYPOGONADISM WITH OR WITHOUT HEARING LOSS; Histiocytosis-lymphadenopathy plus syndrome; SINUS HISTIOCYTOSIS AND MASSIVE LYMPHADENOPATHY; FAISALABAD HISTIOCYTOSIS; Hyperpigmentation, Cutaneous, with Hypertrichosis, Hepatosplenomegaly, Heart Anomalies, and Hypogonadism With or Without Hearing Loss; PHID; HISTIOCYTOSIS WITH JOINT CONTRACTURES AND SENSORINEURAL DEAFNESS; ROSAI-DORFMAN DISEASE, FAMILIAL; HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME; PIGMENTED HYPERTRICHOSIS WITH INSULIN-DEPENDENT DIABETES MELLITUS; H SYNDROME; HJCD",
C1864623,"DIABETES MELLITUS, TRANSIENT NEONATAL, 3 (disorder)",diabetes,"Diabetes mellitus, transient neonatal 3; Diabetes mellitus, transient neonatal 3 (disorder); TNDM3; DIABETES MELLITUS, TRANSIENT NEONATAL, 3; Diabetes Mellitus, Transient Neonatal, 3",
C1864839,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 7 (disorder)",diabetes,"MODY7; Maturity-Onset Diabetes of the Young, Type 7; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 7; Maturity-onset diabetes of the young, type 7 (disorder); Maturity-onset diabetes of the young, type 7",
C1864902,"Hyperinsulinemic hypoglycemia, familial, 7",hypoglycemia,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 7; HHF7; Hyperinsulinemic hypoglycemia, familial, 7; Exercise-induced hyperinsulinaemic hypoglycaemia; Hyperinsulinemic hypoglycemia, exercise-induced; Exercise-induced hyperinsulinemic hypoglycemia; EIHI; Hyperinsulinism due to SLC16A1 deficiency; Exercise-induced hyperinsulinism; Monocarboxylate Transporter 1 Hyperinsulinism; HYPERINSULINEMIC HYPOGLYCEMIA, EXERCISE-INDUCED; Hyperinsulinism due to monocarboxylate transporter 1 deficiency; Exercise-induced hyperinsulinism (disorder)",
C1864903,Hyperinsulinemic hypoglycemia,hypoglycemia,Hyperinsulinemia hypoglycemia; Hyperinsulinemic hypoglycemia; Hyperinsulinemic hypoglycaemia; Hyperinsulinaemic hypoglycaemia,
C1864948,"Hyperinsulinemic Hypoglycemia, Familial, 4",hypoglycemia,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 4; HHF4",
C1864949,Mental retardation due to repeated episodes of hypoglycemia,hypoglycemia,,
C1864952,"Hyperinsulinemic Hypoglycemia, Familial, 5",hypoglycemia,"HHF5; Hyperinsulinemic Hypoglycemia, Familial, 5; HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 5",
C1865290,"Hyperinsulinemic hypoglycemia, familial, 3",hypoglycemia,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",
C1865291,"Diabetes mellitus, insulin-dependent, late onset",diabetes,,
C1865292,Nonketotic hypoglycemia,hypoglycemia,"Hypoglycemia, nonketotic; Nonketotic hypoglycemia",
C1866040,"DIABETES MELLITUS, INSULIN-DEPENDENT, 10",diabetes,"TYPE 1 DIABETES MELLITUS 10; Insulin-Dependent Diabetes Mellitus 10; Diabetes Mellitus, Insulin-Dependent, 10; INSULIN-DEPENDENT DIABETES MELLITUS 10; DIABETES MELLITUS, INSULIN-DEPENDENT, 10; T1D10; IDDM10",
C1866041,"DIABETES MELLITUS, INSULIN-DEPENDENT, 6",diabetes,"TYPE 1 DIABETES MELLITUS 6; IDDM6; Insulin-Dependent Diabetes Mellitus 6; DIABETES MELLITUS, INSULIN-DEPENDENT, 6; Diabetes Mellitus, Insulin-Dependent, 6; INSULIN-DEPENDENT DIABETES MELLITUS 6; T1D6",
C1866519,"DIABETES MELLITUS, INSULIN-DEPENDENT, 15",diabetes,"TYPE 1 DIABETES MELLITUS 15; IDDM15; INSULIN-DEPENDENT DIABETES MELLITUS 15; DIABETES MELLITUS, INSULIN-DEPENDENT, 15; T1D15; Insulin-Dependent Diabetes Mellitus 15; Diabetes Mellitus, Insulin-Dependent, 15",
C1867237,Retinol-Binding Protein Deficiency,hypo,Familial Hypo-RBP,
C1868448,"Attacks precipitated by hypokalemia, administration of glucose or insulin, heavy carbohydrate consumption, stress, fatigue, rest after exercise",glucose,,
C1869633,"pinocembrin-7-O-(3''-O-galloyl-4'',6''-hexahydroxydiphenoyl)-beta-glucose",glucose,P-GHDP-G cpd,
C1869903,"hemoglobin A1c protein, human",a1c,"blood HbA1c protein, human; HbA1c protein, human",
C1871036,"galacto-hexodialdo-1,5-pyranosyl-1-4-glucose",glucose,,
C1871037,"beta-D-galacto-hexodialdo-1,5-pyranosyl-1-4-D-glucose",glucose,LACTA cpd; lactose dialdehyde,
C1871888,DAPD peptide,diabetes,ANC7K2 peptide; dual-acting peptide for diabetes (DAPD),
C1872125,"4beta,8beta,11alpha,14beta-tetrahydroxybufa-5,20,22-trienolide-12-one, 2alpha,3beta-O-4,6-dideoxy-L-glucose",glucose,lydenburgenin,
C1874551,"BILIRUBIN/BLOOD,OCCULT/GLUCOSE/KETONE/NITRITE/pH/PROTEIN/UROBILI",glucose,,
C1874552,"BILIRUBIN/BLOOD,OCCULT/GLUCOSE/KETONE/pH/PROTEIN/UROBILINOGEN TE",glucose,,
C1874553,BILIRUBIN/BLOOD/GLUCOSE/KETONE/LEUKOCYTES/NITRITE/pH/PROTEIN TE,glucose,,
C1874554,BILIRUBIN/BLOOD/GLUCOSE/KETONE/LEUKOCYTES/NITRITE/pH/PROTEIN/SPE,glucose,,
C1874555,BILIRUBIN/BLOOD/GLUCOSE/KETONE/LEUKOCYTES/NITRITE/pH/PROTEIN/URO,glucose,,
C1874556,BILIRUBIN/BLOOD/GLUCOSE/KETONE/LEUKOCYTES/pH/PROTEIN TEST,glucose,,
C1874557,BILIRUBIN/BLOOD/GLUCOSE/KETONE/LEUKOCYTES/pH/PROTEIN/UROBILINOGE,glucose,,
C1874558,BILIRUBIN/BLOOD/GLUCOSE/KETONE/NITRITE/pH/PROTEIN/SPECIFIC/UROBI,glucose,,
C1874559,BILIRUBIN/BLOOD/GLUCOSE/KETONE/NITRITE/pH/PROTEIN/UROBILINOGEN,glucose,,
C1874560,BILIRUBIN/BLOOD/GLUCOSE/KETONE/pH/PROTEIN TEST,glucose,,
C1874561,BILIRUBIN/BLOOD/GLUCOSE/KETONE/pH/PROTEIN/SPECIFIC GRAVITY TEST,glucose,,
C1874562,BILIRUBIN/BLOOD/GLUCOSE/KETONE/pH/PROTEIN/SPECIFIC GRAVITY/UROBI,glucose,,
C1874563,BILIRUBIN/BLOOD/GLUCOSE/KETONE/pH/PROTEIN/UROBILINOGEN TEST,glucose,,
C1874587,BLOOD GLUCOSE REGULATION AGENTS,blood glucose,,
C1874588,BLOOD/GLUCOSE/KETONE/LEUKOCYTES/NITRITE/pH/PROTEIN TEST,glucose,,
C1874589,BLOOD/GLUCOSE/KETONE/LEUKOCYTES/NITRITE/pH/PROTEIN/SPECIFIC GRAV,glucose,,
C1874590,BLOOD/GLUCOSE/KETONE/LEUKOCYTES/pH/PROTEIN TEST,glucose,,
C1874591,BLOOD/GLUCOSE/KETONE/pH/PROTEIN TEST,glucose,,
C1874592,BLOOD/GLUCOSE/LEUKOCYTES/PROTEIN TEST,glucose,,
C1874593,BLOOD/GLUCOSE/pH/PROTEIN TEST,glucose,,
C1875173,fructose / glucose / phosphoric acid,glucose,FRUCTOSE/GLUCOSE/PHOSPHORIC ACID,
C1875193,GLUCOSE/KETONE TEST,glucose,,
C1875194,GLUCOSE/LANOLIN/PARABENS/PETROLATUM,glucose,,
C1875195,GLUCOSE/LEUKOCYTES/NITRITE/PROTEIN TEST,glucose,,
C1875196,GLUCOSE/PROTEIN TEST,glucose,,
C1875197,GLUCOSE/pH/PROTEIN TEST,glucose,,
C1875348,"INVESTIGATIONAL DIAGNOSTIC AGENTS,GLUCOSE TESTING",glucose,,
C1875693,PRECISION XTRA (GLUCOSE) METER,glucose,PRECISION XTRA (GLUCOSE) METER,
C1875876,Alanine 3.48 MG/ML / Arginine 3.56 MG/ML / Aspartate 2.45 MG/ML / Calcium Chloride 0.0025 MEQ/ML / Dibasic potassium phosphate 0.015 MEQ/ML / Glucose 250 MG/ML / Glutamate 2.58 MG/ML / Glycine 1.75 MG/ML / Histidine 1.05 MG/ML / Isoleucine 2.31 MG/ML / Leucine 3.5 MG/ML / Lysine 3.68 MG/ML / Magnesium Chloride 0.0025 MEQ/ML / Methionine 0.6 MG/ML / Phenylalanine 1.04 MG/ML / Potassium Chloride 0.003 MEQ/ML / Proline 2.52 MG/ML / Serine 1.86 MG/ML / Sodium Chloride 0.035 MEQ/ML / Threonine 1.4 MG/ML / Tryptophan 0.7 MG/ML / Tyrosine 0.94 MG/ML / Valine 1.75 MG/ML Injectable Solution [Aminosyn II 3.5 % with Electrolytes in 25 % Dextrose with Calcium],glucose,,
C1876851,Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic potassium phosphate 2.61 MG/ML / Glucose 150 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / Sodium Chloride 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution [Clinimix E 5/15],glucose,"alanine 10.4 MG/ML / arginine 5.75 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 150 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / sodium acetate trihydrate 3.4 MG/ML / sodium chloride 0.01 MEQ/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution [Clinimix E 5/15]; Clinimix E 5/15 (5 % amino acids with electrolytes in dextrose 15 % ) Injectable Solution; parenteral nutrition solution w/electrolytes Amino Acids 5% with 15% Dextrose and Electrolytes (Clinimix E Sulfite-Free) intravenous solution; Clinimix E Sulfite Free, Amino Acids 5% with 15% Dextrose and Electrolytes (Clinimix E Sulfite-Free) intravenous solution; Clinimix E 5/15 Injectable Solution; CLINIMIX E 5/15 INJ; LEUCINE 365 mg in 100 mL / PHENYLALANINE 280 mg in 100 mL / LYSINE 290 mg in 100 mL / METHIONINE 200 mg in 100 mL / ISOLEUCINE 300 mg in 100 mL / VALINE 290 mg in 100 mL / HISTIDINE 240 mg in 100 mL / THREONINE 210 mg in 100 mL / TRYPTOPHAN 90 mg in 100 mL / ALANINE 1035 mg in 100 mL / GLYCINE 515 mg in 100 mL / ARGININE 575 mg in 100 mL / PROLINE 340 mg in 100 mL / SERINE 250 mg in 100 mL / TYROSINE 20 mg in 100 mL / SODIUM ACETATE 340 mg in 100 mL / POTASSIUM PHOSPHATE, DIBASIC 261 mg in 100 mL / MAGNESIUM CHLORIDE 51 mg in 100 mL / SODIUM CHLORIDE 59 mg in 100 mL / CALCIUM CHLORIDE 33 mg in 100 mL / DEXTROSE 15 g in 100 mL INTRAVENOUS INJECTION [CLINIMIX E]; Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 150 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution [Clinimix E 5/15]; Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 150 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution [Clinimix E 5/15]",
C1877553,alanine 5.7 MG/ML / arginine 3.16 MG/ML / glucose 50 MG/ML / glycine 2.83 MG/ML / histidine 1.32 MG/ML / isoleucine 1.65 MG/ML / leucine 2.01 MG/ML / lysine 1.59 MG/ML / methionine 1.1 MG/ML / phenylalanine 1.54 MG/ML / proline 1.87 MG/ML / serine 1.38 MG/ML / threonine 1.16 MG/ML / tryptophan 0.5 MG/ML / tyrosine 0.11 MG/ML / valine 1.6 MG/ML Injectable Solution [Clinimix 2.75/5],glucose,Clinimix 2.75/5 (amino acids 2.75 % in dextrose 5 % ) Injectable Solution; Clinimix 2.75/5 Injectable Solution,
C1877554,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 100 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix 4.25/10],glucose,"alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 100 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix 4.25/10]; Clinimix Sulfite Free, Amino Acids 4.25% with 10% Dextrose (Clinimix Sulfite-Free) intravenous solution; parenteral nutrition solution Amino Acids 4.25% with 10% Dextrose (Clinimix Sulfite-Free) intravenous solution; LEUCINE 311 mg in 100 mL / PHENYLALANINE 238 mg in 100 mL / LYSINE 247 mg in 100 mL / METHIONINE 170 mg in 100 mL / ISOLEUCINE 255 mg in 100 mL / VALINE 247 mg in 100 mL / HISTIDINE 204 mg in 100 mL / THREONINE 179 mg in 100 mL / TRYPTOPHAN 77 mg in 100 mL / ALANINE 880 mg in 100 mL / GLYCINE 438 mg in 100 mL / ARGININE 489 mg in 100 mL / PROLINE 289 mg in 100 mL / SERINE 213 mg in 100 mL / TYROSINE 17 mg in 100 mL / DEXTROSE 10 g in 100 mL INTRAVENOUS INJECTION [CLINIMIX]; CLINIMIX 4.25/10 INJ; Clinimix 4.25/10 (4.25 % amino acids in dextrose 10 % ) Injectable Solution; Clinimix 4.25/10 Injectable Solution",
C1877555,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 200 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix 4.25/20],glucose,Clinimix 4.25/20 Injectable Solution; Clinimix 4.25/20 (4.25 % amino acids in dextrose 20 % ) Injectable Solution,
C1877556,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 250 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix 4.25/25],glucose,Clinimix 4.25/25 Injectable Solution; Clinimix 4.25/25 (4.25 % amino acids in dextrose 25 % ) Injectable Solution,
C1877557,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 50 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix 4.25/5],glucose,"CLINIMIX 4.25/5 INJ; LEUCINE 311 mg in 100 mL / PHENYLALANINE 238 mg in 100 mL / LYSINE 247 mg in 100 mL / METHIONINE 170 mg in 100 mL / ISOLEUCINE 255 mg in 100 mL / VALINE 247 mg in 100 mL / HISTIDINE 204 mg in 100 mL / THREONINE 179 mg in 100 mL / TRYPTOPHAN 77 mg in 100 mL / ALANINE 880 mg in 100 mL / GLYCINE 438 mg in 100 mL / ARGININE 489 mg in 100 mL / PROLINE 289 mg in 100 mL / SERINE 213 mg in 100 mL / TYROSINE 17 mg in 100 mL / DEXTROSE 5 g in 100 mL INTRAVENOUS INJECTION [CLINIMIX]; parenteral nutrition solution Amino Acids 4.25% with 5% Dextrose (Clinimix Sulfite-Free) intravenous solution; Clinimix 4.25/5 (4.25 % amino acids in dextrose 5 % ) Injectable Solution; Clinimix 4.25/5 Injectable Solution; Clinimix Sulfite Free, Amino Acids 4.25% with 5% Dextrose (Clinimix Sulfite-Free) intravenous solution",
C1877558,alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 150 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 290 MG/ML Injectable Solution [Clinimix 5/15],glucose,"parenteral nutrition solution Amino Acids 5% with 15% Dextrose (Clinimix Sulfite-Free) intravenous solution; Clinimix Sulfite Free, Amino Acids 5% with 15% Dextrose (Clinimix Sulfite-Free) intravenous solution; CLINIMIX 5/15 INJ; Clinimix 5/15 Injectable Solution; Clinimix 5/15 (5 % amino acids in dextrose 15 % ) Injectable Solution; LEUCINE 365 mg in 100 mL / PHENYLALANINE 280 mg in 100 mL / LYSINE 290 mg in 100 mL / METHIONINE 200 mg in 100 mL / ISOLEUCINE 300 mg in 100 mL / VALINE 290 mg in 100 mL / HISTIDINE 240 mg in 100 mL / THREONINE 210 mg in 100 mL / TRYPTOPHAN 90 mg in 100 mL / ALANINE 1035 mg in 100 mL / GLYCINE 515 mg in 100 mL / ARGININE 575 mg in 100 mL / PROLINE 340 mg in 100 mL / SERINE 250 mg in 100 mL / TYROSINE 20 mg in 100 mL / DEXTROSE 15 g in 100 mL INTRAVENOUS INJECTION [CLINIMIX]; alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 150 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 290 MG/ML Injectable Solution [Clinimix 5/15]",
C1877559,alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 200 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution [Clinimix 5/20],glucose,"Clinimix 5/20 Injectable Solution; Clinimix Sulfite Free, Amino Acids 5% with 20% Dextrose (Clinimix Sulfite-Free) intravenous solution; parenteral nutrition solution Amino Acids 5% with 20% Dextrose (Clinimix Sulfite-Free) intravenous solution; LEUCINE 365 mg in 100 mL / PHENYLALANINE 280 mg in 100 mL / LYSINE 290 mg in 100 mL / METHIONINE 200 mg in 100 mL / ISOLEUCINE 300 mg in 100 mL / VALINE 290 mg in 100 mL / HISTIDINE 240 mg in 100 mL / THREONINE 210 mg in 100 mL / TRYPTOPHAN 90 mg in 100 mL / ALANINE 1035 mg in 100 mL / GLYCINE 515 mg in 100 mL / ARGININE 575 mg in 100 mL / PROLINE 340 mg in 100 mL / SERINE 250 mg in 100 mL / TYROSINE 20 mg in 100 mL / DEXTROSE 20 g in 100 mL INTRAVENOUS INJECTION [CLINIMIX]; Clinimix 5/20 (5 % amino acids in dextrose 20 % ) Injectable Solution; CLINIMIX 5/20 INJ",
C1877560,alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 250 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution [Clinimix 5/25],glucose,Clinimix 5/25 Injectable Solution; Clinimix 5/25 (5 % amino acids in dextrose 25 % ) Injectable Solution,
C1877561,alanine 5.7 MG/ML / arginine 3.16 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 100 MG/ML / glycine 2.83 MG/ML / histidine 1.32 MG/ML / isoleucine 1.65 MG/ML / leucine 2.01 MG/ML / lysine 1.59 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.1 MG/ML / phenylalanine 1.54 MG/ML / proline 1.87 MG/ML / serine 1.38 MG/ML / sodium acetate trihydrate 2.17 MG/ML / sodium chloride 0.02 MEQ/ML / threonine 1.16 MG/ML / tryptophan 0.5 MG/ML / tyrosine 0.11 MG/ML / valine 1.6 MG/ML Injectable Solution [Clinimix E 2.75/10],glucose,Clinimix E 2.75/10 Injectable Solution; Clinimix E 2.75/10 (2.75 % amino acids with electrolytes in dextrose 10 % ) Injectable Solution; Alanine 5.7 MG/ML / Arginine 3.16 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 100 MG/ML / Glycine 2.83 MG/ML / Histidine 1.32 MG/ML / Isoleucine 1.65 MG/ML / Leucine 2.01 MG/ML / Lysine 1.59 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.1 MG/ML / Phenylalanine 1.54 MG/ML / Proline 1.87 MG/ML / Serine 1.38 MG/ML / Sodium Acetate Trihydrate 2.17 MG/ML / NaCl 0.02 MEQ/ML / Threonine 1.16 MG/ML / Tryptophan 0.5 MG/ML / Tyrosine 0.11 MG/ML / Valine 1.6 MG/ML Injectable Solution [Clinimix E 2.75/10]; Alanine 5.7 MG/ML / Arginine 3.16 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 100 MG/ML / Glycine 2.83 MG/ML / Histidine 1.32 MG/ML / Isoleucine 1.65 MG/ML / Leucine 2.01 MG/ML / Lysine 1.59 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.1 MG/ML / Phenylalanine 1.54 MG/ML / Proline 1.87 MG/ML / Serine 1.38 MG/ML / Sodium Acetate Trihydrate 2.17 MG/ML / NaCl 0.02 MEQ/ML / Threonine 1.16 MG/ML / Tryptophan 0.5 MG/ML / Tyrosine 0.11 MG/ML / Valine 1.6 MG/ML Injectable Solution [Clinimix E 2.75/10],
C1877562,alanine 5.7 MG/ML / arginine 3.16 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 50 MG/ML / glycine 2.83 MG/ML / histidine 1.32 MG/ML / isoleucine 1.65 MG/ML / leucine 2.01 MG/ML / lysine 1.59 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.1 MG/ML / phenylalanine 1.54 MG/ML / proline 1.87 MG/ML / serine 1.38 MG/ML / sodium acetate trihydrate 2.17 MG/ML / sodium chloride 0.02 MEQ/ML / threonine 1.16 MG/ML / tryptophan 0.5 MG/ML / tyrosine 0.11 MG/ML / valine 1.6 MG/ML Injectable Solution [Clinimix E 2.75/5],glucose,"CLINIMIX E 2.75/5 INJ; Clinimix E 2.75/5 (2.75 % amino acids with electrolytes in dextrose 5 % ) Injectable Solution; Alanine 5.7 MG/ML / Arginine 3.16 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 50 MG/ML / Glycine 2.83 MG/ML / Histidine 1.32 MG/ML / Isoleucine 1.65 MG/ML / Leucine 2.01 MG/ML / Lysine 1.59 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.1 MG/ML / Phenylalanine 1.54 MG/ML / Proline 1.87 MG/ML / Serine 1.38 MG/ML / Sodium Acetate Trihydrate 2.17 MG/ML / NaCl 0.02 MEQ/ML / Threonine 1.16 MG/ML / Tryptophan 0.5 MG/ML / Tyrosine 0.11 MG/ML / Valine 1.6 MG/ML Injectable Solution [Clinimix E 2.75/5]; Clinimix E Sulfite Free, Amino Acids 2.75% with 5% Dextrose and Electrolytes (Clinimix E Sulfite-Free) intravenous solution; Alanine 5.7 MG/ML / Arginine 3.16 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 50 MG/ML / Glycine 2.83 MG/ML / Histidine 1.32 MG/ML / Isoleucine 1.65 MG/ML / Leucine 2.01 MG/ML / Lysine 1.59 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.1 MG/ML / Phenylalanine 1.54 MG/ML / Proline 1.87 MG/ML / Serine 1.38 MG/ML / Sodium Acetate Trihydrate 2.17 MG/ML / NaCl 0.02 MEQ/ML / Threonine 1.16 MG/ML / Tryptophan 0.5 MG/ML / Tyrosine 0.11 MG/ML / Valine 1.6 MG/ML Injectable Solution [Clinimix E 2.75/5]; LEUCINE 201 mg in 100 mL / PHENYLALANINE 154 mg in 100 mL / LYSINE 159 mg in 100 mL / METHIONINE 110 mg in 100 mL / ISOLEUCINE 165 mg in 100 mL / VALINE 160 mg in 100 mL / HISTIDINE 132 mg in 100 mL / THREONINE 116 mg in 100 mL / TRYPTOPHAN 50 mg in 100 mL / ALANINE 570 mg in 100 mL / GLYCINE 283 mg in 100 mL / ARGININE 316 mg in 100 mL / PROLINE 187 mg in 100 mL / SERINE 138 mg in 100 mL / TYROSINE 11 mg in 100 mL / SODIUM ACETATE 217 mg in 100 mL / POTASSIUM PHOSPHATE, DIBASIC 261 mg in 100 mL / MAGNESIUM CHLORIDE 51 mg in 100 mL / SODIUM CHLORIDE 112 mg in 100 mL / CALCIUM CHLORIDE 33 mg in 100 mL / DEXTROSE 5 g in 100 mL INTRAVENOUS INJECTION [CLINIMIX E]; Clinimix E 2.75/5 Injectable Solution; parenteral nutrition solution w/electrolytes Amino Acids 2.75% with 5% Dextrose and Electrolytes (Clinimix E Sulfite-Free) intravenous solution",
C1877564,Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic potassium phosphate 2.61 MG/ML / Glucose 250 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / Sodium Chloride 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/25],glucose,Clinimix E 4.25/25 (4.25 % amino acids with electrolytes in dextrose 25 % ) Injectable Solution; alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 250 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/25]; Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 250 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/25]; Clinimix E 4.25/25 Injectable Solution; Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 250 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/25],
C1877565,Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic potassium phosphate 2.61 MG/ML / Glucose 50 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / Sodium Chloride 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/5],glucose,"alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 50 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/5]; Clinimix E 4.25/5 Injectable Solution; CLINIMIX E 4.25/5 INJ; Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 50 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/5]; Clinimix E 4.25/5 (4.25 % amino acids with electrolytes in dextrose 5 % ) Injectable Solution; Clinimix E Sulfite Free, Amino Acids 4.25% with 5% Dextrose and Electrolytes (Clinimix E Sulfite-Free) intravenous solution; parenteral nutrition solution w/electrolytes Amino Acids 4.25% with 5% Dextrose and Electrolytes (Clinimix E Sulfite-Free) intravenous solution; LEUCINE 311 mg in 100 mL / PHENYLALANINE 238 mg in 100 mL / LYSINE 247 mg in 100 mL / METHIONINE 170 mg in 100 mL / ISOLEUCINE 255 mg in 100 mL / VALINE 247 mg in 100 mL / HISTIDINE 204 mg in 100 mL / THREONINE 179 mg in 100 mL / TRYPTOPHAN 77 mg in 100 mL / ALANINE 880 mg in 100 mL / GLYCINE 438 mg in 100 mL / ARGININE 489 mg in 100 mL / PROLINE 289 mg in 100 mL / SERINE 213 mg in 100 mL / TYROSINE 17 mg in 100 mL / SODIUM ACETATE 297 mg in 100 mL / POTASSIUM PHOSPHATE, DIBASIC 261 mg in 100 mL / MAGNESIUM CHLORIDE 51 mg in 100 mL / SODIUM CHLORIDE 77 mg in 100 mL / CALCIUM CHLORIDE 33 mg in 100 mL / DEXTROSE 5 g in 100 mL INTRAVENOUS INJECTION [CLINIMIX E]; Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 50 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/5]",
C1877567,alanine 10.4 MG/ML / arginine 5.75 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 200 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / sodium acetate trihydrate 3.4 MG/ML / sodium chloride 0.01 MEQ/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution [Clinimix E 5/20],glucose,"Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 200 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution [Clinimix E 5/20]; parenteral nutrition solution w/electrolytes Amino Acids 5% with 20% Dextrose and Electrolytes (Clinimix E Sulfite-Free) intravenous solution; Clinimix E Sulfite Free, Amino Acids 5% with 20% Dextrose and Electrolytes (Clinimix E Sulfite-Free) intravenous solution; LEUCINE 365 mg in 100 mL / PHENYLALANINE 280 mg in 100 mL / LYSINE 290 mg in 100 mL / METHIONINE 200 mg in 100 mL / ISOLEUCINE 300 mg in 100 mL / VALINE 290 mg in 100 mL / HISTIDINE 240 mg in 100 mL / THREONINE 210 mg in 100 mL / TRYPTOPHAN 90 mg in 100 mL / ALANINE 1035 mg in 100 mL / GLYCINE 515 mg in 100 mL / ARGININE 575 mg in 100 mL / PROLINE 340 mg in 100 mL / SERINE 250 mg in 100 mL / TYROSINE 20 mg in 100 mL / SODIUM ACETATE 340 mg in 100 mL / POTASSIUM PHOSPHATE, DIBASIC 261 mg in 100 mL / MAGNESIUM CHLORIDE 51 mg in 100 mL / SODIUM CHLORIDE 59 mg in 100 mL / CALCIUM CHLORIDE 33 mg in 100 mL / DEXTROSE 20 g in 100 mL INTRAVENOUS INJECTION [CLINIMIX E]; Clinimix E 5/20 Injectable Solution; Clinimix E 5/20 (5 % amino acids with electrolytes in dextrose 20 % ) Injectable Solution; CLINIMIX E 5/20 INJ; LEUCINE 365 mg in 100 mL / PHENYLALANINE 280 mg in 100 mL / LYSINE 290 mg in 100 mL / METHIONINE 200 mg in 100 mL / ISOLEUCINE 300 mg in 100 mL / VALINE 290 mg in 100 mL / HISTIDINE 240 mg in 100 mL / THREONINE 210 mg in 100 mL / TRYPTOPHAN 90 mg in 100 mL / Alanine 1035 mg in 100 mL / Glycine 515 mg in 100 mL / ARGININE 575 mg in 100 mL / PROLINE 340 mg in 100 mL / SERINE 250 mg in 100 mL / TYROSINE 20 mg in 100 mL / SODIUM ACETATE 340 mg in 100 mL / POTASSIUM PHOSPHATE, DIBASIC 261 mg in 100 mL / MAGNESIUM CHLORIDE 51 mg in 100 mL / SODIUM CHLORIDE 59 mg in 100 mL / CALCIUM CHLORIDE 33 mg in 100 mL / DEXTROSE 20 g in 100 mL INTRAVENOUS INJECTION [CLINIMIX E]; Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 200 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution [Clinimix E 5/20]",
C1877568,alanine 10.4 MG/ML / arginine 5.75 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 250 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / sodium acetate trihydrate 3.4 MG/ML / sodium chloride 0.01 MEQ/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution [Clinimix E 5/25],glucose,Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 250 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution [Clinimix E 5/25]; Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 250 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution [Clinimix E 5/25]; Clinimix E 5/25 Injectable Solution; Clinimix E 5/25 (5 % amino acids with electrolytes in dextrose 25 % ) Injectable Solution; CLINIMIX E 5/25 INJ,
C1877964,"glucose 50 MG/ML / magnesium chloride 0.00148 MEQ/ML / monobasic potassium phosphate 0.0082 MG/ML / potassium chloride 0.00497 MEQ/ML / sodium acetate 0.0272 MEQ/ML / sodium chloride 0.0906 MEQ/ML / sodium gluconate 5 MG/ML / sodium phosphate, dibasic 0.12 MG/ML Injectable Solution [Isolyte S in 5 % Dextrose]",glucose,"Glucose 50 MG/ML / Magnesium Chloride 0.00148 MEQ/ML / Monobasic Pot phosphate 0.0082 MG/ML / Pot Chloride 0.00497 MEQ/ML / Sodium Acetate 0.0272 MEQ/ML / NaCl 0.0906 MEQ/ML / Sodium gluconate 5 MG/ML / Sodium Phosphate, Dibasic 0.12 MG/ML Injectable Solution [Isolyte S in 5 % Dextrose]; Isolyte S in 5 % Dextrose Injectable Solution; ISOLYTE S/DEXTROSE 5% INJ; Glucose 50 MG/ML / Magnesium Chloride 0.00148 MEQ/ML / Monobasic K+ phosphate 0.0082 MG/ML / K+ Chloride 0.00497 MEQ/ML / Sodium Acetate 0.0272 MEQ/ML / NaCl 0.0906 MEQ/ML / Sodium gluconate 5 MG/ML / Sodium Phosphate, Dibasic 0.12 MG/ML Injectable Solution [Isolyte S in 5 % Dextrose]; Isolyte S in 5 % Dextrose (glucose 50 MG/ML / magnesium chloride 0.00148 MEQ/ML / monobasic potassium phosphate 0.0082 MG/ML / potassium chloride 0.00497 MEQ/ML / sodium acetate 0.0272 MEQ/ML / sodium chloride 0.0906 MEQ/ML / sodium gluconate 5 MG/ML / sodium phosphate, dibasic 0.12 MG/ML) Injectable Solution",
C1878549,Alanine 8.8 MG/ML / Arginine 4.4 MG/ML / Dibasic potassium phosphate 2.61 MG/ML / Glucose 100 MG/ML / Glycine 8.8 MG/ML / Histidine 1.86 MG/ML / Isoleucine 2.03 MG/ML / Leucine 2.63 MG/ML / Lysine 2.46 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2.46 MG/ML / Phenylalanine 2.63 MG/ML / Proline 1.78 MG/ML / Sodium Acetate 0.036 MEQ/ML / Sodium Chloride 0.013 MEQ/ML / Threonine 1.78 MG/ML / Tryptophan 0.76 MG/ML / Tyrosine 0.17 MG/ML / Valine 1.95 MG/ML Injectable Solution [Travasol 4.25/10],glucose,,
C1878551,Alanine 8.8 MG/ML / Arginine 4.4 MG/ML / Dibasic potassium phosphate 2.61 MG/ML / Glucose 50 MG/ML / Glycine 8.8 MG/ML / Histidine 1.86 MG/ML / Isoleucine 2.03 MG/ML / Leucine 2.63 MG/ML / Lysine 2.46 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2.46 MG/ML / Phenylalanine 2.63 MG/ML / Proline 1.78 MG/ML / Sodium Acetate 0.036 MEQ/ML / Sodium Chloride 0.013 MEQ/ML / Threonine 1.78 MG/ML / Tryptophan 0.76 MG/ML / Tyrosine 0.17 MG/ML / Valine 1.95 MG/ML Injectable Solution [Travasol 4.25/5],glucose,,
C1881082,HyperCVAD Regimen,hyper,Hyper-CVAD regimen; hyperfractionated cyclophosphamide-vincristine-adriamycin-dexamethasone regimen; HyperCVAD Regimen; Hyper-CVAD Regimen; Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone Regimen,
C1889166,Lepraria sp. BG,BG,Lepraria sp. VM-3199A,
C1892816,Bacillus sp. BG.Sph.051,BG,,
C1892817,Erythrobacter sp. BG.Sph.053,BG,,
C1892818,Pseudomonas sp. BG.Sph.054,BG,,
C1892819,Ralstonia sp. BG.Sph.056,BG,,
C1892820,Serratia sp. BG.Sph.058,BG,,
C1892821,Sphingomonas sp. BG.Sph.059,BG,,
C1892822,Pseudomonas sp. BG.Sph.060,BG,,
C1892823,Pseudomonas sp. BG.Sph.061,BG,,
C1892826,Pseudomonas sp. BG.Sph.065,BG,,
C1892833,soil beta proteobacterium BG.Sph.062,BG,,
C1892836,soil Phyllobacteriaceae bacterium BG.Sph.052,BG,,
C1892837,Oxalobacteraceae bacterium BG.Sph.055,BG,,
C1892838,soil Xanthomonadaceae bacterium BG.Sph.057,BG,,
C1931590,Kodamaea sp. BG-3,BG,,
C1936335,Streptomyces sp. a1c,a1c,,
C1949008,Hyper-Sal,hyper,Hyper-Sal,
C1949011,sodium chloride 70 MG/ML Inhalation Solution [Hyper-Sal],hyper,"Hyper-Sal 1.2 MEQ/ML Inhalation Solution; Hyper-Sal, 7% inhalation solution; Hyper-Sal 7 % Inhalation Solution; NaCl 70 MG/ML Inhalation Solution [Hyper-Sal]",
C1949650,"2-Deoxy-D-glucose, Reagent",glucose,,
C1950476,Valu Strip Glucose Testing Strip,glucose,Valu Strip Glucose Test Strip,
C1950723,PRODIGY (GLUCOSE) TEST STRIP,glucose,PRODIGY (GLUCOSE) TEST STRIP,
C1950727,NOVA MAX (GLUCOSE) TEST STRIP,glucose,Nova Max Glucose Test Strips; NOVA MAX (GLUCOSE) TEST STRIP,
C1951574,FreeStyle LT/Glucose Monitoring NFRS,glucose,,
C1952568,Calcium Chloride 0.00136 MEQ/ML / Glucose 0.8 MG/ML / Magnesium Sulfate 0.00122 MEQ/ML / Potassium Chloride 0.00403 MEQ/ML / Sodium Bicarbonate 0.0226 MEQ/ML / Sodium Chloride 0.125 MEQ/ML / sodium phosphate 0.000746 MEQ/ML Injectable Solution [Elliotts B],glucose,"ELLIOTTS B INJ,SOLN,10ML; sodium chloride 73 mg in 10 mL / sodium bicarbonate 19 mg in 10 mL / anhydrous dextrose 8 mg in 10 mL / MAGNESIUM SULFATE, UNSPECIFIED 3 mg in 10 mL / potassium chloride 3 mg in 10 mL / calcium chloride 2 mg in 10 mL / sodium phosphate 2 mg in 10 mL INTRATHECAL INJECTION [Elliotts B]; ELLIOTTS B INJ SOLN 10ML; Elliots B Solution; Elliot's B Solution; sodium chloride 73 mg in 10 mL / sodium bicarbonate 19 mg in 10 mL / anhydrous dextrose 8 mg in 10 mL / magnesium sulfate 3 mg in 10 mL / potassium chloride 3 mg in 10 mL / calcium chloride 2 mg in 10 mL / sodium phosphate 2 mg in 10 mL INTRATHECAL INJECTION [Elliotts B]",
C1952628,Insulin^pre dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin^pre dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin [Units/volume] in Serum or Plasma --pre dose glucose; Insulin pre Glc SerPl-aCnc; Insulin pre dose glucose Qn,
C1952644,Insulin^5M pre dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin 5 Min pre dose glucose Qn; Insulin^5 minutes pre dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 5M pre Glc SerPl-aCnc; Insulin [Units/volume] in Serum or Plasma --5 minutes pre dose glucose,
C1952715,Glucose^10M post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 10 Min post dose glucose [Mass/Vol]; Glucose 10M p Glc SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --10 minutes post dose glucose; Glucose^10 minutes post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1952716,Glucose^20M post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 20 Min post dose glucose [Mass/Vol]; Glucose^20 minutes post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --20 minutes post dose glucose; Glucose 20M p Glc SerPl-mCnc,
C1952717,Glucose^8 AM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 8 AM specimen [Mass/Vol]; Glucose^8 AM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 8 AM SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --8 AM specimen,
C1952720,Glucose^12 PM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 12 PM specimen [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --12 PM specimen; Glucose^12 PM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 12 PM SerPl-mCnc,
C1952721,Glucose^6 PM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^6 PM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 6 PM SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --6 PM specimen; Glucose 6 PM specimen [Mass/Vol],
C1952722,Glucose^8 PM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^8 PM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 8 PM SerPl-mCnc; Glucose 8 PM specimen [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --8 PM specimen,
C1952814,C peptide^1.5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide 1.5h p Glc SerPl-sCnc; C peptide [Moles/volume] in Serum or Plasma --1.5 hours post dose glucose; C peptide^1.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 1.5 Hr post dose glucose [Moles/Vol],
C1952815,C peptide^10M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide^10 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 10M p Glc SerPl-sCnc; C peptide 10 Min post dose glucose [Moles/Vol]; C peptide [Moles/volume] in Serum or Plasma --10 minutes post dose glucose,
C1952816,C peptide^15M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide^15 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Moles/volume] in Serum or Plasma --15 minutes post dose glucose; C peptide 15 Min post dose glucose [Moles/Vol]; C peptide 15M p Glc SerPl-sCnc,
C1952817,C peptide^1H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide 1 Hr post dose glucose [Moles/Vol]; C peptide^1 hour post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 1h p Glc SerPl-sCnc; C peptide [Moles/volume] in Serum or Plasma --1 hour post dose glucose,
C1952818,C peptide^1M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide^1 minute post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 1 Min post dose glucose [Moles/Vol]; C peptide [Moles/volume] in Serum or Plasma --1 minute post dose glucose; C peptide 1M p Glc SerPl-sCnc,
C1952819,C peptide^2H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide 2 Hr post dose glucose [Moles/Vol]; C peptide^2 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Moles/volume] in Serum or Plasma --2 hours post dose glucose; C peptide 2h p Glc SerPl-sCnc,
C1952820,C peptide^30M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide^30 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Moles/volume] in Serum or Plasma --30 minutes post dose glucose; C peptide 30M p Glc SerPl-sCnc; C peptide 30 Min post dose glucose [Moles/Vol],
C1952821,C peptide^3H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide [Moles/volume] in Serum or Plasma --3 hours post dose glucose; C peptide 3h p Glc SerPl-sCnc; C peptide^3 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 3 Hr post dose glucose [Moles/Vol],
C1952822,C peptide^3M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide^3 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Moles/volume] in Serum or Plasma --3 minutes post dose glucose; C peptide 3 Min post dose glucose [Moles/Vol]; C peptide 3M p Glc SerPl-sCnc,
C1952823,C peptide^5M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide 5 Min post dose glucose [Moles/Vol]; C peptide^5 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Moles/volume] in Serum or Plasma --5 minutes post dose glucose; C peptide 5M p Glc SerPl-sCnc,
C1952824,C peptide^5M pre dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide 5 Min pre dose glucose [Moles/Vol]; C peptide^5 minutes pre dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Moles/volume] in Serum or Plasma --5 minutes pre dose glucose; C peptide 5M pre Glc SerPl-sCnc,
C1952826,C peptide^pre dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide^pre dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide pre dose glucose [Moles/Vol]; C peptide [Moles/volume] in Serum or Plasma --pre dose glucose; C peptide pre Glc SerPl-sCnc,
C1952853,Glucose:SCnc:Pt:Stool:Qn,glucose,Glucose:Substance Concentration:To identify measures at a point in time:Stool:Quantitative; Glucose (Stl) [Moles/Vol]; Glucose Stl-sCnc; Glucose [Moles/volume] in Stool,
C1952854,Glucose.IV:Mass:Pt:Dose:Qn,glucose,Glucose.IV [Mass] of Dose; Glucose.IV:Mass:To identify measures at a point in time:Dose:Quantitative; Glucose IV Dose; Glucose.IV (Dose) [Mass],
C1952855,Glucose.IV,glucose,Glucose.IV; glucose IV,
C1952856,Glucose^pre dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --pre dose glucose; Glucose^pre dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre Glc SerPl-sCnc; Glucose pre dose glucose [Moles/Vol],
C1952895,Insulin^10M post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin^10 minutes post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 10 Min post dose glucose Qn; Insulin 10M p Glc SerPl-aCnc; Insulin [Units/volume] in Serum or Plasma --10 minutes post dose glucose,
C1952897,Insulin^1M post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin 1 Min post dose glucose Qn; Insulin 1M p Glc SerPl-aCnc; Insulin [Units/volume] in Serum or Plasma --1 minute post dose glucose; Insulin^1 minute post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1952898,Insulin^1H post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin 1 Hr post dose glucose Qn; Insulin 1h p Glc SerPl-aCnc; Insulin^1 hour post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin [Units/volume] in Serum or Plasma --1 hour post dose glucose,
C1952899,Insulin^1.5H post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin [Units/volume] in Serum or Plasma --1.5 hours post dose glucose; Insulin^1.5 hours post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 1.5 Hr post dose glucose Qn; Insulin 1.5h p Glc SerPl-aCnc,
C1952900,Insulin^2H post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin [Units/volume] in Serum or Plasma --2 hours post dose glucose; Insulin 2h p Glc SerPl-aCnc; Insulin 2 Hr post dose glucose Qn; Insulin^2 hours post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1952901,Insulin^2.5H post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin 2.5h p Glc SerPl-aCnc; Insulin 2.5 Hr post dose glucose Qn; Insulin^2.5 hours post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin [Units/volume] in Serum or Plasma --2.5 hours post dose glucose,
C1952902,Insulin^20M post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin^20 minutes post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 20M p Glc SerPl-aCnc; Insulin 20 Min post dose glucose Qn; Insulin [Units/volume] in Serum or Plasma --20 minutes post dose glucose,
C1952903,Insulin^3H post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin 3 Hr post dose glucose Qn; Insulin^3 hours post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 3h p Glc SerPl-aCnc; Insulin [Units/volume] in Serum or Plasma --3 hours post dose glucose,
C1952904,Insulin^30M post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin 30M p Glc SerPl-aCnc; Insulin [Units/volume] in Serum or Plasma --30 minutes post dose glucose; Insulin 30 Min post dose glucose Qn; Insulin^30 minutes post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1952905,Insulin^3M post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin [Units/volume] in Serum or Plasma --3 minutes post dose glucose; Insulin 3 Min post dose glucose Qn; Insulin 3M p Glc SerPl-aCnc; Insulin^3 minutes post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1952906,Insulin^5M post dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin^5 minutes post dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 5 Min post dose glucose Qn; Insulin 5M p Glc SerPl-aCnc; Insulin [Units/volume] in Serum or Plasma --5 minutes post dose glucose,
C1952996,Somatotropin^1.5H post dose glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Somatotropin 1.5 Hr post dose glucose PO Qn; GH 1.5h p Glc PO SerPl-aCnc; Somatotropin^1.5 hours post dose glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Somatotropin [Units/volume] in Serum or Plasma --1.5 hours post dose glucose PO,
C1953007,Somatotropin^1H post dose glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Somatotropin [Units/volume] in Serum or Plasma --1 hour post dose glucose PO; Somatotropin 1 Hr post dose glucose PO Qn; GH 1h p Glc PO SerPl-aCnc; Somatotropin^1 hour post dose glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1953069,Somatotropin^2H post dose glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Somatotropin [Units/volume] in Serum or Plasma --2 hours post dose glucose PO; Somatotropin 2 Hr post dose glucose PO Qn; GH 2h p Glc PO SerPl-aCnc; Somatotropin^2 hours post dose glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1953073,Somatotropin^30M post dose glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Somatotropin [Units/volume] in Serum or Plasma --30 minutes post dose glucose PO; Somatotropin^30 minutes post dose glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Somatotropin 30 Min post dose glucose PO Qn; GH 30M p Glc PO SerPl-aCnc,
C1953075,Somatotropin^3H post dose glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Somatotropin^3 hours post dose glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Somatotropin [Units/volume] in Serum or Plasma --3 hours post dose glucose PO; GH 3h p Glc PO SerPl-aCnc; Somatotropin 3 Hr post dose glucose PO Qn,
C1953080,Somatotropin^pre dose glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Somatotropin pre dose glucose PO Qn; GH Pre Glc PO SerPl-aCnc; Somatotropin [Units/volume] in Serum or Plasma --pre dose glucose PO; Somatotropin^pre dose glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1953181,Glucose^5M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^5 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5M p Glc SerPl-sCnc; Glucose 5 Min post dose glucose [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --5 minutes post dose glucose,
C1953334,Glucose:SCnc:Pt:BldCo:Qn,glucose,Glucose:Substance Concentration:To identify measures at a point in time:Blood - cord:Quantitative; Glucose (BldCo) [Moles/Vol]; Glucose BldCo-sCnc; Glucose [Moles/volume] in Cord blood,
C1953410,Glucose:MCnc:Pt:Stool:Qn,glucose,Glucose (Stl) [Mass/Vol]; Glucose:Mass Concentration:To identify measures at a point in time:Stool:Quantitative; Glucose [Mass/volume] in Stool; Glucose Stl-mCnc,
C1953512,Glucose^15M pre dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 15M pre glc SerPl-sCnc; Glucose^15 minutes pre dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15 Min pre dose glucose [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose glucose,
C1953523,Insulin^10M pre dose glucose:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin 10M pre Glc SerPl-aCnc; Insulin^10 minutes pre dose glucose:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin [Units/volume] in Serum or Plasma --10 minutes pre dose glucose; Insulin 10 Min pre dose glucose Qn,
C1954184,Glucose^1H post dose fructose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --1 hour post dose fructose PO; Glucose^1 hour post dose fructose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1 Hr post dose fructose PO [Mass/Vol]; Glucose 1h p fructose PO SerPl-mCnc,
C1954185,Glucose^pre dose fructose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^pre dose fructose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --pre dose fructose PO; Glucose pre dose fructose PO [Mass/Vol]; Glucose Pre fructose PO SerPl-mCnc,
C1954186,Glucose^30M post dose fructose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^30 minutes post dose fructose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30M p fructose PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose fructose PO; Glucose 30 Min post dose fructose PO [Mass/Vol],
C1954424,Glucose^24H post peritoneal dialysis:MCnc:Pt:Periton fld:Qn,glucose,Glucose 24h p PD Prt-mCnc; Glucose 24 Hr post PD (Periton fld) [Mass/Vol]; Glucose [Mass/volume] in Peritoneal fluid --24 hours post peritoneal dialysis; Glucose^24 hours post peritoneal dialysis:Mass Concentration:To identify measures at a point in time:Peritoneal fluid /ascites:Quantitative,
C1954462,Glucose^5H post 50 g glucose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5h p 50 g Glu PO SerPl-mCnc; Glucose 5 Hr post 50 g glucose PO [Mass/Vol]; Glucose^5 hours post 50 g glucose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --5 hours post 50 g glucose PO,
C1954697,Glucose^20M pre XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 20 Min pre Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --20 minutes pre XXX challenge; Glucose 20M pre chal SerPl-mCnc; Glucose^20 minutes pre XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1954698,Glucose^10 PM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 10 PM SerPl-mCnc; Glucose^10 PM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --10 PM specimen; Glucose 10 PM specimen [Mass/Vol],
C1954699,Glucose^12 AM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --12 AM specimen; Glucose 12 AM specimen [Mass/Vol]; Glucose^12 AM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 12 AM SerPl-mCnc,
C1954700,Glucose^3 AM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3 AM specimen [Mass/Vol]; Glucose^3 AM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3 AM SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --3 AM specimen,
C1954701,Glucose^6 AM specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --6 AM specimen; Glucose^6 AM specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 6 AM specimen [Mass/Vol]; Glucose 6 AM SerPl-mCnc,
C1954898,Glucose^2H post dose glucose:MCnc:Pt:Bld:Qn,glucose,Glucose^2 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Whole blood:Quantitative; Glucose 2 Hr post dose glucose (Bld) [Mass/Vol]; Glucose 2h p Glc Bld-mCnc; Glucose [Mass/volume] in Blood --2 hours post dose glucose,
C1955025,Glucose-6-phosphate dehydrogenase phenotype:Impression/interpretation of study:Point in time:Erythrocytes:Narrative,glucose,Glucose-6-Phosphate dehydrogenase phenotype:Imp:Pt:RBC:Nar; Glucose-6-Phosphate dehydrogenase phenotype:Impression/interpretation of study:To identify measures at a point in time:Erythrocytes:Narrative; G6PD phenotype Nar (RBC) [Interp]; G6PD Phenotyp RBC-Imp; Glucose-6-Phosphate dehydrogenase phenotype [Interpretation] in Red Blood Cells Narrative,
C1955086,10 minutes pre dose glucose,glucose,10M pre dose glucose,
C1955093,15 minutes pre dose glucose,glucose,15M pre dose glucose,
C1955112,5 hours post 50 g glucose PO,glucose,5H post 50 g glucose PO,
C1955128,glucose (oral challenge),glucose,glucose PO,
C1955182,Bg group,BG,,
C1955477,Glucose (oral),glucose,Glucose.PO,
C1956531,"glucose-6-phosphatase-beta, mouse",glucose,"G6Pase-beta, mouse; G6PC3 protein, mouse",
C1957112,"SLC5A12 protein, human",glucose,"solute carrier family 5 (sodium-glucose cotransporter), member 12, human; SMCTn protein, human; sodium-coupled monocarboxylate transporter 2, human",
C1957545,"1,3,4,6-tetra-O-galloyl-beta-D-glucose",glucose,,
C1958597,"glucose-dependent insulinotropic polypeptide, Hyp(3)-",glucose,"glucose-dependent insulinotropic polypeptide, hydroxyprolyl(3)-; 3-Hyp-GIP; (Hyp(3))GIP",
C1958598,"glucose-dependent insulinotropic polypeptide, Hyp(3)-palmitoylLys(16)-",glucose,"glucose-dependent insulinotropic polypeptide, hydroxyprolyl(3)-palmitoyllysyl(16)-; (Hyp(3))GIPLys(16)PAL",
C1959393,"BTBD1 protein, mouse",glucose,"1190005H08Rik protein, mouse; BTB-POZ domain containing protein 1, mouse; Glucose signal-repressing protein, mouse; Gsrp protein, mouse",
C1960041,Small vessel disease due to type 1 diabetes mellitus,diabetes,Small vessel disease due to type 1 diabetes mellitus (disorder); Diabetes type 1 with small vessel disease,
C1960042,Small vessel disease due to type 2 diabetes mellitus,diabetes,Small vessel disease due to type 2 diabetes mellitus (disorder),
C1960181,Diabetic glomerulonephritis,diabetes,Glomerulonephritis due to diabetes mellitus (disorder); Glomerulonephritis due to diabetes mellitus,
C1960216,Lumbosacral radiculoplexus neuropathy due to type 1 diabetes mellitus,diabetes,Lumbosacral radiculoplexus neuropathy due to type 1 diabetes mellitus (disorder); Lumbosacral radiculoplexus neuropathy with type I diabetes mellitus; Amyotrophy due to type 1 diabetes mellitus; Lumbosacral radiculoplexus neuropathy with type 1 diabetes mellitus,
C1960217,Lumbosacral radiculoplexus neuropathy due to type 2 diabetes mellitus,diabetes,Lumbosacral radiculoplexus neuropathy due to type 2 diabetes mellitus (disorder); Lumbosacral radiculoplexus neuropathy with type 2 diabetes mellitus; Amyotrophy due to type 2 diabetes mellitus; Diabetes type II with amyotrophy; Diabetes type 2 with amyotrophy,
C1960272,Latent autoimmune diabetes mellitus in adult,diabetes,Latent autoimmune diabetes mellitus in adult (LADA); Latent autoimmune diabetes mellitus in adult (disorder),
C1960626,Diabetes mellitus associated with cystic fibrosis,diabetes,Diabetes mellitus co-occurrent and due to cystic fibrosis (disorder); Diabetes mellitus co-occurrent and due to cystic fibrosis,
C1960678,Autonomic neuropathy due to type 1 diabetes mellitus,diabetes,Autonomic neuropathy with type I diabetes mellitus; Autonomic neuropathy with type 1 diabetes mellitus; Autonomic neuropathy due to type 1 diabetes mellitus (disorder); Diabetic autonomic neuropathy due to type 1 diabetes mellitus,
C1960705,Diabetes mellitus due to cystic fibrosis,diabetes,Diabetes mellitus due to cystic fibrosis (disorder),
C1962190,glucose Prefilled Syringe,glucose,,
C1964925,Prodigy Duo Blood Glucose/Blood Pressure Mete,blood glucose,,
C1966578,"Hyperform Set, 2-Chamber BG",BG,,
C1967400,FreeStyle Lite Glucose Monitor,glucose,,
C1968689,"Hyper-Immunoglobulin E Syndrome, Autosomal Recessive",hyper,"DOCK8 Deficiency; Hyper Immunoglobulin E Syndrome, Autosomal Recessive; Hyper-IgE Syndrome, Autosomal Recessive; Autosomal Recessive HIES; HYPER-IgE SYNDROME, AUTOSOMAL RECESSIVE; HIES, AUTOSOMAL RECESSIVE; Dedicator of Cytokinesis 8 Deficiency; Hyper-IgE Recurrent Infection Syndrome, Autosomal Recessive; HIES, Autosomal Recessive; Autosomal Recessive HIESs; Hyper IgE Recurrent Infection Syndrome, Autosomal Recessive; HIESs, Autosomal Recessive; Hyper IgE Syndrome, Autosomal Recessive",
C1969071,Type 1 diabetes mellitus developed in some patients,diabetes,,
C1969086,Tyrosine Kinase 2 Deficiency,hyper,"Tyrosine Kinase 2 Deficiency; HYPER-IgE SYNDROME WITH ATYPICAL MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE; TYK2 Deficiency; IMD35; HIES WITH ATYPICAL MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE; IMMUNODEFICIENCY 35; Susceptibility to infection due to TYK2 deficiency; Susceptibility to infection due to tyrosine kinase 2 deficiency (disorder); TYK2 DEFICIENCY; Hyper-IgE Syndrome with Atypical Mycobacteriosis, Autosomal Recessive; HIES with Atypical Mycobacteriosis, Autosomal Recessive; Autosomal recessive hyper-IgE syndrome due to TYK2 deficiency; Autosomal recessive hyper-IgE (immunoglobulin E) syndrome due to TYK2 deficiency; TYROSINE KINASE 2 DEFICIENCY; Susceptibility to infection due to tyrosine kinase 2 deficiency",
C1971396,"Sensor; invasive (e.g., subcutaneous), disposable, for use with interstitial continuous glucose monitoring system, one unit = 1 day supply",glucose,,
C1971397,"Transmitter; external, for use with interstitial continuous glucose monitoring system",glucose,,
C1971398,"Receiver (monitor); external, for use with interstitial continuous glucose monitoring system",glucose,,
C1976790,Glucose tolerance 2H gestational panel,glucose,Glucose tolerance 2H gestational panel; Glucose tolerance 2 hours gestational panel,
C1976951,Glucose tolerance^post 75 g glucose PO:Imp:Pt:Ser/Plas:Nar,glucose,GTT p 75 g Glc PO SerPl-Imp; Glucose tolerance post 75 g glucose PO Nar [Interp]; Glucose tolerance [Interpretation] in Serum or Plasma Narrative--post 75 g glucose PO; Glucose tolerance^post 75 g glucose Oral:Impression/interpretation of study:To identify measures at a point in time:Serum/Plasma:Narrative,
C1976952,Glucose tolerance^post 100 g glucose PO:Imp:Pt:Ser/Plas:Nar,glucose,Glucose tolerance post 100 g glucose PO Nar [Interp]; Glucose tolerance^post 100 g glucose Oral:Impression/interpretation of study:To identify measures at a point in time:Serum/Plasma:Narrative; Glucose tolerance [Interpretation] in Serum or Plasma Narrative--post 100 g glucose PO; GTT p 100 g Glc PO SerPl-Imp,
C1977250,Glucose-6-Phosphate dehydrogenase:EntCat:Pt:Bld:Qn,glucose,Glucose-6-Phosphate dehydrogenase:Entitic Catalytic Activity:To identify measures at a point in time:Whole blood:Quantitative; G6PD (Bld) [Entitic Catalytic Activity]; Glucose-6-Phosphate dehydrogenase [Entitic Catalytic Activity] in Blood; G6PD Bld Qn,
C1977694,Glucose^1st specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose spec 1 [Mass/Vol]; Glucose sp1 SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1st specimen; Glucose^1st specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1977695,Glucose^7th specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --7th specimen; Glucose sp7 SerPl-mCnc; Glucose^7th specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 7th specimen [Mass/Vol],
C1977696,Glucose^10th specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose sp10 SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --10th specimen; Glucose^10th specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 10th specimen [Mass/Vol],
C1977738,Sodium^^corrected for glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Sodium^^corrected for glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Sodium [Moles/volume] corrected for glucose in Serum or Plasma; Sodium Glucose cor SerPl-sCnc; Sodium corrected for glucose [Moles/Vol],
C1977802,Glucose-6-Phosphate dehydrogenase:CCnt:Pt:RBC:Qn:Glock & McLean,glucose,G6PD Glock and McLean (RBC) [Catalytic activity/Mass]; Glucose-6-Phosphate dehydrogenase:Catalytic Content:To identify measures at a point in time:Erythrocytes:Quantitative:Glock & McLean; Glucose-6-Phosphate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells by Glock and McLean; G6PD RBC Glock & McLean-cCnt,
C1977803,Glucose-6-Phosphate dehydrogenase:CCnt:Pt:RBC:Qn:WHO method,glucose,Glucose-6-Phosphate dehydrogenase:Catalytic Content:To identify measures at a point in time:Erythrocytes:Quantitative:WHO method; Glucose-6-Phosphate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells by WHO method; G6PD WHO method (RBC) [Catalytic activity/Mass]; G6PD RBC WHO method-cCnt,
C1978045,Glucose^2nd specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose spec 2 [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --2nd specimen; Glucose sp2 SerPl-mCnc; Glucose^2nd specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1978046,Glucose^3rd specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose spec 3 [Mass/Vol]; Glucose sp3 SerPl-mCnc; Glucose^3rd specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --3rd specimen,
C1978047,Glucose^4th specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose spec 4 [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --4th specimen; Glucose^4th specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp4 SerPl-mCnc,
C1978048,Glucose^5th specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5th specimen [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --5th specimen; Glucose^5th specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp5 SerPl-mCnc,
C1978049,Glucose^6th specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --6th specimen; Glucose^6th specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp6 SerPl-mCnc; Glucose 6th specimen [Mass/Vol],
C1978050,Glucose^8th specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^8th specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --8th specimen; Glucose 8th specimen [Mass/Vol]; Glucose sp8 SerPl-mCnc,
C1978051,Glucose^9th specimen:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --9th specimen; Glucose^9th specimen:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp9 SerPl-mCnc; Glucose 9th specimen [Mass/Vol],
C1978482,Glucose:PrThr:Pt:Urine:Ord:Test strip.automated,glucose,Glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip.automated; Glucose Ur Ql Strip.auto; Glucose Auto test strip Ql (U); Glucose [Presence] in Urine by Automated test strip,
C1978526,Glucose tolerance gestational panel:-:Pt:Urine+Ser/Plas:-,glucose,Glucose tolerance gestational panel (U+S/P); Gestational GTT Pnl Ur+SerPl; Glucose tolerance gestational panel:-:To identify measures at a point in time:Urine+Serum/Plasma:-; Glucose tolerance gestational panel - Urine and Serum or Plasma,
C1978528,Glucose screen gestational panel:-:Pt:Urine+Ser/Plas:-,glucose,Glu screen gest Pnl Ur+SerPl; Glucose screen gestational panel (U+S/P); Glucose screen gestational panel:-:To identify measures at a point in time:Urine+Serum/Plasma:-; Glucose screen gestational panel - Urine and Serum or Plasma,
C1978534,Glucose tolerance 3H panel:-:-:Ser/Plas:Qn,glucose,Glucose tolerance 3 hours panel; Glucose tolerance 3H panel:-:-:Serum/Plasma:Quantitative; Glucose tolerance 3 hours panel - Serum or Plasma; GTT 3h Pnl SerPl; Glucose tolerance 3H panel:-:-:Ser/Plas:Qn,
C1978535,Glucose tolerance 3H panel,glucose,Glucose tolerance 3H panel; Glucose tolerance 3 hours panel,
C1978536,Glucose tolerance 4H panel:-:-:Ser/Plas:Qn,glucose,Glucose tolerance 4H panel:-:-:Ser/Plas:Qn; Glucose tolerance 4 hours panel; Glucose tolerance 4H panel:-:-:Serum/Plasma:Quantitative; GTT 4h Pnl SerPl; Glucose tolerance 4 hours panel - Serum or Plasma,
C1978537,Glucose tolerance 4 hours panel,glucose,Glucose tolerance 4H panel; Glucose tolerance 4 hours panel,
C1978538,Glucose tolerance 5H panel:-:-:Ser/Plas:Qn,glucose,Glucose tolerance 5 hours panel; GTT 5h Pnl SerPl; Glucose tolerance 5H panel:-:-:Ser/Plas:Qn; Glucose tolerance 5 hours panel - Serum or Plasma; Glucose tolerance 5H panel:-:-:Serum/Plasma:Quantitative,
C1978539,Glucose tolerance 5 hours panel,glucose,Glucose tolerance 5H panel; Glucose tolerance 5 hours panel,
C1978540,Glucose tolerance 6H panel:-:-:Ser/Plas:Qn,glucose,Glucose tolerance 6 hours panel; Glucose tolerance 6 hours panel - Serum or Plasma; Glucose tolerance 6H panel:-:-:Ser/Plas:Qn; Glucose tolerance 6H panel:-:-:Serum/Plasma:Quantitative; GTT 6h Pnl SerPl,
C1978541,Glucose tolerance 6 hours panel,glucose,Glucose tolerance 6H panel; Glucose tolerance 6 hours panel,
C1978566,Glucose tolerance 3H gestational panel:-:-:Ser/Plas:Qn,glucose,Glucose tolerance 3 hours gestational panel; Glucose tolerance 3 hours gestational panel - Serum or Plasma; GTT gest 3h Pnl SerPl; Glucose tolerance 3H gestational panel:-:-:Ser/Plas:Qn; Glucose tolerance 3H gestational panel:-:-:Serum/Plasma:Quantitative,
C1978567,Glucose tolerance 3H gestational panel,glucose,Glucose tolerance 3 hours gestational panel; Glucose tolerance 3H gestational panel,
C1978646,Glucose tolerance:Impression/interpretation of study:Point in time:Serum/Plasma:Narrative,glucose,Glucose tolerance Nar [Interp]; Glucose tolerance:Imp:Pt:Ser/Plas:Nar; Glucose tolerance:Impression/interpretation of study:To identify measures at a point in time:Serum/Plasma:Narrative; GTT SerPl-Imp; Glucose tolerance [Interpretation] in Serum or Plasma Narrative,
C1978755,Glucose^15M post 0.1 U/kg insulin:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^15 minutes post 0.1 U/kg insulin:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15 Min post 0.1 U/kg insulin [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --15 minutes post 0.1 U/kg insulin; Glucose 15M p 0.1 U/kg Ins SerPl-mCnc,
C1979449,Glucose^pre or post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre or post Unsp challenge [Moles/Vol]; Glucose pre/p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --pre or post XXX challenge; Glucose^pre or post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C1979512,Corrected for glucose,glucose,Corrected for glucose technique (qualifier value); Corrected for glucose technique; corrected for glucose,
C1979574,post 100 g glucose PO,glucose,post 100 g glucose PO,
C1979577,post 75 g glucose PO,glucose,post 75 g glucose PO,
C1995197,ACCU-CHEK AVIVA (GLUCOSE) METER,glucose,Accu-Chek Aviva Meter; ACCU-CHEK AVIVA (GLUCOSE) METER,
C1995415,FREESTYLE (GLUCOSE) METER,glucose,FREESTYLE (GLUCOSE) METER,
C1995416,FREESTYLE LITE (GLUCOSE) TEST STRIP,glucose,FREESTYLE LITE (GLUCOSE) TEST STRIP,
C1995601,MEDISENSE (GLUCOSE) MID CONTROL SOLN,glucose,MEDISENSE (GLUCOSE) MID CONTROL SOLN,
C1997115,Hyperosmolality due to uncontrolled type 1 diabetes mellitus,diabetes,Hyperosmolality due to uncontrolled type 1 diabetes mellitus (disorder),
C1997435,Dietary education for type 2 diabetes mellitus,diabetes,Dietary education for type II diabetes mellitus; Dietary education for type II diabetes mellitus (procedure),
C1997651,Erectile dysfunction due to type 2 diabetes mellitus,diabetes,Erectile dysfunction due to type 2 diabetes mellitus (disorder); Erectile dysfunction with type 2 diabetes mellitus,
C1998445,Dietary education for type 1 diabetes mellitus,diabetes,Dietary education for type I diabetes mellitus; Dietary education for type I diabetes mellitus (procedure),
C1999410,6-Fluoro-6-deoxy-D-glucose,glucose,,
C2000601,"dTDP-3,6-dideoxy-3-(3-hydroxybutyramido)glucose",glucose,"dTDP-3,6-DD-HBG",
C2001438,"(3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-yl)methyl 2-((benzyloxy)carbonyl)amino-3-phenylpropanoate",glucose,Z-Phe-O-glucose; 6-O-(benzyloxycarbonyl-phenylalanyl)glucopyranose,
C2012248,ascorbic acid / glucose,glucose,,
C2054149,History of taking medication for diabetes long-term use of insulin,diabetes,,
C2114083,"Glucose tolerance test, antenatal",glucose,"Glucose tolerance test, antenatal (procedure)",
C2114374,hemoglobin A1C results documented and reviewed - hemoglobin A1C level greater 9.0%,a1c,,
C2114782,Proliferative retinopathy of left eye due to diabetes mellitus,diabetes,Proliferative retinopathy of left eye due to diabetes mellitus (disorder); Proliferative diabetic retinopathy of left eye; Proliferative retinopathy of left eye with diabetes mellitus,
C2114783,Proliferative retinopathy of right eye with diabetes mellitus,diabetes,Proliferative retinopathy of right eye due to diabetes mellitus; Proliferative retinopathy of right eye due to diabetes mellitus (disorder); Proliferative diabetic retinopathy of right eye,
C2118433,diabetes mellitus with postsurgical hypoinsulinemia,diabetes,,
C2119283,uncontrolled type II diabetes mellitus with peripheral neuropathy (diagnosis),diabetes,,
C2119284,uncontrolled type I diabetes mellitus with peripheral neuropathy (diagnosis),diabetes,,
C2171205,Autonomic neuropathy due to type 2 diabetes mellitus,diabetes,Diabetic autonomic neuropathy due to type 2 diabetes mellitus; Autonomic neuropathy with type 2 diabetes mellitus; Autonomic neuropathy with type II diabetes mellitus; Autonomic neuropathy due to type 2 diabetes mellitus (disorder),
C2183115,History of gestational diabetes mellitus,diabetes,History of gestational diabetes mellitus (situation); History of gestational diabetes mellitus,
C2183133,Microaneurysm of left retinal artery due to diabetes mellitus,diabetes,Diabetic retinal microaneurysm of left eye; Microaneurysm of left retinal artery due to diabetes mellitus (disorder); Retinal microaneurysm of left eye with diabetes mellitus,
C2183134,Microaneurysm of right retinal artery due to diabetes mellitus,diabetes,Diabetic retinal microaneurysm of right eye; Microaneurysm of right retinal artery due to diabetes mellitus (disorder); Retinal microaneurysm of right eye with diabetes mellitus,
C2183865,glucose / lidocaine,glucose,Glucose- and lidocaine-containing product; Product containing glucose and lidocaine (medicinal product),
C2188680,urinalysis results: glucose (0-4+),glucose,,
C2231316,Mild nonproliferative retinopathy of right eye due to diabetes mellitus,diabetes,Mild nonproliferative retinopathy of right eye due to diabetes mellitus (disorder); Mild nonproliferative diabetic retinopathy of right eye; Mild nonproliferative retinopathy of right eye; Mild non-proliferative diabetic retinopathy of right eye; Mild non proliferative retinopathy of right eye,
C2231317,Mild nonproliferative retinopathy of left eye due to diabetes mellitus,diabetes,Mild non-proliferative diabetic retinopathy of left eye; Mild non proliferative retinopathy of left eye; Mild nonproliferative diabetic retinopathy of left eye; Mild nonproliferative retinopathy of left eye due to diabetes mellitus (disorder); Mild nonproliferative retinopathy of left eye,
C2231319,Moderate nonproliferative diabetic retinopathy of right eye,diabetes,Moderate nonproliferative retinopathy of right eye due to diabetes mellitus (disorder); Moderate nonproliferative retinopathy of right eye due to diabetes mellitus; Moderate non-proliferative diabetic retinopathy of right eye,
C2231320,Moderate nonproliferative diabetic retinopathy of left eye,diabetes,Moderate non-proliferative diabetic retinopathy of left eye; Moderate nonproliferative retinopathy of left eye due to diabetes mellitus (disorder); Moderate nonproliferative retinopathy of left eye due to diabetes mellitus,
C2231461,Severe nonproliferative retinopathy of right eye due to diabetes mellitus,diabetes,Severe nonproliferative diabetic retinopathy of right eye; Severe NPDR (nonproliferative diabetic retinopathy) of right eye; Severe nonproliferative retinopathy of right eye due to diabetes mellitus (disorder),
C2231462,Severe nonproliferative retinopathy of left eye due to diabetes mellitus,diabetes,Severe NPDR (nonproliferative diabetic retinopathy) of left eye; Severe nonproliferative diabetic retinopathy of left eye; Severe nonproliferative retinopathy of left eye due to diabetes mellitus (disorder),
C2240982,PRODIGY VOICE (GLUCOSE) TEST STRIP,glucose,PRODIGY VOICE (GLUCOSE) TEST STRIP,
C2241891,TrueControl Glucose Solution Level 0,glucose,,
C2241892,TrueControl Glucose Solution Level 1,glucose,,
C2244219,sucrose catabolic process via 3'-ketosucrose,glucose,"sucrose catabolism, using glucoside 3-dehydrogenase; sucrose catabolic process, using glucoside 3-dehydrogenase; sucrose breakdown, using glucoside 3-dehydrogenase; sucrose catabolic process to D-glucose; sucrose degradation, using glucoside 3-dehydrogenase",
C2244358,protein-N(PI)-phosphohistidine-glucose phosphotransferase system transporter activity,glucose,glucose PTS transporter activity,
C2247306,DNA alpha-glucosyltransferase activity,glucose,T2-HMC-alpha-glucosyl transferase activity; T4-HMC-alpha-glucosyl transferase activity; T6-HMC-alpha-glucosyl transferase activity; UDP-glucose:DNA alpha-D-glucosyltransferase activity; uridine diphosphoglucose-deoxyribonucleate alpha-glucosyltransferase activity; UDPglucose-DNA alpha-glucosyltransferase activity,
C2247307,DNA beta-glucosyltransferase activity,glucose,UDP glucose-DNA beta-glucosyltransferase activity; T4-HMC-beta-glucosyl transferase activity; UDPglucose:DNA beta-D-glucosyltransferase activity; T4 phage beta-glucosyltransferase activity; UDP-glucose:DNA beta-D-glucosyltransferase activity; T4-beta-glucosyl transferase activity; uridine diphosphoglucose-deoxyribonucleate beta-glucosyltransferase activity,
C2247308,glucosyl-DNA beta-glucosyltransferase activity,glucose,T6-glucosyl-HMC-beta-glucosyl transferase activity; UDP-glucose:D-glucosyl-DNA beta-D-glucosyltransferase activity; T6-beta-glucosyl transferase activity; uridine diphosphoglucose-glucosyldeoxyribonucleate beta-glucosyltransferase activity; UDPglucose:D-glucosyl-DNA beta-D-glucosyltransferase activity,
C2247309,procollagen glucosyltransferase activity,glucose,UDP-glucose-collagenglucosyltransferase activity; galactosylhydroxylysine-glucosyltransferase activity; uridine diphosphoglucose-collagen glucosyltransferase activity; galactosylhydroxylysine glucosyltransferase activity; UDP-glucose:5-(D-galactosyloxy)-L-lysine-procollagen D-glucosyltransferase activity; collagen glucosyltransferase activity; galactosylhydroxylysyl glucosyltransferase activity; UDPglucose:5-(D-galactosyloxy)-L-lysine-procollagen D-glucosyltransferase activity; collagen hydroxylysyl glucosyltransferase activity,
C2247313,xyloglucan 4-glucosyltransferase activity,glucose,"uridine diphosphoglucose-xyloglucan 4beta-glucosyltransferase activity; UDPglucose:xyloglucan 1,4-beta-D-glucosyltransferase activity; UDP-glucose:xyloglucan 1,4-beta-D-glucosyltransferase activity; xyloglucan 4beta-D-glucosyltransferase activity; xyloglucan glucosyltransferase activity",
C2247315,glucosylglycerol-phosphate synthase activity,glucose,GG-phosphate synthase activity; glucosyl-glycerol-phosphate synthase activity; ADP-glucose:sn-glycerol-3-phosphate 2-beta-D-glucosyltransferase activity; ADPglucose:sn-glycerol-3-phosphate 2-beta-D-glucosyltransferase activity; GGPS,
C2247318,kojibiose phosphorylase activity,glucose,2-alpha-D-glucosyl-D-glucose:phosphate beta-D-glucosyltransferase activity,
C2247324,flavonol 7-O-beta-glucosyltransferase activity,glucose,UDP-glucose:flavonol 7-O-beta-D-glucosyltransferase activity; UDP-glucose:flavonol 7-O-glucosyltransferase activity,
C2247325,anthocyanin 3'-O-beta-glucosyltransferase activity,glucose,3'GT; UDP-glucose:anthocyanin 3'-O-glucosyltransferase activity; UDP-glucose:anthocyanin 3'-O-beta-D-glucosyltransferase activity,
C2247326,flavonol-3-O-glucoside glucosyltransferase activity,glucose,UDP-glucose:flavonol-3-O-glucoside 2''-O-beta-D-glucosyltransferase activity,
C2247327,flavonol-3-O-glycoside glucosyltransferase activity,glucose,UDP-glucose:flavonol-3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside 2'''-O-beta-D-glucosyltransferase activity,
C2247328,NDP-glucose-starch glucosyltransferase activity,glucose,"GBSS; NDP-glucose:1,4-alpha-D-glucan 4-alpha-D-glucosyltransferase activity; NDP-glucose-starch glucosyltransferase activity; GBSSI; starch granule-bound nucleoside diphosphate glucose-starch glucosyltransferase activity; granule-bound starch synthase II activity; starch synthase II activity; NDPglucose-starch glucosyltransferase activity; granule-bound starch synthase I activity; GBSSII; granule-bound starch synthase activity",
C2248667,UTP:glucose-1-phosphate uridylyltransferase regulator activity,glucose,UDP-glucose diphosphorylase regulator activity; glucose-1-phosphate uridylyltransferase regulator activity; UDP-glucose pyrophosphorylase regulator activity,
C2248763,ADP-specific glucokinase activity,glucose,ADP:D-glucose 6-phosphotransferase activity; ADP-dependent glucokinase activity,
C2248856,inhibition of transcription by glucose,glucose,,
C2250020,activation of transcription by glucose,glucose,,
C2250021,stimulation of transcription by glucose,glucose,,
C2250061,inhibition of glucose import,glucose,,
C2250062,activation of glucose import,glucose,,
C2250063,stimulation of glucose import,glucose,,
C2253373,glucose 1-dehydrogenase [NAD(P)] activity,glucose,beta-D-glucose:NAD(P)+ 1-oxidoreductase activity; hexose phosphate dehydrogenase activity; D-glucose dehydrogenase (NAD(P)),
C2262315,hydrogen:glucose symporter activity,glucose,glucose:proton symporter activity; hydrogen:glucose transporter activity; transepithelial hydrogen/glucose transporter activity; transepithelial hydrogen:glucose transporter activity; hydrogen:glucose symporter activity; transepithelial hydrogen:glucose symporter activity,
C2262316,insulin-responsive hydrogen:glucose symporter activity,glucose,insulin-responsive hydrogen:glucose symporter activity; transepithelial hydrogen/glucose transporter activity; insulin-responsive glucose:proton symporter activity; insulin-responsive hydrogen:glucose transporter activity,
C2262724,D-glucose:proton symporter activity,glucose,D-glucose:hydrogen symporter activity,
C2262725,D-glucose transmembrane transporter activity,glucose,,
C2263030,activation of transcription from RNA polymerase II promoter by glucose,glucose,,
C2263031,stimulation of transcription from RNA polymerase II promoter by glucose,glucose,,
C2263034,inhibition of transcription from RNA polymerase II promoter by glucose,glucose,,
C2264787,uridine diphosphate glucose:lipopolysaccharide glucosyltransferase I,glucose,,
C2265604,GDP-galactose:glucose-1-phosphate guanylyltransferase activity,glucose,GDP-L-galactose:glucose-1-phosphate guanylyltransferase activity,
C2265606,glucose-1-phosphate guanylyltransferase (GDP) activity,glucose,GDP:glucose-1-phosphate guanyltransferase activity,
C2265622,"UDP-4-keto-6-deoxy-glucose-3,5-epimerase activity",glucose,,
C2276056,Dienia sp. Hamburg BG 602 B 337,BG,Crepidium sp. Hamburg BG 602 B 337,
C2276057,Cleisostoma sp. Heidelberg BG 123029,BG,Echioglossum sp. Heidelberg BG 123029,
C2276062,Acriopsis sp. Wien BG,BG,,
C2276065,Campylocentrum sp. Heidelberg BG 122375,BG,,
C2276068,Cephalantheropsis sp. Heidelberg BG 125239,BG,,
C2276070,Cyclopogon sp. 1 Hannover BG,BG,Cyclopogon sp. Hannover BG,
C2276081,Jumellea sp. Heidelberg BG 122887,BG,,
C2276084,Oncidium sp. Heidelberg BG 124450,BG,Miltonioides sp. Heidelberg BG 124450,
C2276085,Polystachya sp. Heidelberg BG s.n.,BG,Neobenthamia sp. Heidelberg BG s.n.,
C2276086,Oberonia sp. Heidelberg BG 120006,BG,,
C2276087,Octomeria sp. Heidelberg BG 125079,BG,,
C2276088,Epidendrum sp. Heidelberg BG 101762,BG,Oerstedella sp. Heidelberg BG 101762,
C2276093,Ponera sp. Heidelberg BG 121987,BG,,
C2276097,Rangaeris sp. Heidelberg BG 121559,BG,,
C2276099,Sarcochilus sp. Heidelberg BG 122933,BG,,
C2276101,Sauroglossum sp. Hannover BG,BG,,
C2276106,Telipogon sp. Heidelberg BG 108219,BG,,
C2297182,Alchemilla cf. subnivalis Gehrke BG-Af 362,BG,,
C2302342,Kirramyces sp. BG-2007a,BG,,
C2316286,Family history of diabetes mellitus type 1,diabetes,Family history of diabetes mellitus type 1 (situation),
C2316287,Family history of diabetes mellitus type 2,diabetes,Family history of diabetes mellitus type 2 (situation),
C2317125,Family history of impaired glucose tolerance,glucose,Family history of impaired glucose tolerance (situation),
C2342994,EMBRACE (GLUCOSE) TEST STRIP,glucose,EMBRACE (GLUCOSE) TEST STRIP,
C2343441,Assure 4 Blood Glucose Test Strips,blood glucose,,
C2344042,PRODIGY (GLUCOSE) HIGH CONTROL SOLN,glucose,PRODIGY (GLUCOSE) HIGH CONTROL SOLN,
C2344043,PRODIGY (GLUCOSE) LOW CONTROL SOLN,glucose,PRODIGY (GLUCOSE) LOW CONTROL SOLN,
C2344051,ACCU-CHEK COMPACT (GLUCOSE) HI/LO CONTROL SOLN,glucose,ACCU-CHEK COMPACT HI/LO CONTROL SOLN,
C2344232,calcium chloride / glucose / potassium chloride / sodium chloride Injectable Solution,glucose,,
C2344959,glucose 1.7 MG/ML,glucose,,
C2344964,calcium chloride 0.00014 MEQ/ML / glucose 1.7 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution,glucose,Calcium Chloride 0.00014 MEQ/ML / Glucose 1.7 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution,
C2344966,calcium chloride 0.00014 MEQ/ML / glucose 1.7 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML [Dianeal PD-2/4.25],glucose,,
C2344991,glucose 1 MG/ML,glucose,,
C2345001,glucose 0.6 MG/ML,glucose,,
C2345002,calcium chloride 0.00014 MEQ/ML / glucose 0.6 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution,glucose,Calcium Chloride 0.00014 MEQ/ML / Glucose 0.6 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution,
C2345004,calcium chloride 0.00014 MEQ/ML / glucose 0.6 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML [Dianeal PD-2/1.5],glucose,,
C2345006,calcium chloride 0.00014 MEQ/ML / glucose 1 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution,glucose,Calcium Chloride 0.00014 MEQ/ML / Glucose 1 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution,
C2345007,calcium chloride 0.00014 MEQ/ML / glucose 1 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML [Dianeal PD-2/2.5],glucose,,
C2345009,calcium chloride 0.000996 MEQ/ML / glucose 1.7 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution,glucose,Calcium Chloride 0.000996 MEQ/ML / Glucose 1.7 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution,
C2345013,calcium chloride 0.000996 MEQ/ML / glucose 1.7 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML [Dianeal Low Calcium 4.25],glucose,,
C2345046,calcium chloride 0.000996 MEQ/ML / glucose 1 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution,glucose,Calcium Chloride 0.000996 MEQ/ML / Glucose 1 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution,
C2345048,calcium chloride 0.000996 MEQ/ML / glucose 1 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML [Dianeal Low Calcium 2.5],glucose,,
C2345277,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine Injectable Solution,glucose,,
C2345282,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix E 4.25/5],glucose,,
C2345297,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine Injectable Solution,glucose,,
C2345298,alanine 5.7 MG/ML / arginine 3.16 MG/ML / glucose 50 MG/ML / glycine 2.83 MG/ML / histidine 1.32 MG/ML / isoleucine 1.65 MG/ML / leucine 2.01 MG/ML / lysine 1.59 MG/ML / methionine 1.1 MG/ML / phenylalanine 1.54 MG/ML / proline 1.87 MG/ML / serine 1.38 MG/ML / threonine 1.16 MG/ML / tryptophan 0.5 MG/ML / tyrosine 0.11 MG/ML / valine 1.6 MG/ML Injectable Solution,glucose,,
C2345300,alanine 5.7 MG/ML / arginine 3.16 MG/ML / glucose 50 MG/ML / glycine 2.83 MG/ML / histidine 1.32 MG/ML / isoleucine 1.65 MG/ML / leucine 2.01 MG/ML / lysine 1.59 MG/ML / methionine 1.1 MG/ML / phenylalanine 1.54 MG/ML / proline 1.87 MG/ML / serine 1.38 MG/ML / threonine 1.16 MG/ML / tryptophan 0.5 MG/ML / tyrosine 0.11 MG/ML / valine 1.6 MG/ML [Clinimix 2.75/5],glucose,,
C2345301,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix 2.75/5],glucose,,
C2345302,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 100 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution,glucose,,
C2345304,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 100 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML [Clinimix 4.25/10],glucose,,
C2345305,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix 4.25/10],glucose,,
C2345306,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 200 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution,glucose,,
C2345308,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 200 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML [Clinimix 4.25/20],glucose,,
C2345309,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix 4.25/20],glucose,,
C2345310,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 250 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution,glucose,,
C2345312,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 250 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML [Clinimix 4.25/25],glucose,,
C2345313,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix 4.25/25],glucose,,
C2345314,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 50 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution,glucose,,
C2345316,alanine 8.8 MG/ML / arginine 4.89 MG/ML / glucose 50 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML [Clinimix 4.25/5],glucose,,
C2345317,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix 4.25/5],glucose,,
C2345331,alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 150 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 290 MG/ML Injectable Solution,glucose,,
C2345333,alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 150 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 290 MG/ML [Clinimix 5/15],glucose,,
C2345334,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix 5/15],glucose,,
C2345336,alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 200 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution,glucose,,
C2345338,alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 200 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML [Clinimix 5/20],glucose,,
C2345339,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix 5/20],glucose,,
C2345340,alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 250 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution,glucose,,
C2345342,alanine 10.4 MG/ML / arginine 5.75 MG/ML / glucose 250 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML [Clinimix 5/25],glucose,,
C2345343,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix 5/25],glucose,,
C2345348,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix E 2.75/5],glucose,,
C2345354,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix E 2.75/10],glucose,,
C2345355,calcium chloride 0.000996 MEQ/ML / glucose 0.6 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML Intraperitoneal Solution,glucose,Calcium Chloride 0.000996 MEQ/ML / Glucose 0.6 MG/ML / Magnesium Chloride 0.0000245 MEQ/ML / NaCl 0.00368 MEQ/ML / Sodium Lactate 0.0016 MEQ/ML Intraperitoneal Solution,
C2345356,calcium chloride 0.000996 MEQ/ML / glucose 0.6 MG/ML / magnesium chloride 0.0000245 MEQ/ML / sodium chloride 0.00368 MEQ/ML / sodium lactate 0.0016 MEQ/ML [Dianeal Low Calcium 1.5],glucose,,
C2345359,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix E 4.25/25],glucose,,
C2345367,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix E 5/15],glucose,,
C2345377,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix E 5/20],glucose,,
C2345379,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix E 5/25],glucose,,
C2345479,"dibasic potassium phosphate 1 MG/ML / glucose 50 MG/ML / magnesium chloride 0.00639 MEQ/ML / potassium chloride 0.0134 MEQ/ML / sodium chloride 0.0308 MEQ/ML / sodium lactate 0.025 MEQ/ML / sodium phosphate, monobasic 0.16 MG/ML Injectable Solution",glucose,"Dibasic K+ phosphate 1 MG/ML / Glucose 50 MG/ML / Magnesium Chloride 0.00639 MEQ/ML / K+ Chloride 0.0134 MEQ/ML / NaCl 0.0308 MEQ/ML / Sodium Lactate 0.025 MEQ/ML / Sodium Phosphate, Monobasic 0.16 MG/ML Injectable Solution; Dibasic Pot phosphate 1 MG/ML / Glucose 50 MG/ML / Magnesium Chloride 0.00639 MEQ/ML / Pot Chloride 0.0134 MEQ/ML / NaCl 0.0308 MEQ/ML / Sodium Lactate 0.025 MEQ/ML / Sodium Phosphate, Monobasic 0.16 MG/ML Injectable Solution; electrolyte-B in 5 % dextrose Injectable Solution",
C2345481,"dibasic potassium phosphate 1 MG/ML / glucose 50 MG/ML / magnesium chloride 0.00639 MEQ/ML / potassium chloride 0.0134 MEQ/ML / sodium chloride 0.0308 MEQ/ML / sodium lactate 0.025 MEQ/ML / sodium phosphate, monobasic 0.16 MG/ML [Ionosol-B]",glucose,,
C2345489,"glucose 50 MG/ML / magnesium chloride 0.00361 MEQ/ML / monobasic potassium phosphate 0.15 MG/ML / potassium chloride 0.0189 MEQ/ML / sodium lactate 0.0232 MEQ/ML / sodium phosphate, monobasic 0.25 MG/ML Injectable Solution",glucose,"Glucose 50 MG/ML / Magnesium Chloride 0.00361 MEQ/ML / Monobasic K+ phosphate 0.15 MG/ML / K+ Chloride 0.0189 MEQ/ML / Sodium Lactate 0.0232 MEQ/ML / Sodium Phosphate, Monobasic 0.25 MG/ML Injectable Solution; Glucose 50 MG/ML / Magnesium Chloride 0.00361 MEQ/ML / Monobasic Pot phosphate 0.15 MG/ML / Pot Chloride 0.0189 MEQ/ML / Sodium Lactate 0.0232 MEQ/ML / Sodium Phosphate, Monobasic 0.25 MG/ML Injectable Solution; electrolyte-MB in 5 % dextrose Injectable Solution",
C2345491,"glucose 50 MG/ML / magnesium chloride 0.00361 MEQ/ML / monobasic potassium phosphate 0.15 MG/ML / potassium chloride 0.0189 MEQ/ML / sodium lactate 0.0232 MEQ/ML / sodium phosphate, monobasic 0.25 MG/ML [Ionosol-MB]",glucose,,
C2345612,dibasic potassium phosphate / glucose / magnesium chloride / potassium chloride / sodium acetate Injectable Solution,glucose,,
C2345613,dibasic potassium phosphate 0.26 MG/ML / glucose 50 MG/ML / magnesium chloride 0.00373 MEQ/ML / potassium chloride 0.00174 MEQ/ML / sodium acetate 0.039 MEQ/ML Injectable Solution,glucose,Dibasic Pot phosphate 0.26 MG/ML / Glucose 50 MG/ML / Magnesium Chloride 0.00373 MEQ/ML / Pot Chloride 0.00174 MEQ/ML / Sodium Acetate 0.039 MEQ/ML Injectable Solution; Dibasic K+ phosphate 0.26 MG/ML / Glucose 50 MG/ML / Magnesium Chloride 0.00373 MEQ/ML / K+ Chloride 0.00174 MEQ/ML / Sodium Acetate 0.039 MEQ/ML Injectable Solution,
C2345615,dibasic potassium phosphate 0.26 MG/ML / glucose 50 MG/ML / magnesium chloride 0.00373 MEQ/ML / potassium chloride 0.00174 MEQ/ML / sodium acetate 0.039 MEQ/ML [Isolyte P],glucose,,
C2345616,dibasic potassium phosphate / glucose / magnesium chloride / potassium chloride / sodium acetate Injectable Solution [Isolyte P],glucose,,
C2345755,alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 50 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution,glucose,Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 50 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution; Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 50 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution,
C2345756,alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 50 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML [Clinimix E 4.25/5],glucose,,
C2345759,glucose / magnesium acetate / potassium acetate / sodium chloride Injectable Solution,glucose,,
C2345760,glucose 50 MG/ML / magnesium acetate 0.000979 MEQ/ML / potassium acetate 0.013 MEQ/ML / sodium chloride 0.04 MEQ/ML Injectable Solution,glucose,Glucose 50 MG/ML / magnesium acetate 0.000979 MEQ/ML / Pot Acetate 0.013 MEQ/ML / NaCl 0.04 MEQ/ML Injectable Solution; Glucose 50 MG/ML / magnesium acetate 0.000979 MEQ/ML / K+ Acetate 0.013 MEQ/ML / NaCl 0.04 MEQ/ML Injectable Solution; electrolyte-M in 5 % dextrose Injectable Solution,
C2345762,glucose 50 MG/ML / magnesium acetate 0.000979 MEQ/ML / potassium acetate 0.013 MEQ/ML / sodium chloride 0.04 MEQ/ML [Normosol-M],glucose,,
C2345763,glucose / magnesium acetate / potassium acetate / sodium chloride Injectable Solution [Normosol-M],glucose,,
C2345764,alanine 5.7 MG/ML / arginine 3.16 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 50 MG/ML / glycine 2.83 MG/ML / histidine 1.32 MG/ML / isoleucine 1.65 MG/ML / leucine 2.01 MG/ML / lysine 1.59 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.1 MG/ML / phenylalanine 1.54 MG/ML / proline 1.87 MG/ML / serine 1.38 MG/ML / sodium acetate trihydrate 2.17 MG/ML / sodium chloride 0.02 MEQ/ML / threonine 1.16 MG/ML / tryptophan 0.5 MG/ML / tyrosine 0.11 MG/ML / valine 1.6 MG/ML Injectable Solution,glucose,Alanine 5.7 MG/ML / Arginine 3.16 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 50 MG/ML / Glycine 2.83 MG/ML / Histidine 1.32 MG/ML / Isoleucine 1.65 MG/ML / Leucine 2.01 MG/ML / Lysine 1.59 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.1 MG/ML / Phenylalanine 1.54 MG/ML / Proline 1.87 MG/ML / Serine 1.38 MG/ML / Sodium Acetate Trihydrate 2.17 MG/ML / NaCl 0.02 MEQ/ML / Threonine 1.16 MG/ML / Tryptophan 0.5 MG/ML / Tyrosine 0.11 MG/ML / Valine 1.6 MG/ML Injectable Solution; Alanine 5.7 MG/ML / Arginine 3.16 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 50 MG/ML / Glycine 2.83 MG/ML / Histidine 1.32 MG/ML / Isoleucine 1.65 MG/ML / Leucine 2.01 MG/ML / Lysine 1.59 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.1 MG/ML / Phenylalanine 1.54 MG/ML / Proline 1.87 MG/ML / Serine 1.38 MG/ML / Sodium Acetate Trihydrate 2.17 MG/ML / NaCl 0.02 MEQ/ML / Threonine 1.16 MG/ML / Tryptophan 0.5 MG/ML / Tyrosine 0.11 MG/ML / Valine 1.6 MG/ML Injectable Solution,
C2345765,alanine 5.7 MG/ML / arginine 3.16 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 50 MG/ML / glycine 2.83 MG/ML / histidine 1.32 MG/ML / isoleucine 1.65 MG/ML / leucine 2.01 MG/ML / lysine 1.59 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.1 MG/ML / phenylalanine 1.54 MG/ML / proline 1.87 MG/ML / serine 1.38 MG/ML / sodium acetate trihydrate 2.17 MG/ML / sodium chloride 0.02 MEQ/ML / threonine 1.16 MG/ML / tryptophan 0.5 MG/ML / tyrosine 0.11 MG/ML / valine 1.6 MG/ML [Clinimix E 2.75/5],glucose,,
C2345766,alanine 5.7 MG/ML / arginine 3.16 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 100 MG/ML / glycine 2.83 MG/ML / histidine 1.32 MG/ML / isoleucine 1.65 MG/ML / leucine 2.01 MG/ML / lysine 1.59 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.1 MG/ML / phenylalanine 1.54 MG/ML / proline 1.87 MG/ML / serine 1.38 MG/ML / sodium acetate trihydrate 2.17 MG/ML / sodium chloride 0.02 MEQ/ML / threonine 1.16 MG/ML / tryptophan 0.5 MG/ML / tyrosine 0.11 MG/ML / valine 1.6 MG/ML Injectable Solution,glucose,Alanine 5.7 MG/ML / Arginine 3.16 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 100 MG/ML / Glycine 2.83 MG/ML / Histidine 1.32 MG/ML / Isoleucine 1.65 MG/ML / Leucine 2.01 MG/ML / Lysine 1.59 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.1 MG/ML / Phenylalanine 1.54 MG/ML / Proline 1.87 MG/ML / Serine 1.38 MG/ML / Sodium Acetate Trihydrate 2.17 MG/ML / NaCl 0.02 MEQ/ML / Threonine 1.16 MG/ML / Tryptophan 0.5 MG/ML / Tyrosine 0.11 MG/ML / Valine 1.6 MG/ML Injectable Solution; Alanine 5.7 MG/ML / Arginine 3.16 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 100 MG/ML / Glycine 2.83 MG/ML / Histidine 1.32 MG/ML / Isoleucine 1.65 MG/ML / Leucine 2.01 MG/ML / Lysine 1.59 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.1 MG/ML / Phenylalanine 1.54 MG/ML / Proline 1.87 MG/ML / Serine 1.38 MG/ML / Sodium Acetate Trihydrate 2.17 MG/ML / NaCl 0.02 MEQ/ML / Threonine 1.16 MG/ML / Tryptophan 0.5 MG/ML / Tyrosine 0.11 MG/ML / Valine 1.6 MG/ML Injectable Solution,
C2345767,alanine 5.7 MG/ML / arginine 3.16 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 100 MG/ML / glycine 2.83 MG/ML / histidine 1.32 MG/ML / isoleucine 1.65 MG/ML / leucine 2.01 MG/ML / lysine 1.59 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.1 MG/ML / phenylalanine 1.54 MG/ML / proline 1.87 MG/ML / serine 1.38 MG/ML / sodium acetate trihydrate 2.17 MG/ML / sodium chloride 0.02 MEQ/ML / threonine 1.16 MG/ML / tryptophan 0.5 MG/ML / tyrosine 0.11 MG/ML / valine 1.6 MG/ML [Clinimix E 2.75/10],glucose,,
C2345768,alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 250 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution,glucose,Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 250 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution; Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 250 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution,
C2345769,alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 250 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML [Clinimix E 4.25/25],glucose,,
C2345770,alanine 10.4 MG/ML / arginine 5.75 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 150 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / sodium acetate trihydrate 3.4 MG/ML / sodium chloride 0.01 MEQ/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution,glucose,Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 150 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution; Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 150 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution,
C2345771,alanine 10.4 MG/ML / arginine 5.75 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 150 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / sodium acetate trihydrate 3.4 MG/ML / sodium chloride 0.01 MEQ/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML [Clinimix E 5/15],glucose,,
C2345773,glucose / magnesium chloride / potassium chloride / sodium acetate / sodium chloride / sodium gluconate Injectable Solution,glucose,,
C2345774,glucose 50 MG/ML / magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.00497 MEQ/ML / sodium acetate 0.027 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution,glucose,Glucose 50 MG/ML / Magnesium Chloride 0.00148 MEQ/ML / Pot Chloride 0.00497 MEQ/ML / Sodium Acetate 0.027 MEQ/ML / NaCl 0.0899 MEQ/ML / Sodium gluconate 5.02 MG/ML Injectable Solution; Glucose 50 MG/ML / Magnesium Chloride 0.00148 MEQ/ML / K+ Chloride 0.00497 MEQ/ML / Sodium Acetate 0.027 MEQ/ML / NaCl 0.0899 MEQ/ML / Sodium gluconate 5.02 MG/ML Injectable Solution,
C2345775,glucose 50 MG/ML / magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.00497 MEQ/ML / sodium acetate 0.027 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML [Normosol-R in 5 % Dextrose],glucose,,
C2345776,glucose / magnesium chloride / potassium chloride / sodium acetate / sodium chloride / sodium gluconate Injectable Solution [Normosol-R in 5 % Dextrose],glucose,,
C2345777,alanine 10.4 MG/ML / arginine 5.75 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 200 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / sodium acetate trihydrate 3.4 MG/ML / sodium chloride 0.01 MEQ/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution,glucose,Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 200 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution; Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 200 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution,
C2345778,alanine 10.4 MG/ML / arginine 5.75 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 200 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / sodium acetate trihydrate 3.4 MG/ML / sodium chloride 0.01 MEQ/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML [Clinimix E 5/20],glucose,,
C2345779,alanine 10.4 MG/ML / arginine 5.75 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 250 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / sodium acetate trihydrate 3.4 MG/ML / sodium chloride 0.01 MEQ/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML Injectable Solution,glucose,Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 250 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution; Alanine 10.4 MG/ML / Arginine 5.75 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 250 MG/ML / Glycine 5.15 MG/ML / Histidine 2.4 MG/ML / Isoleucine 3 MG/ML / Leucine 3.65 MG/ML / Lysine 2.9 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 2 MG/ML / Phenylalanine 2.8 MG/ML / Proline 3.4 MG/ML / Serine 2.5 MG/ML / Sodium Acetate Trihydrate 3.4 MG/ML / NaCl 0.01 MEQ/ML / Threonine 2.1 MG/ML / Tryptophan 0.9 MG/ML / Tyrosine 0.2 MG/ML / Valine 2.9 MG/ML Injectable Solution,
C2345780,alanine 10.4 MG/ML / arginine 5.75 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 250 MG/ML / glycine 5.15 MG/ML / histidine 2.4 MG/ML / isoleucine 3 MG/ML / leucine 3.65 MG/ML / lysine 2.9 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 2 MG/ML / phenylalanine 2.8 MG/ML / proline 3.4 MG/ML / serine 2.5 MG/ML / sodium acetate trihydrate 3.4 MG/ML / sodium chloride 0.01 MEQ/ML / threonine 2.1 MG/ML / tryptophan 0.9 MG/ML / tyrosine 0.2 MG/ML / valine 2.9 MG/ML [Clinimix E 5/25],glucose,,
C2345937,glucose 50 MG/ML / magnesium acetate 0.0015 MEQ/ML / potassium acetate 0.013 MEQ/ML / sodium chloride 0.04 MEQ/ML Injectable Solution,glucose,electrolyte 56 with 5 % dextrose Injectable Solution; Glucose 50 MG/ML / magnesium acetate 0.0015 MEQ/ML / K+ Acetate 0.013 MEQ/ML / NaCl 0.04 MEQ/ML Injectable Solution; Glucose 50 MG/ML / magnesium acetate 0.0015 MEQ/ML / Pot Acetate 0.013 MEQ/ML / NaCl 0.04 MEQ/ML Injectable Solution,
C2345939,glucose 50 MG/ML / magnesium acetate 0.0015 MEQ/ML / potassium acetate 0.013 MEQ/ML / sodium chloride 0.04 MEQ/ML [Plasma-Lyte 56 in 5 % Dextrose],glucose,,
C2345940,glucose / magnesium acetate / potassium acetate / sodium chloride Injectable Solution [Plasma-Lyte 56 in 5 % Dextrose],glucose,,
C2346355,"glucose / magnesium chloride / potassium chloride / potassium phosphate / sodium acetate / sodium chloride / sodium gluconate / sodium phosphate, dibasic Injectable Solution",glucose,,
C2346356,"glucose 50 MG/ML / magnesium chloride 0.00148 MEQ/ML / monobasic potassium phosphate 0.0082 MG/ML / potassium chloride 0.00497 MEQ/ML / sodium acetate 0.0272 MEQ/ML / sodium chloride 0.0906 MEQ/ML / sodium gluconate 5 MG/ML / sodium phosphate, dibasic 0.12 MG/ML Injectable Solution",glucose,"Glucose 50 MG/ML / Magnesium Chloride 0.00148 MEQ/ML / Monobasic K+ phosphate 0.0082 MG/ML / K+ Chloride 0.00497 MEQ/ML / Sodium Acetate 0.0272 MEQ/ML / NaCl 0.0906 MEQ/ML / Sodium gluconate 5 MG/ML / Sodium Phosphate, Dibasic 0.12 MG/ML Injectable Solution; Glucose 50 MG/ML / Magnesium Chloride 0.00148 MEQ/ML / Monobasic Pot phosphate 0.0082 MG/ML / Pot Chloride 0.00497 MEQ/ML / Sodium Acetate 0.0272 MEQ/ML / NaCl 0.0906 MEQ/ML / Sodium gluconate 5 MG/ML / Sodium Phosphate, Dibasic 0.12 MG/ML Injectable Solution",
C2346357,"glucose 50 MG/ML / magnesium chloride 0.00148 MEQ/ML / monobasic potassium phosphate 0.0082 MG/ML / potassium chloride 0.00497 MEQ/ML / sodium acetate 0.0272 MEQ/ML / sodium chloride 0.0906 MEQ/ML / sodium gluconate 5 MG/ML / sodium phosphate, dibasic 0.12 MG/ML [Isolyte S in 5 % Dextrose]",glucose,,
C2346358,"glucose / magnesium chloride / potassium chloride / potassium phosphate / sodium acetate / sodium chloride / sodium gluconate / sodium phosphate, dibasic Injectable Solution [Isolyte S in 5 % Dextrose]",glucose,,
C2349361,"Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified",diabetes,"Secondary diabetes mellitus, not stated as uncontrolled, or unspecified",
C2349362,"Secondary diabetes mellitus without mention of complication, uncontrolled",diabetes,"Secondary diabetes mellitus, uncontrolled",
C2349363,"Secondary diabetes mellitus, without mention of complication",diabetes,,
C2349364,Secondary diabetes mellitus without mention of complication or manifestation classifiable to 249.1-249.9,diabetes,,
C2349365,"Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified",diabetes,,
C2349366,"Secondary diabetes mellitus with ketoacidosis, uncontrolled",diabetes,,
C2349367,Secondary diabetes mellitus with ketoacidosis,diabetes,,
C2349368,Secondary diabetes mellitus with diabetic acidosis without mention of coma,diabetes,,
C2349369,Secondary diabetes mellitus with diabetic ketosis without mention of coma,diabetes,,
C2349370,"Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified",diabetes,,
C2349371,"Secondary diabetes mellitus with hyperosmolarity, uncontrolled",diabetes,,
C2349372,Secondary diabetes mellitus with hyperosmolarity,diabetes,,
C2349373,Secondary diabetes mellitus with hyperosmolar (nonketotic) coma,diabetes,,
C2349374,"Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified",diabetes,,
C2349375,"Secondary diabetes mellitus with other coma, uncontrolled",diabetes,,
C2349376,Secondary diabetes mellitus with other coma,diabetes,,
C2349377,Secondary diabetes mellitus with diabetic coma (with ketoacidosis),diabetes,,
C2349378,Secondary diabetes mellitus with diabetic hypoglycemic coma,diabetes,,
C2349379,Secondary diabetes mellitus with insulin coma NOS,diabetes,,
C2349380,"Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified",diabetes,,
C2349381,"Secondary diabetes mellitus with renal manifestations, uncontrolled",diabetes,,
C2349382,Secondary diabetes mellitus with renal manifestations,diabetes,,
C2349383,"Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified",diabetes,,
C2349384,"Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled",diabetes,,
C2349385,Secondary diabetes mellitus with ophthalmic manifestations,diabetes,,
C2349386,"Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified",diabetes,,
C2349387,"Secondary diabetes mellitus with neurological manifestations, uncontrolled",diabetes,,
C2349388,Secondary diabetes mellitus with neurological manifestations,diabetes,,
C2349389,"Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified",diabetes,,
C2349390,"Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled",diabetes,,
C2349391,Secondary diabetes mellitus with peripheral circulatory disorders,diabetes,,
C2349392,"Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified",diabetes,,
C2349393,"Secondary diabetes mellitus with other specified manifestations, uncontrolled",diabetes,,
C2349394,Secondary diabetes mellitus with other specified manifestations,diabetes,,
C2349395,Secondary diabetic hypoglycemia in diabetes mellitus,hypoglycemia,,
C2349396,Secondary hypoglycemic shock in diabetes mellitus,diabetes,,
C2349397,"Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified",diabetes,,
C2349398,"Secondary diabetes mellitus with unspecified complication, uncontrolled",diabetes,,
C2349399,Secondary diabetes mellitus with unspecified complication,diabetes,,
C2350189,"1-O-galloyl-3,6-(R)-hexahydroxydiphenol-beta-D-glucose",glucose,,
C2352419,"2-O-galloyl-4,6-(S)-hexahydroxydiphenol-beta-D-glucose",glucose,,
C2352508,"dTDP-3-acetamido-3,6-dideoxy-alpha-D-glucose",glucose,,
C2353867,2-glucose-SNAP,glucose,2-glu-SNAP,
C2359933,Blood glucose monitors attachment:Finding:Point in time:^Patient:Document,blood glucose,Blood glucose monitors attachment:Finding:To identify measures at a point in time:^Patient:Document; Blood glucose monitor attachment; Blood glucose monitors attachment:Find:Pt:^Patient:Doc,
C2359934,Blood glucose monitors attachment,blood glucose,Blood glucose monitors attachment,
C2360268,Glucose:PrThr:Pt:Stool:Ord,glucose,Glucose Stl Ql; Glucose:Presence or Threshold:To identify measures at a point in time:Stool:Ordinal; Glucose Ql (Stl); Glucose [Presence] in Stool,
C2360269,Glucose:SCnc:Pt:BldC:Qn,glucose,Glucose:Substance Concentration:To identify measures at a point in time:Blood capillary:Quantitative; Glucose (BldC) [Moles/Vol]; Glucose [Moles/volume] in Capillary blood; Glucose BldC-sCnc,
C2360270,Glucose^1H post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1 Hr post 75 g glucose PO [Moles/Vol]; Glucose^1 hour post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1h p 75 g Glc PO SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --1 hour post 75 g glucose PO,
C2360464,Glucose^2.5H post dose fructose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --2.5 hours post dose fructose PO; Glucose^2.5 hours post dose fructose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2.5h p fructose PO SerPl-mCnc; Glucose 2.5 Hr post dose fructose PO [Mass/Vol],
C2360465,Glucose^1.5H post dose fructose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1.5 hours post dose fructose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5h p fructose PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose fructose PO; Glucose 1.5 Hr post dose fructose PO [Mass/Vol],
C2360466,Glucose^3H post dose fructose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --3 hours post dose fructose PO; Glucose 3h p fructose PO SerPl-mCnc; Glucose 3 Hr post dose fructose PO [Mass/Vol]; Glucose^3 hours post dose fructose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2360467,Glucose^2H post dose fructose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --2 hours post dose fructose PO; Glucose 2h p fructose PO SerPl-mCnc; Glucose 2 Hr post dose fructose PO [Mass/Vol]; Glucose^2 hours post dose fructose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2361537,Glucose^pre-meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre-meal [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --pre-meal; Glucose^pre-meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre-meal SerPl-mCnc,
C2361538,Glucose:MCnc:Pt:TPN:Qn,glucose,Glucose:Mass Concentration:To identify measures at a point in time:TPN:Quantitative; Glucose (Total parental nutrition) [Mass/Vol]; Glucose [Mass/volume] in Total parental nutrition; Glucose TPN-mCnc,
C2361572,Glucose:SCnc:Pt:Flu.nonbiological:Qn,glucose,Glucose [Moles/volume] in Nonbiological fluid; Glucose:Substance Concentration:To identify measures at a point in time:Flu.nonbiological:Quantitative; Glucose Fld.NB-sCnc; Glucose (Nonbiological fluid) [Moles/Vol],
C2361581,Glucose^post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose post Unsp challenge [Moles/Vol]; Glucose p chal SerPl-sCnc; Glucose^post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --post XXX challenge,
C2361582,Glucose^post meal:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose post meal [Moles/Vol]; Glucose^post meal:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose p meal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --post meal,
C2361597,Glucose^post CFst:SCnc:Pt:Urine:Qn,glucose,Glucose^post Calorie fast:Substance Concentration:To identify measures at a point in time:Urine:Quantitative; Fasting glucose [Moles/volume] in Urine; Glucose post fast (U) [Moles/Vol]; Glucose p fast Ur-sCnc,
C2361848,Glucose:MCnc:Pt:Urine:Qn:Test strip.automated,glucose,Glucose Ur Strip.auto-mCnc; Glucose Auto test strip (U) [Mass/Vol]; Glucose:Mass Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip.automated; Glucose [Mass/volume] in Urine by Automated test strip,
C2362516,Sugar Diabetes,diabetes,Sugar Diabetes,
C2362900,pregnancy complicated by abnormal glucose tolerance with baby delivered,glucose,,
C2363621,"Immunoassay Analyzers, Point-of-Care, Diabetes Management",diabetes,,
C2365314,glucose 50 MG/ML / magnesium chloride 0.003 MEQ/ML / monobasic potassium phosphate 0.00147 MEQ/ML / potassium chloride 0.0189 MEQ/ML / sodium chloride 0.002 MEQ/ML / sodium lactate 0.0232 MEQ/ML Injectable Solution,glucose,"Dextrose 5% and Electrolyte No. 48, Dextrose 5% with Electrolytes (Electrolyte No. 48) intravenous solution; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM LACTATE 260 mg in 100 mL / POTASSIUM CHLORIDE 141 mg in 100 mL / MAGNESIUM CHLORIDE 31 mg in 100 mL / POTASSIUM PHOSPHATE, MONOBASIC 20 mg in 100 mL / SODIUM CHLORIDE 12 mg in 100 mL INTRAVENOUS INJECTION [Dextrose and Electrolyte No. 48]; LVP solution with potassium Dextrose 5% with Electrolytes (Electrolyte No. 48) intravenous solution; glucose 50 MG/mL / magnesium chloride 0.003 MEQ/mL / monobasic potassium phosphate 0.00147 MEQ/mL / potassium chloride 0.0189 MEQ/mL / sodium chloride 0.002 MEQ/mL / sodium lactate 0.0232 MEQ/mL Injectable Solution; Glucose 50 MG/ML / Magnesium Chloride 0.003 MEQ/ML / Monobasic K+ phosphate 0.00147 MEQ/ML / K+ Chloride 0.0189 MEQ/ML / NaCl 0.002 MEQ/ML / Sodium Lactate 0.0232 MEQ/ML Injectable Solution; DEXTROSE 5%/ELECTROLYTE NO.48 INJ; Glucose 50 MG/ML / Magnesium Chloride 0.003 MEQ/ML / Monobasic Pot phosphate 0.00147 MEQ/ML / Pot Chloride 0.0189 MEQ/ML / NaCl 0.002 MEQ/ML / Sodium Lactate 0.0232 MEQ/ML Injectable Solution",
C2369180,BREEZE 2 (GLUCOSE) METER,glucose,Breeze 2 Meter; BREEZE 2 (GLUCOSE) METER,
C2369183,CONTOUR (GLUCOSE) TEST STRIP,glucose,CONTOUR (GLUCOSE) TEST STRIP; Contour Test Strips,
C2369627,CVS Blood Glucose Monitor,blood glucose,,
C2369628,CVS Blood Glucose STRIPS,blood glucose,,
C2369646,CVS Blood Glucose Test Strip,blood glucose,,
C2584434,Plasma glucose concentration,plasma glucose,Plasma glucose concentration (observable entity),
C2584700,300 minute plasma glucose measurement,plasma glucose,300 minute plasma glucose level; 300 minute plasma glucose measurement (procedure),
C2584954,Ambulatory continuous glucose monitoring of interstitial tissue fluid,glucose,Ambulatory continuous glucose monitoring of interstitial tissue fluid (procedure),
C2584988,Glucose concentration in quality control reagent,glucose,Glucose concentration in quality control reagent (observable entity),
C2585037,240 minute plasma glucose measurement,plasma glucose,240 minute plasma glucose level; 240 minute plasma glucose measurement (procedure),
C2585282,Blood glucose concentration,blood glucose,Blood glucose concentration (observable entity),
C2585875,Glucose- and glutathione- and hypromellose-containing product,glucose,Product containing glucose and glutathione and hypromellose (medicinal product),
C2585876,CHADS2 score,diabetes,"Congestive heart failure, hypertension, age 75 years or older, diabetes, and previous stroke or transient ischaemic attack risk score; Congestive heart failure, hypertension, age 75 years or older, diabetes, and previous stroke or transient ischemic attack risk score; Congestive heart failure, hypertension, age 75 years or older, diabetes, and previous stroke or transient ischemic attack risk score (assessment scale)",
C2586119,Interstitial fluid glucose concentration,glucose,Interstitial fluid glucose concentration (observable entity),
C2586163,Dietary education for gestational diabetes,diabetes,Dietary education for gestational diabetes (procedure),
C2586234,Ambulatory continuous glucose monitoring of interstitial tissue fluid with sensor placement,glucose,Ambulatory continuous glucose monitoring of interstitial tissue fluid with sensor placement (procedure),
C2598075,Glucose^20M post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^20 minutes post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 20 Min post 50 g lactose PO [Mass/Vol]; Glucose 20M p 50 g lac PO SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --20 minutes post 50 g lactose PO,
C2598076,Glucose^40M post 50 g lactose PO:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^40M post 50 g lactose Oral:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 40 Min post 50 g lactose PO [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --40 minutes post 50 g lactose PO; Glucose 40M p 50 g lac PO SerPl-mCnc,
C2598404,Estimated average glucose:SCnc:Pt:Bld:Qn:Estimated from glycated hemoglobin,glucose,Average glucose Estimated from glycated hemoglobin (Bld) [Moles/Vol]; Glucose mean value [Moles/volume] in Blood Estimated from glycated hemoglobin; Estimated average glucose:Substance Concentration:To identify measures at a point in time:Whole blood:Quantitative:Estimated from glycated hemoglobin; Est. average glucose Bld gHb Est-sCnc,
C2598578,Glucose^4 AM specimen:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4 AM specimen [Moles/Vol]; Glucose^4 AM specimen:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4 AM specimen SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --4 AM specimen,
C2598579,Glucose^pre dose betaxolol:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre dose betaxolol [Moles/Vol]; Glucose pre betaxolol SerPl-sCnc; Glucose^pre dose betaxolol:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --pre dose betaxolol,
C2598580,Glucose^2H post dose betaxolol:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --2 hours post dose betaxolol; Glucose^2 hours post dose betaxolol:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2 Hr post dose betaxolol [Moles/Vol]; Glucose 2h p betaxolol SerPl-sCnc,
C2598585,Glucose^2.5H post dose betaxolol:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --2.5 hours post dose betaxolol; Glucose^2.5 hours post dose betaxolol:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2.5h p betaxolol SerPl-sCnc; Glucose 2.5 Hr post dose betaxolol [Moles/Vol],
C2598586,Glucose^15M pre dose betaxolol:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose betaxolol; Glucose 15M pre betaxolol SerPl-sCnc; Glucose 15 Min pre dose betaxolol [Moles/Vol]; Glucose^15 minutes pre dose betaxolol:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2598587,Glucose^3H post dose betaxolol:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3h p betaxolol SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --3 hours post dose betaxolol; Glucose^3 hours post dose betaxolol:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3 Hr post dose betaxolol [Moles/Vol],
C2598588,Glucose^30M post dose betaxolol:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose betaxolol; Glucose 30M p betaxolol SerPl-sCnc; Glucose^30 minutes post dose betaxolol:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min post dose betaxolol [Moles/Vol],
C2598589,Glucose^30M pre dose betaxolol:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --30 minutes pre dose betaxolol; Glucose^30 minutes pre dose betaxolol:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min pre dose betaxolol [Moles/Vol]; Glucose 30M pre betaxolol SerPl-sCnc,
C2598590,Glucose^45M post dose betaxolol:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose betaxolol; Glucose 45M p betaxolol SerPl-sCnc; Glucose^45M post dose betaxolol:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 45 Min post dose betaxolol [Moles/Vol],
C2598591,Glucose^1H post dose betaxolol:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p betaxolol SerPl-sCnc; Glucose^1 hour post dose betaxolol:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --1 hour post dose betaxolol; Glucose 1 Hr post dose betaxolol [Moles/Vol],
C2598592,Glucose^1.5H post dose betaxolol:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^1.5 hours post dose betaxolol:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5 Hr post dose betaxolol [Moles/Vol]; Glucose 1.5h p betaxolol SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --1.5 hours post dose betaxolol,
C2599100,Glucose tetrasaccharide/Creatinine:SRto:Pt:Urine:Qn,glucose,Glucose tetrasaccharide/Creat Ur-sRto; Glucose tetrasaccharide/Creatinine:Substance Ratio:To identify measures at a point in time:Urine:Quantitative; Glucose tetrasaccharide/Creatinine [Molar ratio] in Urine; Glucose tetrasaccharide/Creatinine (U) [Molar ratio],
C2599101,Glucose tetrasaccharide/Creatinine,glucose,Glucose tetrasaccharide/Creatinine,
C2599710,Cell count & Differential panel with Glucose & Protein,glucose,Cell count & Differential panel with Glucose & Protein; Cell count and Diff panel with Gluc and Prot,
C2599779,Glucose and Protein,glucose,Glucose & Protein,
C2606059,6-O-octanoyl-D-glucose,glucose,,
C2606407,"THG1L protein, human",high glucose,"tRNA-histidine guanylyltransferase 1 like protein, human; induced in high glucose protein 1, human; IHG-1 protein, human",
C2607836,Glucose [Mass or Molecules/volume] in Serum or Plasma,glucose,Glucose:MSCnc:Pt:Ser/Plas:Qn; Glucose SerPl-msCnc; Glucose [Mass or Moles/volume] in Serum or Plasma; Glucose [Mass or moles/Vol]; Glucose:Mass or Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2607837,Glucose [Mass or Molecules/volume] in Urine,glucose,Glucose:MSCnc:Pt:Urine:Qn; Glucose [Mass or Moles/volume] in Urine; Glucose Ur-msCnc; Glucose:Mass or Substance Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose (U) [Mass or moles/Vol],
C2607838,Glucose [Mass or Molecules/volume] in Serum or Plasma --post CFst,glucose,Glucose^post CFst:MSCnc:Pt:Ser/Plas:Qn; Glucose post fast [Mass or moles/Vol]; Glucose p fast SerPl-msCnc; Fasting glucose [Mass or Moles/volume] in Serum or Plasma; Glucose^post Calorie fast:Mass or Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2607839,Insulin^pre or post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin^pre or post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin pre or post dose glucose [Moles/Vol]; Insulin [Moles/volume] in Serum or Plasma --pre or post dose glucose; Insulin pre/p Glc SerPl-sCnc,
C2608160,TRUE2go Glucose Meter,glucose,,
C2608161,TRUEresult Glucose Meter,glucose,,
C2609565,OPTIUM PLUS (GLUCOSE) TEST STRIP,glucose,OPTIUM PLUS (GLUCOSE) TEST STRIP,
C2611679,UDP-glucose:4-aminobenzoate acylglucosyltransferase activity,glucose,,
C2611680,UDP-glucose:p-aminobenzoate acylglucosyltransferase activity,glucose,,
C2611681,UDP-glucose:p-aminobenzoate glucosyltransferase activity,glucose,,
C2611682,UDP-glucose:pABA acylglucosyltransferase activity,glucose,,
C2611726,ADP-glucose pyrophosphohydrolase activity,glucose,,
C2612126,regulation of glucose transport,glucose,,
C2612127,positive regulation of glucose transport,glucose,,
C2612128,negative regulation of glucose transport,glucose,,
C2612211,regulation of UDP-glucose catabolic process,glucose,regulation of UDP-glucose catabolism,
C2612212,negative regulation of UDP-glucose catabolic process,glucose,negative regulation of UDP-glucose catabolism,
C2612213,regulation of glucose metabolic process,glucose,regulation of glucose metabolism,
C2612214,positive regulation of glucose metabolic process,glucose,positive regulation of glucose metabolism,
C2632021,Sarcoglottis sp. Heidelberg BG 120137,BG,Zhukowskia sp. Heidelberg BG 120137,
C2632814,Epimedium sp. BG-2008a,BG,,
C2632815,Epimedium sp. BG-2008b,BG,,
C2649223,Bacillus sp. BG-B1,BG,,
C2649224,Bacillus sp. BG-B109,BG,,
C2649225,Bacillus sp. BG-B18,BG,,
C2649226,Bacillus sp. BG-B27,BG,,
C2649227,Bacillus sp. BG-B29,BG,,
C2649234,Lysinibacillus sp. BG-B112,BG,,
C2655217,Diplommatina sp. BG,BG,,
C2658669,Clostridium sp. BG-C122,BG,,
C2658670,Clostridium sp. BG-C124,BG,,
C2658671,Clostridium sp. BG-C130,BG,,
C2658672,Clostridium sp. BG-C131,BG,,
C2658673,Clostridium sp. BG-C151,BG,,
C2658674,Clostridium sp. BG-C36,BG,,
C2658675,Clostridium sp. BG-C4,BG,,
C2658676,Clostridium sp. BG-C51,BG,,
C2658677,Clostridium sp. BG-C66,BG,,
C2658678,Clostridium sp. BG-C8,BG,,
C2658679,Clostridium sp. BG-C9,BG,,
C2666085,Epimedium sp. BG-2009,BG,,
C2673520,"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7 (finding)",diabetes,"PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO; MVCD7; MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7; NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO; NONPROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO",
C2673637,Hypo- and demyelination of the brain,hypo,,
C2674665,"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5 (finding)",diabetes,"RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO; MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5; MVCD5",
C2675066,Lymphedema-Distichiasis Syndrome with Renal Disease and Diabetes Mellitus,diabetes,LYMPHEDEMA-DISTICHIASIS SYNDROME WITH RENAL DISEASE AND DIABETES MELLITUS,
C2675112,"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 4 (finding)",diabetes,"MVCD4; MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 4; NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO",
C2675128,"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 6 (finding)",diabetes,"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 6; MVCD6; NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO",
C2675470,"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3 (finding)",diabetes,"MVCD3; END-STAGE RENAL DISEASE, DIABETIC, SUSCEPTIBILITY TO; MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3; NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO",
C2675471,"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 2 (finding)",diabetes,"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 2; PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO; MVCD2; END-STAGE RENAL DISEASE, DIABETIC, SUSCEPTIBILITY TO",
C2675472,"Diabetes Mellitus, Insulin-Dependent, 23",diabetes,"DIABETES MELLITUS, INSULIN-DEPENDENT, 23; TYPE 1 DIABETES MELLITUS 23; T1D23; IDDM23",
C2675864,"DIABETES MELLITUS, INSULIN-DEPENDENT, 22 (disorder)",diabetes,"IDDM22; Diabetes Mellitus, Insulin-Dependent, 22; TYPE 1 DIABETES MELLITUS 22; T1D22; DIABETES MELLITUS, INSULIN-DEPENDENT, 22",
C2675865,"DIABETES MELLITUS, INSULIN-DEPENDENT, 21 (disorder)",diabetes,"DIABETES MELLITUS, INSULIN-DEPENDENT, 21; TYPE 1 DIABETES MELLITUS 21; Diabetes Mellitus, Insulin-Dependent, 21; T1D21; IDDM21",
C2675866,"DIABETES MELLITUS, INSULIN-DEPENDENT, 20 (disorder)",diabetes,"T1D20; DIABETES MELLITUS, INSULIN-DEPENDENT, 20; Diabetes Mellitus, Insulin-Dependent, 20; IDDM20; TYPE 1 DIABETES MELLITUS 20",
C2676338,Transient neonatal hypoglycemia (2p21del),hypoglycemia,,
C2676663,Hypo- or areflexia,hypo,,
C2676832,"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1(finding)",diabetes,"MVCD1; MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1",
C2676833,"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO",diabetes,,
C2677132,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 9 (disorder)",diabetes,"Maturity-onset diabetes of the young, type 9; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 9; Maturity-Onset Diabetes Of The Young, Type 9; Maturity-onset diabetes of the young, type 9 (disorder); MODY9",
C2677501,FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 1,plasma glucose,FGQTL1,
C2678519,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 3, GLY92ASP (allelic variant)",diabetes,"HNF1A, GLY92ASP",
C2682818,Prodigy Voice Blood Glucose Monitoring System,blood glucose,,
C2683373,FORA V12 Blood Glucose Monitoring System,blood glucose,,
C2683374,FORA V10 Blood Glucose Meter,blood glucose,,
C2683375,FORA D10 Blood Glucose Test Strips,blood glucose,,
C2683376,FORA V12 Blood Glucose Test Strips,blood glucose,,
C2683377,FORA V22 Blood Glucose Monitoring System,blood glucose,,
C2683580,FORA V10 Blood Glucose Test Strips,blood glucose,FORA V10 Blood Glucose Test Strip,
C2684090,PRECISION PCX PLUS (GLUCOSE) TEST STRIP,glucose,PRECISION PCX PLUS (GLUCOSE) TEST STRIP,
C2684139,ACCUTREND (GLUCOSE) TEST STRIP,glucose,ACCUTREND (GLUCOSE) TEST STRIP; Accutrend Glucose Test Strips,
C2684475,glucose 254 MG/ML,glucose,,
C2684476,glucose 254 MG/ML Oral Solution,glucose,"DEXTROSE 15GM/59ML ORAL LIQUID; glucose 250 MG/ML Oral Solution; glucose 15 GM per 2 OZ Oral Solution; TRUEplus Glucose Shot, 25% oral liquid; DEXTROSE 15GM/59ML LIQUID,ORAL; dextrose 25 % Oral Solution; CVS Glucose Shot Grape, 25% oral liquid; Good Sense Grape Glucose, 25% oral liquid; Relion Shot Berry Twist, 25% oral liquid; Good Sense Berry Twist Glucose, 25% oral liquid; glucose 15 GM in 2 FL OZ Oral Solution; glucose 15 GM / 59 ML Oral Solution; CVS Glucose Shot Berry, 25% oral liquid; glucose 15 GM / 60 ML Oral Solution; glucose 25% oral liquid",
C2697505,Glucose to Creatinine Ratio Measurement,glucose,Glucose to Creatinine Ratio Measurement,
C2698187,Astrocytic Phosphoprotein PEA-15,diabetes,Phosphoprotein Enriched In Diabetes; Astrocytic Phosphoprotein PEA-15; PED,
C2699249,SLC5A1 wt Allele,glucose,"SLC5A1 wt Allele; Sodium/Glucose Cotransporter 1 Gene; Sodium-Glucose Cotransporter, Intestinal Gene; D22S675; NAGT; Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 1 wt Allele; SGLT1; Na+/Glucose Cotransporter, High Affinity Gene",
C2703060,elevated random blood glucose level,glucose level,,
C2706793,Cell count & Differential panel with Glucose & Protein:-:Pt:CSF:Qn,glucose,Cell count and Diff panel with Gluc and Prot (CSF); Cell count & Differential panel with Glucose & Protein:-:To identify measures at a point in time:Cerebral spinal fluid:Quantitative; Cell cnt & Diff Pnl with Glu & Prot CSF; Cell count and Diff panel with Gluc and Prot - Cerebral spinal fluid,
C2706797,Cell count & Differential panel with Glucose & Protein:-:Pt:Body fld:-,glucose,"Cell cnt & Diff Pnl with Glu & Prot Fld; Cell count and Diff panel with Gluc and Prot (Body fld); Cell count & Differential panel with Glucose & Protein:-:To identify measures at a point in time:Body fluid, unsp:-; Cell count and Diff panel with Gluc and Prot - Body fluid",
C2706809,Protein & Glucose panel:MCnc:Pt:Body fld:Qn,glucose,"Protein and Glucose panel [Mass/volume] - Body fluid; Protein and Glucose panel (Body fld) [Mass/Vol]; Protein & Glucose panel:Mass Concentration:To identify measures at a point in time:Body fluid, unsp:Quantitative; Prot + Glucose Pnl Fld-mCnc",
C2706811,Glucose^10M pre dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 10M pre Gc SerPl-sCnc; Glucose 10 Min pre dose glucagon [Moles/Vol]; Glucose^10 minutes pre dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --10 minutes pre dose glucagon,
C2706812,Glucose^15M post dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 15M p Gc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose glucagon; Glucose^15 minutes post dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15 Min post dose glucagon [Moles/Vol],
C2706813,Glucose^15M pre dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 15 Min pre dose glucagon [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose glucagon; Glucose 15M pre Gc SerPl-sCnc; Glucose^15 minutes pre dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2706814,Glucose^20M post dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^20 minutes post dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 20M p Gc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --20 minutes post dose glucagon; Glucose 20 Min post dose glucagon [Moles/Vol],
C2706815,Glucose^2M post dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2M p Gc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --2 minutes post dose glucagon; Glucose 2 Min post dose glucagon [Moles/Vol]; Glucose^2 minutes post dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2706816,Glucose^4M post dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4M p Gc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --4 minutes post dose glucagon; Glucose 4 Min post dose glucagon [Moles/Vol]; Glucose^4 minutes post dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2706817,Glucose^5M pre dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --5 minutes pre dose glucagon; Glucose 5 Min pre dose glucagon [Moles/Vol]; Glucose^5 minutes pre dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5M pre Gc SerPl-sCnc,
C2706818,Glucose^6M post dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 6M p Gc SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --6 minutes post dose glucagon; Glucose 6 Min post dose glucagon [Moles/Vol]; Glucose^6 minutes post dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2706819,Glucose^8M post dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 8M p Gc SerPl-sCnc; Glucose^8 minutes post dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 8 Min post dose glucagon [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --8 minutes post dose glucagon,
C2706820,Glucose^pre dose insulin IV:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^pre dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre Ins IV SerPl-sCnc; Glucose pre dose insulin IV [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --pre dose insulin IV,
C2706821,Glucose^2 hours post dose insulin Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Glucose^2H post dose insulin IV:SCnc:Pt:Ser/Plas:Qn; Glucose 2 Hr post dose insulin IV [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --2 hours post dose insulin IV; Glucose 2h p Ins IV SerPl-sCnc; Glucose^2 hours post dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2706822,Glucose^2 1/2 hours post dose insulin Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Glucose^2.5 hours post dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2.5h p Ins IV SerPl-sCnc; Glucose 2.5 Hr post dose insulin IV [Moles/Vol]; Glucose^2.5H post dose insulin IV:SCnc:Pt:Ser/Plas:Qn; Glucose [Moles/volume] in Serum or Plasma --2.5 hours post dose insulin IV,
C2706823,Glucose^15 minutes post dose insulin Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose insulin IV; Glucose 15M p Ins IV SerPl-sCnc; Glucose^15M post dose insulin IV:SCnc:Pt:Ser/Plas:Qn; Glucose^15 minutes post dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15 Min post dose insulin IV [Moles/Vol],
C2706824,Glucose^15M pre dose insulin IV:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^15 minutes pre dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose insulin IV; Glucose 15 Min pre dose insulin IV [Moles/Vol]; Glucose 15M pre Ins IV SerPl-sCnc,
C2706825,Glucose^3H pre dose insulin IV:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3 Hr pre dose insulin IV [Moles/Vol]; Glucose 3h pre Ins IV SerPl-sCnc; Glucose^3 hours pre dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --3 hours pre dose insulin IV,
C2706826,Glucose^30 minutes post dose insulin Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Glucose 30M p Ins IV SerPl-sCnc; Glucose 30 Min post dose insulin IV [Moles/Vol]; Glucose^30M post dose insulin IV:SCnc:Pt:Ser/Plas:Qn; Glucose^30 minutes post dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose insulin IV,
C2706827,Glucose^45M post dose insulin Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Glucose^45M post dose insulin IV:SCnc:Pt:Ser/Plas:Qn; Glucose^45M post dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 45M p Ins IV SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose insulin IV; Glucose 45 Min post dose insulin IV [Moles/Vol],
C2706828,Glucose^1 hour post dose insulin Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Glucose [Moles/volume] in Serum or Plasma --1 hour post dose insulin IV; Glucose^1 hour post dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose^1H post dose insulin IV:SCnc:Pt:Ser/Plas:Qn; Glucose 1 Hr post dose insulin IV [Moles/Vol]; Glucose 1h p Ins IV SerPl-sCnc,
C2706829,Glucose^1.3H post dose insulin IV:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.3h p Ins IV SerPl-sCnc; Glucose 1.3 Hr post dose insulin IV [Moles/Vol]; Glucose^1.3 hours post dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --1.3 hours post dose insulin IV,
C2706830,Glucose^1.5H post dose insulin IV:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5 Hr post dose insulin IV [Moles/Vol]; Glucose 1.5h p Ins IV SerPl-sCnc; Glucose^1.5 hours post dose insulin Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --1.5 hours post dose insulin IV,
C2706831,Glucose^pre dose ornithine alpha-ketoglutarate:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre OKG SerPl-sCnc; Glucose^pre dose ornithine alpha-ketoglutarate:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre dose ornithine alpha-ketoglutarate [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --pre dose ornithine alpha-ketoglutarate,
C2706832,Glucose^2H post dose ornithine alpha-ketoglutarate:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2 hours post dose ornithine alpha-ketoglutarate:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2h p OKG SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --2 hour post dose ornithine alpha-ketoglutarate; Glucose 2 Hr post dose ornithine alpha-ketoglutarate [Moles/Vol],
C2706833,Glucose^2.5H post dose ornithine alpha-ketoglutarate:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --2.5 hour post dose ornithine alpha-ketoglutarate; Glucose 2.5h p OKG SerPl-sCnc; Glucose^2.5 hours post dose ornithine alpha-ketoglutarate:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2.5rHr post dose ornithine alpha-ketoglutarate [Moles/Vol],
C2706834,Glucose^15M post dose ornithine alpha-ketoglutarate:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^15 minutes post dose ornithine alpha-ketoglutarate:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose ornithine alpha-ketoglutarate; Glucose 15 Min post dose ornithine alpha-ketoglutarate [Moles/Vol]; Glucose 15M p OKG SerPl-sCnc,
C2706835,Glucose^15M pre dose ornithine alpha-ketoglutarate:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --15 minutes pre dose ornithine alpha-ketoglutarate; Glucose 15 Min pre dose ornithine alpha-ketoglutarate [Moles/Vol]; Glucose 15M pre OKG SerPl-sCnc; Glucose^15 minutes pre dose ornithine alpha-ketoglutarate:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2706836,Glucose^3H post dose ornithine alpha-ketoglutarate:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^3 hours post dose ornithine alpha-ketoglutarate:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3 Hr post dose ornithine alpha-ketoglutarate [Moles/Vol]; Glucose 3h p OKG SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --3 hours post dose ornithine alpha-ketoglutarate,
C2706837,Glucose^30M post dose ornithine alpha-ketoglutarate:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --30 minutes post dose ornithine alpha-ketoglutarate; Glucose^30 minutes post dose ornithine alpha-ketoglutarate:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min post dose ornithine alpha-ketoglutarate [Moles/Vol]; Glucose 30M p OKG SerPl-sCnc,
C2706838,Glucose^45M post dose ornithine alpha-ketoglutarate:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^45M post dose ornithine alpha-ketoglutarate:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 45 Min post dose ornithine alpha-ketoglutarate [Moles/Vol]; Glucose 45M p OKG SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --45 minutes post dose ornithine alpha-ketoglutarate,
C2706839,Glucose^1H post dose ornithine alpha-ketoglutarate:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1 Hr post dose ornithine alpha-ketoglutarate [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --1 hour post dose ornithine alpha-ketoglutarate; Glucose 1h p OKG SerPl-sCnc; Glucose^1 hour post dose ornithine alpha-ketoglutarate:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2706840,Glucose^1.5H post dose ornithine alpha-ketoglutarate:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5h p OKG SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --1.5 hour post dose ornithine alpha-ketoglutarate; Glucose 1.5 Hr post dose ornithine alpha-ketoglutarate [Moles/Vol]; Glucose^1.5 hours post dose ornithine alpha-ketoglutarate:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2706901,Glucose^post dialysis:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^post dialysis:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --post dialysis; Glucose p dialysis SerPl-sCnc; Glucose post dialysis [Moles/Vol],
C2706902,Glucose^5th specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5th specimen post Unsp challenge [Moles/Vol]; Glucose sp5 p chal SerPl-sCnc; Glucose^5th specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --5th specimen post XXX challenge,
C2706903,Glucose^6th specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 6th specimen post Unsp challenge [Moles/Vol]; Glucose^6th specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --6th specimen post XXX challenge; Glucose sp6 p chal SerPl-sCnc,
C2706904,Glucose^7th specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose sp7 p chal SerPl-sCnc; Glucose 7th specimen post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --7th specimen post XXX challenge; Glucose^7th specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2706905,Glucose^8th specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose sp8 p chal SerPl-sCnc; Glucose^8th specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --8th specimen post XXX challenge; Glucose 8th specimen post Unsp challenge [Moles/Vol],
C2707118,Glucose^1st specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose sp1 p chal SerPl-sCnc; Glucose 1st specimen post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --1st specimen post XXX challenge; Glucose^1st specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2707119,Glucose^10th specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose sp10 p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --10th specimen post XXX challenge; Glucose^10th specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 10th specimen post Unsp challenge [Moles/Vol],
C2707120,Glucose^11th specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --11th specimen post XXX challenge; Glucose sp11 p chal SerPl-sCnc; Glucose^11th specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 11th specimen post Unsp challenge [Moles/Vol],
C2707121,Glucose^12th specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose sp12 p chal SerPl-sCnc; Glucose^12th specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 12th specimen post Unsp challenge [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --12th specimen post XXX challenge,
C2707122,Glucose^2nd specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2nd specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --2nd specimen post XXX challenge; Glucose 2nd specimen post Unsp challenge [Moles/Vol]; Glucose sp2 p chal SerPl-sCnc,
C2707123,Glucose^3rd specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3rd specimen post Unsp challenge [Moles/Vol]; Glucose sp3 p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --3rd specimen post XXX challenge; Glucose^3rd specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2707124,Glucose^4th specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4th specimen post Unsp challenge [Moles/Vol]; Glucose^4th specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose sp4 p chal SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --4th specimen post XXX challenge,
C2707125,Glucose^9th specimen post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose sp9 p chal SerPl-sCnc; Glucose^9th specimen post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --9th specimen post XXX challenge; Glucose 9th specimen post Unsp challenge [Moles/Vol],
C2707126,Glucose^pre dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --pre dose glucagon; Glucose^pre dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose pre Gc SerPl-sCnc; Glucose pre dose glucagon [Moles/Vol],
C2707127,Glucose^10M post dose glucagon:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 10M p Gc SerPl-sCnc; Glucose^10 minutes post dose glucagon:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --10 minutes post dose glucagon; Glucose 10 Min post dose glucagon [Moles/Vol],
C2707235,Glucose:MCnc:Pt:Water:Qn,glucose,Glucose (Water) [Mass/Vol]; Glucose [Mass/volume] in Water; Glucose Wat-mCnc; Glucose:Mass Concentration:To identify measures at a point in time:Water:Quantitative,
C2707236,Glucose:SCnc:Pt:Water:Qn,glucose,Glucose [Moles/volume] in Water; Glucose Wat-sCnc; Glucose:Substance Concentration:To identify measures at a point in time:Water:Quantitative; Glucose (Water) [Moles/Vol],
C2708581,Glucose^1.5H post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --1.5 hours post 75 g glucose PO; Glucose 1.5h p 75 g Glc PO SerPl-sCnc; Glucose 1.5 Hr post 75 g glucose PO [Moles/Vol]; Glucose^1.5 hours post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2708582,Glucose^45M post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --45 minutes post 75 g glucose PO; Glucose 45 Min post 75 g glucose PO [Moles/Vol]; Glucose 45M p 75 g Glc PO SerPl-sCnc; Glucose^45M post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2708621,Glucose^2.5H post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2.5h p 75 g Glc PO SerPl-sCnc; Glucose^2.5 hours post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2.5 Hr post 75 g glucose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --2.5 hours post 75 g glucose PO,
C2708634,Protein & Glucose panel:-:Pt:CSF:Qn,glucose,Protein & Glucose panel:-:To identify measures at a point in time:Cerebral spinal fluid:Quantitative; Protein and Glucose panel (CSF); Protein and Glucose panel - Cerebral spinal fluid; Prot + Glucose Pnl CSF,
C2708643,Diabetes tracking panel:-:Point in time:^Patient:-,diabetes,Diabetes tracking Pnl; Diabetes tracking panel:-:Pt:^Patient:-; Diabetes tracking panel:-:To identify measures at a point in time:^Patient:-; Diabetes tracking panel,
C2708644,Diabetes tracking panel,diabetes,Diabetes tracking panel,
C2708759,Insulin^7M post dose glucose IV:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin [Moles/volume] in Serum or Plasma --7 minutes post dose glucose IV; Insulin 7M p Glc IV SerPl-sCnc; Insulin^7 minutes post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 7 Min post dose glucose IV [Moles/Vol],
C2708760,Insulin^5M pre dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin [Moles/volume] in Serum or Plasma --5 minutes pre dose glucose; Insulin 5 Min pre dose glucose [Moles/Vol]; Insulin^5 minutes pre dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 5M pre Glc SerPl-sCnc,
C2708761,Insulin^10M pre dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin^10 minutes pre dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 10 Min pre dose glucose [Moles/Vol]; Insulin 10M pre Glc SerPl-sCnc; Insulin [Moles/volume] in Serum or Plasma --10 minutes pre dose glucose,
C2708762,Insulin^4H post dose glucose IV:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin^4 hours post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 4 Hr post dose glucose IV [Moles/Vol]; Insulin 4h p Glc IV SerPl-sCnc; Insulin [Moles/volume] in Serum or Plasma --4 hours post dose glucose IV,
C2708763,Insulin^1.5H post dose glucose IV:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin 1.5h p Glc IV SerPl-sCnc; Insulin^1.5 hours post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 1.5 Hr post dose glucose IV [Moles/Vol]; Insulin [Moles/volume] in Serum or Plasma --1.5 hours post dose glucose IV,
C2708764,Insulin^10M post dose glucose IV:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin 10M p Glc IV SerPl-sCnc; Insulin [Moles/volume] in Serum or Plasma --10 minutes post dose glucose IV; Insulin^10 minutes post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 10 Min post dose glucose IV [Moles/Vol],
C2708765,Insulin^1 hour post dose glucose Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Insulin [Moles/volume] in Serum or Plasma --1 hour post dose glucose IV; Insulin^1H post dose glucose IV:SCnc:Pt:Ser/Plas:Qn; Insulin 1 Hr post dose glucose IV [Moles/Vol]; Insulin^1 hour post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 1h p Glc IV SerPl-sCnc,
C2708766,Insulin^1M post dose glucose IV:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin^1 minute post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 1M p Glc IV SerPl-sCnc; Insulin [Moles/volume] in Serum or Plasma --1 minute post dose glucose IV; Insulin 1 Min e post dose glucose IV [Moles/Vol],
C2708767,Insulin^2 1/2 hours post dose glucose Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Insulin 2.5h p Glc IV SerPl-sCnc; Insulin 2.5 Hr post dose glucose IV [Moles/Vol]; Insulin [Moles/volume] in Serum or Plasma --2.5 hours post dose glucose IV; Insulin^2.5H post dose glucose IV:SCnc:Pt:Ser/Plas:Qn; Insulin^2.5 hours post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2708772,Insulin^30 minutes post dose glucose Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Insulin^30M post dose glucose IV:SCnc:Pt:Ser/Plas:Qn; Insulin [Moles/volume] in Serum or Plasma --30 minutes post dose glucose IV; Insulin 30 Min post dose glucose IV [Moles/Vol]; Insulin 30M p Glc IV SerPl-sCnc; Insulin^30 minutes post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2708773,Insulin^3H post dose glucose IV:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin [Moles/volume] in Serum or Plasma --3 hours post dose glucose IV; Insulin 3 Hr post dose glucose IV [Moles/Vol]; Insulin 3hp Glc IV SerPl-sCnc; Insulin^3 hours post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2708774,Insulin^5M post dose glucose IV:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin 5M p Glc IV SerPl-sCnc; Insulin [Moles/volume] in Serum or Plasma --5 minutes post dose glucose IV; Insulin^5 minutes post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 5 Min post dose glucose IV [Moles/Vol],
C2708775,Insulin^45M post dose glucose Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Insulin 45 Min post dose glucose IV [Moles/Vol]; Insulin^45M post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin^45M post dose glucose IV:SCnc:Pt:Ser/Plas:Qn; Insulin 45M p Glc IV SerPl-sCnc; Insulin [Moles/volume] in Serum or Plasma --45 minutes post dose glucose IV,
C2708776,Insulin^2 hours post dose glucose Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Insulin [Moles/volume] in Serum or Plasma --2 hours post dose glucose IV; Insulin 2 Hr post dose glucose IV [Moles/Vol]; Insulin^2 hours post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 2h p Glc IV SerPl-sCnc; Insulin^2H post dose glucose IV:SCnc:Pt:Ser/Plas:Qn,
C2708777,Insulin^3M post dose glucose IV:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin [Moles/volume] in Serum or Plasma --3 minutes post dose glucose IV; Insulin^3 minutes post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 3 Min post dose glucose IV [Moles/Vol]; Insulin 3M p Glc IV SerPl-sCnc,
C2708778,Insulin^7M pre dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin 7M pre Glc SerPl-sCnc; Insulin [Moles/volume] in Serum or Plasma --7 minutes pre dose glucose; Insulin 7 Min pre dose glucose [Moles/Vol]; Insulin^7 minutes pre dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2708779,Insulin^15 minutes post dose glucose Intravenous:Substance Concentration:Point in time:Serum/Plasma:Quantitative,glucose,Insulin^15 minutes post dose glucose Intravenous:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin [Moles/volume] in Serum or Plasma --15 minutes post dose glucose IV; Insulin 15M p Glc IV SerPl-sCnc; Insulin^15M post dose glucose IV:SCnc:Pt:Ser/Plas:Qn; Insulin 15 Min post dose glucose IV [Moles/Vol],
C2708785,Somatotropin^30M post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin 30 Min post dose glucose [Mass/Vol]; GH 30M p Glc SerPl-mCnc; Somatotropin^30 minutes post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Somatotropin [Mass/volume] in Serum or Plasma --30 minutes post dose glucose,
C2708787,Somatotropin^2H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin^2 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose glucose; Somatotropin 2 Hr post dose glucose [Mass/Vol]; GH 2h p Glc SerPl-mCnc,
C2708788,Somatotropin^1H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,GH 1h p Glc SerPl-mCnc; Somatotropin 1 Hr post dose glucose [Mass/Vol]; Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose glucose; Somatotropin^1 hour post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2708790,Somatotropin^1.5H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin^1.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Somatotropin 1.5 Hr post dose glucose [Mass/Vol]; Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post dose glucose; GH 1.5h p Glc SerPl-mCnc,
C2709012,1.5 hours post dose glucose IV,glucose,1.5H post dose glucose IV,
C2709014,10 minutes post dose glucose IV,glucose,10M post dose glucose IV,
C2709016,15 minutes post dose glucose IV,glucose,15M post dose glucose IV,
C2709017,1 hour post dose glucose IV,glucose,1H post dose glucose IV,
C2709018,1 minute post dose glucose IV,glucose,1M post dose glucose IV,
C2709019,2.5 hours post dose glucose IV,glucose,2.5H post dose glucose IV,
C2709022,2 hours post dose glucose IV,glucose,2H post dose glucose IV,
C2709024,30 minutes post dose glucose IV,glucose,30M post dose glucose IV,
C2709025,3 hours post dose glucose IV,glucose,3H post dose glucose IV,
C2709026,3 minutes post dose glucose IV,glucose,3M post dose glucose IV,
C2709028,45 minutes post 75 g glucose PO,glucose,45M post 75 g glucose PO,
C2709030,45 minutes post dose glucose IV,glucose,45M post dose glucose IV,
C2709031,4 hours post dose glucose IV,glucose,4H post dose glucose IV,
C2709033,5 minutes post dose glucose IV,glucose,5M post dose glucose IV,
C2709035,7 minutes post dose glucose IV,glucose,7M post dose glucose IV,
C2709036,7 minutes pre dose glucose,glucose,7M pre dose glucose,
C2710369,10 ML Glucose 25 MG/ML Prefilled Syringe,glucose,,
C2711012,Random blood glucose abnormal,blood glucose,Random blood glucose abnormal (finding),
C2711084,Hyperglycemic crisis due to diabetes mellitus,diabetes,Hyperglycemic crisis due to diabetes mellitus (disorder); Hyperglycemic crisis in diabetes mellitus; Hyperglycaemic crisis in diabetes mellitus; Hyperglycaemic crisis due to diabetes mellitus,
C2711175,Measurement of fasting glucose in urine specimen using dipstick,glucose,Measurement of fasting glucose in urine specimen using dipstick (procedure),
C2711661,Measurement of glucose 1 hour after glucose challenge for glucose tolerance test,glucose,Measurement of glucose 1 hour after glucose challenge for glucose tolerance test (procedure),
C2711723,Measurement of glucose 4 hours after glucose challenge for glucose tolerance test,glucose,Measurement of glucose 4 hours after glucose challenge for glucose tolerance test (procedure),
C2711841,Measurement of protein and glucose in urine specimen using reagent test strip,glucose,Measurement of protein and glucose in urine specimen using reagent test strip (procedure),
C2713143,Deprecated Glucose [Mass/volume] in Serum or Plasma --1 hour post dose insulin IV,glucose,Glucose 1 Hr post dose U/kg insulin IV (P) [Mass/Vol],
C2713144,Deprecated Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose insulin IV,glucose,Glucose 30 Min post dose U/kg insulin IV (P) [Mass/Vol],
C2714504,rutinose,glucose,6-O-(6-deoxy-alpha-L-mannopyranosyl)-D-glucose,
C2715470,"glucose-6-acrylate-1,2,3,4-tetraacetate",glucose,GATA tetraacetate cpd,
C2717148,undecaprenyl phosphate-glucose,glucose,,
C2718131,Deprecated Glucose [Mass/volume] in Serum or Plasma,glucose,Glucose [Mass/Vol],
C2722783,FEEDING BAG UNIVERSAL FBG#1000,FBG,FEEDING BAG UNIVERSAL FBG#1000,
C2723455,ONE TOUCH SELECT (GLUCOSE) CONTROL SOLN,glucose,ONE TOUCH SELECT (GLUCOSE) CONTROL SOLN,
C2723456,ONE TOUCH SELECT (GLUCOSE) METER,glucose,ONE TOUCH SELECT (GLUCOSE) METER,
C2723457,ONE TOUCH SELECT (GLUCOSE) TEST STRIP,glucose,ONE TOUCH SELECT (GLUCOSE) TEST STRIP,
C2723458,ONE TOUCH SELECT HIGH (GLUCOSE) CONTROL SOLN,high glucose,ONE TOUCH SELECT HIGH GLUCOSE CNTRL SOLN,
C2723881,calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution,glucose,,
C2723882,calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal PD-2/4.25],glucose,,
C2723883,calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal PD-2/1.5],glucose,,
C2723884,calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal PD-2/2.5],glucose,,
C2723885,calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 4.25],glucose,,
C2723886,calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 2.5],glucose,,
C2723887,calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5],glucose,,
C2723888,"dibasic potassium phosphate / glucose / lactate / magnesium chloride / potassium chloride / sodium chloride / sodium phosphate, monobasic Injectable Solution",glucose,,
C2723889,"dibasic potassium phosphate / glucose / lactate / magnesium chloride / potassium chloride / sodium chloride / sodium phosphate, monobasic Injectable Solution [Ionosol-B]",glucose,,
C2723890,"glucose / lactate / magnesium chloride / potassium chloride / potassium phosphate / sodium phosphate, monobasic Injectable Solution",glucose,,
C2723891,"glucose / lactate / magnesium chloride / potassium chloride / potassium phosphate / sodium phosphate, monobasic Injectable Solution [Ionosol-MB]",glucose,,
C2723900,glucose / lactate / magnesium chloride / potassium chloride / potassium phosphate / sodium chloride Injectable Solution,glucose,,
C2724146,calcium chloride / glucose / lactate / potassium chloride / sodium chloride Injectable Solution,glucose,,
C2725303,FREESTYLE FREEDOM LITE (GLUCOSE) METER,glucose,FREESTYLE FREEDOM LITE (GLUCOSE) METER; FreeStyle Freedom Lite NFRS,
C2726683,A1C Now Self Check Kit,a1c,,
C2726746,WAVESENSE (GLUCOSE) NORMAL CONTROL SOLN,glucose,WAVESENSE (GLUCOSE) NORMAL CONTROL SOLN,
C2726747,WAVESENSE KEYNOTE (GLUCOSE) TEST STRIP,glucose,WAVESENSE KEYNOTE (GLUCOSE) TEST STRIP,
C2726748,WAVESENSE PRESTO (GLUCOSE) TEST STRIP,glucose,WAVESENSE PRESTO (GLUCOSE) TEST STRIP,
C2729625,glucose 1000 MG,glucose,,
C2729626,glucose 1000 MG Chewable Tablet,glucose,glucose 1 GM Chewable Tablet; dextrose 1 GM Chewable Tablet,
C2732249,Quantitative measurement of glucose in pleural fluid specimen,glucose,Quantitative measurement of mass concentration of glucose in pleural fluid specimen; Quantitative measurement of mass concentration of glucose in pleural fluid specimen (procedure),
C2732342,History of diabetes mellitus in child of subject,diabetes,History of diabetes mellitus in child of subject (situation),
C2732395,Quantitative measurement of concentration of glucose in peritoneal dialysis fluid at 4 hours postperitoneal dialysis,glucose,Quantitative measurement of mass concentration of glucose in peritoneal dialysis fluid specimen at 4 hours postperitoneal dialysis; Quantitative measurement of mass concentration of glucose in peritoneal dialysis fluid specimen at 4 hours postperitoneal dialysis (procedure),
C2732401,Type 1 diabetes mellitus well controlled,diabetes,Type I diabetes mellitus well controlled (finding); Type I diabetes mellitus well controlled,
C2732402,Type 1 diabetes mellitus uncontrolled,diabetes,Type I diabetes mellitus poorly controlled; Type I diabetes mellitus uncontrolled (finding); Type I diabetes mellitus uncontrolled,
C2732668,"Urea, electrolytes and glucose measurement",glucose measurement,"Measurement of urea, sodium, potassium, chloride, bicarbonate and glucose; Measurement of urea, sodium, potassium, chloride, bicarbonate and glucose (procedure)",
C2732678,Finnish diabetes risk score,diabetes,FINDRISC (Finnish Diabetes Risk Score) score; Finnish diabetes risk score (assessment scale); Finnish Diabetes Risk Score; Finnish Diabetes Risk Score (observable entity),
C2732700,Quantitative measurement of glucose in pericardial fluid specimen,glucose,Quantitative measurement of mass concentration of glucose in pericardial fluid specimen; Quantitative measurement of mass concentration of glucose in pericardial fluid specimen (procedure),
C2732716,Quantitative measurement of mass concentration of glucose in postcalorie fasting serum or plasma,glucose,Quantitative measurement of mass concentration of glucose in postcalorie fasting serum or plasma specimen (procedure); Quantitative measurement of mass concentration of glucose in postcalorie fasting serum or plasma specimen,
C2732794,Quantitative measurement of glucose in 1 hour postprandial urine specimen,glucose,Quantitative measurement of mass concentration of glucose in 1 hour postprandial urine specimen; Quantitative measurement of mass concentration of glucose in 1 hour postprandial urine specimen (procedure),
C2732796,Quantitative measurement of glucose in 24 hour urine specimen,glucose,Quantitative measurement of mass rate of excretion of glucose in 24 hour urine specimen; Quantitative measurement of mass rate of excretion of glucose in 24 hour urine specimen (procedure),
C2732804,Quantitative measurement of glucose in synovial fluid specimen,glucose,Quantitative measurement of mass concentration of glucose in synovial fluid specimen (procedure); Quantitative measurement of mass concentration of glucose in synovial fluid specimen,
C2732844,Quantitative measurement of glucose in serum or plasma specimen 120 minutes after 75 gram oral glucose challenge,glucose,Quantitative measurement of mass concentration of glucose in serum or plasma specimen 120 minutes after 75 gram oral glucose challenge; Quantitative measurement of mass concentration of glucose in serum or plasma specimen 120 minutes after 75 gram oral glucose challenge (procedure),
C2732897,Quantitative measurement of glucose in peritoneal dialysis fluid specimen,glucose,Quantitative measurement of mass concentration of glucose in peritoneal dialysis fluid specimen (procedure); Quantitative measurement of mass concentration of glucose in peritoneal dialysis fluid specimen,
C2732911,Quantitative measurement of glucose in predialysis peritoneal dialysis fluid specimen,glucose,Quantitative measurement of mass concentration of glucose in predialysis peritoneal dialysis fluid specimen; Quantitative measurement of mass concentration of glucose in predialysis peritoneal dialysis fluid specimen (procedure),
C2733070,Quantitative measurement of glucose in serum or plasma specimen 6 hours after glucose challenge,glucose,Quantitative measurement of mass concentration of glucose in serum or plasma specimen 6 hours after glucose challenge; Quantitative measurement of mass concentration of glucose in serum or plasma specimen 6 hours after glucose challenge (procedure),
C2733143,Quantitative measurement of substance rate of glucose excretion in urine,glucose,Quantitative measurement of substance rate of glucose excretion in urine specimen (procedure); Quantitative measurement of substance rate of glucose excretion in urine specimen,
C2733146,Type II diabetes mellitus uncontrolled,diabetes,Type II diabetes mellitus poorly controlled; Type II diabetes mellitus uncontrolled (finding); Type 2 diabetes mellitus uncontrolled,
C2733147,Type 2 diabetes mellitus well controlled,diabetes,Type II diabetes mellitus well controlled; Type II diabetes mellitus well controlled (finding),
C2733278,Quantitative measurement of mass concentration of creatinine corrected for glucose concentration in overnight peritoneal dialysis fluid,glucose,Quantitative measurement of mass concentration of creatinine corrected for glucose concentration in overnight peritoneal dialysis fluid specimen; Quantitative measurement of mass concentration of creatinine corrected for glucose concentration in overnight peritoneal dialysis fluid specimen (procedure),
C2733345,Quantitative measurement of glucose in first peritoneal dialysis fluid specimen,glucose,Quantitative measurement of mass concentration of glucose in first peritoneal dialysis fluid specimen (procedure); Quantitative measurement of mass concentration of glucose in first peritoneal dialysis fluid specimen,
C2733523,Ordinal level of hemoglobin A1c (observable entity),a1c,Ordinal level of hemoglobin A1c; Ordinal level of haemoglobin A1c; Ordinal level of hemoglobin A1c (observable entity),
C2733832,Glucose:MRat:24H:Stool:Qn,glucose,Glucose (24H Stl) [Mass/Time]; Glucose 24h Stl-mRate; Glucose:Mass Rate:24 hours:Stool:Quantitative; Glucose [Mass/time] in 24 hour Stool,
C2734078,Glucose^1H post meal:MCnc:Pt:Urine:Qn,glucose,Glucose 1h p meal Ur-mCnc; Glucose^1 hour post meal:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 1 Hr post meal (U) [Mass/Vol]; Glucose [Mass/volume] in Urine --1 hour post meal,
C2734133,Glucose^4H post peritoneal dialysis:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose 4 Hr post PD (Perit dial fld) [Mass/Vol]; Glucose [Mass/volume] in Peritoneal dialysis fluid --4 hours post peritoneal dialysis; Glucose^4 hours post peritoneal dialysis:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose 4h p PD DiafP-mCnc,
C2734972,Glucose^2.17H post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2.17H post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --2.17 hours post XXX challenge; Glucose 2.17 Hr post Unsp challenge [Mass/Vol]; Glucose 2.17h p chal SerPl-mCnc,
C2735220,Hydrogen/Expired gas^30M post dose glucose:VFr:Pt:Exhl gas:Qn,glucose,Hydrogen/Expired gas^30 minutes post dose glucose:Volume Fraction:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Breath H2 30M p Glc; Hydrogen/Expired gas [Volume Fraction] in Exhaled gas --30 minutes post dose glucose; Hydrogen/Expired gas 30 Min post dose glucose (Exhl gas) [Volume fraction],
C2735273,Glucose/Creatinine:MRto:24H:Urine:Qn,glucose,Glucose/Creat 24h Ur; Glucose/Creatinine [Mass Ratio] in 24 hour Urine; Glucose/Creatinine:Mass Ratio:24 hours:Urine:Quantitative; Glucose/Creatinine (24H U) [Mass ratio],
C2735474,Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion:Text:Point in time:Blood filter paper:Narrative,glucose,Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion:Txt:Pt:Bld.dot:Nar; Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion; G6PD NBS comment; Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion:Text:To identify measures at a point in time:Dried blood spot:Narrative; G6PD newborn screening comment-discussion Nar (DBS),
C2735475,Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion,glucose,Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion; Glucose-6-Phosphate dehydrogenase newborn screening comment/discussion,
C2735476,Glucose-6-Phosphate dehydrogenase newborn screen panel:-:Point in time:Blood filter paper:-,glucose,G6PD NBS pnl DBS; G6PD NBS panel (DBS); Glucose-6-Phosphate dehydrogenase newborn screen panel; Glucose-6-Phosphate dehydrogenase newborn screen panel:-:To identify measures at a point in time:Dried blood spot:-; Glucose-6-Phosphate dehydrogenase newborn screen panel:-:Pt:Bld.dot:-,
C2735477,Glucose-6-Phosphate dehydrogenase newborn screen panel,glucose,Glucose-6-Phosphate dehydrogenase newborn screen panel,
C2735752,Glucose^1M post XXX challenge:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1 Min post Unsp challenge [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --1 minute post XXX challenge; Glucose 1M p chal SerPl-mCnc; Glucose^1 minute post XXX challenge:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2736040,Glucose:MCnc:Pt:Stool:Qn:Post hydrolysis,glucose,Glucose Stl Post hydrolysis-mCnc; Glucose p hydrolysis (Stl) [Mass/Vol]; Glucose:Mass Concentration:To identify measures at a point in time:Stool:Quantitative:Post hydrolysis; Glucose [Mass/volume] in Stool by Post hydrolysis,
C2736333,B little g super little a Ab:PrThr:Pt:Ser/Plas:Ord,BG,Bg sup(a) Ab SerPl Ql; Bg sup(a) Ab Ql; Bg^a Antibody:Presence or Threshold:To identify measures at a point in time:Serum/Plasma:Ordinal; Bg sup(a) Ab [Presence] in Serum or Plasma,
C2736335,B little g super little a Ab:Titr:Pt:Ser/Plas:Qn,BG,Bg^a Antibody:Dilution Factor (Titer):To identify measures at a point in time:Serum/Plasma:Quantitative; Bg sup(a) Ab [Titer]; Bg sup(a) Ab [Titer] in Serum or Plasma; Bg sup(a) Ab Titr SerPl,
C2736336,B little g super little a Ag:PrThr:Pt:RBC:Ord,BG,Bg sup(a) Ag RBC Ql; Bg sup(a) Ag Ql (RBC); Bg sup(a) Ag [Presence] on Red Blood Cells; Bg^a Antigen:Presence or Threshold:To identify measures at a point in time:Erythrocytes:Ordinal,
C2736395,Glucose^3H post 75 g glucose PO:MCnc:Pt:Urine:Qn,glucose,Glucose [Mass/volume] in Urine --3 hours post 75 g glucose PO; Glucose 3h p 75 g Glc PO Ur-mCnc; Glucose^3 hours post 75 g glucose Oral:Mass Concentration:To identify measures at a point in time:Urine:Quantitative; Glucose 3 Hr post 75 g glucose PO (U) [Mass/Vol],
C2736396,Glucose^4th specimen post dose lactose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4sp p Lact SerPl-mCnc; Glucose 4th specimen post lactose [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --4th specimen post lactose; Glucose^4th specimen post dose lactose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2736397,Glucose^5th specimen post dose lactose:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --5th specimen post lactose; Glucose^5th specimen post dose lactose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5sp p Lact SerPl-mCnc; Glucose 5th specimen post lactose [Mass/Vol],
C2736579,Glucose-6-Phosphate dehydrogenase:Imp:Pt:Bld.dot:Nar,glucose,G6PD Nar (DBS) [Interp]; Glucose-6-Phosphate dehydrogenase:Impression/interpretation of study:To identify measures at a point in time:Dried blood spot:Narrative; G6PD DBS-Imp; Glucose-6-Phosphate dehydrogenase newborn screen interpretation,
C2736907,Bg^a,BG,B little g super little a,
C2736988,Diabetes mellitus in last 7D,diabetes,Diabetes mellitus in last 7D; Diabetes mellitus in last 7 days,
C2737023,Glucose screen gestational panel,glucose,Glucose screen gestational panel,
C2739366,Diabetes mellitus in last 7D:Find:7D:^Patient:Ord:MDSv3,diabetes,Diabetes mellitus in last 7D:Finding:7 days:^Patient:Ordinal:MDSv3; Diabetes mellitus in last 7 days [MDSv3],
C2741711,"3,4',5-tri(glucose-3-O-succinyl)resveratrol",glucose,,
C2741712,"3,4',5-tri(alpha-D-glucose-3-O-succinyl)resveratrol",glucose,,
C2743699,"SLC2A13 protein, mouse",glucose,"HMIT protein, mouse; solute carrier family 2 (facilitated glucose transporter), member 13 protein, mouse",
C2746731,FORA G20 (GLUCOSE) TEST STRIP,blood glucose,FORA G20 (GLUCOSE) TEST STRIP; FORA G20 Blood Glucose Test Strips; Fora G20 Blood Glucose Test Strip,
C2746732,FORA V20 Blood Glucose Test Strips,blood glucose,,
C2746733,FORA G20 Blood Glucose Monitoring System,blood glucose,,
C2746734,FORA D15g Blood Glucose plus Blood Pressure M,blood glucose,,
C2746812,Publix Glucose Assorted Flavors,glucose,,
C2746881,FORA D15g Blood Glucose Test Strips,blood glucose,,
C2748662,Mitchell-Riley Syndrome,diabetes,"Mitchell-Riley Syndrome; MITCHELL-RILEY SYNDROME; MTCHRS; DIABETES, NEONATAL, WITH PANCREATIC HYPOPLASIA, INTESTINAL ATRESIA, AND GALLBLADDER APLASIA OR HYPOPLASIA",
C2749736,Lethargy associated with hypoglycemia,hypoglycemia,,
C2749737,Encephalopathy associated with hypoglycemia,hypoglycemia,,
C2750485,FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 3,plasma glucose,FGQTL3,
C2750735,FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 2,plasma glucose,FGQTL2,
C2751630,Dursun Syndrome,glucose,"Scn4; NEUTROPENIA, SEVERE CONGENITAL, 4, AUTOSOMAL RECESSIVE; Severe congenital neutropenia-pulmonary hypertension-superficial venous angiectasis syndrome; Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency; SCN4; Neutropenia, Severe Congenital, 4, Autosomal Recessive; Neutropenia, Severe Congenital, Autosomal Recessive 4; Dursun Syndrome; Autosomal recessive severe congenital neutropenia due to glucose-6-phosphatase catalytic subunit 3 deficiency (disorder); Severe congenital neutropenia, pulmonary hypertension, superficial venous angiectasis syndrome; Pulmonary Arterial Hypertension, Leukopenia, And Atrial Septal Defect; Severe Congenital Neutropenia Type 4, Autosomal Recessive; PULMONARY ARTERIAL HYPERTENSION, LEUKOPENIA, AND ATRIAL SEPTAL DEFECT; Autosomal recessive severe congenital neutropenia due to glucose-6-phosphatase catalytic subunit 3 deficiency; Severe congenital neutropenia type 4; DURSUN SYNDROME",
C2751697,"Diabetes Mellitus, Insulin-Dependent, 24",diabetes,"IDDM24; DIABETES MELLITUS, INSULIN-DEPENDENT, 24; T1D24; TYPE 1 DIABETES MELLITUS 24",
C2752405,intestinal D-glucose absorption,glucose,,
C2754534,cellular response to glucose stimulus,glucose,,
C2754682,cellular hypotonic response,hypo,cellular hypo-osmotic response,
C2755291,GDP-D-glucose phosphorylase activity,glucose,,
C2756217,ReliOn Blood Glucose Monitor,blood glucose,,
C2756218,ReliOn Blood Glucose Strip,blood glucose,,
C2756219,ReliOn Confirm Blood Glucose Monitor,blood glucose,,
C2756221,ReliOn Micro Blood Glucose Monitor,blood glucose,,
C2756222,ReliOn Ultima Glucose Monitor,glucose,,
C2756258,Glucagon Emergency Kit for Low Blood Sugar,blood sugar,,
C2756259,GNP Glucose Orange,glucose,,
C2761242,Carex aff. petitiana BG-2008,BG,Carex aff. longipedunculata BG-2008,
C2771624,Fergusobia sp. FBG E. obliqua,FBG,,
C2784895,Fissistigma cf. acuminatissimum BG-2009,BG,,
C2820024,Bacillus sp. BG-CS10,BG,,
C2825162,Fasting Blood Sugar Measurement,blood sugar,Fasting Blood Sugar; Fasting Blood Sugar Measurement,
C2827448,Childhood Diabetes Mellitus,diabetes,,
C2828133,Hyperglycemia Artifact,hyperglycemia,,
C2830475,Impaired glucose tolerance test (oral),glucose,,
C2874119,Diabetes mellitus type 2 with periodontal disease,diabetes,Periodontal disease co-occurrent and due to diabetes mellitus type 2 (disorder); Periodontal disease co-occurrent and due to diabetes mellitus type 2,
C2874124,Diabetes mellitus due to genetic defect in insulin action,diabetes,Diabetes mellitus due to genetic defect in insulin action (disorder),
C2874125,Diabetes mellitus due to genetic defect in beta cell function,diabetes,Diabetes mellitus due to genetic defect in beta cell function (disorder),
C2903681,Gestational diabetes mellitus in childbirth,diabetes,Gestational diabetes mellitus in childbirth (disorder),
C2912120,FORA D10 Blood Glucose Monitoring System,blood glucose,,
C2912126,FORA V20 Blood Glucose Monitoring System,blood glucose,,
C2917807,Fifty50 2.0 Glucose Meter,glucose,,
C2917808,Fifty50 2.0 Glucose Strip,glucose,,
C2918470,Fifty50 Glucose Control Solution,glucose,,
C2919021,Diabetes mellitus during pregnancy - baby not yet delivered,diabetes,Diabetes mellitus during pregnancy - baby not yet delivered (disorder),
C2919264,Glucose transporter protein type 1 deficiency syndrome,glucose,Glucose transporter protein type 1 deficiency syndrome (disorder),
C2919365,Macroalbuminuric nephropathy due to diabetes mellitus,diabetes,Overt diabetic nephropathy; Macroalbuminuric diabetic nephropathy; Macroalbuminuric nephropathy due to diabetes mellitus (disorder),
C2919432,Glucose in blood specimen above reference range,glucose level,Glucose in blood specimen above reference range; Blood glucose level above normal; Hyperglycemia; Glucose in blood specimen above reference range (finding); Blood glucose concentration increased above normal; Blood glucose increased above normal; High glucose level in blood; Blood glucose increased,
C2919483,High hemoglobin A1c level,a1c,Hemoglobin A1c above reference range (finding); Haemoglobin A1c above reference range; Hemoglobin A1c above reference range; High haemoglobin A1c level,
C2919615,Posttransplant diabetes mellitus,diabetes,Posttransplant diabetes mellitus (disorder),
C2919778,Diabetes mellitus service,diabetes,Diabetes mellitus service (qualifier value),
C2919796,Glycogen storage disease type Ia,glucose,GLYCOGEN STORAGE DISEASE Ia; Glycogen storage disease type Ia; VON GIERKE DISEASE; Glycogen storage disease type IA; GSD1; Von Gierke Disease; GSD1A; Glucose-6 Phosphatase Deficiency; Hepatorenal form of glycogen storage disease; HEPATORENAL GLYCOGENOSIS; Glycogen storage disease type Ia (disorder); GSD Ia; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE; GLUCOSE-6-PHOSPHATASE DEFICIENCY; Hepatorenal Glycogenosis; Glycogen Storage Disease Type Ia; GLYCOGEN STORAGE DISEASE I; Hepatorenal glycogenosis,
C2919802,Brittle type 2 diabetes mellitus,diabetes,Labile type II diabetes mellitus; Brittle type II diabetes mellitus; Brittle type II diabetes mellitus (finding); Unstable type II diabetes mellitus,
C2920019,Acura Blood Glucose Starter Kit,blood glucose,,
C2920021,Acura Blood Glucose Meter Kit,blood glucose,,
C2920026,FORA G71a Blood Glucose Monitoring System,blood glucose,,
C2920117,FORA G71a Blood Glucose Test Strips,blood glucose,FORA G71a Blood Glucose Test Strip,
C2923326,Glucose:MRat:18H:Urine:Qn,glucose,Glucose:Mass Rate:18 hours:Urine:Quantitative; Glucose (18H U) [Mass/Time]; Glucose [Mass/time] in 18 hour Urine; Glucose 18h Ur-mRate,
C2923561,Glucose^11 AM specimen:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 11 AM specimen [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --11 AM specimen; Glucose^11 AM specimen:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 11 AM SerPl-sCnc,
C2923562,Glucose^7 AM specimen:SCnc:Pt:BldC:Qn:Glucometer,glucose,Glucose 7 AM BldC Glucomtr-sCnc; Glucose [Moles/volume] in Capillary blood by Glucometer --7 AM specimen; Glucose 7 AM specimen Glucometer (BldC) [Moles/Vol]; Glucose^7 AM specimen:Substance Concentration:To identify measures at a point in time:Blood capillary:Quantitative:Glucometer,
C2923563,Glucose^7 AM specimen:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^7 AM specimen:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 7 AM specimen [Moles/Vol]; Glucose 7 AM SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --7 AM specimen,
C2923665,Hemoglobin A1c/Hemoglobin.total:SFr:Pt:Bld:Qn:IFCC,a1c,Hemoglobin A1c/Hemoglobin.total:Substance Fraction:To identify measures at a point in time:Whole blood:Quantitative:IFCC; Hemoglobin A1c/Hemoglobin.total in Blood by IFCC protocol; HbA1c IFCC protocol (Bld) [Molar fraction]; HbA1c SFr Bld IFCC,
C2924053,Glucose^30M post XXX challenge:SCncDiff:Pt:Ser/Plas:Qn,glucose,Glucose 30M p chal SerPl-SCDiff; Glucose [Molar concentration difference] in Serum or Plasma --30 minutes post XXX challenge; Glucose^30 minutes post XXX challenge:Difference in Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min post Unsp challenge [Molar conc diff],
C2924054,Glucose^1H post XXX challenge:SCncDiff:Pt:Ser/Plas:Qn,glucose,Glucose 1 Hr post Unsp challenge [Molar conc diff]; Glucose [Molar concentration difference] in Serum or Plasma --1 hour post XXX challenge; Glucose^1 hour post XXX challenge:Difference in Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1h p chal SerPl-SCDiff,
C2924055,Glucose^1.5H post XXX challenge:SCncDiff:Pt:Ser/Plas:Qn,glucose,Glucose 1.5h p chal SerPl-SCDiff; Glucose^1.5 hours post XXX challenge:Difference in Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Molar concentration difference] in Serum or Plasma --1.5 hours post XXX challenge; Glucose 1.5 Hr post Unsp challenge [Molar conc diff],
C2924056,Glucose^2H post XXX challenge:SCncDiff:Pt:Ser/Plas:Qn,glucose,Glucose 2 Hr post Unsp challenge [Molar conc diff]; Glucose [Molar concentration difference] in Serum or Plasma --2 hours post XXX challenge; Glucose^2 hours post XXX challenge:Difference in Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2h p chal SerPl-SCDiff,
C2924057,Glucose^3H post XXX challenge:SCncDiff:Pt:Ser/Plas:Qn,glucose,Glucose 3 Hr post Unsp challenge [Molar conc diff]; Glucose^3 hours post XXX challenge:Difference in Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3h p chal SerPl-SCDiff; Glucose [Molar concentration difference] in Serum or Plasma --3 hours post XXX challenge,
C2924058,Glucose^4H post XXX challenge:SCncDiff:Pt:Ser/Plas:Qn,glucose,Glucose^4 hours post XXX challenge:Difference in Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 4 Hr post Unsp challenge [Molar conc diff]; Glucose 4h p chal SerPl-SCDiff; Glucose [Molar concentration difference] in Serum or Plasma --4 hours post XXX challenge,
C2924059,Glucose^5H post XXX challenge:SCncDiff:Pt:Ser/Plas:Qn,glucose,Glucose 5 Hr post Unsp challenge [Molar conc diff]; Glucose^5 hours post XXX challenge:Difference in Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 5h p chal SerPl-SCDiff; Glucose [Molar concentration difference] in Serum or Plasma --5 hours post XXX challenge,
C2924063,Glucose^3 PM specimen:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^3 PM specimen:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 3 PM specimen [Moles/Vol]; Glucose 3 PM SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --3 PM specimen,
C2925729,Glucose:SCnc:Pt:Urine:Qn:Test strip.automated,glucose,Glucose [Moles/volume] in Urine by Automated test strip; Glucose Auto test strip (U) [Moles/Vol]; Glucose Ur Strip.auto-sCnc; Glucose:Substance Concentration:To identify measures at a point in time:Urine:Quantitative:Test strip.automated,
C2925730,Glucose^pre dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --pre dose lactose PO; Glucose pre Lac PO SerPl-sCnc; Glucose pre dose lactose PO [Moles/Vol]; Glucose^pre dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2925954,C peptide^1.5H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide 1.5 Hr post dose glucose [Mass/Vol]; C peptide^1.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Mass/volume] in Serum or Plasma --1.5 hours post dose glucose; C peptide 1.5h p Glc SerPl-mCnc,
C2926035,C peptide^2H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide 2h p Glc SerPl-mCnc; C peptide 2 Hr post dose glucose [Mass/Vol]; C peptide^2 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Mass/volume] in Serum or Plasma --2 hours post dose glucose,
C2926249,C peptide^15M post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide 15 Min post dose glucose [Mass/Vol]; C peptide [Mass/volume] in Serum or Plasma --15 minutes post dose glucose; C peptide^15 minutes post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 15M p Glc SerPl-mCnc,
C2926252,C peptide^1H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide 1 Hr post dose glucose [Mass/Vol]; C peptide [Mass/volume] in Serum or Plasma --1 hour post dose glucose; C peptide 1h p Glc SerPl-mCnc; C peptide^1 hour post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2926254,C peptide^2.5H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide^2.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Mass/volume] in Serum or Plasma --2.5 hours post dose glucose; C peptide 2.5 Hr post dose glucose [Mass/Vol]; C peptide 2.5h p Glc SerPl-mCnc,
C2926255,C peptide^2.5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide 2.5 Hr post dose glucose [Moles/Vol]; C peptide^2.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 2.5h p Glc SerPl-sCnc; C peptide [Moles/volume] in Serum or Plasma --2.5 hours post dose glucose,
C2926257,C peptide^3.5H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide^3.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 3.5h p Glc SerPl-mCnc; C peptide [Mass/volume] in Serum or Plasma --3.5 hours post dose glucose; C peptide 3.5 Hr post dose glucose [Mass/Vol],
C2926258,C peptide^3.5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide 3.5h p Glc SerPl-sCnc; C peptide 3.5 Hr post dose glucose [Moles/Vol]; C peptide^3.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Moles/volume] in Serum or Plasma --3.5 hours post dose glucose,
C2926259,C peptide^30M post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide 30 Min post dose glucose [Mass/Vol]; C peptide^30 minutes post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 30M p Glc SerPl-mCnc; C peptide [Mass/volume] in Serum or Plasma --30 minutes post dose glucose,
C2926260,C peptide^3H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide^3 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 3 Hr post dose glucose [Mass/Vol]; C peptide 3h p Glc SerPl-mCnc; C peptide [Mass/volume] in Serum or Plasma --3 hours post dose glucose,
C2926261,C peptide^4.5H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide [Mass/volume] in Serum or Plasma --4.5 hours post dose glucose; C peptide^4.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 4.5 Hr post dose glucose [Mass/Vol]; C peptide 4.5h p Glc SerPl-mCnc,
C2926262,C peptide^4.5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide 4.5 Hr post dose glucose [Moles/Vol]; C peptide [Moles/volume] in Serum or Plasma --4.5 hours post dose glucose; C peptide^4.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 4.5h p Glc SerPl-sCnc,
C2926263,C peptide^45M post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide 45 Min post dose glucose [Mass/Vol]; C peptide 45M p Glc SerPl-mCnc; C peptide^45M post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Mass/volume] in Serum or Plasma --45 minutes post dose glucose,
C2926264,C peptide^45M post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide^45M post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 45M p Glc SerPl-sCnc; C peptide [Moles/volume] in Serum or Plasma --45 minutes post dose glucose; C peptide 45 Min post dose glucose [Moles/Vol],
C2926265,C peptide^4H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide^4 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide 4 Hr post dose glucose [Mass/Vol]; C peptide [Mass/volume] in Serum or Plasma --4 hours post dose glucose; C peptide 4h p Glc SerPl-mCnc,
C2926266,C peptide^4H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide 4 Hr post dose glucose [Moles/Vol]; C peptide^4 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Moles/volume] in Serum or Plasma --4 hours post dose glucose; C peptide 4h p Glc SerPl-sCnc,
C2926267,C peptide^5H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide 5 Hr post dose glucose [Mass/Vol]; C peptide [Mass/volume] in Serum or Plasma --5 hours post dose glucose; C peptide 5h p Glc SerPl-mCnc; C peptide^5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C2926268,C peptide^5H post dose glucose:SCnc:Pt:Ser/Plas:Qn,glucose,C peptide 5h p Glc SerPl-sCnc; C peptide^5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide [Moles/volume] in Serum or Plasma --5 hours post dose glucose; C peptide 5 Hr post dose glucose [Moles/Vol],
C2926271,C peptide^pre dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,C peptide [Mass/volume] in Serum or Plasma --pre dose glucose; C peptide pre dose glucose [Mass/Vol]; C peptide^pre dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; C peptide pre Glc SerPl-mCnc,
C2926277,Corticotropin^1.5H post dose glucose:MCnc:Pt:Plas:Qn,glucose,Corticotropin^1.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Plasma:Quantitative; Corticotropin 1.5 Hr post dose glucose (P) [Mass/Vol]; Corticotropin [Mass/volume] in Plasma --1.5 hours post dose glucose; ACTH 1.5h p Glc Plas-mCnc,
C2926278,Corticotropin^1.5H post dose glucose:SCnc:Pt:Plas:Qn,glucose,Corticotropin 1.5 Hr post dose glucose (P) [Moles/Vol]; ACTH 1.5h p Glc Plas-sCnc; Corticotropin^1.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Plasma:Quantitative; Corticotropin [Moles/volume] in Plasma --1.5 hours post dose glucose,
C2926298,Corticotropin^1H post dose glucose:MCnc:Pt:Plas:Qn,glucose,Corticotropin [Mass/volume] in Plasma --1 hour post dose glucose; Corticotropin^1 hour post dose glucose:Mass Concentration:To identify measures at a point in time:Plasma:Quantitative; ACTH 1h p Glc Plas-mCnc; Corticotropin 1 Hr post dose glucose (P) [Mass/Vol],
C2926299,Corticotropin^1H post dose glucose:SCnc:Pt:Plas:Qn,glucose,ACTH 1h p Glc Plas-sCnc; Corticotropin 1 Hr post dose glucose (P) [Moles/Vol]; Corticotropin [Moles/volume] in Plasma --1 hour post dose glucose; Corticotropin^1 hour post dose glucose:Substance Concentration:To identify measures at a point in time:Plasma:Quantitative,
C2926309,Corticotropin^2.5H post dose glucose:MCnc:Pt:Plas:Qn,glucose,Corticotropin 2.5 Hr post dose glucose (P) [Mass/Vol]; ACTH 2.5h p Glc Plas-mCnc; Corticotropin [Mass/volume] in Plasma --2.5 hours post dose glucose; Corticotropin^2.5 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Plasma:Quantitative,
C2926310,Corticotropin^2.5H post dose glucose:SCnc:Pt:Plas:Qn,glucose,Corticotropin^2.5 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Plasma:Quantitative; Corticotropin 2.5 Hr post dose glucose (P) [Moles/Vol]; ACTH 2.5h p Glc Plas-sCnc; Corticotropin [Moles/volume] in Plasma --2.5 hours post dose glucose,
C2926316,Corticotropin^2H post dose glucose:MCnc:Pt:Plas:Qn,glucose,Corticotropin^2 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Plasma:Quantitative; Corticotropin [Mass/volume] in Plasma --2 hours post dose glucose; ACTH 2h p Glc Plas-mCnc; Corticotropin 2 Hr post dose glucose (P) [Mass/Vol],
C2926317,Corticotropin^2H post dose glucose:SCnc:Pt:Plas:Qn,glucose,Corticotropin 2 Hr post dose glucose (P) [Moles/Vol]; Corticotropin^2 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Plasma:Quantitative; ACTH 2h p Glc Plas-sCnc; Corticotropin [Moles/volume] in Plasma --2 hours post dose glucose,
C2926325,Corticotropin^30M post dose glucose:MCnc:Pt:Plas:Qn,glucose,Corticotropin 30 Min post dose glucose (P) [Mass/Vol]; Corticotropin [Mass/volume] in Plasma --30 minutes post dose glucose; Corticotropin^30 minutes post dose glucose:Mass Concentration:To identify measures at a point in time:Plasma:Quantitative; ACTH 30M p Glc Plas-mCnc,
C2926326,Corticotropin^30M post dose glucose:SCnc:Pt:Plas:Qn,glucose,Corticotropin [Moles/volume] in Plasma --30 minutes post dose glucose; Corticotropin^30 minutes post dose glucose:Substance Concentration:To identify measures at a point in time:Plasma:Quantitative; Corticotropin 30 Min post dose glucose (P) [Moles/Vol]; ACTH 30M p Glc Plas-sCnc,
C2926338,Corticotropin^3H post dose glucose:MCnc:Pt:Plas:Qn,glucose,Corticotropin [Mass/volume] in Plasma --3 hours post dose glucose; Corticotropin^3 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Plasma:Quantitative; Corticotropin 3 Hr post dose glucose (P) [Mass/Vol]; ACTH 3h p Glc Plas-mCnc,
C2926339,Corticotropin^3H post dose glucose:SCnc:Pt:Plas:Qn,glucose,Corticotropin 3 Hr post dose glucose (P) [Moles/Vol]; Corticotropin [Moles/volume] in Plasma --3 hours post dose glucose; Corticotropin^3 hours post dose glucose:Substance Concentration:To identify measures at a point in time:Plasma:Quantitative; ACTH 3h p Glc Plas-sCnc,
C2926366,Corticotropin^pre dose glucose:MCnc:Pt:Plas:Qn,glucose,Corticotropin [Mass/volume] in Plasma --pre dose glucose; ACTH pre Glc Plas-mCnc; Corticotropin pre dose glucose (P) [Mass/Vol]; Corticotropin^pre dose glucose:Mass Concentration:To identify measures at a point in time:Plasma:Quantitative,
C2926367,Corticotropin^pre dose glucose:SCnc:Pt:Plas:Qn,glucose,Corticotropin [Moles/volume] in Plasma --pre dose glucose; Corticotropin^pre dose glucose:Substance Concentration:To identify measures at a point in time:Plasma:Quantitative; ACTH pre Glc Plas-sCnc; Corticotropin pre dose glucose (P) [Moles/Vol],
C2927184,CONTOUR (GLUCOSE) HIGH CONTROL SOLN,glucose,CONTOUR (GLUCOSE) HIGH CONTROL SOLN,
C2927336,FORA G71a Blood Glucose Monitoring System-gre,blood glucose,,
C2927417,CONTOUR (GLUCOSE) LOW CONTROL SOLN,glucose,CONTOUR (GLUCOSE) LOW CONTROL SOLN,
C2927422,Didget Blood Glucose Monitor,blood glucose,,
C2927563,FORA G71a Blood Glucose Monitoring System-ora,blood glucose,,
C2927564,FORA G71a Blood Glucose Monitoring System-pin,blood glucose,,
C2927831,ethanol / glucose,glucose,,
C2927969,calcium chloride / glucose / lactate / magnesium chloride / sodium chloride,glucose,,
C2927994,"calcium chloride / glucose / glutathione / magnesium chloride / potassium chloride / sodium bicarbonate / sodium chloride / sodium phosphate, dibasic",glucose,,
C2928194,alanine / arginine / aspartate / glucose / glutamate / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine,glucose,,
C2928196,"glucose / potassium chloride / potassium lactate / sodium chloride / sodium phosphate, monobasic",glucose,,
C2928260,glucose / lactate / magnesium chloride / potassium chloride / potassium phosphate / sodium chloride,glucose,,
C2928325,calcium chloride / glucose / potassium chloride / sodium chloride,glucose,,
C2928445,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine,glucose,,
C2928448,"glucose / lactate / magnesium chloride / potassium chloride / potassium phosphate / sodium phosphate, monobasic",glucose,,
C2928454,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine,glucose,,
C2928459,calcium chloride / glucose / lactate / potassium chloride / sodium chloride,glucose,,
C2928467,alanine / arginine / aspartate / glucose / glutamate / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / potassium chloride / proline / serine / sodium chloride / sodium phosphate / threonine / tryptophan / tyrosine / valine,glucose,,
C2928483,calcium lactate / glucose / magnesium citrate / potassium chloride / sodium chloride,glucose,,
C2928636,alanine / arginine / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / sodium chloride / threonine / tryptophan / tyrosine / valine,glucose,,
C2928662,dibasic potassium phosphate / glucose / sodium acetate / sodium chloride,glucose,,
C2928664,dibasic potassium phosphate / glucose / magnesium chloride / potassium chloride / sodium acetate,glucose,,
C2928691,"dibasic potassium phosphate / glucose / lactate / magnesium chloride / potassium chloride / sodium chloride / sodium phosphate, monobasic",glucose,,
C2928892,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / threonine / tryptophan / tyrosine / valine,glucose,,
C2928906,glucose / magnesium chloride / potassium chloride / sodium acetate / sodium chloride / sodium gluconate,glucose,,
C2928907,calcium chloride / glucose / lactate / magnesium chloride / potassium chloride / sodium acetate / sodium chloride,glucose,,
C2928913,glucose / magnesium acetate / potassium acetate / sodium chloride,glucose,,
C2928954,conivaptan / glucose,glucose,,
C2928968,fructose / glucose / sodium citrate,glucose,,
C2929002,clindamycin / glucose,glucose,,
C2929161,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine,glucose,,
C2929370,alanine / arginine / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine,glucose,,
C2929392,adenine / glucose,glucose,,
C2929481,glucose / lactate / potassium chloride / potassium phosphate / sodium chloride,glucose,,
C2929612,alanine / arginine / aspartate / glucose / glutamate / glycine / histidine / isoleucine / leucine / lysine / methionine / N-acetyltyrosine / phenylalanine / proline / serine / threonine / tryptophan / valine,glucose,,
C2929826,alanine / arginine / aspartate / calcium chloride / dibasic potassium phosphate / glucose / glutamate / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / potassium chloride / proline / serine / sodium chloride / threonine / tryptophan / tyrosine / valine,glucose,,
C2929967,glucose / magnesium chloride / potassium chloride / sodium acetate / sodium chloride,glucose,,
C2930036,"glucose / magnesium chloride / potassium chloride / potassium phosphate / sodium acetate / sodium chloride / sodium gluconate / sodium phosphate, dibasic",glucose,,
C2930277,GLUCOSE SENSOR DEXCOM SEVEN,glucose,GLUCOSE SENSOR DEXCOM SEVEN,
C2930283,PRODIGY NO CODE (GLUCOSE) TEST STRIP,glucose,PRODIGY NO CODE (GLUCOSE) TEST STRIP,
C2930293,ACCU-CHEK COMPACT PLUS (GLUCOSE) METER,glucose,ACCU-CHEK COMPACT PLUS (GLUCOSE) METER; Accu-Chek Compact Plus Kit; Accu-Chek Compact Plus Meter,
C2930650,"UDP-glucose sinapate glucosyltransferase, Brassica napus",glucose,"UGT84A9 protein, Brassica napus; SGT enzyme, Brassica napus",
C2931057,"Lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules",diabetes,,
C2931070,Schofer Beetz Bohl syndrome,diabetes,Nephrogenic diabetes insipidus and intracranial calcification syndrome (disorder); Nephrogenic diabetes insipidus and intracranial calcification syndrome; Schofer Beetz Bohl syndrome,
C2931125,Feigenbaum Bergeron Richardson syndrome,diabetes,"Feigenbaum-Bergeron-Richardson syndrome; Atherosclerosis-hearing loss-diabetes-epilepsy-nephropathy syndrome; Feigenbaum Bergeron Richardson syndrome; Atherosclerosis, deafness, diabetes, epilepsy, nephropathy syndrome; Atherosclerosis, deafness, diabetes, epilepsy, nephropathy syndrome (disorder); Atherosclerosis-deafness-diabetes-epilepsy-nephropathy syndrome",
C2931296,Yorifuji Okuno syndrome,diabetes,"Pancreatic hypoplasia diabetes heart disease; Pancreatic hypoplasia, diabetes mellitus, congenital heart disease syndrome (disorder); Pancreatic hypoplasia-diabetes-congenital heart disease syndrome; Pancreatic hypoplasia, diabetes mellitus, congenital heart disease syndrome; Yorifuji Okuno syndrome; Yorifuji-Okuno syndrome",
C2931345,Glucose-6-phosphate translocase deficiency,glucose,,
C2931765,Furukawa Takagi Nakao syndrome,diabetes,Muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome; Furukawa Takagi Nakao syndrome; Furukawa-Takagi-Nakao syndrome,
C2931832,"Hyperinsulinemic hypoglycemia, familial, 1",hypoglycemia,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; Familial Hyperinsulinemic Hypoglycemia 1; Hyperinsulinemic Hypoglycemia Due to Focal Adenomatous Hyperplasia; Hyperinsulinemic Hypoglycemia, Familial, 1; HYPERINSULINEMIC HYPOGLYCEMIA DUE TO FOCAL ADENOMATOUS HYPERPLASIA; HHF1",
C2931833,"Hyperinsulinemic hypoglycemia, familial, 2",hypoglycemia,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2; Hyperinsulinemic Hypoglycemia, Familial, 2; HYPERINSULINEMIC HYPOGLYCEMIA DUE TO FOCAL ADENOMATOUS HYPERPLASIA",
C2931948,"amino-acid, glucose, and electrolyte solution",glucose,,
C2932471,"1,6-diferuloyl glucose",glucose,,
C2932666,Gestational Diabetes Insipidus,diabetes,,
C2932772,"CG11347 protein, Drosophila",diabetes,"Diabetes and obesity regulated protein, Drosophila; dDOR protein, Drosophila",
C2933649,pro-glucose-dependent insulinotropic polypeptide,glucose,pro-GIP; pro-gastric inhibitory polypeptide,
C2933696,"99mTc 1-thio-beta-D-glucose 2,3,4,6-tetra-acetate",glucose,,
C2934971,"glucose 6-phosphate dehydrogenase Palermo, human",glucose,"G6PD Palermo, human; G6PD Palermo R257M, human",
C2936739,"Hyper-Immunoglobulin E Syndrome, Autosomal Dominant",hyper,"HIES, AUTOSOMAL DOMINANT; STAT3 deficiency; HIES, Autosomal Dominant; Autosomal dominant HIES; Hyper-IgE Syndrome, Autosomal Dominant; Autosomal Dominant HIESs; Buckley syndrome; HYPER-IgE SYNDROME, AUTOSOMAL DOMINANT; Hyper IgE Syndrome, Autosomal Dominant; HIESs, Autosomal Dominant; Hyperimmunoglobulin E-recurrent infection syndrome; STAT3 Deficiency; Job Syndrome; Job syndrome; AD-HIES; Hyperimmunoglobulin E syndrome type 1; Autosomal dominant hyper-IgE syndrome; Hyper-Immunoglobulin E Syndrome, Autosomal Dominant; Autosomal Dominant HIES; Hyper-IgE Recurrent Infection Syndrome; Autosomal dominant hyperimmunoglobulin E syndrome; Hyper Immunoglobulin E Syndrome, Autosomal Dominant",
C2937654,FORA D20 Blood Glucose Monitoring System,blood glucose,,
C2937732,FORA D20 Blood Glucose Test Strip,blood glucose,,
C2938519,glucose Oral Solution [Dex4],glucose,,
C2938520,glucose 254 MG/ML Oral Solution [Dex4],glucose,"Dex4 15 GM per 2 OZ Oral Solution; Dex4 Berry Twist, 25% oral liquid; Dex4 254 MG/ML Oral Solution; Dex4 Mango Twist, 25% oral liquid; Dex4 Grape, 25% oral liquid; Dex4 15 GM Oral Solution; Dex4 25 % Oral Solution",
C2939465,Deficiency of glucose-6-phosphate dehydrogenase,glucose,"Glucosephosphate Dehydrogenase Deficiency; deficiency g6pd; Glucosephosphate dehydrogenase deficiency; Glucose 6 Phosphate Dehydrogenase Deficiency; Deficiency of G-6PD; Deficiency, Glucose-6-Phosphate Dehydrogenase; Deficiency of Glucose-6-Phosphate Dehydrogenase; GPD Deficiency; Glucose-6-phosphate dehydrogenase deficiency; glucose 6 phosphate dehydrogenase deficiency; Hemolytic Anemia Due to G6PD Deficiency; Dehydrogenase Deficiencies, Glucosephosphate; Dehydrogenase Deficiencies, Glucose-6-Phosphate; Glucose-6-Phosphate Dehydrogenase Deficiencies; Deficiencies, Glucosephosphate Dehydrogenase; deficiency g 6 pd; Deficiencies, Glucose-6-Phosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiencies; GPD Deficiencies; Deficiencies, G6PD; G6PD Deficiencies; Deficiency of glucose-6-phosphate dehydrogenase (disorder); g-6pd deficiency; anemia g-6-pd deficiency; Deficiency, G6PD; anemia g6pd hemolytic; Deficiencies, GPD; Deficiency of Glucose 6 Phosphate Dehydrogenase; Glucose-6-Phosphate Dehydrogenase Deficiency; Deficiency, GPD; G6PD - Glucose-6-phosphate dehydrogenase deficiency; g6pd deficiency; G6PD deficiency; G6PD Deficiency; Deficiency of glucose-6-phosphate dehydrogenase; Dehydrogenase Deficiency, Glucose-6-Phosphate; glucose-6-phosphate dehydrogenase deficiency; Glucose-6-phosphate dehydrogenase (G6PD) deficiency; Deficiency, Glucosephosphate Dehydrogenase; G6PD DEFICIENCY; Glucose-6-phosphate Dehydrogenase Deficiency; Dehydrogenase Deficiency, Glucosephosphate",
C2945676,obesity in diabetes,diabetes,obesity diabetes; diabete obesity; diabetes obesity; in obesity diabetes,
C2945747,diabete system,diabetes,diabetes systems; diabetes system,
C2946050,glucose 0.4 MG/MG [Glutose],glucose,,
C2946052,glucose Oral Gel [Glutose],glucose,,
C2946053,glucose 0.4 MG/MG Oral Gel [Glutose],glucose,"Glutose 0.4 MG/MG Oral Gel; glutose 40 % Oral Gel; Glutose 15, 40% oral gel; Glutose 5, 40% oral gel; Glutose 40 % Oral Gel",
C2947822,FORA G30 Blood Glucose Monitoring System,blood glucose,,
C2947823,FORA G30 Blood Glucose Test Strips,blood glucose,,
C2947824,FORA G90 Blood Glucose Test Strips,blood glucose,,
C2947825,FORA V22 Blood Glucose Test Strips,blood glucose,,
C2947826,FORA V30a Blood Glucose Monitoring System-Ret,blood glucose,,
C2947827,FORA V30a Blood Glucose Test Strip,blood glucose,,
C2954488,FORA G90 Blood Glucose Monitoring System,blood glucose,,
C2954491,FORA V30 Blood Glucose Monitoring System,blood glucose,,
C2954492,FORA V30 Blood Glucose Test Strip,blood glucose,,
C2954984,glucose 968 MG,glucose,,
C2954986,fructose / glucose / sodium citrate Chewable Tablet,glucose,,
C2954987,fructose 175 MG / glucose 968 MG / sodium citrate 230 MG Chewable Tablet,glucose,dextrose 968 MG / fructose 175 MG / sodium citrate 230 MG Chewable Tablet; dextrose 968 MG / fructose 175 MG / trisodium citrate dihydrate 230 MG Chewable Tablet,
C2955825,Diabetes-Associated Uniparental Disomy Reagents,diabetes,,
C2955826,Diabetes Mellitus Diagnostic Reagents,diabetes,,
C2955828,Transient Neonatal Diabetes Mellitus Diagnostic Reagents,diabetes,,
C2955829,Neonatal Diabetes Mellitus Diagnostic Reagents,diabetes,,
C2955937,Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) Gene Mutation Detection Reagents,hypoglycemia,,
C2955994,Diabetes Gene Mutation Detection Reagents,diabetes,,
C2955995,Nephrogenic Diabetes Insipidus Gene Mutation Detection Reagents,diabetes,,
C2955996,Autosomal Nephrogenic Diabetes Insipidus Gene Mutation Detection Reagents,diabetes,,
C2955998,Diabetes Insipidus Gene Mutation Detection Reagents,diabetes,,
C2956034,X-Linked Nephrogenic Diabetes Insipidus Gene Mutation Detection Reagents,diabetes,,
C2956067,Diabetes Mellitus Gene Mutation Detection Reagents,diabetes,,
C2956384,Maturity Onset Diabetes of the Young Type 2 (MODY2) Gene Mutation Detection Reagents,diabetes,,
C2956907,Glucose Transporter Type 1 Deficiency Syndrome (GLUT1-DS) Gene Mutation Reagents,glucose,,
C2956908,Blood-Brain Barrier Glucose Transport Defect Gene Mutation Reagents,glucose,,
C2956909,Glucose Transporter Protein Syndrome Gene Mutation Reagents,glucose,,
C2959223,"Outpatient intravenous insulin treatment (oivit) either pulsatile or continuous, by any means, guided by the results of measurements for: respiratory quotient; and/or, urine urea nitrogen (uun); and/or, arterial, venous or capillary glucose; and/or potassium concentration",glucose,,
C2960128,Hemoglobin A1c target value using International Federation of Clinical Chemistry and Laboratory Medicine standardized method,a1c,Haemoglobin A1c target value using International Federation of Clinical Chemistry and Laboratory Medicine standardised method; Hemoglobin A1c target value using International Federation of Clinical Chemistry and Laboratory Medicine standardized method (observable entity),
C2961327,glucose 166.7 MG/ML,glucose,,
C2961328,glucose 166.7 MG/ML Oral Solution,glucose,"glucose 50 GM in 300 mL Oral Solution; glucose 50 GM per 300 ML Oral Solution; GLUCOSE 50GM/300ML LIQUID,ORAL; GLUCOSE 50GM/300ML ORAL LIQUID",
C2961492,Advocate Duo Speaking Glucose Plus Blood Pres,glucose,,
C2961493,Advocate Glucose Meter Non-Speaking TD4223B,glucose,,
C2961494,ADVOCATE REDI-CODE+ (GLUCOSE) TEST STRIP,glucose,ADVOCATE REDI-CODE+ (GLUCOSE) TEST STRIP; Advocate Redi-Code Glucose Test Strips,
C2961497,Advocate Talking Blood Glucose Monitor TD-422,blood glucose,,
C2962383,Enfamil Glucose,glucose,,
C2962384,glucose 50 MG/ML [Enfamil Glucose],glucose,,
C2962385,glucose Oral Solution [Enfamil Glucose],glucose,,
C2962386,glucose 50 MG/ML Oral Solution [Enfamil Glucose],glucose,Enfamil Glucose 5 % Oral Solution,
C2962694,Glucose 500 MG/ML includes Injection & Prefilled Syringe,glucose,"DEXTROSE MONOHYDRATE 25 g in 50 mL INTRAVENOUS INJECTION, SOLUTION; Dextrose, 50% intravenous solution; DEXTROSE 50% INJ",
C2970600,Glucose^baseline:MCnc:Pt:Dial fld prt:Qn,glucose,Glucose BS DiafP-mCnc; Glucose^baseline:Mass Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose baseline (Perit dial fld) [Mass/Vol]; Glucose [Mass/volume] in Peritoneal dialysis fluid --baseline,
C2973266,Hemoglobin A1c/Hemoglobin.total:MFr:Pt:Bld:Qn:JDS/JSCC,a1c,Hemoglobin A1c/Hemoglobin.total in Blood by JDS/JSCC protocol; Hemoglobin A1c/Hemoglobin.total:Mass Fraction:To identify measures at a point in time:Whole blood:Quantitative:JDS/JSCC; HbA1c MFr Bld JDS/JSCC; HbA1c JDS/JSCC protocol (Bld) [Mass fraction],
C2974714,4-(F-18)fluoro-4-deoxy-D-glucose,glucose,,
C2974716,alpha-methyl-4-deoxy-4-((18)F)fluoro-D-glucopyranoside,glucose,Me4FDG; Alpha-methyl-4-deoxy-4-(18F)fluoro-D-glucopyranoside; alpha-methyl-4-(F-18)fluoro-4-deoxy-D-glucose; alpha-methyl-4-[F-18]-fluoro-4-deoxy-d-glucopyranoside; Me-4(18F)DG; Me-4FDG; alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside; Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside; alpha-methyl-4-deoxy-4-(18F)fluoro-D-glucopyranoside; Alpha-methyl-4-[F-18]-fluoro-4-deoxy-d-glucopyranoside; a-methyl-4[18F]-4-deoxy-D-glucopyranoside; alpha-methyl-4-deoxy-4-((18)F)fluoro-D-glucopyranoside,
C2975867,"GPI protein, human",glucose,"neuroleukin, human; Glucose-6-Phosphate Isomerase; NLK; glucose phosphate isomerase, human; sperm antigen 36, human; autocrine motility factor, human; glucose-6-phosphate isomerase, human; Glucose Phosphate Isomerase; GPI protein, human; Neuroleukin; PGI; PHI",
C2975868,"pgi protein, E coli",glucose,"glucose-6-phosphate isomerase, E coli; ECK4017 protein, E coli; b4025 protein, E coli; glucosephosphate isomerase, E coli",
C2975869,"Gpi protein, rat",glucose,"glucose-6-phosphate isomerase, rat; glucose phosphate isomerase, rat; neuroleukin, rat; autocrine motility factor, rat",
C2975870,"Gpi1 protein, mouse",glucose,"neuroleukin, mouse; autocrine motility factor, mouse; glucose phosphate isomerase 1, mouse",
C2976256,BG-Cy3-Cy5,BG,,
C2978742,Ascencia Dex 2 Diabetes System,diabetes,,
C2979325,alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 100 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution,glucose,Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 100 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution; Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 100 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution,
C2979327,alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 100 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML [Clinimix E 4.25/10],glucose,,
C2979328,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine Injectable Solution [Clinimix E 4.25/10],glucose,,
C2979329,alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 100 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/10],glucose,"Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic Pot phosphate 2.61 MG/ML / Glucose 100 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/10]; CLINIMIX E 4.25/10 INJ; Clinimix E 4.25/10 Injectable Solution; LEUCINE 311 mg in 100 mL / PHENYLALANINE 238 mg in 100 mL / LYSINE 247 mg in 100 mL / METHIONINE 170 mg in 100 mL / ISOLEUCINE 255 mg in 100 mL / VALINE 247 mg in 100 mL / HISTIDINE 204 mg in 100 mL / THREONINE 179 mg in 100 mL / TRYPTOPHAN 77 mg in 100 mL / ALANINE 880 mg in 100 mL / GLYCINE 438 mg in 100 mL / ARGININE 489 mg in 100 mL / PROLINE 289 mg in 100 mL / SERINE 213 mg in 100 mL / TYROSINE 17 mg in 100 mL / SODIUM ACETATE 297 mg in 100 mL / POTASSIUM PHOSPHATE, DIBASIC 261 mg in 100 mL / MAGNESIUM CHLORIDE 51 mg in 100 mL / SODIUM CHLORIDE 77 mg in 100 mL / CALCIUM CHLORIDE 33 mg in 100 mL / DEXTROSE 10 g in 100 mL INTRAVENOUS INJECTION [CLINIMIX E]; Alanine 8.8 MG/ML / Arginine 4.89 MG/ML / Calcium Chloride 0.004 MEQ/ML / Dibasic K+ phosphate 2.61 MG/ML / Glucose 100 MG/ML / Glycine 4.38 MG/ML / Histidine 2.04 MG/ML / Isoleucine 2.55 MG/ML / Leucine 3.11 MG/ML / Lysine 2.47 MG/ML / Magnesium Chloride 0.01 MEQ/ML / Methionine 1.7 MG/ML / Phenylalanine 2.38 MG/ML / Proline 2.89 MG/ML / Serine 2.13 MG/ML / Sodium Acetate Trihydrate 2.97 MG/ML / NaCl 0.013 MEQ/ML / Threonine 1.79 MG/ML / Tryptophan 0.77 MG/ML / Tyrosine 0.17 MG/ML / Valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/10]; Clinimix E Sulfite Free, Amino Acids 4.25% with 10% Dextrose and Electrolytes (Clinimix E Sulfite-Free) intravenous solution; Clinimix E 4.25/10 (4.25 % amino acids with electrolytes in dextrose 10 % ) Injectable Solution; parenteral nutrition solution w/electrolytes Amino Acids 4.25% with 10% Dextrose and Electrolytes (Clinimix E Sulfite-Free) intravenous solution",
C2981326,high fructose corn syrup,glucose,"Glucose Fructose Syrup; High Fructose Maize Syrup; Isoglucose; Syrup, High-Fructose Maize; Corn Sugar; High-Fructose Maize Syrup; High fructose corn syrup; HIGH FRUCTOSE CORN SYRUP; Syrup, Glucose-Fructose; High fructose corn syrup (substance); High Fructose Corn syrup; high fructose corn syrup; Maize Syrup, High-Fructose; Syrup, Maize; Maize Syrup; High Fructose Corn Syrup; Glucose-Fructose Syrup; Sugar, Corn",
C2982484,SLC2A4 wt Allele,glucose,"GLUT4; Insulin-Responsive Glucose Transporter Type 4 Gene, Glucose Transporter 4 Gene; SLC2A4 wt Allele; Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 4 wt Allele",
C2984262,Maturity Onset Diabetes of the Young Pathway,diabetes,Type II Diabetes Mellitus in Young Patients Pathway; Maturity Onset Diabetes of the Young Pathway,
C2984301,Type II Diabetes Mellitus Pathway,diabetes,Type II Diabetes Mellitus Pathway,
C2984334,Type I Diabetes Mellitus Pathway,diabetes,Type I Diabetes Mellitus Pathway,
C2984428,Insulin-Mediated Glucose Transport Pathway,glucose,,
C3055168,Saccharothrix sp. BG,BG,,
C3069326,Polystachya sp. Heidelberg BG 120940,BG,,
C3084973,Isophya cf. rhodopensis/leonorae BG-2010,BG,,
C3104816,Isophya cf. rhodopensis/longicaudata BG-2010,BG,,
C3132264,Bacillus sp. Bg-1,BG,,
C3132265,Bacillus sp. Bg-2,BG,,
C3132266,Bacillus sp. Bg-3,BG,,
C3132267,Bacillus sp. Bg-4,BG,,
C3132268,Bacillus sp. Bg-5,BG,,
C3132269,Microbacterium sp. Bg-7,BG,,
C3132270,Micrococcus sp. Bg-6,BG,,
C3132271,Pseudomonas sp. Bg-8,BG,,
C3132272,Pseudomonas sp. Bg-9,BG,,
C3149273,"Diabetes, nonautoimmune",diabetes,,
C3149698,"Diabetes mellitus, susceptibility to",diabetes,,
C3150617,"Maturity-onset diabetes of the young, type 10",diabetes,"Maturity-onset diabetes of the young, type 10 (disorder); MODY10; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 10",
C3150618,"Maturity-onset diabetes of the young, type 11",diabetes,"MODY11; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 11; Maturity-onset diabetes of the young, type 11 (disorder)",
C3150710,FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 6,plasma glucose,FGQTL6,
C3150712,"PLASMA GLUCOSE, 2-HOUR, QUANTITATIVE TRAIT LOCUS 1",plasma glucose,PGQTL1,
C3150713,FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 4,plasma glucose,FGQTL4,
C3150714,FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 5,plasma glucose,FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 5; FGQTL5,
C3150730,"HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO GLUCOSE PHOSPHATE ISOMERASE DEFICIENCY",glucose,"HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO GLUCOSE PHOSPHATE ISOMERASE DEFICIENCY",
C3151959,"RENAL TUBULOPATHY, DIABETES MELLITUS, AND CEREBELLAR ATAXIA",diabetes,,
C3154176,ACCU-CHECK COMPACT BLUE (GLUCOSE) HI/NORM CONTROL SOLN,glucose,ACCU-CHEK COMPACT BLUE H/N CONTROL SOLN,
C3154434,glucose 100 g/296 mL oral liquid,glucose,,
C3154544,glucose 50 g/296 mL oral liquid,glucose,,
C3154545,glucose 75 g/296 mL oral liquid,glucose,,
C3154954,UDP-glucose:auxin glucosyltransferase activity,glucose,,
C3155193,abscisic acid glucose ester beta-glucosidase activity,glucose,ABA-GE beta-glucosidase activity,
C3155465,indole-3-butyrate beta-glucosyltransferase activity,glucose,IBA-Glc synthetase activity; UDPglucose:indole-3-butyrate beta-D-glucosyltransferase activity; UDP-glucose:(indol-3-yl)butyrate beta-D-glucosyltransferase activity; UDP-glucose:indol-3-ylbutyrate glucosyltransferase activity; indole-3-butyric acid glucosyltransferase activity; uridine diphosphoglucose-indolebutyrate glucosyltransferase activity; indol-3-ylbutyrylglucose synthase activity; UDP-glucose:indol-3-ylbutyrate glucosyl-transferase activity; UDPG-indol-3-ylbutyryl glucosyl transferase activity; IBA-glucose synthase activity; IBAGlu synthase activity,
C3155466,salicylic acid glucosyltransferase (ester-forming) activity,glucose,UDP:glucose:2-hydroxybenzoic acid glucosyltransferase (ester-forming) activity; UDP:glucose:SA glucosyltransferase (ester-forming) activity; UDP:glucose:salicylate glucosyltransferase (ester-forming) activity; UDP:glucose:salicylic acid glucosyltransferase (ester-forming) activity,
C3155468,salicylic acid glucosyltransferase (glucoside-forming) activity,glucose,UDP:glucose:salicylic acid glucosyltransferase (glucoside-forming) activity; UDP:glucose:salicylate glucosyltransferase (glucoside-forming) activity; UDP:glucose:2-hydroxybenzoic acid glucosyltransferase (glucoside-forming) activity; UDP:glucose:SA glucosyltransferase (glucoside-forming) activity,
C3155469,benzoic acid glucosyltransferase activity,glucose,UDP:glucose:benzoate glucosyltransferase activity; benzoate glucosyltransferase activity; UDP:glucose:benzoic acid glucosyltransferase activity; UDP:glucose:BA glucosyltransferase activity,
C3155708,regulation of insulin secretion involved in cellular response to glucose stimulus,glucose,regulation of insulin secretion in response to glucose,
C3155709,negative regulation of insulin secretion involved in cellular response to glucose stimulus,glucose,negative regulation of insulin secretion involved in cellular response to glucose,
C3155710,negative regulation of insulin secretion in response to glucose,glucose,,
C3157389,regulation of invasive growth in response to glucose limitation,glucose,,
C3157391,negative regulation of invasive growth in response to glucose limitation,glucose,,
C3157393,positive regulation of invasive growth in response to glucose limitation,glucose,,
C3157708,regulation of glycogen (starch) synthase activity,glucose,regulation of glycogen (starch) synthetase activity; regulation of UDPG-glycogen synthetase activity; regulation of uridine diphosphoglucose-glycogen glucosyltransferase activity; regulation of UDP-glycogen synthase activity; regulation of UDP-glucose:glycogen 4-alpha-D-glucosyltransferase activity; regulation of UDPglucose:glycogen 4-alpha-D-glucosyltransferase activity; regulation of UDPG-glycogen transglucosylase activity; regulation of UDP-glucose-glycogen glucosyltransferase activity,
C3157709,negative regulation of glycogen (starch) synthase activity,glucose,negative regulation of uridine diphosphoglucose-glycogen glucosyltransferase activity; negative regulation of UDPG-glycogen synthetase activity; negative regulation of UDP-glucose-glycogen glucosyltransferase activity; negative regulation of UDP-glycogen synthase activity; negative regulation of glycogen (starch) synthetase activity; negative regulation of UDP-glucose:glycogen 4-alpha-D-glucosyltransferase activity; negative regulation of UDPG-glycogen transglucosylase activity; negative regulation of UDPglucose:glycogen 4-alpha-D-glucosyltransferase activity,
C3157710,positive regulation of glycogen (starch) synthase activity,glucose,positive regulation of glycogen (starch) synthetase activity; positive regulation of UDP-glucose:glycogen 4-alpha-D-glucosyltransferase activity; positive regulation of UDP-glucose-glycogen glucosyltransferase activity; positive regulation of UDP-glycogen synthase activity; positive regulation of UDPglucose:glycogen 4-alpha-D-glucosyltransferase activity; positive regulation of uridine diphosphoglucose-glycogen glucosyltransferase activity; positive regulation of UDPG-glycogen transglucosylase activity; positive regulation of UDPG-glycogen synthetase activity,
C3158808,renal glucose absorption,glucose,glucose reabsorption; nephron glucose absorption,
C3158960,insulin secretion involved in cellular response to glucose stimulus,glucose,insulin secretion involved in cellular response to glucose,
C3158961,positive regulation of insulin secretion involved in cellular response to glucose stimulus,glucose,positive regulation of insulin secretion in response to glucose,
C3159160,ethanol biosynthetic process involved in glucose fermentation to ethanol,glucose,,
C3159443,Embrace Blood Glucose Meter,blood glucose,,
C3161145,Personal history of gestational diabetes,diabetes,,
C3165597,PhenX - autoimmune diseases related to type 1 diabetes protocol,diabetes,PhenX - autoimmune diseases related to type 1 diabetes protocol 140101,
C3165682,PhenX - family history of diabetes protocol,diabetes,PhenX - family history of diabetes protocol 140201,
C3165686,PhenX - fasting plasma glucose for diabetes screening - blood draw protocol,plasma glucose,PhenX - fasting plasma glucose for diabetes screening - blood draw protocol 140801,
C3165687,PhenX - fasting plasma glucose for diabetes screening - glucometer protocol,plasma glucose,PhenX - fasting plasma glucose for diabetes screening - glucometer protocol 140802,
C3165699,PhenX - glycosylated hemoglobin assay reflecting long-term glucose concentration protocol,glucose,PhenX - glycosylated hemoglobin assay reflecting long-term glucose concentration protocol 140901,
C3165757,PhenX - oral glucose tolerance test protocol,glucose,PhenX - oral glucose tolerance test protocol 141001,
C3165788,PhenX - personal history of type 1 - type 2 diabetes protocol,diabetes,PhenX - personal history of type 1 - type 2 diabetes protocol 140501,
C3165905,PhenX domain - Diabetes,diabetes,PhenX domain - Diabetes,
C3165942,PhenX measure - autoimmune diseases related to type 1 diabetes,diabetes,PhenX measure - autoimmune diseases related to type 1 diabetes,
C3166013,PhenX measure - family history of diabetes,diabetes,PhenX measure - family history of diabetes,
C3166017,PhenX measure - fasting plasma glucose for diabetes screening - blood draw,plasma glucose,PhenX measure - fasting plasma glucose for diabetes screening - blood draw,
C3166026,PhenX measure - glycosylated hemoglobin assay that reflects long-term glucose concentration,glucose,PhenX measure - glycosylated hemoglobin assay that reflects long-term glucose concentration,
C3166061,PhenX measure - oral glucose tolerance test,glucose,PhenX measure - oral glucose tolerance test,
C3166091,PhenX measure - personal history of type 1- type 2 diabetes,diabetes,PhenX measure - personal history of type 1- type 2 diabetes,
C3166227,Problem related to diabetes,diabetes,Problem related to diabetes,
C3166267,Relation with diabetes-related problem,diabetes,Relation with diabetes-related problem,
C3166528,Was insulin your first diabetes medicine,diabetes,Was insulin your first diabetes medicine,
C3166617,What medication are you taking for diabetes,diabetes,What medication are you taking for diabetes,
C3169500,Glucose/Insulin:Ratio:Pt:Ser/Plas:Qn,glucose,Glucose/Insulin SerPl-Rto; Glucose/Insulin [Ratio]; Glucose/Insulin [Ratio] in Serum or Plasma; Glucose/Insulin:Ratio:To identify measures at a point in time:Serum/Plasma:Quantitative,
C3171755,PhenX domain - Diabetes:-:Point in time:^Patient:-:PhenX,diabetes,Domain - Diabetes; PhenX domain - Diabetes; PhenX domain - Diabetes:-:Pt:^Patient:-:PhenX; PhenX domain - Diabetes:-:To identify measures at a point in time:^Patient:-:PhenX,
C3171756,PhenX measure - autoimmune diseases related to type 1 diabetes:-:Point in time:^Patient:-:PhenX,diabetes,,
C3171757,PhenX - autoimmune diseases related to type 1 diabetes protocol:-:Point in time:^Patient:-:PhenX,diabetes,PhenX - autoimmune diseases related to type 1 diabetes protocol 140101:-:To identify measures at a point in time:^Patient:-:PhenX; PhenX - autoimmune diseases related to type 1 diabetes protocol 140101:-:Pt:^Patient:-:PhenX; Autoimmune dis type 1 diabetes proto; PhenX - autoimmune diseases related to type 1 diabetes protocol 140101,
C3171758,PhenX measure - family history of diabetes:-:Point in time:^Patient:-:PhenX,diabetes,,
C3171759,PhenX - family history of diabetes protocol:-:Point in time:^Patient:-:PhenX,diabetes,PhenX - family history of diabetes protocol 140201; PhenX - family history of diabetes protocol 140201:-:To identify measures at a point in time:^Patient:-:PhenX; Fam hx diabetes proto; PhenX - family history of diabetes protocol 140201:-:Pt:^Patient:-:PhenX,
C3171764,PhenX measure - personal history of type 1- type 2 diabetes:-:Point in time:^Patient:-:PhenX,diabetes,,
C3171765,PhenX - personal history of type 1 - type 2 diabetes protocol:-:Point in time:^Patient:-:PhenX,diabetes,PhenX - personal history of type 1 - type 2 diabetes protocol 140501; Pers hx type 1-2 diabetes proto; PhenX - personal history of type 1 - type 2 diabetes protocol 140501:-:Pt:^Patient:-:PhenX; PhenX - personal history of type 1 - type 2 diabetes protocol 140501:-:To identify measures at a point in time:^Patient:-:PhenX,
C3171856,PhenX measure - fasting plasma glucose for diabetes screening - blood draw:-:Point in time:^Patient:-:PhenX,plasma glucose,,
C3171857,PhenX - fasting plasma glucose for diabetes screening - blood draw protocol:-:Point in time:^Patient:-:PhenX,plasma glucose,PhenX - fasting plasma glucose for diabetes screening - blood draw protocol 140801:-:Pt:^Patient:-:PhenX; PhenX - fasting plasma glucose for diabetes screening - blood draw protocol 140801; Fast plasma gluc blood draw proto; PhenX - fasting plasma glucose for diabetes screening - blood draw protocol 140801:-:To identify measures at a point in time:^Patient:-:PhenX,
C3171858,PhenX - fasting plasma glucose for diabetes screening - glucometer protocol:-:Point in time:^Patient:-:PhenX,plasma glucose,PhenX - fasting plasma glucose for diabetes screening - glucometer protocol 140802; PhenX - fasting plasma glucose for diabetes screening - glucometer protocol 140802:-:To identify measures at a point in time:^Patient:-:PhenX; PhenX - fasting plasma glucose for diabetes screening - glucometer protocol 140802:-:Pt:^Patient:-:PhenX; Fast plasma gluc glucometer proto,
C3171859,PhenX measure - glycosylated hemoglobin assay that reflects long-term glucose concentration:-:Point in time:^Patient:-:PhenX,glucose,,
C3171860,PhenX measure - oral glucose tolerance test:-:Point in time:^Patient:-:PhenX,glucose,,
C3171861,PhenX - oral glucose tolerance test protocol:-:Point in time:^Patient:-:PhenX,glucose,PhenX - oral glucose tolerance test protocol 141001:-:To identify measures at a point in time:^Patient:-:PhenX; PhenX - oral glucose tolerance test protocol 141001:-:Pt:^Patient:-:PhenX; PhenX - oral glucose tolerance test protocol 141001; Oral glucose tolerance test proto,
C3172442,Ketones^1H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Ketones [Presence] in Urine by Test strip --1 hour post dose glucose; Ketones 1h p Glc Ur Ql Strip; Ketones 1 Hr post dose glucose Test strip Ql (U); Ketones^1 hour post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C3172443,Ketones^3H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Ketones [Presence] in Urine by Test strip --3 hours post dose glucose; Ketones 3h p Glc Ur Ql Strip; Ketones 3 Hr post dose glucose Test strip Ql (U); Ketones^3 hours post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C3172444,Ketones^4H post dose glucose:PrThr:Pt:Urine:Ord:Test strip,glucose,Ketones 4 Hr post dose glucose Test strip Ql (U); Ketones 4h p Glc Ur Ql Strip; Ketones [Presence] in Urine by Test strip --4 hours post dose glucose; Ketones^4 hours post dose glucose:Presence or Threshold:To identify measures at a point in time:Urine:Ordinal:Test strip,
C3172453,Glucose^post CFst:MCnc:Pt:Urine:Qn,glucose,Fasting glucose [Mass/volume] in Urine; Glucose p fast Ur-mCnc; Glucose post fast (U) [Mass/Vol]; Glucose^post Calorie fast:Mass Concentration:To identify measures at a point in time:Urine:Quantitative,
C3174885,Has a medical doctor ever told you that diabetes has affected blood vessels in your eyes or that you had diabetic retinopathy or diabetic eye disease:Find:Pt:^Patient:Ord:PhenX,diabetes,Has a medical doctor ever told you that diabetes has affected blood vessels in your eyes or that you had diabetic retinopathy or diabetic eye disease:Finding:To identify measures at a point in time:^Patient:Ordinal:PhenX; Has a medical doctor ever told you that diabetes has affected blood vessels in your eyes or that you had diabetic retinopathy or diabetic eye disease [PhenX]; Diabetic retinopathy ever PhenX,
C3174886,Has a medical doctor ever told you that diabetes has affected blood vessels in your eyes or that you had diabetic retinopathy or diabetic eye disease,diabetes,Has a medical doctor ever told you that diabetes has affected blood vessels in your eyes or that you had diabetic retinopathy or diabetic eye disease,
C3175141,Relation with diabetes-related problem:Find:Pt:^Patient:Nom:PhenX,diabetes,Relation with diabetes-related problem:Finding:To identify measures at a point in time:^Patient:Nominal:PhenX; Relation with diabetes-related problem [PhenX]; Diabetes problem relative PhenX,
C3175142,Problem related to diabetes:Find:Pt:^Patient:Nom:PhenX,diabetes,Problem related to diabetes:Finding:To identify measures at a point in time:^Patient:Nominal:PhenX; Problem related to diabetes [PhenX]; Diabetes problem PhenX,
C3176019,Exclusion criteria for fasting plasma glucose:Find:Pt:^Patient:Nom:PhenX,plasma glucose,Exclusion criteria glucose PhenX; Exclusion criteria for fasting plasma glucose [PhenX]; Exclusion criteria for fasting plasma glucose:Finding:To identify measures at a point in time:^Patient:Nominal:PhenX,
C3176020,Exclusion criteria for fasting plasma glucose,plasma glucose,Exclusion criteria for fasting plasma glucose,
C3176196,Are you now taking diabetic pills to lower your blood sugar:Find:Pt:^Patient:Ord:PhenX,blood sugar,Are you now taking diabetic pills to lower your blood sugar [PhenX]; Are you now taking diabetic pills to lower your blood sugar:Finding:To identify measures at a point in time:^Patient:Ordinal:PhenX; Diabetic pills PhenX,
C3176197,Are you now taking diabetic pills to lower your blood sugar,blood sugar,Are you now taking diabetic pills to lower your blood sugar,
C3176472,Doctor or health care professional ever told you that you have diabetes:Finding:Point in time:^Patient:Ordinal,diabetes,Doctor or health care professional ever told you that you have diabetes; HCP told you that you have diabetes; Doctor or health care professional ever told you that you have diabetes:Finding:To identify measures at a point in time:^Patient:Ordinal; Doctor or health care professional ever told you that you have diabetes:Find:Pt:^Patient:Ord,
C3176474,Are you taking medicine for diabetes:Find:Pt:^Patient:Ord:PhenX,diabetes,Are you taking medicine for diabetes:Finding:To identify measures at a point in time:^Patient:Ordinal:PhenX; Diabetes medicine PhenX; Are you taking medicine for diabetes [PhenX],
C3176475,Are you taking medicine for diabetes,diabetes,Are you taking medicine for diabetes,
C3176476,What medication are you taking for diabetes:Find:Pt:^Patient:Nom:PhenX,diabetes,What medication are you taking for diabetes:Finding:To identify measures at a point in time:^Patient:Nominal:PhenX; Diabetes medicine type PhenX; What medication are you taking for diabetes [PhenX],
C3176477,At what age was diabetes first treated:Time:Pt:^Patient:Qn:PhenX,diabetes,At what age was diabetes first treated [PhenX]; Diabetes age PhenX; At what age was diabetes first treated:Time:To identify measures at a point in time:^Patient:Quantitative:PhenX,
C3176478,At what age was diabetes first treated,diabetes,At what age was diabetes first treated,
C3176479,Was insulin your first diabetes medicine:Find:Pt:^Patient:Ord:PhenX,diabetes,Was insulin your first diabetes medicine:Finding:To identify measures at a point in time:^Patient:Ordinal:PhenX; Was insulin your first diabetes medicine [PhenX]; Diabetes insulin PhenX,
C3176480,Did diabetes occur only during pregnancy:Find:Pt:^Patient:Ord:PhenX,diabetes,Diabetes women pregnancy PhenX; Did diabetes occur only during pregnancy [PhenX]; Did diabetes occur only during pregnancy:Finding:To identify measures at a point in time:^Patient:Ordinal:PhenX,
C3176481,Did diabetes occur only during pregnancy,diabetes,Did diabetes occur only during pregnancy,
C3176624,Do or did you have this diabetes-related problem:Find:Pt:^Patient:Ord:PhenX,diabetes,Diabetes-related problem ever PhenX; Do or did you have this diabetes-related problem:Finding:To identify measures at a point in time:^Patient:Ordinal:PhenX; Do or did you have this diabetes-related problem [PhenX],
C3176625,Do or did you have this diabetes-related problem,diabetes,Do or did you have this diabetes-related problem,
C3176626,Age diabetes-related problem occurred:Time:Pt:^Patient:Qn:PhenX,diabetes,Age diabetes-related problem occurred:Time:To identify measures at a point in time:^Patient:Quantitative:PhenX; Age diabetes-related problem occurred [PhenX]; Diabetes-related problem age PhenX,
C3176627,Age diabetes-related problem occurred,diabetes,Age diabetes-related problem occurred,
C3176975,"Do you have a long-term health problem with heart disease, lung disease, asthma, kidney disease, metabolic disease, diabetes, anemia, or other blood disorder",diabetes,"Do you have a long-term health problem with heart disease, lung disease, asthma, kidney disease, metabolic disease, diabetes, anemia, or other blood disorder",
C3177264,"4-(N-acetyl-l-allothreonyl)amino-4,6-dideoxy-D-glucose",glucose,4-AAA-DG cpd,
C3178015,"glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase, Plasmodium falciparum",glucose,"GluPho protein, Plasmodium falciparum",
C3178509,"GDPGP1 protein, human",glucose,"chromosome 15 open reading frame 58 protein, human; C15orf58 protein, human; GDP-D-glucose phosphorylase 1 protein, human",
C3180071,"suppressor of glucose by autophagy protein, mouse",glucose,"SOGA protein, mouse",
C3180971,"glucose-dependent insulinotropic polypeptide, Ala(2)-",glucose,"2-Ala-glucose-dependent insulinotropic polypeptide; glucose-dependent insulinotropic polypeptide, alanyl(2)-",
C3192129,glucose 1000 MG [Dex4],glucose,,
C3192130,glucose Chewable Tablet [Dex4],glucose,,
C3192131,glucose 1000 MG Chewable Tablet [Dex4],glucose,Dex4 1000 MG Chewable Tablet,
C3192921,glucose 4000 MG [Dex4],glucose,,
C3192922,glucose 4000 MG Chewable Tablet [Dex4],glucose,"Dex4 Vertical Glucose Raspberry, 4 g oral tablet, chewable; Dex4 4 GM Chewable Tablet; Dex4 Raspberry, 4 g oral tablet, chewable; Dex4 Watermelon, 4 g oral tablet, chewable; Dex4 Orange, 4 g oral tablet, chewable; Dex4, 4 g oral tablet, chewable; Dex4 Vertical Glucose Orange, 4 g oral tablet, chewable; Dex4 Vertical Glucose Watermelon, 4 g oral tablet, chewable; Dex4 Citrus Punch, 4 g oral tablet, chewable; Dex4 Vertical Glucose Grape, 4 g oral tablet, chewable; Dex4 4000 MG Chewable Tablet; Dex4 Grape, 4 g oral tablet, chewable; Dex4 Assorted Fruit, 4 g oral tablet, chewable; Dex4 Natural Orange, 4 g oral tablet, chewable; Dex4 Tropical Fruit, 4 g oral tablet, chewable",
C3203069,PhenX - glycosylated hemoglobin assay reflecting long-term glucose concentration protocol:-:Point in time:^Patient:-:PhenX,glucose,Glycosylated hemoglobin assay; PhenX - glycosylated hemoglobin assay reflecting long-term glucose concentration protocol 140901; PhenX - glycosylated hemoglobin assay reflecting long-term glucose concentration protocol 140901:-:To identify measures at a point in time:^Patient:-:PhenX; PhenX - glycosylated hemoglobin assay reflecting long-term glucose concentration protocol 140901:-:Pt:^Patient:-:PhenX,
C3203836,"Software, Physiologic Monitoring, Glucose",glucose,Glucose Monitoring Software,
C3203837,"Smartphone Applications, Glucose Monitoring",glucose,,
C3203838,"Glucose Monitoring Software, Smartphone",glucose,,
C3208621,calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Product,glucose,,
C3208622,calcium chloride / glucose / lactate / potassium chloride / sodium chloride Injectable Product,glucose,,
C3208624,calcium chloride / glucose / potassium chloride / sodium chloride Injectable Product,glucose,,
C3208768,alanine / arginine / glucose / glycine / histidine / isoleucine / leucine / lysine / methionine / phenylalanine / proline / serine / threonine / tryptophan / tyrosine / valine Injectable Product,glucose,,
C3210312,"dibasic potassium phosphate / glucose / lactate / magnesium chloride / potassium chloride / sodium chloride / sodium phosphate, monobasic Injectable Product",glucose,,
C3210313,dibasic potassium phosphate / glucose / magnesium chloride / potassium chloride / sodium acetate Injectable Product,glucose,,
C3217010,fructose / glucose / phosphoric acid Oral Liquid Product,glucose,,
C3217011,fructose / glucose / phosphoric acid Oral Product,glucose,,
C3217013,fructose / glucose / sodium citrate Oral Product,glucose,,
C3217014,fructose / glucose / sodium citrate Pill,glucose,,
C3220045,glucose / lactate / magnesium chloride / potassium chloride / potassium phosphate / sodium chloride Injectable Product,glucose,,
C3220046,"glucose / lactate / magnesium chloride / potassium chloride / potassium phosphate / sodium phosphate, monobasic Injectable Product",glucose,,
C3220048,glucose / lidocaine Injectable Product,glucose,Product containing glucose and lidocaine in parenteral dose form (medicinal product form); Glucose- and lidocaine-containing product in parenteral dose form,
C3220049,glucose / magnesium chloride / potassium chloride / sodium acetate / sodium chloride / sodium gluconate Injectable Product,glucose,,
C3220051,"glucose / magnesium chloride / potassium chloride / potassium phosphate / sodium acetate / sodium chloride / sodium gluconate / sodium phosphate, dibasic Injectable Product",glucose,,
C3220054,glucose / potassium chloride / sodium chloride Injectable Product,glucose,Product containing glucose and potassium chloride and sodium chloride in parenteral dose form (medicinal product form); Glucose- and potassium chloride- and sodium chloride-containing product in parenteral dose form,
C3220055,glucose / potassium chloride Injectable Product,glucose,Product containing glucose and potassium chloride in parenteral dose form (medicinal product form); Glucose- and potassium chloride-containing product in parenteral dose form,
C3220058,glucose / sodium chloride Injectable Product,glucose,,
C3220059,glucose / magnesium acetate / potassium acetate / sodium chloride Injectable Product,glucose,,
C3220060,glucose Injectable Product,glucose,Glucose-containing product in parenteral dose form; Product containing glucose in parenteral dose form (medicinal product form),
C3220062,glucose Ophthalmic Product,glucose,glucose ophthalmic; Glucose Ophthalmic; Glucose-containing product in ocular dose form; Product containing glucose in ocular dose form (medicinal product form),
C3220063,glucose Oral Liquid Product,glucose,,
C3220064,glucose Oral Product,glucose,Product containing glucose in oral dose form (medicinal product form); Glucose-containing product in oral dose form,
C3220065,glucose Pill,glucose,,
C3220635,Enfamil Glucose Oral Liquid Product,glucose,,
C3220636,Enfamil Glucose Oral Product,glucose,,
C3227455,Insta-Glucose Oral Product,glucose,,
C3230090,Hyper-Sal Inhalant Product,hyper,,
C3244192,certified diabetes care,diabetes,,
C3244475,ChoiceDM Blood Glucose Monitoring System,blood glucose,,
C3244476,ChoiceDM Complete Blood Glucose Monitoring Sy,blood glucose,,
C3244650,Prodigy Glucose Control Solution (Low),glucose,,
C3247331,ACCU-CHEK AVIVA PLUS (GLUCOSE) TEST STRIP,glucose,ACCU-CHEK AVIVA PLUS(GLUCOSE) TEST STRIP; Accu-Chek Aviva Plus Test Strips,
C3247413,Element Blood Glucose Test Strips,blood glucose,,
C3248157,"G6PC (glucose-6-phosphatase, catalytic subunit) (eg, Glycogen storage disease, Type 1a, von Gierke disease) gene analysis, common variants (eg, R83C, Q347X)",glucose,,
C3248515,DIABETES SCREENING TEST PERFORMED,diabetes,,
C3250184,Diabetes mellitus caused by chemical,diabetes,Diabetes mellitus caused by chemical (disorder); Chemical-induced diabetes mellitus,
C3252349,"rmlB protein, E coli",glucose,"NAD(P)-binding dTDP-glucose 4,6 dehydratase, E coli; rfbB protein, e coli",
C3252860,penta-O-galloyl-alpha-D-glucopyranose,glucose,penta-O-galloyl-alpha-D-glucose,
C3253048,"Slc2a10 protein, zebrafish",glucose,"facilitative glucose transporter 10, zebrafish; GLUT10 protein, zebrafish",
C3254089,"IHG-1 protein, rat",high glucose,"induced in high glucose protein 1, rat",
C3254553,hydroxyapatite-bioglass,BG,HA BG composite,
C3259017,Do you suffer from diabetes:Hx:Pt:^Patient:Ord:PhenX,diabetes,Do you suffer from diabetes [PhenX]; Do you suffer from diabetes:History:To identify measures at a point in time:^Patient:Ordinal:PhenX; You have diabetes PhenX,
C3259018,Do you suffer from diabetes,diabetes,Do you suffer from diabetes,
C3259218,"Do you have a long-term health problem with heart disease, lung disease, asthma, kidney disease, metabolic disease, diabetes, anemia, or other blood disorder:Find:Pt:^Patient:Ord:PhenX",diabetes,"Long-term health problem PhenX; Do you have a long-term health problem with heart disease, lung disease, asthma, kidney disease, metabolic disease, diabetes, anemia, or other blood disorder [PhenX]; Do you have a long-term health problem with heart disease, lung disease, asthma, kidney disease, metabolic disease, diabetes, anemia, or other blood disorder:Finding:To identify measures at a point in time:^Patient:Ordinal:PhenX",
C3259605,Diabetes:Hx:Pt:^Patient:Ord:PhenX,diabetes,Diabetes:History:To identify measures at a point in time:^Patient:Ordinal:PhenX; Diabetes PhenX; Diabetes [PhenX],
C3264800,OPTIUM EZ (GLUCOSE) TEST STRIP,glucose,OPTIUM EZ (GLUCOSE) TEST STRIP,
C3265553,sodium chloride 35 MG/ML Inhalation Solution [Hyper-Sal],hyper,"Hyper-Sal 0.598 MEQ/ML Inhalation Solution; Hyper-Sal 3.5 % Inhalation Solution; Hyper-Sal, 3.5% inhalation solution; NaCl 35 MG/ML Inhalation Solution [Hyper-Sal]",
C3268446,glucose-6-phosphate dehydrogenase (coenzyme F420) activity,glucose,D-glucose-6-phosphate:F420 1-oxidoreductase activity; coenzyme F420-dependent glucose-6-phosphate dehydrogenase activity; F420-dependent glucose-6-phosphate dehydrogenase activity,
C3268751,positive regulation of transcription from RNA polymerase II promoter in response to glucose starvation,glucose,,
C3270621,regulation of detection of glucose,glucose,regulation of glucose detection,
C3270622,regulation of glucose perception,glucose,,
C3270623,regulation of glucose sensing,glucose,,
C3270624,negative regulation of detection of glucose,glucose,negative regulation of glucose detection,
C3270625,negative regulation of glucose perception,glucose,,
C3270626,negative regulation of glucose sensing,glucose,,
C3270627,positive regulation of detection of glucose,glucose,positive regulation of glucose detection,
C3270628,positive regulation of glucose perception,glucose,,
C3270629,positive regulation of glucose sensing,glucose,,
C3270852,regulation of glycolytic fermentation to ethanol,glucose,regulation of glucose fermentation to ethanol; regulation of ethanol fermentation,
C3270853,negative regulation of glycolytic fermentation to ethanol,glucose,negative regulation of ethanol fermentation; negative regulation of glucose fermentation to ethanol,
C3270876,positive regulation of glycolytic fermentation to ethanol,glucose,positive regulation of ethanol fermentation; positive regulation of glucose fermentation to ethanol,
C3271493,sucrose catabolic process to fructose-6-phosphate and glucose-6-phosphate,glucose,,
C3271980,glucose import in response to insulin stimulus,glucose,cellular glucose import in response to insulin stimulus,
C3272933,Glucose Clearance Measurement,glucose,,
C3273012,BG-9924,BG,,
C3273756,YTH Domain Family Protein 2,glucose,YTH Domain Family Protein 2; Renal Carcinoma Antigen NY-REN-2; YTHDF2; High-Glucose-Regulated Protein 8; CLL-Associated Antigen KW-14,
C3273807,Sodium-Glucose Transporter 2 Inhibitors,glucose,"Sodium Glucose Transporter 2 Inhibitor; Inhibitor, SGLT-2; SGLT 2 Inhibitor; SGLT-2 Inhibitors; SLC5A2 Inhibitor; Sodium Glucose Transporter 2 Inhibitors; SGLT2 Inhibitor; SGLT-2 Inhibitor; Sodium-Glucose Transporter 2 Inhibitor; Inhibitor, SGLT2; Gliflozin; SGLT 2 Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; SGLT2 Inhibitors; Gliflozins",
C3274787,Diabetes Therapy,diabetes,Diabetes Therapy,
C3275118,No Treatment for Diabetes,diabetes,No Treatment for Diabetes,
C3275844,"DIABETES MELLITUS, TYPE II, SUSCEPTIBILITY TO",diabetes,"DIABETES MELLITUS, TYPE II, SUSCEPTIBILITY TO",
C3278053,Hyperglycemia during crises,hyperglycemia,,
C3278311,Renal glucose wasting,glucose,,
C3278384,HYPOINSULINEMIC HYPOGLYCEMIA WITH HEMIHYPERTROPHY,hypoglycemia,HYPOINSULINEMIC HYPOGLYCEMIA WITH HEMIHYPERTROPHY; HYPOINSULINEMIC HYPOGLYCEMIA AND HEMIHYPERTROPHY; HIHGHH,
C3278385,"Reduced consciousness, hypoglycemia-related",hypoglycemia,,
C3278392,Hypoinsulinemic hypoglycemia,hypoglycemia,,
C3278636,Neonatal insulin-dependent diabetes mellitus,diabetes,Neonatal insulin-dependent diabetes mellitus,
C3279610,Low fasting glucose,glucose,,
C3280240,"MICROCEPHALY, EPILEPSY, AND DIABETES SYNDROME",diabetes,"MICROCEPHALY, EPILEPSY, AND DIABETES SYNDROME 1; MEDS; MEDS1",
C3280241,"Diabetes mellitus, infantile",diabetes,,
C3280358,"Wolfram-Like Syndrome, Autosomal Dominant",glucose,"HEARING LOSS, PROGRESSIVE, WITH OPTIC ATROPHY AND/OR IMPAIRED GLUCOSE REGULATION; WFSL; WOLFRAM-LIKE SYNDROME, AUTOSOMAL DOMINANT",
C3327474,Picobirnavirus horse/BG-Eq-3/India/2010,BG,,
C3335359,Platychrysis sp. BG-2011,BG,Prymnesium sp. BG-2011,
C3357239,Chryseobacterium sp. MG-2011-77-BG,BG,,
C3390446,Picobirnavirus pig/BG-Por-2/India/2010,BG,,
C3413182,thioautotrophic extracellular symbiont BG-A of Benthomodiolus geikotsucola,BG,,
C3413183,heterotrophic extracellular symbiont BG-C1 of Benthomodiolus geikotsucola,BG,,
C3413184,heterotrophic extracellular symbiont BG-C2 of Benthomodiolus geikotsucola,BG,,
C3416169,Antirhea sp. BG 573,BG,Antirhea sp. (Mt Lewis BG 5733),
C3464573,ACCU-CHEK SMARTVIEW (GLUCOSE) TEST STRIP,glucose,ACCU-CHEK SMARTVIEW (GLUCOSE) TEST STRIP; Accu-Chek SmartView Test Strips,
C3465479,fructose / glucose / sodium citrate Chewable Product,glucose,,
C3465613,glucose Oral Gel Product,glucose,,
C3466291,glucose Chewable Product,glucose,,
C3467128,Insta-Glucose Oral Gel Product,glucose,,
C3469598,anemia due to glucose phosphate isomerase deficiency,glucose,,
C3469857,SOGA1 gene,glucose,"SOGA1 gene; C20orf117; SOGA1; FLJ44670; KIAA0889; dJ132F21.1; SOGA; suppressor of glucose from autophagy; suppressor of glucose by autophagy; suppressor of glucose, autophagy associated 1; chromosome 20 open reading frame 117",
C3470342,GDPGP1 gene,glucose,GDPGP1 gene; GDPGP1; chromosome 15 open reading frame 58; GDP-D-GLUCOSE PHOSPHORYLASE 1; C15orf58; GDP-D-glucose phosphorylase 1,
C3473050,Bionime GM100 Blood Glucose Meter,blood glucose,,
C3473086,Up & Up Premium Blood Glucose Test Strips,blood glucose,,
C3473283,TRUETEST (GLUCOSE) TEST STRIP,glucose,TRUETEST (GLUCOSE) TEST STRIP,
C3474493,HERBAL GLUCOSE CONTROL CAP/TAB,glucose,HERBAL GLUCOSE CONTROL CAP/TAB,
C3474500,HERBAL GLUCOSE CONTROL,glucose,,
C3481982,Glucose^20M post dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --20 minutes post dose lactose PO; Glucose 20 Min post dose lactose PO [Moles/Vol]; Glucose^20 minutes post dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 20M p Lac PO SerPl-sCnc,
C3481983,Glucose^40M post dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 40M p Lac PO SerPl-sCnc; Glucose^40M post dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 40 Min post dose lactose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --40 minutes post dose lactose PO,
C3481984,Glucose^20M post 50 g lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --20 minutes post 50 g lactose PO; Glucose^20 minutes post 50 g lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 20M p 50 g lac PO SerPl-sCnc; Glucose 20 Min post 50 g lactose PO [Moles/Vol],
C3481985,Glucose^40M post 50 g lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^40M post 50 g lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 40 Min post 50 g lactose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --40 minutes post 50 g lactose PO; Glucose 40M p 50 g lac PO SerPl-sCnc,
C3482270,Glucose^pre 100 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose pre 100 g glucose PO [Moles/Vol]; Glucose [Moles/volume] in Serum or Plasma --pre 100 g glucose PO; Glucose pre 100 g Glc PO SerPl-sCnc; Glucose^pre 100 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C3483458,Glucose-6-Phosphate dehydrogenase:CSub:Pt:RBC:Qn,glucose,Glucose-6-Phosphate dehydrogenase [Enzymatic activity/substance] in Red Blood Cells; G6PD cSub RBC; G6PD (RBC) [Catalytic activity/Moles]; Glucose-6-Phosphate dehydrogenase:Catalytic Substance:To identify measures at a point in time:Erythrocytes:Quantitative,
C3484089,Hemoglobin A1c/Hemoglobin.total:MFr.DF:Pt:Bld:Qn,a1c,Hemoglobin A1c/Hemoglobin.total:Mass Decimal Fraction:To identify measures at a point in time:Whole blood:Quantitative; HbA1c MFr.DF Bld; HbA1c (Bld) [Pure mass fraction]; Hemoglobin A1c/Hemoglobin.total [Pure mass fraction] in Blood,
C3489435,2-deoxy-(18F)-2-fluoro-3-O-methylglucose,glucose,"D-Glucose, 2-deoxy-(18F)2-fluoro-3-O-methyl-",
C3489440,6-O-mycoloyl-D-glucose,glucose,,
C3489795,"Hyper-Ige Recurrent Infection Syndrome, Autosomal Dominant",hyper,"Hyper-Ige Recurrent Infection Syndrome, Autosomal Dominant",
C3490929,"UDP-glucose 4,6-dehydratase, Candida albicans",glucose,"orf19.3674 protein, Candida albicans; GAL102 protein, Candida albicans; CaGAL102 protein, Candida albicans",
C3493855,"1-((2-hydroxyethyl)amino)-2-amino-1,2-dideoxy-D-glucose triphenyltin(IV)",glucose,,
C3493954,(18F)fluoro-deoxy-glucose folate,glucose,,
C3494566,Erectile dysfunction due to type 1 diabetes mellitus,diabetes,Erectile dysfunction due to type 1 diabetes mellitus (disorder); Erectile dysfunction with type 1 diabetes mellitus,
C3495070,Documentation of diabetes medication action plan,diabetes,Documentation of diabetes medication action plan (procedure),
C3495427,Fanconi-Bickel Syndrome,diabetes,"fanconi-bickel syndrome; PSEUDO-PHLORIZIN DIABETES; FANCONI-BICKEL SYNDROME; Fanconi-Bickel Syndromes; Fanconi Type Glycogenosis; GLYCOGEN STORAGE DISEASE XI; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE; Glycogen storage disease due to GLUT2 deficiency; Hepatic Glycogenosis with Amino Aciduria and Glucosuria; Syndrome, Fanconi Bickel; Diabetes, Pseudo-Phlorizin; Syndrome, Fanconi-Bickel; Glycogen Storage Disease Type XI; Lignac-Fanconi Syndrome; FBS; fanconi bickel syndrome; Glycogen Storage Disease XI; Fanconi-Bickel Syndrome; Pseudo Phlorizin Diabetes; Diabete, Pseudo-Phlorizin; GLYCOGENOSIS, FANCONI TYPE; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY; Fanconi Syndrome with Intestinal Malabsorption and Galactose Intolerance; HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME; Bickel Syndrome, Fanconi; Fanconi Bickel Syndrome; Hepatorenal Glycogenosis with Renal Fanconi Syndrome; Glycogenosis, Fanconi Type; GSD due to GLUT2 deficiency; Fanconi-Bickel syndrome; Syndromes, Fanconi-Bickel; Syndrome, Lignac-Fanconi; Lignac Fanconi Syndrome; Glycogen Storage Disease Due to GLUT2 Deficiency; Pseudo-Phlorizin Diabetes; Lignac-Fanconi syndrome; Pseudo-Phlorizin Diabete; Hepatic Glycogenosis with Fanconi Nephropathy; Glycogenosis due to GLUT2 deficiency",
C3495556,Deficiency of aminoacyl-histidine dipeptidase,hyper,Aminoacyl-histidine dipeptidase deficiency; Hyper-beta-carnosinemia; Deficiency of aminoacyl-histidine dipeptidase (disorder); Deficiency of aminoacyl-histidine dipeptidase,
C3495557,Hyper-beta-carnosinemia (disorder),hyper,Hyper-beta-carnosinemia; Hyper-beta-carnosinaemia; Hyper-beta-carnosinemia (disorder),
C3495814,Fulminant type 1 diabetes mellitus,diabetes,Fulminant type 1 diabetes mellitus (disorder),
C3496775,CONTOUR (GLUCOSE) CONTROL SOLN,glucose,CONTOUR (GLUCOSE) CONTROL SOLN,
C3501777,"Renal Tubulopathy, Diabetes Mellitus, and Cerebellar Ataxia due to Duplication of Mitochondrial DNA",diabetes,,
C3502106,"Hypoglycemia, Neonatal, Simulating Foetopathia Diabetica",hypoglycemia,,
C3502481,mannosyl(3)-N-acetyl(2)glucose,glucose,,
C3502945,Glucose 50 MG/ML Prefilled Syringe,glucose,,
C3503297,Glucose 250 MG/ML Prefilled Syringe,glucose,,
C3504920,CONTOUR NEXT (GLUCOSE) TEST STRIP,glucose,Contour Next Medical Test Strips; Contour Next Test Strips; CONTOUR NEXT (GLUCOSE) TEST STRIP,
C3505362,ON CALL PLUS (GLUCOSE) TEST STRIP,glucose,ON CALL PLUS (GLUCOSE) TEST STRIP,
C3527783,"Blood Glucose Monitoring Kit, Silver",blood glucose,,
C3527790,Premium Blood Glucose System,blood glucose,,
C3529422,6-bromo-6-deoxy-D-glucose,glucose,,
C3530586,TRUEplus Glucose Shot,glucose,,
C3531250,PRODIGY AUTOCODE TALKING (GLUCOSE) METER,glucose,PRODIGY AUTOCODE TALKING (GLUCOSE) METER,
C3532257,Gestational diabetes mellitus uncontrolled,diabetes,Gestational diabetes mellitus uncontrolled (finding),
C3532488,History of diabetes mellitus type 2,diabetes,History of diabetes mellitus type 2 (situation); History of diabetes mellitus type II,
C3532489,History of diabetes mellitus type 1,diabetes,History of diabetes mellitus type I; History of diabetes mellitus type 1 (situation),
C3532490,History of maturity onset diabetes mellitus in young,diabetes,History of autosomal dominant diabetes mellitus; History of maturity onset diabetes mellitus in young (situation),
C3532621,Suspected diabetes mellitus,diabetes,Suspected diabetes mellitus (situation),
C3532672,Discussion about hypoglycemia in pregnancy,hypoglycemia,Discussion about hypoglycaemia in pregnancy; Discussion about hypoglycemia in pregnancy (procedure),
C3532679,On subcutaneous insulin for diabetes mellitus,diabetes,On subcutaneous insulin for diabetes mellitus (finding),
C3533045,Glucose.serum-glucose.perition fld,glucose,Glucose.serum-glucose.perition fld; Glucose in serum - glucose in peritoneal fluid,
C3533046,Glucose.serum-glucose.synv fld,glucose,Glucose.serum-glucose.synv fld; Glucose in serum - glucose in synovial fluid,
C3533176,Glucose tolerance 2H panel,glucose,Glucose tolerance 2 hours panel; Glucose tolerance 2H panel,
C3533247,Glucose.serum-glucose.plr fld,glucose,Glucose in serum - glucose in pleural fluid; Glucose.serum-glucose.plr fld,
C3533248,Glucose.serum-glucose.pericard fld,glucose,Glucose.serum-glucose.pericard fld; Glucose in serum - glucose in pericard fld,
C3533474,Glucose.serum-glucose.perition fld:SCncDiff:Pt:Periton fld+Ser/Plas:Qn,glucose,Glucose ser - prt fld-SCDiff; Glucose in serum - glucose in peritoneal fluid (Periton fld+S/P) [Molar conc diff]; Glucose.serum-glucose.perition fld:Difference in Substance Concentration:To identify measures at a point in time:Peritoneal fluid /ascites+Serum/Plasma:Quantitative; Glucose in serum - glucose in peritoneal fluid [Molar concentration difference],
C3533475,Glucose.serum-glucose.synv fld:SCncDiff:Pt:Ser/Plas+Synv fld:Qn,glucose,Glucose in serum - glucose in synovial fluid (S/P+Syn fld) [Molar conc diff]; Glucose.serum-glucose.synv fld:Difference in Substance Concentration:To identify measures at a point in time:Serum/Plasma+Synovial fluid (Joint fluid):Quantitative; Glucose in serum - glucose in synovial fluid [Molar concentration difference]; Glucose ser - synv fld-SCDiff,
C3533512,Insulin^4.5H post 75 g glucose PO:ACnc:Pt:Ser/Plas:Qn,glucose,Insulin [Units/volume] in Serum or Plasma --4.5 hours post 75 g glucose PO; Insulin 4.5 Hr post 75 g glucose PO Qn; Insulin^4.5 hours post 75 g glucose Oral:Arbitrary concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 4.5h p 75 g Glc PO SerPl-aCnc,
C3533585,Glucose:SCnc:Pt:Bld:Qn:Test strip.automated,glucose,Glucose Bld Strip.auto-sCnc; Glucose [Moles/volume] in Blood by Automated test strip; Glucose Auto test strip (Bld) [Moles/Vol]; Glucose:Substance Concentration:To identify measures at a point in time:Whole blood:Quantitative:Test strip.automated,
C3533851,Glucose tolerance 2H panel:-:-:Ser/Plas:Qn,glucose,GTT 2h Pnl SerPl; Glucose tolerance 2H panel:-:-:Ser/Plas:Qn; Glucose tolerance 2 hours panel - Serum or Plasma; Glucose tolerance 2H panel:-:-:Serum/Plasma:Quantitative; Glucose tolerance 2 hours panel,
C3534041,Glucose.serum-glucose.plr fld:SCncDiff:Pt:Ser/Plas+Plr fld:Qn,glucose,Glucose in serum - glucose in pleural fluid [Molar concentration difference]; Glucose.serum-glucose.plr fld:Difference in Substance Concentration:To identify measures at a point in time:Serum/Plasma+Pleural fluid (thoracentesis fld):Quantitative; Glucose in serum - glucose in pleural fluid (S/P+Pleur fld) [Molar conc diff]; Glucose ser - plr fld-SCDiff,
C3534042,Glucose.serum-glucose.pericard fld:SCncDiff:Pt:Pericard fld+Ser/Plas:Qn,glucose,Glucose.serum-glucose.pericard fld:Difference in Substance Concentration:To identify measures at a point in time:Pericardial fluid+Serum/Plasma:Quantitative; Glucose ser - peric fld-SCDiff; Glucose in serum - glucose in pericard fld [Molar concentration difference]; Glucose in serum - glucose in pericard fld (Pericard fld+S/P) [Molar conc diff],
C3534429,Glucose in synovial fluid,glucose,Glucose.synv fld,
C3534430,Serum glucose,serum glucose,Glucose in serum; Glucose.serum,
C3534583,Teens and Diabetes,diabetes,,
C3534584,Children and Diabetes,diabetes,,
C3534592,Diabetes in Children and Teens,diabetes,,
C3536827,Glycogenosis with glucoaminophosphaturia,glucose,Glycogenosis with glucoaminophosphaturia; Pseudo-phlorizin diabetes; Renal glucose-losing syndrome; Glycogenosis with glucoaminophosphaturia (disorder),
C3537659,EasyTouch Glucose Meter Kit,glucose,,
C3537660,EasyTouch Glucose Test Strips,glucose,,
C3537673,EvenCare G3 Glucose Meters,glucose,,
C3537676,Telcare Blood Glucose Meter,blood glucose,,
C3537677,Telcare Blood Glucose Test Strips,blood glucose,,
C3537724,Telcare Blood Glucose Control Solution,blood glucose,,
C3537778,REVEAL (GLUCOSE) TEST STRIP,glucose,REVEAL (GLUCOSE) TEST STRIP,
C3537829,ACCU-CHEK ON CALL VIVID (GLUCOSE) TEST STRIP,glucose,ACCU-CHEK ON CALL VIVID (GLUCO)TEST STRP,
C3537873,FREESTYLE LITE (GLUCOSE) METER,glucose,FreeStyle Lite Glucose Monitoring System; FREESTYLE LITE (GLUCOSE) METER,
C3539002,CDISC SDTM Diabetes Therapy Terminology,diabetes,CDISC SDTM Diabetes Therapy Terminology,
C3539108,"Alpha glucosidase inhibitors, blood glucose lowering",blood glucose,"Alpha glucosidase inhibitors; Alpha glucosidase inhibitors, blood glucose lowering",
C3539178,OTHER DRUGS USED IN DIABETES in ATC,diabetes,OTHER DRUGS USED IN DIABETES in ATC; OTHER DRUGS USED IN DIABETES,
C3539395,GID4 gene,glucose,"C17ORF39; GLUCOSE-INDUCED DEGRADATION-DEFICIENT PROTEIN 4, S. CEREVISIAE, HOMOLOG OF; GID Complex Subunit 4 Homolog Gene; VID24; vacuolar import and degradation 24; CHROMOSOME 17 OPEN READING FRAME 39; GID4 Gene; GID4; GID complex subunit 4; GID4 gene; VACUOLAR IMPORT AND DEGRADATION PROTEIN 24; GID complex subunit 4, VID24 homolog (S. cerevisiae); GID COMPLEX, SUBUNIT 4; chromosome 17 open reading frame 39; C17orf39; GID complex subunit 4 homolog",
C3540012,biguanide blood glucose lower drugs,blood glucose,Biguanides; biguanide blood glucose lower drugs,
C3541957,"Thiazolidinediones, blood glucose lowering drugs",blood glucose,"Thiazolidinediones; Thiazolidinediones, blood glucose lowering drugs",
C3542461,Sodium-Glucose Cotransporter 2 Inhibitor [EPC],glucose,Sodium-Glucose Cotransporter 2 Inhibitor; SGLT2 Inhibitor; Sodium-Glucose Cotransporter 2 Inhibitor [EPC]; Sodium-Glucose Transporter 2 Inhibitor; Glucose-Sodium Symporter 2 Inhibitor; Glucose-Sodium Cotransporter 2 Inhibitor; Sodium-Glucose Symporter 2 Inhibitor; Glucose-Sodium Transporter 2 Inhibitor,
C3542500,ADH-Resistant Diabetes Insipidus,diabetes,ADH-Resistant Diabetes Insipidus; Diabetes Insipidus Renalis; Vasopressin-Resistant Diabetes Insipidus,
C3543909,SLC5A4P1 gene,glucose,"solute carrier family 5 (low affinity glucose cotransporter), member 4 pseudogene 1; solute carrier family 5 member 4 pseudogene 1; SLC5A4P1; SLC5A4P1 gene; solute carrier family 5 (glucose activated ion channel), member 4 pseudogene 1",
C3548562,regulation of gluconeogenesis involved in cellular glucose homeostasis,glucose,,
C3549246,positive regulation of protein export from nucleus in response to glucose starvation,glucose,,
C3549292,mitotic G2 cell cycle arrest in response to glucose starvation,glucose,,
C3549368,adenylate cyclase-activating glucose-activated G protein-coupled receptor signaling pathway,glucose,glucose-sensing PKA pathway; activation of adenylate cyclase activity by glucose involved in G-protein signaling; activation of adenylate cyclase activity by glucose-triggered G-protein signaling pathway; activation of adenylate cyclase activity by glucose-triggered G-protein signalling pathway,
C3553420,Diabetes (in affected males),diabetes,,
C3554874,cholecalciferol / glucose Oral Gel,glucose,,
C3555544,cholecalciferol 6.67 UNT/ML / glucose 250 MG/ML Oral Solution,glucose,"DEXTROSE 15GM/VITAMIN D3 LIQUID,ORAL,60ML; vitamin D3 6.67 UNT/ML / dextrose 250 MG/ML Oral Solution; cholecalciferol 6.67 UNT/mL / glucose 250 MG/mL Oral Solution; DEXTROSE 15GM/VITAMIN D3 ORAL LIQ 60ML",
C3555649,EVENCARE G3 (GLUCOSE) TEST STRIP,glucose,EVENCARE G3 (GLUCOSE) TEST STRIP,
C3555650,EASYMAX 15 (GLUCOSE) TEST STRIP,glucose,EASYMAX 15 GLUCOSE TEST STRIP,
C3556195,cholecalciferol / glucose,glucose,,
C3556827,cholecalciferol / glucose Oral Solution,glucose,,
C3556888,cholecalciferol / glucose Oral Product,glucose,,
C3556889,cholecalciferol / glucose Oral Liquid Product,glucose,,
C3617838,Psammamonas australis,BG,Raphidophyceae sp. BG-2013,
C3640996,Uniformly-labeled [13C]glucose,glucose,[U-13C] Glucose; [U-13C] glucose; uniformly-labeled [U-13C] glucose; U-13C-Glucose,
C3642777,Clever Choice Talk Glucose Sys,glucose,,
C3642788,Pharmacist Choice Glucose Sys,glucose,,
C3642809,Clever Choice Pro Glucose Mtr,glucose,,
C3642811,Clever Choice Glucose Monitor,glucose,,
C3642813,Clever Choice Blood Glucose Syst,blood glucose,,
C3643617,ReliOn Glucose,glucose,,
C3643675,cholecalciferol 6.67 UNT/ML / glucose 250 MG/ML Oral Solution [ReliOn Glucose],glucose,cholecalciferol 400 UNT / glucose 15 GM per 60 ML Oral Solution,
C3643737,cholecalciferol 6.67 UNT/ML / glucose 250 MG/ML [ReliOn Glucose],glucose,,
C3643844,cholecalciferol / glucose Oral Solution [ReliOn Glucose],glucose,,
C3643942,ReliOn Glucose Oral Product,glucose,,
C3643943,ReliOn Glucose Oral Liquid Product,glucose,,
C3644676,cholecalciferol 9.52 UNT/ML / glucose 357 MG/ML Oral Gel,glucose,"DEXTROSE 15GM/32ML ORAL GEL PKT; glucose 15 GM / vitamin D3 400 UNT in 42 mL Oral Gel; cholecalciferol 9.52 UNT/ML / glucose 357.14 MG/ML Oral Gel; vitamin D3 400 UNT / glucose 15,000 MG in 42 ML Oral Gel; DEXTROSE 15GM/32ML GEL,ORAL,PKT",
C3651726,PEG-20 methyl glucose sesquistearate,glucose,PEG-20 methyl glucose sesquistearate; PEG-20 METHYL GLUCOSE SESQUISTEARATE; peg-20 methyl glucose sesquistearate,
C3651750,PPG-10 methyl glucose ether,glucose,,
C3652379,GLUCOCARD EXPRESSION (GLUCOSE) TEST STRIP,glucose,GLUCOCARD EXPRESSN (GLUCOSE) TEST STRIP; Glucocard Expression Strips,
C3652865,"glucose, combinations",glucose,,
C3653297,Dipeptidyl peptidase 4 (DPP-4) inhibitors for blood glucose lowering,blood glucose,Dipeptidyl peptidase 4 (DPP-4) inhibitors,
C3653308,"Insulins and analogues for injection used in Diabetes, intermediate- or long-acting combined with fast-acting",diabetes,"Insulins and analogues for injection used in Diabetes, intermediate- or long-acting combined with fast-acting; Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",
C3653313,Combinations of oral blood glucose lowering drugs,blood glucose,,
C3653344,DRUGS USED IN DIABETES,diabetes,,
C3653359,Sulfonylureas for blood glucose lowering,blood glucose,Sulfonylureas; Sulfonylureas for blood glucose lowering,
C3653361,"Sulfonamides (heterocyclic), blood glucose lowering drugs",blood glucose,Sulfonamides (heterocyclic),
C3653529,Drugs for treatment of hypoglycemia,hypoglycemia,,
C3653824,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",blood glucose,,
C3653889,"Other blood glucose lowering drugs, excl. insulins in ATC",blood glucose,"Other blood glucose lowering drugs, excl. insulins",
C3653979,Aldose reductase inhibitors used in diabetes,diabetes,Aldose reductase inhibitors,
C3654007,Diagnostic agents for diabetes testing,diabetes,Tests for diabetes,
C3655022,Insulin^1H post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin [Moles/volume] in Serum or Plasma --1 hour post 75 g glucose PO; Insulin^1 hour post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 1h p 75 g Glc PO SerPl-sCnc; Insulin 1 Hr post 75 g glucose PO [Moles/Vol],
C3655023,Insulin^2H post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin 2h p 75 g Glc PO SerPl-sCnc; Insulin [Moles/volume] in Serum or Plasma --2 hours post 75 g glucose PO; Insulin^2 hours post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin 2 Hr post 75 g glucose PO [Moles/Vol],
C3655024,Insulin^3H post 75 g glucose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Insulin^3 hours post 75 g glucose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Insulin [Moles/volume] in Serum or Plasma --3 hours post 75 g glucose PO; Insulin 3h p 75 g Glc PO SerPl-sCnc; Insulin 3 Hr post 75 g glucose PO [Moles/Vol],
C3655027,Glucose^15M post dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --15 minutes post dose lactose PO; Glucose 15M p Lac PO SerPl-sCnc; Glucose^15 minutes post dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 15 Min post dose lactose PO [Moles/Vol],
C3655028,Glucose^2.5H post dose lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2.5 hours post dose lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2.5h p Lac PO SerPl-sCnc; Glucose [Moles/volume] in Serum or Plasma --2.5 hours post dose lactose PO; Glucose 2.5 Hr post dose lactose PO [Moles/Vol],
C3657044,3-O-(2'-acetoxy)benzoyl-2-glucopyranose,glucose,glucose-aspirin,
C3657389,lactuside B,glucose,"3beta-glucose-14-hydroxy-11beta, 13-dihydrowoody ene lactone",
C3658177,"glucose regulated protein 78, Leishmania donovani",glucose,"GRP78 protein, Leishmania donovani",
C3661892,Ankle ulcer due to type 1 diabetes mellitus,diabetes,Ulcer of ankle due to type 1 diabetes mellitus (disorder); Ulcer of ankle due to type 1 diabetes mellitus,
C3661932,Angina associated with type 2 diabetes mellitus,diabetes,Angina due to type 2 diabetes mellitus (disorder); Angina due to type 2 diabetes mellitus,
C3661933,Dyslipidemia due to type 2 diabetes mellitus,diabetes,Diabetic dyslipidemia associated with type 2 diabetes mellitus; Dyslipidemia associated with type II diabetes mellitus; Dyslipidemia due to type 2 diabetes mellitus (disorder),
C3661934,Chronic kidney disease stage 1 due to type 2 diabetes mellitus,diabetes,Chronic kidney disease stage 1 due to type 2 diabetes mellitus (disorder); Chronic kidney disease stage 1 due to type II diabetes mellitus; Diabetic stage 1 chronic renal impairment due to type 2 diabetes mellitus,
C3661935,Chronic kidney disease stage 2 due to type 2 diabetes mellitus,diabetes,Chronic kidney disease stage 2 due to type II diabetes mellitus; Diabetic stage 2 chronic renal impairment due to type 2 diabetes mellitus; Chronic kidney disease stage 2 due to type 2 diabetes mellitus (disorder),
C3661936,Chronic kidney disease stage 3 due to type 2 diabetes mellitus,diabetes,Diabetic stage 3 chronic renal impairment due to type 2 diabetes mellitus; Chronic kidney disease stage 3 due to type II diabetes mellitus; Chronic kidney disease stage 3 due to type 2 diabetes mellitus (disorder),
C3661938,Chronic kidney disease stage 4 due to type 2 diabetes mellitus,diabetes,Chronic kidney disease stage 4 due to type II diabetes mellitus; Chronic kidney disease stage 4 due to type 2 diabetes mellitus (disorder); Diabetic stage 4 chronic renal impairment due to type 2 diabetes mellitus,
C3661939,Chronic kidney disease stage 5 due to type 2 diabetes mellitus,diabetes,Chronic kidney disease stage 5 due to type 2 diabetes mellitus (disorder); Chronic kidney disease stage 5 due to type II diabetes mellitus; Diabetic stage 5 chronic renal impairment due to type 2 diabetes mellitus,
C3661941,Mixed hyperlipidemia due to type 2 diabetes mellitus,diabetes,Mixed hyperlipidemia due to type 2 diabetes mellitus (disorder); Mixed hyperlipidemia due to type II diabetes mellitus; Mixed hyperlipidaemia due to type II diabetes mellitus; Mixed hyperlipidaemia due to type 2 diabetes mellitus,
C3661971,Disorder due to well controlled type 2 diabetes mellitus,diabetes,Disorder due to well controlled type 2 diabetes mellitus (disorder),
C3662018,Mixed hyperlipidemia due to type 1 diabetes mellitus,diabetes,Mixed hyperlipidemia due to type 1 diabetes mellitus (disorder); Mixed hyperlipidaemia due to type 1 diabetes mellitus,
C3662019,Pregnancy and type 1 diabetes mellitus,diabetes,Pregnancy and type 1 diabetes mellitus (disorder),
C3662020,Pre-existing diabetes mellitus in pregnancy,diabetes,Pre-existing diabetes mellitus in pregnancy (disorder),
C3662038,Chronic kidney disease due to type 2 diabetes mellitus,diabetes,Diabetic chronic renal impairment due to type 2 diabetes mellitus; Chronic renal impairment due to type II diabetes mellitus; Chronic renal impairment due to type 2 diabetes mellitus; Chronic kidney disease due to type 2 diabetes mellitus (disorder),
C3662121,Neuropathic arthropathy due to type 2 diabetes mellitus,diabetes,Diabetic Charcot's arthropathy associated with type 2 diabetes mellitus; Neuropathic arthropathy due to type 2 diabetes mellitus (disorder),
C3662846,Nonproliferative retinopathy due to type 2 diabetes mellitus,diabetes,Nonproliferative diabetic retinopathy due to type 2 diabetes mellitus; Nonproliferative diabetic retinopathy due to type II diabetes mellitus; Nonproliferative retinopathy due to type 2 diabetes mellitus (disorder),
C3662848,Dermopathy due to type 2 diabetes mellitus,diabetes,Dermopathy due to type 2 diabetes mellitus (disorder),
C3662849,Foot ulcer due to type 2 diabetes mellitus,diabetes,Foot ulcer due to type II diabetes mellitus; Ulcer of foot due to type 2 diabetes mellitus; Ulcer of foot due to type 2 diabetes mellitus (disorder),
C3662850,Peripheral neuropathy due to type 2 diabetes mellitus,diabetes,Peripheral neuropathy with type 2 diabetes; Peripheral neuropathy due to type 2 diabetes mellitus (disorder),
C3662851,Proliferative retinopathy due to type 2 diabetes mellitus,diabetes,Proliferative retinopathy due to type 2 diabetes mellitus (disorder); Proliferative retinopathy with type 2 diabetes mellitus; Proliferative diabetic retinopathy due to type II diabetes mellitus,
C3662852,Vitreous hemorrhage due to type 2 diabetes mellitus,diabetes,Vitreous hemorrhage with type 2 diabetes mellitus; Vitreous haemorrhage due to type 2 diabetes mellitus; Vitreous haemorrhage with type 2 diabetes mellitus; Vitreous hemorrhage due to type 2 diabetes mellitus (disorder),
C3663010,GLUCO NAVI (GLUCOSE) TEST STRIP,glucose,GLUCO NAVI (GLUCOSE) TEST STRIP,
C3665045,Sodium-Glucose Transporter Inhibitors,glucose,Sodium-Glucose Transporter Inhibitors [MoA]; SGLT Inhibitors; Glucose-Sodium Transporter Inhibitors; Sodium-Glucose Cotransporter Inhibitors; Glucose-Sodium Symporter Inhibitors; Sodium-Glucose Symporter Inhibitors; Glucose-Sodium Cotransporter Inhibitors,
C3665046,Sodium-Glucose Transporter 1 Inhibitors,glucose,SGLT1 Inhibitors; Sodium-Glucose Symporter 1 Inhibitors; Sodium-Glucose Cotransporter 1 Inhibitors; Glucose-Sodium Transporter 1 Inhibitors; Glucose-Sodium Cotransporter 1 Inhibitors; Glucose-Sodium Symporter 1 Inhibitors; Sodium-Glucose Transporter 1 Inhibitors [MoA],
C3665047,Sodium-Glucose Transporter 2 Inhibitors [MoA],glucose,Glucose-Sodium Symporter 2 Inhibitors; Sodium-Glucose Cotransporter 2 Inhibitors; Glucose-Sodium Transporter 2 Inhibitors; Sodium-Glucose Transporter 2 Inhibitors [MoA]; Glucose-Sodium Cotransporter 2 Inhibitors; Sodium-Glucose Symporter 2 Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; SGLT2 Inhibitors,
C3665548,Diabetes-nephrosis syndrome,diabetes,Diabetes-nephrosis syndrome,
C3665549,Nephrotic syndrome due to diabetes mellitus,diabetes,Nephrotic syndrome due to diabetes mellitus; Nephrotic syndrome due to diabetes mellitus (disorder); Kimmelstiel - Wilson disease,
C3665770,Acquired lipoatrophic diabetes,diabetes,,
C3668485,Sodium-Glucose Transporter Interactions,glucose,Sodium-Glucose Transporter Interactions [MoA],
C3669205,Blood glucose monitoring (regime/therapy),blood glucose,Blood glucose monitoring; Blood glucose monitoring (regime/therapy),
C3669308,Diabetes type I action plan,diabetes,Diabetes type I action plan; Diabetes Type I action plan,
C3669309,Diabetes type I action plan:Find:Pt:{Setting}:Doc:{Provider},diabetes,Diabetes type I action plan:Find:Pt:{Setting}:Doc:{Role}; Diabetes type I action plan:Finding:To identify measures at a point in time:{Setting}:Document:{Role}; Diabetes type I action plan; Diabetes Type I action plan,
C3669310,Diabetes type II action plan:Finding:Point in time:{Setting}:Document:{Provider},diabetes,Diabetes type II action plan; Diabetes Type II action plan; Diabetes type II action plan:Finding:To identify measures at a point in time:{Setting}:Document:{Role}; Diabetes type II action plan:Find:Pt:{Setting}:Doc:{Role},
C3669311,Diabetes type II action plan,diabetes,Diabetes type II action plan; Diabetes Type II action plan,
C3669330,HEDIS 2014 Value Set - Glucose Tests,glucose,HEDIS 2014 Value Set - Glucose Tests,
C3669331,HEDIS 2014 Value Set - Glucose Tests:-:Point in time:^Patient:-,glucose,HEDIS 2014 GLUC; HEDIS 2014 Value Set - Glucose Tests; HEDIS 2014 Value Set - Glucose Tests:-:To identify measures at a point in time:^Patient:-; HEDIS 2014 Value Set - Glucose Tests:-:Pt:^Patient:-,
C3670603,Amended insulin glucose ratio elevated,glucose,AIGR elevated; AIGR increased; Amended insulin glucose ration increased; Amended insulin glucose ratio elevated (finding),
C3690641,"IVD Test Reagent/Kits, Immunoassay, Autoimmune, Diabetes, Protein Tyrosine Phosphatase Antibody",diabetes,,
C3690642,"IVD Test Reagent/Kits, Immunoassay, Autoimmune, Diabetes, Glutamic Acid Decarboxylase Autoantibody",diabetes,,
C3690643,"IVD Test Reagent/Kits, Immunoassay, Autoimmune, Diabetes, Islet Cell Antibody",diabetes,,
C3690644,"IVD Test Reagent/Kits, Immunoassay, Autoimmune, Diabetes, Insulin Autoantibody",diabetes,,
C3690719,"IVD Test Reagent/Kits, Immunoassay, Standard, Diabetes",diabetes,,
C3690734,"IVD Test Reagent/Kits, Immunoassay, Control, Diabetes",diabetes,,
C3690750,"IVD Test Reagent/Kits, Immunoassay, Calibration, Diabetes",diabetes,,
C3690833,"IVD Test Reagent/Kits, Immunoassay, Diabetes, Proinsulin",diabetes,,
C3690834,"IVD Test Reagent/Kits, Immunoassay, Diabetes, Glucagon",diabetes,,
C3690980,"IVD Test Reagent/Kits, Immunoassay, Diabetes, Glycated Hemoglobin",diabetes,,
C3691007,"IVD Test Reagent/Kits, Home Assay, Urine, Glucose",glucose,,
C3691328,"IVD Test Reagent/Kits, Home Assay, Whole Blood, Glucose",glucose,,
C3691446,"IVD Test Reagent/Kits, Immunoassay, Autoimmune, Diabetes",diabetes,,
C3691491,"IVD Test Reagent/Kits, Immunoassay, Diabetes, Insulin",diabetes,,
C3691492,"IVD Test Reagent/Kits, Immunoassay, Diabetes, C-Peptide",diabetes,,
C3691493,"IVD Test Reagent/Kits, Immunoassay, Diabetes",diabetes,,
C3691599,"IVD Test Reagent/Kits, Clinical Chemistry, Rapid Test, Whole Blood, Glucose",glucose,,
C3691654,"IVD Test Reagent/Kits, Clinical Chemistry, Saccharide, Glucose",glucose,,
C3691685,"IVD Test Reagent/Kits, Clinical Chemistry, Enzyme, Glucose Phosphate Isomerase",glucose,,
C3691747,"IVD Test Reagent/Kits, Clinical Chemistry, Rapid Test, Whole Blood, Glucose, Strip",glucose,,
C3692134,"IVD Test Reagent/Kits, Molecular Assay, Inborn Disorder, Polygenic, Diabetes",diabetes,,
C3692402,OneTouch Glucose Control High-Low,glucose,,
C3692403,OneTouch Glucose Control Normal,glucose,,
C3696087,DIATRUE PLUS (GLUCOSE) TEST STRIP,glucose,DIATRUE PLUS (GLUCOSE) TEST STRIP,
C3697001,Blood glucose test declined,blood glucose,Blood glucose test declined (situation),
C3697053,Diabetes self management plan,diabetes,Diabetes self management plan (record artifact),
C3698145,Dietary education for impaired glucose tolerance,glucose,Dietary education for impaired glucose tolerance (procedure),
C3698325,Education about self management of diabetes,diabetes,Education about self management of diabetes (procedure),
C3698472,Family history of diabetes mellitus with complication,diabetes,Family history of diabetes mellitus with complication (situation),
C3698574,Lifestyle education regarding risk of diabetes,diabetes,Lifestyle education regarding risk of diabetes (procedure),
C3699463,Glucose^15M post 50 g lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 15M p 50 g Lac PO SerPl-sCnc; Glucose 15 Min post 50 g lactose PO [Moles/Vol]; Glucose^15 minutes post 50 g lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --15 minutes post 50 g lactose PO,
C3699629,Glucose-6-Phosphate dehydrogenase/Pyruvate kinase:Ratio:Pt:Bld:Qn,glucose,G6PD/Pyruvate kinase (Bld) [Ratio]; G6PD/PK Bld-Rto; Glucose-6-Phosphate dehydrogenase/Pyruvate kinase:Ratio:To identify measures at a point in time:Whole blood:Quantitative; Glucose-6-Phosphate dehydrogenase/Pyruvate kinase [Ratio] in Blood,
C3699630,Glucose-6-Phosphate dehydrogenase/Pyruvate kinase,glucose,Glucose-6-Phosphate dehydrogenase/Pyruvate kinase,
C3699791,Glucose:SCnc:XXX:Urine:Qn,glucose,Glucose:Substance Concentration:Not specified:Urine:Quantitative; Glucose ?Tm Ur-sCnc; Glucose Unsp time (U) [Moles/Vol]; Glucose [Moles/volume] in Urine collected for unspecified duration,
C3709599,ACCU-CHEK INFORM II (GLUCOSE) TEST STRIP,glucose,ACCU-CHEK INFORM II (GLUCOSE) TEST STRIP; Accu-Chek Inform II System Test Strips,
C3710631,"GFOD2 protein, human",glucose,"glucose-fructose oxidoreductase domain containing 2 protein, human",
C3711391,6q24-Related Transient Neonatal Diabetes Mellitus,diabetes,Tndm Type 1; 6q24-Tndm,
C3712805,1-O-galloyl-6-O-vanilloyl-beta-glucose,glucose,,
C3714202,oleanolic acid-3-O-beta-D-xylopyranose(1-3)-beta-D-pyranoid glucose,glucose,,
C3727439,Flavobacterium sp. S17.05.BG.W.Gill.N,BG,,
C3727487,Flavobacterium sp. S72.05.BG.W.Kidney,BG,,
C3727497,Flavobacterium sp. T1.05.BG.W.Gill.N,BG,,
C3727559,Flavobacterium sp. T1L.05.BG.W.Gill.N,BG,,
C3746301,Sarcocystis elongata,BG,Sarcocystis sp. 1 BG-2013,
C3746302,Sarcocystis truncata,BG,Sarcocystis sp. 2 BG-2013,
C3746357,Comatella sp. BG-2013,BG,,
C3746358,Tropiometra sp. BG-2013,BG,,
C3746781,Cenometra sp. BG-2013,BG,,
C3770677,Acinetobacter sp. BG-9-R4,BG,,
C3770678,Alteromonas sp. BG-6-R2,BG,,
C3770679,Alteromonas sp. BG-7-E3,BG,,
C3770680,Aquimarina sp. BG-3-R2,BG,,
C3770681,Bacillus sp. BG-6-E4,BG,,
C3770682,Bacillus sp. BG-7-E4,BG,,
C3770683,Bacillus sp. BG-7-R5,BG,,
C3770684,Bacillus sp. BG-8-R2,BG,,
C3770695,Chromohalobacter sp. BG-1-R4,BG,,
C3770696,Cobetia sp. BG-6-E1,BG,,
C3770697,Demequina sp. BG-7-R7,BG,,
C3770698,Exiguobacterium sp. BG-6-E3,BG,,
C3770699,Gramella sp. BG-4-R5,BG,,
C3770701,Kushneria sp. BG-3-R5,BG,,
C3770702,Labrenzia sp. BG-3-E2,BG,,
C3770703,Leeuwenhoekiella sp. BG-9-E5,BG,,
C3770704,Marinobacter sp. BG-1-R5,BG,,
C3770705,Marinomonas sp. BG-10-E1,BG,,
C3770706,Marinomonas sp. BG-2-R2,BG,,
C3770707,Marinomonas sp. BG-4-E2,BG,,
C3770711,Mesonia sp. BG-4-E6,BG,,
C3770712,Micrococcus sp. BG-9-R5,BG,,
C3770713,Polaribacter sp. BG-1-R2,BG,,
C3770714,Polaribacter sp. BG-2-E3,BG,,
C3770715,Pseudoalteromonas sp. BG-1-E1,BG,,
C3770716,Pseudoalteromonas sp. BG-10-R2,BG,,
C3770717,Pseudoalteromonas sp. BG-7-R2,BG,,
C3770718,Pseudoalteromonas sp. BG-9-E1,BG,,
C3770719,Pseudomonas sp. BG-2-R4,BG,,
C3770720,Pseudomonas sp. BG-4-E5,BG,,
C3770722,Psychrobacter sp. BG-4-R2,BG,,
C3770726,Rhodovulum sp. BG-4-R8,BG,,
C3770728,Sagittula sp. BG-9-E2,BG,,
C3770730,Shewanella sp. BG-2-E1,BG,,
C3770731,Tenacibaculum sp. BG-4-E3,BG,,
C3770732,Thalassospira sp. BG-8-E3,BG,,
C3770733,Vibrio sp. BG-1-E3,BG,,
C3770734,Vibrio sp. BG-10-E3,BG,,
C3770735,Vibrio sp. BG-3-E4,BG,,
C3770736,Vibrio sp. BG-5-R4,BG,,
C3770737,Vibrio sp. BG-8-E5,BG,,
C3772285,Santessoniella sp. Anderson 942 (BG),BG,,
C3772293,Parmeliella cf. thysanota Galloway 847 (BG),BG,,
C3782776,Cycloclasticus sp. BG-2,BG,,
C3792238,Peltigera sp. 1 NM-2016,BG,Peltigera sp. 1 BG-2014,
C3792239,Peltigera sp. 2 NM-2016,BG,Peltigera sp. 2 BG-2014,
C3792240,Peltigera sp. 3 NM-2016,BG,Peltigera sp. 3 BG-2014,
C3792241,Peltigera sp. 4 NM-2016,BG,Peltigera sp. 4 BG-2014,
C3792242,Peltigera sp. 5 NM-2016,BG,Peltigera sp. 5 BG-2014,
C3792243,Peltigera sp. 6 NM-2016,BG,Peltigera sp. 6 BG-2014,
C3792244,Peltigera sp. 7 NM-2016,BG,Peltigera sp. 7 BG-2014,
C3792337,Peltigera sp. 8 NM-2016,BG,Peltigera sp. 8 BG-2014,
C3802812,Algoriphagus sp. BG-10-R1,BG,,
C3802813,Citreicella sp. BG-5-R6,BG,,
C3802815,Zunongwangia sp. BG-8-R4,BG,,
C3806046,Hypo- or areflexia during attacks,hypo,,
C3806204,Hypoketotic hypoglycemia under fasting conditions,hypoglycemia,,
C3806278,Hyperglycemia-induced osmotic diuresis,hyperglycemia,,
C3806370,"Hypoglycemia, oral protein-induced",hypoglycemia,,
C3807853,De- or hypo-pigmented macules,hypo,,
C3809554,"Hyperglycemia, insulin-responsive, episodic",hyperglycemia,,
C3809719,"Severe dermatitis, multiple allergies, metabolic wasting syndrome",hyper,"Congenital erythroderma-hypotrichosis-recurrent infections-multiple food allergies syndrome; Severe dermatitis-multiple allergies-metabolic wasting syndrome; SAM syndrome; SEVERE DERMATITIS, MULTIPLE ALLERGIES, AND METABOLIC WASTING SYNDROME; Congenital erythroderma, hypotrichosis, recurrent infections, multiple food allergies syndrome; EPKHE; Severe dermatitis, multiple allergies, metabolic wasting syndrome (disorder); ERYTHRODERMA, CONGENITAL, WITH PALMOPLANTAR KERATODERMA, HYPOTRICHOSIS, AND HYPER-IgE; Severe dermatitis, multiple allergies, metabolic wasting syndrome; SAM SYNDROME",
C3809996,"Hypoglycemia, intermittent",hypoglycemia,,
C3810542,PDIA3 wt Allele,glucose,"ER60; Glucose-Regulated Protein, 58kD Gene; Glucose Regulated Protein, 58kDa Gene; ERp60; PI-PLC; GRP57; ERp57; PDIA3 wt Allele; Protein Disulfide Isomerase-Associated 3 Gene; HsT17083; GRP58; ERp61; P58; Protein Disulfide Isomerase Family A, Member 3 wt Allele",
C3813125,"Islet Amyloid Polypeptide, human",diabetes,Amylin; Diabetes-Associated Peptide; Insulinoma Amyloid Peptide; Islet Amyloid Polypeptide; DAP,
C3813126,IAPP wt Allele,diabetes,IAPDAP; Islet Amyloid Polypeptide wt Allele; IAPP wt Allele; AMYLIN; IAP; Islet Amyloid Polypeptide (Diabetes-Associated Peptide; Amylin) Gene; DAP,
C3813726,Diabetes mellitus in mother complicating childbirth,diabetes,Diabetes mellitus in childbirth; Diabetes mellitus in mother complicating childbirth (disorder),
C3817783,HORSE CHESTNUT 1 [hp_X] in 1 mL / ARNICA MONTANA 3 [hp_X] in 1 mL / ARSENIC ACID 200 [hp_C] in 1 mL / HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK 3 [hp_X] in 1 mL / CHAMAELIRIUM LUTEUM ROOT 3 [hp_X] in 1 mL / PORK LIVER 6 [hp_X] in 1 mL / IRIS VERSICOLOR ROOT 200 [hp_C] in 1 mL / SUS SCROFA PANCREAS 6 [hp_X] in 1 mL / PHOSPHORIC ACID 200 [hp_C] in 1 mL / ROSMARINUS OFFICINALIS FLOWERING TOP 3 [hp_X] in 1 mL / CLAVICEPS PURPUREA SCLEROTIUM 30 [hp_C] in 1 mL / SYZYGIUM CUMINI SEED 3 [hp_X] in 1 mL / URANYL NITRATE HEXAHYDRATE 30 [hp_C] in 1 mL ORAL SPRAY [Diabetes Type II],diabetes,,
C3819005,RELION ULTIMA (GLUCOSE) TEST STRIP,glucose,RELION ULTIMA (GLUCOSE) TEST STRIP; ReliOn Ultima Test Strips,
C3819011,UNISTRIP1 (GLUCOSE) TEST STRIP,glucose,UNISTRIP1 (GLUCOSE) TEST STRIP,
C3819012,ONE TOUCH VERIO (GLUCOSE) TEST STRIP,glucose,ONE TOUCH VERIO (GLUCOSE) TEST STRIP,
C3819013,GENSTRIP (GLUCOSE) TEST STRIP,glucose,GENSTRIP GLUCOSE TEST STRIP,
C3820618,cellular response to glucose-phosphate stress,glucose,,
C3820650,gastric inhibitory peptide signaling pathway,glucose,gastric inhibitory polypeptide receptor signaling pathway; glucose-dependent insulinotropic polypeptide signaling; GIP signaling,
C3820853,glucose 6-phosphate:inorganic phosphate antiporter activity,glucose,,
C3820887,"glycogen synthase activity, transferring glucose-1-phosphate",glucose,,
C3820966,galactose to glucose-1-phosphate metabolic process,glucose,,
C3820974,glycolytic process through glucose-6-phosphate,glucose,,
C3820976,glycolytic process through glucose-1-phosphate,glucose,,
C3821039,protein-phosphocysteine-glucose phosphotransferase system transporter activity,glucose,,
C3821056,glycolysis from storage polysaccharide through glucose-1-phosphate,glucose,,
C3822961,regulation of glucose mediated signaling pathway,glucose,regulation of glucose mediated signalling,
C3822962,negative regulation of glucose mediated signaling pathway,glucose,down-regulation of glucose mediated signaling pathway; down regulation of glucose mediated signaling pathway; down regulation of glucose mediated signalling; down-regulation of glucose mediated signalling; downregulation of glucose mediated signaling pathway; downregulation of glucose mediated signalling; negative regulation of glucose mediated signalling,
C3822963,inhibition of glucose mediated signaling pathway,glucose,,
C3822964,inhibition of glucose mediated signalling,glucose,,
C3822965,positive regulation of glucose mediated signaling pathway,glucose,upregulation of glucose mediated signaling pathway; positive regulation of glucose mediated signalling; up regulation of glucose mediated signalling; up regulation of glucose mediated signaling pathway; up-regulation of glucose mediated signalling; upregulation of glucose mediated signalling; up-regulation of glucose mediated signaling pathway,
C3822966,activation of glucose mediated signaling pathway,glucose,,
C3822967,activation of glucose mediated signalling,glucose,,
C3823705,poly(hydroxyalkanoate) biosynthetic process from glucose,glucose,poly(hydroxyalkanoate) synthesis from glucose; poly(hydroxyalkanoate) formation from glucose; poly(hydroxyalkanoate) anabolism from glucose; poly(hydroxyalkanoate) biosynthesis from glucose,
C3824558,glucose transporter complex,glucose,glucose transporter complex location,
C3825243,Blood sugar monitoring,blood sugar,,
C3825246,Diabetes in old age,diabetes,,
C3825256,Hypoglycemia in newborn infants,hypoglycemia,,
C3825343,Diabetes in adolescence,diabetes,,
C3825462,Diabetes in youth,diabetes,,
C3826457,Diabetes in children,diabetes,,
C3827342,Have Trouble Controlling Blood Sugar,blood sugar,,
C3828492,Pre-Gestational Diabetes,diabetes,Pregestational Diabetes,
C3829535,Intact Glucose-dependent Insulinotropic Peptide Measurement,glucose,,
C3829717,Hemoglobin A1C to Hemoglobin Ratio Measurement,a1c,,
C3829804,Have Diabetes,diabetes,,
C3829828,Has End Organ Damage from Diabetes,diabetes,,
C3829829,Has Diabetes that Requires Treatment,diabetes,,
C3830315,End Organ Damage from Diabetes,diabetes,,
C3830519,Diabetes Diagnosis Since Steroid Treatment,diabetes,,
C3831991,"ACCU-CHEK COMPACT PLUS (GLUCOSE) TEST DRUM,102",glucose,"ACCU-CHEK CMPT PLUS(GLUCOSE)TEST DRM,102",
C3831992,"ACCU-CHEK COMPACT PLUS (GLUCOSE) TEST DRUM,17",glucose,"ACCU-CHEK CMPT PLUS(GLUCOSE) TEST DRM,17",
C3832028,ON CALL EXPRESS (GLUCOSE) TEST STRIP,glucose,ON CALL EXPRESS (GLUCOSE) TEST STRIP,
C3832029,ON CALL VIVID (GLUCOSE) TEST STRIP,glucose,ON CALL VIVID (GLUCOSE) TEST STRIP,
C3832539,Lt Caresens Voice Blood Glucose Meter,blood glucose,,
C3833093,salicyloyl phytosphingosine 0.2 MG/ML Medicated Shampoo,hypo,salicyloyl phytosphingosine 0.02 % Medicated Shampoo; SALICYLOYL PHYTOSPHINGOSINE 0.2 mg in 1 mL TOPICAL SHAMPOO [Suffusion PS Hypo-Allergenic]; SALICYLOYL PHYTOSPHINGOSINE 0.2 mg in 1 mL TOPICAL SHAMPOO [Phyto EFA],
C3833360,dipotassium glucose-6-phosphate,glucose,DIPOTASSIUM GLUCOSE-6-PHOSPHATE,
C3834503,HEALTHPRO (GLUCOSE) TEST STRIP,glucose,HEALTHPRO (GLUCOSE) TEST STRIP,
C3837958,"Diabetes Mellitus, Ketosis-Prone",diabetes,"ketosis prone diabetes; DIABETES MELLITUS, KETOSIS-PRONE; Ketosis-prone diabetes mellitus (disorder); Diabetes Mellitus, Ketosis-Prone; Ketosis-prone diabetes mellitus; Ketosis-Prone Diabetes Mellitus; Diabetes Mellitus, Ketosis Prone; KPD",
C3837967,"TYPE 2 DIABETES MELLITUS, SUSCEPTIBILITY TO",diabetes,"TYPE 2 DIABETES MELLITUS, SUSCEPTIBILITY TO; DIABETES MELLITUS, TYPE 2, SUSCEPTIBILITY TO",
C3837968,"DIABETES MELLITUS, TYPE 1, SUSCEPTIBILITY TO",diabetes,,
C3838944,Sodium glucose cotransporter subtype 2 inhibitor,glucose,Substance with sodium glucose cotransporter subtype 2 inhibitor mechanism of action (substance); Substance with sodium glucose cotransporter subtype 2 inhibitor mechanism of action; Product containing sodium glucose cotransporter subtype 2 inhibitor (product); Sodium glucose cotransporter subtype 2 inhibitor; Sodium glucose cotransporter subtype 2 inhibitor-containing product,
C3839006,Pre-existing diabetes mellitus in mother complicating childbirth,diabetes,Pre-existing diabetes mellitus in mother complicating childbirth (disorder); Pre-existing diabetes mellitus in childbirth,
C3839274,Education about diabetes and driving,diabetes,Education about diabetes and driving (procedure),
C3839440,Diabetes mellitus in remission,diabetes,Diabetes mellitus in remission (disorder),
C3839501,Diabetes foot care clinic,diabetes,Diabetes foot care clinic (environment),
C3839591,Type II diabetes mellitus in remission,diabetes,Type 2 diabetes mellitus in remission; Type II diabetes mellitus in remission (disorder),
C3839604,Postpartum gestational diabetes mellitus,diabetes,"Postpartum gestational diabetes mellitus (disorder); Gestational diabetes, delivered",
C3839636,Diabetes clinic,diabetes,Diabetes clinic (environment),
C3839722,Type I diabetes mellitus in remission,diabetes,Type I diabetes mellitus in remission (disorder); Type 1 diabetes mellitus in remission,
C3839840,Diabetes in pregnancy clinic,diabetes,Diabetes in pregnancy clinic (environment),
C3840057,Supervision of high risk pregnancy with history of gestational diabetes mellitus,diabetes,Supervision of high risk pregnancy with history of gestational diabetes mellitus (regime/therapy),
C3840174,Agreeing on diabetes care plan,diabetes,Agreeing on diabetes care plan (procedure),
C3840222,Supervision of high risk pregnancy with history of gestational diabetes mellitus done,diabetes,Supervision of high risk pregnancy with history of gestational diabetes mellitus done (situation),
C3840385,Glucose challenge,glucose,Glucose challenge,
C3840451,Glucose challenge panel,glucose,Glucose challenge (hydrogen breath test) panel; Glucose challenge panel,
C3840472,Pyruvate kinase/Glucose-6-Phosphate dehydrogenase,glucose,Pyruvate kinase/Glucose-6-Phosphate dehydrogenase,
C3841294,Diabetes prepregnancy,diabetes,,
C3842020,Medical-hypoglycemia/diabetic emergency,hypoglycemia,,
C3842022,Medical-hyperglycemia,hyperglycemia,,
C3842544,Type 2 diabetes (Adult onset),diabetes,,
C3842545,Type 1 diabetes (Juvenile onset),diabetes,,
C3842789,Taking oral medications for diabetes,diabetes,,
C3843079,Diabetes or high blood sugar,blood sugar,,
C3843187,Prescription medicine for diabetes,diabetes,,
C3844818,Attention Deficit Hyper Activity,hyper,,
C3845514,"Hypo/hyperglycemia, diabetes out of control",hypo,,
C3847131,Glucose challenge:Imp:Pt:Exhl gas:Nom,glucose,Glucose challenge:Impression/interpretation of study:To identify measures at a point in time:Exhaled gas (breath):Nominal; Glucose challenge (hydrogen breath test) [Interpretation] in Exhaled gas; Glucose HBT ExG-Imp; Glucose challenge (hydrogen breath test) (Exhl gas) [Interp],
C3847148,Glucose:MCnc:Pt:Ser/Plas/Bld:Qn,glucose,"Glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma/Whole blood:Quantitative; Glucose (S/P/Bld) [Mass/Vol]; Glucose SerPlBld-mCnc; Glucose [Mass/volume] in Serum, Plasma or Blood",
C3847237,Glucose:SCnc:12H:Urine:Qn,glucose,Glucose (12H U) [Moles/Vol]; Glucose 12h Ur-sCnc; Glucose:Substance Concentration:12 hours:Urine:Quantitative; Glucose [Moles/volume] in 12 hour Urine,
C3847238,Glucose:SRat:12H:Urine:Qn,glucose,Glucose:Substance Rate:12 hours:Urine:Quantitative; Glucose (12H U) [Moles/Time]; Glucose [Moles/time] in 12 hour Urine; Glucose 12h Ur-sRate,
C3847288,Glucose challenge panel:-:Pt:Exhl gas:Qn,glucose,Glucose challenge (hydrogen breath test) panel - Exhaled gas; Glucose challenge panel:-:To identify measures at a point in time:Exhaled gas (breath):Quantitative; Glucose HBT Pnl ExG; Glucose challenge (hydrogen breath test) panel (Exhl gas),
C3847363,Pyruvate kinase/Glucose-6-Phosphate dehydrogenase:CRto:Pt:RBC:Qn,glucose,PK/G6PD RBC-cRto; Pyruvate kinase/Glucose-6-Phosphate dehydrogenase:Catalytic Ratio:To identify measures at a point in time:Erythrocytes:Quantitative; Pyruvate kinase/Glucose-6-Phosphate dehydrogenase (RBC) [Catalytic ratio]; Pyruvate kinase/Glucose-6-Phosphate dehydrogenase [Enzymatic activity ratio] in Red Blood Cells,
C3849515,"UGGT2 protein, mouse",glucose,"UDP-glucose:glycoprotein glucosyltransferase 2, mouse",
C3849516,"UGGT1 protein, mouse",glucose,"UDP-glucose:glycoprotein glucosyltransferase 1, mouse",
C3853189,Glucose water infant formula,glucose,Glucose water infant formula (product),
C3853362,Diabetes mellitus type 2 without retinopathy,diabetes,Diabetes mellitus type 2 without retinopathy (disorder),
C3853619,Glucose-6-phosphate dehydrogenase (G6PD) (Chemistry Procedures),glucose,,
C3853633,Sports mouth guard,BG,Mouth guard; MG - Mouth guard; Athletic Mouth Guards; Sports mouth guard (physical object); Sports mouth guard; Bite guard; Gum shield; MOUTHGUARD; Mouth protector; Mouth Guards; BG - Bite guard,
C3853667,glucose 0.774 MG/MG Oral Gel,glucose,dextrose 77.4 % Oral Gel; glucose 24 g/31 g oral gel; DEXTROSE 24GM/31GM SQUEEZE TUBE,
C3854193,HEDIS 2015 Value Set - Glucose Tests,glucose,HEDIS 2015-2018 Value Set - Glucose Tests,
C3854194,HEDIS 2015 Value Set - Glucose Tests:-:Pt:^Patient:-,glucose,HEDIS 2015-2018 Value Set - Glucose Tests:-:Pt:^Patient:-; HEDIS 2015-2018 Value Set - Glucose Tests; HEDIS 2015-2018 Value Set - Glucose Tests:-:To identify measures at a point in time:^Patient:-; HEDIS 2015-18 Glucose Tests,
C3858009,ONE TOUCH VERIO (GLUCOSE) MID CONTROL SOLN,glucose,ONE TOUCH VERIO (GLUCOSE) MID CNTRL SOLN; OneTouch Verio Control Solution MID,
C3858010,ONE TOUCH VERIO (GLUCOSE) HIGH CONTROL SOLN,glucose,ONE TOUCH VERIO (GLUCOSE) HI CNTRL SOLN,
C3858011,TRUE METRIX (GLUCOSE) TEST STRIP,glucose,TRUE METRIX (GLUCOSE) TEST STRIP,
C3859157,methyl glucose sesquistearate,glucose,Methyl Glucose Sesquistearate; methyl glucose sesquistearate; METHYL GLUCOSE SESQUISTEARATE,
C3859277,CONTOUR NEXT (GLUCOSE) METER,glucose,CONTOUR NEXT (GLUCOSE) METER; Contour Next Meter,
C3859304,PRECISION XCEED PRO (GLUCOSE) TEST STRIP,glucose,PRECISION XCEED PRO (GLUCOSE) TEST STRIP,
C3859586,Kroger Premium Blood Glucose Test Strips,blood glucose,,
C3864367,glucose 0.774 MG/MG Oral Gel [Insta-Glucose],glucose,"Insta-Glucose, 24 g/31 g oral gel; Insta-Glucose 77.4 % Oral Gel",
C3869944,Erythrocytes.hyperchromic/100 erythrocytes:NFr:Pt:Bld:Qn:Automated count,hyper,%HYPER/100 RBC NFr Bld Auto; RBC.hyperchromic/100 RBC Auto (Bld); Erythrocytes.hyperchromic/100 erythrocytes in Blood by Automated count; Erythrocytes.hyperchromic/100 erythrocytes:Number Fraction:To identify measures at a point in time:Whole blood:Quantitative:Automated count,
C3869965,Erythrocytes.hypochromic/100 erythrocytes:NFr:Pt:Bld:Qn:Automated count,hypo,RBC.hypochromic/100 RBC Auto (Bld); %HYPO/100 RBC NFr Bld Auto; Erythrocytes.hypochromic/100 erythrocytes:Number Fraction:To identify measures at a point in time:Whole blood:Quantitative:Automated count; Erythrocytes.hypochromic/100 erythrocytes in Blood by Automated count,
C3870240,Glucose^45M post 50 g lactose PO:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Moles/volume] in Serum or Plasma --45 minutes post 50 g lactose PO; Glucose 45 Min post 50 g lactose PO [Moles/Vol]; Glucose^45M post 50 g lactose Oral:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 45M p 50 g Lac PO SerPl-sCnc,
C3870547,Glucose^1.5H post dose triple bolus:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5h p Triple Bolus SerPl-sCnc; Glucose 1.5 Hr post dose triple bolus [Moles/Vol]; Glucose^1.5 hours post dose triple bolus:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --1.5 hours post dose triple bolus,
C3871401,"Artificial pancreas device system (e.g., low glucose suspend (lgs) feature) including continuous glucose monitor, blood glucose device, insulin pump and computer algorithm that communicates with all of the devices",blood glucose,,
C3872180,glucose 0.774 MG/MG [Insta-Glucose],glucose,,
C3872325,glucose 0.774 MG/MG,glucose,,
C3872439,Ulcer of lower limb due to type 2 diabetes mellitus,diabetes,Ulcer of lower extremity due to type 2 diabetes mellitus; Ulcer of lower limb due to type 2 diabetes mellitus (disorder); Leg ulcer due to type 2 diabetes mellitus; Ulcer of lower extremity due to diabetes mellitus type 2,
C3872441,Proliferative retinopathy following surgery due to diabetes mellitus,diabetes,Proliferative retinopathy following surgery due to diabetes mellitus (disorder); Proliferative diabetic retinopathy following surgery,
C3872824,"Assessment using congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2 - vascular disease, age, sex category score",diabetes,"Assessment using congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2 - vascular disease, age, sex category score (procedure)",
C3873629,Neuropathy due to unstable diabetes mellitus type 1,diabetes,Neuropathy due to unstable diabetes mellitus type 1 (disorder); Neuropathy due to brittle type I diabetes mellitus,
C3873632,Retinopathy due to unstable diabetes mellitus type 1,diabetes,Retinopathy due to unstable diabetes mellitus type 1 (disorder); Retinopathy due to brittle type I diabetes mellitus,
C3874266,Maternal history of non-insulin dependent diabetes mellitus,diabetes,Maternal history of non-insulin dependent diabetes mellitus (situation),
C3874269,Maternal history of diabetes mellitus,diabetes,Maternal history of diabetes mellitus (situation),
C3874273,Maternal history of insulin dependent diabetes mellitus,diabetes,Maternal history of insulin dependent diabetes mellitus (situation),
C3874354,Diabetes monitoring invitation by short message service text messaging,diabetes,Diabetes monitoring invitation by short message service text messaging (procedure),
C3874779,Hypertension in chronic kidney disease due to type 1 diabetes mellitus,diabetes,Hypertension in chronic kidney disease due to type 1 diabetes mellitus (disorder); Hypertension in chronic kidney disease due to type I diabetes mellitus,
C3874791,End stage renal disease on dialysis due to type 1 diabetes mellitus,diabetes,End stage renal disease on dialysis due to type 1 diabetes mellitus (disorder),
C3874812,Ischemia of retina due to type 1 diabetes mellitus,diabetes,Ischemia of retina due to type 1 diabetes mellitus (disorder); Retinal ischemia due to type 1 diabetes mellitus; Retinal ischaemia with type 1 diabetes mellitus; Retinal ischaemia due to type 1 diabetes mellitus; Ischaemia of retina due to type 1 diabetes mellitus; Retinal ischemia with type 1 diabetes mellitus,
C3874826,Hypertension concurrent and due to end stage renal disease on dialysis due to type 2 diabetes mellitus,diabetes,Hypertension concurrent and due to end stage renal disease on dialysis due to type 2 diabetes mellitus (disorder),
C3874843,Diabetes mellitus type 1 without retinopathy,diabetes,Diabetes mellitus type 1 without retinopathy (disorder),
C3874846,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,diabetes,Hypertension in chronic kidney disease due to type II diabetes mellitus; Hypertension in chronic kidney disease due to type 2 diabetes mellitus (disorder),
C3874859,Hypertension concurrent and due to end stage renal disease on dialysis due to type 1 diabetes mellitus,diabetes,Hypertension concurrent and due to end stage renal disease on dialysis due to type 1 diabetes mellitus (disorder),
C3874878,Hypertension in chronic kidney disease stage 4 due to type 2 diabetes mellitus,diabetes,Hypertension in chronic kidney disease stage 4 due to type II diabetes mellitus; Hypertension in chronic kidney disease stage 4 due to type 2 diabetes mellitus (disorder),
C3874882,Osteomyelitis due to type 1 diabetes mellitus,diabetes,Osteomyelitis due to type 1 diabetes mellitus (disorder),
C3874900,End stage renal disease on dialysis due to type 2 diabetes mellitus,diabetes,End stage renal disease on dialysis due to type 2 diabetes mellitus (disorder),
C3874944,Ischemic ulcer of foot due to type 2 diabetes mellitus,diabetes,Ischaemic foot ulcer due to type 2 diabetes mellitus; Ischemic ulcer of foot due to type 2 diabetes mellitus (disorder); Ischaemic ulcer of foot due to type 2 diabetes mellitus; Ischemic foot ulcer due to type 2 diabetes mellitus,
C3874945,Neuropathic ulcer of toe due to type 2 diabetes mellitus,diabetes,Neuropathic ulcer of toe due to type 2 diabetes mellitus (disorder); Neuropathic toe ulcer due to type 2 diabetes mellitus,
C3874951,Ulcer of forefoot due to type 1 diabetes mellitus,diabetes,Forefoot ulcer due to type 1 diabetes mellitus; Ulcer of forefoot due to type 1 diabetes mellitus (disorder),
C3874956,Moderate nonproliferative retinopathy due to type 2 diabetes mellitus,diabetes,Moderate nonproliferative retinopathy due to type 2 diabetes mellitus (disorder),
C3874958,Neuropathic ulcer of foot due to type 2 diabetes mellitus,diabetes,Neuropathic ulcer of foot due to type 2 diabetes mellitus (disorder); Neuropathic foot ulcer due to type 2 diabetes mellitus,
C3874959,Macular edema and retinopathy due to type 2 diabetes mellitus,diabetes,Macular edema and retinopathy due to type 2 diabetes mellitus (disorder); Macular oedema and retinopathy due to type 2 diabetes mellitus,
C3874960,Chronic ulcer of skin due to type 1 diabetes mellitus,diabetes,Chronic ulcer of skin due to type 1 diabetes mellitus (disorder),
C3874961,Stasis ulcer due to type 2 diabetes mellitus,diabetes,Stasis ulcer due to type 2 diabetes mellitus (disorder),
C3874964,Sensory neuropathy due to type 1 diabetes mellitus,diabetes,Sensory neuropathy due to type 1 diabetes mellitus (disorder),
C3874971,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,diabetes,Chronic kidney disease stage 5 due to type I diabetes mellitus; Chronic kidney disease stage 5 due to type 1 diabetes mellitus (disorder),
C3874974,Severe malnutrition due to type 2 diabetes mellitus,diabetes,Severe malnutrition due to type 2 diabetes mellitus (disorder),
C3874977,Ulcer of foot due to type 1 diabetes mellitus,diabetes,Foot ulcer due to type 1 diabetes mellitus; Ulcer of foot due to type 1 diabetes mellitus (disorder),
C3874978,Chronic kidney disease stage 4 due to type 1 diabetes mellitus,diabetes,Chronic kidney disease stage 4 due to type 1 diabetes mellitus (disorder); Chronic kidney disease stage 4 due to type I diabetes mellitus,
C3874981,Nephrotic syndrome due to type 1 diabetes mellitus,diabetes,Nephrotic syndrome due to type 1 diabetes mellitus (disorder),
C3874986,Hyperlipidemia due to type 2 diabetes mellitus,diabetes,Hyperlipidaemia due to type 2 diabetes mellitus; Hyperlipidemia due to type 2 diabetes mellitus (disorder),
C3874994,Ulcer of forefoot due to type 2 diabetes mellitus,diabetes,Ulcer of forefoot due to type 2 diabetes mellitus (disorder); Forefoot ulcer due to type 2 diabetes mellitus,
C3875001,Type 2 diabetes mellitus controlled by diet,diabetes,Type 2 diabetes mellitus controlled by diet (finding),
C3875008,Nephrotic syndrome due to type 2 diabetes mellitus,diabetes,Nephrotic syndrome due to type 2 diabetes mellitus (disorder),
C3875009,Insulin reactive hypoglycemia due to type 2 diabetes mellitus,hypoglycemia,Insulin reactive hypoglycemia due to type 2 diabetes mellitus (disorder); Insulin reactive hypoglycaemia in type 2 diabetes mellitus; Insulin reactive hypoglycaemia due to type 2 diabetes mellitus; Insulin reactive hypoglycemia in type 2 diabetes mellitus,
C3875010,Traction detachment of retina due to type 1 diabetes mellitus,diabetes,Traction retinal detachment due to type 1 diabetes mellitus; Traction detachment of retina due to type 1 diabetes mellitus (disorder); Traction retinal detachment with type 1 diabetes mellitus,
C3875028,Rubeosis iridis due to type 2 diabetes mellitus,diabetes,Rubeosis iridis with type 2 diabetes mellitus; Rubeosis iridis due to type 2 diabetes mellitus (disorder),
C3875033,Mild nonproliferative retinopathy due to type 2 diabetes mellitus,diabetes,Mild nonproliferative retinopathy due to type 2 diabetes mellitus (disorder),
C3875035,Traction detachment of retina due to type 2 diabetes mellitus,diabetes,Traction retinal detachment due to type 2 diabetes mellitus; Traction detachment of retina due to type 2 diabetes mellitus (disorder); Traction retinal detachment with type 2 diabetes mellitus,
C3875036,Hyperlipidemia due to type 1 diabetes mellitus,diabetes,Hyperlipidemia due to type 1 diabetes mellitus (disorder); Hyperlipidaemia due to type 1 diabetes mellitus,
C3875046,Partial nephrogenic diabetes insipidus,diabetes,Partial nephrogenic diabetes insipidus (disorder),
C3875048,Proliferative retinopathy due to type 1 diabetes mellitus,diabetes,Proliferative retinopathy with type 1 diabetes mellitus; Proliferative retinopathy due to type 1 diabetes mellitus (disorder),
C3875050,Chronic kidney disease stage 3 due to type 1 diabetes mellitus,diabetes,Chronic kidney disease stage 3 due to type I diabetes mellitus; Chronic kidney disease stage 3 due to type 1 diabetes mellitus (disorder),
C3875051,Invitation for diabetes screening,diabetes,Invitation for diabetes screening (procedure),
C3875055,Osteomyelitis due to type 2 diabetes mellitus,diabetes,Osteomyelitis due to type 2 diabetes mellitus (disorder),
C3875057,Ulcer of lower limb due to type 1 diabetes mellitus,diabetes,Ulcer of lower limb due to type 1 diabetes mellitus (disorder),
C3875062,Ischemia of retina due to type 2 diabetes mellitus,diabetes,Ischemia of retina due to type 2 diabetes mellitus (disorder); Retinal ischaemia due to type 2 diabetes mellitus; Ischaemia of retina due to type 2 diabetes mellitus; Retinal ischemia with type 2 diabetes mellitus; Retinal ischemia due to type 2 diabetes mellitus; Retinal ischaemia with type 2 diabetes mellitus,
C3875072,Hypertension in chronic kidney disease stage 3 due to type 2 diabetes mellitus,diabetes,Hypertension in chronic kidney disease stage 3 due to type II diabetes mellitus; Hypertension in chronic kidney disease stage 3 due to type 2 diabetes mellitus (disorder),
C3875073,Proteinuria due to type 2 diabetes mellitus,diabetes,Proteinuria due to type 2 diabetes mellitus (disorder),
C3875077,Cranial nerve palsy due to type 2 diabetes mellitus,diabetes,Cranial nerve palsy with type II diabetes mellitus; Cranial nerve palsy with type 2 diabetes mellitus; Cranial nerve palsy due to type 2 diabetes mellitus (disorder),
C3875079,Ulcer of toe due to type 2 diabetes mellitus,diabetes,Ulcer of toe due to type 2 diabetes mellitus (disorder),
C3875080,Microalbuminuria due to type 1 diabetes mellitus,diabetes,Microalbuminuria due to type 1 diabetes mellitus (disorder),
C3875082,Chronic kidney disease due to type 1 diabetes mellitus,diabetes,Chronic kidney disease due to type 1 diabetes mellitus (disorder); Chronic kidney disease due to type I diabetes mellitus,
C3875083,Hypertension in chronic kidney disease stage 5 due to type 2 diabetes mellitus,diabetes,Hypertension in chronic kidney disease stage 5 due to type II diabetes mellitus; Hypertension in chronic kidney disease stage 5 due to type 2 diabetes mellitus (disorder),
C3875084,Microalbuminuria due to type 2 diabetes mellitus,diabetes,Microalbuminuria due to type 2 diabetes mellitus (disorder),
C3875086,Hypertension in chronic kidney disease stage 2 due to type 2 diabetes mellitus,diabetes,Hypertension in chronic kidney disease stage 2 due to type 2 diabetes mellitus (disorder); Hypertension in chronic kidney disease stage 2 due to type II diabetes mellitus,
C3875088,Nonproliferative diabetic retinopathy due to type 1 diabetes mellitus,diabetes,Nonproliferative diabetic retinopathy due to type 1 diabetes mellitus (disorder),
C3875089,Proteinuria due to type 1 diabetes mellitus,diabetes,Proteinuria due to type 1 diabetes mellitus (disorder),
C3875136,Vitreous hemorrhage due to type 1 diabetes mellitus,diabetes,Vitreous hemorrhage due to type 1 diabetes mellitus (disorder); Vitreous hemorrhage with type 1 diabetes mellitus; Vitreous haemorrhage with type 1 diabetes mellitus; Vitreous haemorrhage due to type 1 diabetes mellitus,
C3875174,Blindness due to type 2 diabetes mellitus,diabetes,Blindness due to type 2 diabetes mellitus (disorder),
C3875181,Blindness due to type 1 diabetes mellitus,diabetes,Blindness due to type 1 diabetes mellitus (disorder),
C3875213,Retinal edema due to type 2 diabetes mellitus,diabetes,Retinal edema due to type 2 diabetes mellitus (disorder); Retinal edema with type 2 diabetes mellitus; Retinal oedema with type 2 diabetes mellitus; Retinal oedema due to type 2 diabetes mellitus,
C3875214,Proliferative retinopathy with retinal edema due to type 2 diabetes mellitus,diabetes,Proliferative retinopathy with retinal oedema due to type 2 diabetes mellitus; Proliferative retinopathy with retinal edema due to type 2 diabetes mellitus (disorder),
C3875216,Retinal edema due to type 1 diabetes mellitus,diabetes,Retinal edema with type 1 diabetes mellitus; Retinal oedema due to type 1 diabetes mellitus; Retinal oedema with type 1 diabetes mellitus; Retinal edema due to type 1 diabetes mellitus (disorder),
C3875248,Peripheral sensory neuropathy due to type 2 diabetes mellitus,diabetes,Peripheral sensory neuropathy due to type 2 diabetes mellitus (disorder),
C3875263,Hypoglycemic unawareness due to type 1 diabetes mellitus,diabetes,Hypoglycemic unawareness in type 1 diabetes mellitus; Hypoglycemic unawareness due to type 1 diabetes mellitus (disorder); Hypoglycaemic unawareness due to type 1 diabetes mellitus; Hypoglycaemic unawareness in type 1 diabetes mellitus,
C3875296,Dyslipidemia with high density lipoprotein below reference range and triglyceride above reference range due to type 2 diabetes mellitus,diabetes,Dyslipidemia with high density lipoprotein below reference range and triglyceride above reference range due to type 2 diabetes mellitus (disorder),
C3875297,Fetal hypertrophic cardiomyopathy due to maternal diabetes mellitus,diabetes,Fetal hypertrophic cardiomyopathy due to maternal diabetes mellitus (disorder); Foetal hypertrophic cardiomyopathy due to maternal diabetes mellitus,
C3875322,Hypoglycemia due to type 1 diabetes mellitus,hypoglycemia,Hypoglycaemia due to type 1 diabetes mellitus; Hypoglycemia due to type 1 diabetes mellitus (disorder),
C3875335,Chronic kidney disease stage 2 due to type 1 diabetes mellitus,diabetes,Chronic kidney disease stage 2 due to type I diabetes mellitus; Chronic kidney disease stage 2 due to type 1 diabetes mellitus (disorder),
C3875338,Rubeosis iridis due to type 1 diabetes mellitus,diabetes,Rubeosis iridis due to type 1 diabetes mellitus (disorder); Rubeosis iridis with type 1 diabetes mellitus,
C3875354,Dermopathy due to type 1 diabetes mellitus,diabetes,Diabetic dermopathy due to type 1 diabetes mellitus; Dermopathy due to type 1 diabetes mellitus (disorder),
C3875450,Severe malnutrition due to type 1 diabetes mellitus,diabetes,Severe malnutrition due to type 1 diabetes mellitus (disorder),
C3875459,Glaucoma due to type 2 diabetes mellitus,diabetes,Glaucoma due to type 2 diabetes mellitus (disorder),
C3875485,Hypoglycemia due to type 2 diabetes mellitus,hypoglycemia,Hypoglycaemia due to type 2 diabetes mellitus; Hypoglycemia due to type 2 diabetes mellitus (disorder),
C3875486,Partial diabetes insipidus,diabetes,Partial diabetes insipidus (disorder),
C3875496,Ankle ulcer due to type 2 diabetes mellitus,diabetes,Ulcer of ankle due to type 2 diabetes mellitus (disorder); Ulcer of ankle due to type 2 diabetes mellitus,
C3875503,Diabetes mellitus due to pancreatic injury,diabetes,Diabetes mellitus due to pancreatic injury (disorder),
C3875519,Chronic kidney disease stage 1 due to type 1 diabetes mellitus,diabetes,Chronic kidney disease stage 1 due to type I diabetes mellitus; Chronic kidney disease stage 1 due to type 1 diabetes mellitus (disorder),
C3875546,Hypoglycemia unawareness due to type 2 diabetes mellitus,hypoglycemia,Hypoglycaemia unawareness in type 2 diabetes mellitus; Hypoglycemia unawareness in type 2 diabetes mellitus; Hypoglycaemia unawareness due to type 2 diabetes mellitus; Hypoglycemia unawareness due to type 2 diabetes mellitus (disorder),
C3875649,Invasive interstitial fluid glucose monitoring/insulin infusion system,glucose,Invasive interstitial fluid glucose monitoring/insulin infusion system (physical object),
C3875662,Home-use/point-of-care blood glucose spot-check analysis system,blood glucose,Home-use/point-of-care blood glucose spot-check analysis system (physical object),
C3875984,Non-invasive interstitial-fluid glucose monitoring system,glucose,Non-invasive interstitial-fluid glucose monitoring system (physical object),
C3876038,Subcutaneous glucose sensor,glucose,Subcutaneous glucose sensor (physical object),
C3876081,Noninvasive diabetes screening unit,diabetes,Noninvasive diabetes screening unit (physical object),
C3876336,Ambulatory insulin infusion pump/blood glucose analyzer system,blood glucose,Ambulatory insulin infusion pump/blood glucose analyser system; Ambulatory insulin infusion pump/blood glucose analyzer system (physical object),
C3877051,Invasive interstitial-fluid glucose monitoring system,glucose,Invasive interstitial-fluid glucose monitoring system (physical object),
C3877513,Point-of-care blood glucose continuous monitoring system patient cartridge,blood glucose,Point-of-care blood glucose continuous monitoring system patient cartridge (physical object),
C3880576,Point-of-care blood glucose continuous monitoring system,blood glucose,Point-of-care blood glucose continuous monitoring system (physical object),
C3881369,Point-of-care blood glucose continuous monitoring system control unit,blood glucose,Point-of-care blood glucose continuous monitoring system control unit (physical object),
C3881648,Point-of-care blood glucose continuous monitoring system heparin syringe,blood glucose,Point-of-care blood glucose continuous monitoring system heparin syringe (physical object),
C3881998,Point-of-care blood glucose continuous monitoring system connector cap,blood glucose,Point-of-care blood glucose continuous monitoring system connector cap (physical object),
C3884382,"pGLCT protein, Arabidopsis",glucose,"plastidic glucose translocator, Arabidopsis",
C3887645,Job Syndrome,hyper,"hie syndrome; Buckley's syndrome; Hyperimmunoglobulin E syndrome; hyper ige syndrome; JOB SYNDROME; Hyper IgE Syndrome; Jobs Syndrome; Job's Syndrome; Hyperimmunoglobulin E Recurrent Infection Syndrome; Hyperimmunoglobulin E-Recurrent Infection Syndrome; hyper-ige syndrome; hyperimmunoglobulin e syndrome; Buckley Syndrome; Syndromes, Job; Job's syndrome; Hyperimmunoglobulin E Syndrome; job-buckley syndrome; Syndrome, Job; Job-Buckley Syndrome; Job-Buckley syndrome; Hyper-IgE syndrome; Quie-Hill syndrome; HIE Syndromes; DERMATITIS, ATOPIC, WITH IMPAIRED NEUTROPHIL CHEMOTAXIS; Job Syndrome; jobs syndrome; Job Syndromes; Hyperimmunoglobulinemia E Syndrome; Job syndrome; Hyperimmunoglobulin E, Recurrent Infection Syndrome; Hyperimmunoglobulinemia E Syndromes; syndrome job; Hyper-IgE Syndromes; job syndrome; Job's syndrome (disorder); Buckley Syndromes; HIE Syndrome; Hyper-IgE Syndrome; Job-Buckley Syndromes; Job Buckley Syndrome; job's syndrome; HIE syndrome; Recurring cold staphylococcal abscesses",
C3888018,Congenital Hyperinsulinism,hypoglycemia,"Persistent Hyperinsulinemic Hypoglycemia of Infancy; Neonatal Hyperinsulinisms; Hypoglycemias, PHHI; Familial Hyperinsulinemic Hypoglycemia-1; Hypoglycemia, Hyperinsulinemic, of Infancy; PHHI Hypoglycemias; HYPERINSULINISM, CONGENITAL; Persistent Hyperinsulinemic Hypoglycemia; Persistent hyperinsulinemic hypoglycemia of infancy (disorder); Hyperinsulinemic Hypoglycemias, Persistent; Congenital isolated hyperinsulinism; Nesidioblastosis; Hypoglycemia, Persistent Hyperinsulinemic; Familial hyperinsulinemic hypoglycemia; Familial Hyperinsulinisms; Persistent Hyperinsulinemia Hypoglycemia of Infancy; Hyperinsulinism, Congenital; Congenital Hyperinsulinisms; Hyperinsulinism, Neonatal; Infancy Hyperinsulinemia Hypoglycemias; Hypoglycemias, Persistent Hyperinsulinemic; HYPERINSULINISM, FAMILIAL; Hypoglycemia, PHHI; Hyperinsulinisms, Neonatal; Persistent Hyperinsulinemic Hypoglycemias; Hyperinsulinemic Hypoglycemia, Persistent; Congenital Hyperinsulinism; Congenital hyperinsulinism; Hyperinsulinemia Hypoglycemia of Infancy; Hyperinsulinisms, Familial; HYPERINSULINISM, NEONATAL; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; FHI; Hyperinsulinisms, Congenital; PHHI Hypoglycemia; Familial Hyperinsulinism; Familial hyperinsulinism; Infancy Hyperinsulinemia Hypoglycemia; Neonatal Hyperinsulinism; Persistent hyperinsulinaemic hypoglycaemia of infancy; HYPERINSULINEMIC HYPOGLYCEMIA, PERSISTENT; Hyperinsulinism, Familial; HYPOGLYCEMIA, HYPERINSULINEMIC, OF INFANCY; PHHI; Persistent hyperinsulinemic hypoglycemia of infancy",
C3888631,Monogenic diabetes,diabetes,Monogenic Diabetes,
C3888846,Hyperosmolar Hyperglycemic State,diabetes,"Hyperosmolar non-ketotic state due to diabetes mellitus; Hyperosmolar non-ketotic state due to diabetes mellitus (disorder); Hyperosmolar Hyperglycemic States; HHS - Hyperosmolar hyperglycemic syndrome; Hyperglycemic Syndromes, Hyperosmolar; Hyperglycemic Syndrome, Hyperosmolar; Hyperosmolar hyperglycemic syndrome; Hyperglycemic States, Hyperosmolar; HHS - Hyperosmolar hyperglycaemic syndrome; Syndromes, Hyperosmolar Hyperglycemic; Diabetic hyperosmolar non-ketotic state; Syndrome, Hyperosmolar Hyperglycemic; Hyperosmolar Hyperglycemic Syndromes; HONKS - Diabetic hyperosmolar non-ketotic state; Hyperglycemic State, Hyperosmolar; Hyperosmolar Hyperglycemic Syndrome",
C3889450,SLC2A3 wt Allele,glucose,"SLC2A3 wt Allele; GLUT3; Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 wt Allele",
C3889451,SLC2A2 wt Allele,glucose,"SLC2A2 wt Allele; Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 2 wt Allele; GLUT2; Glucose Transporter, Liver/Islet Gene",
C3889457,HSP90B1 wt Allele,glucose,"HSP90B1 wt Allele; Glucose-Regulated Protein, 94-kD Gene; Tumor Rejection Antigen (Gp96) 1 Gene; ECGP; GP96; Heat-Shock Protein, 90-kD, Beta, 1 Gene; Heat Shock Protein 90 Beta Family Member 1 wt Allele; TRA1; HEL35; GRP94; HEL-S-125m; Heat Shock Protein 90kDa Beta (Grp94), Member 1 Gene",
C3890005,SLC5A2 wt Allele,glucose,"SGLT2; Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 2 wt Allele; Solute Carrier Family 5 (Sodium/Glucose Transporter), Member 2; SLC5A2 wt Allele; Sodium-Glucose Cotransporter, Kidney Low Affinity Gene; Sodium-Glucose Cotransporter, Renal Gene",
C3893409,transport-coupled glycolytic process through glucose-6-phosphate,glucose,,
C3893465,undecaprenyl-phosphate glucose phosphotransferase activity,glucose,,
C3893667,glucose import across plasma membrane,glucose,glucose import into cell,
C3894146,regulation of hexokinase activity,glucose,regulation of glucose ATP phosphotransferase activity; regulation of hexokinase type IV (glucokinase) activity; regulation of ATP-dependent hexokinase activity; regulation of hexokinase type IV glucokinase activity; regulation of hexokinase (phosphorylating); regulation of ATP:D-hexose 6-phosphotransferase activity,
C3894152,negative regulation of hexokinase activity,glucose,down regulation of ATP:D-hexose 6-phosphotransferase activity; negative regulation of hexokinase type IV glucokinase activity; down regulation of hexokinase type IV (glucokinase) activity; downregulation of ATP:D-hexose 6-phosphotransferase activity; down-regulation of glucose ATP phosphotransferase activity; down regulation of hexokinase (phosphorylating); downregulation of ATP-dependent hexokinase activity; downregulation of hexokinase (phosphorylating); down regulation of hexokinase type IV glucokinase activity; negative regulation of glucose ATP phosphotransferase activity; down regulation of glucose ATP phosphotransferase activity; downregulation of hexokinase type IV glucokinase activity; downregulation of hexokinase activity; downregulation of glucose ATP phosphotransferase activity; down-regulation of hexokinase (phosphorylating); down-regulation of hexokinase activity; negative regulation of hexokinase type IV (glucokinase) activity; negative regulation of ATP-dependent hexokinase activity; negative regulation of hexokinase (phosphorylating); down regulation of ATP-dependent hexokinase activity; down regulation of hexokinase activity; down-regulation of hexokinase type IV (glucokinase) activity; down-regulation of ATP-dependent hexokinase activity; down-regulation of ATP:D-hexose 6-phosphotransferase activity; negative regulation of ATP:D-hexose 6-phosphotransferase activity; down-regulation of hexokinase type IV glucokinase activity,
C3894160,inhibition of glucose ATP phosphotransferase activity,glucose,,
C3894169,positive regulation of hexokinase activity,glucose,positive regulation of ATP-dependent hexokinase activity; upregulation of hexokinase activity; up-regulation of hexokinase activity; up-regulation of ATP:D-hexose 6-phosphotransferase activity; upregulation of hexokinase (phosphorylating); up-regulation of hexokinase type IV glucokinase activity; up regulation of glucose ATP phosphotransferase activity; upregulation of glucose ATP phosphotransferase activity; up regulation of hexokinase activity; up-regulation of glucose ATP phosphotransferase activity; upregulation of ATP:D-hexose 6-phosphotransferase activity; up regulation of ATP:D-hexose 6-phosphotransferase activity; positive regulation of ATP:D-hexose 6-phosphotransferase activity; positive regulation of hexokinase (phosphorylating); positive regulation of glucose ATP phosphotransferase activity; upregulation of ATP-dependent hexokinase activity; up regulation of ATP-dependent hexokinase activity; up-regulation of ATP-dependent hexokinase activity; up-regulation of hexokinase (phosphorylating); up regulation of hexokinase (phosphorylating),
C3894170,activation of ATP-dependent hexokinase activity,glucose,activation of hexokinase (phosphorylating); activation of glucose ATP phosphotransferase activity; activation of ATP:D-hexose 6-phosphotransferase activity; activation of hexokinase activity,
C3895765,regulation of intestinal D-glucose absorption,glucose,,
C3895900,regulation of glucose catabolic process to lactate via pyruvate,glucose,regulation of homofermentative pathway; regulation of homofermentation; regulation of homofermentative lactate fermentation; regulation of glucose fermentation to lactate via pyruvate; regulation of homolactic fermentation; regulation of homolactate fermentation,
C3895901,negative regulation of glucose catabolic process to lactate via pyruvate,glucose,negative regulation of glucose fermentation to lactate via pyruvate; down-regulation of glucose catabolic process to lactate via pyruvate; down-regulation of homolactic fermentation; downregulation of glucose fermentation to lactate via pyruvate; negative regulation of homolactate fermentation; negative regulation of homolactic fermentation; down regulation of homofermentation; negative regulation of homofermentative lactate fermentation; down regulation of homofermentative lactate fermentation; downregulation of homofermentative lactate fermentation; down regulation of homolactic fermentation; down-regulation of homofermentation; down regulation of glucose catabolic process to lactate via pyruvate; down-regulation of homofermentative pathway; downregulation of homofermentative pathway; downregulation of homofermentation; down-regulation of homofermentative lactate fermentation; down-regulation of glucose fermentation to lactate via pyruvate; down-regulation of homolactate fermentation; negative regulation of homofermentation; negative regulation of homofermentative pathway; down regulation of glucose fermentation to lactate via pyruvate; downregulation of homolactic fermentation; down regulation of homofermentative pathway; down regulation of homolactate fermentation; downregulation of homolactate fermentation; downregulation of glucose catabolic process to lactate via pyruvate,
C3895902,inhibition of glucose catabolic process to lactate via pyruvate,glucose,,
C3895903,inhibition of glucose fermentation to lactate via pyruvate,glucose,,
C3895908,positive regulation of glucose catabolic process to lactate via pyruvate,glucose,positive regulation of homofermentative lactate fermentation; up-regulation of glucose catabolic process to lactate via pyruvate; up regulation of homofermentation; up regulation of homofermentative pathway; up regulation of homolactic fermentation; up-regulation of homolactic fermentation; up regulation of glucose fermentation to lactate via pyruvate; upregulation of homofermentative lactate fermentation; up regulation of homofermentative lactate fermentation; up-regulation of homofermentative pathway; up regulation of homolactate fermentation; upregulation of homofermentation; positive regulation of homolactic fermentation; upregulation of glucose fermentation to lactate via pyruvate; positive regulation of glucose fermentation to lactate via pyruvate; up-regulation of homofermentation; up-regulation of homolactate fermentation; upregulation of homolactic fermentation; upregulation of homolactate fermentation; positive regulation of homofermentation; upregulation of glucose catabolic process to lactate via pyruvate; up regulation of glucose catabolic process to lactate via pyruvate; positive regulation of homolactate fermentation; positive regulation of homofermentative pathway; up-regulation of homofermentative lactate fermentation; upregulation of homofermentative pathway; up-regulation of glucose fermentation to lactate via pyruvate,
C3895909,activation of glucose catabolic process to lactate via pyruvate,glucose,,
C3895910,activation of glucose fermentation to lactate via pyruvate,glucose,,
C3896359,G protein-coupled glucose receptor activity,glucose,G-protein coupled glucose receptor activity,
C3896643,New Onset Diabetes After Transplant,diabetes,,
C3898103,Olive Oil/Soybean Oil/Multi-amino Acid/Glucose Parenteral Nutrition Emulsion,glucose,olive oil/soybean oil/multi-amino acid/glucose parenteral nutrition emulsion,
C3899024,Glucose Urine Excretion Rate,glucose,,
C3900208,"1,2-Carbon C 13-labeled Glucose",glucose,"[1,2-13C] glucose; D-Glucose-1,2-13C2; Dextrose-1,2-13C2; 1,2-carbon C 13-labeled glucose; [1,2-13C]glucose",
C3932399,Leptolyngbya sp. L21-BG-2,BG,,
C3932400,Synechococcus sp. L21-BG-1,BG,,
C3938374,Exiguobacterium sp. BG-1-M-5,BG,,
C3938375,Exiguobacterium sp. BG-4-X-3,BG,,
C3938376,Exiguobacterium sp. BG-5-R-1,BG,,
C3938377,Exiguobacterium sp. BG-9-J-1,BG,,
C3982954,Ramalodium sp. BG_L87074,BG,Ramalodium sp. BG L87074,
C3987698,Halomonas sp. BG-3a,BG,,
C3987699,Lutibacterium sp. BG-4a,BG,,
C4009172,Thalassospira sp. BG-3b,BG,,
C4012176,Insulin-resistant diabetes mellitus in adulthood,diabetes,,
C4013228,Intermittent severe hypoglycemia,hypoglycemia,"Hypoglycemia, intermittent severe",
C4013230,Low to undetectable insulin levels in the presence of hyperglycemia,hyperglycemia,,
C4014361,ABDOMINAL OBESITY-METABOLIC SYNDROME 3,diabetes,"ABDOMINAL OBESITY-METABOLIC SYNDROME 3; CENTRAL OBESITY, TYPE 2 DIABETES, HYPERTENSION, AND EARLY-ONSET CORONARY ARTERY DISEASE; AOMS3",
C4014362,Type 2 diabetes mellitus (T2D),diabetes,,
C4014371,IMMUNODEFICIENCY 23,hyper,Phosphoglucomutase 3-related congenital disorder of glycosylation; IMMUNODEFICIENCY WITH HYPER IgE AND COGNITIVE IMPAIRMENT; PGM3 Deficiency; IVMS; PGM3-CDG; Combined immunodeficiency due to PGM3 deficiency; PGM3-related congenital disorder of glycosylation; Immunodeficiency 23; CID due to PGM3 deficiency; IMMUNODEFICIENCY-VASCULITIS-MYOCLONUS SYNDROME; PGM3-Associated Immunodeficiency; Phosphoglucomutase 3-related congenital disorder of glycosylation (disorder); PGM3-CDG - phosphoglucomutase 3-related congenital disorder of glycosylation; IMMUNODEFICIENCY 23; Combined immunodeficiency due to PGM3 (phosphoglucomutase 3) deficiency; IMD23,
C4014611,Hyper IgA,hyper,,
C4014962,FANCONI RENOTUBULAR SYNDROME 4 WITH MATURITY-ONSET DIABETES OF THE YOUNG,diabetes,"FANCONI RENOTUBULAR SYNDROME 4, WITH MATURITY-ONSET DIABETES OF THE YOUNG; FRTS4 WITH MODY; FRTS4",
C4014997,"MICROCEPHALY, SHORT STATURE, AND IMPAIRED GLUCOSE METABOLISM 1",glucose,MSSGM1,
C4014999,"Diabetes, early-onset",diabetes,,
C4015001,Hypoglycemia-related seizures,hypoglycemia,,
C4015183,TYPE 2 DIABETES 5,diabetes,"T2D5; DIABETES MELLITUS, NONINSULIN-DEPENDENT, 5; NIDDM5",
C4015266,Episodic asymptomatic severe hypoglycemia in childhood,hypoglycemia,,
C4015267,Nonautoimmune insulin-dependent diabetes in second decade of life,diabetes,,
C4015436,"ATAXIA, COMBINED CEREBELLAR AND PERIPHERAL, WITH HEARING LOSS AND DIABETES MELLITUS",diabetes,"Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome; ATAXIA, COMBINED CEREBELLAR AND PERIPHERAL, WITH HEARING LOSS AND DIABETES MELLITUS; ACPHD; Combined cerebellar and peripheral ataxia-hearing loss-diabetes mellitus syndrome; Combined cerebellar and peripheral ataxia-deafness-diabetes mellitus syndrome",
C4015606,Serum transferrin shows normal or mild hypo-glycosylation,hypo,,
C4016306,"DIABETES MELLITUS, KETOSIS-PRONE, SUSCEPTIBILITY TO",diabetes,,
C4016321,"HEMOLYTIC ANEMIA, NONSPHEROCYTIC, AND NEUROLOGIC DEFICITS, DUE TO GLUCOSE PHOSPHATE ISOMERASE DEFICIENCY",glucose,,
C4016430,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL, AUTOSOMAL RECESSIVE",diabetes,,
C4016608,"MYOPATHY, MITOCHONDRIAL, WITH DIABETES MELLITUS",diabetes,,
C4016628,"CEREBELLAR ATAXIA, CATARACT, AND DIABETES MELLITUS",diabetes,,
C4016690,"DIABETES, TYPE II, SUSCEPTIBILITY TO",diabetes,,
C4016735,"TYPE 2 DIABETES MELLITUS, MODIFIER OF",diabetes,,
C4016768,"OBESITY, SEVERE, AND TYPE II DIABETES",diabetes,"OBESITY, SEVERE, AND TYPE II DIABETES",
C4016960,"TYPE 2 DIABETES MELLITUS, ASSOCIATION WITH",diabetes,,
C4017238,"TYPE 2 DIABETES MELLITUS, PROTECTION AGAINST",diabetes,"DIABETES MELLITUS, TYPE 2, PROTECTION AGAINST",
C4017627,"DIABETES MELLITUS, NONINSULIN-DEPENDENT, MATERNALLY TRANSMITTED",diabetes,,
C4017629,"DIABETES MELLITUS, TYPE II, DIGENIC",diabetes,,
C4017715,Early-onset type II diabetes,diabetes,,
C4017829,"MICROVASCULAR COMPLICATIONS OF DIABETES, PROTECTION AGAINST",diabetes,,
C4018521,glucose 0.45 MG/MG,glucose,,
C4018522,glucose 0.45 MG/MG Oral Gel,glucose,"Good Sense Fruit Punch Glucose, 45% oral gel; glucose 15 GM per 33 GM Oral Gel; glucose 45 % Oral Gel; Relion Gel Fruit Punch, 45% oral gel; glucose 45% oral gel",
C4018523,glucose 0.45 MG/MG [Dex4],glucose,,
C4018524,glucose 0.45 MG/MG Oral Gel [Dex4],glucose,"Dex4 Gel Tropical Blast, 45% oral gel; Dex4 45 % Oral Gel; Dex4 Mango Twist, 45% oral gel; Dex4 15 GM per 33 GM Oral Gel; Dex4 Fruit Punch, 45% oral gel; glucose 15 GM per 33 GM Oral Gel [Dex4]",
C4019565,"TRIBASIC CALCIUM PHOSPHATE 12 [hp_X] in 29.6 mL / CARPINUS BETULUS FLOWER 12 [hp_X] in 29.6 mL / FERROSOFERRIC PHOSPHATE 12 [hp_X] in 29.6 mL / POTASSIUM PHOSPHATE, DIBASIC 6 [hp_X] in 29.6 mL / SODIUM CHLORIDE 6 [hp_X] in 29.6 mL / SODIUM SULFATE 6 [hp_X] in 29.6 mL / OLEA EUROPAEA FLOWER 5 [hp_X] in 29.6 mL / SILICON DIOXIDE 12 [hp_X] in 29.6 mL / SINAPIS ARVENSIS FLOWERING/FRUITING TOP 5 [hp_X] in 29.6 mL ORAL SPRAY [blood sugar]",blood sugar,,
C4019718,Gmate Smart Blood Glucose Meter,blood glucose,,
C4019719,Gmate Voice Blood Glucose Meter,blood glucose,,
C4019720,Gmate Voice Blood Glucose Test Strips,blood glucose,,
C4020280,Enlite Glucose Sensor,glucose,,
C4020778,maternal hyperglycemia,hyperglycemia,,
C4021573,Patchy hypo- and hyperpigmentation,hypo,Patchy hypo- and hyper-pigmentation,
C4021644,Recurrent infantile hypoglycemia,blood sugar,Episodic infantile hypoglycemia; Recurrent low blood sugar in infant,
C4023597,Abnormal blood glucose concentration,blood glucose,Abnormality of blood glucose concentration,
C4023598,Abnormal glucose homeostasis,glucose,,
C4024584,Mixed hypo- and hyperpigmentation of the skin,hypo,,
C4026030,CONTOUR NEXT (GLUCOSE) NORMAL CONTROL SOLN,glucose,CONTOUR NEXT (GLUCOSE) NORMAL CNTRL SOLN,
C4026031,CONTOUR NEXT (GLUCOSE) LOW CONTROL SOLN,glucose,Contour Next Low Control Solution; CONTOUR NEXT (GLUCOSE) LOW CONTROL SOLN,
C4026746,glucose 254 MG/ML [Dex4],glucose,,
C4026909,Gmate Smart/Voice Blood Glucose Test Strips,blood glucose,,
C4035727,Diabetes Management - Advanced,diabetes,,
C4036714,Glucose^11H post XXX challenge:SCnc:Pt:Ser/Plas:Qn,glucose,Glucose 11h p chal SerPl-sCnc; Glucose^11H post XXX challenge:Substance Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Moles/volume] in Serum or Plasma --11 hour post XXX challenge; Glucose 11 Hr post Unsp challenge [Moles/Vol],
C4036718,Glucose^2H post meal:SCnc:Pt:Ser/Plas/Bld:Qn,glucose,"Glucose^2 hours post meal:Substance Concentration:To identify measures at a point in time:Serum/Plasma/Whole blood:Quantitative; Glucose 2h p meal SerPlBld-sCnc; Glucose [Moles/volume] in Serum, Plasma or Blood --2 hours post meal; Glucose 2 Hr post meal (S/P/Bld) [Moles/Vol]",
C4037156,Glucose^post CFst:SCnc:Pt:Ser/Plas/Bld:Qn,glucose,"Glucose p fast SerPlBld-sCnc; Fasting glucose [Moles/volume] in Serum, Plasma or Blood; Glucose^post Calorie fast:Substance Concentration:To identify measures at a point in time:Serum/Plasma/Whole blood:Quantitative; Glucose post fast (S/P/Bld) [Moles/Vol]",
C4037158,Glucose:SCnc:Pt:Ser/Plas/Bld:Qn,glucose,"Glucose SerPlBld-sCnc; Glucose (S/P/Bld) [Moles/Vol]; Glucose:Substance Concentration:To identify measures at a point in time:Serum/Plasma/Whole blood:Quantitative; Glucose [Moles/volume] in Serum, Plasma or Blood",
C4037566,Glucose^4th tube:SCnc:Pt:CSF:Qn,glucose,Glucose 4th tube (CSF) [Moles/Vol]; Glucose^4th tube:Substance Concentration:To identify measures at a point in time:Cerebral spinal fluid:Quantitative; Glucose tube4 CSF-sCnc; Glucose [Moles/volume] in Cerebral spinal fluid --4th tube,
C4037567,Glucose^3rd tube:SCnc:Pt:CSF:Qn,glucose,Glucose [Moles/volume] in Cerebral spinal fluid --3rd tube; Glucose tube3 CSF-sCnc; Glucose^3rd tube:Substance Concentration:To identify measures at a point in time:Cerebral spinal fluid:Quantitative; Glucose 3rd tube (CSF) [Moles/Vol],
C4037568,Glucose^2nd tube:SCnc:Pt:CSF:Qn,glucose,Glucose 2nd tube (CSF) [Moles/Vol]; Glucose tube2 CSF-sCnc; Glucose^2nd tube:Substance Concentration:To identify measures at a point in time:Cerebral spinal fluid:Quantitative; Glucose [Moles/volume] in Cerebral spinal fluid --2nd tube,
C4037569,Glucose^1st tube:SCnc:Pt:CSF:Qn,glucose,Glucose 1st tube (CSF) [Moles/Vol]; Glucose [Moles/volume] in Cerebral spinal fluid --1st tube; Glucose^1st tube:Substance Concentration:To identify measures at a point in time:Cerebral spinal fluid:Quantitative; Glucose tube1 CSF-sCnc,
C4037599,Glucose^post CFst:SCnc:Pt:Bld:Qn,glucose,Glucose post fast (Bld) [Moles/Vol]; Glucose p fast Bld-sCnc; Fasting glucose [Moles/volume] in Blood; Glucose^post Calorie fast:Substance Concentration:To identify measures at a point in time:Whole blood:Quantitative,
C4038683,History of small vessel disease due to diabetes mellitus,diabetes,History of small vessel disease due to diabetes mellitus (situation),
C4039056,History of nocturnal hypoglycemia,hypoglycemia,History of nocturnal hypoglycaemia; History of nocturnal hypoglycemia (situation),
C4039071,Skin ulcer of toe due to diabetes mellitus type 2,diabetes,"Diabetes type 2 with diabetic ulcer of toe, skin breakdown; Ulcer of skin of toe due to type 2 diabetes mellitus (disorder); Ulcer of skin of toe due to type 2 diabetes mellitus",
C4039110,Frequency of hypoglycemia attack,hypoglycemia,Frequency of hypoglycemia attack (observable entity); Frequency of hypoglycaemia attack,
C4039625,Gingivitis co-occurrent with diabetes mellitus,diabetes,Gingivitis co-occurrent with diabetes mellitus (disorder),
C4039683,Frequency of general practitioner treated hypoglycemia attack,hypoglycemia,Frequency of general practitioner treated hypoglycaemia attack; Frequency of general practitioner treated hypoglycemia attack (observable entity),
C4040089,Protein-bound glucose,glucose,Glucose.protein bound; Protein-bound glucose (substance),
C4040935,Skin ulcer of toe due to diabetes mellitus type 1,diabetes,"Ulcer of skin of toe due to type 1 diabetes mellitus (disorder); Diabetes type 1 with diabetic ulcer of toe, skin breakdown; Ulcer of skin of toe due to type 1 diabetes mellitus",
C4041423,Frequency of paramedic treated hypoglycemia attack,hypoglycemia,Frequency of paramedic treated hypoglycemia attack (observable entity); Frequency of paramedic treated hypoglycaemia attack,
C4041650,"UGGT1 protein, human",glucose,"UDP-glucose-glycoprotein glucosyltransferase 1, human",
C4042478,(99m)Tc-2-((3-carboxy-1-oxopropyl)amino)-2-deoxy-D-glucose,glucose,(99m)Tc-CPADG,
C4044036,bg-34 compound,BG,,
C4046153,CVS Advanced Glucose Test Strips,glucose,CVS Advanced Glucose Meter Test Strips,
C4046154,CVS Advanced Glucose Meter,glucose,,
C4046331,Breeze 2 Diabetes System,diabetes,,
C4048640,Bupivacaine 0.5%+glucose injection solution 4mL ampule (product,glucose,,
C4049268,CHA2DS2-VASc score,diabetes,"Congestive heart failure, hypertension, age 75 years or older, diabetes, previous stroke or transient ischaemic attack, vascular disease, age 65-74 years, and sex category risk score; Congestive heart failure, hypertension, age 75 years or older, diabetes, previous stroke or transient ischemic attack, vascular disease, age 65-74 years, and sex category risk score; Congestive heart failure, hypertension, age 75 years or older, diabetes, previous stroke or transient ischemic attack, vascular disease, age 65-74 years, and sex category risk score (assessment scale)",
C4049845,2-deoxyglucose,glucose,"2-DG; 2-Desoxy-D-glucose; D-arabino-Hexose, 2-deoxy-; 2 Desoxy D glucose; 2-deoxyglucose; 2 Deoxyglucose; 2 Deoxy D glucose; 2-Deoxy-D-arabino-hexose; 2-Deoxy-D-glucose; 2-deoxy-d-glucose; Deoxyglucose; deoxyglucose; 2-deoxy-D-glucose; 2-Deoxy-D-Glucose; 2-Deoxyglucose; D-arabino-2-desoxyhexose; 2-DEOXYGLUCOSE",
C4050442,Glucose^overnight dwell:SCnc:Pt:Dial fld prt:Qn,glucose,Glucose^overnight dwell:SCnc:Pt:Dial fld prt:Qn; Glucose^overnight dwell:Substance Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose overnight dwell (Perit dial fld) [Moles/Vol]; Glucose [Moles/volume] in Peritoneal dialysis fluid --overnight dwell; Glucose Ovrngt Dwell DiafP-sCnc,
C4050931,GENULTIMATE (GLUCOSE) TEST STRIP,glucose,GENULTIMATE (GLUCOSE) TEST STRIP,
C4050939,MEIJER BLOOD (GLUCOSE) TEST STRIP,glucose,MEIJER BLOOD (GLUCOSE) TEST STRIP,
C4050944,CLEVER CHOICE (GLUCOSE) TEST STRIP,glucose,Clever Choice Strips; CLEVER CHOICE (GLUCOSE) TEST STRIP,
C4052605,"Analyzers, Point-of-Care, Whole Blood, Glucose/Lipid Profile",glucose,,
C4052668,"Monitors, Physiologic, Glucose",glucose,Glucose Physiologic Monitors,
C4052669,"Glucose Monitors, Implantable",glucose,,
C4052670,"Monitors, Physiologic, Glucose, Telemetric",glucose,"Glucose Physiologic Telemetric Monitors; Glucose Monitors, Telemetric; Monitors, Telemetric, Glucose",
C4055719,CVS Glucose Shot Grape,glucose,,
C4055720,CVS Glucose Shot Berry,glucose,,
C4055783,Meijer Essential Blood Glucose Meter,blood glucose,,
C4059367,Good Sense Premium Blood Glucose Test Strips,blood glucose,,
C4059376,Up & Up Blood Glucose Test Strips,blood glucose,,
C4059515,Element Compact V Glucose Meter,glucose,,
C4060027,GS (GLUCOSE) TEST STRIP,glucose,GS (GLUCOSE) TEST STRIP,
C4060028,FORA (GLUCOSE) NORMAL CONTROL SOLN,glucose,FORA (GLUCOSE) NORMAL CONTROL SOLN,
C4060029,EVENCARE MINI (GLUCOSE) TEST STRIP,glucose,EVENCARE MINI (GLUCOSE) TEST STRIP,
C4060030,EVENCARE MINI (GLUCOSE) NORMAL CONTROL SOLN,glucose,EVENCARE MINI (GLUCOSE) NORM CONTRL SOLN,
C4067591,Patients aged 40 to 75 years at the beginning of the measurement period with type 1 or type 2 diabetes and with an ldl-c result of 70-189 mg/dl recorded as the highest fasting or direct laboratory test result in the measurement year or during the two years prior to the beginning of the measurement period,diabetes,,
C4070134,Uridine diphosphate glucose-4-Epimerase:CCnt:Pt:RBC:Qn,glucose,Uridine diphosphate glucose-4-Epimerase:Catalytic Content:To identify measures at a point in time:Erythrocytes:Quantitative; Uridine diphosphate glucose-4-Epimerase [Enzymatic activity/mass] in Red Blood Cells; Uridine diphosphate glucose-4-Epimerase (RBC) [Catalytic activity/Mass]; UDPG4Epimerase RBC-cCnt,
C4070391,Glucose^1H post dose arginine+insulin:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --1 hour post dose arginine+insulin; Glucose^1 hour post dose arginine+insulin:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1 Hr post dose arginine+insulin [Mass/Vol]; Glucose 1h p Arg+Ins SerPl-mCnc,
C4070392,Glucose^45M post dose arginine+insulin:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --45 minutes post dose arginine+insulin; Glucose 45 Min post dose arginine+insulin [Mass/Vol]; Glucose 45M p Arg+Ins SerPl-mCnc; Glucose^45M post dose arginine+insulin:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C4070393,Glucose^30M post dose arginine+insulin:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose arginine+insulin; Glucose^30 minutes post dose arginine+insulin:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min post dose arginine+insulin [Mass/Vol]; Glucose 30M p Arg+Ins SerPl-mCnc,
C4070394,Glucose^15M post dose arginine+insulin:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 15M p Arg+Ins SerPl-mCnc; Glucose 15 Min post dose arginine+insulin [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --15 minutes post dose arginine+insulin; Glucose^15 minutes post dose arginine+insulin:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C4070988,Glucose^4H dwell specimen:SCnc:Pt:Dial fld prt:Qn,glucose,Glucose 4H dwell spec DiafP-sCnc; Glucose 4 hour dwell specimen (Perit dial fld) [Moles/Vol]; Glucose [Moles/volume] in Peritoneal dialysis fluid --4 hour dwell specimen; Glucose^4 hours dwell specimen:Substance Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative,
C4070989,Glucose^2H dwell specimen:SCnc:Pt:Dial fld prt:Qn,glucose,Glucose 2H dwell spec DiafP-sCnc; Glucose 2 Hr dwell specimen (Perit dial fld) [Moles/Vol]; Glucose^2 hours dwell specimen:Substance Concentration:To identify measures at a point in time:Peritoneal dialysis fluid:Quantitative; Glucose [Moles/volume] in Peritoneal dialysis fluid --2 hour dwell specimen,
C4073102,Hypoautofluorescent macular lesion,hypo,Hypo-autofluorescent macular lesion,
C4073162,Elevated hemoglobin A1c,a1c,Elevated glycated haemoglobin; Elevated glycosylated haemoglobin; Elevated HbA1c; Elevated haemoglobin A1c; HEMOGLOBIN A1C ELEVATED; Elevated glycated hemoglobin; Elevated hemoglobin A1C; Hemoglobin A1c Increased; HgbA1c Increased; GLYCOSYLATED HEMOGLOBIN ELEVATED; Elevated glycosylated hemoglobin; Increased HbA1c levels,
C4073651,Good Sense Fruit Punch Glucose,glucose,,
C4073657,Good Sense Orange Glucose,glucose,,
C4073658,Good Sense Grape Glucose,glucose,,
C4073663,Up and Up Raspberry Glucose,glucose,,
C4073664,Up and Up Orange Glucose,glucose,,
C4073665,Kroger Orange Glucose,glucose,,
C4073666,Kroger Grape Glucose,glucose,,
C4073667,Kroger Citrus Punch Glucose,glucose,,
C4073668,Good Sense Tropical Fruit Glucose,glucose,,
C4073669,Good Sense Raspberry Glucose,glucose,,
C4073670,Good Sense Citrus Punch Glucose,glucose,,
C4073671,Good Sense Berry Twist Glucose,glucose,,
C4073672,Good Sense Assorted Fruit Glucose,glucose,,
C4073688,Up & Up Premium Blood Glucose Monitor,blood glucose,,
C4073692,Up & Up Blood Glucose Monitor,blood glucose,,
C4073695,Kroger Premium Blood Glucose Monitor,blood glucose,,
C4073698,Kroger Blood Glucose Monitor,blood glucose,,
C4073701,Good Sense Premium Blood Glucose Monitor,blood glucose,,
C4074798,Gestational diabetes mellitus complicating pregnancy,diabetes,Gestational diabetes mellitus complicating pregnancy (disorder); Gestational DM antepartum,
C4074922,Moderate nonproliferative retinopathy due to secondary diabetes mellitus,diabetes,Moderate non-proliferative retinopathy due to secondary diabetes mellitus (disorder); Moderate non-proliferative retinopathy due to secondary diabetes mellitus,
C4075481,At risk of ulcer of foot due to diabetes mellitus,diabetes,At risk of ulcer of foot due to diabetes mellitus (finding); At risk of diabetic foot ulcer,
C4075820,Polyneuropathy due to type 1 diabetes mellitus,diabetes,Polyneuropathy due to type 1 diabetes mellitus (disorder); Polyneuropathy due to diabetes mellitus type I,
C4075823,Gastroparesis due to type 1 diabetes mellitus,diabetes,Gastroparesis with type 1 diabetes mellitus; Gastroparesis due to diabetes mellitus type I; Gastroparesis due to type 1 diabetes mellitus (disorder),
C4075825,Polyneuropathy due to type 2 diabetes mellitus,diabetes,Polyneuropathy due to type 2 diabetes mellitus (disorder); Polyneuropathy due to diabetes mellitus type II,
C4075839,Gastroparesis due to type 2 diabetes mellitus,diabetes,Gastroparesis due to diabetes mellitus type II; Gastroparesis with type 2 diabetes mellitus; Gastroparesis due to type 2 diabetes mellitus (disorder),
C4076027,Dyslipidemia due to type 1 diabetes mellitus,diabetes,Dyslipidemia due to type 1 diabetes mellitus (disorder),
C4076044,Moderate nonproliferative retinopathy due to type 1 diabetes mellitus,diabetes,Moderate nonproliferative retinopathy due to type 1 diabetes mellitus (disorder),
C4076052,Mild nonproliferative retinopathy due to type 1 diabetes mellitus,diabetes,Mild nonproliferative retinopathy due to type 1 diabetes mellitus (disorder),
C4076054,Mild nonproliferative retinopathy due to secondary diabetes mellitus,diabetes,Mild nonproliferative retinopathy due to secondary diabetes mellitus (disorder),
C4076064,Peripheral neuropathy due to type 1 diabetes mellitus,diabetes,Peripheral neuropathy with type 1 diabetes mellitus; Peripheral neuropathy due to type 1 diabetes mellitus (disorder),
C4076067,Non-proliferative retinopathy due to secondary diabetes mellitus,diabetes,Non-proliferative retinopathy due to secondary diabetes mellitus (disorder),
C4076158,Neovascular glaucoma due to diabetes mellitus,diabetes,Neovascular glaucoma with diabetes mellitus; Neovascular glaucoma due to diabetes mellitus (disorder),
C4076198,Supervision of high risk pregnancy with family history of diabetes mellitus,diabetes,Supervision of high risk pregnancy with family history of diabetes mellitus (regime/therapy),
C4076312,Hyperosmolar coma due to secondary diabetes mellitus,diabetes,Hyperosmolar coma due to secondary diabetes mellitus (disorder),
C4076317,Dermatitis due to drug induced diabetes mellitus,diabetes,Dermatitis due to drug induced diabetes mellitus (disorder),
C4076319,Diabetic hand syndrome due to type 2 diabetes mellitus,diabetes,Cheiroarthropathy due to diabetes mellitus type 2; Cheiroarthropathy due to diabetes mellitus type 2 (disorder); Cheiropathy due to type 2 diabetes mellitus; Cheiroarthropathy due to type 2 diabetes mellitus,
C4076547,Neuropathy due to type 2 diabetes mellitus,diabetes,Neuropathy due to type 2 diabetes mellitus (disorder),
C4076703,Hyperglycemia due to type 1 diabetes mellitus,hyperglycemia,Hyperglycaemia due to type 1 diabetes mellitus; Hyperglycemia due to type 1 diabetes mellitus (disorder),
C4076711,Hyperglycemia due to type 2 diabetes mellitus,hyperglycemia,Hyperglycemia due to type 2 diabetes mellitus (disorder); Hyperglycaemia due to type 2 diabetes mellitus,
C4076966,glucose-6-phosphate dehydrogenase Herlev,glucose,G6PD Herlev,
C4077695,"SOGA1 protein, human",glucose,"suppressor of glucose from autophagy, human; suppressor of glucose, autophagy associated 1 protein, human; SOGA protein, human",
C4077792,"2,4-diacetamido-2,4,6-trideoxy-D-glucose",glucose,,
C4081660,Unable to afford glucose monitoring device,glucose,Unable to afford glucose monitoring device (finding),
C4081750,Diabetes mellitus caused by drug without complication,diabetes,Diabetes mellitus caused by drug without complication (disorder),
C4081782,Peripheral vascular disease due to secondary diabetes mellitus,diabetes,Peripheral vascular disease due to secondary diabetes mellitus (disorder),
C4081783,Nephropathy due to secondary diabetes mellitus,diabetes,Nephropathy due to secondary diabetes mellitus (disorder),
C4081784,Retinopathy due to secondary diabetes mellitus,diabetes,Retinopathy due to secondary diabetes mellitus (disorder),
C4081807,Severe nonproliferative retinopathy due to diabetes mellitus type 2,diabetes,Severe nonproliferative retinopathy due to diabetes mellitus type 2 (disorder),
C4081808,Neuropathic ankle ulcer due to diabetes mellitus type 2,diabetes,Neuropathic ankle ulcer due to diabetes mellitus type 2 (disorder),
C4081809,Ischemic ankle ulcer due to diabetes mellitus type 2,diabetes,Ischemic ankle ulcer due to diabetes mellitus type 2 (disorder),
C4081812,Severe nonproliferative retinopathy due to diabetes mellitus type 1,diabetes,Severe nonproliferative retinopathy due to diabetes mellitus type 1 (disorder),
C4081813,Neurogenic erectile dysfunction due to diabetes mellitus type 2,diabetes,Neurogenic erectile dysfunction due to diabetes mellitus type 2 (disorder),
C4081814,Cranial nerve palsy due to type 1 diabetes mellitus,diabetes,Cranial nerve palsy with type 1 diabetes mellitus; Cranial nerve palsy with type I diabetes mellitus; Cranial nerve palsy due to type 1 diabetes mellitus (disorder),
C4081815,Glaucoma due to diabetes mellitus type 1,diabetes,Glaucoma due to diabetes mellitus type 1 (disorder),
C4081838,Hyperosmolarity due to secondary diabetes mellitus,diabetes,Hyperosmolarity due to secondary diabetes mellitus (disorder),
C4081839,Ketoacidosis due to secondary diabetes mellitus,diabetes,Ketoacidosis due to secondary diabetes mellitus (disorder),
C4081840,Complication due to secondary diabetes mellitus,diabetes,Complication due to secondary diabetes mellitus (disorder),
C4082275,"Gastric Inhibitory Polypeptide Receptor, human",glucose,Gastric Inhibitory Polypeptide Receptor; GIPR; GIP-R; Glucose-Dependent Insulinotropic Polypeptide,
C4082636,250 ML glucose 50 MG/ML / sodium chloride 2 MG/ML Injection,glucose,"DEXTROSE 5%/NACL 0.2% INJ_#1; Dextrose 5% and 0.2% Sodium Chloride, Dextrose 5% with 0.2% NaCl intravenous solution_#1; dextrose 5 % / sodium chloride 0.2 % per 250 ML Injection; 250 ML Glucose 50 MG/ML / NaCl 2 MG/ML Injection; dextrose 5 % / sodium chloride 0.2 % in 250 ML Injection; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.2 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]_#1; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 200 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION_#1",
C4082638,1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection,glucose,"1000 ML Glucose 50 MG/ML / NaCl 4.5 MG/ML Injection; 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION_#2; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]_#3; dextrose 5 % / sodium chloride 0.45 % in 1000 ML Injection; Dextrose 5% and 0.45% Sodium Chloride, Dextrose 5% with 0.45% NaCl intravenous solution_#3; DEXTROSE 5%/NACL 0.45% INJ_#3; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#3; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#1; dextrose 5 % / sodium chloride 0.45 % per 1000 ML Injection",
C4082639,500 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION_#1; dextrose 5 % / sodium chloride 0.45 % in 500 ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#2; Dextrose 5% and 0.45% Sodium Chloride, Dextrose 5% with 0.45% NaCl intravenous solution_#2; 500 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection; DEXTROSE 5%/NACL 0.45% INJ_#2; 500 ML Glucose 50 MG/ML / NaCl 4.5 MG/ML Injection; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]_#2; dextrose 5 % / sodium chloride 0.45 % per 500 ML Injection",
C4082640,500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection,glucose,"500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 900 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION_#1; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.9 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]_#2; Dextrose 5% and 0.9% Sodium Chloride, Dextrose 5% with 0.9% NaCl intravenous solution_#1; 500 ML Glucose 50 MG/ML / NaCl 9 MG/ML Injection; DEXTROSE 5%/NACL 0.9% INJ_#2; dextrose 5 % / sodium chloride 0.9 % in 500 ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.9 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#1; dextrose 5 % / sodium chloride 0.9 % per 500 ML Injection",
C4082641,1000 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection,glucose,"dextrose 5 % / sodium chloride 0.9 % per 1000 ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.9 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#2; 1000 ML Glucose 50 MG/ML / NaCl 9 MG/ML Injection; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.9 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]_#3; DEXTROSE 5%/NACL 0.9% INJ_#3; dextrose 5 % / sodium chloride 0.9 % in 1000 ML Injection; Dextrose 5% and 0.9% Sodium Chloride, Dextrose 5% with 0.9% NaCl intravenous solution_#2; 1000 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 900 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION_#2",
C4082715,Glucose 500 MG/ML Injection,glucose,parenteral nutrition solution Dextrose 50% in Water intravenous solution; glucose 50% intravenous solution,
C4082716,50 ML Glucose 500 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 25 g in 50 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; dextrose 50 % in 50 ML Injection; Dextrose, 50% intravenous solution_#1; 50 ML glucose 500 MG/ML Injection; dextrose 50 % per 50 ML Injection; Dextrose Monohydrate 25 g in 50 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; DEXTROSE MONOHYDRATE 25 g in 50 mL INTRAVENOUS INJECTION, SOLUTION; DEXTROSE 50% INJ_#2",
C4082718,500 ML Glucose 500 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 50 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; DEXTROSE MONOHYDRATE 50 g in 100 mL INTRAMUSCULAR INJECTION, SOLUTION; 500 ML glucose 500 MG/ML Injection; dextrose 50 % per 500 ML Injection; DEXTROSE MONOHYDRATE 50 g in 100 mL SUBCUTANEOUS INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 50 g in 100 mL INTRAVENOUS INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 50 g in 100 mL INTRAPERITONEAL INJECTION, SOLUTION; Dextrose 50% and Water, Dextrose 50% in Water intravenous solution; DEXTROSE 50% INJ_#3; dextrose 50 % in 500 ML Injection",
C4082721,Glucose 700 MG/ML Injectable Solution includes 500 ML & 1000 ML Injection,glucose,"Dextrose 70% and Water, Dextrose 70% in Water intravenous solution",
C4082722,Glucose 700 MG/ML Injection,glucose,,
C4082723,500 ML Glucose 700 MG/ML Injection,glucose,500 ML glucose 700 MG/ML Injection; dextrose 70 % in 500 ML Injection; dextrose 70 % per 500 ML Injection,
C4082724,1000 ML Glucose 700 MG/ML Injection,glucose,"Dextrose 70% and Water, Dextrose 70% in Water intravenous solution_#2; dextrose 70 % per 1000 ML Injection; dextrose 70 % in 1000 ML Injection; 1000 ML glucose 700 MG/ML Injection",
C4082744,500 ML Glucose 100 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 10 g in 100 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Dextrose]; DEXTROSE MONOHYDRATE 10 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 10% Dextrose]_#2; 500 ML glucose 100 MG/ML Injection; DEXTROSE 10 g in 100 mL INTRAVENOUS SOLUTION_#2; dextrose 10 % in 500 ML Injection; dextrose 10 % per 500 ML Injection; DEXTROSE MONOHYDRATE 100 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]_#2; DEXTROSE MONOHYDRATE 100 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#2; DEXTROSE MONOHYDRATE 10 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#2; Dextrose 10% and Water, Dextrose 10% in Water intravenous solution_#2; DEXTROSE 10% INJ_#2",
C4082745,1000 ML glucose 100 MG/ML Injection,glucose,"DEXTROSE 10% INJ_#3; DEXTROSE MONOHYDRATE 10 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#3; Dextrose 10% and Water, Dextrose 10% in Water intravenous solution_#3; DEXTROSE MONOHYDRATE 100 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#3; DEXTROSE MONOHYDRATE 10 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 10% Dextrose]_#3; dextrose 10 % in 1000 ML Injection; dextrose 10 % per 1000 ML Injection; DEXTROSE MONOHYDRATE 100 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]_#3; DEXTROSE 10 g in 100 mL INTRAVENOUS SOLUTION_#3",
C4082772,100 ML glucose 50 MG/ML Injection,glucose,"dextrose 5 % per 100 ML Injection; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION_#2; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#3; DEXTROSE MONOHYDRATE 50 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]_#3; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 50% Dextrose]_#1; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#2; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 5% Dextrose]_#1; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION [Dextrose]; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION [Dextrose]_#2; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#1; DEXTROSE 5% INJ,BAG 100ML; 100 ML glucose 50 MG/ML Injection; DEXTROSE 5% INJ BAG 100ML; dextrose 5 % in 100 ML Injection; Dextrose 5% and Water, Dextrose 5% in Water intravenous solution_#3; DEXTROSE 5% INJ_#4; Dextrose 5% and Water ADD-Vantage, Dextrose 5% in Water intravenous solution_#2; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION",
C4082773,Glucose 50 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 50 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]; Dextrose 5% and Water ADD-Vantage, Dextrose 5% in Water intravenous solution; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 50% Dextrose]; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 5% Dextrose]; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION; Dextrose 5% and Water, Dextrose 5% in Water intravenous solution; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; LVP solution Dextrose 5% in Water intravenous solution; DEXTROSE 5 g in 100 mL INTRAVENOUS SOLUTION; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION [Dextrose]",
C4082774,1000 ML glucose 50 MG/ML Injection,glucose,"DEXTROSE 5 g in 100 mL INTRAVENOUS SOLUTION_#3; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#4; DEXTROSE 5% INJ_#7; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#4; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 50% Dextrose]_#4; DEXTROSE MONOHYDRATE 50 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]_#7; DEXTROSE 5% INJ,BAG,1000ML; dextrose 5 % per 1000 ML Injection; dextrose 5 % in 1000 ML Injection; 1000 ML glucose 50 MG/ML Injection; DEXTROSE 5% INJ BAG 1000ML; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 5% Dextrose]_#3; Dextrose 5% and Water, Dextrose 5% in Water intravenous solution_#7",
C4082775,150 ML glucose 50 MG/ML Injection,glucose,"DEXTROSE 5% INJ BAG 150ML; 150 ML glucose 50 MG/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#1; DEXTROSE 5% INJ,BAG,150ML; dextrose 5 % in 150 ML Injection; Dextrose 5% and Water, Dextrose 5% in Water intravenous solution_#4; DEXTROSE MONOHYDRATE 50 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]_#4; dextrose 5 % per 150 ML Injection",
C4082776,Glucose 50 MG/ML includes Injectable Solution & Injection,glucose,DEXTROSE 5% INJ,
C4082777,250 ML glucose 50 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION; Dextrose 5% and Water ADD-Vantage, Dextrose 5% in Water intravenous solution_#3; DEXTROSE 5% INJ BAG 250ML; DEXTROSE 5% INJ_#5; DEXTROSE 5 g in 100 mL INTRAVENOUS SOLUTION_#1; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#2; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 50% Dextrose]_#2; dextrose 5 % in 250 ML Injection; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#2; DEXTROSE MONOHYDRATE 12500 mg in 250 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; dextrose 5 % per 250 ML Injection; DEXTROSE MONOHYDRATE 50 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]_#5; Dextrose 5% and Water, Dextrose 5% in Water intravenous solution_#5; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 5% Dextrose]_#4; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]; 250 ML glucose 50 MG/ML Injection; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#3; DEXTROSE 5% INJ,BAG,250ML",
C4082778,25 ML glucose 50 MG/ML Injection,glucose,"Dextrose 5% and Water, Dextrose 5% in Water intravenous solution_#1; dextrose 5 % in 25 ML Injection; dextrose 5 % per 25 ML Injection; DEXTROSE MONOHYDRATE 50 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]_#1; DEXTROSE 5% INJ_#2; 25 ML glucose 50 MG/ML Injection; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION_#1; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#2",
C4082779,50 ML glucose 50 MG/ML Injection,glucose,"50 ML glucose 50 MG/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#1; Dextrose 5% and Water, Dextrose 5% in Water intravenous solution_#2; Dextrose 5% and Water ADD-Vantage, Dextrose 5% in Water intravenous solution_#1; dextrose 5 % per 50 ML Injection; DEXTROSE MONOHYDRATE 2500 mg in 50 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; DEXTROSE 5% INJ,BAG,50ML; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#5; DEXTROSE 5% INJ BAG 50ML; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#1; dextrose 5 % in 50 ML Injection; DEXTROSE MONOHYDRATE 2.5 g in 50 mL INTRAVENOUS INJECTION [Dextrose]; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION_#3; DEXTROSE MONOHYDRATE 50 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]_#2; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION [Dextrose]_#1; DEXTROSE 5% INJ_#3",
C4082780,500 ML glucose 50 MG/ML Injection,glucose,"dextrose 5 % per 500 ML Injection; dextrose 5 % in 500 ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 50% Dextrose]_#3; DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 5% Dextrose]_#2; DEXTROSE 5% INJ_#6; DEXTROSE 5% INJ,BAG,500ML; DEXTROSE MONOHYDRATE 25000 mg in 500 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; DEXTROSE 5% INJ BAG 500ML; DEXTROSE MONOHYDRATE 50 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]_#6; 500 ML glucose 50 MG/ML Injection; DEXTROSE 5 g in 100 mL INTRAVENOUS SOLUTION_#2; Dextrose 5% and Water, Dextrose 5% in Water intravenous solution_#6; DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#3; DEXTROSE MONOHYDRATE 50 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#3",
C4083036,1000 ML glucose 50 MG/ML / sodium chloride 2.25 MG/ML Injection,glucose,"Dextrose 5% and 0.225% Sodium Chloride, Dextrose 5% with 0.225% NaCl intravenous solution_#3; dextrose 5 % / sodium chloride 0.225 % in 1000 ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.225 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#1; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.225 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#3; dextrose 5 % / sodium chloride 0.225 % per 1000 ML Injection; 1000 ML glucose 50 MG/ML / sodium chloride 2.25 MG/ML Injection; 1000 ML Glucose 50 MG/ML / NaCl 2.25 MG/ML Injection; DEXTROSE 5%/NACL 0.225% INJ",
C4083037,250 ML glucose 50 MG/ML / sodium chloride 2.25 MG/ML Injection,glucose,"dextrose 5 % / sodium chloride 0.225 % per 250 ML Injection; 250 ML Glucose 50 MG/ML / NaCl 2.25 MG/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.225 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#3; Dextrose 5% and 0.225% Sodium Chloride, Dextrose 5% with 0.225% NaCl intravenous solution_#1; dextrose 5 % / sodium chloride 0.225 % in 250 ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.225 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#1; 250 ML glucose 50 MG/ML / sodium chloride 2.25 MG/ML Injection",
C4083038,500 ML glucose 50 MG/ML / sodium chloride 3 MG/ML Injection,glucose,"dextrose 5 % / sodium chloride 0.3 % in 500 ML Injection; 500 ML glucose 50 MG/ML / sodium chloride 3 MG/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.3 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#1; 500 ML Glucose 50 MG/ML / NaCl 3 MG/ML Injection; Dextrose 5% and 0.3% Sodium Chloride, Dextrose 5% with 0.3% NaCl intravenous solution_#1; DEXTROSE 5%/NACL 0.3% INJ_#2; dextrose 5 % / sodium chloride 0.3 % per 500 ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.3 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#2",
C4083039,500 ML glucose 50 MG/ML / sodium chloride 3.3 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 5.5 g in 100 mL / SODIUM CHLORIDE 900 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary Dextrose and Sodium Chloride]_#3; dextrose 5 % / sodium chloride 0.33 % in 500 ML Injection; Dextrose 5% and 0.33% Sodium Chloride, Dextrose 5% with 0.33% NaCl intravenous solution_#1; dextrose 5 % / sodium chloride 0.33 % per 500 ML Injection; 500 ML Glucose 50 MG/ML / NaCl 3.3 MG/ML Injection; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.33 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]_#2; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 330 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION; DEXTROSE MONOHYDRATE 5.5 g in 100 mL / SODIUM CHLORIDE 330 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 5% Dextrose in 0.33% Sodium Chloride]_#3; DEXTROSE 5%/NACL 0.33% INJ_#2",
C4083057,1000 ML glucose 25 MG/ML / sodium chloride 4.5 MG/ML Injection,glucose,"1000 ML Glucose 25 MG/ML / NaCl 4.5 MG/ML Injection; dextrose 2.5 % / sodium chloride 0.45 % per 1000 ML Injection; DEXTROSE MONOHYDRATE 2.5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE AND SODIUM CHLORIDE]; DEXTROSE 2.5%/NACL 0.45% INJ; DEXTROSE MONOHYDRATE 2.5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION; Dextrose 2.5% and 0.45% Sodium Chloride, Dextrose 2.5% with 0.45% NaCl intravenous solution; dextrose 2.5 % / sodium chloride 0.45 % in 1000 ML Injection",
C4083058,Glucose 25 MG/ML / Sodium Chloride 4.5 MG/ML Injection,glucose,LVP solution Dextrose 2.5% with 0.45% NaCl intravenous solution,
C4083105,500 ML glucose 200 MG/ML Injection,glucose,"DEXTROSE 20% INJ; parenteral nutrition solution Dextrose 20% in Water intravenous solution; Glucose 200 mg/mL solution for injection; Dextrose 20% and Water, Dextrose 20% in Water intravenous solution; dextrose 20 % in 500 ML Injection; DEXTROSE MONOHYDRATE 20 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]; Product containing precisely glucose 200 milligram/1 milliliter conventional release solution for injection (clinical drug); dextrose 20 % per 500 ML Injection",
C4084161,FORA D40-G31 (GLUCOSE) TEST STRIP,glucose,FORA D40-G31 (GLUCOSE) TEST STRIP,
C4084162,FREESTYLE PRECISION NEO (GLUCOSE) TEST STRIP,glucose,FREESTYLE PRECISION (GLUCOSE) TEST STRIP; Freestyle Precision Neo Strips,
C4112057,Cystobasidium sp. 920 FbG,FBG,Rhodotorula sp. 920 FbG,
C4112058,Cystobasidium sp. 586 FbG,FBG,Rhodotorula sp. 586 FbG,
C4112059,Cystobasidium sp. 589 FbG,FBG,Rhodotorula sp. 589 FbG,
C4114822,Dothideomycetes sp. 785 FbG,FBG,,
C4130976,Cryptococcus sp. 734 FbG,FBG,,
C4130977,Exophiala sp. 821 FbG,FBG,,
C4130998,Rhodotorula sp. 826 FbG,FBG,,
C4130999,Exophiala sp. 801 FbG,FBG,,
C4131090,Bjerkandera sp. 544 FbG,FBG,,
C4131100,Hypocreales sp. 853 FbG,FBG,,
C4131107,Penicillium sp. 568 FbG,FBG,,
C4131109,Hypocreales sp. 758 FbG,FBG,,
C4138711,Santessoniella sp. Neily 942 (BG),BG,,
C4144455,Squamiana sp. BG-2015,BG,Platycleis (Squamiana) sp. BG-2015,
C4153145,Platycleis sp. BG-2015,BG,,
C4181737,Leptophyes sp. BG-2015,BG,,
C4181738,Phaneropteridae sp. 2 BG-2015,BG,,
C4181739,Phaneropteridae sp. 1 BG-2015,BG,,
C4181741,Isophya aff. sureyai BG-2015,BG,,
C4201836,Colletotrichum sp. Bg,BG,,
C4203413,Desulfosporosinus sp. BG,BG,,
C4207040,Ochromonas sp. BG-1,BG,,
C4224267,"Boost Glucose Control, chocolate",glucose,,
C4225195,"MICROCEPHALY, SHORT STATURE, AND IMPAIRED GLUCOSE METABOLISM 2",glucose,"MSSGM2; MICROCEPHALY, SHORT STATURE, AND IMPAIRED GLUCOSE METABOLISM 2",
C4225299,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 14",diabetes,"MODY14; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 14",
C4225365,"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 13",diabetes,"MODY, TYPE 13; MODY13; MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 13",
C4227726,Insulin administration required for glucose control,glucose,,
C4227728,Young-onset diabetes,diabetes,,
C4228400,Mildly elevated glucose,glucose,,
C4228506,Elevated fasting plasma glucose,plasma glucose,,
C4228639,Hypoglycemia during episodes,hypoglycemia,,
C4229396,"Diabetes, childhood-onset",diabetes,,
C4234408,"activation of glycogen synthase activity, transferring glucose-1-phosphate",glucose,,
C4234409,"inhibition of glycogen synthase activity, transferring glucose-1-phosphate",glucose,,
C4235050,glucose catabolic process to mixed acids,glucose,,
C4235874,glucose transmembrane transport,glucose,,
C4235981,regulation of cellular response to glucose starvation,glucose,,
C4236286,"positive regulation of glycogen synthase activity, transferring glucose-1-phosphate",glucose,"up-regulation of glycogen synthase activity, transferring glucose-1-phosphate; up regulation of glycogen synthase activity, transferring glucose-1-phosphate; upregulation of glycogen synthase activity, transferring glucose-1-phosphate",
C4236287,"negative regulation of glycogen synthase activity, transferring glucose-1-phosphate",glucose,"down-regulation of glycogen synthase activity, transferring glucose-1-phosphate; downregulation of glycogen synthase activity, transferring glucose-1-phosphate; down regulation of glycogen synthase activity, transferring glucose-1-phosphate",
C4236288,"regulation of glycogen synthase activity, transferring glucose-1-phosphate",glucose,,
C4236405,UDP-glucose: 9-methylthiononylhydroximate S-glucosyltransferase activity,glucose,,
C4236406,UDP-glucose:8-methylthiooctylhydroximate S-glucosyltransferase activity,glucose,,
C4236407,UDP-glucose:7-methylthioheptylhydroximate S-glucosyltransferase activity,glucose,,
C4236408,UDP-glucose: 6-methylthiohexylhydroximate S-glucosyltransferase activity,glucose,,
C4236409,UDP-glucose:5-methylthiopentylhydroximate S-glucosyltransferase activity,glucose,,
C4236780,cellular response to oxygen-glucose deprivation,glucose,cellular response to OGD,
C4236781,response to oxygen-glucose deprivation,glucose,response to OGD,
C4236841,glucose catabolic process to pyruvate utilizing ADP,glucose,,
C4236842,glucose catabolic process to pyruvate,glucose,glucose catabolism to pyruvate,
C4236854,glycolytic process from sucrose through glucose and fructose,glucose,,
C4236855,sucrose catabolic process to fructose-6-phosphate through glucose and fructose,glucose,,
C4238397,ASSURE PRISM MULTI (GLUCOSE) TEST STRIP,glucose,ASSURE PRISM MULTI (GLUCOSE) TEST STRIP,
C4238415,COOL CONTROL A (GLUCOSE) NORMAL CONTROL SOLN,glucose,COOL CONTROL A(GLUCOSE) NORML CNTRL SOLN,
C4238416,COOL CONTROL B (GLUCOSE) HIGH CONTROL SOLN,glucose,COOL CONTROL B (GLUCOSE) HI CNTRL SOLN,
C4238495,RELION PRIME (GLUCOSE) TEST STRIP,glucose,RELION PRIME (GLUCOSE) TEST STRIP,
C4238497,INFINITY (GLUCOSE) TEST STRIP,glucose,INFINITY (GLUCOSE) TEST STRIP,
C4256330,250 ML glucose 100 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 10 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#1; DEXTROSE MONOHYDRATE 100 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [DEXTROSE]_#1; dextrose 10 % in 250 ML Injection; DEXTROSE MONOHYDRATE 100 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose]_#1; dextrose 10 % per 250 ML Injection; Dextrose 10% and Water, Dextrose 10% in Water intravenous solution_#1; DEXTROSE 10% INJ_#1; DEXTROSE 10 g in 100 mL INTRAVENOUS SOLUTION_#1; DEXTROSE MONOHYDRATE 10 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 10% Dextrose]_#4",
C4256331,250 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection,glucose,"dextrose 5 % / sodium chloride 0.45 % per 250 ML Injection; 250 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection; DEXTROSE 5%/NACL 0.45% INJ_#1; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]_#1; 250 ML Glucose 50 MG/ML / NaCl 4.5 MG/ML Injection; Dextrose 5% and 0.45% Sodium Chloride, Dextrose 5% with 0.45% NaCl intravenous solution_#1; dextrose 5 % / sodium chloride 0.45 % in 250 ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#3; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#1",
C4256332,1000 ML glucose 50 MG/ML / sodium chloride 3.3 MG/ML Injection,glucose,"Dextrose 5% and 0.33% Sodium Chloride, Dextrose 5% with 0.33% NaCl intravenous solution_#2; DEXTROSE MONOHYDRATE 5.5 g in 100 mL / SODIUM CHLORIDE 900 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary Dextrose and Sodium Chloride]_#4; dextrose 5 % / sodium chloride 0.33 % per 1000 ML Injection; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.33 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]_#3; dextrose 5 % / sodium chloride 0.33 % in 1000 ML Injection; DEXTROSE 5%/NACL 0.33% INJ_#3; DEXTROSE MONOHYDRATE 5.5 g in 100 mL / SODIUM CHLORIDE 330 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 5% Dextrose in 0.33% Sodium Chloride]_#4; 1000 ML Glucose 50 MG/ML / NaCl 3.3 MG/ML Injection",
C4256333,1000 ML glucose 50 MG/ML / sodium chloride 2 MG/ML Injection,glucose,"DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.2 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]_#3; 1000 ML Glucose 50 MG/ML / NaCl 2 MG/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 200 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION_#3; dextrose 5 % / sodium chloride 0.2 % per 1000 ML Injection; dextrose 5 % / sodium chloride 0.2 % in 1000 ML Injection; Dextrose 5% and 0.2% Sodium Chloride, Dextrose 5% with 0.2% NaCl intravenous solution_#3; DEXTROSE 5%/NACL 0.2% INJ_#3",
C4256334,500 ML glucose 50 MG/ML / sodium chloride 2 MG/ML Injection,glucose,"dextrose 5 % / sodium chloride 0.2 % per 500 ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 200 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION_#2; Dextrose 5% and 0.2% Sodium Chloride, Dextrose 5% with 0.2% NaCl intravenous solution_#2; 500 ML Glucose 50 MG/ML / NaCl 2 MG/ML Injection; DEXTROSE 5%/NACL 0.2% INJ_#2; dextrose 5 % / sodium chloride 0.2 % in 500 ML Injection; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.2 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose And Sodium Chloride]_#2",
C4256335,1000 ML glucose 500 MG/ML Injection,glucose,dextrose 50 % in 1000 ML Injection; DEXTROSE 50% INJ_#4; dextrose 50 % per 1000 ML Injection,
C4256336,250 ML Glucose 50 MG/ML / Sodium Chloride 9 MG/ML Injection,glucose,DEXTROSE 5%/NACL 0.9% INJ_#1; dextrose 5 % / sodium chloride 0.9 % per 250 ML Injection; 250 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection; dextrose 5 % / sodium chloride 0.9 % in 250 ML Injection; 250 ML Glucose 50 MG/ML / NaCl 9 MG/ML Injection,
C4256337,250 ML glucose 50 MG/ML / sodium chloride 3.3 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 5.5 g in 100 mL / SODIUM CHLORIDE 900 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary Dextrose and Sodium Chloride]_#2; DEXTROSE MONOHYDRATE 5.5 g in 100 mL / SODIUM CHLORIDE 330 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 5% Dextrose in 0.33% Sodium Chloride]_#2; dextrose 5 % / sodium chloride 0.33 % per 250 ML Injection; DEXTROSE 5%/NACL 0.33% INJ_#1; 250 ML Glucose 50 MG/ML / NaCl 3.3 MG/ML Injection; dextrose 5 % / sodium chloride 0.33 % in 250 ML Injection",
C4256338,1000 ML glucose 50 MG/ML / sodium chloride 3 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.3 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#3; Dextrose 5% and 0.3% Sodium Chloride, Dextrose 5% with 0.3% NaCl intravenous solution_#2; 1000 ML Glucose 50 MG/ML / NaCl 3 MG/ML Injection; dextrose 5 % / sodium chloride 0.3 % per 1000 ML Injection; DEXTROSE 5%/NACL 0.3% INJ_#3; dextrose 5 % / sodium chloride 0.3 % in 1000 ML Injection; 1000 ML glucose 50 MG/ML / sodium chloride 3 MG/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.3 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#2",
C4256339,250 ML glucose 50 MG/ML / sodium chloride 3 MG/ML Injection,glucose,"dextrose 5 % / sodium chloride 0.3 % in 250 ML Injection; dextrose 5 % / sodium chloride 0.3 % per 250 ML Injection; Dextrose 5% and 0.3% Sodium Chloride, Dextrose 5% with 0.3% NaCl intravenous solution_#3; DEXTROSE 5%/NACL 0.3% INJ_#1; 250 ML glucose 50 MG/ML / sodium chloride 3 MG/ML Injection; 250 ML Glucose 50 MG/ML / NaCl 3 MG/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.3 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#1",
C4256340,500 ML glucose 50 MG/ML / sodium chloride 2.25 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 0.225 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Dextrose and Sodium Chloride]_#2; 500 ML Glucose 50 MG/ML / NaCl 2.25 MG/ML Injection; Dextrose 5% and 0.225% Sodium Chloride, Dextrose 5% with 0.225% NaCl intravenous solution_#2; dextrose 5 % / sodium chloride 0.225 % in 500 ML Injection; dextrose 5 % / sodium chloride 0.225 % per 500 ML Injection",
C4257321,glucose Injection,glucose,,
C4257322,glucose / sodium chloride Injection,glucose,,
C4263426,Glucose meter to reference method correlation,glucose,Glucose meter to reference method correlation,
C4265404,Glucose meter to reference method correlation:Ratio:Pt:Ser/Plas/Bld:Qn:Calculated,glucose,"Glucose meter to reference method correlation [Ratio] in Serum, Plasma or Blood by calculation; Glucose meter to reference method correlation Calc (S/P/Bld) [Ratio]; Glucose meter to reference method correlation:Ratio:To identify measures at a point in time:Serum/Plasma/Whole blood:Quantitative:Calculated; Glucose correlation SerPlBld Calc-Rto",
C4265504,Glucose tolerance 2H gestational panel:-:-:Ser/Plas:-,glucose,Glucose tolerance 2 hours gestational panel - Serum or Plasma; Glucose tolerance 2H gestational panel:-:-:Serum/Plasma:-; Glucose tolerance 2 hours gestational panel; GTT gest 2h Pnl SerPl; Glucose tolerance 2H gestational panel:-:-:Ser/Plas:-,
C4265799,Glucose^1.5H post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5h p meal SerPl-mCnc; Glucose 1.5 Hr post meal [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --1.5 hours post meal; Glucose^1.5 hours post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C4271836,TRUE METRIX LEVEL 3 (GLUCOSE) HIGH CONTROL SOLN,glucose,TRUE METRIX LEVEL 3 (GLUCOSE) HIGH CNTRL,
C4271837,TRUE METRIX LEVEL 2 (GLUCOSE) NORMAL CONTROL SOLN,glucose,TRUE METRIX LEVEL 2 (GLUCOSE) NORM CNTRL,
C4271838,TRUE METRIX LEVEL 1 (GLUCOSE) LOW CONTROL SOLN,glucose,TRUE METRIX LEVEL 1 (GLUCOSE) LOW CNTRL,
C4274019,Hyperinsulinism due to deficiency of glucokinase,hypoglycemia,Hyperinsulinemic hypoglycemia due to glucokinase deficiency; Hyperinsulinism due to deficiency of glucokinase (disorder); Hyperinsulinism due to glucokinase deficiency,
C4274078,Hyperinsulinism due to HNF4A deficiency,hypoglycemia,Hyperinsulinism due to HNF4A deficiency; Hyperinsulinism due to hepatocyte nuclear factor 4-alpha deficiency; Hyperinsulinemic hypoglycemia due to HNF4A deficiency; Hyperinsulinism due to hepatocyte nuclear factor 4-alpha deficiency (disorder),
C4274080,Autosomal dominant hyperinsulinism due to SUR1 deficiency,hypoglycemia,Autosomal dominant hyperinsulinemic hypoglycemia due to SUR1 deficiency; Autosomal dominant hyperinsulinism due to sulfonylurea receptor 1 deficiency; Autosomal dominant hyperinsulinism due to sulfonylurea receptor 1 deficiency (disorder); Autosomal dominant hyperinsulinism due to SUR1 deficiency,
C4274081,Autosomal dominant hyperinsulinism due to Kir6.2 deficiency,hypoglycemia,Autosomal dominant hyperinsulinism due to Kir6.2 deficiency (disorder); Dominant KATP hyperinsulinism due to Kir6.2 deficiency; Autosomal dominant hyperinsulinism due to Kir6.2 deficiency; Autosomal dominant hyperinsulinemic hypoglycemia due to Kir6.2 deficiency,
C4274082,Adult onset non-insulinoma persistent hyperinsulinemic hypoglycemia,hypoglycemia,NIPHS; Non-insulinoma pancreatogenous hypoglycemia syndrome; Adult onset non-insulinoma persistent hyperinsulinaemic hypoglycaemia; Adult onset non-insulinoma persistent hyperinsulinemic hypoglycemia (disorder),
C4274658,Hemoglobin A1C test not done,a1c,Hemoglobin A1C measurement not done; Haemoglobin A1C test not done; Hemoglobin A1C test not done (situation); Haemoglobin A1C measurement not done,
C4274674,Gingival disease co-occurrent with diabetes mellitus,diabetes,Gingival disease co-occurrent with diabetes mellitus (disorder),
C4274951,Provision of written information about diabetes mellitus,diabetes,Provision of written information about diabetes mellitus (procedure),
C4274959,Provision of written information about diabetes and high cholesterol,diabetes,Provision of written information about diabetes and high cholesterol (procedure),
C4275020,Provision of written information about diabetes and hypertension,diabetes,Provision of written information about diabetes and hypertension (procedure),
C4275280,Referral to diabetes service,diabetes,Referral to diabetes service (procedure),
C4275887,1000 ML glucose 50 MG/ML / potassium chloride 0.01 MEQ/ML / sodium chloride 2.25 MG/ML Injection,glucose,potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.225 % in 1000 ML Injection; potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.225 % per 1000 ML Injection; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.01 MEQ/ML / NaCl 2.25 MG/ML Injection; DEXTROSE 5%/NACL 0.225%/KCL 10MEQ/L INJ; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.01 MEQ/ML / NaCl 2.25 MG/ML Injection,
C4277479,N-(9-phenylpropyl-1-methyl-beta-carboline 7-oxyacetyl)-(2-amino-2-deoxy)glucose,glucose,2DG-Har-01,
C4279822,BG-323,BG,,
C4280909,Polyneuropathy due to secondary diabetes mellitus,diabetes,Polyneuropathy due to secondary diabetes mellitus (disorder),
C4281023,Hemoglobin A1c greater than 9% indicating poor diabetic control,a1c,Hemoglobin A1c greater than nine percent indicating poor diabetic control (finding); Hemoglobin A1c greater than nine percent indicating poor diabetic control,
C4281024,Hemoglobin A1c between 7%-9% indicating borderline diabetic control,a1c,Hemoglobin A1c between seven and nine percent indicating borderline diabetic control; Hemoglobin A1c between seven and nine percent indicating borderline diabetic control (finding),
C4281850,"immunoglobulin G, human 5000 MG Injection",glucose,"GLOBULIN,IMMUNE (GLUCOSE) 5GM/VIL INJ; immune globulin intravenous 5 g intravenous powder for injection; immunoglobulin G, human 5 GM Injection; GLOBULIN,IMMUNE (IV) (GLUCOSE) 5GM/VIL INJ; Human immunoglobulin G 5 G powder for solution for injection vial; Product containing precisely human immunoglobulin G 5 gram/1 vial powder for conventional release solution for injection (clinical drug)",
C4281875,1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection,glucose,"POTASSIUM CHLORIDE 150 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 450 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]_#2; potassium chloride 20 MEQ / dextrose 5 % / sodium chloride 0.45 % in 1000 ML Injection; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.02 MEQ/ML / NaCl 4.5 MG/ML Injection; Dextrose 5% and 0.45% Sodium Chloride with Potassium Chloride 20 mEq/L, Dextrose 5% with 0.45% NaCl and KCl 20 mEq/L intravenous solution_#2; potassium chloride 20 MEQ / dextrose 5 % / sodium chloride 0.45 % per 1000 ML Injection; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.02 MEQ/ML / NaCl 4.5 MG/ML Injection; DEXTROSE 5%/NACL 0.45%/KCL 20MEQ/L INJ_#2; DEXTROSE MONOHYDRATE 50 g in 1000 mL / SODIUM CHLORIDE 4.5 g in 1000 mL / POTASSIUM CHLORIDE 1.49 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]_#2; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.45 g in 100 mL / POTASSIUM CHLORIDE 0.15 g in 100 mL INTRAVENOUS INJECTION [Potassium Chloride in Dextrose and Sodium Chloride]",
C4281877,500 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 3 MG/ML Injection,glucose,500 ML Glucose 50 MG/ML / K+ Chloride 0.02 MEQ/ML / NaCl 3 MG/ML Injection; DEXTROSE 5%/NACL 0.33%/KCL 20MEQ/L INJ; potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.3 % in 500 ML Injection; 500 ML Glucose 50 MG/ML / Pot Chloride 0.02 MEQ/ML / NaCl 3 MG/ML Injection; potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.3 % per 500 ML Injection,
C4281925,"immunoglobulin G, human 10000 MG Injection",glucose,"Product containing precisely human immunoglobulin G 10 gram/1 vial powder for conventional release solution for injection (clinical drug); immunoglobulin G, human 10 GM Injection; Human immunoglobulin G 10 G powder for solution for injection vial; GLOBULIN,IMMUNE (IV) (GLUCOSE) 10GM/VIL INJ; immune globulin intravenous 10 g intravenous powder for injection; GLOBULIN,IMMUNE (GLUCOSE) 10GM/VIL INJ",
C4282014,250 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection,glucose,"250 ML Glucose 50 MG/ML / Pot Chloride 0.02 MEQ/ML / NaCl 2.25 MG/ML Injection; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.2 g in 100 mL / POTASSIUM CHLORIDE 0.15 g in 100 mL INTRAVENOUS INJECTION [Potassium Chloride in Dextrose and Sodium Chloride]_#1; 250 ML Glucose 50 MG/ML / K+ Chloride 0.02 MEQ/ML / NaCl 2.25 MG/ML Injection; potassium chloride 5 MEQ / dextrose 5 % / sodium chloride 0.225 % per 250 ML Injection; Dextrose 5% and 0.2% Sodium Chloride with Potassium Chloride 20 mEq/L, Dextrose 5% with 0.2% NaCl and KCl 20 mEq/L intravenous solution_#1",
C4282015,500 ML Glucose 50 MG/ML / Potassium Chloride 0.02 MEQ/ML / Sodium Chloride 2.25 MG/ML Injection,glucose,"potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.225 % per 500 ML Injection; 500 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection; Dextrose 5% and 0.2% Sodium Chloride with Potassium Chloride 20 mEq/L, Dextrose 5% with 0.2% NaCl and KCl 20 mEq/L intravenous solution_#2; potassium chloride 10 MEQ / dextrose 5 % / sodium chloride 0.225 % in 500 ML Injection; 500 ML Glucose 50 MG/ML / K+ Chloride 0.02 MEQ/ML / NaCl 2.25 MG/ML Injection; POTASSIUM CHLORIDE 150 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 200 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]_#1; 500 ML Glucose 50 MG/ML / Pot Chloride 0.02 MEQ/ML / NaCl 2.25 MG/ML Injection; DEXTROSE 5%/NACL 0.2%/KCL 20MEQ/L INJ_#1",
C4282024,1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML Injection,glucose,"DEXTROSE 5 g in 100 mL / POTASSIUM CHLORIDE 0.15 g in 100 mL INTRAVENOUS SOLUTION [POTASSIUM CHLORIDE IN DEXTROSE]; DEXTROSE 5%/KCL 20MEQ/L INJ; potassium chloride 20 MEQ / glucose 5 % per 1000 ML Injection; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.02 MEQ/ML Injection; DEXTROSE MONOHYDRATE 5 g in 100 mL / POTASSIUM CHLORIDE 0.149 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose]; potassium chloride 20 MEQ / dextrose 5 % per 1000 ML Injection; Potassium Chloride 150 mg in 100 mL / Dextrose Monohydrate 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride]; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.02 MEQ/ML Injection; dextrose 5 % / potassium chloride 20 MEQ per 1000 ML Injection; potassium chloride 20 MEQ / glucose 5 % in 1000 ML Injection; POTASSIUM CHLORIDE 150 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose]; Dextrose 5% and Water with Potassium Chloride 20 mEq/L, Dextrose 5% in Water with KCl 20 mEq/L intravenous solution",
C4282147,1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection,glucose,"DEXTROSE 5%/NACL 0.2%/KCL 20MEQ/L INJ_#2; 1000 ML Glucose 50 MG/ML / K+ Chloride 0.02 MEQ/ML / NaCl 2.25 MG/ML Injection; 1000 ML Glucose 50 MG/ML / Pot Chloride 0.02 MEQ/ML / NaCl 2.25 MG/ML Injection; DEXTROSE MONOHYDRATE 50 g in 1000 mL / SODIUM CHLORIDE 2.25 g in 1000 mL / POTASSIUM CHLORIDE 1.49 g in 1000 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]; potassium chloride 20 MEQ / dextrose 5 % / sodium chloride 0.225 % in 1000 ML Injection; POTASSIUM CHLORIDE 150 mg in 100 mL / DEXTROSE MONOHYDRATE 5 g in 100 mL / SODIUM CHLORIDE 200 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Potassium Chloride in Dextrose and Sodium Chloride]_#2; DEXTROSE 5 g in 100 mL / SODIUM CHLORIDE 0.2 g in 100 mL / POTASSIUM CHLORIDE 0.15 g in 100 mL INTRAVENOUS INJECTION [Potassium Chloride in Dextrose and Sodium Chloride]_#3; Dextrose 5% and 0.2% Sodium Chloride with Potassium Chloride 20 mEq/L, Dextrose 5% with 0.2% NaCl and KCl 20 mEq/L intravenous solution_#3; 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection; Dextrose 5% and 0.225% Sodium Chloride with Potassium Chloride 20 mEq/L, Dextrose 5% with 0.225% NaCl and KCl 20 mEq/L intravenous solution; potassium chloride 20 MEQ / dextrose 5 % / sodium chloride 0.225 % per 1000 ML Injection",
C4282196,Calcium Chloride 0.001 MEQ/ML / Glucose 50 MG/ML / Potassium Chloride 0.044 MEQ/ML / Sodium Chloride 0.103 MEQ/ML / Sodium Lactate 0.028 MEQ/ML Injectable Solution,glucose,Calcium Chloride 0.001 MEQ/ML / Glucose 50 MG/ML / K+ Chloride 0.044 MEQ/ML / NaCl 0.103 MEQ/ML / Sodium Lactate 0.028 MEQ/ML Injectable Solution; Calcium Chloride 0.001 MEQ/ML / Glucose 50 MG/ML / Pot Chloride 0.044 MEQ/ML / NaCl 0.103 MEQ/ML / Sodium Lactate 0.028 MEQ/ML Injectable Solution; DEXTROSE 5%/LACTATED RINGER'S/KCL 40MEQ/L INJ; calcium chloride 0.001 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.044 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution; potassium chloride 40 MEQ/L in lactated Ringers solution with dextrose 5 % Injectable Solution,
C4283742,"Ceramide Glucosyltransferase, human",glucose,UDP-Glucose Ceramide Glucosyltransferase; UDP-Glucose:N-Acylsphingosine D-Glucosyltransferase; GLCT-1; UGCG; Ceramide Glucosyltransferase; GCS; Glucosylceramide Synthase; EC 2.4.1.80,
C4283933,UGCG wt Allele,glucose,UDP-Glucose Ceramide Glucosyltransferase wt Allele; UGCG wt Allele; GLCT1; GCS,
C4286334,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes",diabetes,Diabetes Gene Panel Reagents,
C4286335,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Diabetes Mellitus Type 1",diabetes,Type 1 Diabetes Gene Panel Reagents; Diabetes Mellitus Type 1 Gene Panel Reagents; Juvenile Diabetes Gene Panel Reagents,
C4286336,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Diabetes Mellitus Type 1, Mutation",diabetes,Diabetes Mellitus Type 1 Gene Mutation Panel Reagents,
C4286337,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Diabetes Mellitus Type 1, Del/Dup",diabetes,Diabetes Mellitus Type 1 Gene Deletion/Duplication Panel Reagents,
C4286339,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Diabetes Mellitus Type 2",diabetes,Non-Insulin Dependent Diabetes Gene Panel Reagents; Diabetes Mellitus Type 2 Gene Panel Reagents; Adult-Onset Diabetes Gene Panel Reagents; Type 2 Diabetes Gene Panel Reagents,
C4286340,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Diabetes Mellitus Type 2, Mutation",diabetes,Diabetes Mellitus Type 2 Gene Mutation Panel Reagents,
C4286341,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Diabetes Mellitus Type 2, Del/Dup",diabetes,Diabetes Mellitus Type 2 Gene Deletion/Duplication Panel Reagents,
C4286342,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Nephrogenic Diabetes Insipidus",diabetes,Nephrogenic Diabetes Insipidus Gene Panel Reagents,
C4286343,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Nephrogenic Diabetes Insipidus, Mutation",diabetes,Nephrogenic Diabetes Insipidus Gene Mutation Panel Reagents,
C4286344,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Nephrogenic Diabetes Insipidus, Del/Dup",diabetes,Nephrogenic Diabetes Insipidus Gene Deletion/Duplication Panel Reagents,
C4286345,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Maturity-Onset Diabetes of the Young (MODY)",diabetes,MODY Gene Panel Reagents; Maturity-Onset Diabetes of the Young Gene Panel Reagents,
C4286346,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Maturity-Onset Diabetes of the Young (MODY), Mutation",diabetes,Maturity-Onset Diabetes of the Young Gene Mutation Panel Reagents,
C4286347,"IVD Panels, Human Genetics, Metabolic Disorder, Diabetes, Maturity-Onset Diabetes of the Young (MODY), Del/Dup",diabetes,Maturity-Onset Diabetes of the Young Gene Deletion/Duplication Panel Reagents,
C4289128,GAIA Level 3 Gestational Diabetes Mellitus,diabetes,Global Alignment of Immunization safety Assessment in pregnancy Level 3 Gestational Diabetes Mellitus,
C4289173,GAIA Level 2 Gestational Diabetes Mellitus,diabetes,Global Alignment of Immunization safety Assessment in pregnancy Level 2 Gestational Diabetes Mellitus,
C4289216,GAIA Level 1 Gestational Diabetes Mellitus,diabetes,Global Alignment of Immunization safety Assessment in pregnancy Level 1 Gestational Diabetes Mellitus,
C4289229,GAIA Insufficient Evidence for Diagnosis of Gestational Diabetes Mellitus,diabetes,Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Gestational Diabetes Mellitus,
C4289233,GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty,diabetes,Global Alignment of Immunization safety Assessment in pregnancy Gestational Diabetes Mellitus Level of Diagnostic Certainty,
C4289234,GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology,diabetes,Global Alignment of Immunization safety Assessment in pregnancy Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology,
C4291382,GLUCOCARD SHINE (GLUCOSE) TEST STRIP,glucose,GLUCOCARD SHINE (GLUCOSE) TEST STRIP,
C4291383,GLUCOCARD VITAL (GLUCOSE) TEST STRIP,glucose,Glucocard Vital Test Strip; Glucocard Vital Test Strips; GLUCOCARD VITAL (GLUCOSE) TEST STRIP,
C4291384,GLUCOCARD 01 SENSOR PLUS (GLUCOSE) TEST STRIP,glucose,GLUCOCARD 01 SENSOR PLS(GLUCOSE)TEST STR,
C4291385,GLUCOCARD VITAL SENSOR (GLUCOSE) TEST STRIP,glucose,GLUCOCARD VITAL SENSOR (GLUCOSE)TEST STR,
C4291386,EASY TOUCH (GLUCOSE) HIGH/LOW CONTROL SOLN,glucose,EASY TOUCH (GLUCOSE) HI/LO CONTROL SOLN,
C4291387,EASY TOUCH (GLUCOSE) TEST STRIP,glucose,EASY TOUCH (GLUCOSE) TEST STRIP,
C4292403,True Metrix Go Blood Glucose Meter Kit,blood glucose,,
C4294701,glucose / potassium chloride Injection,glucose,,
C4301269,glucose / potassium chloride / sodium chloride Injection,glucose,,
C4301634,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,glucose,,
C4302025,Background retinopathy due to impaired glucose regulation,glucose,Background retinopathy due to impaired glucose regulation (disorder),
C4302104,Renal papillary necrosis due to diabetes mellitus,diabetes,Renal papillary necrosis due to diabetes mellitus (disorder),
C4302120,Atypical diabetes mellitus,diabetes,ADM - atypical diabetes mellitus; Atypical diabetes mellitus (disorder),
C4302207,Neonatal hyperglycemia due to insulin deficiency,hyperglycemia,Neonatal hyperglycaemia due to insulin deficiency; Neonatal hyperglycemia due to insulin deficiency (disorder),
C4302519,Ulcer of right foot due to type 2 diabetes mellitus,diabetes,Ulcer of right foot due to type 2 diabetes mellitus (disorder); Diabetic ulcer of right foot due to diabetes mellitus type 2; Diabetes type 2 with diabetic ulcer of right foot,
C4302527,Ulcer of left foot due to type 2 diabetes mellitus,diabetes,Diabetic ulcer of left foot due to diabetes mellitus type 2; Ulcer of left foot due to type 2 diabetes mellitus (disorder); Diabetes type 2 with diabetic ulcer of left foot,
C4302789,Diabetes mellitus screening not done,diabetes,Diabetes mellitus screening not done (situation),
C4303082,Hyperinsulinism due to uncoupling protein 2 deficiency,hypoglycemia,Hyperinsulinism due to uncoupling protein 2 deficiency (disorder); Hyperinsulinism due to UCP2 deficiency; Hyperinsulinism due to UCP2 (uncoupling protein 2) deficiency; Hyperinsulinemic hypoglycemia due to UCP2 deficiency,
C4303433,Acidosis due to type 2 diabetes mellitus,diabetes,Acidosis due to type 2 diabetes mellitus (disorder),
C4303434,Acidosis due to type 1 diabetes mellitus,diabetes,Acidosis due to type 1 diabetes mellitus (disorder),
C4303473,Hyperinsulinism due to short chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency,hypoglycemia,Hyperinsulinism due to SCHAD deficiency; Hyperinsulinism due to short chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency; Hyperinsulinism due to short chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (disorder); Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency; SCHAD deficiency; Hyperinsulinism due to glutamodehydrogenase deficiency; Hyperinsulinemic hypoglycemia due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency,
C4303475,Hyperinsulinism due to HNF1A deficiency,hypoglycemia,Hyperinsulinism due to HNF1A deficiency; Hyperinsulinism due to hepatocyte nuclear factor 1-alpha deficiency (disorder); Hyperinsulinemic hypoglycemia due to HNF1A deficiency; Hyperinsulinism due to hepatocyte nuclear factor 1-alpha deficiency,
C4303558,Maternal history of gestational diabetes,diabetes,Maternal history of gestational diabetes (situation),
C4303593,DEND syndrome,diabetes,"K ATP Associated Developmental Delay, Epilepsy and Neonatal Diabetes; DEND (developmental delay, epilepsy, neonatal diabetes) syndrome; Developmental delay, epilepsy, neonatal diabetes syndrome (disorder); Developmental delay-epilepsy-neonatal diabetes syndrome; DEND syndrome; Developmental delay, epilepsy, neonatal diabetes syndrome",
C4303751,Hypoglycemia self management plan,hypoglycemia,Hypoglycemia self management plan (record artifact); Hypoglycaemia self management plan,
C4303752,Hyperglycemia self management plan,hyperglycemia,Hyperglycaemia self management plan; Hyperglycemia self management plan (record artifact),
C4303886,Has diabetes identity card,diabetes,Has diabetes identity card (finding),
C4303904,Hypoglycemia clinical management plan,hypoglycemia,Hypoglycaemia clinical management plan; Hypoglycemia clinical management plan (record artifact),
C4303905,Hyperglycemia clinical management plan,hyperglycemia,Hyperglycaemia clinical management plan; Hyperglycemia clinical management plan (record artifact),
C4304029,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,diabetes,Not suitable for DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) programme; Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program (finding); Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed programme; Not suitable for DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) program,
C4304156,Seen by diabetes specialist nurse,diabetes,Seen by diabetes specialist nurse (finding),
C4304316,Provision of written information about diabetes and high hemoglobin A1c level,diabetes,Provision of written information about diabetes and high hemoglobin A1c level (procedure); Provision of written information about diabetes and high haemoglobin A1c level,
C4304438,Maternal history of diabetes mellitus type 2,diabetes,Maternal history of diabetes mellitus type 2 (situation),
C4304440,Maternal history of diabetes mellitus type 1,diabetes,Maternal history of diabetes mellitus type 1 (situation),
C4304601,Provision of diabetes identity card,diabetes,Provision of diabetes identity card (procedure),
C4304957,Peripheral angiopathy due to type 1 diabetes mellitus,diabetes,Peripheral angiopathy due to type 1 diabetes mellitus (disorder); Peripheral vascular disease due to type I diabetes,
C4305143,Skin ulcer due to type 2 diabetes mellitus,diabetes,Ulcer of skin due to type 2 diabetes mellitus; Ulcer of skin due to type 2 diabetes mellitus (disorder),
C4305899,BG-777,BG,,
C4306791,FORA V10-V12-D10-D20 (GLUCOSE) TEST STRIP,glucose,FORA V10-V12-D10-D20 (GLUCOSE)TEST STRIP,
C4307636,shenxiong glucose,glucose,danshen-chuanxiongqin,
C4308097,"At1g32490 protein, Arabidopsis",glucose,"ESP3 protein, Arabidopsis; RSW12 protein, Arabidopsis; GLUCOSE-HYPERSENSITIVE MUTANT 1 protein, Arabidopsis; GSM1 protein, Arabidopsis; EMBRYO DEFECTIVE 2733 protein, Arabidopsis; EMB2733 protein, Arabidopsis; ENHANCED SILENCING PHENOTYPE 3 protein, Arabidopsis",
C4313271,Elevated fasting blood glucose,blood glucose,,
C4314325,Hypo- or agammaglobulinemia,hypo,,
C4315035,Elevated hemoglobin A1c (HbA1c),a1c,,
C4315209,Elevated fasting glucose levels,glucose,,
C4315955,Neonatal hyperinsulinemic hypoglycemia,hypoglycemia,,
C4316344,Disorder of vision due to secondary diabetes mellitus,diabetes,Disorder of vision due to secondary diabetes mellitus (disorder),
C4316357,Referral to certified diabetes educator,diabetes,Referral to certified diabetes educator (procedure),
C4316453,Education about blood glucose monitor,blood glucose,Education about blood glucose monitor (procedure),
C4317739,ACCU-CHEK GUIDE (GLUCOSE) METER,glucose,ACCU-CHECK Guide Meter; ACCU-CHEK GUIDE (GLUCOSE) METER,
C4318103,Trueplus Glucose Gel,glucose,,
C4318564,"Diabetes mellitus (DM) (e.g., diabetic retinopathy, nephropathy, and neuropathy)",diabetes,,
C4321446,K ATP Permanent Neonatal Diabetes,diabetes,K ATP Permanent Neonatal Diabetes,
C4324853,ACCU-CHEK GUIDE (GLUCOSE) TEST STRIP,glucose,ACCU-CHEK GUIDE (GLUCOSE) TEST STRIP,
C4324998,ACCU-CHEK GUIDE (GLUCOSE) HIGH/LOW CONTROL SOLN,glucose,ACCU-CHEK GUIDE(GLUCOSE)HI/LO CNTRL SOLN,
C4328104,"UDP-glucose:4-hydroxylamino-2,6-dinitrotoluene-O-glucosyltransferase activity",glucose,,
C4328105,"UDP-glucose:2-hydroxylamino-4,6-dinitrotoluene-O-glucosyltransferase activity",glucose,,
C4328120,UDP-3-dehydro-alpha-D-glucose dehydrogenase activity,glucose,,
C4328228,UDP-D-glucose:delphinidin 3-O-glucosyl-5-O-caffeoylglucoside -O-beta-D-glucosyltransferase activity,glucose,,
C4328249,UDP-D-glucose:pelargonidin-3-O-beta-D-glucoside 5-O-glucosyltransferase activity,glucose,,
C4328281,UDP-glucose:cis-zeatin 7-N-glucosyltransferase activity,glucose,,
C4328283,UDP-glucose:kinetin 7-N-glucosyltransferase activity,glucose,,
C4328285,UDP-glucose:benzyladenine 7-N-glucosyltransferase activity,glucose,,
C4328286,UDP-glucose:isopentenyladenine 7-N-glucosyltransferase activity,glucose,,
C4328288,UDP-glucose:dihydrozeatin 7-N-glucosyltransferase activity,glucose,,
C4328289,UDP-glucose:trans-zeatin 9-N-glucosyltransferase,glucose,,
C4328290,UDP-glucose:trans-zeatin 7-N-glucosyltransferase activity,glucose,,
C4328307,indole-3-acetyl-beta-1-D-glucose hydrolase activity,glucose,,
C4328308,indole-3-acetyl-beta-4-D-glucose hydrolase activity,glucose,,
C4328315,UDP-glucose: 4-methylthiobutylhydroximate S-glucosyltransferase activity,glucose,,
C4328368,cyanidin 7-O-(6-O-(4-O-(glucosyl)-oxybenzoyl)-glucoside) acyltransferase (acyl-glucose dependent) activity,glucose,,
C4328369,cyanidin 7-O-glucoside acyltransferase(acyl-glucose dependent) activity,glucose,,
C4328370,delphinidin 7-O-(6-O-(4-O-(glucosyl)-oxybenzoyl)-glucoside) acyltransferase (acyl-glucose dependent activity,glucose,,
C4328371,delphinidin 7-O-glucoside acyltransferase (acyl-glucose dependent) activity,glucose,,
C4328372,delphinidin 3-O-rutinoside 7-O-glucosyltransferase (acyl-glucose dependent) activity,glucose,,
C4328404,delphinidin 3-O-glucoside 7-O-glucosyltransferase (feruloyl-glucose dependent) activity,glucose,,
C4328405,pelargonidin 3-O-glucoside 7-O-glucosyltransferase (feruloyl-glucose dependent) activity,glucose,,
C4328406,cyanidin 3-O-glucoside 7-O-glucosyltransferase (feruloyl-glucose dependent) activity,glucose,,
C4328407,delphinidin 3-O-glucoside 5-O-glucosyltransferase (vanilloyl-glucose dependent) activity,glucose,,
C4328408,delphinidin 3-O-glucoside 5-O-glucosyltransferase (acyl-glucose dependent) activity,glucose,,
C4328409,pelargonidin 3-O-glucoside 7-O-glucosyltransferase (acyl-glucose dependent) activity,glucose,,
C4328410,pelargonidin 3-O-glucoside 5-O-glucosyltransferase (acyl-glucose dependent) activity,glucose,,
C4328413,cyanidin 3-O-glucoside 7-O-glucosyltransferase (hydroxybenzoly-glucose dependent) activity,glucose,,
C4328414,cyanidin 3-O-glucoside 5-O-glucosyltransferase (acyl-glucose dependent) activity,glucose,,
C4328442,cyanidin 3-O-glucoside 5-O glucosyltransferase (vanilloyl-glucose dependent) activity,glucose,,
C4328443,cyanidin 3-O-glucoside 7-O-glucosyltransferase (vanilloyl-glucose dependent) activity,glucose,,
C4328444,cyanidin 3-O-glucoside 5-O-glucosyltransferase (sinapoyl-glucose dependent) activity,glucose,,
C4328488,"dTDP-3-amino-4-oxo-2,3,6-trideoxy-alpha-D-glucose N,N-dimethyltransferase activity",glucose,,
C4328489,"dTDP-3-N-methylamino-4-oxo-2,3,6-trideoxy-alpha-D-glucose N-methyltransferase activity",glucose,,
C4328490,"dTDP-3-amino-4-oxo-2,3,6-trideoxy-alpha-D-glucose N-methyltransferase activity",glucose,,
C4328548,"dTDP-4-oxo-2,6-dideoxy-D-glucose 4-ketoreductase (dTDP-D-oliose producing) activity",glucose,,
C4328682,demethylrebeccamycin--D-glucose O-methyltransferase activity,glucose,,
C4329279,Adipsic Diabetes Insipidus,diabetes,,
C4330472,Idiopathic Ketotic Hypoglycemia,hypoglycemia,,
C4330509,K ATP Channel-Associated Diabetes Mellitus,diabetes,,
C4330524,Kir6.2-Associated Diabetes Mellitus,diabetes,,
C4330695,Mitochondrial Diabetes,diabetes,Mitochondrial Diabetes,
C4330923,PRKDC Gene Mutation,hyper,"Protein Kinase, DNA-Activated, Catalytic Polypeptide Gene Mutation; XRCC7 Gene Mutation; p350 Gene Mutation; HYRC1 Gene Mutation; HYRC Gene Mutation; DNA-PKcs Gene Mutation; Hyper-Radiosensitivity of Murine SCID Mutation, Complementing 1 Gene Mutation; DNPK1 Gene Mutation; DNAPK Gene Mutation; Hyperradiosensitivity Complementing 1, Mouse, Homolog of Gene Mutation",
C4331268,SUR1-Associated Diabetes Mellitus,diabetes,,
C4331425,Transcription Factor-Associated Monogenic Diabetes,diabetes,,
C4331814,2-Hour Postprandial Glucose,glucose,2h Postprandial Glucose; 2h Glucose; 2 Hour Glucose; 2 Hour Postprandial Glucose; 2-Hour Glucose; 2 hr Glucose; 2 hr Postprandial Glucose,
C4331824,Autosomal Dominant Neurohypophyseal Diabetes Insipidus,diabetes,,
C4410244,Rhyacophila sp. A BG,BG,,
C4410274,Brachycentrus aff. americanus A BG,BG,Brachycentrus americanus A BG,
C4410275,Brachycentrus aff. americanus B BG,BG,Brachycentrus americanus B BG,
C4430562,Kentrophoros sp. FBG,FBG,,
C4439558,Beihai hypo-like virus 1,hypo,,
C4473938,glucose 357 MG/ML,glucose,,
C4473939,cholecalciferol / glucose Oral Gel Product,glucose,,
C4476624,Hypoautofluorescent retinal lesion,hypo,Hypo-autofluorescent retinal lesion,
C4476656,Triggered by glucose ingestion,glucose,,
C4478635,Hypoketotic hypoglycemia when fasting,hypoglycemia,,
C4479484,Widespread irregular peripheral hypo-autofluorescence,hypo,,
C4482969,B little g super little b Ag:PrThr:Pt:RBC:Ord,BG,Bg sup(b) Ag RBC Ql; Bg^b Antigen:Presence or Threshold:To identify measures at a point in time:Erythrocytes:Ordinal; Bg sup(b) Ag Ql (RBC); Bg sup(b) Ag [Presence] on Red Blood Cells,
C4482970,B little g super little b Ag,BG,Bg^b Antigen; Bg^b Ag; B little g super little b Ag,
C4482971,B little g super little c Ag:PrThr:Pt:RBC:Ord,BG,Bg^c Antigen:Presence or Threshold:To identify measures at a point in time:Erythrocytes:Ordinal; Bg sup(c) Ag Ql (RBC); Bg sup(c) Ag [Presence] on Red Blood Cells; Bg sup(c) Ag RBC Ql,
C4482972,B little g super little c Ag,BG,Bg^c Ag; B little g super little c Ag; Bg^c Antigen,
C4484151,Bg^b,BG,B little g super little b,
C4484152,Bg^c,BG,B little g super little c,
C4489792,GLUCOSE SENSOR FREESTYLE LIBRE PRO,glucose,GLUCOSE SENSOR FREESTYLE LIBRE PRO,
C4505389,Glycated Hemoglobin A1c,a1c,"Glycated haemoglobin-A1c; Glycated Hemoglobin A1c; Hemoglobin A1c, Glycosylated; HbA1c - Glycated haemoglobin-A1c; Glycated hemoglobin-A1c; HbA1c - Glycated hemoglobin-A1c; Glycated hemoglobin-A1c (substance); Hemoglobin A1c, Glycated; Glycosylated Hemoglobin A1c",
C4506083,"PGR protein, Arabidopsis",glucose,"plasma membrane glucose-responsive regulator, Arabidopsis; AtPGR protein, Arabidopsis",
C4507209,gastric inhibitory polypeptide (3-30)-amide,glucose,GIP(3-30)NH2; GIP (3-30)NH2; glucose insulinotropic polypeptide(3-30)amide,
C4510367,"Neonatal diabetes, congenital hypothyroidism, congenital glaucoma, hepatic fibrosis, polycystic kidney syndrome",diabetes,"Neonatal diabetes, congenital hypothyroidism, congenital glaucoma, hepatic fibrosis, polycystic kidney syndrome (disorder); Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome",
C4510539,Diabetes screening declined,diabetes,Diabetes screening declined (situation),
C4510722,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,diabetes,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus (disorder); Lumbosacral radiculoplexus neuropathy with diabetes mellitus; Diabetic lumbosacral radiculoplexus neuropathy; DLRPN - diabetic lumbosacral radiculoplexus neuropathy; Diabetic lumbosacral plexopathy,
C4511231,Lesion of skin due to diabetes mellitus,diabetes,Lesion of skin due to diabetes mellitus (disorder),
C4511846,Hyperosmolarity due to drug induced diabetes mellitus,diabetes,Hyperosmolarity due to drug induced diabetes mellitus (disorder),
C4517296,"X-linked intellectual disability, limb spasticity, retinal dystrophy, diabetes insipidus syndrome",diabetes,"X-linked intellectual disability, limb spasticity, retinal dystrophy, diabetes insipidus syndrome (disorder); X-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome",
C4518326,Permanent neonatal diabetes mellitus with cerebellar agenesis syndrome,diabetes,Pancreatic and cerebellar agenesis syndrome; Permanent neonatal diabetes mellitus with cerebellar agenesis syndrome (disorder),
C4521078,"ACCU-CHEK COMPACT PLUS (GLUCOSE) TEST DRUM,51",glucose,"ACCU-CHEK CMPT PLUS(GLUCOSE) TEST DRM,51",
C4521164,100 ML Glucose 500 MG/ML Injection,glucose,"dextrose 50 % in 100 ML Injection; dextrose 50 % per 100 ML Injection; DEXTROSE MONOHYDRATE 50 g in 100 mL INTRAVENOUS INJECTION, SOLUTION; 100 ML glucose 500 MG/ML Injection",
C4521592,United States Military Commissioned Officer O7 (qualifier value),BG,United States Military Commissioned Officer O7; O7; BGen; Brigadier General; US Military Commissioned Officer O7; United States Military Commissioned Officer O7 (qualifier value); BG; RDML; Brig Gen; Rear Admiral Lower Half,
C4521595,United States Military enlisted E3 (qualifier value),a1c,E3; SN; Lcpl; PFC; United States Military enlisted E3 (qualifier value); A1C; United States Military enlisted E3; US Military enlisted E3; Private First Class; Lance Corporal; Seaman; Airman First Class,
C4521965,Sodium glucose cotransporter subtype 2 inhibitor (disposition),glucose,Sodium glucose cotransporter subtype 2 inhibitor (disposition); Sodium glucose cotransporter subtype 2 inhibitor,
C4523509,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s)",glucose,,
C4523945,Continuous glucose monitoring,glucose,,
C4528791,"IVD Test Reagent/Kits, Clinical Chemistry, Enzyme, Glucose-6-PhosphateDehydrogenase",glucose,,
C4528792,"Analyzers, Point-of-Care, Whole Blood, Glucose-6-Phosphate Dehydrogenase",glucose,"G6PD Biosensors; Analyzers, Point-of-Care, Whole Blood, G6PD",
C4528926,Glucose-6-Phosphate Dehydrogenase Enzyme Assays,glucose,,
C4529145,Peripheral Diabetes Insipidus Gene Panel Reagents,diabetes,,
C4529146,Congenital Diabetes Insipidus Gene Panel Reagents,diabetes,,
C4530024,SYZYGIUM CUMINI SEED 3 [hp_X] in 1 mL / SUS SCROFA ADRENAL GLAND 6 [hp_X] in 1 mL / GOLDENSEAL 6 [hp_X] in 1 mL / SUS SCROFA PITUITARY GLAND 6 [hp_X] in 1 mL / SUS SCROFA PANCREAS 6 [hp_X] in 1 mL / KIDNEY BEAN 9 [hp_X] in 1 mL / ACETIC ACID 12 [hp_X] in 1 mL / LACTIC ACID 12 [hp_X] in 1 mL / PHOSPHORIC ACID 12 [hp_X] in 1 mL / PHOSPHORUS 12 [hp_X] in 1 mL / URANYL NITRATE HEXAHYDRATE 12 [hp_X] in 1 mL ORAL LIQUID [Glucose Control T015],glucose,,
C4530820,FREESTYLE (GLUCOSE) NORMAL CONTROL SOLN,glucose,FREESTYLE (GLUCOSE) NORMAL CNTRL SOLN,
C4530823,INFINITY CONTROL (GLUCOSE) NORMAL CONTROL SOLN,glucose,INFINITY CONTRL (GLUCOSE) NORM CNTRL SOL,
C4531912,Hemoglobin A1c/Hemoglobin.total goal:MFr:Pt:Bld:Qn,a1c,Hemoglobin A1c/Hemoglobin.total goal:Mass Fraction:To identify measures at a point in time:Whole blood:Quantitative; Hgb A1c goal MFr Bld; Hemoglobin A1c/Hemoglobin.total goal Blood,
C4531913,Hemoglobin A1c/Hemoglobin.total goal,a1c,Hemoglobin A1C/Hemoglobin.total goal,
C4532703,Glucose^pre-meal:MCnc:-:Bld:Qn,glucose,Glucose pre-meal (Bld) [Mass/Vol],
C4532704,Glucose^post meal:MCnc:Pt:Bld:Qn,glucose,Glucose [Mass/volume] in Blood --post meal; Glucose p meal Bld-mCnc; Glucose post meal (Bld) [Mass/Vol]; Glucose^post meal:Mass Concentration:To identify measures at a point in time:Whole blood:Quantitative,
C4534908,FreeStyle Libre 10-d Reader Glucose Monitorin,glucose,,
C4534909,FreeStyle Libre 10-d Sensor Glucose Monitorin,glucose,,
C4540369,"Diabetes mellitus type 2, childhood-onset",diabetes,,
C4541689,TD GOLD LEVEL 2 (GLUCOSE) NORMAL CONTROL SOLN,glucose,TD GOLD LEVEL 2 (GLUCOSE) LOW CNTRL SOLN,
C4541690,TD GOLD LEVEL 3 (GLUCOSE) HIGH CONTROL SOLN,glucose,TD GOLD LEVEL 3 (GLUCOSE) LOW CNTRL SOLN,
C4541691,TD GOLD LEVEL 1 (GLUCOSE) LOW CONTROL SOLN,glucose,TD GOLD LEVEL 1 (GLUCOSE) LOW CNTRL SOLN,
C4542579,Diabetes Management Training Services,diabetes,,
C4542676,Medicare diabetes prevention program (mdpp) virtual make-up session,diabetes,,
C4542796,"Supply allowance for therapeutic continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service",glucose,,
C4542797,"Receiver (monitor), dedicated, for use with therapeutic glucose continuous monitor system",glucose,,
C4543426,Diabetic education service,diabetes,Diabetes mellitus education service (qualifier value); Diabetes mellitus education service,
C4543604,History of diabetes related lower limb amputation,diabetes,History of lower extremity amputation as a complication of diabetes mellitus; History of diabetes related lower extremity amputation; History of diabetes related lower limb amputation (situation),
C4543623,Absence of lower limb due to diabetes mellitus,diabetes,Absence of lower limb due to diabetes mellitus (disorder); Absence of lower extremity due to diabetes mellitus,
C4543635,"CHA2DS2-VASc (congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category) score",diabetes,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category score; Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category score (assessment scale)",
C4543636,"CHA2DS2-VASc (congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category) stroke risk score",diabetes,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score; Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score (observable entity)",
C4543785,Transient neonatal hypoglycemia due to hyperinsulinemia,hypoglycemia,Transient hyperinsulinaemic neonatal hypoglycaemia; Transient neonatal hypoglycemia due to hyperinsulinemia (disorder); Transient hyperinsulinemic neonatal hypoglycemia; Transient neonatal hypoglycaemia due to hyperinsulinaemia,
C4543786,Transitory iatrogenic neonatal hypoglycemia,hypoglycemia,Transitory iatrogenic neonatal hypoglycemia (disorder); Transitory iatrogenic neonatal hypoglycaemia,
C4543812,Hyperosmolar hyperglycemic coma due to diabetes mellitus without ketoacidosis,diabetes,Hyperosmolar hyperglycaemic coma due to diabetes mellitus without ketoacidosis; Hyperosmolar hyperglycemic coma due to diabetes mellitus without ketoacidosis (disorder),
C4543813,Lactic acidosis due to diabetes mellitus,diabetes,Lactic acidosis with diabetes mellitus; Diabetic lactic acidosis; Lactic acidosis due to diabetes mellitus (disorder),
C4543814,Metabolic acidosis due to diabetes mellitus,diabetes,Metabolic acidosis with diabetes mellitus; Metabolic acidosis due to diabetes mellitus (disorder); Diabetic metabolic acidosis,
C4544538,Hyperosmolarity due to type 1 diabetes mellitus,diabetes,Hyperosmolarity due to type 1 diabetes mellitus (disorder),
C4544825,Disorder of nerve co-occurrent and due to type 1 diabetes mellitus,diabetes,Disorder of nerve co-occurrent and due to type 1 diabetes mellitus (disorder),
C4545497,Diabetes Treatment Satisfaction Questionnaire change version,diabetes,Diabetes Treatment Satisfaction Questionnaire change version (assessment scale); DTSQc - Diabetes Treatment Satisfaction Questionnaire change version,
C4545498,Diabetes Treatment Satisfaction Questionnaire status version,diabetes,Diabetes Treatment Satisfaction Questionnaire status version (assessment scale); DTSQs - Diabetes Treatment Satisfaction Questionnaire status version,
C4545499,Disorder of eye due to type 1 diabetes mellitus,diabetes,Diabetic oculopathy due to type I diabetes mellitus; Disorder of eye due to type 1 diabetes mellitus (disorder); Diabetic oculopathy due to type 1 diabetes mellitus; Disorder of eye with type 1 diabetes mellitus,
C4546089,Neonatal hyperglycemia due to iatrogenic intravenous therapy,hyperglycemia,Neonatal hyperglycaemia due to iatrogenic intravenous therapy; Neonatal hyperglycemia due to iatrogenic intravenous therapy (disorder),
C4546244,Acute complication due to diabetes mellitus,diabetes,Acute complication due to diabetes mellitus (disorder); Acute complication with diabetes mellitus,
C4547954,Dmt-c(SEtS)(DCys-Aic-DPen)-Ser(beta-glucose)-NH2,glucose,,
C4549361,"TDP-glucose 4,6-dehydratase, human",glucose,"TGDS protein, human",
C4549614,"G6PC1 protein, human",glucose,"glucose-6-phosphatase, catalytic subunit 1, human",
C4550540,iGlucose Blood Glucose Monitoring System,blood glucose,,
C4550658,IGLUCOSE (GLUCOSE) TEST STRIP,glucose,IGLUCOSE (GLUCOSE) TEST STRIP,
C4552103,"MICROCEPHALY, SHORT STATURE, AND IMPAIRED GLUCOSE METABOLISM",glucose,MSSGM,
C4552609,WDR26 wt Allele,glucose,"GID Complex Subunit 7 Homolog (S. cerevisiae) Gene; CDW2; WDR26 wt Allele; WD Repeat Domain 26 wt Allele; GID7; MIP2; GID Complex, Subunit 7 Gene; PRO0852; SKDEAS; Glucose-Induced Degradation-Deficient Protein 7, S. cerevisiae, Homolog of Gene; FLJ21016",
C4552833,"Hyperglycemia, CTCAE",hyperglycemia,"Hyperglycemia, CTCAE",
C4553030,Fasting blood glucose metabolic function,blood glucose,,
C4553159,Estimated Average Glucose,glucose measurement,Glucose measurement estimated from glycated hemoglobin (procedure); Calculation of estimated average glucose based on hemoglobin A1c; Estimated average glucose; Calculation of estimated average glucose based on haemoglobin A1c; Glucose measurement estimated from glycated haemoglobin; Estimated Average Glucose Measurement; Glucose measurement estimated from glycated hemoglobin,
C4553202,"Glucose Intolerance, CTCAE",glucose,"Glucose Intolerance, CTCAE",
C4553352,APOH wt Allele,BG,"Apolipoprotein H wt Allele; Glycoprotein 1, Beta-2 Gene; B2GP1; BG; APOH wt Allele; B2G1; Glycoprotein I, Beta-2 Gene; Apolipoprotein H (Beta-2-Glycoprotein I) Gene",
C4553524,GID4 wt Allele,glucose,"Vacuolar Import and Degradation 24 Gene; GID Complex Subunit 4 Homolog wt Allele; VID24; GID Complex Subunit 4, VID24 Homolog (S. cerevisiae) Gene; Glucose-Induced Defradation-Deficient Protein 4, S cerevisiae, Homolog of Gene; Chromosome 17 Open Reading Frame 39 Gene; C17orf39; GID Complex Subunit 4, VID24 Homolog Gene; VID2; GID4 wt Allele",
C4553636,GUSB wt Allele,BG,"GUS; GUSB wt Allele; Glucuronidase, Beta Gene; Glucuronidase Beta wt Allele; BG; MPS7",
C4553659,"Hypoglycemia, CTCAE",hypoglycemia,"Hypoglycemia, CTCAE",
C4553678,"Glucose-Induced Degradation Protein 4 Homolog, human",glucose,Vacuolar Import and Degradation Protein 24 Homolog; GID Complex Subunit 4; GID4; Glucose-Induced Degradation Protein 4 Homolog; Vacuolar Import and Degradation Protein 24,
C4554797,CPEB2-DT gene,diabetes,DRAIR; CPEB2-DT gene; CPEB2 divergent transcript; CPEB2 antisense RNA 1 (head to head); CPEB2-DT; Diabetes Regulated anti-inflammatory RNA; CPEB2-AS1,
C4555574,Smartsit Ad-on BG Access,BG,,
C4605816,Apatococcus sp. BG-L-92375,BG,,
C4605817,Apatococcus sp. BG-L-92376,BG,,
C4605819,Apatococcus sp. BG-L-87100,BG,,
C4605820,Apatococcus sp. BG-L-92374,BG,,
C4682705,R-Hyper-CVAD Regimen,hyper,Rituximab Plus HyperCVAD; Hyper-CVAD Plus Rituximab; Rituximab-HyperCVAD; Rituximab and Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone Regimen,
C4682710,R-HyperCVAD Alternating with High-dose MTX AraC Regimen,hyper,R-hyperCVAD Alternating with R-Methotrexate-Cytarabine; Rituximab Plus HyperCVAD Alternating with R-Methotrexate/Cytarabine; R-HCVAD Plus Methotrexate/Cytarabine; Rituximab-Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone Alternating with Rituximab/Cytarabine/Methotrexate; Rituximab Plus HyperCVAD Alternating with Rituximab Plus High-dose Cytarabine and Methotrexate; R-HyperCVAD/HD MTX AraC Regimen; Rituximab Plus HyperCVAD Alternating with Rituximab-Methotrexate/Cytarabine; Rituximab Plus Hyper-CVAD Alternating with R-Methotrexate/Cytarabine,
C4685171,"Grade 1 Glucose Intolerance, CTCAE",glucose,,
C4685198,"Grade 1 Hyperglycemia, CTCAE",hyperglycemia,,
C4685215,"Grade 1 Hypoglycemia, CTCAE",hypoglycemia,,
C4685680,"Grade 2 Glucose Intolerance, CTCAE",glucose,,
C4685705,"Grade 2 Hyperglycemia, CTCAE",hyperglycemia,,
C4685719,"Grade 2 Hypoglycemia, CTCAE",hypoglycemia,,
C4686243,"Grade 3 Glucose Intolerance, CTCAE",glucose,,
C4686269,"Grade 3 Hyperglycemia, CTCAE",hyperglycemia,,
C4686284,"Grade 3 Hypoglycemia, CTCAE",hypoglycemia,,
C4686747,"Grade 4 Glucose Intolerance, CTCAE",glucose,,
C4686765,"Grade 4 Hyperglycemia, CTCAE",hyperglycemia,,
C4686776,"Grade 4 Hypoglycemia, CTCAE",hypoglycemia,,
C4687144,"Grade 5 Glucose Intolerance, CTCAE",glucose,,
C4687161,"Grade 5 Hyperglycemia, CTCAE",hyperglycemia,,
C4687170,"Grade 5 Hypoglycemia, CTCAE",hypoglycemia,,
C4689050,INFINITY VOICE (GLUCOSE) TEST STRIP,glucose,INFINITY VOICE (GLUCOSE) TEST STRIP,
C4689051,INFINITY VOICE (GLUCOSE) NORMAL CONTROL SOLN,glucose,INFINITY VOICE (GLUCOSE) NORM CNTRL SOL,
C4689061,RELION PREMIER (GLUCOSE) TEST STRIP,glucose,RELION PREMIER (GLUCOSE) TEST STRIP,
C4689072,Accu-Chek Aviva+ Mtr Kit 59634 Blood-Glucose,glucose,,
C4689073,Accu-Chek Guide Meter Blood-Glucose Meter,glucose,,
C4689820,regulation of glucose transmembrane transport,glucose,,
C4689821,positive regulation of glucose transmembrane transport,glucose,,
C4689822,negative regulation of glucose transmembrane transport,glucose,,
C4690159,negative regulation of transcription by glucose,glucose,,
C4690160,negative regulation of transcription from RNA polymerase II promoter by glucose,glucose,,
C4690280,high affinity glucose import,glucose,,
C4690411,2-acetamido-4-O-(2-amino-2-deoxy-beta-D-glucopyranosyl)-2-deoxy-D-glucose exo-beta-D-glucosaminidase activity,glucose,,
C4690467,ADP-glucose-starch glucosyltransferase activity,glucose,,
C4690494,UDP-glucose: N-methylanthranilate glucosyltransferase activity,glucose,,
C4690510,UDP-glucose:curcumin glucosyltransferase activity,glucose,,
C4690511,UDP-glucose:curcumin monoglucoside glucosyltransferase activity,glucose,,
C4690527,UDP-alpha-D-glucose:glucosyl-glycogenin alpha-D-glucosyltransferase activity,glucose,,
C4690549,UDP-D-glucose:cyanidin 5-O-beta-D-glucosyltransferase activity,glucose,,
C4690560,UDP-D-glucose:cyanidin 3-(p-coumaroyl)-glucoside 5-O-glucosyltransferase activity,glucose,,
C4690601,UDP-glucose:coniferaldehyde 4-beta-D-glucosyltransferase activity,glucose,,
C4690604,UDP-glucose:sinapaldehyde 4-beta-D-glucosyltransferase activity,glucose,,
C4690638,glucose-6-phosphate 3-dehydrogenase activity,glucose,,
C4690775,regulation of adenylate cyclase-activating glucose-activated G protein-coupled receptor signaling pathway,glucose,regulation of adenylate cyclase-activating glucose-activated G-protein coupled receptor signaling pathway,
C4690776,negative regulation of adenylate cyclase-activating glucose-activated G protein-coupled receptor signaling pathway,glucose,negative regulation of adenylate cyclase-activating glucose-activated G-protein coupled receptor signaling pathway,
C4690915,UDP-glucose transmembrane transport into endoplasmic reticulum,glucose,,
C4691054,high-affinity glucose transmembrane transporter activity,glucose,,
C4691756,CARETOUCH (GLUCOSE) TEST STRIP,glucose,CARETOUCH (GLUCOSE) TEST STRIP,
C4691770,GOODLIFE AC-302 (GLUCOSE) TEST STRIP,glucose,GOODLIFE AC-302 (GLUCOSE) TEST STRIP,
C4692511,Low serum glucose with inappropriately high insulin levels,serum glucose,,
C4692512,Elevated serum glucose,serum glucose,,
C4693601,Reduced numbers of melanocytes in hypo- and depigmented macules,hypo,,
C4693605,Fibrillar aggregates in borders of hypo- and depigmented lesions,hypo,,
C4693732,"Hypoglycemia, episodic",hypoglycemia,,
C4694378,GLUCOSE SENSOR DEXCOM G6,glucose,GLUCOSE SENSOR DEXCOM G6,
C4694461,Dexcom G6 Sensor 3 pack blood-glucose sensor,glucose,,
C4694462,Dexcom G6 blood-glucose transmitter,glucose,,
C4695404,Glucose^pre-meal:MCnc:Pt:Bld:Qn,glucose,Glucose pre-meal Bld-mCnc; Glucose [Mass/volume] in Blood --pre-meal; Glucose^pre-meal:MCnc:Pt:Bld:Qn; Glucose pre-meal (Bld) [Mass/Vol]; Glucose^pre-meal:Mass Concentration:To identify measures at a point in time:Whole blood:Quantitative,
C4697750,diabetic symptoms (hypoglycemia),hypoglycemia,,
C4698930,Integumentary: Neuropathic wounds due to diabetes,diabetes,,
C4698940,Med: Diabetes mellitus,diabetes,,
C4703596,Abnormal CSF glucose concentration,glucose level,Abnormal CSF glucose level,
C4703662,Abnormal glucose-6-phosphate dehydrogenase level,glucose,Abnormal G6PD level,
C4703663,Abnormal glucose-6-phosphate dehydrogenase level in blood,glucose,Abnormal G6PD level in blood,
C4703664,Increased glucose-6-phosphate dehydrogenase level in blood,glucose,Increased G6PD level in blood,
C4703665,Decreased glucose-6-phosphate dehydrogenase level in blood,glucose,Decreased G6PD level in blood,
C4703666,Abnormal glucose-6-phosphate dehydrogenase level in dried blood spot,glucose,Abnormal G6PD level in dried blood spot; Abnormal glucose-6-phosphate dehydrogenase level in DBS,
C4703667,Increased glucose-6-phosphate dehydrogenase level in dried blood spot,glucose,Increased G6PD level in dried blood spot; Increased glucose-6-phosphate dehydrogenase level in DBS,
C4703668,Decreased glucose-6-phosphate dehydrogenase level in dried blood spot,glucose,Decreased glucose-6-phosphate dehydrogenase level in DBS; Decreased G6PD level in dried blood spot,
C4703669,Abnormal glucose-6-phosphate dehydrogenase level in leukocytes,glucose,Abnormal G6PD level in leukocytes,
C4703670,Abnormal glucose-6-phosphate dehydrogenase level in red blood cells,glucose,Abnormal G6PD level in red blood cells; Abnormal G6PD level in RBCs,
C4703671,Abnormal glucose-6-phosphate dehydrogenase level in tissue,glucose,Abnormal G6PD level in tissue,
C4703672,Increased glucose-6-phosphate dehydrogenase level in tissue,glucose,Increased G6PD level in tissue,
C4703673,Decreased glucose-6-phosphate dehydrogenase level in tissue,glucose,Decreased G6PD level in tissue,
C4703674,Decreased glucose-6-phosphate dehydrogenase level in red blood cells,glucose,Decreased G6PD level in RBCs; Decreased G6PD level in red blood cells,
C4703675,Increased glucose-6-phosphate dehydrogenase level in red blood cells,glucose,Increased G6PD level in red blood cells; Increased G6PD level in RBCs,
C4703676,Decreased glucose-6-phosphate dehydrogenase level in leukocytes,glucose,Decreased G6PD level in leukocytes,
C4703677,Increased glucose-6-phosphate dehydrogenase level in leukocytes,glucose,Increased G6PD level in leukocytes,
C4703678,Abnormal uridine diphosphate glucose-4-epimerase level,glucose,Abnormal UDP-glucose 4-epimerase level,
C4703679,Abnormal uridine diphosphate glucose-4-epimerase level in plasma,glucose,Abnormal UDP-glucose 4-epimerase activity level in plasma,
C4703680,Increased uridine diphosphate glucose-4-epimerase level in plasma,glucose,Increased UDP-glucose 4-epimerase level in plasma,
C4703681,Decreased uridine diphosphate glucose-4-epimerase level in plasma,glucose,Decreased UDP-glucose 4-epimerase level in plasma,
C4703682,Abnormal uridine diphosphate glucose-4-epimerase level in red blood cells,glucose,Abnormal UDP-glucose 4-epimerase level in RBCs; Abnormal UDP-glucose 4-epimerase level in red blood cells,
C4703683,Increased uridine diphosphate glucose-4-epimerase level in red blood cells,glucose,Increased UDP-glucose 4-epimerase level in red blood cells; Increased UDP-glucose 4-epimerase level in RBCs,
C4703684,Decreased uridine diphosphate glucose-4-epimerase level in red blood cells,glucose,Decreased UDP-glucose 4-epimerase level in RBCs; Decreased UDP-glucose 4-epimerase level in red blood cells,
C4704117,BlueStar OTC Diabetes Self-Management Digital,diabetes,,
C4704118,Dexcom G6 Receiver Continuous Blood-Glucose M,glucose,,
C4704248,"TAPE,GLUCOSE SENSOR MMT-7015NA",glucose,"TAPE,GLUCOSE SENSOR MMT-7015NA",
C4705333,3-O-propargyl-D-glucose,glucose,,
C4705334,13C-labeled 3-O-propargyl-D-glucose,glucose,3-OPG-13C(3),
C4706243,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",diabetes,"Assessment using congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack score; Assessment using congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack score (procedure); Assessment using congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischaemic attack score; Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischaemic attack) score",
C4706244,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",diabetes,"Congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack score (observable entity); Congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack score; Congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischaemic attack score; CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischaemic attack) score",
C4706290,Assessment using FINDRISC (Finnish Diabetes Risk Score),diabetes,Assessment using Finnish Diabetes Risk Score; Assessment using Finnish Diabetes Risk Score (procedure),
C4706423,Familial progressive hyperpigmentation and hypopigmentation of skin,hyper,Familial progressive hyper- and hypopigmentation; Familial progressive hyperpigmentation and hypopigmentation of skin (disorder); FPHH; Familial progressive hyperpigmentation and hypopigmentation of skin; Familial progressive hyper and hypopigmentation,
C4706578,Provision of patient held diabetes record declined,diabetes,Provision of patient held diabetes record refused; Provision of patient held diabetes record declined (situation),
C4706579,Provision of patient held diabetes record,diabetes,Provision of patient held diabetes record (procedure),
C4707335,DTSQs (Diabetes Treatment Satisfaction Questionnaire status version) score,diabetes,Diabetes Treatment Satisfaction Questionnaire status version score; Diabetes Treatment Satisfaction Questionnaire status version score (observable entity),
C4707336,Assessment using DTSQs (Diabetes Treatment Satisfaction Questionnaire status version),diabetes,Assessment using Diabetes Treatment Satisfaction Questionnaire status version (procedure); Assessment using Diabetes Treatment Satisfaction Questionnaire status version,
C4708193,Remote control insulin infusion patch pump blood glucose analyzer,blood glucose,Remote control insulin infusion patch pump blood glucose analyzer (physical object); Remote control insulin infusion patch pump blood glucose analyser,
C4708556,Cataract of right eye due to diabetes mellitus,diabetes,Diabetic cataract of right eye; Cataract of right eye due to diabetes mellitus (disorder),
C4708557,Cataract of left eye due to diabetes mellitus,diabetes,Diabetic cataract of left eye; Cataract of left eye due to diabetes mellitus (disorder),
C4708558,Diabetic cataract of bilateral eyes,diabetes,Bilateral diabetic cataracts; Cataract of bilateral eyes due to diabetes mellitus; Cataract of bilateral eyes due to diabetes mellitus (disorder); Bilateral cataracts due to diabetes mellitus,
C4708559,Iritis of right eye due to diabetes mellitus,diabetes,Diabetic iritis of right eye; Iritis of right eye due to diabetes mellitus (disorder),
C4708560,Iritis of left eye due to diabetes mellitus,diabetes,Diabetic iritis of left eye; Iritis of left eye due to diabetes mellitus (disorder),
C4708561,Bilateral iritis due to diabetes mellitus,diabetes,Iritis of bilateral eyes due to diabetes mellitus; Iritis of bilateral eyes due to diabetes mellitus (disorder); Bilateral diabetic iritis,
C4708707,Preproliferative retinopathy of right eye due to diabetes mellitus,diabetes,Preproliferative retinopathy of right eye due to diabetes mellitus (disorder); Preproliferative diabetic retinopathy of right eye,
C4708708,Preproliferative retinopathy of left eye due to diabetes mellitus,diabetes,Preproliferative retinopathy of left eye due to diabetes mellitus (disorder); Preproliferative diabetic retinopathy of left eye,
C4708710,Very severe nonproliferative retinopathy of right eye due to diabetes mellitus,diabetes,Very severe nonproliferative retinopathy of right eye due to diabetes mellitus (disorder); Very severe NPDR (nonproliferative diabetic retinopathy) of right eye; Very severe nonproliferative diabetic retinopathy of right eye,
C4708711,Very severe nonproliferative retinopathy of left eye due to diabetes mellitus,diabetes,Very severe nonproliferative retinopathy of left eye due to diabetes mellitus (disorder); Very severe nonproliferative diabetic retinopathy of left eye; Very severe NPDR (nonproliferative diabetic retinopathy) of left eye,
C4708769,Macular edema of right eye due to diabetes mellitus,diabetes,Diabetic macular oedema of right eye; Macular oedema of right eye due to diabetes mellitus; Macular edema of right eye due to diabetes mellitus (disorder); Diabetic macular edema of right eye,
C4708770,Macular edema of left eye due to diabetes mellitus,diabetes,Macular edema of left eye due to diabetes mellitus (disorder); Macular oedema of left eye due to diabetes mellitus; Diabetic macular oedema of left eye; Diabetic macular edema of left eye,
C4708771,Clinically significant macular edema of right eye due to diabetes mellitus,diabetes,Clinically significant macular edema of right eye due to diabetes mellitus (disorder); Clinically significant macular oedema of right eye due to diabetes mellitus,
C4708772,Clinically significant macular edema of left eye due to diabetes mellitus,diabetes,Clinically significant macular oedema of left eye due to diabetes mellitus; Clinically significant macular edema of left eye due to diabetes mellitus (disorder),
C4708778,Macular edema due to type 1 diabetes mellitus,diabetes,Macular edema due to type 1 diabetes mellitus (disorder); Macular oedema due to type 1 diabetes mellitus,
C4708779,Macular edema due to type 2 diabetes mellitus,diabetes,Macular edema due to type 2 diabetes mellitus (disorder); Macular oedema due to type 2 diabetes mellitus,
C4709215,Cervical radiculoplexus neuropathy due to diabetes mellitus,diabetes,CRPN - diabetic cervical radiculoplexus neuropathy; Cervical radiculoplexus neuropathy due to diabetes mellitus (disorder); Cervical radiculoplexus neuropathy with diabetes mellitus; Diabetic cervical radiculoplexoneuropathy,
C4709216,Cranial nerve palsy due to diabetes mellitus,diabetes,Cranial nerve palsy with diabetes mellitus; Cranial nerve palsy due to diabetes mellitus (disorder),
C4709217,Erectile dysfunction due to diabetes mellitus,diabetes,Erectile dysfunction due to diabetes mellitus (disorder); Erectile dysfunction with diabetes mellitus,
C4709218,Clinically significant macular edema due to diabetes mellitus,diabetes,Clinically significant macular edema with diabetes mellitus; Clinically significant macular oedema due to diabetes mellitus; Clinically significant macular edema due to diabetes mellitus (disorder); Clinically significant macular oedema with diabetes mellitus,
C4709310,Retinal edema due to diabetes mellitus,diabetes,Retinal edema with diabetes mellitus; Retinal oedema due to diabetes mellitus; Retinal oedema with diabetes mellitus; Retinal edema due to diabetes mellitus (disorder),
C4709311,Ischemia of retina due to diabetes mellitus,diabetes,Ischaemia of retina due to diabetes mellitus; Retinal ischaemia due to diabetes mellitus; Retinal ischemia with diabetes mellitus; Ischemia of retina due to diabetes mellitus (disorder); Retinal ischaemia with diabetes mellitus; Retinal ischemia due to diabetes mellitus,
C4719378,TRUE METRIX PRO (GLUCOSE) TEST STRIP,glucose,TRUE METRIX PRO (GLUCOSE) TEST STRIP,
C4719535,MATRICARIA CHAMOMILLA FLOWERING TOP OIL 5 [hp_M] in 1 mL / SANGUINARIA CANADENSIS ROOT 8 [hp_M] in 1 mL / ACHILLEA MILLEFOLIUM 4 [hp_M] in 1 mL / BERBERIS VULGARIS FRUIT 9 [hp_M] in 1 mL / CONIUM MACULATUM FRUIT 21 [hp_M] in 1 mL / RHUS SPP. WHOLE 13 [hp_M] in 1 mL / PHYTOLACCA OCTANDRA LEAF 11 [hp_M] in 1 mL / AESCULUS HIPPOCASTANUM SEED OIL 4 [hp_M] in 1 mL TOPICAL CREAM [Metaderm Hyper-Moisturizing Daily Cream],hyper,,
C4721528,"Gastric Inhibitory Polypeptide, human",glucose,Gastric Inhibitory Polypeptide; Incretin Hormone; Glucose-Dependent Insulinotropic Polypeptide,
C4721531,"HYPER-IgE RECURRENT INFECTION SYNDROME 1, AUTOSOMAL DOMINANT",hyper,"HYPER-IgE RECURRENT INFECTION SYNDROME 1, AUTOSOMAL DOMINANT; HIES1",
C4722052,Blood Glucose Regulators [TC],blood glucose,Blood Glucose Regulators; Blood Glucose Regulators [TC],
C4722305,"HYPER-IgE RECURRENT INFECTION SYNDROME 2, AUTOSOMAL RECESSIVE",hyper,"HIES2; HYPER-IgE RECURRENT INFECTION SYNDROME 2, AUTOSOMAL RECESSIVE",
C4722841,HARMONY (GLUCOSE) TEST STRIP,glucose,HARMONY (GLUCOSE) TEST STRIP,
C4723177,HARMONY CONTROL (GLUCOSE) HIGH/LOW CONTROL SOLN,glucose,HARMONY CONTROL(GLUCOSE)HI/LO CNTRL SOLN,
C4723179,EVENCARE PROVIEW (GLUCOSE) HIGH/LOW CONTROL SOLN,glucose,EVENCARE PROVIEW(GLUCOSE)HI/LO CNTRL SOL,
C4723182,EVENCARE PROVIEW (GLUCOSE) TEST STRIP,glucose,EVENCARE PROVIEW (GLUCOSE) TEST STRIP,
C4723662,UGGT2 wt Allele,glucose,MGC150689; FLJ11485; UDP-Glucose Glycoprotein Glucosyltransferase 2 wt Allele; HUGT2; UGT2; MGC117360; FLJ10873; MGC87276; UGCGL2; UGGT2 wt Allele,
C4723709,Galactose-1-Phosphate Uridylyltransferase,glucose,UDP-Glucose--Hexose-1-Phosphate Uridylyltransferase; Galactose-1-Phosphate Uridylyltransferase; GALT; Gal-1-P Uridylyltransferase; EC 2.7.7.12,
C4723714,UDP-Glucose:Glycoprotein Glucosyltransferase 2,glucose,UDP-Glucose:Glycoprotein Glucosyltransferase 2; UDP-Glc:Glycoprotein Glucosyltransferase 2; hUGT2; UDP--Glc:Glycoprotein Glucosyltransferase 2; UGT2; UDP-Glucose Ceramide Glucosyltransferase-Like 2; EC 2.4.1.-; UGGT2; UDP-Glucose Ceramide Glucosyltransferase-Like 1,
C4723967,HEDIS 2019 Value Set - Glucose Tests,glucose,HEDIS 2019-2020 Value Set - Glucose Tests,
C4724413,Doctor or health care professional ever told you that you have diabetes,diabetes,Doctor or health care professional ever told you that you have diabetes,
C4724483,HEDIS 2019 Value Set - Glucose Tests:-:Point in time:^Patient:-,glucose,HEDIS 2019-20 Glucose Tests; HEDIS 2019-2020 Value Set - Glucose Tests:-:To identify measures at a point in time:^Patient:-; HEDIS 2019-2020 Value Set - Glucose Tests:-:Pt:^Patient:-; HEDIS 2019-2020 Value Set - Glucose Tests,
C4726010,Glucose Excretion Rate,glucose,,
C4728361,Diabetes Mellitus Type 2 Gene Anomaly Detection Reagents,diabetes,,
C4728363,Familial Hyperinsulinemic Hypoglycemia 1 (HHF1) Gene Anomaly Detection Reagents,hypoglycemia,,
C4728365,Familial Infantile Hypoglycemia Precipitated by Leucine Gene Anomaly Detection Reagents,hypoglycemia,,
C4728366,Hyperinsulinemic Hypoglycemia Due to Focal Adenomatous Hyperplasia Gene Anomaly Detection Reagents,hypoglycemia,,
C4728367,Leucine-Induced Hypoglycemia (LIH) Gene Anomaly Detection Reagents,hypoglycemia,,
C4728368,Leucine-Sensitive Hypoglycemia of Infancy Gene Anomaly Detection Reagents,hypoglycemia,,
C4728369,Maturity-Onset Diabetes Gene Anomaly Detection Reagents,diabetes,,
C4728371,Noninsulin-Dependent Diabetes Mellitus (NIDDM) Gene Anomaly Detection Reagents,diabetes,,
C4728372,Permanent Diabetes Mellitus of Infancy Gene Anomaly Detection Reagents,diabetes,,
C4728373,Permanent Neonatal Diabetes Mellitus (PNDM) Gene Anomaly Detection Reagents,diabetes,,
C4728374,Persistent Hyperinsulinemia Hypoglycemia of Infancy Gene Anomaly Detection Reagents,hypoglycemia,,
C4728375,Persistent Hyperinsulinemic Hypoglycemia of Infancy Gene Anomaly Detection Reagents,hypoglycemia,,
C4728376,Transient Neonatal Diabetes Mellitus 2 (TNDM2) Gene Anomaly Detection Reagents,diabetes,,
C4728377,Type II Diabetes Mellitus Gene Anomaly Detection Reagents,diabetes,,
C4728412,Microvascular Complications of Diabetes 3 (MVCD3) Gene Anomaly Detection Reagents,diabetes,,
C4728660,Autosomal Nephrogenic Diabetes Insipidus Gene Anomaly Detection Reagents,diabetes,,
C4728661,Type II Nephrogenic Diabetes Insipidus Gene Anomaly Detection Reagents,diabetes,,
C4728772,X-Linked Nephrogenic Diabetes Insipidus (NDI) Gene Anomaly Detection Reagents,diabetes,,
C4728833,"Growth Deficiency, Sun-Sensitive, Telangiectatic, Hypo and Hyperpigmented Skin, Predisposition to Malignancy, and Chromosomal Instability Gene Anomaly Detection Reagents",hypo,,
C4729352,Glucose-6-Phosphatase Catalytic Subunit Deletion/Duplication Detection Reagents,glucose,,
C4729353,Glucose-6-Phosphatase Deficiency Gene Anomaly Detection Reagents,glucose,,
C4729354,Glucose-6-Phosphatase Deficiency Glycogen Storage Disease Gene Anomaly Detection Reagents,glucose,,
C4729365,Glucose-6-Phosphatase Catalytic Subunit Mutation Detection Reagents,glucose,,
C4729437,Hyperinsulinemic Hypoglycemia Familial 3 (HHF3) Gene Anomaly Detection Reagents,hypoglycemia,,
C4729441,Maturity-Onset Diabetes of the Young (MODY) Gene Anomaly Detection Reagents,diabetes,,
C4729442,Maturity-Onset Diabetes of the Young Type 2 Gene Anomaly Detection Reagents,diabetes,,
C4729443,Permanent Neonatal Diabetes Mellitus Gene Anomaly Detection Reagents,diabetes,,
C4729485,Hyper-Low-Density-Lipoproteinemia Gene Anomaly Detection Reagents,hyper,,
C4729654,Hyper IgM Syndrome 1 Gene Anomaly Detection Reagents,hyper,,
C4729655,"Hyper-IgM Immunodeficiency Syndrome, Type 1 Gene Anomaly Detection Reagents",hyper,,
C4729656,Immunodeficiency with Hyper IgM Type 1 (HIGM1) Gene Anomaly Detection Reagents,hyper,,
C4729657,X-Linked Hyper IgM Syndrome Gene Anomaly Detection Reagents,hyper,,
C4729714,Diabetes Mellitus MODY Type 8 Gene Anomaly Detection Reagents,diabetes,,
C4729715,Diabetes and Pancreatic Exocrine Dysfunction Syndrome Gene Anomaly Detection Reagents,diabetes,,
C4729716,Maturity-Onset Diabetes of the Young Type 8 (MODY8) Gene Anomaly Detection Reagents,diabetes,,
C4729907,Carnitine Palmitoyltransferase II Deficiency with Hypoketotic Hypoglycemia Gene Anomaly Detection Reagents,hypoglycemia,,
C4730080,Blood Glucose/Blood Pressure Monitors,blood glucose,,
C4730461,"Cerebellar Vermis Hypo/Aplasia, Oligophrenia, Ataxia Congenital, Coloboma, and Hepatic Fibrosis Gene Anomaly Detection Reagents",hypo,,
C4730462,"Cerebellar Vermis Hypo/Aplasia, Oligophrenia, Congenital Ataxia, Ocular Coloboma, and Hepatic Fibrosis Gene Anomaly Detection Reagents",hypo,,
C4730776,Blood Glucose Analyzer/Sphygmomanometers,blood glucose,,
C4731278,FORA 6 CONNECT (GLUCOSE) TEST STRIP,glucose,FORA 6 CONNECT (GLUCOSE) TEST STRIP,
C4731281,GLUCOSE SENSOR (3) GUARDIAN MMT-7020A,glucose,GLUCOSE SENSOR (3) GUARDIAN MMT-7020A,
C4731290,MEDISENSE (GLUCOSE) HI/LO CONTROL SOLN,glucose,MEDISENSE (GLUCOSE) HI/LO CONTROL SOLN,
C4731292,PRO VOICE V8-V9 (GLUCOSE) TEST STRIP,glucose,PRO VOICE V8-V9 (GLUCOSE) TEST STRIP,
C4731314,GLUCOSE SENSOR ENLITE MMT-7008A,glucose,GLUCOSE SENSOR ENLITE MMT-7008A,
C4734701,EMBRACE PRO (GLUCOSE) METER,glucose,EMBRACE PRO (GLUCOSE) METER,
C4734702,EMBRACE PRO (GLUCOSE) TEST STRIP,glucose,EMBRACE PRO (GLUCOSE) TEST STRIP,
C4734703,EMBRACE TALK (GLUCOSE) TEST STRIP,glucose,EMBRACE TALK (GLUCOSE) TEST STRIP,
C4741223,hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose),glucose,ADRABETADEX; HYDROXYPROPYL BETADEX (0.6 HYDROXYPROPYL RESIDUES PER GLUCOSE); hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose); Adrabetadex,
C4741259,EMBRACE TALK (GLUCOSE) HIGH CONTROL SOLN,glucose,EMBRACE TALK (GLUCOSE) HI CNTRL SOLN,
C4741260,EMBRACE TALK (GLUCOSE) LOW CONTROL SOLN,glucose,EMBRACE TALK (GLUCOSE) LOW CNTRL SOLN,
C4742874,"G6PD protein, human",glucose,"Glucose-6-Phosphate 1-Dehydrogenase; EC 1.1.1.49; glucose-6-phosphate dehydrogenase, human; Glucose-6-Phosphate Dehydrogenase; G6PD protein, human; G6PD1 protein, human",
C4745685,GLUCOSE SENSOR FREESTYLE LIBRE 14 DAY,glucose,GLUCOSE SENSOR FREESTYLE LIBRE 14 DAY,
C4745826,sodium chloride 35 MG/ML [Hyper-Sal],hyper,,
C4745827,sodium chloride Inhalation Solution [Hyper-Sal],hyper,,
C4745831,sodium chloride 70 MG/ML [Hyper-Sal],hyper,,
C4746386,First medicare diabetes prevention program (mdpp) core session was attended by an mdpp beneficiary under the mdpp expanded model (em). a core session is an mdpp service that: (1) is furnished by an mdpp supplier during months 1 through 6 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for core sessions,diabetes,,
C4746387,Four total medicare diabetes prevention program (mdpp) core sessions were attended by an mdpp beneficiary under the mdpp expanded model (em). a core session is an mdpp service that: (1) is furnished by an mdpp supplier during months 1 through 6 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for core sessions,diabetes,,
C4746388,Nine total medicare diabetes prevention program (mdpp) core sessions were attended by an mdpp beneficiary under the mdpp expanded model (em). a core session is an mdpp service that: (1) is furnished by an mdpp supplier during months 1 through 6 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for core sessions,diabetes,,
C4746389,"Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 7-9 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary did not achieve at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 7-9",diabetes,,
C4746390,"Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 10-12 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary did not achieve at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 10-12",diabetes,,
C4746391,"Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 7-9 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions.the beneficiary achieved at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 7-9",diabetes,,
C4746392,"Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 10-12 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary achieved at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 10-12",diabetes,,
C4746395,"Two medicare diabetes prevention program (mdpp) ongoing maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 13-15 under the mdpp expanded model (em). an ongoing maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 13 through 24 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary maintained at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 13-15",diabetes,,
C4746396,"Two medicare diabetes prevention program (mdpp) ongoing maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 16-18 under the mdpp expanded model (em). an ongoing maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 13 through 24 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary maintained at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 16-18",diabetes,,
C4746397,"Two medicare diabetes prevention program (mdpp) ongoing maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 19-21 under the mdpp expanded model (em). an ongoing maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 13 through 24 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary maintained at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 19-21",diabetes,,
C4746398,"Two medicare diabetes prevention program (mdpp) ongoing maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 22-24 under the mdpp expanded model (em). an ongoing maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 13 through 24 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary maintained at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 22-24",diabetes,,
C4746399,"Bridge payment: a one-time payment for the first medicare diabetes prevention program (mdpp) core session, core maintenance session, or ongoing maintenance session furnished by an mdpp supplier to an mdpp beneficiary during months 1-24 of the mdpp expanded model (em) who has previously received mdpp services from a different mdpp supplier under the mdpp expanded model. a supplier may only receive one bridge payment per mdpp beneficiary",diabetes,,
C4746823,"Hypoglycemia, stress-induced (precipitated by infection)",hypoglycemia,,
C4748942,"Hypo- or areflexia, particularly of the lower limbs",hypo,,
C4748969,"HYPER-IgE RECURRENT INFECTION SYNDROME 3, AUTOSOMAL RECESSIVE",hyper,"HYPER-IgE RECURRENT INFECTION SYNDROME 3, AUTOSOMAL RECESSIVE; HIES3",
C4749223,Vitreous hemorrhage of right eye due to diabetes mellitus,diabetes,Vitreous haemorrhage of right eye with diabetes mellitus; Vitreous haemorrhage of right eye due to diabetes mellitus; Vitreous hemorrhage of right eye due to diabetes mellitus (disorder); Diabetic vitreous haemorrhage of right eye; Vitreous hemorrhage of right eye with diabetes mellitus; Diabetic vitreous hemorrhage of right eye,
C4749265,Vitreous hemorrhage of left eye due to diabetes mellitus,diabetes,Diabetic vitreous haemorrhage of left eye; Vitreous hemorrhage of left eye with diabetes mellitus; Diabetic vitreous hemorrhage of left eye; Vitreous haemorrhage of left eye due to diabetes mellitus; Vitreous hemorrhage of left eye due to diabetes mellitus (disorder); Vitreous haemorrhage of left eye with diabetes mellitus,
C4749338,Venous beading of right retina due to diabetes mellitus,diabetes,Venous beading of right retina due to diabetes mellitus (disorder); Retinal venous beading of right eye with diabetes mellitus; Diabetic retinal venous beading of right eye,
C4749339,Venous beading of left retina due to diabetes mellitus,diabetes,Diabetic retinal venous beading of left eye; Venous beading of left retina due to diabetes mellitus (disorder); Retinal venous beading of left eye with diabetes mellitus,
C4749457,Seen in diabetes preconception counseling clinic,diabetes,Seen in diabetes preconception counselling clinic; Seen in diabetes preconception counseling clinic (finding),
C4749504,Referral to community diabetes antenatal clinic,diabetes,Referral to community diabetes antenatal clinic (procedure),
C4749523,Referral to hospital diabetes antenatal clinic,diabetes,Referral to hospital diabetes antenatal clinic (procedure),
C4750532,Assessment of risk of type 2 diabetes mellitus,diabetes,Assessment of risk of type 2 diabetes mellitus (procedure); Assessment of risk of type II diabetes mellitus,
C4750533,Type 2 diabetes mellitus risk assessment declined,diabetes,Type II diabetes mellitus risk assessment declined; Type 2 diabetes mellitus risk assessment declined (situation),
C4751124,Hypoinsulinemic hypoglycemia and body hemihypertrophy,hypoglycemia,Hypoinsulinemic hypoglycemia and body hemihypertrophy (disorder); Hypoinsulinemic hypoglycemia and body hemihypertrophy; Hypoinsulinemic hypoglycaemia and body hemihypertrophy,
C4751520,"Age, Blood pressure, Clinical features, Duration, Diabetes 2 score",diabetes,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score; ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score; Age, Blood pressure, Clinical features, Duration, Diabetes 2 score (observable entity)",
C4751521,"Assessment using Age, Blood pressure, Clinical features, Duration, Diabetes 2 score",diabetes,"Assessment using ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score; Assessment using ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score; Assessment using Age, Blood pressure, Clinical features, Duration, Diabetes 2 score (procedure)",
C4752252,Caffeine and glucose only product,glucose,Product containing only caffeine and glucose (medicinal product),
C4753385,Glucose only product,glucose,Product containing only glucose (medicinal product),
C4753386,Glucose and glutathione and hypromellose only product,glucose,Product containing only glucose and glutathione and hypromellose (medicinal product),
C4753387,Glucose and molasses only product,glucose,Glucose and treacle only product; Product containing only glucose and molasses (medicinal product),
C4753388,Glucose and potassium chloride only product,glucose,Product containing only glucose and potassium chloride (medicinal product),
C4753389,Glucose and potassium chloride and sodium chloride only product,glucose,Product containing only glucose and potassium chloride and sodium chloride (medicinal product),
C4753390,Glucose and sodium chloride only product,glucose,Product containing only glucose and sodium chloride (medicinal product),
C4756516,Glucose and potassium chloride and sodium chloride only product in parenteral dose form,glucose,Product containing only glucose and potassium chloride and sodium chloride in parenteral dose form (medicinal product form),
C4756517,Glucose and potassium chloride only product in parenteral dose form,glucose,Product containing only glucose and potassium chloride in parenteral dose form (medicinal product form),
C4756518,Glucose and sodium chloride only product in parenteral dose form,glucose,Product containing only glucose and sodium chloride in parenteral dose form (medicinal product form),
C4756519,Glucose only product in ocular dose form,glucose,Product containing only glucose in ocular dose form (medicinal product form),
C4756520,Glucose only product in oral dose form,glucose,Product containing only glucose in oral dose form (medicinal product form),
C4756521,Glucose only product in parenteral dose form,glucose,Product containing only glucose in parenteral dose form (medicinal product form),
C4758360,Anhydrous glucose 50 mg/mL and potassium chloride 2 mg/mL solution for infusion,glucose,Product containing precisely anhydrous glucose 50 milligram/1 milliliter and potassium chloride 2 milligram/1 milliliter conventional release solution for infusion (clinical drug),
C4758361,Anhydrous glucose 40 mg/mL and potassium chloride 1.5 mg/mL and sodium chloride 1.8 mg/mL solution for infusion,glucose,Product containing precisely anhydrous glucose 40 milligram/1 milliliter and potassium chloride 1.5 milligram/1 milliliter and sodium chloride 1.8 milligram/1 milliliter conventional release solution for infusion (clinical drug),
C4758364,Anhydrous glucose 40 mg/mL and potassium chloride 3 mg/mL and sodium chloride 1.8 mg/mL solution for infusion,glucose,Product containing precisely anhydrous glucose 40 milligram/1 milliliter and potassium chloride 3 milligram/1 milliliter and sodium chloride 1.8 milligram/1 milliliter conventional release solution for infusion (clinical drug),
C4758365,Anhydrous glucose 50 mg/mL and potassium chloride 3 mg/mL solution for infusion,glucose,Product containing precisely anhydrous glucose 50 milligram/1 milliliter and potassium chloride 3 milligram/1 milliliter conventional release solution for infusion (clinical drug),
C4758366,Anhydrous glucose 50 mg/mL and potassium chloride 1.5 mg/mL solution for infusion,glucose,Product containing precisely anhydrous glucose 50 milligram/1 milliliter and potassium chloride 1.5 milligram/1 milliliter conventional release solution for infusion (clinical drug),
C4758372,Anhydrous glucose 40 mg/mL and potassium chloride 2 mg/mL and sodium chloride 1.8 mg/mL solution for infusion,glucose,Product containing precisely anhydrous glucose 40 milligram/1 milliliter and potassium chloride 2 milligram/1 milliliter and sodium chloride 1.8 milligram/1 milliliter conventional release solution for infusion (clinical drug),
C4758373,Anhydrous glucose 50 mg/mL and potassium chloride 1.5 mg/mL and sodium chloride 4.5 mg/mL solution for infusion,glucose,Product containing precisely anhydrous glucose 50 milligram/1 milliliter and potassium chloride 1.5 milligram/1 milliliter and sodium chloride 4.5 milligram/1 milliliter conventional release solution for infusion (clinical drug),
C4759621,Referral to CDC-recognized diabetes prevention program,diabetes,Referral to CDC-recognized diabetes prevention program (procedure),
C4759622,Referral to diabetes prevention program,diabetes,Referral to DPP-diabetes prevention program; Referral to diabetes prevention program (procedure),
C4759705,Intracapillary glomerulosclerosis due to diabetes mellitus,diabetes,"Nodular glomerulosclerosis; Kimmelstiel Wilson Syndrome; Nodular glomerulosclerosis (morphologic abnormality); Intracapillary glomerulosclerosis of kidney due to diabetes mellitus; Intracapillary glomerulosclerosis due to diabetes mellitus; Kimmelstiel-Wilson Disease; Nodular Glomerulosclerosis; Intracapillary Glomerulosclerosis; Glomerulosclerosis, Nodular; Intracapillary glomerulosclerosis of kidney due to diabetes mellitus (disorder); Kimmelstiel-Wilson Syndrome; Glomerulosclerosis, nodular; Syndrome, Kimmelstiel-Wilson; Kimmelstiel Wilson Disease; Diabetic intracapillary glomerulosclerosis",
C4759706,Diabetic Glomerulosclerosis,diabetes,"Kimmelstiel-Wilson lesion; kimmelstiel-wilson syndrome; Kimmelstiel-Wilson syndrome (disorder); Diabetic Glomerulosclerosis; Glomerulosclerosis of kidney due to diabetes mellitus (disorder); diabetic glomerulopathy; Diabetic glomerulosclerosis; Glomerulosclerosis of kidney due to diabetes mellitus; Diabetic glomerulopathy; Glomerulosclerosis, Diabetic; Diabetic intracapillary glomerulosclerosis; disease kimmelstiel wilson; Kimmelstiel-Wilson syndrome",
C4759707,Glomerulopathy due to diabetes mellitus,diabetes,Diabetic glomerulopathy; Glomerulopathy due to diabetes mellitus; Glomerulopathy due to diabetes mellitus (disorder),
C4759837,78 kDa Glucose-Regulated Protein,glucose,"Heat Shock 70 kDa Protein 5; 78 kDa Glucose-Regulated Protein; Immunoglobulin Heavy Chain-Binding Protein; BiP, Molecular Chaperone; Grp78; Heat Shock Protein 5; Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein grp78; Protein, HSPA5; HSPA5; BiP; GRP 78 Protein; GRP78; Binding immunoglobulin Protein Molecular Chaperone; HSPA5 Protein; Molecular Chaperone GRP78; BiP Protein; Immunoglobulin Heavy Chain Binding Protein; Heat-Shock Protein 5; Endoplasmic Reticulum Chaperone BiP; Binding-immunoglobulin Protein Molecular Chaperone; Molecular Chaperone BiP; Glucose Regulated Protein 78 kDa; GRP78, Molecular Chaperone",
C4762587,Embrace Pro Control Solution Blood Glucose Co,blood glucose,,
C4763864,Chronic Kidney Disease due to Diabetes Mellitus,diabetes,,
C4765103,EASY STEP (GLUCOSE) HIGH CONTROL SOLN,glucose,EASY STEP (GLUCOSE) HIGH CONTROL SOLN,
C4765104,EASY STEP (GLUCOSE) LOW CONTROL SOLN,glucose,EASY STEP (GLUCOSE) LOW CONTROL SOLN,
C4765105,EASY STEP (GLUCOSE) NORMAL CONTROL SOLN,glucose,EASY STEP (GLUCOSE) NORMAL CNTRL SOLN,
C4773447,Amytta sp. 1 BG-2017,BG,,
C4773448,Amytta sp. 2 BG-2017,BG,,
C4773449,Amytta sp. 3 BG-2017,BG,,
C4782607,Candidatus Kentron sp. FBG,FBG,,
C4893782,Asparagaceae sp. Wairere BG,BG,,
C4893783,Asparagaceae sp. Dunedin BG,BG,,
C4893784,Asparagaceae sp. Smith BG 6360PA,BG,,
C4893786,Dracaena sp. Moscow BG,BG,,
C4893787,Dracaena sp. Toronto BG,BG,,
C4893788,Dracaena sp. StPetersburg BG,BG,,
C4893789,Dracaena sp. Brest BG 80-0330,BG,,
C4893790,Dracaena sp. Nancy BG 1989.3.056,BG,,
C4893791,Dracaena sp. Paris BG 7460,BG,,
C4916857,Xiphinema sp. Kra-BG,BG,,
C4916858,Xiphinema sp. Per-BG,BG,,
C5059887,Ameletus sp. A BG-2018,BG,,
C5059888,Ameletus sp. B BG-2018,BG,,
C5059889,Anacroneuria sp. A BG-2018,BG,,
C5059890,Anacroneuria sp. B BG-2018,BG,,
C5059891,Anacroneuria sp. D BG-2018,BG,,
C5059892,Anacroneuria sp. E BG-2018,BG,,
C5059893,Anacroneuria sp. F BG-2018,BG,,
C5059894,Anacroneuria sp. G BG-2018,BG,,
C5059895,Anacroneuria sp. H BG-2018,BG,,
C5059896,Andesiops sp. A BG-2018,BG,,
C5059897,Andesiops sp. B BG-2018,BG,,
C5059898,Andesiops sp. C BG-2018,BG,,
C5059899,Andesiops sp. D BG-2018,BG,,
C5059900,Andesiops sp. E BG-2018,BG,,
C5059901,Andesiops sp. F BG-2018,BG,,
C5059902,Andesiops sp. G BG-2018,BG,,
C5059903,Andesiops sp. H BG-2018,BG,,
C5059904,Andesiops sp. I BG-2018,BG,,
C5059905,Andesiops sp. K BG-2018,BG,,
C5059906,Andesiops sp. L BG-2018,BG,,
C5059907,Andesiops sp. M BG-2018,BG,,
C5059908,Andesiops sp. N BG-2018,BG,,
C5059909,Andesiops sp. O BG-2018,BG,,
C5059910,Atanatolica sp. A BG-2018,BG,,
C5059911,Atanatolica sp. B BG-2018,BG,,
C5059912,Atanatolica sp. C BG-2018,BG,,
C5059913,Atanatolica sp. D BG-2018,BG,,
C5059914,Atanatolica sp. E BG-2018,BG,,
C5059915,Atanatolica sp. F BG-2018,BG,,
C5059916,Atanatolica sp. G BG-2018,BG,,
C5059917,Atanatolica sp. H BG-2018,BG,,
C5059918,Atopsyche sp. A BG-2018,BG,,
C5059919,Atopsyche sp. B BG-2018,BG,,
C5059920,Atopsyche sp. C BG-2018,BG,,
C5059921,Atopsyche sp. D BG-2018,BG,,
C5059922,Atopsyche sp. G BG-2018,BG,,
C5059923,Atopsyche sp. H BG-2018,BG,,
C5059924,Atopsyche sp. I BG-2018,BG,,
C5059925,Atopsyche sp. J BG-2018,BG,,
C5059926,Atopsyche sp. K BG-2018,BG,,
C5059927,Atopsyche sp. L BG-2018,BG,,
C5059928,Atopsyche sp. M BG-2018,BG,,
C5059929,Atopsyche sp. N BG-2018,BG,,
C5059930,Atopsyche sp. O BG-2018,BG,,
C5059931,Atopsyche sp. P BG-2018,BG,,
C5059932,Atopsyche sp. Q BG-2018,BG,,
C5059933,Atopsyche sp. R BG-2018,BG,,
C5059934,Baetodes sp. A BG-2018,BG,,
C5059935,Baetodes sp. B BG-2018,BG,,
C5059936,Baetodes sp. C BG-2018,BG,,
C5059937,Baetodes sp. E BG-2018,BG,,
C5059938,Baetodes sp. F BG-2018,BG,,
C5059939,Baetodes sp. G BG-2018,BG,,
C5059940,Baetodes sp. H BG-2018,BG,,
C5059941,Baetodes sp. I BG-2018,BG,,
C5059942,Baetodes sp. J BG-2018,BG,,
C5059943,Baetodes sp. K BG-2018,BG,,
C5059944,Baetodes sp. L BG-2018,BG,,
C5059945,Baetodes sp. M BG-2018,BG,,
C5059946,Banyallarga sp. A. BG-2018,BG,,
C5059947,Cailloma sp. A. BG-2018,BG,,
C5059948,Cailloma sp. B BG-2018,BG,,
C5059949,Cinygmula sp. A BG-2018,BG,,
C5059950,Cinygmula sp. B BG-2018,BG,,
C5059951,Cinygmula sp. C BG-2018,BG,,
C5059952,Cinygmula sp. D BG-2018,BG,,
C5059953,Contulma sp. A BG-2018,BG,,
C5059954,Contulma sp. B BG-2018,BG,,
C5059955,Helicopsyche sp. A BG-2018,BG,,
C5059956,Helicopsyche sp. B BG-2018,BG,,
C5059957,Helicopsyche sp. C BG-2018,BG,,
C5059958,Helicopsyche sp. D BG-2018,BG,,
C5059959,Helicopsyche sp. E BG-2018,BG,,
C5059960,Hesperophylax sp. A BG-2018,BG,,
C5059961,Lachlania sp. A BG-2018,BG,,
C5059962,Lachlania sp. B BG-2018,BG,,
C5059963,Lepidostoma sp. A BG-2018,BG,,
C5059964,Lepidostoma sp. B BG-2018,BG,,
C5059965,Leptohyphes sp. A BG-2018,BG,,
C5059966,Leptohyphes sp. B BG-2018,BG,,
C5059967,Leptohyphes sp. C BG-2018,BG,,
C5059968,Leptohyphes sp. D BG-2018,BG,,
C5059969,Leptohyphes sp. E BG-2018,BG,,
C5059970,Leptohyphes sp. F BG-2018,BG,,
C5059971,Leptohyphes sp. G BG-2018,BG,,
C5059972,Leptohyphes sp. H BG-2018,BG,,
C5059973,Leptohyphes sp. I BG-2018,BG,,
C5059974,Leptohyphes sp. J BG-2018,BG,,
C5059975,Leptohyphes sp. K BG-2018,BG,,
C5059976,Leptohyphes sp. L BG-2018,BG,,
C5059977,Leucotrichia sp. A BG-2018,BG,,
C5059978,Metrichia sp. A BG-2018,BG,,
C5059979,Nectopsyche sp. A BG-2018,BG,,
C5059980,Nectopsyche sp. B BG-2018,BG,,
C5059981,Nectopsyche sp. C BG-2018,BG,,
C5059982,Nectopsyche sp. D BG-2018,BG,,
C5059983,Nectopsyche sp. E BG-2018,BG,,
C5059984,Nectopsyche sp. F BG-2018,BG,,
C5059985,Nectopsyche sp. G BG-2018,BG,,
C5059986,Nectopsyche sp. H BG-2018,BG,,
C5059987,Nectopsyche sp. I BG-2018,BG,,
C5059988,Nectopsyche sp. J BG-2018,BG,,
C5059989,Nectopsyche sp. K BG-2018,BG,,
C5059990,Nectopsyche sp. L BG-2018,BG,,
C5059991,Nectopsyche sp. M BG-2018,BG,,
C5059992,Phylloicus sp. A BG-2018,BG,,
C5059993,Phylloicus sp. B BG-2018,BG,,
C5059994,Phylloicus sp. C BG-2018,BG,,
C5059995,Phylloicus sp. D BG-2018,BG,,
C5059996,Phylloicus sp. E BG-2018,BG,,
C5059997,Psychoglypha sp. A BG-2018,BG,,
C5059998,Smicridea sp. A BG-2018,BG,,
C5059999,Smicridea sp. B BG-2018,BG,,
C5060000,Smicridea sp. C BG-2018,BG,,
C5060001,Smicridea sp. D BG-2018,BG,,
C5060002,Smicridea sp. E BG-2018,BG,,
C5060003,Smicridea sp. F BG-2018,BG,,
C5060004,Smicridea sp. G BG-2018,BG,,
C5060005,Smicridea sp. H BG-2018,BG,,
C5060006,Suwallia sp. A BG-2018,BG,,
C5060007,Suwallia sp. B BG-2018,BG,,
C5060008,Thraulodes sp. A BG-2018,BG,,
C5060009,Thraulodes sp. B BG-2018,BG,,
C5060010,Alloperla pilosa complex sp. A BG-2018,BG,,
C5060011,Anacroneuria cajas complex sp. A BG-2018,BG,,
C5060012,Anacroneuria cajas complex sp. B BG-2018,BG,,
C5060013,Anacroneuria guambiana complex sp. A BG-2018,BG,,
C5060014,Anacroneuria guambiana complex sp. B BG-2018,BG,,
C5060015,Anacroneuria guambiana complex sp. C BG-2018,BG,,
C5060016,Baetis tricaudatus complex sp. A BG-2018,BG,,
C5060017,Baetis tricaudatus complex sp. B BG-2018,BG,,
C5060018,Baetis tricaudatus complex sp. C BG-2018,BG,,
C5060019,Baetis tricaudatus complex sp. D BG-2018,BG,,
C5060020,Diphetor hageni group sp. BG-2018,BG,,
C5060021,Drunella coloradensis complex sp. A BG-2018,BG,,
C5060022,Drunella coloradensis complex sp. B BG-2018,BG,,
C5060024,Ecuaphlebia sp. A BG-2018,BG,,
C5060025,Ecuaphlebia sp. B BG-2018,BG,,
C5060026,Ecuaphlebia sp. C BG-2018,BG,,
C5060027,Epeorus longimanus complex sp. A BG-2018,BG,,
C5060028,Epeorus longimanus complex sp. B BG-2018,BG,,
C5060029,Ephemerella dorothea infrequens group sp. A BG-2018,BG,,
C5060030,Ephemerella dorothea infrequens group sp. B BG-2018,BG,,
C5060031,Ephemerella dorothea infrequens group sp. C BG-2018,BG,,
C5060032,Ephemerella dorothea infrequens group sp. D BG-2018,BG,,
C5060033,Fallceon quilleri complex sp. A BG-2018,BG,,
C5060034,Fallceon quilleri complex sp. B BG-2018,BG,,
C5060035,Lepidostoma podagrum complex sp. A BG-2018,BG,,
C5060036,Lepidostoma podagrum complex sp. B BG-2018,BG,,
C5060037,Leptonema sp. A BG-2018,BG,,
C5060038,Leptonema sp. B BG-2018,BG,,
C5060039,Leptonema sp. C BG-2018,BG,,
C5060040,Leptonema sp. D BG-2018,BG,,
C5060041,Leptonema sp. E BG-2018,BG,,
C5060042,Leptonema sp. F BG-2018,BG,,
C5060043,Leptonema sp. G BG-2018,BG,,
C5060044,Limnephilus abbreviatus group sp. BG-2018,BG,,
C5060046,Mayobaetis sp. A BG-2018,BG,,
C5060047,Mayobaetis sp. B BG-2018,BG,,
C5060048,Mayobaetis sp. C BG-2018,BG,,
C5060049,Mayobaetis sp. D BG-2018,BG,,
C5060050,Mayobaetis sp. E BG-2018,BG,,
C5060051,Megarcys signata complex sp. B BG-2018,BG,,
C5060052,Mortoniella sp. A BG-2018,BG,,
C5060053,Nectopsyche gemma group sp. BG-2018,BG,,
C5060054,Paraleuctra occidentalis complex sp. A BG-2018,BG,,
C5060055,Paraleuctra occidentalis complex sp. B BG-2018,BG,,
C5060056,Paraleuctra vershina complex sp. A BG-2018,BG,,
C5060057,Paraleuctra vershina complex sp. B BG-2018,BG,,
C5060059,Prebaetodes sp. A BG-2018,BG,,
C5060060,Prebaetodes sp. B BG-2018,BG,,
C5060061,Prebaetodes sp. C BG-2018,BG,,
C5060062,Prebaetodes sp. D BG-2018,BG,,
C5060063,Rhithrogena hageni complex sp. A BG-2018,BG,,
C5060064,Siphlonurus occidentalis complex sp. A BG-2018,BG,,
C5060065,Siphlonurus occidentalis complex sp. B BG-2018,BG,,
C5060066,Zapada oregonensis group sp. A BG-2018,BG,,
C5060067,Zapada oregonensis group sp. B BG-2018,BG,,
C5065936,Clerodendrum sp. BG-2018,BG,,
C5135011,Andesiops sp. J BG-2018,BG,,
C5135012,Atopsyche sp. F BG-2018,BG,,
C5135013,Baetodes sp. D BG-2018,BG,,
C5135014,Contulma sp. C BG-2018,BG,,
C5135015,Oecetis sp. A BG-2018,BG,,
C5135431,Ecuaphlebia sp. D BG-2018,BG,,
C5135432,Megarcys signata complex sp. A BG-2018,BG,,
C5135665,Contour Next Glucose Test Strips by Ascensia,glucose,,
C5135669,Contour Blood Glucose Test Strips by Ascensia,blood glucose,,
C5137114,FORA GTEL (GLUCOSE) TEST STRIP,glucose,FORA GTEL (GLUCOSE) TEST STRIP,
C5137116,FREESTYLE LIBRE 14 DAY (GLUCOSE) READER,glucose,FREESTYLE LIBRE 14 DAY (GLUCOSE) READER,
C5137278,Cdc24p-Far1p-Gbetagamma complex,BG,CDC24-FAR1-BG complex; Cdc24p-Far1p-BG complex; CDC24-FAR1-BG complex location; Cdc24p-Far1p-Gbetagamma complex location; CDC24-FAR1-Gbetagamma complex location; Cdc24p-Far1p-BG complex location; CDC24-FAR1-Gbetagamma complex,
C5140759,VIVAGUARD (GLUCOSE) LOW/NORMAL/HIGH CONTROL SOLN,glucose,VIVAGUARD(GLUCOSE)L0W/NORM/HI CONTL SOLN,
C5140781,VIVAGUARD INO (GLUCOSE) TEST STRIP,glucose,VIVAGUARD INO (GLUCOSE) TEST STRIP,
C5142565,Growth hormone & glucose post cloNIDine stimulation panel,glucose,Growth hormone and glucose post cloNIDine stimulation panel; Growth hormone & glucose post cloNIDine stimulation panel,
C5142631,Glucose post glucagon stimulation panel,glucose,Glucose post glucagon stimulation panel,
C5144555,Age diabetes-related problem occurred:Time:Pt:^Family member:Qn,diabetes,Age diabetes-related problem occurred for Family member; Age diabetes-related problem occurred:Time:To identify measures at a point in time:^Family member:Quantitative; Diabetes-related problem age Fam Mem,
C5144558,Problem related to diabetes:Find:Pt:^Family member:Ord,diabetes,Problem related to diabetes:Finding:To identify measures at a point in time:^Family member:Ordinal; Problem related to diabetes Family member; Diabetes problem Fam Mem,
C5144561,Growth hormone & glucose post cloNIDine stimulation panel:-:Pt:Ser/Plas:Qn,glucose,Growth hormone & glucose post cloNIDine stimulation panel:-:Pt:Ser/Plas:Qn; Growth hormone and glucose post cloNIDine stimulation panel - Serum or Plasma; GH + glucose p cloNIDine stim pnl SerPl; Growth hormone & glucose post cloNIDine stimulation panel:-:To identify measures at a point in time:Serum/Plasma:Quantitative; Growth hormone and glucose post cloNIDine stimulation panel,
C5144562,Glucose^30M post dose cloNIDine:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose cloNIDine; Glucose^30 minutes post dose cloNIDine:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30 Min post dose cloNIDine [Mass/Vol]; Glucose 30M p CLN SerPl-mCnc,
C5144563,Glucose^1H post dose cloNIDine:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p CLN SerPl-mCnc; Glucose^1 hour post dose cloNIDine:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1 Hr post dose cloNIDine [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --1 hour post dose cloNIDine,
C5144564,Glucose^1.5H post dose cloNIDine:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1.5h p CLN SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose cloNIDine; Glucose^1.5 hours post dose cloNIDine:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5 Hr post dose cloNIDine [Mass/Vol],
C5144565,Glucose^2H post dose cloNIDine:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^2 hours post dose cloNIDine:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 2h p CLN SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --2 hours post dose cloNIDine; Glucose 2 Hr post dose cloNIDine [Mass/Vol],
C5144706,Glucose^30M post dose glucagon:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30 Min post dose glucagon [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose glucagon; Glucose^30 minutes post dose glucagon:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30M p Gc SerPl-mCnc,
C5144707,Glucose^20M post dose glucagon:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose^20 minutes post dose glucagon:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 20 Min post dose glucagon [Mass/Vol]; Glucose 20M p Gc SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --20 minutes post dose glucagon,
C5144708,Glucose^10M post dose glucagon:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --10 minutes post dose glucagon; Glucose 10 Min post dose glucagon [Mass/Vol]; Glucose^10 minutes post dose glucagon:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 10M p Gc SerPl-mCnc,
C5144709,Glucose post glucagon stimulation panel:-:Pt:Ser/Plas:Qn,glucose,Glucose post glucagon stimulation panel:-:Pt:Ser/Plas:Qn; Glucose p glucagon stimulation Pnl SerPl; Glucose post glucagon stimulation panel - Serum or Plasma; Glucose post glucagon stimulation panel:-:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose post glucagon stimulation panel,
C5145418,Alpha-1-Fetoprotein^^adjusted for diabetes,diabetes,Alpha-1-Fetoprotein^^adjusted for diabetes,
C5145419,Alpha-1-Fetoprotein^^adjusted for diabetes+weight,diabetes,Alpha-1-Fetoprotein^^adjusted for diabetes+weight,
C5145629,C peptide^1.5H post dose glucose,glucose,C peptide^1.5H post dose glucose,
C5145633,C peptide^10M post dose glucose,glucose,C peptide^10M post dose glucose,
C5145642,C peptide^15M post dose glucose,glucose,C peptide^15M post dose glucose,
C5145647,C peptide^1H post dose glucose,glucose,C peptide^1H post dose glucose,
C5145650,C peptide^1M post dose glucose,glucose,C peptide^1M post dose glucose,
C5145655,C peptide^2H post dose glucose,glucose,C peptide^2H post dose glucose,
C5145661,C peptide^3.5H post dose glucose,glucose,C peptide^3.5H post dose glucose,
C5145662,C peptide^30M post dose glucose,glucose,C peptide^30M post dose glucose,
C5145664,C peptide^3H post dose glucose,glucose,C peptide^3H post dose glucose,
C5145666,C peptide^3M post dose glucose,glucose,C peptide^3M post dose glucose,
C5145669,C peptide^4.5H post dose glucose,glucose,C peptide^4.5H post dose glucose,
C5145671,C peptide^45M post dose glucose,glucose,C peptide^45M post dose glucose,
C5145673,C peptide^4H post dose glucose,glucose,C peptide^4H post dose glucose,
C5145678,C peptide^5H post dose glucose,glucose,C peptide^5H post dose glucose,
C5145681,C peptide^5M post dose glucose,glucose,C peptide^5M post dose glucose,
C5145683,C peptide^5M pre dose glucose,glucose,C peptide^5M pre dose glucose,
C5145704,C peptide^pre dose glucose,glucose,C peptide^pre dose glucose,
C5146041,Corticotropin^1.5H post dose glucose,glucose,Corticotropin^1.5H post dose glucose,
C5146063,Corticotropin^1H post dose glucose,glucose,Corticotropin^1H post dose glucose,
C5146072,Corticotropin^2.5H post dose glucose,glucose,Corticotropin^2.5H post dose glucose,
C5146080,Corticotropin^2H post dose glucose,glucose,Corticotropin^2H post dose glucose,
C5146090,Corticotropin^30M post dose glucose,glucose,Corticotropin^30M post dose glucose,
C5146098,Corticotropin^3H post dose glucose,glucose,Corticotropin^3H post dose glucose,
C5146146,Corticotropin^pre dose glucose,glucose,Corticotropin^pre dose glucose,
C5146913,Glucose and lactose and lactulose and XXX challenge panel,glucose,,
C5146914,Glucose tolerance^post 100 g glucose PO,glucose,Glucose tolerance^post 100 g glucose PO,
C5146915,Glucose tolerance^post 75 g glucose PO,glucose,Glucose tolerance^post 75 g glucose PO,
C5146916,Glucose^ 6M post XXX challenge,glucose,Glucose^ 6M post XXX challenge; Glucose^6M post XXX challenge,
C5146917,Glucose^1.3H post dose glucose,glucose,Glucose^1.3H post dose glucose,
C5146918,Glucose^1.3H post dose insulin IV,glucose,Glucose^1.3H post dose insulin IV,
C5146919,Glucose^1.5H post 0.05-0.15 U insulin/kg IV post 12H CFst,glucose,Glucose^1.5H post 0.05-0.15 U insulin/kg IV post 12H CFst,
C5146920,Glucose^1.5H post 0.5 g/kg glucose IV,glucose,Glucose^1.5H post 0.5 g/kg glucose IV,
C5146921,Glucose^1.5H post 100 g glucose PO,glucose,Glucose^1.5H post 100 g glucose PO,
C5146922,Glucose^1.5H post 50 g lactose PO,glucose,Glucose^1.5H post 50 g lactose PO,
C5146923,Glucose^1.5H post 75 g glucose PO,glucose,Glucose^1.5H post 75 g glucose PO,
C5146924,Glucose^1.5H post dose betaxolol,glucose,Glucose^1.5H post dose betaxolol,
C5146925,Glucose^1.5H post dose cloNIDine,glucose,Glucose^1.5H post dose cloNIDine,
C5146926,Glucose^1.5H post dose fructose PO,glucose,Glucose^1.5H post dose fructose PO,
C5146927,Glucose^1.5H post dose glucose,glucose,Glucose^1.5H post dose glucose,
C5146928,Glucose^1.5H post dose insulin IV,glucose,Glucose^1.5H post dose insulin IV,
C5146929,Glucose^1.5H post dose lactose PO,glucose,Glucose^1.5H post dose lactose PO,
C5146930,Glucose^1.5H post dose ornithine alpha-ketoglutarate,glucose,Glucose^1.5H post dose ornithine alpha-ketoglutarate,
C5146931,Glucose^1.5H post dose triple bolus,glucose,Glucose^1.5H post dose triple bolus,
C5146932,Glucose^1.5H post meal,glucose,Glucose^1.5H post meal,
C5146933,Glucose^1.5H post XXX challenge,glucose,Glucose^1.5H post XXX challenge,
C5146934,Glucose^1.6H post dose glucose,glucose,Glucose^1.6H post dose glucose,
C5146935,Glucose^10 AM specimen,glucose,Glucose^10 AM specimen,
C5146936,Glucose^10 PM specimen,glucose,Glucose^10 PM specimen,
C5146937,Glucose^10.5H post XXX challenge,glucose,Glucose^10.5H post XXX challenge,
C5146938,Glucose^10.75H post XXX challenge,glucose,Glucose^10.75H post XXX challenge,
C5146939,Glucose^100M post XXX challenge,glucose,Glucose^100M post XXX challenge,
C5146940,Glucose^105M post dose glucose,glucose,Glucose^105M post dose glucose,
C5146941,Glucose^105M post XXX challenge,glucose,Glucose^105M post XXX challenge,
C5146942,Glucose^10H post XXX challenge,glucose,Glucose^10H post XXX challenge,
C5146943,Glucose^10M post 0.5 g/kg glucose IV,glucose,Glucose^10M post 0.5 g/kg glucose IV,
C5146944,Glucose^10M post dose glucagon,glucose,Glucose^10M post dose glucagon,
C5146945,Glucose^10M post dose glucose,glucose,Glucose^10M post dose glucose,
C5146946,Glucose^10M pre dose glucagon,glucose,Glucose^10M pre dose glucagon,
C5146947,Glucose^10M pre XXX challenge,glucose,Glucose^10M pre XXX challenge,
C5146948,Glucose^10th specimen,glucose,Glucose^10th specimen,
C5146949,Glucose^10th specimen post XXX challenge,glucose,Glucose^10th specimen post XXX challenge,
C5146950,Glucose^11 AM specimen,glucose,Glucose^11 AM specimen,
C5146951,Glucose^11.5H post XXX challenge,glucose,Glucose^11.5H post XXX challenge,
C5146952,Glucose^110M post XXX challenge,glucose,Glucose^110M post XXX challenge,
C5146953,Glucose^11H post XXX challenge,glucose,Glucose^11H post XXX challenge,
C5146954,Glucose^11th specimen post XXX challenge,glucose,Glucose^11th specimen post XXX challenge,
C5146955,Glucose^12 AM specimen,glucose,Glucose^12 AM specimen,
C5146956,Glucose^12 PM specimen,glucose,Glucose^12 PM specimen,
C5146957,Glucose^12.5H post XXX challenge,glucose,Glucose^12.5H post XXX challenge,
C5146958,Glucose^12H post 50 g lactose PO,glucose,Glucose^12H post 50 g lactose PO,
C5146959,Glucose^12H post peritoneal dialysis,glucose,Glucose^12H post peritoneal dialysis,
C5146960,Glucose^12H post XXX challenge,glucose,Glucose^12H post XXX challenge,
C5146961,Glucose^12M post XXX challenge,glucose,Glucose^12M post XXX challenge,
C5146962,Glucose^12th specimen post XXX challenge,glucose,Glucose^12th specimen post XXX challenge,
C5146963,Glucose^13.5H post XXX challenge,glucose,Glucose^13.5H post XXX challenge,
C5146964,Glucose^13H post XXX challenge,glucose,Glucose^13H post XXX challenge,
C5146965,Glucose^13M pre XXX challenge,glucose,Glucose^13M pre XXX challenge,
C5146966,Glucose^13th specimen post XXX challenge,glucose,Glucose^13th specimen post XXX challenge,
C5146967,Glucose^14H post XXX challenge,glucose,Glucose^14H post XXX challenge,
C5146968,Glucose^14M post XXX challenge,glucose,Glucose^14M post XXX challenge,
C5146969,Glucose^14th specimen post XXX challenge,glucose,Glucose^14th specimen post XXX challenge,
C5146970,Glucose^15.5H post XXX challenge,glucose,Glucose^15.5H post XXX challenge,
C5146971,Glucose^15M post 0.1 U/kg insulin,glucose,Glucose^15M post 0.1 U/kg insulin,
C5146972,Glucose^15M post 100 g glucose PO,glucose,Glucose^15M post 100 g glucose PO,
C5146973,Glucose^15M post 50 g lactose PO,glucose,Glucose^15M post 50 g lactose PO,
C5146974,Glucose^15M post dose arginine+insulin,glucose,Glucose^15M post dose arginine+insulin,
C5146975,Glucose^15M post dose glucagon,glucose,Glucose^15M post dose glucagon,
C5146976,Glucose^15M post dose glucose,glucose,Glucose^15M post dose glucose,
C5146977,Glucose^15M post dose lactose PO,glucose,Glucose^15M post dose lactose PO,
C5146978,Glucose^15M post dose ornithine alpha-ketoglutarate,glucose,Glucose^15M post dose ornithine alpha-ketoglutarate,
C5146979,Glucose^15M post dose triple bolus,glucose,Glucose^15M post dose triple bolus,
C5146980,Glucose^15M post XXX challenge,glucose,Glucose^15M post XXX challenge,
C5146981,Glucose^15M pre dose betaxolol,glucose,Glucose^15M pre dose betaxolol,
C5146982,Glucose^15M pre dose glucagon,glucose,Glucose^15M pre dose glucagon,
C5146983,Glucose^15M pre dose glucose,glucose,Glucose^15M pre dose glucose,
C5146984,Glucose^15M pre dose insulin IV,glucose,Glucose^15M pre dose insulin IV,
C5146985,Glucose^15M pre dose ornithine alpha-ketoglutarate,glucose,Glucose^15M pre dose ornithine alpha-ketoglutarate,
C5146986,Glucose^15M pre XXX challenge,glucose,Glucose^15M pre XXX challenge,
C5146987,Glucose^15th specimen post XXX challenge,glucose,Glucose^15th specimen post XXX challenge,
C5146988,Glucose^16H post XXX challenge,glucose,Glucose^16H post XXX challenge,
C5146989,Glucose^16M post XXX challenge,glucose,Glucose^16M post XXX challenge,
C5146990,Glucose^17.5H post XXX challenge,glucose,Glucose^17.5H post XXX challenge,
C5146991,Glucose^18.5H post XXX challenge,glucose,Glucose^18.5H post XXX challenge,
C5146992,Glucose^18H post XXX challenge,glucose,Glucose^18H post XXX challenge,
C5146993,Glucose^19.5H post XXX challenge,glucose,Glucose^19.5H post XXX challenge,
C5146994,Glucose^19M post XXX challenge,glucose,Glucose^19M post XXX challenge,
C5146995,Glucose^1H post 0.05-0.15 U insulin/kg IV post 12H CFst,glucose,Glucose^1H post 0.05-0.15 U insulin/kg IV post 12H CFst,
C5146996,Glucose^1H post 0.5 g/kg glucose IV,glucose,Glucose^1H post 0.5 g/kg glucose IV,
C5146997,Glucose^1H post 1.2 g/kg lactose PO,glucose,Glucose^1H post 1.2 g/kg lactose PO,
C5146998,Glucose^1H post 100 g glucose PO,glucose,Glucose^1H post 100 g glucose PO,
C5146999,Glucose^1H post 50 g glucose PO,glucose,Glucose^1H post 50 g glucose PO,
C5147000,Glucose^1H post 50 g lactose PO,glucose,Glucose^1H post 50 g lactose PO,
C5147001,Glucose^1H post 75 g glucose PO,glucose,Glucose^1H post 75 g glucose PO,
C5147002,Glucose^1H post dose arginine+insulin,glucose,Glucose^1H post dose arginine+insulin,
C5147003,Glucose^1H post dose betaxolol,glucose,Glucose^1H post dose betaxolol,
C5147004,Glucose^1H post dose cloNIDine,glucose,Glucose^1H post dose cloNIDine,
C5147005,Glucose^1H post dose fructose PO,glucose,Glucose^1H post dose fructose PO,
C5147006,Glucose^1H post dose glucose,glucose,Glucose^1H post dose glucose,
C5147007,Glucose^1H post dose insulin IV,glucose,Glucose^1H post dose insulin IV,
C5147008,Glucose^1H post dose lactose PO,glucose,Glucose^1H post dose lactose PO,
C5147009,Glucose^1H post dose ornithine alpha-ketoglutarate,glucose,Glucose^1H post dose ornithine alpha-ketoglutarate,
C5147010,Glucose^1H post dose triple bolus,glucose,Glucose^1H post dose triple bolus,
C5147011,Glucose^1H post dose U/kg insulin IV,glucose,Glucose^1H post dose U/kg insulin IV,
C5147012,Glucose^1H post meal,glucose,Glucose^1H post meal,
C5147013,Glucose^1H post XXX challenge,glucose,Glucose^1H post XXX challenge,
C5147014,Glucose^1M post 0.5 g/kg glucose IV,glucose,Glucose^1M post 0.5 g/kg glucose IV,
C5147015,Glucose^1M post XXX challenge,glucose,Glucose^1M post XXX challenge,
C5147016,Glucose^1st specimen,glucose,Glucose^1st specimen,
C5147017,Glucose^1st specimen post dose lactose,glucose,Glucose^1st specimen post dose lactose,
C5147018,Glucose^1st specimen post XXX challenge,glucose,Glucose^1st specimen post XXX challenge,
C5147019,Glucose^1st tube,glucose,Glucose^1st tube,
C5147020,Glucose^2 PM specimen,glucose,Glucose^2 PM specimen,
C5147021,Glucose^2.17H post XXX challenge,glucose,Glucose^2.17H post XXX challenge,
C5147022,Glucose^2.3H post dose glucose,glucose,Glucose^2.3H post dose glucose,
C5147023,Glucose^2.5H post 100 g glucose PO,glucose,Glucose^2.5H post 100 g glucose PO,
C5147024,Glucose^2.5H post 50 g lactose PO,glucose,Glucose^2.5H post 50 g lactose PO,
C5147025,Glucose^2.5H post 75 g glucose PO,glucose,Glucose^2.5H post 75 g glucose PO,
C5147026,Glucose^2.5H post dose betaxolol,glucose,Glucose^2.5H post dose betaxolol,
C5147027,Glucose^2.5H post dose glucose,glucose,Glucose^2.5H post dose glucose,
C5147028,Glucose^2.5H post dose insulin IV,glucose,Glucose^2.5H post dose insulin IV,
C5147029,Glucose^2.5H post dose lactose PO,glucose,Glucose^2.5H post dose lactose PO,
C5147030,Glucose^2.5H post dose ornithine alpha-ketoglutarate,glucose,Glucose^2.5H post dose ornithine alpha-ketoglutarate,
C5147031,Glucose^2.5H post XXX challenge,glucose,Glucose^2.5H post XXX challenge,
C5147032,Glucose^2.6H post dose glucose,glucose,Glucose^2.6H post dose glucose,
C5147033,Glucose^20.5H post XXX challenge,glucose,Glucose^20.5H post XXX challenge,
C5147034,Glucose^20H post XXX challenge,glucose,Glucose^20H post XXX challenge,
C5147035,Glucose^20M post 0.5 g/kg glucose IV,glucose,Glucose^20M post 0.5 g/kg glucose IV,
C5147036,Glucose^20M post 50 g lactose PO,glucose,Glucose^20M post 50 g lactose PO,
C5147037,Glucose^20M post dose glucagon,glucose,Glucose^20M post dose glucagon,
C5147038,Glucose^20M post dose glucose,glucose,Glucose^20M post dose glucose,
C5147039,Glucose^20M post dose lactose PO,glucose,Glucose^20M post dose lactose PO,
C5147040,Glucose^20M post XXX challenge,glucose,Glucose^20M post XXX challenge,
C5147041,Glucose^20M pre XXX challenge,glucose,Glucose^20M pre XXX challenge,
C5147042,Glucose^21.5H post XXX challenge,glucose,Glucose^21.5H post XXX challenge,
C5147043,Glucose^22H post XXX challenge,glucose,Glucose^22H post XXX challenge,
C5147044,Glucose^22M post XXX challenge,glucose,Glucose^22M post XXX challenge,
C5147045,Glucose^23.5H post XXX challenge,glucose,Glucose^23.5H post XXX challenge,
C5147046,Glucose^24H post peritoneal dialysis,glucose,Glucose^24H post peritoneal dialysis,
C5147047,Glucose^25H post XXX challenge,glucose,Glucose^25H post XXX challenge,
C5147048,Glucose^25M post XXX challenge,glucose,Glucose^25M post XXX challenge,
C5147049,Glucose^26H post XXX challenge,glucose,Glucose^26H post XXX challenge,
C5147050,Glucose^27H post XXX challenge,glucose,Glucose^27H post XXX challenge,
C5147051,Glucose^27M post XXX challenge,glucose,Glucose^27M post XXX challenge,
C5147052,Glucose^28H post XXX challenge,glucose,Glucose^28H post XXX challenge,
C5147053,Glucose^29H post XXX challenge,glucose,Glucose^29H post XXX challenge,
C5147054,Glucose^2D post XXX challenge,glucose,Glucose^2D post XXX challenge,
C5147055,Glucose^2H dwell specimen,glucose,Glucose^2H dwell specimen,
C5147056,Glucose^2H post 1.2 g/kg lactose PO,glucose,Glucose^2H post 1.2 g/kg lactose PO,
C5147057,Glucose^2H post 100 g glucose PO,glucose,Glucose^2H post 100 g glucose PO,
C5147058,Glucose^2H post 50 g glucose PO,glucose,Glucose^2H post 50 g glucose PO,
C5147059,Glucose^2H post 50 g lactose PO,glucose,Glucose^2H post 50 g lactose PO,
C5147060,Glucose^2H post dose betaxolol,glucose,Glucose^2H post dose betaxolol,
C5147061,Glucose^2H post dose cloNIDine,glucose,Glucose^2H post dose cloNIDine,
C5147062,Glucose^2H post dose fructose PO,glucose,Glucose^2H post dose fructose PO,
C5147063,Glucose^2H post dose glucose,glucose,Glucose^2H post dose glucose,
C5147064,Glucose^2H post dose insulin IV,glucose,Glucose^2H post dose insulin IV,
C5147065,Glucose^2H post dose lactose PO,glucose,Glucose^2H post dose lactose PO,
C5147066,Glucose^2H post dose ornithine alpha-ketoglutarate,glucose,Glucose^2H post dose ornithine alpha-ketoglutarate,
C5147067,Glucose^2H post dose triple bolus,glucose,Glucose^2H post dose triple bolus,
C5147068,Glucose^2H post meal,glucose,Glucose^2H post meal,
C5147069,Glucose^2H post peritoneal dialysis,glucose,Glucose^2H post peritoneal dialysis,
C5147070,Glucose^2H post XXX challenge,glucose,Glucose^2H post XXX challenge,
C5147071,Glucose^2H specimen,glucose,Glucose^2H specimen,
C5147072,Glucose^2M post dose glucagon,glucose,Glucose^2M post dose glucagon,
C5147073,Glucose^2M post XXX challenge,glucose,Glucose^2M post XXX challenge,
C5147074,Glucose^2nd specimen,glucose,Glucose^2nd specimen,
C5147075,Glucose^2nd specimen post dose lactose,glucose,Glucose^2nd specimen post dose lactose,
C5147076,Glucose^2nd specimen post XXX challenge,glucose,Glucose^2nd specimen post XXX challenge,
C5147077,Glucose^2nd tube,glucose,Glucose^2nd tube,
C5147078,Glucose^3 PM specimen,glucose,Glucose^3 PM specimen,
C5147079,Glucose^3.3H post dose glucose,glucose,Glucose^3.3H post dose glucose,
C5147080,Glucose^3.5H post 100 g glucose PO,glucose,Glucose^3.5H post 100 g glucose PO,
C5147081,Glucose^3.5H post 75 g glucose PO,glucose,Glucose^3.5H post 75 g glucose PO,
C5147082,Glucose^3.5H post dose glucose,glucose,Glucose^3.5H post dose glucose,
C5147083,Glucose^3.5H post dose lactose PO,glucose,Glucose^3.5H post dose lactose PO,
C5147084,Glucose^3.5H post XXX challenge,glucose,Glucose^3.5H post XXX challenge,
C5147085,Glucose^3.6H post dose glucose,glucose,Glucose^3.6H post dose glucose,
C5147086,Glucose^30H post XXX challenge,glucose,Glucose^30H post XXX challenge,
C5147087,Glucose^30M post 0.05-0.15 U insulin/kg IV post 12H CFst,glucose,Glucose^30M post 0.05-0.15 U insulin/kg IV post 12H CFst,
C5147088,Glucose^30M post 0.1 U/kg insulin,glucose,Glucose^30M post 0.1 U/kg insulin,
C5147089,Glucose^30M post 0.5 g/kg glucose IV,glucose,Glucose^30M post 0.5 g/kg glucose IV,
C5147090,Glucose^30M post 1.2 g/kg lactose PO,glucose,Glucose^30M post 1.2 g/kg lactose PO,
C5147091,Glucose^30M post 100 g glucose PO,glucose,Glucose^30M post 100 g glucose PO,
C5147092,Glucose^30M post 50 g lactose PO,glucose,Glucose^30M post 50 g lactose PO,
C5147093,Glucose^30M post 75 g glucose PO,glucose,Glucose^30M post 75 g glucose PO,
C5147094,Glucose^30M post dose arginine+insulin,glucose,Glucose^30M post dose arginine+insulin,
C5147095,Glucose^30M post dose betaxolol,glucose,Glucose^30M post dose betaxolol,
C5147096,Glucose^30M post dose cloNIDine,glucose,Glucose^30M post dose cloNIDine,
C5147097,Glucose^30M post dose fructose PO,glucose,Glucose^30M post dose fructose PO,
C5147098,Glucose^30M post dose glucagon,glucose,Glucose^30M post dose glucagon,
C5147099,Glucose^30M post dose glucose,glucose,Glucose^30M post dose glucose,
C5147100,Glucose^30M post dose insulin IV,glucose,Glucose^30M post dose insulin IV,
C5147101,Glucose^30M post dose lactose PO,glucose,Glucose^30M post dose lactose PO,
C5147102,Glucose^30M post dose ornithine alpha-ketoglutarate,glucose,Glucose^30M post dose ornithine alpha-ketoglutarate,
C5147103,Glucose^30M post dose triple bolus,glucose,Glucose^30M post dose triple bolus,
C5147104,Glucose^30M post dose U/kg insulin IV,glucose,Glucose^30M post dose U/kg insulin IV,
C5147105,Glucose^30M post XXX challenge,glucose,Glucose^30M post XXX challenge,
C5147106,Glucose^30M pre dose betaxolol,glucose,Glucose^30M pre dose betaxolol,
C5147107,Glucose^30M pre XXX challenge,glucose,Glucose^30M pre XXX challenge,
C5147108,Glucose^31H post XXX challenge,glucose,Glucose^31H post XXX challenge,
C5147109,Glucose^36H post XXX challenge,glucose,Glucose^36H post XXX challenge,
C5147110,Glucose^3H post 1.2 g/kg lactose PO,glucose,Glucose^3H post 1.2 g/kg lactose PO,
C5147111,Glucose^3H post 50 g lactose PO,glucose,Glucose^3H post 50 g lactose PO,
C5147112,Glucose^3H post 75 g glucose PO,glucose,Glucose^3H post 75 g glucose PO,
C5147113,Glucose^3H post dose betaxolol,glucose,Glucose^3H post dose betaxolol,
C5147114,Glucose^3H post dose fructose PO,glucose,Glucose^3H post dose fructose PO,
C5147115,Glucose^3H post dose glucose,glucose,Glucose^3H post dose glucose,
C5147116,Glucose^3H post dose lactose PO,glucose,Glucose^3H post dose lactose PO,
C5147117,Glucose^3H post dose ornithine alpha-ketoglutarate,glucose,Glucose^3H post dose ornithine alpha-ketoglutarate,
C5147118,Glucose^3H post dose triple bolus,glucose,Glucose^3H post dose triple bolus,
C5147119,Glucose^3H post XXX challenge,glucose,Glucose^3H post XXX challenge,
C5147120,Glucose^3H pre dose insulin IV,glucose,Glucose^3H pre dose insulin IV,
C5147121,Glucose^3M post 0.5 g/kg glucose IV,glucose,Glucose^3M post 0.5 g/kg glucose IV,
C5147122,Glucose^3M post XXX challenge,glucose,Glucose^3M post XXX challenge,
C5147123,Glucose^3M pre XXX challenge,glucose,Glucose^3M pre XXX challenge,
C5147124,Glucose^3rd specimen,glucose,Glucose^3rd specimen,
C5147125,Glucose^3rd specimen post dose lactose,glucose,Glucose^3rd specimen post dose lactose,
C5147126,Glucose^3rd specimen post XXX challenge,glucose,Glucose^3rd specimen post XXX challenge,
C5147127,Glucose^3rd tube,glucose,Glucose^3rd tube,
C5147128,Glucose^4 AM specimen,glucose,Glucose^4 AM specimen,
C5147129,Glucose^4 PM specimen,glucose,Glucose^4 PM specimen,
C5147130,Glucose^4.5H post 100 g glucose PO,glucose,Glucose^4.5H post 100 g glucose PO,
C5147131,Glucose^4.5H post 75 g glucose PO,glucose,Glucose^4.5H post 75 g glucose PO,
C5147132,Glucose^4.5H post dose glucose,glucose,Glucose^4.5H post dose glucose,
C5147133,Glucose^4.5H post XXX challenge,glucose,Glucose^4.5H post XXX challenge,
C5147134,Glucose^40M post 0.5 g/kg glucose IV,glucose,Glucose^40M post 0.5 g/kg glucose IV,
C5147135,Glucose^40M post 50 g lactose PO,glucose,Glucose^40M post 50 g lactose PO,
C5147136,Glucose^40M post dose glucose,glucose,Glucose^40M post dose glucose,
C5147137,Glucose^40M post dose lactose PO,glucose,Glucose^40M post dose lactose PO,
C5147138,Glucose^40M post XXX challenge,glucose,Glucose^40M post XXX challenge,
C5147139,Glucose^45M post 100 g glucose PO,glucose,Glucose^45M post 100 g glucose PO,
C5147140,Glucose^45M post 50 g lactose PO,glucose,Glucose^45M post 50 g lactose PO,
C5147141,Glucose^45M post 75 g glucose PO,glucose,Glucose^45M post 75 g glucose PO,
C5147142,Glucose^45M post dose arginine+insulin,glucose,Glucose^45M post dose arginine+insulin,
C5147143,Glucose^45M post dose betaxolol,glucose,Glucose^45M post dose betaxolol,
C5147144,Glucose^45M post dose glucose,glucose,Glucose^45M post dose glucose,
C5147145,Glucose^45M post dose lactose PO,glucose,Glucose^45M post dose lactose PO,
C5147146,Glucose^45M post dose ornithine alpha-ketoglutarate,glucose,Glucose^45M post dose ornithine alpha-ketoglutarate,
C5147147,Glucose^45M post dose triple bolus,glucose,Glucose^45M post dose triple bolus,
C5147148,Glucose^45M post XXX challenge,glucose,Glucose^45M post XXX challenge,
C5147149,Glucose^4H dwell specimen,glucose,Glucose^4H dwell specimen,
C5147150,Glucose^4H post 100 g glucose PO,glucose,Glucose^4H post 100 g glucose PO,
C5147151,Glucose^4H post 50 g lactose PO,glucose,Glucose^4H post 50 g lactose PO,
C5147152,Glucose^4H post 75 g glucose PO,glucose,Glucose^4H post 75 g glucose PO,
C5147153,Glucose^4H post dose glucose,glucose,Glucose^4H post dose glucose,
C5147154,Glucose^4H post dose lactose PO,glucose,Glucose^4H post dose lactose PO,
C5147155,Glucose^4H post peritoneal dialysis,glucose,Glucose^4H post peritoneal dialysis,
C5147156,Glucose^4H post XXX challenge,glucose,Glucose^4H post XXX challenge,
C5147157,Glucose^4H specimen,glucose,Glucose^4H specimen,
C5147158,Glucose^4M post dose glucagon,glucose,Glucose^4M post dose glucagon,
C5147159,Glucose^4M post XXX challenge,glucose,Glucose^4M post XXX challenge,
C5147160,Glucose^4th specimen,glucose,Glucose^4th specimen,
C5147161,Glucose^4th specimen post dose lactose,glucose,Glucose^4th specimen post dose lactose,
C5147162,Glucose^4th specimen post XXX challenge,glucose,Glucose^4th specimen post XXX challenge,
C5147163,Glucose^5 PM specimen,glucose,Glucose^5 PM specimen,
C5147164,Glucose^5.5H post 100 g glucose PO,glucose,Glucose^5.5H post 100 g glucose PO,
C5147165,Glucose^5.5H post 75 g glucose PO,glucose,Glucose^5.5H post 75 g glucose PO,
C5147166,Glucose^5.5H post dose glucose,glucose,Glucose^5.5H post dose glucose,
C5147167,Glucose^5.5H post XXX challenge,glucose,Glucose^5.5H post XXX challenge,
C5147168,Glucose^50M post XXX challenge,glucose,Glucose^50M post XXX challenge,
C5147169,Glucose^5H post 100 g glucose PO,glucose,Glucose^5H post 100 g glucose PO,
C5147170,Glucose^5H post 50 g glucose PO,glucose,Glucose^5H post 50 g glucose PO,
C5147171,Glucose^5H post 50 g lactose PO,glucose,Glucose^5H post 50 g lactose PO,
C5147172,Glucose^5H post 75 g glucose PO,glucose,Glucose^5H post 75 g glucose PO,
C5147173,Glucose^5H post dose glucose,glucose,Glucose^5H post dose glucose,
C5147174,Glucose^5H post dose lactose PO,glucose,Glucose^5H post dose lactose PO,
C5147175,Glucose^5H post XXX challenge,glucose,Glucose^5H post XXX challenge,
C5147176,Glucose^5M post 0.5 g/kg glucose IV,glucose,Glucose^5M post 0.5 g/kg glucose IV,
C5147177,Glucose^5M post dose glucose,glucose,Glucose^5M post dose glucose,
C5147178,Glucose^5M post XXX challenge,glucose,Glucose^5M post XXX challenge,
C5147179,Glucose^5M pre dose glucagon,glucose,Glucose^5M pre dose glucagon,
C5147180,Glucose^5M pre XXX challenge,glucose,Glucose^5M pre XXX challenge,
C5147181,Glucose^5th specimen,glucose,Glucose^5th specimen,
C5147182,Glucose^5th specimen post dose lactose,glucose,Glucose^5th specimen post dose lactose,
C5147183,Glucose^5th specimen post XXX challenge,glucose,Glucose^5th specimen post XXX challenge,
C5147184,Glucose^6 AM specimen,glucose,Glucose^6 AM specimen,
C5147185,Glucose^6 PM specimen,glucose,Glucose^6 PM specimen,
C5147186,Glucose^6.5H post XXX challenge,glucose,Glucose^6.5H post XXX challenge,
C5147187,Glucose^6H post 100 g glucose PO,glucose,Glucose^6H post 100 g glucose PO,
C5147188,Glucose^6H post 50 g lactose PO,glucose,Glucose^6H post 50 g lactose PO,
C5147189,Glucose^6H post 75 g glucose PO,glucose,Glucose^6H post 75 g glucose PO,
C5147190,Glucose^6H post dose glucose,glucose,Glucose^6H post dose glucose,
C5147191,Glucose^6H post dose lactose PO,glucose,Glucose^6H post dose lactose PO,
C5147192,Glucose^6H post XXX challenge,glucose,Glucose^6H post XXX challenge,
C5147193,Glucose^6M post dose glucagon,glucose,Glucose^6M post dose glucagon,
C5147194,Glucose^6th specimen,glucose,Glucose^6th specimen,
C5147195,Glucose^6th specimen post dose lactose,glucose,Glucose^6th specimen post dose lactose,
C5147196,Glucose^6th specimen post XXX challenge,glucose,Glucose^6th specimen post XXX challenge,
C5147197,Glucose^7.5H post XXX challenge,glucose,Glucose^7.5H post XXX challenge,
C5147198,Glucose^70M post XXX challenge,glucose,Glucose^70M post XXX challenge,
C5147199,Glucose^75M post dose glucose,glucose,Glucose^75M post dose glucose,
C5147200,Glucose^75M post XXX challenge,glucose,Glucose^75M post XXX challenge,
C5147201,Glucose^7H post meal,glucose,Glucose^7H post meal,
C5147202,Glucose^7H post XXX challenge,glucose,Glucose^7H post XXX challenge,
C5147203,Glucose^7th specimen,glucose,Glucose^7th specimen,
C5147204,Glucose^7th specimen post XXX challenge,glucose,Glucose^7th specimen post XXX challenge,
C5147205,Glucose^8 AM specimen,glucose,Glucose^8 AM specimen,
C5147206,Glucose^8 PM specimen,glucose,Glucose^8 PM specimen,
C5147207,Glucose^8.5H post XXX challenge,glucose,Glucose^8.5H post XXX challenge,
C5147208,Glucose^80M post XXX challenge,glucose,Glucose^80M post XXX challenge,
C5147209,Glucose^8H post XXX challenge,glucose,Glucose^8H post XXX challenge,
C5147210,Glucose^8M post dose glucagon,glucose,Glucose^8M post dose glucagon,
C5147211,Glucose^8M post XXX challenge,glucose,Glucose^8M post XXX challenge,
C5147212,Glucose^8M pre XXX challenge,glucose,Glucose^8M pre XXX challenge,
C5147213,Glucose^8th specimen,glucose,Glucose^8th specimen,
C5147214,Glucose^9.5H post XXX challenge,glucose,Glucose^9.5H post XXX challenge,
C5147215,Glucose^9H post XXX challenge,glucose,Glucose^9H post XXX challenge,
C5147216,Glucose^9M post XXX challenge,glucose,Glucose^9M post XXX challenge,
C5147217,Glucose^9th specimen,glucose,Glucose^9th specimen,
C5147218,Glucose^9th specimen post XXX challenge,glucose,Glucose^9th specimen post XXX challenge,
C5147219,Glucose^baseline,glucose,Glucose^baseline,
C5147220,Glucose^overnight,glucose,Glucose^overnight,
C5147221,Glucose^overnight dwell,glucose,Glucose^overnight dwell,
C5147222,Glucose^post 10H CFst,glucose,Glucose^post 10H CFst,
C5147223,Glucose^post 12H CFst,glucose,Glucose^post 12H CFst,
C5147224,Glucose^post 50 g glucose,glucose,Glucose^post 50 g glucose,
C5147225,Glucose^post CFst,glucose,Glucose^post CFst,
C5147226,Glucose^post dialysis,glucose,Glucose^post dialysis,
C5147227,Glucose^post dose glucose,glucose,Glucose^post dose glucose,
C5147228,Glucose^post meal,glucose,Glucose^post meal,
C5147229,Glucose^post XXX challenge,glucose,Glucose^post XXX challenge,
C5147230,Glucose^pre 0.5 g/kg glucose IV,glucose,Glucose^pre 0.5 g/kg glucose IV,
C5147231,Glucose^pre 100 g glucose PO,glucose,Glucose^pre 100 g glucose PO,
C5147232,Glucose^pre 12H CFst,glucose,Glucose^pre 12H CFst,
C5147233,Glucose^pre 50 g glucose PO,glucose,Glucose^pre 50 g glucose PO,
C5147234,Glucose^pre 50 g lactose PO,glucose,Glucose^pre 50 g lactose PO,
C5147235,Glucose^pre 75 g glucose PO,glucose,Glucose^pre 75 g glucose PO,
C5147236,Glucose^pre dialysis,glucose,Glucose^pre dialysis,
C5147237,Glucose^pre dose betaxolol,glucose,Glucose^pre dose betaxolol,
C5147238,Glucose^pre dose fructose PO,glucose,Glucose^pre dose fructose PO,
C5147239,Glucose^pre dose glucagon,glucose,Glucose^pre dose glucagon,
C5147240,Glucose^pre dose glucose,glucose,Glucose^pre dose glucose,
C5147241,Glucose^pre dose insulin IV,glucose,Glucose^pre dose insulin IV,
C5147242,Glucose^pre dose ornithine alpha-ketoglutarate,glucose,Glucose^pre dose ornithine alpha-ketoglutarate,
C5147243,Glucose^pre dose triple bolus,glucose,Glucose^pre dose triple bolus,
C5147244,Glucose^pre or post dose arginine,glucose,Glucose^pre or post dose arginine,
C5147245,Glucose^pre or post dose cloNIDine,glucose,Glucose^pre or post dose cloNIDine,
C5147246,Glucose^pre or post dose glucagon,glucose,Glucose^pre or post dose glucagon,
C5147247,Glucose^pre or post dose glucose,glucose,Glucose^pre or post dose glucose,
C5147248,Glucose^pre or post dose insulin,glucose,Glucose^pre or post dose insulin,
C5147249,Glucose^pre or post XXX challenge,glucose,Glucose^pre or post XXX challenge,
C5147250,Glucose^pre XXX challenge,glucose,Glucose^pre XXX challenge,
C5147251,Glucose^pre-meal,glucose,Glucose^pre-meal,
C5147444,Hydrogen/Expired gas^1.5H post dose glucose,glucose,Hydrogen/Expired gas^1.5H post dose glucose,
C5147455,Hydrogen/Expired gas^1H post dose glucose,glucose,Hydrogen/Expired gas^1H post dose glucose,
C5147462,Hydrogen/Expired gas^2.5H post dose glucose,glucose,Hydrogen/Expired gas^2.5H post dose glucose,
C5147471,Hydrogen/Expired gas^2H post dose glucose,glucose,Hydrogen/Expired gas^2H post dose glucose,
C5147475,Hydrogen/Expired gas^3.5H post dose glucose,glucose,Hydrogen/Expired gas^3.5H post dose glucose,
C5147479,Hydrogen/Expired gas^30M post dose glucose,glucose,Hydrogen/Expired gas^30M post dose glucose,
C5147484,Hydrogen/Expired gas^3H post dose glucose,glucose,Hydrogen/Expired gas^3H post dose glucose,
C5147488,Hydrogen/Expired gas^4.5H post dose glucose,glucose,Hydrogen/Expired gas^4.5H post dose glucose,
C5147494,Hydrogen/Expired gas^4H post dose glucose,glucose,Hydrogen/Expired gas^4H post dose glucose,
C5147496,Hydrogen/Expired gas^5.5H post dose glucose,glucose,Hydrogen/Expired gas^5.5H post dose glucose,
C5147500,Hydrogen/Expired gas^5H post dose glucose,glucose,Hydrogen/Expired gas^5H post dose glucose,
C5147502,Hydrogen/Expired gas^6H post dose glucose,glucose,Hydrogen/Expired gas^6H post dose glucose,
C5147505,Hydrogen/Expired gas^post 50 g glucose PO,glucose,Hydrogen/Expired gas^post 50 g glucose PO,
C5147507,Hydrogen/Expired gas^post dose glucose,glucose,Hydrogen/Expired gas^post dose glucose,
C5147510,Hydrogen/Expired gas^pre dose glucose,glucose,Hydrogen/Expired gas^pre dose glucose,
C5147571,Insulin^1.5H post 75 g glucose PO,glucose,Insulin^1.5H post 75 g glucose PO,
C5147573,Insulin^1.5H post dose glucose,glucose,Insulin^1.5H post dose glucose,
C5147574,Insulin^1.5H post dose glucose IV,glucose,Insulin^1.5H post dose glucose IV,
C5147580,Insulin^10M post dose glucose,glucose,Insulin^10M post dose glucose,
C5147581,Insulin^10M post dose glucose IV,glucose,Insulin^10M post dose glucose IV,
C5147583,Insulin^10M pre dose glucose,glucose,Insulin^10M pre dose glucose,
C5147593,Insulin^15M post dose glucose IV,glucose,Insulin^15M post dose glucose IV,
C5147600,Insulin^1H post 75 g glucose PO,glucose,Insulin^1H post 75 g glucose PO,
C5147602,Insulin^1H post dose glucose,glucose,Insulin^1H post dose glucose,
C5147603,Insulin^1H post dose glucose IV,glucose,Insulin^1H post dose glucose IV,
C5147606,Insulin^1M post dose glucose IV,glucose,Insulin^1M post dose glucose IV,
C5147611,Insulin^2.5H post 75 g glucose PO,glucose,Insulin^2.5H post 75 g glucose PO,
C5147612,Insulin^2.5H post dose glucose,glucose,Insulin^2.5H post dose glucose,
C5147613,Insulin^2.5H post dose glucose IV,glucose,Insulin^2.5H post dose glucose IV,
C5147618,Insulin^20M post dose glucose,glucose,Insulin^20M post dose glucose,
C5147623,Insulin^2H post 75 g glucose PO,glucose,Insulin^2H post 75 g glucose PO,
C5147624,Insulin^2H post dose glucose,glucose,Insulin^2H post dose glucose,
C5147625,Insulin^2H post dose glucose IV,glucose,Insulin^2H post dose glucose IV,
C5147634,Insulin^30M post 75 g glucose PO,glucose,Insulin^30M post 75 g glucose PO,
C5147636,Insulin^30M post dose glucose,glucose,Insulin^30M post dose glucose,
C5147637,Insulin^30M post dose glucose IV,glucose,Insulin^30M post dose glucose IV,
C5147644,Insulin^3H post 75 g glucose PO,glucose,Insulin^3H post 75 g glucose PO,
C5147645,Insulin^3H post dose glucose,glucose,Insulin^3H post dose glucose,
C5147646,Insulin^3H post dose glucose IV,glucose,Insulin^3H post dose glucose IV,
C5147649,Insulin^3M post dose glucose,glucose,Insulin^3M post dose glucose,
C5147650,Insulin^3M post dose glucose IV,glucose,Insulin^3M post dose glucose IV,
C5147659,Insulin^45M post dose glucose IV,glucose,Insulin^45M post dose glucose IV,
C5147661,Insulin^4H post 75 g glucose PO,glucose,Insulin^4H post 75 g glucose PO,
C5147662,Insulin^4H post dose glucose IV,glucose,Insulin^4H post dose glucose IV,
C5147671,Insulin^5H post 75 g glucose PO,glucose,Insulin^5H post 75 g glucose PO,
C5147672,Insulin^5M post dose glucose,glucose,Insulin^5M post dose glucose,
C5147673,Insulin^5M post dose glucose IV,glucose,Insulin^5M post dose glucose IV,
C5147675,Insulin^5M pre dose glucose,glucose,Insulin^5M pre dose glucose,
C5147681,Insulin^6H post 75 g glucose PO,glucose,Insulin^6H post 75 g glucose PO,
C5147689,Insulin^7H post 75 g glucose PO,glucose,Insulin^7H post 75 g glucose PO,
C5147691,Insulin^7M post dose glucose IV,glucose,Insulin^7M post dose glucose IV,
C5147692,Insulin^7M pre dose glucose,glucose,Insulin^7M pre dose glucose,
C5147704,Insulin^pre 100 g glucose PO,glucose,Insulin^pre 100 g glucose PO,
C5147705,Insulin^pre 75 g glucose PO,glucose,Insulin^pre 75 g glucose PO,
C5147707,Insulin^pre dose glucose,glucose,Insulin^pre dose glucose,
C5147709,Insulin^pre or post dose glucose,glucose,Insulin^pre or post dose glucose,
C5147816,Ketones^1H post 50 g glucose PO,glucose,Ketones^1H post 50 g glucose PO,
C5147817,Ketones^1H post dose glucose,glucose,Ketones^1H post dose glucose,
C5147820,Ketones^2H post dose glucose,glucose,Ketones^2H post dose glucose,
C5147824,Ketones^3H post dose glucose,glucose,Ketones^3H post dose glucose,
C5147825,Ketones^4H post dose glucose,glucose,Ketones^4H post dose glucose,
C5148881,Sodium^^corrected for glucose,glucose,Sodium^^corrected for glucose,
C5148886,Somatotropin^1.5H post 1 g/kg glucose PO,glucose,Somatotropin^1.5H post 1 g/kg glucose PO,
C5148891,Somatotropin^1.5H post dose glucose,glucose,Somatotropin^1.5H post dose glucose,
C5148892,Somatotropin^1.5H post dose glucose PO,glucose,Somatotropin^1.5H post dose glucose PO,
C5148952,Somatotropin^1H post 1 g/kg glucose PO,glucose,Somatotropin^1H post 1 g/kg glucose PO,
C5148958,Somatotropin^1H post dose glucose,glucose,Somatotropin^1H post dose glucose,
C5148959,Somatotropin^1H post dose glucose PO,glucose,Somatotropin^1H post dose glucose PO,
C5148998,Somatotropin^2H post 1 g/kg glucose PO,glucose,Somatotropin^2H post 1 g/kg glucose PO,
C5149004,Somatotropin^2H post dose glucose,glucose,Somatotropin^2H post dose glucose,
C5149005,Somatotropin^2H post dose glucose PO,glucose,Somatotropin^2H post dose glucose PO,
C5149025,Somatotropin^30M post dose glucose,glucose,Somatotropin^30M post dose glucose,
C5149026,Somatotropin^30M post dose glucose PO,glucose,Somatotropin^30M post dose glucose PO,
C5149035,Somatotropin^30M pre 1 g/kg glucose PO,glucose,Somatotropin^30M pre 1 g/kg glucose PO,
C5149050,Somatotropin^3H post 1 g/kg glucose PO,glucose,Somatotropin^3H post 1 g/kg glucose PO,
C5149054,Somatotropin^3H post dose glucose PO,glucose,Somatotropin^3H post dose glucose PO,
C5149118,Somatotropin^pre 1 g/kg glucose PO,glucose,Somatotropin^pre 1 g/kg glucose PO,
C5149125,Somatotropin^pre dose glucose PO,glucose,Somatotropin^pre dose glucose PO,
C5149135,Somatotropin^pre or post dose glucose,glucose,Somatotropin^pre or post dose glucose,
C5154934,Bg^a Ab &#x7C; Serum or Plasma &#x7C; Blood bank,BG,,
C5154935,Bg^a Ag &#x7C; Red Blood Cells &#x7C; Blood bank,BG,,
C5154936,Bg^b Ag &#x7C; Red Blood Cells &#x7C; Blood bank,BG,,
C5154937,Bg^c Ag &#x7C; Red Blood Cells &#x7C; Blood bank,BG,,
C5163917,Estimated average glucose &#x7C; Blood &#x7C; Chemistry - non-challenge,glucose,,
C5165726,Glucose &#x7C; Amniotic fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165727,Glucose &#x7C; Blood &#x7C; Chemistry - challenge,glucose,,
C5165728,Glucose &#x7C; Blood &#x7C; Chemistry - non-challenge,glucose,,
C5165729,Glucose &#x7C; Blood arterial &#x7C; Chemistry - non-challenge,glucose,,
C5165730,Glucose &#x7C; Blood capillary &#x7C; Chemistry - challenge,glucose,,
C5165731,Glucose &#x7C; Blood capillary &#x7C; Chemistry - non-challenge,glucose,,
C5165732,Glucose &#x7C; Blood cord &#x7C; Chemistry - non-challenge,glucose,,
C5165733,Glucose &#x7C; Blood venous &#x7C; Chemistry - challenge,glucose,,
C5165734,Glucose &#x7C; Blood venous &#x7C; Chemistry - non-challenge,glucose,,
C5165735,Glucose &#x7C; Body fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165736,Glucose &#x7C; Cerebral spinal fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165737,Glucose &#x7C; Dialysis fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165738,Glucose &#x7C; Dialysis fluid peritoneal &#x7C; Chemistry - challenge,glucose,,
C5165739,Glucose &#x7C; Dialysis fluid peritoneal &#x7C; Chemistry - non-challenge,glucose,,
C5165740,Glucose &#x7C; Gastric fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165741,Glucose &#x7C; Milk &#x7C; Chemistry - challenge,glucose,,
C5165742,Glucose &#x7C; Nonbiological fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165743,Glucose &#x7C; Pericardial fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165744,Glucose &#x7C; Peritoneal fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165745,Glucose &#x7C; Plasma &#x7C; Chemistry - challenge,glucose,,
C5165746,Glucose &#x7C; Pleural fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165747,Glucose &#x7C; Serum &#x7C; Chemistry - challenge,glucose,,
C5165748,Glucose &#x7C; Serum or Plasma &#x7C; Chemistry - challenge,glucose,,
C5165749,Glucose &#x7C; Serum or Plasma &#x7C; Chemistry - non-challenge,glucose,,
C5165750,"Glucose &#x7C; Serum, Plasma or Blood &#x7C; Chemistry - challenge",glucose,,
C5165751,"Glucose &#x7C; Serum, Plasma or Blood &#x7C; Chemistry - non-challenge",glucose,,
C5165752,Glucose &#x7C; Stool &#x7C; Chemistry - non-challenge,glucose,,
C5165753,Glucose &#x7C; Synovial fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165754,Glucose &#x7C; Total parental nutrition &#x7C; Chemistry - non-challenge,glucose,,
C5165755,Glucose &#x7C; Urine &#x7C; Chemistry - challenge,glucose,,
C5165756,Glucose &#x7C; Urine &#x7C; Chemistry - non-challenge,glucose,,
C5165757,Glucose &#x7C; Urine &#x7C; Urinalysis,glucose,,
C5165758,Glucose &#x7C; Vitreous fluid &#x7C; Chemistry - non-challenge,glucose,,
C5165759,Glucose &#x7C; Water &#x7C; Chemistry - non-challenge,glucose,,
C5165760,Glucose &#x7C; XXX &#x7C; Chemistry - non-challenge,glucose,,
C5165761,Glucose and lactose and lactulose and XXX challenge panel &#x7C; Exhaled gas &#x7C; Chemistry Panels,glucose,,
C5165762,Glucose challenge (hydrogen breath test) panel &#x7C; Exhaled gas &#x7C; Challenge Bank Panels,glucose,,
C5165763,Glucose challenge &#x7C; Exhaled gas &#x7C; Chemistry - challenge,glucose,,
C5165764,"Glucose meter to reference method correlation &#x7C; Serum, Plasma or Blood &#x7C; Chemistry - non-challenge",glucose,,
C5165765,Glucose phosphate isomerase &#x7C; Red Blood Cells &#x7C; Chemistry - non-challenge,glucose,,
C5165766,Glucose phosphate isomerase &#x7C; Serum &#x7C; Chemistry - non-challenge,glucose,,
C5165767,Glucose screen gestational panel &#x7C; Urine and Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5165768,Glucose tetrasaccharide/Creatinine &#x7C; Urine &#x7C; Chemistry - non-challenge,glucose,,
C5165769,Glucose tolerance &#x7C; Serum or Plasma &#x7C; Chemistry - challenge,glucose,,
C5165770,Glucose tolerance 2 hours gestational panel &#x7C; Serum or Plasma &#x7C; Chemistry Panels,glucose,,
C5165771,Glucose tolerance 2 hours gestational panel &#x7C; Urine and Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5165772,Glucose tolerance 2 hours panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5165773,Glucose tolerance 3 hours gestational panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5165774,Glucose tolerance 3 hours panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5165775,Glucose tolerance 4 hours panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5165776,Glucose tolerance 5 hours panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5165777,Glucose tolerance 6 hours panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5165778,Glucose tolerance gestational panel &#x7C; Urine and Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5165779,Glucose.IV &#x7C; Dose &#x7C; Drug doses,glucose,,
C5165780,Glucose.PO &#x7C; Dose &#x7C; Drug doses,glucose,,
C5165781,Glucose.protein bound &#x7C; Serum or Plasma &#x7C; Chemistry - non-challenge,glucose,,
C5165782,Glucose/Creatinine &#x7C; Urine &#x7C; Chemistry - non-challenge,glucose,,
C5165783,Glucose/Insulin &#x7C; Serum or Plasma &#x7C; Chemistry - non-challenge,glucose,,
C5165784,Glucose-6-Phosphatase &#x7C; Red Blood Cells &#x7C; Chemistry - non-challenge,glucose,,
C5165785,Glucose-6-Phosphatase &#x7C; Serum &#x7C; Chemistry - non-challenge,glucose,,
C5165786,Glucose-6-Phosphatase &#x7C; Tissue and Smears &#x7C; Chemistry - non-challenge,glucose,,
C5165787,Glucose-6-Phosphate dehydrogenase &#x7C; Blood &#x7C; Chemistry - non-challenge,glucose,,
C5165788,Glucose-6-Phosphate dehydrogenase &#x7C; DBS &#x7C; Chemistry - non-challenge,glucose,,
C5165789,Glucose-6-Phosphate dehydrogenase &#x7C; Red Blood Cells &#x7C; Chemistry - non-challenge,glucose,,
C5165790,Glucose-6-Phosphate dehydrogenase &#x7C; Serum &#x7C; Chemistry - non-challenge,glucose,,
C5165791,Glucose-6-Phosphate dehydrogenase &#x7C; Tissue and Smears &#x7C; Chemistry - non-challenge,glucose,,
C5165792,Glucose-6-Phosphate dehydrogenase &#x7C; White blood cells &#x7C; Chemistry - non-challenge,glucose,,
C5165793,Glucose-6-Phosphate dehydrogenase newborn screen panel &#x7C; DBS &#x7C; Chemistry Panels,glucose,,
C5165794,Glucose-6-Phosphate dehydrogenase newborn screening comment/discussion &#x7C; DBS &#x7C; Chemistry - non-challenge,glucose,,
C5165795,Glucose-6-Phosphate dehydrogenase phenotype &#x7C; Red Blood Cells &#x7C; Chemistry - non-challenge,glucose,,
C5165796,Glucose-6-Phosphate dehydrogenase/Pyruvate kinase &#x7C; Blood &#x7C; Chemistry - non-challenge,glucose,,
C5166140,Growth hormone and glucose post cloNIDine stimulation panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5178487,Protein and Glucose panel &#x7C; Body fluid &#x7C; Chemistry Panels,glucose,,
C5178488,Protein and Glucose panel &#x7C; Cerebral spinal fluid &#x7C; Chemistry Panels,glucose,,
C5178489,Protein and Glucose panel &#x7C; Urine &#x7C; Chemistry Panels,glucose,,
C5178885,Pyruvate kinase/Glucose-6-Phosphate dehydrogenase &#x7C; Red Blood Cells &#x7C; Chemistry - non-challenge,glucose,,
C5184613,Uridine diphosphate glucose-4-Epimerase &#x7C; Plasma &#x7C; Chemistry - non-challenge,glucose,,
C5184614,Uridine diphosphate glucose-4-Epimerase &#x7C; Red Blood Cells &#x7C; Chemistry - non-challenge,glucose,,
C5184959,Vendor device name &#x7C; Glucose meter device &#x7C; Devices,glucose,,
C5184990,Vendor serial number &#x7C; Glucose meter device &#x7C; Devices,glucose,,
C5185004,Vendor software version &#x7C; Glucose meter device &#x7C; Devices,glucose,,
C5186278,Glucose meter device panel &#x7C; Patient &#x7C; Panel.devices,glucose,,
C5186379,HEDIS 2014 Value Set - Glucose Tests &#x7C; Patient &#x7C; HEDIS panels,glucose,,
C5186409,HEDIS 2015-2018 Value Set - Glucose Tests &#x7C; Patient &#x7C; HEDIS panels,glucose,,
C5186435,HEDIS 2019-2020 Value Set - Glucose Tests &#x7C; Patient &#x7C; HEDIS panels,glucose,,
C5187255,C peptide^2.5H post dose glucose,glucose,C peptide^2.5H post dose glucose,
C5187289,Somatotropin^30M post 1 g/kg glucose PO,glucose,Somatotropin^30M post 1 g/kg glucose PO,
C5187394,Glucose^10M post XXX challenge,glucose,Glucose^10M post XXX challenge,
C5187395,Glucose^15M post dose insulin IV,glucose,Glucose^15M post dose insulin IV,
C5187396,Glucose^1D post XXX challenge,glucose,Glucose^1D post XXX challenge,
C5187397,Glucose^2.5H post dose fructose PO,glucose,Glucose^2.5H post dose fructose PO,
C5187398,Glucose^2H post 75 g glucose PO,glucose,Glucose^2H post 75 g glucose PO,
C5187399,Glucose^3 AM specimen,glucose,Glucose^3 AM specimen,
C5187400,Glucose^3H post 100 g glucose PO,glucose,Glucose^3H post 100 g glucose PO,
C5187401,Glucose^45M post dose insulin IV,glucose,Glucose^45M post dose insulin IV,
C5187402,Glucose^4th tube,glucose,Glucose^4th tube,
C5187403,Glucose^7 AM specimen,glucose,Glucose^7 AM specimen,
C5187404,Glucose^8th specimen post XXX challenge,glucose,Glucose^8th specimen post XXX challenge,
C5187405,Glucose^post 8H CFst,glucose,Glucose^post 8H CFst,
C5187406,Glucose^pre dose lactose PO,glucose,Glucose^pre dose lactose PO,
C5187415,Insulin^1M post dose glucose,glucose,Insulin^1M post dose glucose,
C5187417,Insulin^4.5H post 75 g glucose PO,glucose,Insulin^4.5H post 75 g glucose PO,
C5187434,TRUE METRIX (GLUCOSE) METER,glucose,TRUE METRIX (GLUCOSE) METER,
C5187892,glucose 15 g/32 mL oral gel,glucose,,
C5188028,"Trueplus Glucose Gel, 15 g/32 mL oral gel",glucose,,
C5190597,"Primary microcephaly, mild intellectual disability, young-onset diabetes syndrome",diabetes,"Primary microcephaly-mild intellectual disability-young-onset diabetes syndrome; Primary microcephaly, mild intellectual disability, young-onset diabetes syndrome (disorder)",
C5190632,"Primary microcephaly, epilepsy, permanent neonatal diabetes syndrome",diabetes,"Primary microcephaly, epilepsy, permanent neonatal diabetes syndrome (disorder); Primary microcephaly-epilepsy-permanent neonatal diabetes syndrome",
C5190885,Hyperimmunoglobulin M syndrome with susceptibility to opportunistic infection,hyper,Hyperimmunoglobulin M syndrome with susceptibility to opportunistic infection (disorder); Hyper-IgM syndrome with susceptibility to opportunistic infections; HIGM with susceptibility to opportunistic infections,
C5190886,Hyperimmunoglobulin M syndrome without susceptibility to opportunistic infection,hyper,Hyper-IgM syndrome without susceptibility to opportunistic infections; HIGM without susceptibility to opportunistic infections; Hyperimmunoglobulin M syndrome without susceptibility to opportunistic infection (disorder),
C5191051,Myopathy and diabetes mellitus,diabetes,Myopathy and diabetes mellitus (disorder); Myopathy and diabetes mellitus,
C5191059,Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency,hypoglycemia,"Hyperinsulinemic hypoglycemia due to SUR1 deficiency, diazoxide-resistant focal form; Diazoxide-resistant focal hyperinsulinism due to sulfonylurea receptor 1 deficiency; Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency; Hyperinsulinemic hypoglycaemia due to SUR1 deficiency, diazoxide-resistant focal form; Diazoxide-resistant focal hyperinsulinism due to sulfonylurea receptor 1 deficiency (disorder)",
C5191060,Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency,hypoglycemia,"Hyperinsulinemic hypoglycemia due to Kir6.2 deficiency, diazoxide-resistant focal form; Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency; Hyperinsulinemic hypoglycaemia due to Kir6.2 deficiency, diazoxide-resistant focal form; Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency (disorder)",
C5191077,Autosomal recessive hyperinsulinism due to SUR1 deficiency,hypoglycemia,Autosomal recessive hyperinsulinism due to SUR1 deficiency; Autosomal recessive hyperinsulinemic hypoglycaemia due to SUR1 deficiency; Autosomal recessive hyperinsulinism due to sulfonylurea receptor 1 deficiency; Autosomal recessive hyperinsulinemic hypoglycemia due to SUR1 deficiency; Autosomal recessive hyperinsulinism due to sulfonylurea receptor 1 deficiency (disorder),
C5191078,Autosomal recessive hyperinsulinism due to Kir6.2 deficiency,hypoglycemia,Autosomal recessive hyperinsulinism due to Kir6.2 deficiency (disorder); Autosomal recessive hyperinsulinism due to Kir6.2 deficiency; Autosomal recessive hyperinsulinemic hypoglycaemia due to Kir6.2 deficiency; Autosomal recessive hyperinsulinemic hypoglycemia due to Kir6.2 deficiency,
C5192324,Glucose 100 mg/mL and sodium chloride 1.8 mg/mL solution for injection,glucose,Product containing precisely glucose 100 milligram/1 milliliter and sodium chloride 1.8 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5192325,Glucose 40 mg/mL and sodium chloride 1.8 mg/mL solution for injection,glucose,Product containing precisely glucose 40 milligram/1 milliliter and sodium chloride 1.8 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5192326,Glucose 50 mg/mL and sodium chloride 1.8 mg/mL solution for injection,glucose,Product containing precisely glucose 50 milligram/1 milliliter and sodium chloride 1.8 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5193141,"HYPER-IgE RECURRENT INFECTION SYNDROME 4B, AUTOSOMAL RECESSIVE",hyper,"HIES4B; HYPER-IgE RECURRENT INFECTION SYNDROME 4B, AUTOSOMAL RECESSIVE",
C5194338,Transient neonatal diabetes mellitus (TNDM),diabetes,,
C5194339,Late predisposition to type 2 (insulin resistant) diabetes,diabetes,,
C5195064,Hypo- and hyperpigmented macules,hypo,,
C5195065,Reticular hypo- and hyperpigmentation of distal extremities,hypo,,
C5195213,Increased risk of type 2 diabetes,diabetes,,
C5195795,Glucocard Shine Connex Blood Glucose Meter,blood glucose,,
C5195796,Glucocard Shine Express Blood Glucose Meter,blood glucose,,
C5197368,"GFOD1 protein, human",glucose,"glucose-fructose oxidoreductase domain containing 1 protein, human",
C5197386,"Slc2a6 protein, mouse",glucose,"solute carrier family 2 (facilitated glucose transporter), member 6 protein, mouse",
C5197769,Diabulimia,diabetes,Eating Disorder Diabetes Mellitus Type 1,
C5198007,"UDP-2,6-dideoxy 2-acetamido 4-keto glucose",glucose,,
C5198309,arginyl-fructosyl-glucose,glucose,,
C5202852,Continuous Glucose Monitoring System,glucose,CGM; Continuous Glucose Monitoring System; Continuous Glucose Monitoring,
C5203239,Sensory polyneuropathy due to diabetes mellitus,diabetes,Sensory polyneuropathy due to diabetes mellitus; Diabetic sensory polyneuropathy; Sensory polyneuropathy due to diabetes mellitus (disorder),
C5203922,Did the Physician Diagnose Diabetes,diabetes,,
C5205102,Physician Diagnosed Diabetes Present,diabetes,,
C5205103,Physician Diagnosed Diabetes Unknown,diabetes,,
C5205104,Physician Diagnosed Diabetes Absent,diabetes,,
C5205736,CDISC Diabetes Therapeutic Area User Guide Version 1.0 - Supplement for ADaM,diabetes,,
C5205978,Diabetes Distress Scale for Adults with Type 1 Diabetes Questionnaire,diabetes,T1-DDS,
C5206025,T1-DDS - Not Skilled at Managing Diabetes,diabetes,,
C5206027,T1-DDS - Don't Notice Signs of Hypoglycemia,hypoglycemia,,
C5206029,T1-DDS - Discouraged See High Blood Glucose,blood glucose,,
C5206030,T1-DDS - Family Make Bigger Deal Diabetes,diabetes,,
C5206033,T1-DDS - Too Much Diabetes Equipment With Me,diabetes,,
C5206034,T1-DDS - Have to Hide My Diabetes,diabetes,,
C5206035,T1-DDS - Family Worry About Hypoglycemia,hypoglycemia,,
C5206036,T1-DDS - Don't Check Glucose as I Should,glucose,,
C5206044,T1-DDS - Family Act Like Diabetes Police,diabetes,,
C5206045,T1-DDS - Be Perfect With Diabetes Management,diabetes,,
C5206051,T1-DDS - Don't Give Diabetes Attention,diabetes,,
C5206055,T1-DDS - Subscale 3: Hypoglycemia Distress,hypoglycemia,,
C5207205,One Touch Ultra2 Syst 024-046 blood glucose m,blood glucose,,
C5208642,Autosomal Dominant Hyper IgE Syndrome Gene Anomaly Detection Reagents,hyper,,
C5208643,Autosomal Dominant Hyper-IgE Recurrent Infection Syndrome Gene Anomaly Detection Reagents,hyper,,
C5208645,Hyper IgE Syndrome Gene Anomaly Detection Reagents,hyper,,
C5209100,Blood-Brain Barrier Glucose Transport Defect Gene Anomaly Detection Reagents,glucose,,
C5209101,Glucose-6-Phosphate Transport Defect Gene Anomaly Detection Reagents,glucose,,
C5210336,alanine / arginine / calcium chloride / dibasic potassium phosphate / glucose / glycine / histidine / isoleucine / leucine / lysine / magnesium chloride / methionine / phenylalanine / proline / serine / sodium acetate / sodium chloride / threonine / tryptophan / tyrosine / valine Injectable Product,glucose,,
C5210444,ReliOn Premier Blood Glucose Test Strips,blood glucose,,
C5210963,100 ML glucose 100 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 10 g in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 10% Dextrose]_#1; dextrose 10 % in 100 ML Injection",
C5211378,"Are you feeling bothered, upset, or worried at this point in your pregnancy about the effect of ongoing health problems such as high blood pressure or diabetes on your pregnancy:Find:Pt:^Patient:Ord:NuPDQ",diabetes,"Are you feeling bothered, upset, or worried at this point in your pregnancy about the effect of ongoing health problems such as high blood pressure or diabetes on your pregnancy:Finding:To identify measures at a point in time:^Patient:Ordinal:NuPDQ; Are you feeling bothered, upset, or worried at this point in your pregnancy about the effect of ongoing health problems such as high blood pressure or diabetes on your pregnancy [NuPDQ]",
C5211379,"Are you feeling bothered, upset, or worried at this point in your pregnancy about the effect of ongoing health problems such as high blood pressure or diabetes on your pregnancy",diabetes,"Are you feeling bothered, upset, or worried at this point in your pregnancy about the effect of ongoing health problems such as high blood pressure or diabetes on your pregnancy",
C5212330,Glucose:MCnc:Stdy^mean:Ser/Plas:Qn,glucose,Glucose:Mass Concentration:Duration of the study^Mean of all of the values observed on the interval:Serum/Plasma:Quantitative; Glucose [Mass/volume] mean in Serum or Plasma; Glucose (Stdy mean) [Mass/Vol]; Glucose Mean SerPl-mCnc,
C5212334,Glucose tolerance & insulin sensitivity 2H panel:-:-:Ser/Plas:-,glucose,Glucose tolerance and insulin sensitivity 2 hour panel; Glucose tolerance & insulin sensitivity 2H panel:-:-:Ser/Plas:-; Glucose tolerance & insulin sensitivity 2H panel:-:-:Serum/Plasma:-; GTT ISI 2h Pnl SerPl; Glucose tolerance and insulin sensitivity 2 hour panel - Serum or Plasma,
C5212335,Glucose tolerance & insulin sensitivity 2H panel,glucose,Glucose tolerance and insulin sensitivity 2 hour panel; Glucose tolerance & insulin sensitivity 2H panel,
C5213240,Diabetes Type I action plan &#x7C; {Setting} &#x7C; Document ontology,diabetes,,
C5213241,Diabetes Type II action plan &#x7C; {Setting} &#x7C; Document ontology,diabetes,,
C5213443,Glucose &#x7C; Blood &#x7C; Chemistry - routine challenge,glucose,,
C5213444,Glucose &#x7C; Serum or Plasma &#x7C; Chemistry - routine challenge,glucose,,
C5213445,Glucose tolerance and insulin sensitivity 2 hour panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5214259,VA C and P exam.diabetes mellitus &#x7C; {Setting} &#x7C; Document ontology,diabetes,,
C5215330,Glucose phosphate isomerase&#x7C;CCnc&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5215331,Glucose tolerance&#x7C;Imp&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5215332,Glucose^2H post meal&#x7C;SCnc&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5215333,Glucose^6H post 100 g glucose PO&#x7C;MCnc&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5215334,Glucose^7 AM specimen&#x7C;SCnc&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5215335,Glucose^baseline&#x7C;MCnc&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5215336,Glucose^post CFst&#x7C;MCnc&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5215337,Glucose^post CFst&#x7C;PrThr&#x7C;Pt&#x7C;ANYUrine,glucose,,
C5215338,Glucose^post CFst&#x7C;SCnc&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5215339,Glucose&#x7C;MCnc&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5215340,Glucose&#x7C;MCnc&#x7C;Pt&#x7C;Stool,glucose,,
C5215341,Glucose&#x7C;SCnc&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5215342,Glucose-6-Phosphate dehydrogenase phenotype&#x7C;Imp&#x7C;Pt&#x7C;RBC,glucose,,
C5215343,Glucose-6-Phosphate dehydrogenase&#x7C;CCnt&#x7C;Pt&#x7C;RBC,glucose,,
C5215446,Insulin^1.5H post 75 g glucose PO&#x7C;ACnc&#x7C;Pt&#x7C;ANYBldSerPl,glucose,,
C5216742,C peptide^1.5H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216749,C peptide^15M post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216752,C peptide^1H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216755,C peptide^2.5H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216756,C peptide^2H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216760,C peptide^3.5H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216761,C peptide^30M post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216763,C peptide^3H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216766,C peptide^4.5H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216767,C peptide^45M post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216769,C peptide^4H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216772,C peptide^5H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5216782,C peptide^pre dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217002,Corticotropin^1.5H post dose glucose&#x7C;Pt&#x7C;Plas,glucose,,
C5217021,Corticotropin^1H post dose glucose&#x7C;Pt&#x7C;Plas,glucose,,
C5217027,Corticotropin^2.5H post dose glucose&#x7C;Pt&#x7C;Plas,glucose,,
C5217036,Corticotropin^30M post dose glucose&#x7C;Pt&#x7C;Plas,glucose,,
C5217043,Corticotropin^3H post dose glucose&#x7C;Pt&#x7C;Plas,glucose,,
C5217066,Corticotropin^pre dose glucose&#x7C;Pt&#x7C;Plas,glucose,,
C5217325,Estimated average glucose&#x7C;Pt&#x7C;Bld&#x7C;Estimated from glycated hemoglobin,glucose,,
C5217434,Glucose^1.5H post 50 g lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217435,Glucose^1.5H post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217436,Glucose^1.5H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217437,Glucose^1.5H post dose insulin IV&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217438,Glucose^1.5H post dose lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217439,Glucose^1.5H post meal&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217440,Glucose^1.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217441,Glucose^10.75H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217442,Glucose^10H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217443,Glucose^10M post dose glucagon&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217444,Glucose^10M post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217445,Glucose^10M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217446,Glucose^10M pre XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217447,Glucose^10th specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217448,Glucose^11 AM specimen&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217449,Glucose^11.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217450,Glucose^11H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217451,Glucose^11th specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217452,Glucose^12 AM specimen&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217453,Glucose^12 PM specimen&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217454,Glucose^12.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217455,Glucose^12H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217456,Glucose^12M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217457,Glucose^12th specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217458,Glucose^13.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217459,Glucose^13H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217460,Glucose^14H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217461,Glucose^14M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217462,Glucose^15.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217463,Glucose^15M post 50 g lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217464,Glucose^15M post dose lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217465,Glucose^15M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217466,Glucose^15M pre XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217467,Glucose^16H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217468,Glucose^16M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217469,Glucose^17.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217470,Glucose^18.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217471,Glucose^18H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217472,Glucose^19.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217473,Glucose^19M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217474,Glucose^1D post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217475,Glucose^1H post 100 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217476,Glucose^1H post 50 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217477,Glucose^1H post 50 g lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217478,Glucose^1H post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217479,Glucose^1H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217480,Glucose^1H post dose insulin IV&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217481,Glucose^1H post dose lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217482,Glucose^1H post meal&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217483,Glucose^1H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217484,Glucose^1st specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217485,Glucose^2.5H post 50 g lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217486,Glucose^2.5H post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217487,Glucose^2.5H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217488,Glucose^2.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217489,Glucose^20.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217490,Glucose^20H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217491,Glucose^20M post 50 g lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217492,Glucose^20M post dose glucagon&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217493,Glucose^20M post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217494,Glucose^20M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217495,Glucose^20M pre XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217496,Glucose^21.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217497,Glucose^22M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217498,Glucose^23.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217499,Glucose^25H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217500,Glucose^25M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217501,Glucose^26H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217502,Glucose^27H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217503,Glucose^27M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217504,Glucose^28H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217505,Glucose^29H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217506,Glucose^2D post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217507,Glucose^2H dwell specimen&#x7C;Pt&#x7C;Dial fld prt,glucose,,
C5217508,Glucose^2H post 100 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217509,Glucose^2H post 50 g lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217510,Glucose^2H post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217511,Glucose^2H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217512,Glucose^2H post dose lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217513,Glucose^2H post meal&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217514,Glucose^2H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217515,Glucose^2H specimen&#x7C;Pt&#x7C;Dial fld,glucose,,
C5217516,Glucose^2M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217517,Glucose^2nd specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217518,Glucose^3 PM specimen&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217519,Glucose^3.5H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217520,Glucose^3.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217521,Glucose^30H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217522,Glucose^30M post 50 g lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217523,Glucose^30M post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217524,Glucose^30M post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217525,Glucose^30M post dose insulin IV&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217526,Glucose^30M post dose lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217527,Glucose^30M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217528,Glucose^30M pre XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217529,Glucose^31H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217530,Glucose^36H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217531,Glucose^3H post 100 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217532,Glucose^3H post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217533,Glucose^3H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217534,Glucose^3H post dose lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217535,Glucose^3H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217536,Glucose^3M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217537,Glucose^3M pre XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217538,Glucose^3rd specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217539,Glucose^4 PM specimen&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217540,Glucose^4.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217541,Glucose^40M post 50 g lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217542,Glucose^40M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217543,Glucose^45M post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217544,Glucose^45M post dose insulin IV&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217545,Glucose^45M post dose lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217546,Glucose^45M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217547,Glucose^4H dwell specimen&#x7C;Pt&#x7C;Dial fld prt,glucose,,
C5217548,Glucose^4H post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217549,Glucose^4H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217550,Glucose^4H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217551,Glucose^4H specimen&#x7C;Pt&#x7C;Dial fld,glucose,,
C5217552,Glucose^4M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217553,Glucose^4th specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217554,Glucose^5.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217555,Glucose^50M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217556,Glucose^5H post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217557,Glucose^5H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217558,Glucose^5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217559,Glucose^5M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217560,Glucose^5M pre XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217561,Glucose^5th specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217562,Glucose^6.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217563,Glucose^6H post dose glucose&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217564,Glucose^6H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217565,Glucose^6th specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217566,Glucose^7.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217567,Glucose^70M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217568,Glucose^75M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217569,Glucose^7H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217570,Glucose^8 AM specimen&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217571,Glucose^8 PM specimen&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217572,Glucose^8.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217573,Glucose^8H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217574,Glucose^8M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217575,Glucose^8th specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217576,Glucose^9.5H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217577,Glucose^9H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217578,Glucose^9M post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217579,Glucose^9th specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217580,Glucose^baseline&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217581,Glucose^post CFst&#x7C;Pt&#x7C;BldC&#x7C;Glucometer,glucose,,
C5217582,Glucose^post CFst&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217583,Glucose^post CFst&#x7C;Pt&#x7C;Urine,glucose,,
C5217584,Glucose^post meal&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217585,Glucose^post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217586,Glucose^pre 100 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217587,Glucose^pre 12H CFst&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217588,Glucose^pre 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217589,Glucose^pre dose insulin IV&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217590,Glucose^pre dose lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217591,Glucose^pre XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217592,Glucose^pre-meal&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217593,Glucose&#x7C;24H&#x7C;Urine&#x7C;180.156 g/mole,glucose,,
C5217594,Glucose&#x7C;Pt&#x7C;Bld&#x7C;180.156 g/mole,glucose,,
C5217595,Glucose&#x7C;Pt&#x7C;Bld&#x7C;Test strip.automated&#x7C;180.156 g/mole,glucose,,
C5217596,Glucose&#x7C;Pt&#x7C;BldA&#x7C;180.156 g/mole,glucose,,
C5217597,Glucose&#x7C;Pt&#x7C;BldC&#x7C;180.156 g/mole,glucose,,
C5217598,Glucose&#x7C;Pt&#x7C;BldC&#x7C;Glucometer&#x7C;180.156 g/mole,glucose,,
C5217599,Glucose&#x7C;Pt&#x7C;BldV&#x7C;180.156 g/mole,glucose,,
C5217600,Glucose&#x7C;Pt&#x7C;Body fld&#x7C;180.156 g/mole,glucose,,
C5217601,Glucose&#x7C;Pt&#x7C;CSF&#x7C;180.156 g/mole,glucose,,
C5217602,Glucose&#x7C;Pt&#x7C;Dial fld prt&#x7C;180.156 g/mole,glucose,,
C5217603,Glucose&#x7C;Pt&#x7C;Dial fld&#x7C;180.156 g/mole,glucose,,
C5217604,Glucose&#x7C;Pt&#x7C;Pericard fld&#x7C;180.156 g/mole,glucose,,
C5217605,Glucose&#x7C;Pt&#x7C;Periton fld&#x7C;180.156 g/mole,glucose,,
C5217606,Glucose&#x7C;Pt&#x7C;Plr fld&#x7C;180.156 g/mole,glucose,,
C5217607,Glucose&#x7C;Pt&#x7C;Ser/Plas/Bld&#x7C;180.156 g/mole,glucose,,
C5217608,Glucose&#x7C;Pt&#x7C;Ser/Plas&#x7C;180.156 g/mole,glucose,,
C5217609,Glucose&#x7C;Pt&#x7C;Stool&#x7C;180.156 g/mole,glucose,,
C5217610,Glucose&#x7C;Pt&#x7C;Synv fld&#x7C;180.156 g/mole,glucose,,
C5217611,Glucose&#x7C;Pt&#x7C;Urine&#x7C;180.156 g/mole,glucose,,
C5217612,Glucose&#x7C;Pt&#x7C;Urine&#x7C;Test strip.automated&#x7C;180.156 g/mole,glucose,,
C5217613,Glucose&#x7C;Pt&#x7C;Urine&#x7C;Test strip&#x7C;180.156 g/mole,glucose,,
C5217614,Glucose&#x7C;Pt&#x7C;Vitr fld&#x7C;180.156 g/mole,glucose,,
C5217615,Glucose&#x7C;Pt&#x7C;Water&#x7C;180.156 g/mole,glucose,,
C5217616,Glucose&#x7C;XXX&#x7C;Urine&#x7C;180.156 g/mole,glucose,,
C5217717,Insulin^1H post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217719,Insulin^2H post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5217722,Insulin^3H post 75 g glucose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5219040,Glucose/Creatinine&#x7C;MRto&#x7C;Urine,glucose,,
C5219041,Glucose^post CFst&#x7C;PrThr&#x7C;Urine,glucose,,
C5219042,Glucose&#x7C;MCnc&#x7C;Urine,glucose,,
C5219043,Glucose&#x7C;MRat&#x7C;Urine,glucose,,
C5219044,Glucose&#x7C;PrThr&#x7C;Urine,glucose,,
C5219045,Glucose&#x7C;SCnc&#x7C;Urine,glucose,,
C5219046,Glucose&#x7C;SRat&#x7C;Urine,glucose,,
C5221007,Corticotropin^2H post dose glucose&#x7C;Pt&#x7C;Plas,glucose,,
C5221030,Glucose&#x7C;Urine/Urine sed,glucose,,
C5221046,Glucose^13M pre XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5221076,Glucose^22H post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5221077,Glucose^45M post 50 g lactose PO&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5221078,Glucose^7th specimen post XXX challenge&#x7C;Pt&#x7C;Ser/Plas,glucose,,
C5225758,Pancreatic disorders (excluding diabetes),diabetes,,
C5225824,"Diabetes mellitus, due to underlying condition, drug or chemical induced, or other specified type",diabetes,,
C5226076,"Hspa9 protein, rat",glucose,"Grp75 protein, rat; heat shock protein family A (Hsp70) member 9 protein, rat; glucose-regulated protein 75, rat",
C5228995,"Supplies for maintenance of insulin infusion pump with dosage rate adjustment using therapeutic continuous glucose sensing, per week",glucose,,
C5229023,"External ambulatory infusion pump, insulin, dosage rate adjustment using therapeutic continuous glucose sensing",glucose,,
C5229432,Coronary artery disease due to type 2 diabetes mellitus,diabetes,Coronary artery disease due to type 2 diabetes mellitus (disorder),
C5230569,Neuropathy due to type 1 diabetes mellitus,diabetes,Neuropathy due to type 1 diabetes mellitus (disorder),
C5230580,Ulcer of heel due to diabetes mellitus,diabetes,Ulcer of heel due to diabetes mellitus (disorder),
C5230581,Ulcer of heel due to type 2 diabetes mellitus,diabetes,Ulcer of heel due to type 2 diabetes mellitus (disorder),
C5230582,Ulcer of midfoot due to diabetes mellitus,diabetes,Ulcer of midfoot due to diabetes mellitus (disorder),
C5230583,Neuropathic ulcer of heel due to type 2 diabetes mellitus,diabetes,Neuropathic ulcer of heel due to type 2 diabetes mellitus (disorder),
C5230584,Neuropathic ulcer of midfoot due to type 2 diabetes mellitus,diabetes,Neuropathic ulcer of midfoot due to type 2 diabetes mellitus (disorder),
C5230585,Ulcer of heel due to type 1 diabetes mellitus,diabetes,Ulcer of heel due to type 1 diabetes mellitus (disorder),
C5230586,Ulcer of midfoot due to type 1 diabetes mellitus,diabetes,Ulcer of midfoot due to type 1 diabetes mellitus (disorder),
C5230589,Insulin dose calculated by insulin sensitivity factor,blood sugar,Insulin dose calculated by insulin sensitivity factor (observable entity); Insulin sensitivity factor dose; High blood sugar correction dose,
C5230812,Armanni-Ebstein kidney due to diabetes mellitus,diabetes,Armanni-Ebstein kidney due to diabetes mellitus (disorder),
C5230907,Nonproliferative retinopathy of left eye due to diabetes mellitus,diabetes,Nonproliferative retinopathy of left eye due to diabetes mellitus (disorder),
C5230908,Nonproliferative retinopathy of right eye due to diabetes mellitus,diabetes,Nonproliferative retinopathy of right eye due to diabetes mellitus (disorder),
C5230939,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,diabetes,Stable treated proliferative retinopathy of right eye due to diabetes mellitus (disorder),
C5230940,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,diabetes,Stable treated proliferative retinopathy of left eye due to diabetes mellitus (disorder),
C5231105,Hyperglycemia due to diabetes mellitus,hyperglycemia,Hyperglycemia due to diabetes mellitus (disorder); Hyperglycaemia due to diabetes mellitus,
C5233441,Postprandial reactive hypoglycemia,hypoglycemia,,
C5234159,100 ML glucose 50 MG/ML / sodium chloride 3.3 MG/ML Injection,glucose,"DEXTROSE MONOHYDRATE 5.5 g in 100 mL / SODIUM CHLORIDE 330 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 5% Dextrose in 0.33% Sodium Chloride]_#1; dextrose 5 % / sodium chloride 0.33 % in 100 ML Injection; dextrose 5 % / sodium chloride 0.33 % per 100 ML Injection; DEXTROSE MONOHYDRATE 5.5 g in 100 mL / SODIUM CHLORIDE 900 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary Dextrose and Sodium Chloride]_#1; 100 ML Glucose 50 MG/ML / NaCl 3.3 MG/ML Injection",
C5235039,Decreased glucosephosphate isomerase level,glucose,Glucosephosphate isomerase deficiency; Decreased glucosephosphate isomerase level; Phosphohexose isomerase deficiency; Decreased glucose phosphate isomerase activity,
C5235410,CDISC SDTM Type 1 Diabetes Findings About Test Code Terminology,diabetes,,
C5235411,CDISC SDTM Type 1 Diabetes Findings About Test Name Terminology,diabetes,,
C5235429,CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology,diabetes,,
C5235430,CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology,diabetes,,
C5235439,GMSS Version Type 1 Diabetes Questionnaire Question,diabetes,,
C5235480,Plasma Equivalent Glucose Measurement,glucose measurement,Plasma-Equivalent Glucose Measurement,
C5235481,Plasma Equivalent Glucose Distribution Measurement,glucose,Plasma-Equivalent Glucose Distribution Measurement,
C5235707,The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes Questionnaire,glucose,GMSS Version Type 1 Diabetes,
C5235709,Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes Questionnaire,diabetes,PARENT-DDS,
C5235710,Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes Questionnaire,diabetes,PARTNER-DDS,
C5235733,GMSS Version Type 1 Diabetes - More Satisfied With My Diabetes,diabetes,,
C5235734,GMSS Version Type 1 Diabetes - Think About Diabetes More,diabetes,,
C5235735,GMSS Version Type 1 Diabetes - Takes Too Much Time to Use,diabetes,,
C5235736,GMSS Version Type 1 Diabetes - Doesn't Seem as Accurate,diabetes,,
C5235737,GMSS Version Type 1 Diabetes - Makes Me Worry a Lot,diabetes,,
C5235738,GMSS Version Type 1 Diabetes - Is Too Much of a Hassle to Use,diabetes,,
C5235739,GMSS Version Type 1 Diabetes - Gives Me Numbers I Don't Trust,diabetes,,
C5235740,GMSS Version Type 1 Diabetes - Feel Less Restricted by Diabetes,diabetes,,
C5235741,GMSS Version Type 1 Diabetes - More Frustrated With My Diabetes,diabetes,,
C5235742,GMSS Version Type 1 Diabetes - Be More Spontaneous in My Life,diabetes,,
C5235743,GMSS Version Type 1 Diabetes - Too Many Skin Irritations/Bruises,diabetes,,
C5235744,GMSS Version Type 1 Diabetes - Gives Me Results Don't Make Sense,diabetes,,
C5235745,GMSS Version Type 1 Diabetes - Feel More Down and Depressed,diabetes,,
C5235746,GMSS Version Type 1 Diabetes - More Open to New Experiences,diabetes,,
C5235747,GMSS Version Type 1 Diabetes - Is Too Painful to Use,diabetes,,
C5235748,GMSS Version Type 1 Diabetes - Subscale: Openness,diabetes,,
C5235749,GMSS Version Type 1 Diabetes - Subscale: Emotional Burden,diabetes,,
C5235750,GMSS Version Type 1 Diabetes - Subscale: Behavioral Burden,diabetes,,
C5235751,GMSS Version Type 1 Diabetes - Subscale: Trust,diabetes,,
C5235752,GMSS Version Type 1 Diabetes - Total Scale,diabetes,,
C5235765,PARENT-DDS - Trust Teen Take Care of Diabetes,diabetes,,
C5235766,PARENT-DDS - Low Blood Sugars Away From Home,blood sugars,,
C5235767,PARENT-DDS - Teen Ignore or Forget Diabetes,diabetes,,
C5235770,PARENT-DDS - Low Blood Sugars When Sleeping,blood sugars,,
C5235771,PARENT-DDS - No One Notices Diabetes Hard on Me,diabetes,,
C5235772,PARENT-DDS - Doesn't Do Enough Manage Diabetes,diabetes,,
C5235778,PARENT-DDS - Motivate Teen Take Care Diabetes,diabetes,,
C5235797,PARTNER-DDS - Worry About Low Blood Sugars,blood sugars,,
C5235798,PARTNER-DDS - How Involved Managing Diabetes,diabetes,,
C5235803,PARTNER-DDS - Silent About My Partner's Diabetes,diabetes,,
C5235805,PARTNER-DDS - No One Notices Diabetes Hard On Me,diabetes,,
C5235812,PARTNER-DDS - Diabetes Often Interrupts Plans,diabetes,,
C5235813,PARTNER-DDS - Low Blood Sugars When Sleeping,blood sugars,,
C5235814,PARTNER-DDS - Partner Driving Low Blood Sugars,blood sugars,,
C5235815,PARTNER-DDS - Leaving Alone Low Blood Sugars,blood sugars,,
C5235820,PARTNER-DDS - Partner Diabetes Management: Sum,diabetes,,
C5235821,PARTNER-DDS - Partner Diabetes Management: Mean,diabetes,,
C5235822,PARTNER-DDS - Partner Diabetes Manage: Moderate,diabetes,,
C5235826,PARTNER-DDS - Diabetes and Me: Sum,diabetes,,
C5235827,PARTNER-DDS - Diabetes and Me: Mean,diabetes,,
C5235828,PARTNER-DDS - Diabetes and Me: Moderate,diabetes,,
C5235829,PARTNER-DDS - Hypoglycemia: Sum,hypoglycemia,,
C5235830,PARTNER-DDS - Hypoglycemia: Mean,hypoglycemia,,
C5235831,PARTNER-DDS - Hypoglycemia: Moderate,hypoglycemia,,
C5237214,Non-FDG-Positron Emission Tomography,glucose,Non-Fluoro-2-deoxy-D-glucose- Positron Emission Tomography; Non-FDG-PET,
C5237440,HSP90B1 Protein Variant,glucose,Heat Shock Protein 90 kDa Beta Member 1 Protein Variant; Endoplasmin Protein Variant; Stress-Inducible Tumor Rejection Antigen Gp96 Protein Variant; 94 kDa Glucose-Regulated Protein Variant; Tumor Rejection Antigen 1 Protein Variant; Gp96 Homolog Protein Variant; GRP-94 Protein Variant,
C5239508,HSP90B1 NP_003290.1:p.I66T,glucose,NP_003290.1:p.I66T; Stress-Inducible Tumor Rejection Antigen Gp96 Ile66Thr; GRP-94 Ile66Thr; 94 kDa Glucose-Regulated I66T; Endoplasmin Ile66Thr; HSP90B1 NP_003290.1:p.Ile66Thr; Gp96 Homolog Ile66Thr; Tumor Rejection Antigen 1 Ile66Thr; HSP90B1 Ile66Thr; GRP-94 I66T; Heat Shock Protein 90 kDa Beta Member 1 I66T; Heat Shock Protein 90 kDa Beta Member 1 Ile66Thr; Stress-Inducible Tumor Rejection Antigen Gp96 I66T; Tumor Rejection Antigen 1 I66T; Gp96 Homolog I66T; Endoplasmin I66T; HSP90B1 p.I66T; HSP90B1 p.Ile66Thr; 94 kDa Glucose-Regulated Ile66Thr; NP_003290.1:p.Ile66Thr; HSP90B1 I66T,
C5240557,Glucose post fasting and meal stimulation panel:-:Pt:Ser/Plas:-,glucose,Glucose post fasting and meal stimulation panel:-:To identify measures at a point in time:Serum/Plasma:-; Glucose post fasting and meal stimulation panel - Serum or Plasma; Glucose post fasting and meal stimulation panel:-:Pt:Ser/Plas:-; Glucose p Cfst + meal Pnl SerPl; Glucose post fasting and meal stimulation panel,
C5240558,Glucose post fasting and meal stimulation panel,glucose,Glucose post fasting and meal stimulation panel,
C5241567,ACCU-CHEK GUIDE ME (GLUCOSE) METER,glucose,ACCU-CHEK GUIDE ME (GLUCOSE) METER,
C5245215,diphenhydramine hydrochloride 10 MG/ML Medicated Shampoo,hypo,DIPHENHYDRAMINE HYDROCHLORIDE 10 mg in 1 mL TOPICAL SHAMPOO [GNC PET WELLNESS ULTRA MEDICATED HYPO-ALLERGENIC]; diphenhydrAMINE hydrochloride 10 MG/ML Medicated Shampoo; diphenhydrAMINE HCl 1 % Medicated Shampoo; diphenhydramine HCl 1 % Medicated Shampoo,
C5274872,Acetobacteraceae bacterium Megachile.234.BG.G_2689,BG,,
C5274874,Acetobacteraceae bacterium Carduus.5.BG.F_23866,BG,,
C5277538,Chlamydomonas sp. BG.603,BG,,
C5302808,Simocephalus sp. IMP-BG-Z017,BG,,
C5302809,Simocephalus sp. IMP-BG-Z021,BG,,
C5302810,Simocephalus sp. IMP-BG-Z028,BG,,
C5340412,Ektaphelenchoides sp. 2 BG-2019,BG,,
C5356748,Lobosphaera sp. BG-2019a,BG,,
C5371808,Mecistorhabdia sp. 1 BG-2020,BG,,
C5377379,Chlorella sp. BG.601,BG,,
C5380949,Lipid & glucose panel,glucose,Lipid & glucose panel; Lipid and glucose panel,
C5381614,Glucose^2.5H post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 2.5 Hr post meal [Mass/Vol]; Glucose 2.5h p meal SerPl-mCnc; Glucose^2.5 hours post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --2.5 hours post meal,
C5381615,Glucose^3.5H post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3.5h p meal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --3.5 hours post meal; Glucose 3.5 Hr post meal [Mass/Vol]; Glucose^3.5 hours post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C5381616,Glucose^30M post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30 Min post meal [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --30 min post meal; Glucose^30 minutes post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 30M p meal SerPl-mCnc,
C5381617,Glucose^4.5H post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 4.5h p meal SerPl-mCnc; Glucose 4.5 Hr post meal [Mass/Vol]; Glucose^4.5 hours post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --4.5 hours post meal,
C5381618,Glucose^4H post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --4 hours post meal; Glucose 4h p meal SerPl-mCnc; Glucose 4 Hr post meal [Mass/Vol]; Glucose^4 hours post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C5381619,Glucose^5H post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 5h p meal SerPl-mCnc; Glucose 5 Hr post meal [Mass/Vol]; Glucose^5 hours post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --5 hours post meal,
C5381634,Lipid & glucose panel:-:Pt:Ser/Plas:Qn,glucose,Lipid & glucose Pnl SerPl; Lipid & glucose panel:-:Pt:Ser/Plas:Qn; Lipid and glucose panel; Lipid and glucose panel - Serum or Plasma; Lipid & glucose panel:-:To identify measures at a point in time:Serum/Plasma:Quantitative,
C5381795,Glucose^15M post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 15M p meal SerPl-mCnc; Glucose [Mass/volume] in Serum or Plasma --15 min post meal; Glucose 15 Min post meal [Mass/Vol]; Glucose^15 minutes post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C5381797,Glucose^3H post meal:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 3h p meal SerPl-mCnc; Glucose 3 Hr post meal [Mass/Vol]; Glucose^3 hours post meal:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --3 hours post meal,
C5382102,Diabetes risk:Score:Pt:^Patient:Qn:Calculated,diabetes,Diabetes risk:Score:To identify measures at a point in time:^Patient:Quantitative:Calculated; Diabetes risk [Score] Calculated; Diabetes risk Score Calc,
C5382598,Glucose^15M post meal,glucose,Glucose^15M post meal,
C5382599,Glucose^2.5H post meal,glucose,Glucose^2.5H post meal,
C5382600,Glucose^3.5H post meal,glucose,Glucose^3.5H post meal,
C5382601,Glucose^30M post meal,glucose,Glucose^30M post meal,
C5382602,Glucose^3H post meal,glucose,Glucose^3H post meal,
C5382603,Glucose^4.5H post meal,glucose,Glucose^4.5H post meal,
C5382604,Glucose^4H post meal,glucose,Glucose^4H post meal,
C5382868,Glucose post fasting and meal stimulation panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5382956,Lipid and glucose panel &#x7C; Serum or Plasma &#x7C; Chemistry Panels,glucose,,
C5383277,Glucose^5H post meal,glucose,Glucose^5H post meal,
C5384217,"2,3 di-o-methyl-d-glucose",glucose,"2,3 DI-O-METHYL-D-GLUCOSE",
C5389835,Glucose transport disorder,glucose,,
C5391599,"UGDH protein, human",glucose,"UDP-glucose 6-dehydrogenase, human; UDP-glucose dehydrogenase, human",
C5391856,"Glk1 protein, S cerevisiae",glucose,"Glk-1 protein, S cerevisiae; glucokinase-1, S cerevisiae; glucose kinase 1, S cerevisiae; YCL040W protein, S cerevisiae",
C5392125,Glycemic Control,blood glucose,"Blood Glucose Control; Control, Glycemic; Glucose Control, Blood; Control, Blood Glucose",
C5393177,"Nonautoimmune diabetes mellitus, juvenile-onset",diabetes,,
C5393570,"DIABETES MELLITUS, PERMANENT NEONATAL, 1",diabetes,"PDMI; DIABETES MELLITUS, PERMANENT NEONATAL, 1; DIABETES MELLITUS, PERMANENT, OF INFANCY; PNDM1",
C5393957,Flat growth hormone response to clonidine or insulin-induced hypoglycemia,hypoglycemia,,
C5394296,"DIABETES MELLITUS, PERMANENT NEONATAL, 2",diabetes,"PNDM2; DIABETES MELLITUS, PERMANENT NEONATAL, 2",
C5394303,"DIABETES MELLITUS, PERMANENT NEONATAL, 3",diabetes,"PNDM3; DIABETES MELLITUS, PERMANENT NEONATAL, 3",
C5394304,"DEVELOPMENTAL DELAY, EPILEPSY, AND NEONATAL DIABETES 2",diabetes,DEND2,
C5394307,"DIABETES MELLITUS, PERMANENT NEONATAL, 4",diabetes,"PNDM4; DIABETES MELLITUS, PERMANENT NEONATAL, 4",
C5394550,"HYPER-IgE RECURRENT INFECTION SYNDROME 5, AUTOSOMAL RECESSIVE",hyper,"HIES5; HYPER-IgE RECURRENT INFECTION SYNDROME 5, AUTOSOMAL RECESSIVE",
C5394566,"DIABETES MELLITUS, PERMANENT NEONATAL, 3, WITH NEUROLOGIC FEATURES",diabetes,,
C5394568,"DIABETES MELLITUS, PERMANENT NEONATAL, 2, WITH NEUROLOGIC FEATURES",diabetes,,
C5394597,"DEVELOPMENTAL DELAY, EPILEPSY, AND NEONATAL DIABETES 1",diabetes,DEND1,
C5395739,Autonomic neuropathy due to medication induced hypoglycemia,hypoglycemia,Hypoglycemia-associated autonomic failure; Hypoglycaemia-associated autonomic failure; Autonomic neuropathy due to medication induced hypoglycemia (disorder); Autonomic neuropathy due to medication induced hypoglycaemia,
C5395835,No retinopathy of right eye due to diabetes mellitus,diabetes,No diabetic retinopathy of right eye; No disorder of retina of right eye due to diabetes mellitus (situation); No disorder of retina of right eye due to diabetes mellitus,
C5395836,No retinopathy of left eye due to diabetes mellitus,diabetes,No diabetic retinopathy of left eye; No disorder of retina of left eye due to diabetes mellitus (situation); No disorder of retina of left eye due to diabetes mellitus,
C5395837,No maculopathy of left eye due to diabetes mellitus,diabetes,No disorder of macula of left eye due to diabetes mellitus; No diabetic maculopathy of left eye; No disorder of macula of left eye due to diabetes mellitus (situation),
C5395838,No maculopathy of right eye due to diabetes mellitus,diabetes,No disorder of macula of right eye due to diabetes mellitus (situation); No diabetic maculopathy of right eye; No disorder of macula of right eye due to diabetes mellitus,
C5395839,No diabetic maculopathy of bilateral eyes,diabetes,No disorder of macula of bilateral eyes due to diabetes mellitus (situation); No disorder of macula of both eyes due to diabetes mellitus; No bilateral maculopathy due to diabetes mellitus; No disorder of macula of bilateral eyes due to diabetes mellitus,
C5395840,Diabetic maculopathy of bilateral eyes present,diabetes,Disorder of macula of bilateral eyes due to diabetes mellitus present; Disorder of macula of both eyes due to diabetes mellitus present; Disorder of macula of bilateral eyes due to diabetes mellitus present (situation); Bilateral maculopathy due to diabetes mellitus present,
C5395848,Disorder of macula of bilateral eyes due to diabetes mellitus,diabetes,Disorder of macula of bilateral eyes due to diabetes mellitus (disorder),
C5395900,Glaucoma due to diabetes mellitus,diabetes,Glaucoma due to diabetes mellitus (disorder),
C5395951,Generalized diabetic autonomic neuropathy,diabetes,Generalised diabetic autonomic neuropathy; Generalized autonomic neuropathy due to diabetes mellitus (disorder); Generalised autonomic neuropathy due to diabetes mellitus; Generalized autonomic neuropathy due to diabetes mellitus,
C5396068,Ulcer of right foot due to diabetes mellitus,diabetes,Ulcer of right foot due to diabetes mellitus (disorder),
C5396069,Ulcer of left foot due to diabetes mellitus,diabetes,Ulcer of left foot due to diabetes mellitus (disorder),
C5396070,Chronic ulcer of right foot due to diabetes mellitus,diabetes,Chronic ulcer of right foot due to diabetes mellitus (disorder),
C5396071,Chronic ulcer of left foot due to diabetes mellitus,diabetes,Chronic ulcer of left foot due to diabetes mellitus (disorder),
C5396092,At low risk of ulcer of right foot due to diabetes mellitus,diabetes,At low risk of ulcer of right foot due to diabetes mellitus (finding),
C5396093,At low risk of ulcer of left foot due to diabetes mellitus,diabetes,At low risk of ulcer of left foot due to diabetes mellitus (finding),
C5396094,At moderate risk of ulcer of left foot due to diabetes mellitus,diabetes,At moderate risk of ulcer of left foot due to diabetes mellitus (finding),
C5396095,At risk of ulcer of left foot due to diabetes mellitus,diabetes,At risk of ulcer of left foot due to diabetes mellitus (finding),
C5396096,At risk of ulcer of right foot due to diabetes mellitus,diabetes,At risk of ulcer of right foot due to diabetes mellitus (finding),
C5396097,At high risk of ulcer of right foot due to diabetes mellitus,diabetes,At high risk of ulcer of right foot due to diabetes mellitus (finding),
C5396098,At moderate risk of ulcer of right foot due to diabetes mellitus,diabetes,At moderate risk of ulcer of right foot due to diabetes mellitus (finding),
C5396099,At high risk of ulcer of left foot due to diabetes mellitus,diabetes,At high risk of ulcer of left foot due to diabetes mellitus (finding),
C5396273,Frequency of blood glucose self-monitoring,blood glucose,Frequency of blood glucose self-monitoring (observable entity),
C5396293,Hemoglobin A1C test declined,a1c,Hemoglobin A1C test declined (situation); Haemoglobin A1C test declined,
C5396807,Severe nonproliferative diabetic retinopathy with venous beading,diabetes,Severe nonproliferative retinopathy with venous beading of retina due to diabetes mellitus; Severe nonproliferative retinopathy with venous beading of retina due to diabetes mellitus (disorder),
C5396808,Cystoid macular edema due to diabetes mellitus,diabetes,Cystoid macular edema due to diabetes mellitus (disorder); Cystoid macular oedema due to diabetes mellitus,
C5396809,Assessment of self management of diabetes mellitus,diabetes,Assessment of self management of diabetes mellitus (procedure),
C5396911,Newly diagnosed type 1 diabetes mellitus,diabetes,Newly diagnosed type 1 diabetes mellitus (finding); Newly diagnosed diabetes mellitus type 1,
C5396912,Persistent macular edema due to diabetes mellitus,diabetes,Persistent macular oedema due to diabetes mellitus; Persistent macular edema due to diabetes mellitus (disorder),
C5397373,Non centrally involved macular edema due to diabetes mellitus,diabetes,Non centrally involved macular oedema due to diabetes mellitus; Non centrally involved macular edema due to diabetes mellitus (disorder),
C5397375,Centrally involved macular edema due to diabetes mellitus,diabetes,Centrally involved macular edema due to diabetes mellitus (disorder); Centrally involved macular oedema due to diabetes mellitus,
C5399580,AGAMATRIX PRESTO (GLUCOSE) TEST STRIP,glucose,AGAMATRIX PRESTO (GLUCOSE) TEST STRIP,
C5399618,FREESTYLE LIBRE 2 (GLUCOSE) READER,glucose,FREESTYLE LIBRE 2 (GLUCOSE) READER,
C5399619,GLUCOSE RECEIVER DEXCOM G6,glucose,GLUCOSE RECEIVER DEXCOM G6,
C5399620,GLUCOSE SENSOR FREESTYLE LIBRE 2,glucose,GLUCOSE SENSOR FREESTYLE LIBRE 2,
C5399621,GLUCOSE TRANSMITTER DEXCOM G6,glucose,GLUCOSE TRANSMITTER DEXCOM G6,
C5399713,Blood Glucose Regulator [APC],blood glucose,Blood Glucose Regulator; Blood Glucose Regulator [APC],
C5401805,EASY TRAK II (GLUCOSE) CONTROL SOLN,glucose,EASY TRAK II (GLUCOSE) CONTROL SOLN,
C5418623,Glucose Target Level,glucose,,
C5419735,Juvenile Diabetes Foundation Unit,diabetes,JDF Unit,
C5419985,Human SARS-CoV-2 Immune Globulin,hyper,Anti-SARS-CoV-2 Hyper Immunoglobulins; SARS-CoV-2 Hyperimmune Globulin,
C5420694,Glucose Management Indicator Percentage Formula,glucose,,
C5420695,Glucose Management Indicator Mmol/mol Formula,glucose,,
C5420701,Glucose Management Indicator,glucose,Glucose Management Indicator; Glucose management indicator,
C5421296,Glucose Alert Threshold,glucose,,
C5422907,"Monitors, Physiologic, Glucose, Bedside",glucose,"Monitors, Bedside, Glucose; Bedside Glucose Monitors",
C5423876,CONTOUR NEXT EZ (GLUCOSE) METER,glucose,CONTOUR NEXT EZ (GLUCOSE) METER,
C5424121,glucose glutamate,glucose,,
C5424629,Diabetes 8Y risk,diabetes,Diabetes 8Y risk,
C5424901,HEDIS Measurement Year 2020 Value Set - Glucose Tests,glucose,HEDIS MY 2020 Value Set - Glucose Tests; HEDIS Measurement Year 2020 Value Set - Glucose Tests,
C5425358,Osmotic fragility^10% glucose 48H 37 deg C incubation:NFr:Pt:RBC:Qn,glucose,Osmotic fragility 10% glucose 48 Hr 37 degree C incubation (RBC); Osmotic fragility^10% glucose 48H 37 deg C incubation:Number Fraction:To identify measures at a point in time:Erythrocytes:Quantitative; Osmotic fragility of Red Blood Cells--10% glucose 48 hour 37 degree C incubation; OF 10% Glu 48h Inc NFr RBC,
C5425382,HEDIS Measurement Year 2020 Value Set - Glucose Tests:-:Pt:^Patient:-,glucose,HEDIS MY 2020 Value Set - Glucose Tests; HEDIS MY 2020 Glucose Tests; HEDIS Measurement Year 2020 Value Set - Glucose Tests:-:To identify measures at a point in time:^Patient:-; HEDIS Measurement Year 2020 Value Set - Glucose Tests:-:Pt:^Patient:-,
C5425630,Glucose:MCnc:Pt:Bld.dot:Qn,glucose,Glucose:Mass Concentration:To identify measures at a point in time:Dried blood spot:Quantitative; Glucose DBS-mCnc; Glucose (DBS) [Mass/Vol]; Glucose [Mass/volume] in DBS,
C5425631,Hemoglobin A1c/Hemoglobin.total:MFr:Pt:Bld.dot:Qn,a1c,Hemoglobin A1c/Hemoglobin.total in DBS; Hemoglobin A1c/Hemoglobin.total:Mass Fraction:To identify measures at a point in time:Dried blood spot:Quantitative; HbA1c (DBS) [Mass fraction]; HbA1c MFr DBS,
C5426129,Diabetes 8Y risk:Likelihood:Pt:^Patient:Qn:Calculation,diabetes,Diabetes 8Y risk:Likelihood:To identify measures at a point in time:^Patient:Quantitative:Calculation; Diabetes 8Y risk Calcn; Diabetes 8Y risk [Likelihood] Calculation,
C5426607,10% glucose 48 hour 37 degree C incubation,glucose,10% glucose 48H 37 deg C incubation,
C5426900,Class &#x7C; Glucose meter device &#x7C; Devices,glucose,,
C5427134,Glucose &#x7C; DBS &#x7C; Chemistry - non-challenge,glucose,,
C5427495,HEDIS MY 2020 Value Set - Glucose Tests &#x7C; Patient &#x7C; HEDIS panels,glucose,,
C5427581,Osmotic fragility^10% glucose 48H 37 deg C incubation,glucose,Osmotic fragility^10% glucose 48H 37 deg C incubation,
C5432434,glucose 15000 MG Powder for Oral Solution,glucose,glucose 15 GM Powder for Oral Solution,
C5432446,glucose 15000 MG Chewable Tablet,glucose,glucose 15 GM Chewable Tablet,
C5433167,glucose 15000 MG,glucose,,
C5433188,glucose Powder for Oral Solution,glucose,,
C5433200,glucose Oral Powder Product,glucose,,
C5433237,GE100 (GLUCOSE) TEST STRIP,glucose,GE100 (GLUCOSE) TEST STRIP,
C5435660,TYPE 1 DIABETES MELLITUS 1,diabetes,T1D1,
C5435696,"Ketoacidosis, episodic without hypoglycemia",hypoglycemia,,
C5436940,"TYPE 1 DIABETES MELLITUS, INSULIN-DEPENDENT, 10",diabetes,,
C5436961,"TYPE 2 DIABETES MELLITUS 1, SUSCEPTIBILITY TO",diabetes,,
C5436964,"TYPE 2 DIABETES MELLITUS 5, SUSCEPTIBILITY TO",diabetes,,
C5436965,"TYPE 1 DIABETES MELLITUS 12, SUSCEPTIBILITY TO",diabetes,,
C5436966,"TYPE 2 DIABETES MELLITUS, DIGENIC",diabetes,,
C5437054,Moderate deficiency of glucose-6-phosphate dehydrogenase,glucose,G6PD (glucose-6-phosphate dehydrogenase) moderately deficient activity; Moderate deficiency of glucose-6-phosphate dehydrogenase (disorder),
C5437062,No evidence of diabetic nephropathy,diabetes,No evidence of disorder of kidney due to diabetes mellitus (situation); No evidence of disorder of kidney due to diabetes mellitus,
C5437192,Self management of diabetes,diabetes,Diabetes self management; Self management of diabetes (procedure),
C5437241,Telehealth monitoring for diabetes mellitus,diabetes,Telehealth diabetes mellitus monitoring; Telehealth monitoring for diabetes mellitus (regime/therapy),
C5437336,Severe nonproliferative retinopathy of left eye due to diabetes mellitus type 2,diabetes,Severe nonproliferative retinopathy of left eye due to diabetes mellitus type 2 (disorder),
C5437337,Severe nonproliferative retinopathy of right eye due to diabetes mellitus type 2,diabetes,Severe nonproliferative retinopathy of right eye due to diabetes mellitus type 2 (disorder),
C5437338,Bilateral severe nonproliferative retinopathy of eyes due to diabetes mellitus type 2,diabetes,Severe nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 2; Severe nonproliferative retinopathy of both eyes due to diabetes mellitus type 2; Severe nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 2 (disorder),
C5437402,Severe nonproliferative retinopathy of right eye due to diabetes mellitus type 1,diabetes,Severe nonproliferative retinopathy of right eye due to diabetes mellitus type 1 (disorder),
C5437403,Severe nonproliferative retinopathy of left eye due to diabetes mellitus type 1,diabetes,Severe nonproliferative retinopathy of left eye due to diabetes mellitus type 1 (disorder),
C5437404,Bilateral severe nonproliferative retinopathy of eyes due to diabetes mellitus type 1,diabetes,Severe nonproliferative diabetic retinopathy of bilateral eyes due to diabetes mellitus type 1; Severe nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 1 (disorder); Severe nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 1; Severe nonproliferative retinopathy of both eyes due to diabetes mellitus type 1,
C5437432,Polyneuropathy due to drug induced diabetes mellitus,diabetes,Polyneuropathy due to drug induced diabetes mellitus (disorder),
C5437438,Proliferative retinopathy of left eye due to diabetes mellitus type 1,diabetes,Proliferative retinopathy of left eye due to diabetes mellitus type 1 (disorder),
C5437439,Proliferative retinopathy of right eye due to diabetes mellitus type 1,diabetes,Proliferative retinopathy of right eye due to diabetes mellitus type 1 (disorder),
C5437440,Bilateral proliferative retinopathy of eyes due to diabetes mellitus type 1,diabetes,Proliferative retinopathy of both eyes due to diabetes mellitus type 1; Proliferative retinopathy of bilateral eyes due to diabetes mellitus type 1 (disorder); Proliferative retinopathy of bilateral eyes due to diabetes mellitus type 1,
C5437485,Nonproliferative retinopathy of left eye due to diabetes mellitus type 1,diabetes,Nonproliferative retinopathy of left eye due to diabetes mellitus type 1 (disorder),
C5437486,Bilateral nonproliferative retinopathy of eyes due to diabetes mellitus type 1,diabetes,Nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 1; Nonproliferative retinopathy of both eyes due to diabetes mellitus type 1; Nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 1 (disorder),
C5437487,Nonproliferative retinopathy of right eye due to diabetes mellitus type 1,diabetes,Nonproliferative retinopathy of right eye due to diabetes mellitus type 1 (disorder),
C5437506,Proliferative retinopathy of left eye due to diabetes mellitus type 2,diabetes,Proliferative retinopathy of left eye due to diabetes mellitus type 2 (disorder),
C5437507,Proliferative retinopathy of right eye due to diabetes mellitus type 2,diabetes,Proliferative retinopathy of right eye due to diabetes mellitus type 2 (disorder),
C5437508,Bilateral proliferative retinopathy due to diabetes mellitus type 2,diabetes,Proliferative retinopathy of both eyes due to diabetes mellitus type 2; Proliferative retinopathy of bilateral eyes due to diabetes mellitus type 2; Proliferative retinopathy of bilateral eyes due to diabetes mellitus type 2 (disorder),
C5437570,Nonproliferative retinopathy of left eye due to diabetes mellitus type 2,diabetes,Nonproliferative retinopathy of left eye due to diabetes mellitus type 2 (disorder),
C5437571,Nonproliferative retinopathy of right eye due to diabetes mellitus type 2,diabetes,Nonproliferative retinopathy of right eye due to diabetes mellitus type 2 (disorder),
C5437572,Moderate nonproliferative retinopathy of left eye due to diabetes mellitus type 1,diabetes,Moderate nonproliferative retinopathy of left eye due to diabetes mellitus type 1 (disorder),
C5437573,Moderate nonproliferative retinopathy of right eye due to diabetes mellitus type 1,diabetes,Moderate nonproliferative retinopathy of right eye due to diabetes mellitus type 1 (disorder),
C5437574,Bilateral nonproliferative retinopathy due to diabetes mellitus type 2,diabetes,Nonproliferative retinopathy of both eyes due to diabetes mellitus type 2; Nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 2 (disorder); Nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 2,
C5437575,Bilateral moderate nonproliferative retinopathy due to diabetes mellitus type 1,diabetes,Moderate nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 1; Moderate nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 1 (disorder); Moderate nonproliferative retinopathy of both eyes due to diabetes mellitus type 1,
C5437576,Moderate nonproliferative retinopathy of left eye due to diabetes mellitus type 2,diabetes,Moderate nonproliferative retinopathy of left eye due to diabetes mellitus type 2 (disorder),
C5437578,Moderate nonproliferative retinopathy of right eye due to diabetes mellitus type 2,diabetes,Moderate nonproliferative retinopathy of right eye due to diabetes mellitus type 2 (disorder),
C5437580,History of nonproliferative diabetic retinopathy,diabetes,History of nonproliferative retinopathy due to diabetes mellitus; History of nonproliferative diabetic retinopathy (situation),
C5437581,Bilateral moderate nonproliferative retinopathy due to diabetes mellitus type 2,diabetes,Moderate nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 2; Moderate nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 2 (disorder); Moderate nonproliferative retinopathy of both eyes due to diabetes mellitus type 2,
C5437608,Bilateral mild nonproliferative retinopathy due to diabetes mellitus type 1,diabetes,Mild nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 1 (disorder); Mild nonproliferative retinopathy of both eyes due to diabetes mellitus type 1; Mild nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 1,
C5437609,Mild nonproliferative retinopathy of right eye due to diabetes mellitus type 1,diabetes,Mild nonproliferative retinopathy of right eye due to diabetes mellitus type 1 (disorder),
C5437610,Mild nonproliferative retinopathy of left eye due to diabetes mellitus type 1,diabetes,Mild nonproliferative retinopathy of left eye due to diabetes mellitus type 1 (disorder),
C5437611,Mild nonproliferative retinopathy of left eye due to diabetes mellitus type 2,diabetes,Mild nonproliferative retinopathy of left eye due to diabetes mellitus type 2 (disorder),
C5437612,Mild nonproliferative retinopathy of right eye due to diabetes mellitus type 2,diabetes,Mild nonproliferative retinopathy of right eye due to diabetes mellitus type 2 (disorder),
C5437613,Bilateral mild nonproliferative retinopathy due to diabetes mellitus type 2,diabetes,Mild nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 2 (disorder); Mild nonproliferative retinopathy of both eyes due to diabetes mellitus type 2; Mild nonproliferative retinopathy of bilateral eyes due to diabetes mellitus type 2,
C5437657,Inflammatory dermatosis due to type 2 diabetes mellitus,diabetes,Inflammatory dermatosis due to type 2 diabetes mellitus (disorder); Dermatitis due to type 2 diabetes mellitus,
C5437658,Inflammatory dermatosis due to type 1 diabetes mellitus,diabetes,Inflammatory dermatosis due to type 1 diabetes mellitus (disorder); Dermatitis due to type 1 diabetes mellitus,
C5437830,End stage renal disease on dialysis due to drug induced diabetes mellitus,diabetes,End stage renal disease on dialysis due to drug induced diabetes mellitus (disorder),
C5437908,Chronic kidney disease stage 2 due to drug induced diabetes mellitus,diabetes,Chronic kidney disease stage 2 due to drug induced diabetes mellitus (disorder),
C5437909,Chronic kidney disease stage 4 due to drug induced diabetes mellitus,diabetes,Chronic kidney disease stage 4 due to drug induced diabetes mellitus (disorder),
C5437910,Chronic kidney disease stage 3 due to drug induced diabetes mellitus,diabetes,Chronic kidney disease stage 3 due to drug induced diabetes mellitus (disorder),
C5437911,Chronic kidney disease stage 5 due to drug induced diabetes mellitus,diabetes,Chronic kidney disease stage 5 due to drug induced diabetes mellitus (disorder),
C5437974,Disorder of kidney due to drug induced diabetes mellitus,diabetes,Diabetic renal disease due to drug induced diabetes mellitus; Disorder of kidney due to drug induced diabetes mellitus (disorder); Nephropathy due to drug induced diabetes mellitus; Diabetic nephropathy due to drug induced diabetes mellitus,
C5437986,Chronic kidney disease stage 1 due to drug induced diabetes mellitus,diabetes,Chronic kidney disease stage 1 due to drug induced diabetes mellitus (disorder),
C5438210,Hyperosmolar coma due to drug induced diabetes mellitus,diabetes,Diabetic hyperosmolar coma due to drug induced diabetes mellitus; Diabetic coma due to drug induced diabetic hyperosmolarity; Hyperosmolar coma due to drug induced diabetes mellitus (disorder),
C5438212,Coronary artery disease due to type 1 diabetes mellitus,diabetes,Coronary artery disease due to type 1 diabetes mellitus (disorder),
C5438214,Autonomic neuropathy due to drug induced diabetes mellitus,diabetes,Diabetic autonomic neuropathy due to drug induced diabetes mellitus; Autonomic neuropathy due to drug induced diabetes mellitus (disorder),
C5438215,Cataract due to drug induced diabetes mellitus,diabetes,Diabetic cataract due to drug induced diabetes mellitus; Cataract due to drug induced diabetes mellitus (disorder),
C5438258,History of proliferative retinopathy due to diabetes mellitus,diabetes,History of proliferative retinopathy due to diabetes mellitus (situation); History of proliferative diabetic retinopathy,
C5438291,Ulcer of foot due to drug induced diabetes mellitus,diabetes,Diabetic foot ulcer due to drug induced diabetes mellitus; Ulcer of foot due to drug induced diabetes mellitus (disorder); Foot ulcer due to drug induced diabetes mellitus,
C5438325,Cheiroarthropathy due to diabetes mellitus type 1,diabetes,Cheiroarthropathy due to diabetes mellitus type 1 (disorder); Cheiropathy due to type 1 diabetes mellitus,
C5438409,Diabetes management using closed-loop delivery system,diabetes,Diabetes management using closed-loop delivery system (procedure),
C5438614,Noninvasive interstitial fluid glucose spot-check device,glucose,Noninvasive interstitial fluid glucose spot-check device (physical object),
C5438615,Glucose monitoring equipment,glucose,Glucose monitoring equipment (physical object),
C5438646,Glaucoma suspect due to diabetes mellitus type 2,diabetes,Glaucoma suspect due to diabetes mellitus type II; Glaucoma suspect due to diabetes mellitus type 2 (disorder),
C5439134,Severe deficiency of glucose-6-phosphate dehydrogenase,glucose,Severe deficiency of glucose-6-phosphate dehydrogenase (disorder); G6PD (glucose-6-phosphate dehydrogenase) severely deficient activity,
C5441053,Tryptone glucose yeast extract agar,glucose,Tryptone glucose yeast extract agar (substance),
C5441152,"Chopped meat broth with glucose, vitamin K, and Hemin",glucose,"Chopped meat broth with glucose, vitamin K, and Hemin (substance); Cooked meat broth with glucose, vitamin K, and Hemin",
C5441869,"HMGA1 protein, human",a1c,High Mobility Group Protein HMG Isoform HMG-R; High Mobility Group AT-Hook Protein 1c; HMGA1; HMG-I/R; High Mobility Group Protein R; High Mobility Group AT-Hook 1c; HMGA1c; High Mobility Group Protein A1c; High Mobility Group Protein HMG-R,
C5442767,PSEUDOMONAS GLUCOSE FERMENTATION RHAMNOLIPIDS,glucose,,
C5443122,GLUCOSE SENSOR (3) GUARDIAN MMT-7020LA,glucose,GLUCOSE SENSOR (3) GUARDIAN MMT-7020LA,
C5443551,glucose 3750 MG,glucose,,
C5443552,glucose 3750 MG Chewable Tablet,glucose,"glucose 3.75 GM Chewable Tablet; glucose 3.75 g oral tablet, chewable; dextrose 3.75 GM Chewable Tablet; TRUEplus, 3.75 g oral tablet, chewable",
C5444242,Glucose management indicator:NFr:RptPeriod:Interstitial fluid:Qn:Calculated,glucose,Glucose management indicator:Number Fraction:Reporting period:Interstitial fluid:Quantitative:Calculated; Glucose management indicator:NFr:RptPeriod:Interstitial fluid:Qn:Calculated; Glucose management indicator; Glucose management indicator Calc (Reporting Period Interstitial fluid),
C5444299,G6PC3 wt Allele,glucose,"G6PC3 wt Allele; Glucose-6-Phosphatase, Beta Gene; UGRP; SCN4; Glucose-6-Phosphatase, Catalytic, 3 Gene; Glucose 6 Phosphatase, Catalytic, 3 Gene; Glucose-6-Phosphatase Catalytic Subunit 3 wt Allele",
C5444430,Diabetes:Hx:Pt:^Family member:Ord,diabetes,Family history of Diabetes; Family hx of Diabetes; Diabetes:History:To identify measures at a point in time:^Family member:Ordinal; Diabetes:Hx:Pt:^Family member:Ord,
C5444643,Glucose-6-Phosphatase 3,glucose,G6PC3; G6Pase-Beta; G-6-Pase 3; G6Pase 3; Glucose-6-Phosphatase 3; Ubiquitously Expressed G6Pase Catalytic Subunit-Related Protein; Ubiquitous Glucose-6-Phosphatase Catalytic Subunit-Related Protein; EC 3.1.3.9; Glucose-6-Phosphatase Catalytic Subunit 3; Glucose-6-Phosphatase Beta,
C5444649,Cortisol & glucose & somatotropin post arginine stimulation panel:-:Pt:Ser/Plas:Qn,glucose,"Cortisol+glucose+GH p arginine Pnl SerPl; Cortisol & glucose & somatotropin post arginine stimulation panel:-:To identify measures at a point in time:Serum/Plasma:Quantitative; Cortisol, glucose, and somatotropin post arginine stimulation panel; Cortisol & glucose & somatotropin post arginine stimulation panel:-:Pt:Ser/Plas:Qn; Cortisol, glucose, and somatotropin post arginine stimulation panel - Serum or Plasma",
C5444650,Cortisol & glucose & somatotropin post arginine stimulation panel,glucose,"Cortisol, glucose, and somatotropin post arginine stimulation panel; Cortisol & glucose & somatotropin post arginine stimulation panel",
C5444859,Somatotropin post glucose stimulation panel:-:Pt:Ser/Plas:-,glucose,Somatotropin post glucose stimulation panel; Somatotropin post glucose stimulation panel:-:Pt:Ser/Plas:-; Somatotropin post glucose stimulation panel:-:To identify measures at a point in time:Serum/Plasma:-; GH p glucose Pnl SerPl; Somatotropin post glucose stimulation panel - Serum or Plasma,
C5444860,Somatotropin post glucose stimulation panel,glucose,Somatotropin post glucose stimulation panel,
C5447171,Whole Blood Equivalent Glucose Measurement,glucose measurement,,
C5448628,RIGHTEST GC700 LEVEL 2 (GLUCOSE) NORMAL CONTROL SOLN,glucose,RIGHTEST GC700 (GLUCOSE) NORM CNTRL SOL,
C5448629,RIGHTEST GS700 (GLUCOSE) TEST STRIP,glucose,RIGHTEST GS700 (GLUCOSE) TEST STRIP,
C5448630,RIGHTEST GT333 (GLUCOSE) TEST STRIP,glucose,RIGHTEST GT333 (GLUCOSE) TEST STRIP,
C5448631,RIGHTEST GT333 LEVEL 2 (GLUCOSE) NORMAL CONTROL SOLN,glucose,RIGHTEST GT333 (GLUCOSE) NORM CNTRL SOL,
C5448632,RIGHTEST MAX (GLUCOSE) TEST STRIP,glucose,RIGHTEST MAX (GLUCOSE) TEST STRIP,
C5448657,FORA TN'G ADVAN PRO (GLUCOSE) TEST STRIP,glucose,FORA TN'G ADVAN PRO (GLUCOSE) TEST STRIP,
C5448658,GE333 (GLUCOSE) NORMAL CONTROL SOLN,glucose,GE333 (GLUCOSE) NORMAL CONTROL SOLN,
C5448659,GE333 (GLUCOSE) TEST STRIP,glucose,GE333 (GLUCOSE) TEST STRIP,
C5451823,Finnish diabetes risk score panel,diabetes,Finnish diabetes risk score panel,
C5451862,Glucose standard deviation,glucose,Glucose standard deviation,
C5451863,Glucose measurements in range/Total glucose measurements,glucose,Glucose measurements in range/Total glucose measurements,
C5452054,Glucose^30M post dose arginine:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 30 Min post dose arginine [Mass/Vol]; Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose arginine; Glucose 30M p Arg SerPl-mCnc; Glucose^30 minutes post dose arginine:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C5452055,Glucose^1H post dose arginine:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose 1h p Arg SerPl-mCnc; Glucose^1 hour post dose arginine:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose [Mass/volume] in Serum or Plasma --1 hour post dose arginine; Glucose 1 Hr post dose arginine [Mass/Vol],
C5452057,Glucose^1.5H post dose arginine:MCnc:Pt:Ser/Plas:Qn,glucose,Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose arginine; Glucose 1.5 Hr post dose arginine [Mass/Vol]; Glucose^1.5 hours post dose arginine:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative; Glucose 1.5h p Arg SerPl-mCnc,
C5452324,Glucose standard deviation:MCnc:RptPeriod:Interstitial fluid:Qn:Calculated,glucose,Glucose SD Calc; Glucose standard deviation Calc (Reporting Period Interstitial fluid) [Mass/Vol]; Glucose standard deviation Calculated; Glucose standard deviation:Mass Concentration:Reporting period:Interstitial fluid:Quantitative:Calculated,
C5452325,Glucose:MCnc:RptPeriod^mean:Interstitial fluid:Qn:Calculated,glucose,Glucose:Mass Concentration:Reporting period^Mean of all of the values observed on the interval:Interstitial fluid:Quantitative:Calculated; Glucose Calc (Reporting Period mean Interstitial fluid) [Mass/Vol]; Ave Glucose Interstitial fld RptPeriod; Average glucose [Mass/volume] in Interstitial fluid during Reporting Period,
C5452326,Glucose measurements in range/Total glucose measurements:NFr:RptPeriod:Interstitial fluid:Qn:Calculated,glucose,% Glucose measurements in range; Glucose measurements in range/Total glucose measurements Calc (Reporting Period Interstitial fluid); Glucose measurements in range/Total glucose measurements:Number Fraction:Reporting period:Interstitial fluid:Quantitative:Calculated; Glucose measurements in range out of Total glucose measurements during reporting period,
C5452348,Somatotropin^3H post dose glucose:MCnc:Pt:Ser/Plas:Qn,glucose,Somatotropin [Mass/volume] in Serum or Plasma --3 hours post dose glucose; GH 3h p Glc SerPl-mCnc; Somatotropin 3 Hr post dose glucose [Mass/Vol]; Somatotropin^3 hours post dose glucose:Mass Concentration:To identify measures at a point in time:Serum/Plasma:Quantitative,
C5452488,Glucose^1H specimen:SCnc:Pt:Dial fld:Qn,glucose,Glucose [Moles/volume] in Dialysis fluid --1 hour specimen; Glucose^1 hour specimen:Substance Concentration:To identify measures at a point in time:Dialysis fluid:Quantitative; Glucose 1h spec Dial fld-sCnc; Glucose 1 hour specimen (Dial fld) [Moles/Vol],
C5452716,Diabetes with end organ damage,diabetes,,
C5453320,Finnish diabetes risk score panel:-:Pt:^Patient:-:FINDRISC,diabetes,FINDRISC pnl FINDRISC; Finnish diabetes risk score panel FINDRISC; Finnish diabetes risk score panel:-:To identify measures at a point in time:^Patient:-:Finnish Diabetes Risk Score,
C5453321,High blood glucose:Hx:Pt:^Patient:Ord,blood glucose,Hx of High blood glucose; History of High blood glucose; High blood glucose:History:To identify measures at a point in time:^Patient:Ordinal,
C5453322,Total risk score:Score:Pt:^Patient:Qn:FINDRISC,diabetes,Total risk score:Score:To identify measures at a point in time:^Patient:Quantitative:Finnish Diabetes Risk Score; Total risk score FINDRISC,
C5453626,Hemoglobin A1c/Hemoglobin.total&#x7C;MFr&#x7C;Pt&#x7C;ANYBldSerPl,a1c,,
C5453784,Glucose measurements in range,glucose,Glucose measurements in range,
C5453792,Glucose^1.5H post dose arginine,glucose,Glucose^1.5H post dose arginine,
C5453793,Glucose^1H post dose arginine,glucose,Glucose^1H post dose arginine,
C5453794,Glucose^30M post dose arginine,glucose,Glucose^30M post dose arginine,
C5453795,Somatotropin^3H post dose glucose,glucose,Somatotropin^3H post dose glucose,
C5453798,Glucose^1H specimen,glucose,Glucose^1H specimen,
C5453876,Total glucose measurements,glucose,Total glucose measurements,
C5454323,Glucose management indicator &#x7C; Interstitial fluid &#x7C; Chemistry - non-challenge,glucose,,
C5454324,Glucose measurements in range/Total glucose measurements &#x7C; Interstitial fluid &#x7C; Chemistry - non-challenge,glucose,,
C5454325,Glucose standard deviation &#x7C; Interstitial fluid &#x7C; Chemistry - non-challenge,glucose,,
C5454326,Glucose &#x7C; Interstitial fluid &#x7C; Chemistry - non-challenge,glucose,,
C5454327,Glucose CSF:SerPl &#x7C; Plasma and CSF &#x7C; Chemistry - non-challenge,glucose,,
C5454368,"Cortisol, glucose, and somatotropin post arginine stimulation panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels",glucose,,
C5454369,Somatotropin post glucose stimulation panel &#x7C; Serum or Plasma &#x7C; Challenge Bank Panels,glucose,,
C5455028,ReliOn Prime Blood Glucose Test Strips,blood glucose,,
C5490892,Basilaphelenchus sp. h BG-2019,BG,,
C5540784,EASY TOUCH BLU LINK (GLUCOSE) TEST STRIP,glucose,EASY TOUCH BLU LINK (GLUCOSE) TEST STRIP,
C5540792,EASY TOUCH BLU LINK (GLUCOSE) HIGH/LOW CONTROL SOLN,glucose,EASY TOUCH BLU LINK (GLUCOSE) HI/LO SOLN,
C5542974,"Increased risk diabetes mellitus, type 2 (decreased Lp(a))",diabetes,,
C5543275,ODONTOCHONDRODYSPLASIA 2 WITH HEARING LOSS AND DIABETES,diabetes,ODCD2,
C5543294,"MICROCEPHALY, EPILEPSY, AND DIABETES SYNDROME 2",diabetes,"MICROCEPHALY, EPILEPSY, AND DIABETES SYNDROME 2; MEDS2",
C5543295,Diabetes (neonatal or early-onset),diabetes,,
C5543298,"Diabetes, neonatal/early-onset",diabetes,,
C5543376,"Diabetes mellitus, insulin-dependent (early childhood-onset)",diabetes,,
C5543655,"DIABETES INSIPIDUS, NEPHROGENIC, 2, AUTOSOMAL RECESSIVE",diabetes,,
C5543656,"DIABETES INSIPIDUS, NEPHROGENIC, 2, AUTOSOMAL DOMINANT",diabetes,,
C5543681,ODONTOCHONDRODYSPLASIA WITH HEARING LOSS AND DIABETES,diabetes,,
C5545650,Pre-existing malnutrition-related diabetes mellitus in pregnancy,diabetes,Pre-existing malnutrition-related diabetes mellitus in pregnancy (disorder),
C5545924,Estimated daily glycemic index value,glycaemic,Estimated daily glycaemic index value; Estimated daily glycemic index value (observable entity),
C5545925,Estimated daily glycemic load,glycaemic,Estimated daily glycaemic load; Estimated daily glycemic load (observable entity),
C5546098,Peripheral autonomic neuropathy due to diabetes mellitus,diabetes,Peripheral autonomic neuropathy due to diabetes mellitus (disorder),
C5546339,Anhydrous glucose 50 mg/mL and potassium chloride 3 mg/mL solution for injection,glucose,Product containing precisely anhydrous glucose 50 milligram/1 milliliter and potassium chloride 3 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5546340,Anhydrous glucose 50 mg/mL and potassium chloride 2 mg/mL solution for injection,glucose,Product containing precisely anhydrous glucose 50 milligram/1 milliliter and potassium chloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5546341,Anhydrous glucose 50 mg/mL and potassium chloride 1.5 mg/mL and sodium chloride 4.5 mg/mL solution for injection,glucose,Product containing precisely anhydrous glucose 50 milligram/1 milliliter and potassium chloride 1.5 milligram/1 milliliter and sodium chloride 4.5 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5546342,Anhydrous glucose 50 mg/mL and potassium chloride 1.5 mg/mL solution for injection,glucose,Product containing precisely anhydrous glucose 50 milligram/1 milliliter and potassium chloride 1.5 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5546343,Anhydrous glucose 40 mg/mL and potassium chloride 3 mg/mL and sodium chloride 1.8 mg/mL solution for injection,glucose,Product containing precisely anhydrous glucose 40 milligram/1 milliliter and potassium chloride 3 milligram/1 milliliter and sodium chloride 1.8 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5546344,Anhydrous glucose 40 mg/mL and potassium chloride 2 mg/mL and sodium chloride 1.8 mg/mL solution for injection,glucose,Product containing precisely anhydrous glucose 40 milligram/1 milliliter and potassium chloride 2 milligram/1 milliliter and sodium chloride 1.8 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5546345,Anhydrous glucose 40 mg/mL and potassium chloride 1.5 mg/mL and sodium chloride 1.8 mg/mL solution for injection,glucose,Product containing precisely anhydrous glucose 40 milligram/1 milliliter and potassium chloride 1.5 milligram/1 milliliter and sodium chloride 1.8 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5546398,Deficiency of glucose-6-phosphate dehydrogenase with normal enzyme activity,glucose,Deficiency of G6PD (glucose-6-phosphate dehydrogenase) with normal enzyme activity; Deficiency of glucose-6-phosphate dehydrogenase with normal enzyme activity (disorder); Class IV G6PD (glucose-6-phosphate dehydrogenase) deficiency,
C5546630,Postoperative central diabetes insipidus,diabetes,Postoperative central diabetes insipidus (disorder); Postoperative cranial diabetes insipidus; Postoperative neurohypophyseal diabetes insipidus,
C5547841,History of pregnancy with abnormal glucose tolerance test,glucose,History of abnormal glucose tolerance test in pregnancy; History of pregnancy with abnormal glucose tolerance test (situation),
C5547842,History of pregnancy with normal glucose tolerance test,normal glucose,History of normal glucose tolerance test in pregnancy; History of pregnancy with normal glucose tolerance test (situation),
C5549653,Finnish diabetes risk score panel &#x7C; Patient &#x7C; Clinical Risk Panel,diabetes,,
C5549801,Allergy to substance with sodium glucose cotransporter subtype 2 inhibitor mechanism of action,glucose,Allergy to substance with sodium glucose cotransporter subtype 2 inhibitor mechanism of action (finding),
C5549802,Adverse reaction to substance with sodium glucose cotransporter subtype 2 inhibitor mechanism of action,glucose,Adverse reaction to substance with sodium glucose cotransporter subtype 2 inhibitor mechanism of action (disorder),
C5550869,FORTISCARE G1 (GLUCOSE) TEST STRIP,glucose,FORTISCARE G1 (GLUCOSE) TEST STRIP,
C5551128,SLC37A4 wt Allele,glucose,"G6PT2; G6PT; GSD1d; Glucose-6-Phosphatase, Transport (Glucose-6-Phosphate) Protein 1 Gene; PRO0685; G6PT3; Glucose-6-Phosphatase, Transport (Phosphate/Pyrophosphate) Protein Gene; TRG-19; Solute Carrier Family 37 (Glucose-6-Phosphate Transporter), Member 4 Gene; Glucose-6-Phosphatase, Transport (Glucose) Protein Gene; GSD1b; SLC37A4 wt Allele; Transformation-Related Gene 19; G6PT1; TRG19; GSD1c; Solute Carrier Family 37 Member 4 wt Allele",
C5552770,Oral Hypoglycemic Diabetes Therapy,diabetes,Oral Hypoglycemic Diabetes Therapy; Therapeutic Oral Hypoglycemic; Oral Hypoglycemic Therapy,
C5552803,Injected Insulin Diabetes Therapy,diabetes,Injected Insulin Diabetes Therapy; Therapeutic Insulin Injection; Insulin Injection; Injected Insulin Therapy; Injected Insulin,
C5552920,G6PC3 Loss of Function Gene Mutation,glucose,G6PC3 Loss of Function Gene Mutation; Glucose-6-Phosphatase Catalytic Subunit 3 Loss of Function Gene Mutation; G6PC3 Deficient; SCN4 Loss of Function Gene Mutation; G6PC3 Deficiency; Glucose-6-Phosphatase 3 Loss of Function Gene Mutation; G6PC3 Loss of Function Mutation; UGRP Loss of Function Gene Mutation; Inactivating G6PC3 Mutation; G6PC3 Inactivating Gene Mutation; G6PC3 Inactivating Mutation; Inactivating G6PC3 Gene Mutation,
C5552921,Glucose-6-Phosphatase 3 Deficiency,glucose,G6PC3 Deficiency; Glucose-6-phosphatase Catalytic Subunit 3 Deficiency; Glucose-6-Phosphatase 3 Deficiency,
C5553232,Care Touch Blood Glucose Test Strips (100 Cou,blood glucose,,
C5553233,Care Touch Blood Glucose Test Strips (50 Coun,blood glucose,,
C5553241,Care Touch Diabetes Testing Kit,diabetes,,
C5553354,FORA G20-D30-V20 (GLUCOSE) TEST STRIP,glucose,FORA G20-D30-V20 (GLUCOSE) TEST STRIP,
C5553406,FORTISCARE T1 (GLUCOSE) METER,glucose,FORTISCARE T1 (GLUCOSE) METER,
C5554765,CDISC Type 1 Diabetes Therapeutic Area User Guide v1.0 - Pediatrics and Devices Modules,diabetes,,
C5554891,BG8 IHC Staining Method,BG,BG-8 Staining Method; BG8 Antibody Staining Method; Anti-LeY BG8 Staining Method; Antibody BG8 Staining Method; Anti-Anti-Lewis-Y BG8 Staining Method; Anti-Anti-Lewis Y BG8 Staining Method; BG8 Staining Method,
C5555637,Inactivating PRKDC Gene Mutation,hyper,"Inactivating p350 Gene Mutation; Inactivating XRCC7 Gene Mutation; PRKDC Inactivating Mutation; Inactivating HYRC Gene Mutation; Inactivating DNA-PKcs Gene Mutation; PRKDC Loss of Function Mutation; Inactivating Protein Kinase, DNA-Activated, Catalytic Polypeptide Gene Mutation; Inactivating PRKDC Mutation; PRKDC Inactivating Gene Mutation; Inactivating DNPK1 Gene Mutation; PRKDC Loss of Function Gene Mutation; PRKDC Gene Inactivation; Inactivating Hyper-Radiosensitivity of Murine SCID Mutation, Complementing 1 Gene Mutation; Inactivating DNAPK Gene Mutation; Inactivating HYRC1 Gene Mutation",
C5555926,G6PC3 Gene Mutation,glucose,SCN4 Gene Mutation; Glucose-6-Phosphatase Catalytic Subunit 3 Gene Mutation; Glucose-6-Phosphatase 3 Gene Mutation; UGRP Gene Mutation,
C5561044,EASY TALK PLUS II (GLUCOSE) TEST STRIP,glucose,EASY TALK PLUS II (GLUCOSE) TEST STRIP,
C5561678,Glucose Control Software,glucose,,
C5561679,Glucose Management Software,glucose,,
C5561877,"Software, Infusion Pump System, Control/Programming, Glucose/Insulin",glucose,,
C5562113,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL, X-LINKED",diabetes,,
C5565010,delta inulin,glucose,"beta-D-(2, 1) poly(fructo-furanosyl) alpha-D-glucose; beta-D-(2 -> 1) poly(fructo-furanosyl) alpha-D-glucose",
C5565076,"HSPA5 protein, human",glucose,"BiP670 protein, human; glucose-regulated protein, 78kDa, human; heat shock protein family A (Hsp70) member 5 protein, human; GRP78 protein, human; heat shock 70kDa protein 5, human; GPR78 protein, human; G protein-coupled receptor GPR78, human",
C5565180,"Hspa5 protein, mouse",glucose,"heat shock 70kD protein 5 (glucose-regulated protein), mouse; Bip protein, mouse; Grp78 protein, mouse",
C5565499,3-O-beta-cellobiosyl-d-glucose,glucose,,
C5567327,Disorder due to malnutrition related diabetes mellitus,diabetes,Disorder due to malnutrition related diabetes mellitus (disorder),
C5568676,Post-traumatic central diabetes insipidus,diabetes,Central diabetes insipidus due to and following traumatic event (disorder); Central diabetes insipidus due to and following traumatic event,
C5570326,Glucose:MCnc:Pt:Interstitial fluid:Qn,glucose,Glucose Interstitial fld-mCnc; Glucose:Mass Concentration:To identify measures at a point in time:Interstitial fluid:Quantitative; Glucose (Interstitial fluid) [Mass/Vol]; Glucose [Mass/volume] in Interstitial fluid,
C5570368,Glucose/Creatinine:SRto:24H:Urine:Qn,glucose,Glucose/Creatinine [Molar ratio] in 24 hour Urine; Glucose/Creatinine:Substance Ratio:24 hours:Urine:Quantitative; Glucose/Creat 24h Ur-sRto; Glucose/Creatinine (24H U) [Molar ratio],
C5570689,Diabetes (Type I or II),diabetes,,
C5570979,1.5% Glucose,glucose,,
C5570980,2.5% Glucose,glucose,,
C5570981,4.25% Glucose,glucose,,
C5571693,Glucose/Creatinine&#x7C;SRto&#x7C;Urine,glucose,,
C5572827,Contour Next EZ Blood Glucose Monitoring,blood glucose,,
C5573411,CHROMIUM 2 [hp_X] in 59 mL / OXOGLURIC ACID 3 [hp_X] in 59 mL / CORN SYRUP 6 [hp_X] in 59 mL / FRUCTOSE 6 [hp_X] in 59 mL / MOMORDICA BALSAMINA WHOLE 6 [hp_X] in 59 mL / BOS TAURUS PANCREAS 6 [hp_X] in 59 mL / PYRIDOXINE 6 [hp_X] in 59 mL / SUCROSE 6 [hp_X] in 59 mL / VANADIUM 6 [hp_X] in 59 mL / MANGANESE GLUCONATE 8 [hp_X] in 59 mL / LYCOPODIUM CLAVATUM SPORE 9 [hp_X] in 59 mL / MANDRAGORA OFFICINARUM ROOT 9 [hp_X] in 59 mL / PHOSPHORIC ACID 12 [hp_X] in 59 mL / GONORRHEAL URETHRAL SECRETION HUMAN 30 [hp_X] in 59 mL ORAL LIQUID [Glucose Drops 2031],glucose,,
C5574250,CONTOUR NEXT LINK 2.4 (GLUCOSE) METER,glucose,CONTOUR NEXT LINK 2.4 (GLUCOSE) METER,
C5574950,Netherton Syndrome,hyper,"Comel-Netherton syndrome; nethertons syndrome; Bamboo hair syndrome; netherton syndrome; Axial osteosclerosis with bamboo hair; NS; NETHERTON SYNDROME; Netherton Syndrome; Netherton Disease; Netherton syndrome; Netherton's syndrome; Netherton's syndrome (disorder); NETH; Netherton's disease; Comèl-Netherton syndrome; netherton's syndrome; COMEL-NETHERTON SYNDROME; ERYTHRODERMA, ICHTHYOSIFORM, WITH HYPOTRICHOSIS AND HYPER-IgE; NETHERTON DISEASE",
C5575811,Ketosis-resistant diabetes mellitus,diabetes,Ketosis-resistant diabetes mellitus (disorder); Ketosis-resistant diabetes mellitus,
C5576975,ONE TOUCH ULTRA-2 (GLUCOSE) METER,glucose,ONE TOUCH ULTRA-2 (GLUCOSE) METER,
C5577435,MOMORDICA CHARANTIA FRUIT 0.5 g in 1 mL ORAL LIQUID [Diabetes Out],diabetes,,
C5578277,PIP (GLUCOSE) TEST STRIP,glucose,PIP (GLUCOSE) TEST STRIP,
C5603168,Ctenophora sp. BG LMC-2021,BG,,
C5604722,Yunnan sediment hypo-like virus,hypo,,
C5604723,Jiangsu sediment hypo-like virus 1,hypo,,
C5604724,Jiangsu sediment hypo-like virus 2,hypo,,
C5604725,Sichuan sediment hypo-like virus 1,hypo,,
C5604726,Sichuan sediment hypo-like virus 2,hypo,,
C5604727,Sichuan hypo-like virus 3,hypo,,
C5604728,Zhejiang hypo-like virus,hypo,,
C5611073,Drieschia cf. elegans BG-2021,BG,,
C5646699,Bunodosoma goanense,BG,Bunodosoma sp. NIO BG,
C5669509,Diabetes Is Controlled by Diet,diabetes,Diet Controlled Diabetes; Diet-Controlled Diabetes,
C5669517,Diabetes Is Controlled by Insulin,diabetes,Insulin Controlled Diabetes; Insulin-Controlled Diabetes,
C5670268,Radiolabeled Glucose to Glucose Ratio Measurement,glucose,,
C5671635,EASY TALK PLUS II (GLUCOSE) LOW CONTROL SOLN,glucose,EASY TALK PLUS II (GLUCOSE) LO CNTRL SOL,
C5671636,EASY TALK PLUS II (GLUCOSE) HIGH CONTROL SOLN,glucose,EASY TALK PLUS II (GLUCOSE) HI CNTRL SOL,
C5671727,"Transcend Glucose Orange, 15 g/31 g oral gel",glucose,,
C5671728,"Transcend Glucose Strawberry, 15 g/31 g oral gel",glucose,,
C5671746,glucose 15 g/31 g oral gel,glucose,,
C5671878,Transcend Glucose Strawberry,glucose,,
C5671879,Transcend Glucose Orange,glucose,,
C5673012,"glucose dehydrogenase (FAD, quinone) activity",glucose,,
C5673339,"Glucose SOS Green Apple Crisp, oral powder",glucose,,
C5673348,glucose oral powder,glucose,,
C5673375,Glucose SOS Green Apple Crisp,glucose,,
C5676920,"HYPER-IgE RECURRENT INFECTION SYNDROME 4A, AUTOSOMAL DOMINANT",hyper,"HIES4A; HYPER-IgE RECURRENT INFECTION SYNDROME 4A, AUTOSOMAL DOMINANT",
C5677940,Hypoglycemia (severe form),hypoglycemia,,
C5677967,Noninsulin-dependent diabetes mellitus (in second decade of life),diabetes,,
C5677970,Hypoketotic hypoglycemia (at birth),hypoglycemia,,
C5678160,"Hyper- and hypopigmented macules of variable size and shape located primarily on face, neck, trunk, and dorsa of hands and feet",hyper,,
C5679550,ONE TOUCH SOLUTIONS REFILL (GLUCOSE) TEST STRIP,glucose,ONE TOUCH SOLNS REF (GLUCOSE) TEST STRIP,
C5679569,Diazoxide-resistant diffuse hyperinsulinism,hypoglycemia,"Hyperinsulinemic hypoglycemia, diazoxide-resistant diffuse form",
C5679570,Diazoxide-sensitive diffuse hyperinsulinism,hypoglycemia,"Hyperinsulinemic hypoglycemia, diazoxide-sensitive diffuse form",
C5679586,Rare diabetes mellitus type 1,diabetes,Rare insulin-dependent diabetes mellitus,
C5679587,Rare diabetes mellitus type 2,diabetes,Rare insulin-independent diabetes mellitus,
C5679694,Hyperinsulinism due to INSR deficiency,hypoglycemia,Hyperinsulinemic hypoglycemia due to insulin receptor deficiency; Hyperinsulinemic hypoglycemia due to INSR deficiency,
C5679778,Diazoxide-resistant hyperinsulinism,hypoglycemia,Diazoxide-resistant hyperinsulinemic hypoglycemia,
C5680005,Class I glucose-6-phosphate dehydrogenase deficiency,glucose,Severe hemolytic anemia due to G6PD deficiency; Class I G6PD deficiency,
C5680110,Hereditary central diabetes insipidus,diabetes,Hereditary neurogenic diabetes insipidus; Hereditary CDI,
C5680202,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,glucose,GSD due to G6P deficiency type 1a; GSDIa; Glycogen storage disease type 1a; Glycogenosis type Ia; Glycogenosis due to glucose-6-phosphatase deficiency type 1a; GSD type 1a; GSD due to G6P deficiency type Ia; Glycogen storage disease due to G6P deficiency type Ia; Glycogenosis due to glucose-6-phosphatase deficiency type Ia; G6P deficiency type 1a,
C5680204,Diazoxide-resistant focal hyperinsulinism,hypoglycemia,"Hyperinsulinemic hypoglycemia, diazoxide-resistant focal form",
C5680256,Acquired central diabetes insipidus,diabetes,Acquired CDI; Acquired neurogenic diabetes insipidus,
C5680384,Isolated permanent neonatal diabetes mellitus,diabetes,Monogenic diabetes of infancy; Isolated PNDM,
C5680423,Intermediate DEND syndrome,diabetes,"Developmental delay-epilepsy-neonatal diabetes syndrome, intermediate form",
C5680476,Other rare diabetes mellitus,diabetes,,
C5680537,Rare genetic diabetes mellitus,diabetes,,
C5680732,Nephrogenic diabetes insipidus-intracranial calcification-facial dysmorphism syndrome,diabetes,,
C5681180,"Intrauterine growth restriction, short stature, early adult-onset diabetes syndrome",diabetes,"Intrauterine growth restriction, short stature, early adult-onset diabetes syndrome (disorder); Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome",
C5681799,Rare diabetes mellitus,diabetes,,
C5686053,Neovascular glaucoma due to diabetes mellitus type 2,diabetes,Neovascular glaucoma due to type II diabetes mellitus; Neovascular glaucoma due to diabetes mellitus type 2 (disorder),
C5686054,Neovascular glaucoma due to diabetes mellitus type 1,diabetes,Neovascular glaucoma due to type I diabetes mellitus; Neovascular glaucoma due to diabetes mellitus type 1 (disorder),
C5686794,Glucose 75 mg/mL and lidocaine hydrochloride 50 mg/mL solution for injection,glucose,Product containing precisely glucose 75 milligram/1 milliliter and lidocaine hydrochloride 50 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5686795,Glucose and lidocaine only product,glucose,Product containing only glucose and lidocaine (medicinal product),
C5686803,Glucose and lidocaine only product in parenteral dose form,glucose,Product containing only glucose and lidocaine in parenteral dose form (medicinal product form),
C5686844,Glucose 8 g and potassium chloride 300 mg and sodium bicarbonate 300 mg and sodium chloride 200 mg powder for oral solution sachet,glucose,Product containing precisely glucose 8 gram and potassium chloride 300 milligram and sodium bicarbonate 300 milligram and sodium chloride 200 milligram/1 sachet powder for conventional release oral solution (clinical drug),
C5686845,Glucose- and potassium chloride- and sodium bicarbonate- and sodium chloride-containing product,glucose,Product containing glucose and potassium chloride and sodium bicarbonate and sodium chloride (medicinal product),
C5686846,Glucose and potassium chloride and sodium bicarbonate and sodium chloride only product,glucose,Product containing only glucose and potassium chloride and sodium bicarbonate and sodium chloride (medicinal product),
C5686847,Glucose- and potassium chloride- and sodium bicarbonate- and sodium chloride-containing product in oral dose form,glucose,Product containing glucose and potassium chloride and sodium bicarbonate and sodium chloride in oral dose form (medicinal product form),
C5686848,Glucose and potassium chloride and sodium bicarbonate and sodium chloride only product in oral dose form,glucose,Product containing only glucose and potassium chloride and sodium bicarbonate and sodium chloride in oral dose form (medicinal product form),
C5686853,Glucose 13.5 g and potassium chloride 1.5 g and sodium chloride 2.6 g and sodium citrate 2.9 g powder for oral solution sachet,glucose,Product containing precisely glucose 13.5 gram and potassium chloride 1.5 gram and sodium chloride 2.6 gram and sodium citrate 2.9 gram/1 sachet powder for conventional release oral solution (clinical drug),
C5686854,Glucose- and potassium chloride- and sodium chloride- and sodium citrate-containing product,glucose,Product containing glucose and potassium chloride and sodium chloride and sodium citrate (medicinal product),
C5686855,Glucose and potassium chloride and sodium chloride and sodium citrate only product,glucose,Product containing only glucose and potassium chloride and sodium chloride and sodium citrate (medicinal product),
C5686856,Glucose- and potassium chloride- and sodium chloride- and sodium citrate-containing product in oral dose form,glucose,Product containing glucose and potassium chloride and sodium chloride and sodium citrate in oral dose form (medicinal product form),
C5686857,Glucose and potassium chloride and sodium chloride and sodium citrate only product in oral dose form,glucose,Product containing only glucose and potassium chloride and sodium chloride and sodium citrate in oral dose form (medicinal product form),
C5686993,Glucose 50 mg/mL solution for injection,glucose,Product containing precisely glucose 50 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5686995,Glucose 100 mg/mL solution for injection,glucose,Product containing precisely glucose 100 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5686996,Glucose 500 mg/mL solution for injection,glucose,Product containing precisely glucose 500 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5687038,Glucose 50 mg/mL and sodium chloride 4.5 mg/mL solution for injection,glucose,Product containing precisely glucose 50 milligram/1 milliliter and sodium chloride 4.5 milligram/1 milliliter conventional release solution for injection (clinical drug),
C5688175,Diabetic neurotrophic keratitis,diabetes,Neurotrophic keratitis due to diabetes mellitus; Neurotrophic keratitis due to diabetes mellitus (disorder),
C5688987,Hyper extension internal rotation test,hyper,HERI (hyperextension internal rotation) test; Hyper extension internal rotation test (procedure),
C5689260,Giardia lamblia bg gene,BG,Giardia lamblia bg gene,
C5689534,Giardia lamblia bg gene:Geno:Pt:XXX:Nom:Molgen,BG,G. lamblia bg gene Spec-Geno; Giardia lamblia bg gene:Genotype:To identify measures at a point in time:Not specified:Nominal:Molecular Genetics; Giardia lamblia bg gene genotype Molgen (Specimen); Giardia lamblia bg gene [Genotype] in Specimen by Molecular genetics method,
C5689582,Glucose:SCnc:Pt:BldMV:Qn,glucose,Glucose (BldMV) [Moles/Vol]; Glucose BldMV-sCnc; Glucose [Moles/volume] in Mixed venous blood; Glucose:Substance Concentration:To identify measures at a point in time:Blood- mixed Venous:Quantitative,
C5690188,Giardia lamblia bg gene &#x7C; XXX &#x7C; Microbiology,BG,,
C5690214,Glucose &#x7C; Blood mixed venous &#x7C; Chemistry - non-challenge,glucose,,
C5690697,penta-O-galloyl-D-glucose,glucose,"1,2,3,4,6-pentagalloyl-D-glucose; D-glucopyranose, pentakis(3,4,5-trihydroxybenzoate)",
C5691217,"3,6-di-O-acetyl-2-deoxy-D-glucose",glucose,,
C5698704,Freestyle Libre 3 Glucose Monitoring System,glucose,,
C5699690,PIP (GLUCOSE) HIGH/LOW CONTROL SOLN,glucose,PIP (GLUCOSE) HI/LO CONTROL SOLN,
C0006681,calcium carbonate,normal blood sugar,"calcium carbonate; Carbonate, Calcium; Product containing calcium carbonate (medicinal product); Carbonato de calcio; CALCIUM (AS CALCIUM CARBONATE); CALCIUM CARBONATE; CaCO3; CALCIUM (AS CARBONATE); calcium carbonated; Calcium carbonate (substance); Calcium Carbonate; Carbonic acid calcium salt (1:1); Calcium carbonate-containing product; Calcio carbonato; calcium carbonates; Calcium carbonate (1:1); Calcium carbonate; Kalziumkarbonat; Calciumcarbonat; Carbonate de calcium; Kohlensaurer kalk; Antacid (Calcium Carbonate); calcium (as carbonate)",
